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In 2013, the Tobacco Policy Review Group published Tobacco Free Ireland, a report which set a target 
for Ireland to reduce smoking prevalence to less than 5% by 2025. The report identified tobacco-
related harm reduction as a key issue for consideration. Since e-cigarettes’ launch in the European 
Union (EU) in 2006 and in the United States of America (USA) in 2007, research on their potential 
benefits in terms of tobacco-related harm reduction, and on their public health harms, has grown. 
This mapping exercise describes the nature and extent of the literature on the public health harms 
and benefits of e-cigarettes and heat-not-burn tobacco products to the human population. An e-
cigarette is an umbrella term for an electronic device that delivers nicotine and other products 
including flavourings while a heat-not-burn tobacco product is an umbrella term for devices that heat 
but do not burn tobacco. They have similar but not identical yields of tar, nicotine, and other 
products, such as carbon monoxide. 
Research question 
This research addresses two questions posed by the Irish Department of Health: 
1. What are the public health benefits and harms of e-cigarettes?  
2. What are the public health benefits and harms of heat-not-burn tobacco products?’ 
Methods 
Mapping exercises provide an overview of the nature and extent of the available evidence, with 
limited description of the data. The mapping period covers peer review literature published between 
January 2005 and November 2019 on e-cigarettes, and between January 1988 and November 2019 
for heat-not-burn tobacco products. Comprehensive searches were completed and updated three 
times during the mapping period. The mapping exercise was completed between April 2019 and 
January 2020. The literature was retrieved from seven databases and one search engine – Ovid 
MEDLINE, Cochrane Library, Ovid PsycINFO, Elsevier Embase, PROSPERO, LILACS, CORE.ac.uk and 
Google Scholar. There were three rounds of screening, using predefined inclusion and exclusion 
criteria, to identify the papers included in this review. The study summaries are presented, or 
arranged, by headings (epidemiological study design with the addition of surveillance reports) and 
subheadings (dependence and abuse liability; cardiovascular diseases; cancers; respiratory diseases; 
oral diseases; developmental and reproductive effects; and injuries and poisonings) in order to 
describe, design and develop effective research questions and programmes. The subheadings were 
adapted from the United States National Academies of Sciences, Engineering, and Medicine.  
The authors of this mapping exercise added two further headings – exposure to e-cigarette toxins, 
and other outcomes – in order to categorise literature that did not align under the existing headings. 
Harms and benefits could be the result of either use of, or exposure to, e-cigarettes or e-liquid or 
heat-not-burn tobacco products. 
The outcomes measured were clinically diagnosed diseases or injuries, biological risk markers for 
disease, measures of organ function, presence of toxins and toxicants, and self-reported signs and 
symptoms. 
Findings 
This mapping exercise describes findings from published peer reviewed journal articles and organises 
the information in a way that enables discussion and decision-making by researchers, policy makers, 
and practitioners. This mapping exercise describes findings from published peer-reviewed journal 
articles which examine the relationship between two nicotine-related products and their impact on 
human health. We identified 388 papers eligible for inclusion in the map, 361 reporting the harms 





products, with one paper reporting both exposures. An e-cigarette is an umbrella term for a device 
that delivers nicotine and other products including flavourings while a heat-not-burn tobacco product 
is an umbrella term for devices that heat but do not burn tobacco. They have similar but not identical 
yields of tar, nicotine, and other products, such as carbon monoxide. 
E-cigarette summary map 
The 361 included studies on possible harms and benefits of e-cigarettes were mapped by study design 
and by the adapted Academies of Sciences’ umbrella terms. All types of epidemiological study designs 
were used to investigate the recent e-cigarette phenomenon. The highest number of studies were 
case reports, followed by interventional trials and then cross-sectional surveys. Papers reporting 
surveillance data are also presented as they characterise clinical presentation of the harms and 
benefits of e-cigarettes at a community-level. The e-cigarette-related health harms, harm reduction, 
and benefits known to date are presented in this mapping exercise. However, there may be unknown 
harms.  
Most of our observed clinical harms were due to acute harmful events associated with the use of e-
cigarettes and were reported in descriptive case reports, case series, surveillance system papers, and 
cross-sectional survey papers (Table A). They included poisonings (mainly nicotine and some e-liquid 
constituents), injuries (mainly burns and some fractures), and respiratory diseases (mainly injuries to 
the lungs and exacerbation of asthma). There were fatalities among the poisonings and respiratory 
disease cases, and long-term disability among some burn cases. Both the poisoning cases and the 
respiratory disease cases highlighted a possible association between e-cigarettes and the use of other 
drugs such as alcohol, synthetic cannabinoids, and opiates. There was some early evidence of damage 
to cardiovascular and respiratory tissue, mainly due to metals and volatile organic compounds. Four 
cross-sectional surveys on cancers identified the presence of carcinogens for lung, oral, and 
oesophageal cancer, and one identified biomarkers for bladder cancers. Some respiratory, 
cardiovascular, and oral diseases were noted to be less harmful in e-cigarette users than in 
conventional cigarette smokers, but were as harmful as in dual users (i.e. users of both conventional 
tobacco cigarettes and e-cigarettes) (Table B). However, these respiratory, cardiovascular, and oral 
disease findings were not consistent across all studies.  
The evidence map featured few reported benefits (Table C). The most common benefits, which were 
reported by a small number of heavy smokers of conventional tobacco cigarettes, were smoking 
cessation and smoking reduction. Alongside this map, two systematic reviews on e-cigarettes were 
completed by the HRB. In the first review, we found that e-cigarettes were not more effective than 
approved nicotine replacement therapies (NRTs), which questions the need for e-cigarettes as a 
smoking cessation intervention. In the second review, we found that e-cigarettes were associated 
with initiation of conventional cigarette smoking among adolescents, which identifies a potentially 
serious harm.  
In addition, we note that many studies showed that dual use of both e-cigarettes and conventional 
tobacco cigarettes was not less harmful than smoking conventional tobacco cigarettes alone, thereby 
raising questions about the smoking reduction benefit of e-cigarettes.  
Generally, our thematic findings align with the high-level findings of six reviews and have some 
contrasting findings with a seventh systematic review. Given the time gap between the existing 
systematic reviews and our mapping exercise, we identified additional recent papers covering oral 






Table A Possible e-cigarette-related negative outcomes, mapped by study design and by adapted 
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Table B Possible e-cigarette-related harms, but less harmful than those related to conventional 
tobacco cigarettes, mapped by study design and by adapted Academies of Sciences’ umbrella terms 
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Table C Possible e-cigarette-related beneficial outcomes, mapped by study design and by adapted 
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Cancers Possible 
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Oral diseases Possible 
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benefits       1 
 
The peer-reviewed published studies were drawn from all over the Globe, with the highest number 
from the USA, followed by Italy. The study participants were mainly adults. However, young children 
were common in studies examining injuries and poisonings. Never-smokers were also observed to use 
e-cigarettes.  
The study designs were a mix of randomised controlled trials, randomised and non-randomised 
crossover trials including Latin square trials, and non-randomised before and after studies. The 
follow-up periods in the mapped studies ranged from minutes to 24 months and did not have a 
sufficient timeframe to detect chronic disease outcomes such as cardiovascular diseases, cancers, or 
chronic respiratory diseases. For example, a total of 8 (9%) of the 86 interventional trials reported on 
an exposure outcome effect measured between 12 weeks and 24 months, while the remaining 78 
trials reported on outcomes measured within 8 weeks or less. It is important to note that e-cigarettes 
and their e-liquids were not a standard intervention in the included studies; rather, they are an 
umbrella term for a device that delivers nicotine and other products including flavourings. By 2017, 
611 brands of e-cigarette products had been developed, and to generalise findings from the 
randomised trial of one specific e-cigarette as an assessment of the expected impact of all e-cigarette 
types discounts the differences in the chemical composition of various e-cigarette brands and types. 
The content of the e-liquids was another confounding factor due to the variation in nicotine dosages 
and other contents. To date, of the 86 trials examining health benefits and harms in people included 
in the map, only 62 trials identified the device used and only 39 e-cigarette devices were tested out of 
Not more effective than NRTs 
No benefits identified 
No benefits identified 
No benefits identified 
No benefits identified 





more than 611 brands ever available on the market, which gives a sense of the small number of e-
cigarette devices that have been tested in trials involving people, and the small number of 
corresponding research papers published in peer-reviewed literature. A total of 9% of the 
interventional trials were completed by the e-cigarette industry. Care must be taken in the area of e-
cigarettes when generalising findings from the studied populations to other populations with 
different characteristics, and when generalising findings from populations where different kinds of 
interventions (e-cigarettes) were used. Most of the observational and interventional studies identify 
associations between e-cigarettes and the outcomes of interest, but these associations do not prove 
causality. 
Heat-not-burn tobacco products summary map 
Heat-not-burn tobacco products were not authorised for sale in Ireland by February 2020. The 28 
included published, peer-reviewed studies on possible harms and benefits of heat-not-burn tobacco 
products have been mapped by study design and by the adapted umbrella terms identified by 
Academies of Sciences’. There were two case reports and one cross-sectional survey covering these 
products. There were 25 interventional trials, 23 of which were completed by authors working in the 
tobacco industry and 2 of which were completed by authors in universities, indicating a dearth of 
independent research on heat-not-burn tobacco products. Among the 25 published interventional 
trial papers, just under half (12) reported biomarkers of exposure to harmful or potentially harmful 
smoke constituents (Table D). Eight interventional trial papers reported outcomes of cardiovascular 
health, and this represented the second most reported area of interest. One crossover interventional 
trial paper reported on measures of respiratory function, and four interventional trial papers reported 
on measures of dependence and abuse liability.  
The possible harm and benefit outcomes measured under the ‘dependence and abuse liability’ 
heading included cigarette craving/urge to smoke, withdrawal symptoms, nicotine and its 
metabolites, and various measures of carbon monoxide. The outcomes measured under the 
‘cardiovascular diseases’ heading included a wide range of biomarkers that may indicate organ and 
tissue damage. The reported respiratory outcomes included measures of airway resistance, lung 
function, and lung volume. The outcomes measured under the ‘exposure to heat-not-burn toxins’ 
heading were an extensive array of harmful or potentially harmful constituents of conventional 
tobacco cigarette smoke. 
The overall conclusions of the primary study authors were that the impacts of heat-not-burn tobacco 
constituents measured for cardiovascular and respiratory health and well-being may be less harmful 
than those of conventional tobacco cigarettes, but more harmful than those observed in study 
participants who abstained from smoking. In a similar fashion, lower levels of the measured harmful 
and potentially harmful constituents in cigarette smoke were present in heat-not-burn tobacco 
product users than in smokers of conventional combustible tobacco cigarettes, but the lowest levels 
of these harmful and potentially harmful constituents were observed in study participants who 
abstained from smoking during the study period. However, the long-term consequences of these 
outcomes cannot be addressed by the study designs examined in this mapping exercise.  
Our findings on heat-not-burn tobacco products agreed with two recent systematic reviews, in that, 
the measured harmful and potentially harmful constituent levels were lower in heat-not-burn 
tobacco product users relative to the conventional cigarette user and that most research on heat-not 
burn tobacco products was industry funded. The review by the World Health Organization concluded 
the there is insufficient evidence to conclude that heat-not-burn tobacco products are less harmful 
than conventional tobacco cigarettes. In fact, the Organization concluded that the there is insufficient 
evidence to deem that heat-not-burn tobacco products are less harmful than conventional tobacco 
cigarettes. The Organization goes on to say that there are reservations, as heat-not-burn tobacco 
products may expose users to lower levels of some toxicants than conventional tobacco cigarettes, 
but they may also expose users to higher levels of other toxicants, and it is not clear how this 






Table D Possible heat-not-burn tobacco product-related negative outcomes, mapped by study 
design and by adapted Academies of Sciences’ umbrella terms 
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No studies  No 
studies  
No studies  Perceived 
stress (N=1) 







No studies  No 
studies  
No studies  No studies  No studies  No studies  Indicators of 
cardiovascular health 
(N=8) 
Cancers No studies  No 
studies  








No studies  No studies  No studies  No studies  Indicators of 
respiratory function 
(N=1) 
Oral diseases No studies  No 
studies  





No studies  No 
studies  
No studies  No studies  No studies  No studies  No studies  
Injuries  No studies  No 
studies  
No studies  No studies  No studies  No studies  No studies  
Poisonings No studies  No 
studies  




No studies  No 
studies  





In general, study participants were adults. However, there were some exceptions: adolescents were 
the subject of one cross-sectional study, and a 16-year-old male was the subject of one case report. 
Approximately half of the studies were conducted in Belgium, Italy, Poland, South Africa, the UK, and 
the USA, and approximately the same number were conducted in Asia (Japan and South Korea). The 
two case reports each described one individual’s experience of acute eosinophilic pneumonia; the 
cross-sectional survey reported findings from 60,040 participants, and the sample sizes in the 
remaining papers (all interventional trials) varied from 18 to 316 participants.  
The majority of trials were classified as randomised controlled trials, or crossover trials. The time 
frames of 24 of the 25 interventional trials were short; outcomes were gathered within a 10-day 
period or less. For the remaining trial, outcomes were gathered for 24 weeks. Biological measures 
were frequently gathered minutes or hours after exposure. The data collection time frames were 
adequate to report on transient effects following short-term heat-not-burn tobacco product use, but 
not the possible deleterious effects arising from long-term exposure. In general, the impact of heat-
not-burn tobacco product use on outcomes beyond the short trial timeframe parameters was not 
quantified. The mapped interventional trials’ follow-up periods were not long enough to detect heat-





diseases. No peer-reviewed studies on humans were published on cancers, oral diseases, or 
developmental and reproductive effects up to mid-November 2019. There were no acute poisonings 
or injuries as a result of heat-not-burn tobacco products. We note that the majority of trials reporting 
on this area have compared a small number of commercially available heat-not-burn tobacco 
products with a range of conventional combustible tobacco cigarettes, both releasing varying 
chemical yields. In a number of trials, comparisons have also been made with persons who have 
abstained from smoking for the trial duration or for a period during a crossover trial.  
It is important to note that heat-not-burn tobacco products were not standardised interventions (i.e. 
products), but rather that ‘heat-not-burn tobacco products’ is an umbrella term for devices with 
similar but not identical yields of tar, nicotine, and other products, such as carbon monoxide. There 
was variation in the types of devices examined, the chemical yield of the devices, and the trial 
comparator products used. Data on the chemical yield of the comparator conventional cigarette were 
not always available, as in several trials, participants were asked to bring and smoke their own 
preferred brand of conventional tobacco cigarettes.  
Long-term longitudinal cohort studies with detailed measures of exposure, specifically frequency of 
use and the chemical nature of the nicotine product used, are required in order to better understand 
if changes in the use of smoking-related products, such as the use of heat-not-burn tobacco products 
and e-cigarettes, have a positive or negative impact on later life health outcomes.  
Research gaps 
The reporting framework used in this mapping exercise allows a clear view of the published, peer-
reviewed, English-language research which has been undertaken to assess the impacts of e-cigarettes 
and heat-not-burn tobacco products on human health. The evidence map will serve as a framework 
for developing questions for scientific appraisal of the nature and direction of the observed 
relationship within different population groups and different clinical areas. The combination of the 
hierarchy of evidence and the adapted Academies of Sciences’ umbrella terms was a very useful 
method for categorising the retrieved papers. Presenting the papers in this way highlights that some 
areas are well described using epidemiological studies, but that there is a dearth of longitudinal 
cohort studies with well-designed protocols that capture the true effects of e-cigarettes and heat-not-
burn tobacco products. Long-term longitudinal cohort studies with detailed measures of exposure, 
specifically frequency of use and the chemical nature of the product used, are required in order to 
better understand if changes in the use of smoking-related products, such as the use of e-cigarettes 
and heat-not-burn tobacco products, have a positive or negative impact on later life health outcomes. 
The multitude of possible outcomes require targeted long-term cohort studies to answer research 
questions under all of the adapted Academies of Sciences’ umbrella terms in order to quantify 
outcome-specific differences between conventional cigarette smokers, e-cigarette users, heat-not-
burn tobacco product users, dual users of any combination of these product types, and non-users of 
any type of cigarette. In the absence of long-term studies, modelling of levels of biological markers for 
exposure to harmful or potentially harmful constituents in cigarette smoke may allow us to gain a 
preliminary understanding of some adverse effects of e-cigarettes and heat-not-burn tobacco 
products. At present, the USA, among other countries, is identifying the research needs, solutions, 
and funding requirements to progress an understanding of the health effects of e-cigarettes and heat-
not-burn tobacco products. It should be noted that there may be unknown harms which are yet to be 
identified. Some specific research areas that need to be examined thoroughly are the effects of 
deposits and accumulation of toxins from e-cigarettes and heat-not-burn tobacco products on 
respiratory, cardiovascular, neurological, and other body tissues; this will also require long-term 
studies examining the incidence of degenerative diseases and cancers among e-cigarette and heat-
not-burn tobacco product users. In addition, preliminary data indicate that a thorough examination of 
the effects of e-cigarettes and heat-not-burn tobacco products on embryos and newborns is required.  
There are four areas which we believe would enhance our understanding of the impacts not only of e-
cigarettes and heat-not-burn tobacco products, but also of other tobacco-related products that 
people can smoke, chew, or sniff. First, the comparison populations regarding smoking-related 





temperature at which the tobacco is heated for both the heat-not-burn tobacco products and the 
comparison conventional tobacco cigarettes needs to be closely examined and more clearly 
delineated in order to detect meaningful findings. Third, what, if any, difference do changes in levels 
of biomarkers of exposure to harmful or potentially harmful vapour or smoke constituents have on 
the subsequent development of associated deleterious outcomes needs to be understood. Fourth, 
there is a dearth of longitudinal information on specific populations where evidence on the impact of 







1.1 Policy background 
In 2013, the Department of Health’s Tobacco Policy Review Group published the report Tobacco Free 
Ireland, which set a target for Ireland to reduce smoking prevalence to less than 5% by 2025.2 
Tobacco Free Ireland was the first policy document to be launched under the Healthy Ireland 
framework, and it was endorsed by the Government. Achieving the target in the reduction of smoking 
prevalence would play a major role in realising the vision set out in Healthy Ireland.  
The Tobacco Free Ireland report identified tobacco-related harm reduction as a key issue for 
consideration.2 It specifically highlighted the role of electronic cigarettes (e-cigarettes) as a potential 
harm reduction strategy. Since the introduction of e-cigarettes in 2006, research has expanded on 
their potential benefits in terms of tobacco-related harm reduction and on the public health harms of 
e-cigarettes. This mapping exercise outlines what is known to date about e-cigarette benefits, harm 
reduction, and harms to humans, which will help to inform the Department of Health’s policy position 
with respect to e-cigarettes. 
The Department of Health asked the Health Research Board (HRB) to complete a programme of 
research and answer five research questions: 
1. What are the public health benefits and harms of e-cigarettes? 
2. What are the public health benefits and harms of heat-not-burn tobacco products? 
3. What is the efficacy of e-cigarettes in helping people who smoke to achieve abstinence (smoking 
cessation)? 
4. What is the efficacy of heat-not-burn tobacco products in helping people who smoke to achieve 
abstinence (smoking cessation)? 
5. Does e-cigarette use by adolescents who are cigarette naive at baseline lead to subsequent ciga-
rette smoking? 
1.2 Research questions 
The questions addressed in this mapping exercise are: 
3. What are the public health benefits and harms of e-cigarettes? 
4. What are the public health benefits and harms of heat-not-burn tobacco products? 
The HRB authors defined public health harms as both clinically diagnosed pathological outcomes 
(diagnosis of disease or injury) and damage or an injury to biological tissue which can have a short- or 
long-term outcome leading to disease. We defined public health benefits as when a substance, or 
activity improves health. 
When we use the term conventional tobacco cigarettes in the text, we mean conventional 








The aim of the background section is to provide an understanding of e-cigarettes. Due to time 
limitations, the background section on e-cigarette relies heavily on one high-quality peer-reviewed 
document by Academies of Sciences, Engineering, and Medicine and an infographic from the National 
Institute on Drug Abuse.  
It is generally accepted that e-cigarettes were introduced to Europe in 2006 and to the USA in 2007. 
The e-cigarette economy represents a burgeoning dynamic market with rapid product innovation. 
Currently, researchers group e-cigarette devices as belonging to one of four generations (Figure 1), 
reflecting changes in device models. Notably, many devices are now modifiable by users. As of 2014, 
466 different e-cigarette brands and 7,000 unique e-liquid flavours were reported to have been on 
sale on English language internet sites.3 Hsu et al. updated the inventory of websites in 2016-2017 
and they reported that 178 (38%) of the 466 brands identified in the 2013-2014 survey were no 
longer in operation as of July 2016, while 288 (62%) brands were still available. The authors identified 
145 additional brands giving a total of 433 brands in 2017.4  In addition, they report that the number 




Figure 1 Examples of e-cigarettes currently available on the market e-cigarettes 
(Image reproduced from the National Institute on Drug Abuse)5  
2.1.1 E-cigarette characteristics 
E-cigarettes are battery-operated devices with an element and a liquid-containing reservoir that is 
heated to allow people to inhale an aerosol. The aerosol arising from the carrier solvents 
(humectants) typically (although not always) contains nicotine, flavourings, and other chemicals. 
Other terms used to identify e-cigarettes include e-vaporisers, or electronic nicotine delivery systems 
(ENDS), e-hookahs, hookah pens, vapers, vape pens, and mods (short for modifiable devices). Mods 
are customisable e-cigarettes and contain more powerful vaporisers than earlier e-cigarette models. 
Although there are variations in the appearance of e-cigarettes, the National Institute on Drug Abuse 
has reported that regardless of their design and appearance, the devices generally operate in a similar 






E-cigarettes can resemble conventional tobacco cigarettes (cig-a-likes), cigars, or pipes. However, 
they can also resemble everyday items such as pens and USB memory sticks or they can be designed 
to appeal to specific sub-groups and cultural identities. 
The primary components of e-cigarette are: 
• A cartridge or reservoir, which holds a liquid solution (e-liquid or e-juice) containing varying 
amounts of nicotine, flavourings, and other chemicals 
• A heating element (atomiser or cartomisers) 
• A power source (usually a battery) 
• A mouthpiece that the person uses to inhale 
In many e-cigarettes, puffing activates the battery-powered heating device, which vaporises the liquid 
in the cartridge.5 
2.1.2 E-cigarette liquids 
The Academies of Sciences have stated that the types and concentrations of chemical constituents 
produced in the e-cigarette vapour depend not just on the formulation and flavour of the e-liquid but 
also on the voltage used.6 There are thousands of e-liquid brands available; coupled with the rate of 
market expansion and the time required to study the impact of individual products, a systematic 
understanding of the chemical contents of the aerosols arising from different brands and their 
relationship with health outcomes is not yet available.  
The Health and Medicine Division of the Academies of Sciences 6 has identified e-cigarettes and e-
liquids as having the following constituents: 
• Humectants (delivery solvents usually propylene glycol and vegetable glycerine) 
• Flavourings 
• Carbonyl compounds including dicarbonyls and hydroxycarbonyls 
• Minor tobacco alkaloids 
• Free radicals and reactive oxygen species 
• Tobacco-specific nitrosamines 
• Other toxicants such as volatile organic compounds, polycyclic aromatic carbons, 
• Metals 
2.1.3 E-cigarette carrier compounds 
The Academies of Sciences’ publication, Public Health Consequences of E-Cigarettes,6 citing other 
authors, reported that most e-cigarette solvents have been reported to contain propylene glycol and 
glycerol as the carrier compounds, but newer products are reported to contain a nicotine base and a 
weak organic acid that forms a nicotine salt. The Academies of Sciences stated that these devices are 
patterned after technology described by Rose et al.(2008). These nicotine salt forming products, 
JUUL™ by JUUL Labs and P3L by Philip Morris Products, have reported chemical compositions as 
follows. The JUUL™ pods (i.e. prefilled cartridges) contain benzoic acid and nicotine in a 0.97–1 molar 
concentration ratio, indicating that benzoic acid is a major ingredient of this device. The nicotine salt 
(nicotine benzoate) forms when the device is activated and is delivered to the user in an aerosol form. 
The P3L stores its nicotine base and lactic acid in separate cavities, which on activation and controlled 
heating, release the nicotine salt (nicotine lactate) as an aerosol. Both products indicate the potential 
use of nicotine salts to deliver nicotine. In addition to variations in chemical composition arising from 
the constituent parts of e-liquid and voltage strength, distinctions in sensory perceptions, both of 
feeling and taste, arise from e-liquid constituent variations. Propylene glycol, thinner than glycerol, 





is reported to be ‘smoother’ than propylene glycol. These are all factors which influence the appeal of 
specific e-cigarettes.6 
2.1.4 Flavourings 
There were 7,764 unique e-liquid flavours identified as available to e-cigarette users as of 2014.3 In 
Hsu et al. published update in 2016-2017, they report that the number of flavourings more than 
doubled to 15,586 flavours.4 Little is known about the health implications of their presence. The 
Academies of Sciences publication, Public Health Consequences of E-Cigarettes,6 citing other authors, 
reported that flavouring components are often not included in the ingredient lists of e-cigarette 
products. According to the Academies of Sciences, the United States Flavor and Extract 
Manufacturers Association considers many flavours as being generally safe in food products for 
ingestion and at recommended levels of intended use, but these ingredients are not safety-tested for 
exposure routes such as inhalation. Therefore, the effects of these chemicals when aerosolised and 
inhaled is not known. 
2.1.5 Nicotine intake and absorption 
The Academies of Sciences’ report Public Health Consequences of E-Cigarettes6 included an overview 
of nicotine intake and absorption based on the findings of four research studies. They reported that 
nicotine makes up approximately 95% of the alkaloid content of conventional tobacco cigarettes and 
1.5% by weight in cigarette tobacco.6 The nicotine content of commercially available e-liquids varies 
from low to high – it is commonly 0.3–5% by volume.  
The Academies of Sciences reported that following e-cigarette activation, nicotine is released from 
the e-liquid on the aerosol particles and inhaled.6 The Academies of Sciences, based on Benowitz 
2009, described the process by which nicotine bound to particles drawn into the mouth and upper 
airways is absorbed into the circulation and even more rapidly absorbed into the pulmonary venous 
circulation as the particles reach the lungs. Absorption in the mouth and upper airways is thought to 
account for the sensory effects of nicotine in the mouth and throat. Following nicotine entry into the 
circulation, it passes into the arterial circulation and moves across the blood–brain barrier into the 
brain, diffusing readily in brain tissue and binding stereoselectively with nicotinic cholinergic 
receptors. This release of multiple neurotransmitters in the brain generates dopamine, which is 
related to nicotine’s pharmacodynamics associated with pleasure and appetite suppression, in the 
mesolimbic area, the frontal cortex, and the corpus striatum. The pleasurable dopamine effect is 
regarded as a critical role in nicotine’s reinforcing effects. Other nicotine-induced behaviours are 
mediated by a variety of neurotransmitters that are also released, including norepinephrine (arousal, 
appetite suppression), acetylcholine (arousal, cognitive enhancement), serotonin (mood modulation, 
appetite suppression), gamma-aminobutyric acid (reduction of anxiety and tension), glutamate 
(learning, memory enhancement), and endorphins (reduction of anxiety and tension).6 
The Academies of Sciences’ publication, Public Health Consequences of E-Cigarettes,6 based on two 
research studies, also reported that nicotine addiction develops as a neurobiological adaptation to 
chronic nicotine exposure. One nicotine dependence characteristic is the emergence of withdrawal 
symptoms on abrupt cessation of nicotine administration. Tolerance (neuroadaptation) to nicotine 
develops for some nicotinic effects on repeated exposure to nicotine. The number of nicotinic 
cholinergic receptors binding sites in the brain increases, which is thought to represent upregulation 
in the response of nicotine-mediated desensitisation of receptors. During periods of abstinence in 
chronic smokers, such as during night-time sleep, previously desensitised a4b2 nicotinic cholinergic 
receptors become unoccupied and recover to a responsive state. Abstinence symptoms are believed 
to develop when these nicotinic cholinergic receptors revert to this unoccupied and responsive state. 
Craving and withdrawal symptoms are alleviated through nicotine binding and desensitisation of the 
receptors. Stimulation of these globally expressed nicotinic cholinergic receptors causes wide-ranging 
physiological effects such as nicotine intoxication syndrome. Symptoms of nicotine intoxication 
syndrome include nausea and vomiting. More severe poisoning can progress to diarrhoea, increased 
salivation and respiratory secretions, bradycardia, seizures, and respiratory depression. The rapid 
development of tolerance to nicotine with repeated administration helps counter the development of 





2.1.6 Pharmacokinetics and pharmacodynamics of nicotine 
In the Public Health Consequences of E-Cigarettes, the Academies of Sciences completed an overview 
of the pharmacokinetics and pharmacodynamics of nicotine by synthesising the findings of 10 
research studies.6 They reported that the amount and mode of nicotine intake influences the 
addictiveness of a tobacco product. The abuse liability of tobacco products increases with higher 
delivery, faster rate of absorption, and higher blood nicotine concentrations. The dose and route of 
administration influences the release of nicotine in the brain and thus the pharmacological effects. 
Nicotine in tobacco smoke is rapidly absorbed into the pulmonary venous circulation once it reaches 
the small airways and alveolar region of the lungs, progressing to the left ventricle of the heart, the 
systemic arterial circulation, and finally the brain. High levels of nicotine reach the brain 
approximately 15 seconds after a puff on a conventional cigarette. This rapid increase in nicotine 
levels in the brain leads to activation of the dopaminergic reward system, producing rapid 
behavioural reinforcement. This therefore makes smoking, over products such as patches and gums, 
the most reinforcing and dependence-producing form of nicotine administration.6 
From a review of literature, the Academies of Sciences found that nicotine delivery from e-cigarettes 
through the pulmonary route is similar to delivery via conventional tobacco cigarettes and has a 
similar plasma nicotine profile.6 This potential high and rapid nicotine delivery can be expected to 
produce nicotine-related psychoactive effects that can cause or maintain nicotine dependence. The 
receptor-binding capacity of nicotine in the brain is higher in smokers compared with non-smokers, 
due to the upregulation of nicotinic cholinergic receptors in the brains of smokers. Nicotine is rapidly 
delivered and absorbed when smoking, and as such, blood nicotine concentration rises while smoking 
and peaks at the end of smoking. Nicotine levels decline rapidly during the 20 minutes following 
smoking as nicotine distributes to tissue, with a distribution half-life of 8 minutes. The elimination 
half-life of nicotine is approximately 2 hours. Thus, nicotine from regular smoking accumulates in the 
body during waking hours. Therefore, while smoking results in exposure to nicotine in an intermittent 
and transient manner, exposure lasts 24 hours per day. Exposure leads to the persistent presence of 
nicotine in the brain, with resulting structural and functional changes in nicotinic receptors and in the 
intracellular processes of neuroadaptation.6 
2.1.7 Metals 
The Academies of Sciences’ publication, Public Health Consequences of E-Cigarettes,6 identified eight 
studies reporting on toxic metals in e-liquid emissions, including lead, nickel, and chromium. The 
report also noted that toxic metals may originate from any of several parts of an e-cigarette device. 
This includes the metallic coil that heats the e-liquid to produce the aerosol inhaled by the user, as 
well as seams and wires in the devices. Alloys found in e-cigarettes include kanthal, which contains 
aluminium, chromium, and iron; Ni-200, made of nickel; and nichrome, which comprises chromium 
and nickel. Furthermore, metals such as tin have been found in the joints or seams. Aside from the 
metals in the device itself, e-liquids may also contain metals, and some e-liquid solutions have been 
reported to contain arsenic.6 
2.2 Heat-not-burn tobacco products 
The aim of the background section is to provide an understanding of heat-not-burn tobacco products. 
2.2.1 Product types 
Heat-not-burn devices appear to have arrived on the American market in 1988, when R. J. Reynolds 
introduced the Premier™.7 This product was later withdrawn. A related product, the Eclipse, was test-
marketed in 1996 and reintroduced with a modified filter in 1997.8 Since then, several other brands 
have been successfully introduced to the market. The WHO heated tobacco products (also known as 
heat-not-burn devices) market monitoring information sheet9 notes that early versions of heat-not-
burn devices were developed in the early 1980s, and that the three main manufacturers in this sector 
are Philip Morris International, Japan Tobacco International and British American Tobacco. It is also 
noted in this 2018 document that sales figures for heated tobacco products were expected to reach 





The earlier versions of heat-not-burn devices were developed further and results in many variations 
on the design (Table 1). The iQOS, developed by Philip Morris International, was launched in 2014 in 
Japan10 and by 2018 was available in 35 countries.9 Caputi notes that iQOS had captured 2.4% of 
Tokyo’s market share for tobacco within 6 months of release.11 Other examples of these product 
types include glo by British American Tobacco, launched in Japan in 2016, 12 and ModelOne, released 
by Ploom in 2010.13 Ploom later became Pax Labs. Ploom vaporisers, by Japan Tobacco International, 
were originally introduced in 201314 and are considered to be loose-leaf tobacco vaporisers,15 while 
Ploom Tech, also by Japan Tobacco International were launched in 2016.16 The Korea Tobacco and 
Ginseng Corporation put lil on the market in 2017.17 Imperial Brands launched a heat-not-burn device 
(Pulze) in Japan in 2019.18 
Lopez (2016) notes that there has been much less study of heat-not-burn devices than there has of e-
cigarettes.15 
Table 1 Heat-not-burn tobacco product types, manufacturer, and year of launch 
Product Manufacturer  Year launched 
ModelOne Ploom (later Pax Labs) 2010 
Ploom vaporizers Japan Tobacco International 2013 
IQOS Philip Morris International 2014 
glo iFuse British American Tobacco 2015 
Ploom tech Japan Tobacco International 2016 
glo  British American Tobacco 2016 
lil Korea Tobacco & Ginseng Corporation 2017 
TEEPS Philip Morris International 2017 
Pulze Imperial Brands 2019 
2.2.2 Product characteristics 
The primary characteristic of the heat-not-burn device is that the tobacco in the device is heated, 
rather than undergoing combustion. The Committees on Toxicity, Carcinogenicity and Mutagenicity of 
Chemicals in Food, Consumer Products and the Environment describe three basic types of heat-not-
burn mechanisms.19 These are:  
• Direct heating of processed tobacco to produce a vapour,  
• Heating of processed tobacco in a vaporiser, and 
• Passing of vapour (from non-tobacco sources) over processed tobacco in order to give the vapour 
a flavour. 
Mallock et al. (2019) notes that while in typical cigarettes, combustion takes place at 700-950°C, in 
heat-not-burn devices heating of up to 350°C results in vapour or aerosol.20. The temperature of the 
stick is controlled at 150-350° C without combustion, fire, ash, or smoke (Figure 2).20 Direct heating of 
the tobacco may be carried out by heating disposable tobacco sticks via a thin metallic blade. 
The heat-not-burn tobacco product comprises three components, each with a different function. 
These are the tobacco stick, a pen-like heater (or holder) and the charger. The tobacco stick, which 
contains processed tobacco, is inserted in the holder and is heated by a controlled electrical element 
energised by a charge. The emissions are inhaled via a mouthpiece. In their review, Dautzenberg and 
Dautzenberg21 noted that some devices were time-limited – the user was required to inhale within a 
set period (often 3.5 minutes to 10 minutes) before the device would automatically turn off. This was 
designed, they state, to maintain peaks of nicotine and upregulate nicotinic receptors.  
In contrast to e-cigarettes, heat-not-burn tobacco products do not vaporise liquid-containing 
flavourings, propylene glycol, or vegetable glycerol.22 In contrast to conventional tobacco cigarettes, 
heat-not-burn tobacco products heat, rather than burn, tobacco and thus are purported to be less 





To date, independent reporting on the constituent properties of heat-not-burn tobacco products do 
not seem to be available, although Simonavicius23 notes the preparation of a review by committees 
advising the UK government which excluded research funded by producers of heat-not-burn 
devices.19 However, analysis of contents of smoke from heat-not-burn tobacco products compared 
with that of conventional tobacco cigarettes reported a range of volatile organic compounds (such as 
acetaldehyde, acetone, acroleine, benzaldehyde, crotonaldehyde, formaldehyde, isovaleraldehyde), 
polycyclic aromatic hydrocarbons (such as naphthalene, acenaphthylene, acenaphthene, fluorene) 
and inorganic compounds (such as nitric oxide) in the mainstream smoked. 24 
 
Figure 2 Conventional cigarette temperature versus 3 types of heat-not-burn products with their 
peak temperatures 
(Image reproduced from Mallock et al.20) 
2.3 Regulation of e-cigarettes and heat-not-burn products 
2.3.1 Europe 
In February 2014, the European Parliament approved new regulations for tobacco products, including 
e-cigarettes, prohibiting the sale of e-cigarettes to persons under 18 years.25 The Tobacco Products 
Directive (2014/40/EU) was issued on 19 May 2014 and became applicable in European Union (EU) 
countries on 20 May 2016. The Directive lays down rules governing the manufacture, presentation 
and sale of tobacco and related products including e-cigarettes. In addition to prohibiting sales to 
persons under 18 years, Article 20 of the new regulations which prohibit promotional elements on e-
cigarette packaging, and cross-border advertising and promotion of e-cigarettes, sets limits on 
maximum concentrations of nicotine in liquids, limits maximum volumes of liquid that can be sold in a 
single container, requires childproof and tamper-proof packaging of liquid, sets requirements on 
purity of ingredients, requires that the devices deliver consistent doses of vapour, requires disclosure 
of ingredients and nicotine content, and allows member state regulators to act if the regulations are 
violated. In addition, warning labels can be placed on e-cigarettes. The regulations do not ban vaping 
in public places.25 
2.3.2 Ireland 
According to the Health Services Executive website, the Minister for Health in Ireland signed the 
Regulations transposing the EU Tobacco Products Directive into Irish law.26 On 20 May 2016, the 





2016 (S.I. No. 271 of 2016) (with Part 5 on electronic cigarettes and herbal products for smoking) 
came into force and, in September 2018, the amended Regulations (S.I. No. 365 of 2018)(with 
regulations on the sale of e-liquids) came into effect.26 In addition, Ireland is in the process of 
enacting legislation to license retailers of e-cigarettes and introducing a minimum age of sale of 18 
years. 
Manufacturers and importers of tobacco products, e- cigarettes, refill containers, and other tobacco-
related products must apply for permission to market their products by submitting key information 
on the nature of these products to authorities in the Member States of the European Union.26 In a 
personal communication to the research team, the Revenue Commissioners (in Ireland) reported that 
applications for the marketing of e-cigarettes have been made and approved, but to date, no heat-
not-burn tobacco products have been authorised for sale in Ireland. [Personal correspondence, 
Revenue Commissioners Ireland Date and European Union, April 2020]. Ireland’s Revenue 
Commissions also state that its systems do not record data on the brands of e-cigarette retailed in 
Ireland. With respect to e-cigarettes, there is no independent overview of brands sold in Ireland. 
This mapping exercise presents findings from peer review journal articles. The findings relate to the 
product(s) examined in these papers. These findings may not apply to other e-cigarette or heat-not-
burn products unless the other products have the exact same chemical composition and/or the 
device has the same design.  
2.4 Research needs 
Given the relatively short time that e-cigarettes have been in use, the evidence base regarding their 
effects is limited. In 2015, The Academies of Sciences’ publication,6 citing Walton et al.(2015) 
reported that there was enormous need for more evidence on e-cigarette devices, constituents, and 
exposures.  
Heat-not-burn tobacco products have been in use since 1988 and only a small range of the marketed 
products have been evaluated in peer reviewed published articles. Most published articles are 
authored by industry and provide an incomplete assessment of their impact on health outcomes 
compared to conventional tobacco cigarettes or non-smokers. In addition, there are limitations 
regarding the generalisability of findings on these products due to differences between products.  
This research project sought to map the current available English language research on e-cigarettes 
and heat-not-burn tobacco products in humans, aligning the findings with the identified areas of 








3.1 Conceptual methods and coding framework 
Mapping exercises provide an overview of the nature and extent of the available evidence, with 
limited description of the data. A standard systematic search approach was used for this programme 
of research including the mapping exercise. Published studies and other material were sourced via 
database and supplemental searches. Articles were double-screened until a final core set of relevant 
articles that would speak to the five research questions in Section 1.1 was agreed upon.  
The information to answer the two questions pertaining to this mapping exercise, the harms and 
benefits of e-cigarettes and heat-not-burn tobacco products, was identified in a variety of 
epidemiological study designs, including case reports, case series, cross-sectional surveys, case-
control studies, longitudinal cohort studies, and interventional trials (with the addition of surveillance 
reports).27 These study designs are used to outline the differing levels of evidence in existing research 
(Figure 3). The purpose of coding the included papers by epidemiological study design was to allow 
readers consider each article taking account of the strengths and limitations of the study design 
employed to complete the research. Descriptive study designs are useful to describe health outcomes 
by person, place, and time, while observational studies are useful for identifying associations between 
exposure and outcomes. Randomised control trials are useful to determine the incidence of outcomes 
in an intervention group compared to a control or gold standard intervention group. Under certain 
conditions, randomised control trials are said to provide the highest level of evidence in primary 
research studies and may meet the criteria for causality. The Bradford-Hill criteria for causality are: 
strength of association or effect size, consistency of findings across studies known as reproducibility, 
biological credibility (plausibility), specificity (other explanations), a temporal relationship (exposure 
occurred before the outcome) and biological gradient known as a dose-response relationship, 
coherence (consistent with other lines of evidence); and analogy (similar agents act similarly).28 
 
Figure 3 Hierarchy of evidence employed in mapping exercise 
As the number of articles (n=6510) found was extensive, it was decided to map the data by study 
design and then by outcome (harm, benefit, or outcome measurement) in order to give an accurate 
picture of current evidence for the possible harms and benefits of e-cigarettes and heat-not-burn 
tobacco products (Figures 3 and 4).  
Following examination of the full text papers, the lead researcher (AMcC) noted that there was a wide 
array of reported outcomes which included: clinical pathological outcomes (such as injuries, poisoning 


















cholesterol), organ functionality (such as forced vital capacity, forced expiratory volume in the first 
second, and forced expiratory ratio) and measures of chemical toxicity (such as carbon monoxide, 
nicotine, metals, volatile organic compounds, tobacco-specific smoking-related carcinogens). The 
health outcomes would need to be categorised using an acceptable coding framework. Coding 
frameworks for the various measures of, or influences on, health include volumes such as the 
International Classification of Diseases (ICD)29 and the Medical Dictionary for Regulatory Activities 
(MedDRA Medical Coding).30 These coding frameworks were considered, but the time requirement to 
code the identified outcomes would be prohibitive. Google searches were undertaken to identify if 
other reporting frameworks had been adopted or advocated taking account of the observed diversity 
of findings. Websites of the World Health Organization, federal-level health and regulatory 
organisations of Australia, Canada and the United States of America (USA), the European Union (EU) 
and the United Kingdom (UK) were searched. AMcC identified the Public Health Consequences of E-
Cigarettes by the Academies of Sciences in the USA as a viable reporting framework.6 Outcomes 
arising from smoking conventional tobacco cigarettes and other nicotine products can be grouped 
under umbrella terms identified by the Academies of Sciences: dependence and abuse liability; 
cardiovascular diseases; cancers; respiratory diseases; oral diseases; developmental and reproductive 
effects; and injuries and poisonings.6 The authors of this mapping exercise added two further 
headings – exposure to e-cigarette toxins; and other outcomes – in order to categorise literature that 
did not align under the existing headings. Harms and benefits could be the result of either use of, or 
exposure to, e-cigarettes or e-liquid or heat-not-burn tobacco products (Figure 4). 
 
Figure 4 Adapted Academies of Sciences’ framework 
3.2 Inclusion and exclusion criteria 
The identification of the public health harms and benefits of e-cigarettes and heat-not-burn products 
required inclusion of quantitative epidemiological studies on the human population specifically case 
reports, case series, cross-sectional surveys, case-control studies, longitudinal cohort studies, and 
interventional trials. One additional publication type, surveillance reports, which did not fit within the 
classic epidemiologic study design framework were included in this work. Surveillance reports, 
disseminated findings from the systematic collection and analysis of health events, allow for planning, 
implementation, and evaluation of public health programmes. They provide a picture on the current 
incidence of events which merit a public health appraisal to identify possible harms or benefits if e-
cigarettes.  
National Academies of Sciences, 
Engineering, and Medicine 















Publication types to be excluded were: 
• Letters (except for primary study-type letters) 
• Systematic reviews 
• Meeting abstracts 
• Summary reviews and commentaries, and 
• Review and study protocols. 
Study types and topics to be excluded were: 
• News items 
• Editorials 
• Validation of diagnostic tests 
• Animal studies 
• In vitro papers 
• Cell line studies 
• Chemistry 
• Articles on puffing topography 
• Drug-taking using e-cigarette devices 
• Development of biomarker measurement 
• Measurement of nicotine levels in non-clinical studies on the devices used 
• Occupational safety standards 
• Regulation of devices 
• User perceptions 
• Studies on taste (without harms) 
• Prevalence 
• Marketing 
• Economics, and 
• Modelling. 
The date limits used were 2005–2019 for e-cigarettes and 1988–2019 for heat-not-burn tobacco 
products (reflecting their respective introduction dates). While versions of these products had been 
introduced at different timepoints, these are considered the introduction dates for the products as 
they are currently understood. 
No language limit was imposed initially (apart from the implicit limit of using databases that index 
primarily English-language research). However, on immersion in the full extent of the topic, it became 
clear that a rudimentary translation of non-English-language articles would not be adequate to 
understand such technical material and there would not be time or resources to have all the non-
English results translated professionally within the time limit of the review. Thus, reluctantly, non-





the authors are aware that a body of research published in other languages exists which could add to 
the body of literature being mapped. 
Where duplicate articles occurred, only one of the two articles was included. Despite ‘deduplicating’ 
the articles prior to screening, some duplicates were noted at ‘title and abstract’ and at full-text 
screening stages. These are likely to have got through the deduplication process due to inaccurate or 
incomplete information in some of the search fields, for example, wrong or missing titles or authors, 
missing digital object identifiers, or other information types. 
Table 2 presents the population, intervention (or exposure), comparator, or outcome (PICO) for the 
two questions regarding the benefits and harms of e-cigarettes and heat-not-burn tobacco products 
answered in this mapping exercise. 
Table 2 Population, intervention (exposure), comparator, or outcome for mapping exercise 
Question E-cigarettes benefits and harms Heat-not-burn tobacco 
products benefits and harms 
Population All human subjects  All human subjects 
Intervention or exposure E-cigarettes Heat-not-burn tobacco products 
Comparator None/any, including other e-
cigarette users with and without 
nicotine, conventional 
combustible tobacco cigarette 
smokers, non-smokers 
None/any, including other e-
cigarette users with and without 
nicotine, conventional 
combustible tobacco cigarette 
smokers, non-smokers 
Outcome Any public benefits or medical 
harms to individuals or the 
population, including clinical 
pathology (disease and injury) 
and/or measures of organ 
function, levels of toxicants 
Any public benefits or medical 
harms to individuals or the 
population, including clinical 
pathology (disease and injury) 
and/or measures of organ 
function, levels of toxicants 
Study type All epidemiology study types 
and surveillance system related 
papers 
All epidemiology study types 
and surveillance systems 
Exclusion criteria post-
screening 
Non-English-language articles Non-English-language articles 
Search dates 2005–2019 1988–2019 
 
We defined public health harms as both clinically diagnosed pathological outcomes (diagnosis of 
disease or injury) and damage or an injury to biological tissue that can have a short- or long-term 
outcome, leading to disease. 
We defined public health benefits as when a substance, or activity improves health.  
Harms and benefits could be the result of either use of, or exposure to, e-cigarettes or e-liquid or 
heat-not- burn products. 
3.3 Information searches 
Following scoping searches in late March 2019 using Ovid MEDLINE and Ovid PsycINFO, and the 
search engine Google, a search plan was designed by the information specialist (CL) to capture 
relevant studies and other data. The plan included literature searches using bibliographic databases, 
registries, repositories, and search engines. Supplemental searches were planned and carried out, 
including forward and backward citation searching of recent systematic reviews and authoritative 
reports. Follow-up searches of Ovid MEDLINE were scheduled to be carried out after the initial main 





The initial database searches were carried out from 4 to 10 April 2019. These results were combined 
using EndNote X7, and were uploaded to EPPI-Reviewer 4 (V. 4.11.0.0).31 Subsequent supplemental 
searches were carried out in August, October, and November 2019. In the subsequent supplementary 
database searches, due to resource constraints, searching was limited to Ovid MEDLINE.  
3.3.1 Bibliographic databases 
The primary database searches were carried out in April 2019. The databases included were: 
• Ovid MEDLINE (Ovid MEDLINE® and Epub Ahead of Print, In-Process & Other Non-Indexed 
Citations, Daily and Versions® 1946 to April 12, 2019) 
• Elsevier Embase 
• Ovid PsycINFO 
• Wiley Cochrane Database of Systematic Reviews 
• Wiley Cochrane Central Register of Controlled Trials 
• PAHO/WHO/Bireme LILACS (including the databases LILACS, IBECS, CUMED, BDENF – Nursing, 
BBO – Dentistry, WHO IRIS, PAHO IRIS, Index Psychology – Scientific journals and MedCarib), and 
• PROSPERO international prospective register for systematic reviews (Centre for Reviews and 
Dissemination, University of York). 
• Search engine: Google Scholar 
Peer review of the search strategy by another information specialist, as recommended in the PRESS 
Peer Review of Electronic Search Strategies: 2015 Guideline Statement,32 was not carried out, as 
resources were unavailable when conducting the searches. However, every effort was made by the 
information specialist to critically appraise the search strategies using the checklist outlined in the 
PRESS guidelines in order to follow the PRESS recommendations. The results of the April 2019 search 
were screened for inclusion by two researchers (AMcC and DOB) and the information specialist (CL). 
In August 2019, a two-part supplemental search was carried out. This included a literature search 
using Ovid MEDLINE (with the same search terms as the original search but limited to recent articles), 
and a citation search based on core reviews and reports. The list of reports and reviews used for this 
search is included in Appendix 1. The review titles were sourced by combining the Ovid MEDLINE e-
cigarette and heat-not-burn tobacco product searches with a customised version of the Ovid Expert 
Searches systematic review filter and then limiting them to publications from the previous five years. 
The titles were screened for clinical relevance in accordance with PICO (e.g. smoking cessation, 
harms, benefits, and initiation) by the information specialist (CL), and titles were confirmed for 
inclusion with the lead author (AMcC). The results from these searches were added to EndNote X7 
and screened initially for duplicates, then for relevance using the PICO mapping exercise (Table 2), 
and then for originality (whether they were already included in the original search results). 
Further simple supplemental searches were carried out on the 11th October 2019 and the 18th 
November 2019 using Ovid MEDLINE, with the same search terms as before. The results were 
screened initially by the information specialist to eliminate articles that had already been screened in 
other searches, and to eliminate highly irrelevant articles (e.g. articles not relating to e-cigarettes or 
heat-not-burn tobacco products). The remaining results were screened by the lead researcher (AMcC) 
and any relevant articles were retained. 
The full search strategies used in the initial searches of Ovid MEDLINE and other databases are 
included in Appendix 1. The MEDLINE searches used in the supplemental searches were the same as 
the initial MEDLINE strategy. 
The searches were robust and comprehensive but not exhaustive. The use of journal hand-searching, 





this mapping exercise, but due to time considerations, it was not possible to incorporate all these 
methods in this project. 
3.3.2 Keywords 
Keywords for these searches were compiled from scoping searches on the topic carried out in 
MEDLINE and Google, and with the assistance of PubMed PubReMiner,33 the PubMed text-mining 
software. This software allowed the easy capture of relevant medical subject headings (MeSH) terms. 
The keywords used in building the searches were based on variations of terms for e-cigarette and 
heat-not-burn tobacco products, for example, e-cig*, e-liquid, vape, vaping, cigalike, HnB [heat-not-
burn tobacco products], heatsticks, electronic nicotine delivery system (ENDS), and electronic non-
nicotine delivery. Non-English terms for these concepts were also included, for example, e-sigaret*, E-
Zigarette, and e-papieros. Some high-profile brand names, such as JUUL and IQOS, were included. 
For databases with a controlled vocabulary, such as MEDLINE, Cochrane, PsycINFO, PROSPERO, and 
Embase, terms from the relevant thesaurus (e.g. MeSH, Emtree, PsycINFO Thesaurus) were also 
incorporated. 
Given the considerable body of literature published to date mentioning e-cigarettes and heat-not-
burn tobacco products and the limited amount of time available to complete this mapping exercise, 
additional search terms were used to broadly exclude some categories of study, for example, MeSH 
and free terms for animal studies and cell line studies. 
Rather than split the single e-cigarette/heat-not-burn tobacco products search into three separate 
searches for smoking cessation, harms and benefits, and initiation studies, a single search was used 
for all three subtopics, and results were filtered via the screening process to the appropriate subtopic. 
It was anticipated that several results would be relevant to more than one question. 
3.3.3 Grey literature 
To increase the opportunity to capture as much relevant data as possible, it was decided to include 
CORE (Core.ac.uk) and Google Scholar in the search plan. CORE is an open access research repository 
and Google Scholar is a search engine which primarily includes scholarly publications. The search 
strategies used with these resources were very much simplified and reduced, relative to the extended 
search strategies possible with Ovid MEDLINE or PsycINFO. 
Some grey literature was also included with the supplemental citation search of reviews and reports 
carried out in August 2019 and outlined above.  
3.3.4 Screening 
A comprehensive screening process was carried out. Results (n=6,510 after deduplication) from the 
literature searches were exported to EPPI-Reviewer 4. Title/abstract screening was carried out by two 
researchers (AMcC and DOB) and the information specialist (CL). A pilot group consisting of 10% of 
the results was initially screened to test the screening questions and process. The remainder of the 
results was then screened using the same criteria. The screening questions comprised the five 
research questions inclusion and exclusion criteria (see Section 1.2 and Section 3.3). Where there was 
doubt about the relevance of an article, it was included for the next round of screening. 
For the mapping exercise, inclusion and exclusion criteria for the title and abstract screening process 
were those outlined in Section 3.3 and Table 2. A more limited set of terms were used for heat-not-
burn tobacco products such as HnB and heatsticks. 
After the title/abstract stage of screening, 526 papers relating to harms and benefits of e-cigarettes 
were retained, while 25 papers relating to heat-not-burn devices were retained; this gave 551 papers 
in total. The full texts of the relevant 551 papers were sourced and then screened to answer specific 
inclusion queries that could not be answered using the published abstracts alone. This stage of 
screening was carried out by two researchers (AMcC and DOB), using the same inclusion and 
exclusion criteria in Section 3.3 and Table 2. One hundred and eighty-two articles were excluded on 





text reading stage – 339 papers relating to e-cigarettes and 30 papers relating to heat-not-burn 
devices. The main reason for exclusion was details of study design or methods were unclear. Five 
papers were re-assigned from the e-cigarette category to the heat-not-burn tobacco product 
category, bringing this total up to 30 papers. 
Title/abstract screening of the outputs of the three supplemental searches (these are described in 
Section 3.4.1) was carried out by the information specialist to eliminate any obviously out-of-scope 
results. Potentially relevant results were then screened by one researcher (AMcC). From the 110 
supplemental results relating to e-cigarette and heat-not-burn tobacco product harms and benefits 
retrieved over the three searches, 96 additional relevant results were retrieved, all of which pertained 
to e-cigarettes. These were added to the 369 papers (e-cigarettes: N=339 and heat-not-burn 
products: N=30) remaining after full text screening (e-cigarettes: N=435 and heat-not-burn products: 
N=30)). Following full text screening, 77 papers were excluded at this stage and one paper had to be 
reclassified from one question to another. The screening process resulted in a total of 388 papers 
eligible for inclusion in the final mapping exercise. Of this total, 361 papers dealt with the topic of e-
cigarettes and 28 papers covered heat-not-burn devices, with one paper1 dealing with both types of 
devices and included in both categories. The results of the search and screening process is outlined in 
the PRISMA flow chart in Figure 5 in Section 4.1. 
3.4 Data extraction 
The initial plan was to complete a systematic review of the health-related benefits and harms of e-
cigarettes and heat-not-burn tobacco products, but in September, it emerged that the number of 
papers for inclusion would be circa 370 primary epidemiological papers, and given the resources 
available to the project and the tight deadline (April 2019 to January 2020 and 1.4 FTE staff), it was 
decided by the unit manager (JL) to map the included primary studies on harms and benefits so as to 
provide the Department of Health with an indicative view of the harms and benefits of e-cigarettes 
and heat-not-burn products. One researcher (AMcC) extracted data from the included papers into 
bespoke extraction tables by study design and by Academies of Sciences categories. Data aligning 
with, and representative of, the following headings were extracted: author and year; main 
relationship or outcomes reported; age; sex; country; ethnicity; data source; study or trial duration 
(for the longitudinal cohort and intervention studies); population size; data collection period; e-
cigarette use, smoking, and other related behaviours; actual outcomes; authors’ summary 
conclusions; and information on the device and smoking-related products (for the observational and 
interventional studies). For case reports, case series and surveillance reports, we extracted: author 
and year; product and dose ingested; outcome; as well as age, sex, and country if the data were 
available. The data measures for extraction were not reported in all papers, and where data were 
missing, this is acknowledged in the tables in Sections 4 and 5, and in the Appendices 2-5. The data 
extraction was not validated by another researcher. 
3.5 Quality assessment 
As this is a mapping exercise, there was no quality assessment of individual primary papers required. 
Quality assessment normally requires the use of an appropriate validated tool to evaluate the quality 
of a peer review paper. The assessment tool is study design specific. Such tools allow the researcher 
to assess: appropriateness of the study design to answer the research question; method(s) employed 
to minimise biases; validity of measures of exposures and outcomes; suitability of the statistical 
analysis; control for confounding; and accuracy in reporting. This is a feature of mapping exercises 
that we have discussed in Section 6.4 of the discussion. 
3.6 Literature mapping and summarisation of extracted information 
A mapping exercise was completed to describe the nature and extent of the literature on harms and 
benefits of e-cigarettes and heat-not-burn tobacco products. A mapping exercise is a methodical 
review of all the published literature in a subject area. Study summaries are presented, or arranged, 
by headings and subheadings in order to describe, design, and develop effective research questions, 





impact of e-cigarettes or heat-not-burn tobacco products, but to identify possible harms, benefits, 
and areas for consideration.  
As this is a mapping exercise, we describe the nature and extend of the literature by study design and 
scientific heading. In addition to normal mapping exercises, we presented a brief summary within the 
main body of the report which summarised the relationship as described by the primary paper 
authors in their concluding text. A more detailed tabulation of the primary authors self-reported 
findings for each paper is presented in the appendices. The heterogeneity in study findings was 
identified when present, but due to the nature of the mapping exercise, the potential underlying 
reasons for the heterogeneity were not examined. 
Benefits and harms of e-cigarettes are categorised by epidemiological study design in order to assign 
a notional hierarchy of evidence to the literature. The HRB authors begin with descriptive 
epidemiological studies (case series, case reports, with the addition of surveillance studies) that are 
deemed to provide the lowest level of evidence. In the middle, we present observational studies 
(cross-sectional surveys, case-control studies, and longitudinal cohort studies) and we end with 
epidemiological studies that are said to provide the highest level of epidemiological evidence 
available in primary study papers (interventional trials). The HRB authors have included these studies 
in order to present a comprehensive map of the current situation. Regarding intervention trials, it 
should be noted that there are two approaches to allocation of the intervention: randomised and 
non-randomised. Randomised trials provide the highest level of epidemiological evidence available in 
primary study papers. In this mapping exercise, we identified the use of several trial designs including: 
randomised controlled trials; randomised crossover or Latin-square trials; non-randomised crossover 
or Latin-square trials; and non-randomised before and after studies. While we have presented trials 
with both types of randomisation within the same set of tables, and assigned a study design 
descriptor in the final column of each of the intervention study tables. We did not include systematic 
reviews of the literature in the map, as these would duplicate the material up to 2017. We did 
consider doing a review of reviews, but decided against this course of action as it is unlikely that 
published reviews would include material for the years 2018 and 2019. Information on the harms and 
benefits of e-cigarettes and heat-not-burn tobacco products is a rapidly changing field, so it is best 
mapped using primary studies. 
The benefits and harms outcomes that were identified through this mapping exercise are presented 
under nine headings. Seven of these were identified by the Academies of Sciences: (i) dependence 
and abuse liability; (ii) cardiovascular diseases; (iii) cancers; (iv) respiratory diseases; (v) oral diseases; 
(vi) developmental and reproductive effects; and (vii) injuries and poisonings.6 We added two further 
categories for outcomes that did not align with the Academies of Sciences’ framework; these were 
(viii) exposure to e-cigarette toxins; and (ix) other outcomes. When we use the term conventional 
tobacco cigarettes in the text, we mean conventional combustible tobacco cigarettes.  
The mapping exercise identified a range of papers reporting findings from surveillance systems that 
cover the new and emerging topic of e-cigarette and vaping associated lung injury (EVALI). We have 
presented these studies in Appendix 2 for the convenience of readers. The tables are summarised in 
text under the following four headings: clinical presentation; diagnostic criteria and technologies; 
development of algorithm and guidelines as diagnostic aids; and pathogenesis and disease aetiology. 
3.6.1 Presentation of e-cigarette summaries 
Summaries of the 361 e-cigarette articles are presented in tables, which are organised according to 
the nine outcome categories and by study design. Within each table, articles are organised by year 
(starting with the earliest) and then by ascending alphabetical order within each year, based on the 
lead author’s surname. In some tables we have categorised the tables into subject themes. Each 
paper is also categorised as a potential benefit or harm. For some studies, potential harms or benefits 
are described relative to conventional tobacco cigarettes.  
For ease of reading, we have minimised references in text. Also, we have referenced the papers 
included in the mapping exercise in their respective table. The information presented in the tables is 
primarily based on each article’s abstract for case reports, case series, and surveillance studies; full-





text. Full-text articles were used to complete the tabular contents for observational studies and 
interventional studies. However, it should be noted that the authors’ conclusions in the tables were 
taken from the authors’ own summary or conclusions, using their own words.  
The tables for cross-sectional surveys, longitudinal cohort studies, and interventional trials that are 
presented in Chapter 4 include information on each article’s authors, study objectives, exposure, 
intervention, and summary concluding findings. For observational studies (cross-sectional and 
longitudinal cohort) and interventional trials, additional details are presented in Appendices 3–5. The 
tables in the appendices present the study objectives, participant numbers and characteristics, 
exposure or intervention, detailed descriptions of the e-cigarette or e-liquid used, outcomes 
measured, and authors’ conclusions.  
3.6.2 Presentation of heat-not-burn summaries 
Summaries of the included heat-not-burn articles are presented in tables, which are organised by the 
nine outcome categories and by study design. Due to the nature of the findings on heat-not burn 
tobacco products, the layout of the tables in Section 5 differs from the layout used for e-cigarettes 
mentioned above. We observed that the trial papers included in Section 5 of the report were written 
by either industry- or academic-based authors, and we have organised the tables to reflect the 
authors’ place of work. In addition, we observed in several instances that the same lead trial author 
reported on studies employing a very similar design and frequently testing the same product, or a 
close variation of it, in different geographical populations. Therefore, in order to ensure a better 
understanding of the relationship pattern between the exposure and the outcome, the papers by the 
same team of authors are grouped together by team, by product, and then listed in chronological 
order.  
For ease of reading, we have minimised references in text. Also, we have referenced the papers 
included in the mapping exercise in their respective table. The information presented in the tables is 
primarily based on each article’s abstract for case reports. Full-text articles were used to complete the 
tabular contents for observational studies and intervention studies. However, it should be noted that 
the authors’ conclusions in the tables were taken from the authors’ own summary or conclusions, 
using their own words. Papers reporting on heat-not burn-products are referenced in the text and 
tables. Each paper is also categorised as a possible benefit or harm. For some studies, possible harms 
or benefits are described relative to conventional tobacco cigarettes. 
The tables for interventional trials that are presented in Chapter 5 include information on each 
article’s authors, study objectives, exposure, intervention, and summary concluding findings. For 
interventional trials, additional details are presented in Appendix 6. The tables in Appendix 6 present 
the study objectives, participant numbers and characteristics, exposure or intervention, detailed 








3.7 Reading the mapping exercise 
The harm or benefit arising from e-cigarette or heat-not-burn product use is of an absolute or relative 
nature depending on the smoking status of the study participants and the presence of a study 
comparison group. In epidemiology, the population impact of health is considered from a clinical 
perspective (e.g. the health of persons with smoking-related behaviours). If the risk of developing a 
smoking-related disease (e.g. cardiovascular disease) changes in accordance with a change in product 
use, the risk, where a decrease is noted, may be considered to indicate an absolute or relative 
beneficial effect. Likewise, an increase in the risk of occurrence associated with product use may be 
considered to indicate an absolute or relative harm. Due to the mapping nature of the work 
undertaken here, we have stated the direction of effect for the observed relationships in 
observational and interventional studies, but not quantified the direction of effect. It is important to 
consider if harms or benefits from e-cigarettes or heat-not-burn tobacco products are greater or less 
than harms or benefits arising from the use of conventional tobacco cigarettes or other nicotine 
products which is defined as a relative effect. In order to help the reader identify the main 
comparative groups in each study, we identified six umbrella terms which reported on e-cigarette use 
and smoking related behaviours. We named these: (1) e-cigarettes or heat-not-burn products 
themselves; (2) conventional combustible tobacco cigarettes users; (3) dual or poly users of nicotine 







4 Findings: e-cigarettes harms and benefits 
4.1 Introduction: e-cigarettes 
The possible benefits and harms of e-cigarettes are categorised by epidemiological study design to 
assign a notional hierarchy of evidence to the literature and presented in a mapping exercise in 
Chapter 4 as described in Sections 3.1 and 3.6. There were 361 peer reviewed papers on the harms 
and benefits of e-cigarettes which comprise 94 case report papers, 37 case series, 34 surveillance 
reports, 86 cross-sectional surveys, 2 case-control studies, 22 longitudinal cohort studies, and 86 
interventional trials.  
The benefits and harms outcomes that were identified through this mapping exercise are presented 
under nine headings described in Sections 3.1 and 3.6. There were 361 peer reviewed papers on the 
harms and benefits of e-cigarettes which comprise: 60 papers on possible harms or benefits of 
dependence and abuse liability, 32 on cardiovascular diseases, 7 on cancers, 78 on respiratory 
diseases, 24 on oral diseases, 2 on developmental and reproductive effects, 100 on injuries and 
poisonings, 28 on exposure to e-cigarette toxins, and 30 on other outcomes. 
Summaries of the included articles are presented in tables, which are organised by the adapted 
Academies of Sciences nine outcome categories and by study design as described in Section 3.6.1.  
The tables for cross-sectional surveys, longitudinal cohort studies, and interventional trials that are 
presented in Chapter 4 include information on each article’s authors, study objectives, and summary 
concluding findings. For observational studies (cross-sectional and longitudinal cohort) and 
interventional trials, additional details are presented in Appendices 3–5. The tables in the appendices 
present the study objectives, participant numbers and characteristics, exposure or intervention, 
detailed descriptions of the e-cigarette or e-liquid used, outcomes measured, and authors’ 









Figure 5 PRISMA flow chart 
Records included after title and 
abstract screening (n = 551) 
(e-cigarettes (n = 526);  
heat-not-burn devices (n = 25)) 
Records excluded (n = 5,675) 
Duplicate records excluded 
(n = 8,163) 
Records assigned to other review 
questions (n = 284) 
Records reassigned from e-cigarettes to 
heat-not-burn devices (n = 5) 
Records included after full-text 
screening: (n = 369) 
(e-cigarettes (n = 339);  
heat-not-burn devices (n = 30)) 
Records excluded from e-cigarettes:  
(n = 182) 
Records identified through database and search engine (n = 14,673) 
(Databases including registries and repositories: Ovid MEDLINE: n = 3,874; Elsevier Embase: n = 4,212; Ovid 
PsycINFO: n = 1,519; Wiley Cochrane Central Register of Controlled Trials: n = 527 and Wiley Cochrane Database of 
Systematic Reviews: n = 14; LILACS: n = 4,042; PROSPERO: n = 93; Core.ac.uk: n = 192. Search engine: Google 
Scholar: n = 200) 
Records after duplicates removed 
(n = 6,510) 
Papers included in final analysis 
 (n = 388) 
(e-cigarettes (n = 361; heat-not-burn 
devices (n = 28)) 
(Note: One paper is included in both 
e-cigarettes and heat-not-burn 
devices: (Adriaens, 2018)1 
Records included from supplemental 
results (n = 96) (e-cigarettes: (n = 96)) 
Records excluded from final analysis:  
(n = 76)  
(e-cigarettes (n = 74);  
heat-not-burn devices (n = 2)) 
Records reassigned from e-cigarettes to 
both e-cigarettes and heat-not-burn 





4.2 Descriptive epidemiological studies: e-cigarettes 
Incidents of mainly harms and a small number of benefits associated with e-cigarette devices or e-
liquid were reported in 165 papers. Stratification by research design allowed us to categorise the 
papers into 94 case reports, 37 case series papers, and 34 surveillance papers reporting data from 
information or surveillance systems.  
The authors of the 94 case reports described a single hospital case of a unique event, benefit, or harm 
that the authors attributed to e-cigarette devices or e-liquid.27 However, case reports can identify a 
hypothesis, but cannot prove causation. 
The authors of the 37 case series reports described cases of similar – and medically interesting – 
success, morbidity, or mortality outcomes that the authors attributed to e-cigarette devices or e-
liquids.27 A case series can identify a hypothesis, but cannot prove causation. 
The 34 surveillance papers reported data from information or surveillance systems to describe the 
geographic distribution and temporal trends in e-cigarette- and e-liquid-related harms. In some 
papers, incidence of harms was calculated.  
4.2.1 Case reports: e-cigarettes - study characterisation, harms and benefits 
The authors of the 94 case reports described a single hospital case of a unique event that they 
attributed to e-cigarette devices or e-liquids and resulted in a harm or a benefit (Tables 3–17). The 
presentation format of the case report for each paper was not standardised; some papers provided 
diagnosis only, other papers provided diagnosis and investigation, and the remaining papers provided 
diagnosis, investigation, and treatment. We did not present information on treatment in our mapping 
exercise, as we were focusing on describing the harms and benefits of e-cigarettes and e-liquids 
documented in the literature.  
The 94 case reports described harms and benefits associated with e-cigarettes and e-liquids between 
2012 and 2019. Overall, there were 4 case reports categorised as having a beneficial outcome and 90 
case reports categorised as having a harmful outcome. Ten cases died. The sex of the cases, where 
reported, was 33 males and 27 females. The ages of the cases, where reported, ranged from 15 
months to 66 years. 
The number of case reports categorised under each of the seven umbrella headings within the 
adapted Academies of Sciences’ framework ranged from 2 for cardiovascular diseases to 49 for 
injuries and poisonings; of these, 28 were injury cases and 22 were poisoning cases. Twenty-three 
case reports were categorised under the heading respiratory diseases (i.e. a total of 21 harms and 2 
benefits); almost all harms affected the lower respiratory tract (for example, pneumonia). There were 
four case reports on harms categorised under the oral diseases heading, and another four harms 
under the exposure to e-cigarette toxins heading (for example, contact dermatitis). Twelve case 
reports were categorised as other outcomes. Of these case reports, two were considered benefits (for 
example, reduction of ulcerative colitis symptoms in one case, and reversal of blood condition in one 
case), and ten were considered harms (for example, affected clozapine therapeutic doses in four 
cases and oxygen tissue perfusion in four cases). No case reports were categorised under the 
headings ‘cancers’ or ‘developmental and reproductive effects’.  
4.2.1.1 Dependence and abuse liability: case reports 
There were no case reports on the relationship between e-cigarettes and dependence and abuse 
liability outcomes. 
4.2.1.2 Cardiovascular diseases: case reports  
The two papers on cardiovascular outcomes reported (Table 3) the occurrence of paroxysmal atrial 
fibrillation in an elderly female,34 and the development of a spontaneous coronary artery dissection in 






Table 3 Case reports on cardiovascular diseases, benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case reports on cardiovascular diseases 
Monroy et al.34 
2012 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Paroxysmal atrial fibrillation 
Ahmed et al.35 
2018 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Habitual e-cigarette smoker 
Outcome: Spontaneous coronary artery dissection 
4.2.1.3 Cancers: case reports  
There were no case reports on the relationship between e-cigarettes and cancers. 
4.2.1.4 Respiratory diseases: case reports 
The 23 papers on respiratory diseases reported findings from 12 males, 9 females, and 2 people for 
whom sex was not reported. The ages for males ranged from 16 to 43 years, and for females ranged 
from 18 to 47 years, with five females aged 42 years or over. One case died. The following diagnoses 
or signs and symptoms were reported for males: eosinophilic pneumonia,36 deterioration of 
pulmonary function,37 acute onset dyspnoea,38 acute hypersensitivity pneumonitis,39 dyspnoea and 
haemoptysis,40 bronchiolitis,41 respiratory bronchiolitis-interstitial-lung disease,42 spontaneous 
pneumomediastinum,43 recurrent spontaneous pneumothoraces, 44 and lipoid pneumonia.45-47 Three 
male patients were reported to have used e-liquid containing tetrahydrocannabinol. Among females, 
cases of eosinophilic pneumonia,48 dyspnoea,49-52 multiple pulmonary nodules and liver lesions,53 and 
lipoid pneumonia54 55 were observed. A small number of patients had underlying medical conditions. 
Overall, 21 respiratory harms and 2 respiratory benefits were reported as a result of e-cigarette or e-
liquid use (Table 4). One case of complete resolution of chronic tonsillitis and one case of resolution 







Table 4 Case reports on respiratory diseases, benefits or harms 
Author(s), year Possible 
benefit 
or harm 




Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Recent product use in the last 
seven months 
Outcome: Dyspnoea, productive cough, and subjective fever 
Hureaux et al.37 
2014  
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Commenced vaping of either of 
two e-liquids both 19 mg/mL of nicotine about 25 times a day to stop 
smoking.  
Outcome: After 48 hours, an onset of cough with whitish secretions, and 
subsequent development of progressive breathlessness on minimal exertion 
over a period of one-week giving rise to bronchial syndrome associated with 
deterioration of pulmonary function, with symptoms resolving seven days 
after stopping use of e-cigarettes 
Thota et al.36 
2014  
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Acute eosinophilic pneumonia 
Ring Madsen et 
al.53 
2016 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Use of e-cigarettes with 38 
mg/mL nicotine, 10 mL per week 
Outcome: Abdominal pain and fever, and multiple pulmonary nodules and 
liver lesions, lung biopsy revealed multinucleated giant cells, suggestive of a 
foreign body reaction to a lipophilic material 
Carter et al.54 
2017 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Current user of e-cigarettes 
Outcome: Sudden onset dyspnoea suspected chemical injury 
Flower et al.42 
2017 
Harm Product: E-cigarette and conventional combustible tobacco cigarette 
Dose taken or reported relevant behaviour: Commenced vaping 10 to 15 
times per day while continuing to smoke 10 conventional combustible 
tobacco cigarettes per day 
Outcome: Respiratory bronchiolitis-interstitial lung disease 
Miler et al.56 
2017 
Benefit Product: E-cigarette 
Dose taken or reported relevant behaviour: A few months of e-cigarette use 
Outcome: Resolution of chronic tonsillitis 
Agustin et al.40 
2018 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Vaping for the past two months 
with overtly increased exposure time and new flavours experimentation 
Outcome: Dyspnoea and haemoptysis, diagnosed as diffuse alveolar 
haemorrhage syndrome 
Khan et al.57 
2018 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Increased use of e cigarettes 
during past month to help quit smoking 
Outcome: Pulmonary toxicity 
Marasco et al.43 
2018 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Information not available 




Benefit Product: Glycerol-based nicotine vaporizer (e-cigarette) 
Dose taken or reported relevant behaviour: A few weeks of e-cigarette use 
containing vegetable glycerine with low levels of nicotine (3 mg/ml) 





Author(s), year Possible 
benefit 
or harm 




Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Acute respiratory distress syndrome 
Viswam et al.55 
2018 
Harm Product: E-cigarette (containing vegetable glycerine) 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Lipoid pneumonia 
Arter et al.48 
2019 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Two months prior to presentation 
the patient started vaping using a Baby Smok Beast Mod device with 6% 
nicotine fluid five times per day for 30 minutes  
Outcome: Acute eosinophilic pneumonia 
Bakre et al.51 
2019 
Harm Product: E-cigarette  
Dose taken or reported relevant behaviour: E-cigarettes use for three years 
prior to presentation  
Outcome: Alveolar septal thickening due to fibroblastic proliferation and 
alveolar lining hyperplasia 
Bonilla et al.44 
2019 
Harm Product: Vaping product (e-cigarette) 
Dose taken or reported relevant behaviour: A history of vaping just prior to 
both episodes of illness 




Harm Product: Street purchased vape cartridge 
Dose taken or reported relevant behaviour: Symptoms presented two weeks 
after initiating use of a street-purchased tetrahydrocannabinol-containing 
vape cartridge.  




Harm Product: E-liquid solution mixture contained vanillin, aldehydes, alcohols and 
other chemicals  
Dose taken or reported relevant behaviour: Symptoms began nine months 
after the subject quit smoking traditional cigarettes and transitioned solely to 
heavy vaping 
Outcome: Bronchiolitis 
Maddock et al.38 
2019 
Harm Product: E-cigarette containing nicotine and tetrahydrocannabinol 
Dose taken or reported relevant behaviour: Daily vaping  
Outcome: Respiratory distress syndrome 
Nair et al.39 
2019 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Recent commencement of vaping 
and frequent use of two over the counter purchased e-cigarettes liquids  
Outcome: Hypersensitivity pneumonitis 
Ocampo-
Gonzalez et al.46 
2020 
Harm Product: E-cigarette with e-liquid containing both tetrahydrocannabinol and 
nicotine as well as occasional marijuana use 
Dose taken or reported relevant behaviour: Daily vaping with a recent change 
in product provider 
Outcome: Interlobular septal thickening and diffuse ground glass opacities 
in both lungs 
Sechrist et al.47 
2019 
Harm Product: E-liquid containing both tetrahydrocannabinol 
Dose taken or reported relevant behaviour: Vaping 
Outcome: Vaping-associated lung disease 
Twohig et al.52 
2019 
Harm Product: E-cigarette  
Dose taken or reported relevant behaviour: Use more than 10 times daily for 
two weeks 





4.2.1.5 Oral diseases: case reports 
Four papers reported measures of oral health. Three addressed issues related to mucosal membranes 
or the tongue, and one related to dental caries (Table 5). The age range for three females and one 
male was 51–66 years. The mucosal tissue morbidities were lingua villosa nigra,59 oral lichen planus,60 
and asymptomatic hyperpigmented tongue.61 The identified dental-related measures were multiple 
smooth surface carious lesions.62 
Table 5 Case reports on oral diseases, benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case reports on oral diseases 
Farinha et al.59 
2015 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: The subject had stopped tobacco 
smoking and initiated electronic cigarette a few weeks before presentation 
Outcome: Lingua villosa nigra (asymptomatic black discoloration) 
Bartram et al.60 
2016 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Commencement of e-cigarette 
use  
Outcome: Oral lichen planus 
Lilleker et al.62 
2017 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Multiple smooth surface-active carious lesions 
St Claire et al.61 
2017 
Harm Product: E-cigarette cappuccino-flavoured 
Dose taken or reported relevant behaviour: The patient began vaping in the 
week before presentation Information not available 
Outcome: Asymptomatic hyperpigmented tongue 
4.2.1.6 Developmental and reproductive effects: case reports  
There were no case reports on the relationship between e-cigarettes and developmental and 
reproductive effects. 
4.2.1.7 Injuries and poisonings: case reports  
There were 49 papers on injuries and poisonings. Of these, 28 were on injuries (Tables 6–10) and 21 
were on poisonings (Tables 11–13).  
4.2.1.7.1 Injuries 
The 28 papers reporting on injuries were grouped by injury type and, where possible, by anatomical 
location of the sustained injuries (Tables 6–10). The causes of injury included burns (chemical and 
thermal) and explosions. Anatomical injury locations were further described by features such as part 
of the body, percentage of total skin surface area involved, thickness of the burn, presence of 
embedded shrapnel, and/or bone fractured. The parts of the body injured included head, face, eye, 
mouth (including teeth), thigh, and leg.  
Eight papers were grouped under thermal burns which occurred between 2015 and 2019; they 
reported findings on 4 males, 2 females and 2 persons whose sex was not reported (Table 6). The age 
range of males was 26–35 years and for females was 30–49 years. Most burns were to the thigh and 
leg,63-67 but burns to the shoulder,68 chest,68 and face66 69 were also reported. The location of injury 
was usually indicative of whether the e-cigarette was in use or not. In general, injuries to the thigh 
region indicated the location of storage, whereas upper body injuries indicated that the injury 
occurred when the e-cigarette was in use. The percentage of total skin surface area burned ranged 
from 1.5% to 8%. Two papers report chemical burns, one in 2016 and one in 2018 (Table 7). Sex or 
age were not identified. Both injuries were the result of the inadvertent administration of e-cigarette 





Four papers reported on fractures arising from e-cigarette use between 2016 and 2019; all cases were 
male and were aged between 17 years and 59 years (Table 8). In most cases, the main injury was to 
the face and head,72-74 for example, maxillofacial fracture, premaxilla fracture, and anterior nasal 
spine damage, with associated soft tissue and organ damage, as well as one spinal fracture.75 Injuries 
were severe and required surgical repair and intensive care.  
Eight papers were categorised as blast injuries, with injuries to the eyes,76 nose, 77 face,77-79 hands,78 80-
82 and chest78 being reported (Table 9). The injuries occurred between 2016 and 2018. Most papers 
did not report sex or age. Again, surgical intervention was required, and two patients sustained 
chronic neurological damage with sensory loss and decreased motor control.  
The remaining six injury papers consisted of a number of injuries arising from a combination of 
thermal and chemical burns and fractures which occurred between 2016 and 2018 (Table 10).83-88 The 
only major difference in outcome observed from those previously reported was the reporting of a 
non-malignant necrotic ulcer in one case.86 For a small number of papers, information on modification 
of the e-cigarette device was reported, and both no modification and modification activities were 
recorded. The age and sex were reported for two of the six cases; in both cases, the subjects were 
young males.  
Table 6 Case reports on injuries and poisonings, presenting as thermal burns, benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case reports on injuries and poisonings presenting as thermal burns 
Jablow et al.63 
2015 
Harm Product: E-cigarette which ignited 
Dose taken or reported relevant behaviour: Not reported 
Outcome: Partial thickness burns to patient’s right leg and circumferentially 




Harm Product: E-cigarette which exploded 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Thigh burns  
Hassan et al.89 
2016 
Harm Product: E-cigarette which exploded 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Burns 
Shastry et al. 68 
2016 
Harm Product: E-cigarette experimental device which exploded 
Dose taken or reported relevant behaviour: The patient was a paid tester for 
an E-cigarette company 
Outcome: Burns to the shoulder and chest 
Walsh et al. 65 
2016 
Harm Product: E-cigarette lithium battery which self-combusted 
Dose taken or reported relevant behaviour: Information not available  
Outcome: 1.5% total body surface area mixed-depth burn to the lateral 




Harm Product: E-cigarette which exploded 
Dose taken or reported relevant behaviour: Information not available 
Outcome: 2% total body surface area burns to the face, forearm, and thigh, 
and bilateral corneal burns 
Serror et al.67 
2017 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Not reported 
Outcome: Deep thigh burns 
Benowitz et al.69 
2019 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: A previous smoker who longer 
smoked regular cigarettes, asked her friend to bring her e-cigarette in hospital 
which sparked an explosion on use 






Table 7 Case reports on injuries and poisonings, presenting as chemical burns, benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case reports on injuries and poisonings presenting as chemical burns 
Jamison et al.70 
2016 
Harm Product: E-cigarette liquid 
Dose taken or reported relevant behaviour: Inadvertent administration of e-
cigarette liquid to the eye  




Harm Product: E-cigarette liquid 
Dose taken or reported relevant behaviour: Accidental administration of e-
cigarette liquid  
Outcome: Ocular chemical burn 
 
Table 8 Case reports on injuries and poisonings, presenting as fractures with or without additional 
injuries, benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case reports on injuries and poisonings presenting as fractures with or 




Harm Product: E-cigarette which exploded 
Dose taken or reported relevant behaviour: The patient had received the 
device two days prior to presentation after purchasing it online and 
reportedly made no modifications 
Outcome: Complex facial fractures and pneumocephalus 
Brooks et al.73 
2017 
Harm Product: E-cigarette which exploded 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Severe damage to the anterior dentition (fractured teeth, 
avulsions, and luxation) along with fractured premaxilla and anterior nasal 
spine, and sustained lacerations to the upper lip, labial mucosa, gingivae, 
tongue, hard palate, and facial skin 
Norii et al.75 
2017 
Harm Product: E-cigarette which exploded 
Dose taken or reported relevant behaviour: Information not available  
Outcome: Spinal fracture 
Katz et al.74 
2019 
 
Harm Product: E-cigarette which exploded 
Dose taken or reported relevant behaviour: Not reported 
Outcome: Comminuted and displaced mandibular fracture with disruption of 







Table 9 Case reports on injuries and poisonings, presenting as blast injuries to anatomical sites, 
benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case reports on injuries and poisonings presenting as blast injuries to 
anatomical sites 
Bohr et al.90 
2016 
Harm Product: E-cigarette battery which exploded 
Dose taken or reported relevant behaviour: Information not available 




Harm Product: E-cigarette which exploded 
Dose taken or reported relevant behaviour: The e-cigarette exploded a result 
of a modification made to the heating element of the e-cigarette device by a 
non-professional 
Outcome: Extensive ocular injury 
Moore et al.78 
2016 
Harm Product: E-cigarette which exploded 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Injuries and burns to the face, left hand, and chest 
Ban et al.79 
2017 
Harm Product: E-cigarette which exploded 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Ballistic injury to the maxilla, and associated injuries resulting in 
an avulsive injury  
Foran et al.80 
2017 
Harm Product: E-cigarette which exploded 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Injection injury to finger 
Satteson et al.81 
2017 
Harm  
Product: E-cigarette which exploded 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Extensive thermal and blast injuries to hand 
Vaught et al.77 
2017 
Harm Product: E-cigarette which exploded 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Projectile fracturing to the right naso-orbital-ethmoid complex 
and the anterior and posterior frontal sinus tables, with frontal sinus outflow 
tract involvement 
Ackley et al.82 
2018 
Harm Product: E-cigarette which exploded 
Dose taken or reported relevant behaviour: Not reported 








Table 10 Case reports on injuries and poisonings, presenting as novel or combination injuries, 
benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case reports on injuries and poisonings presenting as novel or combination 
injuries 
Cason et al.83 
2016 
Harm Product: E-cigarette which exploded 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Injuries and burns to face, left hand, and chest 
Harrison et al.84 
2016 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Intraoral burns, luxation injuries, and alveolar fractures 
Roger et al.85 
2016 
Harm Product: E-cigarette which exploded when the patient pressed the device’s 
button 
Dose taken or reported relevant behaviour: No additional relevant 
information reported 
Outcome: Oral and abdominal burns, oral lacerations, tooth fracture, and 
tooth avulsion 
Cant et al.86 
2017 
Harm Product: E-cigarette  
Dose taken or reported relevant behaviour: The patient had previously been 
smoking 20 cigarettes a day for 30 years before starting to use electronic 
cigarettes to aid his smoking cessation. He reported a history of inhaling 
strongly on his e-cigarette and suffered extreme discomfort immediately 
afterwards prior to hospital presentation 




Harm Product: E-cigarette (patient fell with the device in his mouth) 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Diffuse supraglottic enema, most severe in the epiglottis, 
arytenoids, and aryepiglottic folds 
Chi et al.88 
2018 
Harm Product: E-cigarette which exploded 
Dose taken or reported relevant behaviour: Information not available 








The 21 papers on poisonings were grouped by intent: intentional, accidental, or undeterminable 
(Tables 11–13). Aside from the chemical products of AB-FUBINACA, ADB-FUBINACA and 
acetylfentanyl, most of the papers suggested toxic nicotine levels as the principal poisoning agent. 
Overall, seven cases died. 
The authors of six papers reported that the poisoning-related injury was intentional for the cases 
examined.91-96 There was one fatality. Three suicide attempts were made by ingesting e-liquid, two 
injected e-liquid, and the mode of use in the sixth case was not recorded (Table 11). The cases 
occurred between 2013 and 2019. Sex was reported for five cases; four were male and one was 
female. Age was reported for 2 of the 10 cases; one of these was aged 29 years while the other was 
aged 51 years. A pre-diagnosis of an underlying psychiatric condition was reported in two cases, and 
one of these cases also reported a sexual identity disorder. Two patients self-presented at the 
emergency department. In one case, treatment was requested by relatives. In the remaining three 
cases, the nature of help sought was unknown.  
Among the six cases of accidental poisonings between 2014 and 2017,97-101 four involved children 
whose ages ranged from 15 months to 6 years; two of these four children died (Table 12). Sex was 
known for five cases; one was male and four were female. Both age and sex were not known for one 
case. One adult poisoning was the result of a chronic, rather than an acute, use of e-liquid. The 36-
year-old adult male had been using propylene glycol with acetylfentanyl, purchased online, as a 
relaxation aid. Treatment with naloxone corrected his respiratory compromised condition, and he 
was subsequently discharged from intensive care.  
In nine of the case reports, published between 2012 and 2018, the poisoning intent was not 
determined.102-110 The mode of poisoning for all cases was through ingestion of e-liquid (Table 12). In 
one case, the patient had also consumed alcohol, and in another, the e-liquid contained a synthetic 
cannabinoid (AB-FUBINACA and ADB-FUBINACA). Events initiated by ingestion of the e-liquid included 
cardiac arrest, supraventricular tachycardia, bradycardia, and hypotension. Sex was known for five 
cases; all were male. Age was known for three men (24-39 years) and one child (aged 6 years). Four 






Table 11 Case reports on injuries and poisonings, presenting as intentional poisonings, benefits or 
harms 
Author(s), year Possible 
benefit 
or harm 




Harm Product: E-liquid injection 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Cardiopulmonary arrest 
Eberlein et al 92 
2014 
Harm Product: E-liquid ingestion of one capsule of nicotine containing liquid 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Intentional poisoning 
Schipper et al.93 
2014 
Harm Product: E-liquid ingestion 
Dose taken or reported relevant behaviour: The e-liquid fillings contained a 
total of 420 mg of nicotine and unknown amounts of propylene glycol and 
glycerine 
Outcome: Suicide attempt 
Chen et al.94 
2015 
Harm Product: E-liquid ingestion 
Dose taken or reported relevant behaviour: A partially ingested bottle of 
whiskey, and two empty 15 mL vials of concentrated liquid nicotine (100 
mg/mL) 
Outcome: Multiple acute infarcts, consistent with severe anoxic brain injury 




Harm Product: E-liquid ingestion 
Dose taken or reported relevant behaviour: 115 mL of e-liquid purchased via 
the Internet (propylene glycol >75%, water <3%, alcohol <2%, nicotine 19.9 
mg/mL) 




Harm Product: E-liquid intravenous injection 
Dose taken or reported relevant behaviour: Injection of 10 mL of e-liquid 
(1000 mg of nicotine diluted in propylene glycol)  
Outcome: Transitory neurological impairment with the appearance of 






Table 12 Case reports on injuries and poisonings, presenting as accidental poisonings, benefits or 
harms 
Author(s), year Possible 
benefit 
or harm 
Case reports on injuries and poisonings presenting as accidental poisonings 
Gupta et al.97 
2014 
Harm Product: Nicotine solution in refill cartridge bottle 
Dose taken or reported relevant behaviour: Child picked up and place refill 
cartridge bottle in her mouth 
Outcome: Potential accidental ingestion of nicotine solution but subsequent 




Harm Product: E-cigarette liquid exposure 
Dose taken or reported relevant behaviour: No paper info not in abstract 
Outcome: Paediatric death 
Gomolka et al.99 
2016 
Harm  Product: E-liquid containing nicotine 
Dose taken or reported relevant behaviour: Accident drinking of e-liquid 
containing nicotine at concentration 6 mg/ml. 
Outcome: Symptoms of overdose: dizziness, flushed cheeks, dry skin, dry 
conjunctivae, medium-wide pupils, nervous twitching, tachycardia, and 
elevated blood pressure. 
Rogers et al.100 
2016 
Harm Product: Propylene glycol e-cigarette filled with acetylfentanyl 
Dose taken or reported relevant behaviour: Patient had developed the habit 
of using an e-cigarette with increasing frequency containing propylene glycol 
e-cigarette filled with acetylfentanyl in order to aid relaxation 
Outcome: Respiratory depression, pinpoint pupils, hypoxaemia, and a 
Glasgow Coma Scale score of 6 
Seo et al.101 
2016 
Harm The authors reported on a 15-month-old child fatality where the child 
ingested liquid nicotine, having mistaken been given it for cold medicine. 
Product: E-liquid containing nicotine 
Dose taken or reported relevant behaviour: Accidental ingested of liquid 
nicotine, having mistaken it for cold medicine  
Outcome: Pulseless electrical activity resulting in death 
Noble et al.111 
2017 
Harm  Product: E-liquid containing nicotine 
Dose taken or reported relevant behaviour: 703 mg (35 mg/kg) of liquid 
nicotine ingested 







Table 13 Case reports on injuries and poisonings, presenting as poisonings with intention 
undetermined, benefits or harms 
Author(s), year Possible 
benefit 
or harm 





Harm Product: Nicotine from cartridges of e-cigarettes 
Dose taken or reported relevant behaviour: Information not available 




Harm Product: Nicotine solution vials of the brand Titanium Ice (50 mL each) 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Poisoning (toxicological analysis revealed nicotine concentrations 
of 5.5 mg/mL in femoral venous blood, 136.0 mg/mL in heart blood, 12.0 
mg/kg in brain tissue, 42.6 mg/kg in kidney tissue, 89.5 mg/kg in lung tissue, 
and a total amount of 3950 mg in the gastric contents) resulting in death 
Garat et al.104 
2016 
Harm Product: E-liquid containing propylene glycol 
Dose taken or reported relevant behaviour: Information not available 
Outcome: Acute propylene glycol poisoning not nicotine toxicity 
You et al.105 
2016 
Harm Product: Oral ingestion of e-cigarette liquid 
Dose taken or reported relevant behaviour: Oral injection of at least 714 mg 
of nicotine 
Outcome: Death 
Lam et al.106 
2017 
Harm Product: E-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA 
(synthetic cannabis). 
Dose taken or reported relevant behaviour: Two drops 
Outcome: Somnolent, confused, and agitated, with palpitation, vomiting and 
a short run of supraventricular tachycardia 
Morley et al.107 
2017 
Harm  Product: E-liquid containing nicotine 
Dose taken or reported relevant behaviour: Ingestion of nicotine-containing 
e-liquid while under the influence of alcohol  
Outcome: Ingested nicotine-containing e-liquid resulting in death 
van der Meer et 
al.108 
2017 
Harm Product: E-cigarette liquid 
Dose taken or reported relevant behaviour: Injection of highly concentrated 
liquid nicotine 




Harm Product: E-cigarette liquid 
Dose taken or reported relevant behaviour: Once off drinking of e-cigarette 
liquid 
Outcome: Bilateral sudden sensorineural hearing loss 
Paik et al.110 
2018 
Harm Product: A commercial liquid nicotine bottle was found together with a cup 
filled with liquid suspected to be nicotine 
Dose taken or reported relevant behaviour: Once off oral ingestion of a high 
concentration of liquid nicotine 







4.2.1.8 Exposure to e-cigarette toxins: case reports  
Four papers reported on outcomes resulting from toxic exposure to the e-cigarette device or e-liquid 
(Table 14). Two cases involving females reported on allergic contact dermatitis,112 113 and one case 
involving a female reported on facial, lip, and eyelid swelling with erythema and itching over a 6-
month period.114 The cases of allergic contact dermatitis were attributed to the material in the e-
cigarette device in one instance and to the e-liquid, Cigavapor, in the other instance. The causal factor 
in the case of swelling with erythema and itching was unclear, but potentially included the e-cigarette 
device, the e-liquid, and another metal device, an eyelash curler. The fourth case involved a 13-year-
old female who presented with cardiac and neurological disturbances and subsequently admitted to 
vaping the entire contents of an e-cigarette prior to symptom onset.115 All cases of toxicity were 
resolved following medical treatment.  
Table 14 Case reports on exposure to e-cigarette toxins, presenting as dermatological or poisoning 
symptoms, benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case reports on exposure to e-cigarette toxins presenting as dermatological 
or poisoning symptoms 
Maridet et al.112 
2015 
Harm Product: E-cigarette device 
Dose taken or reported relevant behaviour: Exposure to a patient’s own 
corroded e-cigarette, corrosion deemed to be probably due to patient’s hands 
sweat 
Outcome: Allergic contact dermatitis diagnosed following a dimethylglyoxime 




Harm Product: Metal e-cigarette and metal eyelash curlers used intermittently 
Dose taken or reported relevant behaviour: Exposure prior to symptoms 
unknown but following two months of product avoidance no further episodes 
of facial rash/swelling was noted and an improvement in the patient’s hand 
dermatitis was observed 
Outcome: Facial, lip, and eyelid swelling, erythema, and itching, mild hand 
dermatitis. Patch testing demonstrated a positive reaction to nickel and 




Harm Product: E-cigarette vaping liquid (Cigavapor which contains herbal extract, 
5%, glycerine and propylene glycol) 
Dose taken or reported relevant behaviour: Use of e-cigarette around the time 
of onset of the hand dermatitis was reported 
Outcome: Allergic contact dermatitis 
Hughes et al.115 
2020 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Entire contents of an e-cigarette 
cartridge just prior to symptom onset 
Outcome: Sinus tachycardia (heart rate of 124 beats per minute) with a QRS 
of 86 ms and QTc of 443 ms. Urine immunoassay positive for 






4.2.1.9 Other outcomes: case reports  
The remaining 12 papers did not align with the adapted Academies of Sciences’ umbrella terms, and 
are presented in Tables 15–17. 
Four papers, published between 2015 and 2018, reported on the impact of changing from smoking 
conventional tobacco cigarettes to using e-cigarettes on therapeutic drug levels.116-119 Patients on 
clozapine who switched from conventional tobacco cigarettes to e-cigarettes were reported to exhibit 
changes in behaviour or in clozapine levels which required adjustment to the prescribed therapeutic 
dosage (Table 15). Only one of the four papers reported age and sex. 
Three cases reported on oxygen tissue perfusion being compromised postoperatively in e-cigarette 
users attending for breast surgery, including reconstruction surgery, or other post-injury skin grafting 
between 2016 and 2018 (Table 16).120-122 A fourth case of oxygen depletion, due to reversible cerebral 
vasoconstriction, was also attributed to e-cigarette use and was reported in 2015.123 
Two cases reported benefits attributed to e-cigarette use (Table 17). One case of decreasing severity 
of the symptoms of ulcerative colitis were reported.124 The second case reporting a potential 
beneficial outcome of e-cigarette use was observed in a patient who switched from conventional 
cigarette smoking to e-cigarette vaping.125 The previous adverse blood measures of leukocyte count 
and C-reactive protein normalised in the patient, who had chronic idiopathic neutrophilia. Two cases 
of organ donation (kidney and liver) following an intentional overdose using e-liquids with nicotine 
were described.126 127  
Table 15 Case reports on other outcomes, presenting as clozapine concentrations, benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case reports on other outcomes presenting as clozapine concentrations 
Berm et al.116 
2015 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Switched from smoking 
conventional combustible tobacco cigarettes to using e-cigarettes in a subject 
with a suspected active psychosis 
Outcome: Unexpected changes to clozapine levels 
Nonner et al.117 
2016 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Switched from smoking 
conventional combustible tobacco cigarettes to using e-cigarettes 
Outcome: Unexpected changes to clozapine levels, resulting in a 
requirement to reduce the patient’s clozapine dosage 
Khorassani et al. 
118 
2018 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Conversion from smoking 
conventional combustible tobacco cigarettes to using an e-cigarette over a 
12-month period 
Outcome: Unexpected changes to clozapine levels 
Kocar et al.119 
2018 
Harm Product: Switch from smoking conventional combustible tobacco cigarettes 
to e-cigarettes 
Dose taken or reported relevant behaviour: Switch from smoking 
conventional combustible tobacco cigarettes to using an e-cigarette 







Table 16 Case reports on other outcomes, presenting as oxygen perfusion or depletion, benefits or 
harms 
Author(s), year Possible 
benefit 
or harm 
Case reports on other outcomes presenting as oxygen perfusion or 
depletion 
Vannier et al.123 
2015 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: Information not available 




Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: E-cigarette users until the date of 
surgery 
Outcome: Drop in ViOptix tissue oximeter reading in left breast post-
operatively following autologous breast reconstruction 
Fracol et al.121 
2017 
Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: E-cigarette use 





Harm Product: E-cigarette 
Dose taken or reported relevant behaviour: E-cigarette use 
Outcome: Compromised perfusion to the skin flap (autologous transfer) 
post-operatively 
 
Table 17 Case reports on other outcomes, presenting as miscellaneous outcomes, harms or benefits 
Author(s), year Possible 
benefit 
or harm 




Benefit Product: E-cigarette 
Dose taken or reported relevant behaviour: Six-month e-cigarette use 
following a decade of conventional tobacco cigarette use  
Outcome: Reversal of chronic idiopathic neutrophilia 
Camus et al.124 
2014 
Benefit Product: E-cigarette (smoking 20 cigarettes per day, converted to e-cigarette 
use) 
Dose taken or reported relevant behaviour: E-cigarette use following 
cessation of conventional tobacco cigarette use 
Outcome: Ulcerative colitis symptoms abatement 
Rasanen et al.126 
2017 
 Harm Product: Subcutaneous nicotine overdose of liquid nicotine from an e-
cigarette cartridge resulting in fatality in patient zero 
Dose taken or reported relevant behaviour: No paper info not in abstract 
Outcome: Kidney donation after subcutaneous nicotine overdose to donor 
recipient 
Lee et al.127 
2018 
 Harm Product: E-cigarette cartridge 
Dose taken or reported relevant behaviour: 10 mL of 99% liquid nicotine (990 
mg/mL) from e-cigarette cartridge  








4.2.2 Case series: e-cigarettes - study characterisation, harms and benefits 
The authors of 37 case series reports described cases of similar, and medically interesting, morbidity 
or mortality outcomes that the authors attributed to e-cigarette devices or e-liquids (Tables 18–25). 
These case series reports quantify and characterise the aggregation of cases over a defined time 
period. The 37 case series papers report findings on benefits (2 papers), harms (34 papers) and 
possible harms (1 paper) arising from e-cigarette use or exposure. Thirty-six papers were published 
between 2016 and 2019, and one was published in 2011. The number of cases in the case series 
papers range from 2 to 371, with 15 papers reporting findings based on 2 cases and 4 papers 
reporting findings based on 3 cases. Six papers reported findings on between 6 and 10 cases, and 
eight papers reported findings on between 12 and 19 cases. The remaining four papers reported on 
26, 53, 60, and 371 cases. Eight of the papers reporting on 10 or more cases were hospital chart 
reviews from burns centres. The earliest period covered was January 2007 to July 2016. Subsequent 
reports cover the period from 2012 to 2017.  
The number of case series papers categorised under each of the seven umbrella headings within the 
adapted Academies of Sciences’ framework ranged from 1 paper each under cardiovascular diseases, 
cancers (specifically oral carcinoma), and exposure to e-cigarette toxins (for instance, dermatitis) to 
24 under injuries and poisonings, of which 19 papers were on burn and/or blast injury cases and 5 
papers were on poisoning cases (mainly e-liquid intoxication). Fourteen of the poisoning cases were 
fatal. There were two papers under dependence and abuse liability, and both were categorised as 
benefits (smoking cessation). Eight case series paper were categorised under respiratory diseases. All 
were categorised as harms, and almost all harms were related to the lower respiratory tract (for 
example, acute lung injury). In total, there were six fatalities reported. No case series reports were 
categorised under the headings ‘oral diseases’ ‘developmental and reproductive effects’ or ‘other 
outcomes’. 
We did not present information on treatment in our mapping exercise, as we were focusing on 






4.2.2.1 Dependence and abuse liability: case series  
The two case series papers reporting under the heading dependence and abuse liability were from 
the same lead author and reported a total of five cases with a long history of conventional cigarette 
dependence who were able to discontinue smoking, with two cases who also eventually ceased 
vaping as well.128 129 Both papers were published in 2011 (Table 18).  
Table 18 Case series papers on dependence and abuse liability, benefits or harms 
Author(s), year Possible 
benefit 
or harm 




Benefit Product: Three study participants with a history of combustible tobacco 
cigarettes use and a documented history of recurring relapses commenced 
using e-cigarettes to quit smoking 
Dose taken or reported relevant behaviour: The three participants 
commenced using: (1) an e-cigarette loaded with a high nicotine 
concentration of 7.2 mg of nicotine per cartridge two 2 years previously (2) 
an e-cigarette loaded with a high nicotine concentration of 7.2 mg of nicotine 
per cartridge 2 years previously, and (3) an e-cigarette loaded with nicotine 
cartridges two months previously 
Outcome: Each of the three study participants discontinued combustible 




Benefit Product: Two study participants with a history of combustible tobacco 
cigarettes use and suffering from depression commenced using e-cigarettes 
to quit smoking 
Dose taken or reported relevant behaviour: The participant’s smoking history 
was and e-cigarette use commencement was: (1) 30 cigarettes per day (44 
pack-years), e-cigarette loaded with a high nicotine concentration of 7.2 mg 
of nicotine per cartridge (2) 20–30 cigarettes per day (29 pack-years) with a 
significant level of nicotine dependence, e-cigarette loaded with a high 
nicotine concentration 7.2 mg of nicotine per cartridge 
Outcome: Both study participants discontinued combustible tobacco 
smoking between three and six months after commencing use of e-cigarettes 
 
4.2.2.2 Cardiovascular diseases: case series 






Table 19). The paper explored the relationships between potentially cardiotoxic volatile organic 
compounds in non-users of tobacco (n=87), e-cigarette users (n=17), conventional cigarette smokers 
(n=237), and dual users of e-cigarettes and conventional tobacco cigarettes (n=30).130 The authors 
found that there were moderate differences in the raw levels of cotinine across subjects in each 
product category, with conventional cigarette smokers having a slightly higher cotinine level than e-
cigarette users or dual users. E-cigarette users, however, had comparable mean levels of cotinine as 
dual users. The authors also stated that although the contribution of volatile organic compounds to 
tobacco-induced disease is unclear, the observation that volatile organic compound metabolites are 
elevated in e-cigarette users suggests that the use of these products results in volatile organic 
compound exposure. E-cigarette users may potentially be at a higher risk of cardiovascular injury 






Table 19 Case series papers on cardiovascular diseases, benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case series on cardiovascular diseases 
Keith et al. 130 
2019 
Harm Product: Non-users of tobacco (n=87), sole e-cigarette users (n=17), sole 
conventional combustible tobacco cigarette users (n=237), and dual users of 
e-cigarettes and conventional combustible tobacco cigarettes (n=30). Total 
population:n=371 
Dose taken or reported relevant behaviour: Information on dosage or 
relevant behaviours was not reported. However, multivariable-adjusted 
models were employed to assess twenty-three urinary metabolites of 
tobacco-induced aldehydes and other volatile organic compounds 
Outcome: Sole e-cigarette users had higher levels of cardiotoxic metabolites 
of acrolein, acrylamide, acrylonitrile, and xylene compared with non-users of 
tobacco, but lower levels of most volatile organic compound metabolites 
compared with cigarette smokers or dual users 
4.2.2.3 Cancers: case series  
The case series paper reporting on cancer-related outcomes was published in 2017 and described two 
cases of oral carcinoma in older males (aged 59 and 66 years) with no known risk factors for oral 
cancer (such as family history, human papillomavirus infection, or chronic oral infections), but with a 
10-year history of e-cigarette use (Table 20).131  
Table 20 Case series papers on cancers, benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case series on cancers 
Nguyen et al. 131 
2017 
Harm Product: Two study participants with a history of e-cigarette use 
Dose taken or reported relevant behaviour: The participant’s e-cigarette 
history was: (1) e-cigarettes 20 times per day for the past 13 years, and (2) 30 
e-cigarettes per day for the past 13 years 
Outcome: (1) Histopathology revealed a moderately collagenous connective 
tissue stroma infiltrated with nests and islands arising from e-cigarette use (2) 
a diagnosis of basaloid squamous cell carcinoma was made. 
4.2.2.4 Respiratory diseases: case series  
The eight paper on respiratory diseases reported findings of between 2 and 60 cases each and were 
published in 2019 (Table 21). The first paper reported on 60 young adult patients (48 males and 12 
females) with lung injury associated with e-cigarettes or vaping, who were seen in Intermountain 
Healthcare (13 hospitals or outpatient clinics), Utah.132 More than half were admitted to intensive 
care, and two died. Many of the 58 survivors had residual abnormalities at short-term follow-up. The 
second paper reported on two adolescents, one male and one female, with a history of asthma who 
experienced respiratory failure.133 The third paper reported on six males presenting with a variety of 
respiratory and gastrointestinal symptoms who had computer tomography scans of the chest which 
revealed multilobar ground glass opacities with subpleural sparing in the lungs.134 All six reported 
regular use of vaporised cannabis and nicotine products. The patients were treated, and no fatalities 
occurred. The seventh paper in Table 21 reported on eight American males with a history of e-
cigarette use who presented with common features of serious lung damage; seven recovered and one 
died.135 The authors concluded that the respiratory tract damage arose from their vaping practices. 
The remaining four papers described other respiratory-related damage.136-138 139 These four papers 
reported on observed pathologies in 12–53 cases. These included, but were not limited to, 
hypoxaemic respiratory failure, acute lung injury, diffuse alveolar damage, and/or pneumonia. The 
histological findings were not specific, but foamy macrophages and pneumocyte vacuolisation were 





hypersensitivity pneumonitis, and diffuse alveolar haemorrhage. There were three fatalities reported 
in these four papers; the other patients recovered, but only after hospitalisation. 
Table 21 Case series papers on respiratory diseases, benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case series on respiratory diseases 
Blagev et al.132 
2019 
Harm Product: Sixty patients using e-cigarettes or vaping 
Dose taken or reported relevant behaviour: Use of e-cigarettes 
Outcome: Severe lung injury with constitutional and gastrointestinal 




Harm Product: Two study participants with a history of recent and past e-cigarette 
use and asthma 
Dose taken or reported relevant behaviour: The was limited recorded history 
on the participant’s e-cigarette history: for participant (1) a significant 
personal history of e-cigarette use but specific sue was not specified, (2) a 
history of e-cigarette use, the extent of which was not documented and 
secondary exposure to cigarette smoke at home. 
Outcome: Hypercarbic respiratory failure secondary to status asthmaticus 
requiring veno-venous extracorporeal membrane oxygenation, with slow 
recovery on extensive bronchodilator and steroid regimens, in both patients 
Butt et al.134 
2019 
Harm Product: Seventeen patients using e-cigarettes or vaping 
Dose taken or reported relevant behaviour: Use of e-cigarettes 
Outcome: Acute lung injury 
Henry et al.136 
2019 
Harm Product: Nineteen patients using e-cigarettes or vaping 
Dose taken or reported relevant behaviour: Use of e-cigarettes 
Outcome: Acute eosinophilic pneumonia, diffuse alveolar damage, 




Harm Product: Twelve patients using e-cigarettes or vaping 
Dose taken or reported relevant behaviour: Use of e-cigarette containing 
tetrahydrocannabinol oil 
Outcome: Admission to the intensive care unit for hypoxaemic respiratory 
failure, no deaths occurred 
Layden et al.138 
2020 
Harm Product: Fifty-three persons using e-cigarettes 
Dose taken or reported relevant behaviour: Not reported 
Outcome: Respiratory symptoms (bilateral infiltrates), gastrointestinal 
symptoms and constitutional symptoms requiring hospitalisation, one third 




Harm Product: Eight persons using e-cigarettes 
Dose taken or reported relevant behaviour: Not reported 
Outcome: Diffuse bilateral ground glass opacities, acute lung injury, including 




Harm Product: Six persons using e-cigarettes 
Dose taken or reported relevant behaviour: Use of vaporised cannabis and 
nicotine product 
Outcome: Bilateral, multifocal alveolar opacifications on chest x-ray. No 
fatalities occurred. 
4.2.2.5 Oral diseases: case series  
There were no case series papers on the relationship between e-cigarettes and oral diseases. 
4.2.2.6 Developmental and reproductive effects: case series  






4.2.2.7 Injuries and poisonings: case series  
Twenty-four papers reported on injuries and poisonings arising from e-cigarette use and exposure; of 
these papers, 19 reported on injuries (Table 22). and 5 reported on poisonings (Tables 23 and 24). 
4.2.2.7.1 Injuries 
The 19 case series papers on injuries were published between 2016 and 2019 (Table 22). Of the 19 
case series papers which reported on burns and blast injuries, 10 reported two or three cases each 
and 9 reported on 8 to 14 cases. Burns were categorised by body location, the percentage of total 
body surface area covered, and the nature of the accident. Injuries were reported on the lower body 
(thigh, buttock, leg hand, scrotum, penis, and calf), upper body (finger, hand, wrist, forearm, upper 
arm, and ipsilateral fingers), and face (face, bilateral corneal burns and decreased visual acuity, and a 
unilateral corneoscleral laceration with prolapsed iris tissue and hyphaemia). The greatest proportion 
of injuries were to the thigh67 140-150 151 and hand.67 140 142 143 146 148-150 152-154 Burns ranged from 1% to 
16% of total body surface area and ranged from minor superficial burns to deep tissue injury that 
necessitated autologous split-thickness skin grafts. One case series reported that 8 of 14 patients 
required skin grafting. 
Four different mechanisms of burns were described: thermal burns with flames due to the 
phenomenon of ‘thermal runaway’, chemical alkali burns caused by spreading of the electrolyte 
solution, thermal burns without flames due to overheating, and blast lesions following explosion. 67 
146 
E-cigarette explosions or blasts were explicitly reported in 12 papers..67 140-143 146 148 151-156 As well as 
burns, some cases also experienced other injuries. These included injury to the maxilla, resulting in 
bone and anterior maxillary tooth loss requiring reconstruction, while another patient experienced a 
severe blast injury to the mouth and hand, which ultimately resulted in loss of a digit and extensive 
injury to the soft palate and front teeth. 
No fatalities were reported. Some patients achieved full recovery, although a number of patients had 
a lifetime disability that required ongoing medical attention. 
Table 22 Case series papers on injuries and poisonings, presenting as burns and blast injuries, 
benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case series on injuries and poisonings, presenting as burns and blast injuries 
Brownson et al. 
140 
2016 
Harm Product: E-cigarette the lithium-ion battery explosions  
Dose taken or reported relevant behaviour: Not reported 
Outcome: Patients experienced flame burns, chemical burns, and blast 
injuries, to the face, hands, and thigh or groin injuries with substantial 
implications for cosmetic and functional outcomes in the 15 people reported 
on. Tooth loss, traumatic tattooing, and extensive loss of soft tissue, 
requiring operative debridement and closure of tissue defects also occurred 
Herlin et al. 141 
2016 
Harm Product: E-cigarette battery explosion 
Dose taken or reported relevant behaviour: Not reported 
Outcome: Two study participants experienced: (1) 5% total body surface area 
burn lesion on his right thigh followed by a well-conducted excision, however 
he had an incomplete skin graft take and persistent severe pain, suggesting a 
partial elimination of chemical agents during excision (2) 3% total body 
surface area burn on the inner side of his thigh requiring excision and a split-
thickness skin graft on the burn area 
Kite et al. 152 
2016 
Harm Product: E-cigarettes devices explosion 
Dose taken or reported relevant behaviour: Use of homemade vaporizer, and 
commercially purchased mechanical vaporizer 
Outcome: Two study participants experienced: (1) a combustion injury to the 





Author(s), year Possible 
benefit 
or harm 
Case series on injuries and poisonings, presenting as burns and blast injuries 
reconstruction, and (2) a severe blast injury to the hand, which ultimately 
resulted in loss of a digit 
Kumetz et al. 142 
2016 
Harm Product: E-cigarette device which exploded or ignited spontaneously 
Dose taken or reported relevant behaviour: Patients experienced adverse 
events from: (1) e-cigarette device exploded in the patient’s mouth, (2) the 
spontaneous ignition of an e-cigarette in the patient’s pocket 
Outcome: Two study participants experienced injury: (1) facial injuries and 
burns sustained following presentation, the patient was fitted for a maxillary 
prosthetic retainer and underwent several dental implant surgeries, and (2) 
thermal injuries to the right hand and full-thickness injury to the patent’s 
thigh 
Nicoll et al. 143 
2016 
Harm Product: E-cigarette device in which the single-cell rechargeable lithium-ion 
exploded  
Dose taken or reported relevant behaviour: Patients experienced adverse 
events from the explosion of a single-cell rechargeable lithium-ion 
Outcome: Two study participants experienced burns: (1) 4% total body 
surface area superficial partial-thickness burns in addition to minor 
superficial right hand burns which was debrided and grafted (2) 3% total body 
surface area superficial partial-thickness burns to thigh and right hand minor 
superficial burns excised under general anaesthetic 
Sheckter et al. 
144 
2016 
Harm Product: E-cigarette device which spontaneous combustion 
Dose taken or reported relevant behaviour: Patients experienced adverse 
events from the spontaneous explosion of an e-cigarette device 
Outcome: Three study participants experienced burns: (1) a 15% total body 
surface area circumferential deep partial-thickness and full-thickness leg burn 
(2) a 7% total body surface area non-circumferential mixed partial-thickness 
and full-thickness burn to the lateral thigh and calf, and (3) a 2% total body 
surface area burn to his right lateral thigh, all patients recovered 
Arnaout et al. 
145 
2017 
Harm Product: E-cigarette-related burns 
Dose taken or reported relevant behaviour: Patients experienced adverse 
events from the spontaneous explosion or ignition of an e-cigarette device 
Outcome: Twelve study participants experienced burns with a mean total 
body surface area of burns sustained was 2.5% of mixed depth. The most 
common anatomical area burned was the thigh (83%; n=10) with a mean 
duration of 23.1 days (±5 days) to heal with conservative management 
Jiwani et al. 146 
2017 
Harm Product: E-cigarette-related thermally injured 
Dose taken or reported relevant behaviour: Patients experienced adverse 
events from the explosion of e-cigarette devices 
Outcome: Ten study participants experienced burns located on the thigh 
(80%) and the hand (50%), with a mean of 3% of total body surface area 
affected by thermal burns with flames, blast lesions, chemical alkali burns and 
thermal burns without flames 
Paley et al.155 
2017 
Harm Product: E-cigarette-related explosion  
Dose taken or reported relevant behaviour: Patients experienced adverse 
events from the explosion of e-cigarette devices 
Outcome: Two study participants experienced (1) bilateral corneal burns and 
decreased visual acuity, and (2) bilateral corneal burns, decreased visual 
acuity and unilateral corneoscleral laceration with prolapsed iris tissue and 
hyphaemia. 
Patterson et al. 
147 
2017 
Harm Product: E-cigarette-related ignition and explosion 
Dose taken or reported relevant behaviour: Patients experienced adverse 





Author(s), year Possible 
benefit 
or harm 
Case series on injuries and poisonings, presenting as burns and blast injuries 
Outcome: Two study participants experienced (1) injury to thigh and penis, 
and (2) facial burn and corneal abrasions 
Ramirez et al.148 
2017 
Harm Product: E-cigarette-related burns 
Dose taken or reported relevant behaviour: Patients experienced adverse 
events from the explosion of e-cigarette devices 
Outcome: Thirty study participants experienced adverse events arising from 
mainly explosions (identified as the inciting event in 26 of the 30 injuries 
(87%) requiring hospital admission and nine requiring surgery) with 4% of 
total body surface area burns. The thighs, hands, and genitalia were the most 
common sites of injury 
Serror et al.157 
2017 
Harm Product: E-cigarettes related explosions 
Dose taken or reported relevant behaviour: Patients experienced adverse 
events from the explosion of e-cigarette devices 
Outcome: Ten study participants experienced burns mainly to the thigh 
(80%) and the hand (50%) with a mean coverage of 3% of total body surface 
area due to thermal burns with flames, blast lesions, chemical alkali burns 
caused by spreading of the electrolyte solution and thermal burns without 
flames due to overheating 
Smith et al. 149 
2017 
Harm Product: E-cigarettes related explosions 
Dose taken or reported relevant behaviour: Patients experienced adverse 
events from the burns caused by e-cigarette device’s exploding 
Outcome: Two hundred and nineteen study participants experienced adverse 
events arising from burns mainly located at the face, fingers, hands, wrists, 
forearms, upper arms, thighs, knees, lower legs, feet, and buttocks. 
Significant morbidity was reported, with pain both from the burn injury itself 
and because of surgical treatment. Additional lifelong morbidity resulted 
from permanent scar formation was also noted 
Treitl et al.158 
2017 
Harm Product: E-cigarettes related spontaneous combustion of lithium-ion 
batteries  
Dose taken or reported relevant behaviour: Patients experienced adverse 
events from the burns caused by e-cigarette device’s exploding 
Outcome: Three study participants experienced adverse events arising from 
spontaneous combustion. All were treated with debridement and local 
wound care and fully recovered without sequelae. 
Harshman et al. 
150 
2018 
Harm Product: E-cigarettes related spontaneous combustion of device 
Dose taken or reported relevant behaviour: Patients experienced adverse 
events from burns caused by e-cigarette device’s exploding 
Outcome: Two study participants experienced adverse events from burns 
had: (1) mixed partial-thickness and full-thickness flame burns to right 
anterolateral thigh, buttock, and leg, and inner thigh, burns were debrided 
and successfully covered with autologous split-thickness skin grafts, and (2) 
deep partial-thickness and full-thickness burns to right anteromedial thigh 
and superficial partial-thickness burns to his right hand, covering 3% total 
body surface area burns were debrided 
Hickey et al. 153 
2018 
Harm Product: E-cigarettes related spontaneous combustion of device 
Dose taken or reported relevant behaviour: Patients experienced adverse 
events from the burns caused by e-cigarette device’s exploding 
Outcome: Fourteen study participants experienced the adverse events of 
second- and third-degree burns followed by deep and superficial second-
degree burns. The average total body surface area affected was 4.7%. 
Isolated lower extremity burns, and lower extremity and hand burns 
occurred. Nine patients required surgery under general anaesthesia, eight 





Author(s), year Possible 
benefit 
or harm 
Case series on injuries and poisonings, presenting as burns and blast injuries 
Maraqa et al. 154 
2018 
Harm Product: E-cigarette explosion predominantly attributed to its lithium-ion 
battery 
Dose taken or reported relevant behaviour: Patients experienced adverse 
events from the burns caused by e-cigarette device’s exploding 
Outcome: Eight study participants experienced adverse events arising from, 
mainly, explosions resulting in partial- and full-thickness burns, 4% to 16% 
total body surface area to lower extremities, hand, scrotum/penis and chest. 
Two patients (29%) required skin grafting 
Gibson et al. 151. 
2019 
Harm Product: E-cigarette burns from e-cigarette device or from batteries 
Dose taken or reported relevant behaviour: Not reported 
Outcome: Fourteen participants experienced adverse events arising mainly 
from burns. Burn size ranged from <1% to 6% total body surface area, 
majority to thighs with partial- or full-thickness burns. Three patients required 
excision and autografting; all three had suffered full-thickness burns. The 
average time to recovery was 24.5 days 
Simpson et al. 
156 
2019 
Harm Product: e-cigarette-related injuries arising from blast injuries from explosion 
of the device, chemical injuries from leakage of battery fluid, and flame 
injuries from ignition of the lighter’s contents 
Dose taken or reported relevant behaviour: Patients experienced adverse 
events from e-cigarette device’s malfunction 
Outcome: Twelve study participants experienced blast injuries from 
explosion of the device, chemical injuries from leakage of battery fluid, and 
flame injuries from ignition of the lighter’s contents 
4.2.2.7.2 Poisonings 
Five case series papers on poisonings were published between 2016 and 2019 (Tables 23 and 24). 
Three papers reported intentional nicotine poisoning in six cases (three papers each reported on two 
cases), one of which resulted in death.159-161 One paper reported on two fatalities arising from the use 
of a new fentanyl derivative, 4-fluorobutyrfentanyl, vaped via an e-cigarette.162 The fifth paper was a 
retrospective evaluation of the scientific literature on cases of e-liquid nicotine intoxication. The 
authors identified 26 case reports or case series describing a total of 31 patients who suffered from e-
liquid intoxication.163 All intoxications in patients up to the age of 6 years were reported as 
unintentional, whereas nearly all cases of patients between the ages of 13 and 53 years were due to 
suicide attempts. Eleven of the 31 patients captured in the retrospective evaluation died. Three of the 
more prevalent symptoms of e-liquid intoxication were tachycardia, altered mental status, and 
vomiting. The paper concluded that the role of propylene glycol and vegetable glycerine in e-liquid 
intoxications was unclear, but suggested that the similarity between nicotine and propylene glycol 






Table 23 Case series papers on injuries and poisonings, presenting as intentional poisonings, 
benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case series on injuries and poisonings presenting as intentional poisonings 
Jalkanen et al. 
159 
2016 
Harm Product: E-cigarette liquid containing nicotine 
Dose taken or reported relevant behaviour: Patients attempted suicide using 
(1) 100 mg/mL) liquid nicotine (2) taking alcohol and 75 mg of diazepam and 
10 mL of nicotine-containing fluid injected subcutaneously  
Outcome: Two study participants attempted suicide with the following 
outcomes (1) metabolic acidosis, treatment in intensive care and fully 
recovery, and (2) loss of consciousness, treatment in emergency medical care 




Harm Product: E-liquid containing nicotine use for suicide attempts by oral and 
intravenous poisoning 
Dose taken or reported relevant behaviour: Patients attempted suicide via (1) 
oral poisonings with a nicotine concentration at admission of 0.8mg/L, and (2) 
intravenous poisonings with a cotinine concentration at admission of 1.3 
mg/L 
Outcome: Two study participants attempted suicide with the following 
outcomes (1) acute nicotine poisoning without convulsions, and (2) 
unconsciousness and slow respiration 
Rojkiewicz et al. 
162 
2017 
Harm Product: E-liquid containing fentanyl derivative, 4-fluorobutyrfentanyl 
Dose taken or reported relevant behaviour: Two cases of intoxication with a 
(1) 91 ng/mL blood concentration of 4-fluorobutyrfentanyl, and (2) blood 
concentration 112 ng/mL of 4-fluorobutyrfentanyl  
Outcome: Death in both cases 
Park et al. 161 
2018 
Harm Product: E-liquid containing nicotine 
Dose taken or reported relevant behaviour: Patients attempted suicide via 
oral poisonings presenting with levels of (1) 23 mg/kg of nicotine, and (2) 30 
mg/kg of nicotine 
Outcome: Two study participants presented with (1) metabolic acidosis 
leading to cardiac arrest, and (2) transient cardiomyopathy leading to cardiac 
arrest. Both patients survived 
 
Table 24 Case series papers on injuries and poisonings, presenting as accidental poisonings, benefits 
or harms 
Author(s), year Possible 
benefit 
or harm 




Harm Product: E-liquid containing nicotine 
Dose taken or reported relevant behaviour: In the survivors, the highest 
plasma concentration of nicotine was 800 µg/L-1, while the lowest 
concentration in the non-survivors was 1600 µg/L-1 
Outcome: Thirty-one patients presented with unintentional or intentional 
intoxications following e-liquid containing nicotine ingestion. Intoxications 
under the age of 6 years were unintentional, whereas nearly all cases 
between the ages of 13 and 53 years were suicide attempts. The three most 
prevalent symptoms of e-liquid intoxication were tachycardia, altered mental 





4.2.2.8 Exposure to e-cigarette toxins: case series 
One paper reported on two cases of contact dermatitis caused by nickel release from e-cigarettes in 
2018 (Table 25). The first case was a 50-year-old man and the second was a 38-year-old care 
assistant.164 Symptoms in both patients receded on following medical advice to stop vaping. 
Table 25 Case series papers on exposure to e-cigarette toxins, presenting as dermatological 
symptoms, benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case series on exposure to e-cigarette toxins presenting as dermatological 
symptoms 
Shim et al. 164 
2018 
Harm Product: E-cigarettes device material: nickel release 
Dose taken or reported relevant behaviour: Two patients presented with 
adverse skin condition cause by materials in the composition of e-cigarette 
device, the conditions were (1) intermittent facial and hand dermatitis, and (2) 
pruritic patches on palmar surface of right hand  
Outcome: Two study participants experienced adverse events of contact 
dermatitis. Symptoms in both patients receded on following medical advice to 
stop vaping 
4.2.2.9 Other outcomes: case series  






4.2.3 Information or surveillance system reports: e-cigarettes 
4.2.3.1 Study characterisation: e-cigarettes 
There were 34 papers reporting data on e-cigarette and e-liquid-related harms from information or 
surveillance systems (Tables 26–31). Surveillance systems are the systematic and continuous 
collection, analysis, and interpretation of data, which are closely integrated with the timely and 
coherent dissemination of the results so that action can be taken.27 
Reports from surveillance systems provided statistical quantification of the geographic distribution 
and temporal trends in e-cigarette-related adverse outcomes. The 34surveillance papers reporting on 
harms or possible harms related to e-cigarettes were published between 2013 and 2019. The 
surveillance papers were based on reports from Canada, Spain, the UK, the USA, and one survey 
included populations from 10 countries across Europe. The majority of surveillance papers (27 out of 
34) were on injuries and poisonings, while the other category of note was respiratory diseases (4 
papers out of 34). The number of surveillance papers categorised under the adapted Academies of 
Sciences’ framework were: 1 on dependence and abuse liability; 4 on respiratory diseases (mainly 
lung injury); 1 on developmental and reproductive effects; 27 on injuries and poisonings, of which 4 
describe injuries (mainly thermal burns) and 23 describe poisonings (mainly nicotine); and 1 on 
exposure to e-cigarette toxins. No surveillance papers were categorised under the headings 
‘cardiovascular diseases’, ‘cancers’, ‘oral diseases’ or ‘other outcomes’.  
4.2.3.2 Harms: e-cigarettes 
A selection of recent harms identified through surveillance systems reports are as follows: 
• As of 20 September 2019, investigators identified a total of 908 cases of vaping-related pulmo-
nary disease across 45 states in the USA and the U.S. Virgin Islands; of these, 495 were confirmed 
cases and 413 were suspected cases.165  
• As of 15 October 2019, 86% of 867 patients in the USA with lung injury associated with use of e-
cigarettes or other vaping products reported using tetrahydrocannabinol-containing products in 
the 3 months preceding symptom onset.166  
• There was an estimated annual national incidence of 835 injuries in the USA related to e-ciga-
rettes between 2008 and 2017; these injuries were mainly thermal burns.167  
• In 2018, the annual number of e-cigarette poisoning cases increased to 2,901 in the USA.168 Ap-
proximately two-thirds (64.8%) of all poisonings occurred in children aged under 5 years, and 
14.7% were children aged 5–17 years or young adults aged 18–24 years. A small proportion of 
cases, equating to two or three cases each year since 2013, developed life-threatening symptoms, 
and cases with more serious medical outcomes tended to be exposed to a higher quantity of e-
liquid or nicotine. The same trends over time, and pattern of poisonings occurring in children, 
were identified in Canada and the UK. 
• A surveillance paper on the toxicology of e-cigarette constituents reported adverse events affect-







4.2.3.2.1 Dependence and abuse liability: surveillance papers 
The 2013 surveillance paper reported under the heading of dependence and abuse liability was based 
on findings from state tobacco quit lines in the USA (Table 26). Both e-cigarette user groups (those 
who had tried e-cigarettes for 1 month or more, and those who had used e-cigarettes for less than 1 
month) were significantly less likely to be tobacco abstinent at the end of a 7-month survey period 
compared with participants who had never tried e-cigarettes. 170 
Table 26 Surveillance papers on dependence and abuse liability, benefits or harms 
Author(s), year Possible 
benefit 
or harm 




Harm  The authors investigated the prevalence of e-cigarette use among tobacco 
users who sought help from state tobacco quit lines, the reasons for their use, 
and whether e-cigarettes impact a user’s ability to successfully quit tobacco, 
and described the differences between state quit line callers who had used e-
cigarettes for 1 month or more, had used e-cigarettes for less than 1 month, 
or had never tried e-cigarettes. Nearly one-third (30.9%) of respondents 
reported ever using or trying e-cigarettes; most of those had used e-
cigarettes for a short period of time (61.7% for less than 1 month). The most 
frequently reported reasons for use were to help quit other tobacco (51.3%) 
or to replace other tobacco (15.2%). Both e-cigarette user groups were 
significantly less likely to be tobacco abstinent at the time of the 7-month 
survey compared with participants who had never tried e-cigarettes (30-day 
point prevalence quit rates: 21.7% and 16.6% versus 31.3%, p<0.001).  
4.2.3.2.2 Cardiovascular diseases: surveillance papers 
There were no surveillance papers on the relationship between e-cigarettes and cardiovascular 
diseases. 
4.2.3.2.3 Cancers: surveillance papers 






4.2.3.2.4 Respiratory diseases: surveillance papers 
Four papers reported on respiratory outcomes in e-cigarette users (Table 27). All papers reported on 
populations in the USA and were published in 2019.  
The first surveillance paper investigated the national outbreak of lung injury associated with e-
cigarette or other vaping product use in the USA.166 Based on data collected by 15 October 2019, 86% 
of 867 patients with lung injury associated with the use of e-cigarettes or other vaping products 
reported using tetrahydrocannabinol-containing products in the 3 months preceding symptom onset. 
Analyses of tetrahydrocannabinol-containing products identified potentially harmful constituents, 
such as vitamin E acetate and medium-chain triglyceride oil.  
The second surveillance paper reported on more than 200 probable cases of acute lung injury, 
potentially associated with vaping, in 25 states.171 Five adults aged 18–35 years (out of the more than 
200 probable cases) were diagnosed with acute lung injury potentially associated with e-cigarette 
use. Patients experienced several days of worsening dyspnoea, nausea, vomiting, abdominal 
discomfort, and fever. All patients demonstrated tachypnoea, hypoxaemia, and bilateral lung 
infiltrates on chest X-ray. All shared a history of recent use of marijuana oils or concentrates in e-
cigarettes. All of the products used were electronic vaping pens/e-cigarettes that had refillable 
chambers or interchangeable cartridges with tetrahydrocannabinol vaping concentrates or oils, all of 
which were purchased on the street. Three patients also used nicotine-containing e-cigarettes, and 
two of the patients smoked marijuana or conventional tobacco cigarettes. No other illicit drugs were 
used by the patients. All patients were hospitalised for hypoxaemic respiratory failure. All patients 
survived following intensive treatment. 
The third surveillance paper reported on a vaping-related pulmonary disease outbreak in the USA and 
covered the period from July to September 2019.165 Using an online mining tool, a total of 119 
confirmed and suspected cases were detected in 16 states by 28 August 2019. The number of cases 
more than doubled by 6 September 2019, reaching a total of 288 cases across 28 states. As of 20 
September 2019, investigators identified a total of 908 cases of vaping-related pulmonary disease 
across 45 states in the USA and the U.S. Virgin Islands, of which 495 were confirmed cases and 413 
were suspected cases. 
The final surveillance paper described the characteristics of medical care, potentially related 
conditions, and exposures among 83 patients in Utah.172 Of the total study population, 70 (89%) were 
hospitalised, 39 (49%) required breathing assistance, and many reported pre-existing respiratory and 
mental health conditions. Among 53 interviewed patients, all of whom reported using e-cigarette (or 
vaping) products within 3 months of the onset of an acute lung injury, 49 (92%) reported using 
products containing tetrahydrocannabinol (without nicotine), 35 (66%) reported using nicotine-
containing products (without tetrahydrocannabinol), and 32 (60%) reported using both 
tetrahydrocannabinol- and nicotine-containing products.  
Table 27 Surveillance papers on respiratory diseases, benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Surveillance papers on respiratory diseases 
Blount et al.166 
2019 
Harm The authors investigated a national outbreak of lung injury associated with e-
cigarette, or vaping, product use. Based on data collected as of 15 October 
2019, 86% of 867 e-cigarette, or vaping, product use-associated lung injury 
patients reported using tetrahydrocannabinol-containing products in the 3 
months preceding symptom onset. Analyses of tetrahydrocannabinol-
containing product samples by Food and Drug Administration and state public 
health laboratories have identified potentially harmful constituents in these 
products, such as vitamin E acetate, medium-chain triglyceride oil, and other 
products. Vitamin E acetate, in particular, might be used as an additive in the 
production of e-cigarette, or vaping, products; it can also be used as a 
thickening agent in tetrahydrocannabinol products. Inhalation of vitamin E 





Author(s), year Possible 
benefit 
or harm 




Harm The authors reported on more than 200 possible cases of acute lung injury 
potentially associated with vaping reported from 25 states. During July and 
August 2019, five patients were identified at two hospitals in North Carolina 
with acute lung injury potentially associated with e-cigarette use. The 
patients were adults aged 18–35 years, and all experienced several days of 
worsening dyspnoea, nausea, vomiting, abdominal discomfort, and fever. All 
patients demonstrated tachypnoea with increased difficulty with breathing 
on examination, hypoxaemia (pulse oximetry <90% on room air), and bilateral 
lung infiltrates on chest X-ray. All five patients shared a history of recent use 
of marijuana oils or concentrates in e-cigarettes. All of the products used 
were electronic vaping pens/e-cigarettes that had refillable chambers or 
interchangeable cartridges with tetrahydrocannabinol vaping concentrates or 
oils, which were all purchased on the street. Three of the patients also used 
nicotine-containing e-cigarettes, and two of the patients smoked marijuana or 
conventional combustible tobacco cigarettes, although none used other illicit 
drugs. All five patients were hospitalised for hypoxaemic respiratory failure. 
All of the patients survived.  
Hswen et al.165 
2019 
Harm The authors reported, using real-time digital surveillance techniques, an 
integrated view of the vaping-related pulmonary disease outbreak in the USA 
since late July 2019. The authors collected online information from disparate 
sources including news aggregators, eyewitness reports, and validated official 
alerts. The authors curated and classified the data by disease case, location, 
and time. The first 8 suspected cases were detected by the authors’ online 
mining tool on 25 July 2019 in Wisconsin. By 28 August, a total of 119 
confirmed and suspected cases had been detected in 16 states. The number 
of cases more than doubled by 6 September 2019, reaching a total of 288 
cases across 28 states. By 11 September, the number of cases had increased 
to 522, spanning 39 states and the U.S. Virgin Islands. As of 20 September 
2019, the authors identified a total of 908 cases of vaping-associated severe 
pulmonary disease across 45 states in the USA and the U.S. Virgin Islands: 495 
confirmed cases and 413 suspected cases. A total of 8 deaths were identified 
in California, Kansas, Illinois, Indiana, Minnesota, Oregon, and Missouri. The 
authors concluded that their findings highlighted the emerging epidemic.  
Lewis et al.172 
2019 
Harm The authors described the characteristics of medical care, potentially related 
conditions, and exposures among 83 patients in Utah, and detailed medical 
abstractions were completed for 79 patients (95%). Of the 79 patients, 70 
(89%) were hospitalised, 39 (49%) required breathing assistance, and many 
reported pre-existing respiratory and mental health conditions. Among 53 
interviewed patients, all of whom reported using e-cigarette, or vaping, 
products within 3 months of the acute lung injury, 49 (92%) reported using 
any products containing tetrahydrocannabinol, 35 (66%) reported using any 
nicotine-containing products, and 32 (60%) reported using both. Product 
sample testing at the Utah Public Health Laboratory showed evidence of 
vitamin E acetate in 17 of 20 (89%) tetrahydrocannabinol-containing 
cartridges, which were provided by 6 of the 53 interviewed patients.  
4.2.3.2.5 Oral diseases: surveillance papers 
There were no surveillance papers on the relationship between e-cigarettes and oral diseases. 
4.2.3.2.6 Developmental and reproductive effects: surveillance papers 
Trends in e-cigarette use among pregnant women in the USA were reported in one surveillance paper 
and indicate that 7% of women with a live birth in Oklahoma and Texas reported using e-cigarettes 
shortly before, during, or after pregnancy (Table 28).173 Of note, 1.4% reported using e-cigarettes 





Table 28 Surveillance papers on developmental and reproductive effects, benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Surveillance papers on developmental and reproductive effects 




The authors reported on the use of electronic vaping products in women 
around the time of pregnancy in 2015. The authors found that 7% of women 
with a recent live birth in Oklahoma and Texas reported using electronic 
vaping products shortly before, during, or after pregnancy, with 1.4% 
reporting use during pregnancy. Among prenatal electronic vaping product 
users, 38.4% reported using products containing nicotine, and 26.4% did not 
know if the products they used contained nicotine.  
4.2.3.2.7 Injuries and poisonings: surveillance papers 
Twenty-seven surveillance papers reported findings on injuries and poisonings arising from e-
cigarette use and exposure. Four papers reported on burns (Table 29) and 23 papers reported on 
poisonings (Table 30).  
4.2.3.2.7.1 Injuries 
All papers publishing surveillance data on burn-related injuries were from the USA and were prepared 
using information from six federal agencies: the United States Department of Health and Human 
Services; the Food and Drug Administration; the Federal Aviation Administration; the United States 
Consumer Product Safety Commission, including the National Electronic Injury Surveillance System; 
the United States Coast Guard; and the United States Fire Administration (Table 29). Concerns within 
federal agencies regarding e-cigarette-related burn injuries arose following alarms raised by a range 
of individuals and regulatory bodies. Information from professionals on the ground, in the media, in 
the scientific literature, and in reports raised awareness of a new fire risk leading to possible adverse 
events; for example, a report on fire risk arising from e-cigarettes in flight baggage and e-cigarette-
related burns presenting for hospital admissions.  
A number of reports from USA hospital emergency departments have identified e-cigarettes as a new 
mechanical and chemical risk to health. Using actual case reports from emergency departments, it has 
been estimated that the USA national average of e-cigarette injury between 2008 and 2017 was 835 
per year.167 
Most of the injuries were thermal burns.167 174 175 The primary location of injury was in the lower 
extremity,167 174 followed by the upper extremity, including hands.167 The authors determined that the 
findings demonstrated a significant increase in the number of e-cigarette-related injuries over the 






Table 29 Surveillance papers on injuries and poisonings, presenting as burns and/or blast injuries, 
benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Surveillance papers on injuries and poisonings presenting as burns and/or 
blast injuries 
Corey et al. 174 
2016 
Harm The authors reported findings from 2016 United States National Electronic 
Injury Surveillance System data. In that year, 26 ENDS battery-related burn 
cases were reported, which translates to a national estimate of 1,007 (95% CI: 
357–1,657) injuries presenting in the USA due to ENDS. The burns were 
mainly thermal in nature (80.4%) and mainly affected the upper leg/lower 
trunk (77.3%). Examination of the case narrative field indicated that at least 
20 of the burn injuries occurred while ENDS batteries were in the user’s 
pocket.  
Rudy et al. 175 
2016 
Harm The authors reported on electronic nicotine delivery system (ENDS)-
associated overheating, fire, or explosion events since 2009. Using data from 
4 USA federal agencies, scientific literature, and media outlets, the authors 
identified 92 overheating, fire, or explosion events in the USA, of which 45 
(49%) injured 47 people, and 67 (73%) involved property damage beyond the 
product. Events were identified in media outlets (n=50; 54%) and reported to 
4 agencies (n=42; 46%). The report rate peaked at an average of 6 reports per 
month in late 2013 with a smaller peak of 3–4 reports per month in the 
second quarter of 2015. All reports were incomplete, and events exhibited 
variability. The authors suggested that more comprehensive reporting could 
assist future analyses and may help to identify root causes and contributors 
to the overheating, fire, or explosion events.  
Rossheim et al. 
176 
2018 
Harm The authors used current surveillance data to estimate the actual occurrence 
of cases of explosions and burn injuries on the basis that the recorded 
incidence is likely to underestimate actual occurrences. Sampling weights 
were applied in order to make conservative national incidence estimates. The 
authors concluded that, from 2015 to 2017, there were an estimated 2,035 e-
cigarette explosion and burn injuries presenting to USA hospital emergency 
departments (95% CI: 1,107–2,964). The authors concluded that there were 
more e-cigarette explosion and burn injuries in the USA than estimated in 
previously published reports.  
Dohnalek et al. 
167 
2019 
Harm The authors, using information from a national database of emergency 
department visits, characterised the nature and frequency of ENDS injuries 
over a 10-year study period. Using archived information from the National 
Electronic Injury Surveillance System for the years 2008–2017, incidents of 
ENDS-related trauma were manually identified. A total of 49 incidents were 
recorded between the years 2008 and 2017, including 18 cases in 2017, 25 
cases in 2016, 5 cases in 2015, and 1 case in 2013. There were no identified 
emergency department visits for an e-cigarette-related burn or explosion 
prior to 2013. Using statistical weights, the estimated annual national 
incidence is 835 cases. Most of the injuries were thermal burns. The primary 
location of injury was in the lower extremity, followed by the upper extremity 
and hand. The authors concluded that the study demonstrated a significant 
increase in the number of ENDS-related injuries over the study period, 







Twenty-three papers reported on e-cigarette-related poisonings: 18 from the USA, 2 from Canada, 
and 3 from Europe (Spain, the UK, and 10 de-identified European Union member states). Summaries 
of these papers are presented in Table 30.  
4.2.3.2.7.2.1 Canada 
Two surveillance papers reported on e-cigarettes with adverse outcomes in the Canadian population.  
The first is a report from the British Columbia Drug and Poison Information Centre,177 and the second 
is a one-time survey of all paediatricians in Canada.178 
The British Columbia data reported on the content of calls to the British Columbia Drug and Poison 
Information Centre between 2012 and 2017. 177 Over this 5-year period, 186 (76%) of 243 calls were 
related to exposures to e-cigarette devices, e-liquid, e-cigarette cartridges, and other associated 
paraphernalia. There was a six-fold increase in calls between 2012 and 2013, which then remained at 
a steady volume until 2017. Just under 45% of the calls related to exposures, predominantly 
accidental, in children under the age of 4 years. The predominant route of poisoning was through 
ingestion, and almost 48% of those exposed to poisoning reported symptoms.  
The second paper also reported on e-cigarette-related adverse events, but additionally elicited 
information on a range of factors, including the nature of injury, treatment provided, and how 
products were accessed.178 From 520 completed surveys, 220 adverse events were identified, 135 of 
which experienced adverse events due to product inhalation. Most inhalation-related adverse events 
occurred in males aged 15–19 years. The 85 adverse events arising from ingestion were mainly 
reported in children aged 1–4 years and resulted in gastric and respiratory symptoms. The cases 
involving younger patients accessed e-liquid at home, while the cases involving older patients 
accessed e-liquid in kiosks and stores.  
4.2.3.2.7.2.2 Europe 
Three surveillance papers based in Europe reported on e-cigarettes and their adverse outcomes. The 
three papers were from Spain,179 and the UK,180 and one paper covered 10 de-identified European 
Union member states.181 
The findings from Spain noted an increase in the number of reported poisoning cases between 
January 2013 and April 2014, with a total of 64 cases, predominantly resulting after ingestion of e-
liquid from refillable cartridges; 28% of these cases involved children.179  
The UK had 278 reported queries to its poison centre between January 2008 and March 2016. There 
were few cases reported prior to 2012.180 The cases reported in the 3-year period from 2013 to 2016 
were mainly accidental in nature and asymptomatic. Of the intentional poisonings in the UK during 
this period, four out of five involved male adolescents. Symptoms, where present, were usually 
minor, consisting of vomiting, tachycardia, dysaesthesias, irritation, and increased creatine kinase. 
Data from the national poison centres of 10 European Union member states were reported in a 2012–
2015 European-based surveillance paper.181 Of 277 e-liquid-related poisoning incidents, 71% were 
unintentional, and 67% occurred as a result of ingestion. The other exposure routes were inhalation, 
and ocular. 
4.2.3.2.7.2.3 USA 
The USA’s 18 papers predominantly reported findings from the USA’s National Poison Data System or 
its state-level centres (Arizona, California, Mississippi, Oregon, Texas, and Wisconsin). In total, there 
were 15 poison centre reports, 7 reporting at national level 182-185 186 187 168 and 8 at state level. 188-190 
191-193 194 195 
Reporting was facilitated by the introduction of new unique codes to better capture e-cigarette-





generic codes 0200620 and 0200622 were developed to better classify e-cigarette-related 
information. 196  
The seven national-level reports covered five overlapping time periods between January 2001 and 
December 2018.182-185 186 187 168 The incidences of poisoning reports were described using health 
determinants (age and sex), body part affected, geographic location (residence, work, state), mode of 
poisoning (ingestion, intravenous, topical absorption), and poisoning intent. For instance, poisonings 
in children aged under 5 years usually occurred by accidental ingestion in their own residence, as was 
highlighted in the American Association of Poison Control Centers 2014 paper.183 In addition to the 
determinants of age and sex, the two additional principal determinants of poisoning were individual 
behaviours (e.g. suicidal intent) and the regulatory environment (determining the packaging 
requirements for e-liquids).  
The eight state-level reports covered six states and time periods between 2009 and 2015.188-190 191-193 
194 195 In brief, some of the reporting characteristics were: poisoning intent, age, sex, vital signs, 
offending agent(s), medication(s) dosage, laboratory values, interventions, and outcomes. In addition, 
some state bodies undertook chemical analysis of the e-liquid. Among other issues, in a number of e-
liquids, they identified differences between the printed and actual chemical composition of the 
examined products.  
The most recent poisoning data were reported by Wang et al. (2019).168 The authors described trends 
and characteristics of poisoning exposure cases involving e-cigarettes and e-liquids in the USA 
reported to the National Poison Data System by year (2010–2018) and by other characteristics. The 
annual number of e-cigarette exposure cases increased greatly between 2010 and 2014, reaching a 
peak of 3,742 in 2014, and then decreasing each year between 2015 and 2017. Between 2017 and 
2018, the overall number of e-cigarette exposure cases increased again by 25% (from 2,320 in 2017 to 
2,901 in 2018). Approximately two-thirds (64.8%) of all poisonings were in children aged under 5 
years, 6.4% were children aged 5–17 years, and 8.3% were young adults aged 18–24 years. A small 
proportion of cases developed life-threatening symptoms (0.1%, equating to two or three cases per 
year), and cases with more serious medical outcomes tended to be exposed to a higher quantity of e-
liquid or nicotine. 
Recent findings from the USA’s National Electronic Injury Surveillance System were also reported in 
two surveillance papers.197 198 Data from 2013 to 2017 and from 2018 were used to calculate national 
estimates (95% CIs) of liquid nicotine-related poisonings among children aged under 5 years treated 
in USA hospital emergency departments. The number of e-liquid-related poisoning cases treated in 
hospitals increased from 181 (95% CI: 0–369) in 2013 to 1,736 (95% CI: 871–2,602) in 2015, and then 
decreased to 411 (95% CI: 84–738) in 2017, rising again to an estimated 885 (95% CI: 397–1,374) in 
2018. The most common mode of poisoning was ingestion. Authors of the 2013–2017 estimates 
noted that at the time of reporting, the National Electronic Injury Surveillance System data did not 
include product codes specific to e-cigarettes or provide information on poisoning severity as a result 
of e-liquids; the authors were therefore required to use general keywords to capture these events 
and concluded that this might underestimate the population burden. 
Finally, adverse events related to smoking cessation treatments and e-cigarettes in the United States 
Food and Drug Administration’s Adverse Event Reporting System covering the period from April 2004 
to December 2016 were reported by Motooka et al. (2018).199 The total number of cases related to 
the administration of nicotine (after exclusion of duplicates) was 7,348,357. Adverse events were 
coded to the preferred terms of MedDRA Version 19.0. The number of adverse events (specifically 
nausea, nicotine dependence, and dizziness) for all forms of nicotine replacement therapy (NRT) was 
1,673 for transdermally administered NRT, 1,016 for buccal NRT, 425 for oral NRT, and 56 for inhaled 
NRT. Regarding e-cigarettes, adverse events such as dizziness, dyspnoea, nausea, increased heart 
rate, and tremor were reported. For e-cigarettes, there were 27 cases where e-liquids were 
categorised as the primary suspect responsible for an adverse event. These included the adverse 
events of dizziness (n=4) and dyspnoea (n=4). There were two reported cases of each of the following: 
nausea, chest pain, increased heart rate, tremor, disorientation, cough, and wheezing. There was one 
reported case each of thermal burn, pulmonary oedema, and throat irritation. Other detected terms 





altered visual depth perception, chills, device component issue, device deposit issue, device physical 
property issue, fear, headache, insomnia, lung disorder, malaise, migraine, product label issue, 
productive cough, panic reaction, sensation of heaviness, and seventh nerve paralysis, and two cases 
each of device malfunction and of pain. 
Table 30 Surveillance papers on injuries and poisonings, presenting as poisonings, benefits or harms 
Author(s), year Possible 
benefit or 
harm 
Surveillance papers on injuries and poisonings presenting as poisonings 




Harm The authors reported on symptoms related to inhalation in e-cigarette users 
in order to understand the relationship between hazardous materials in e-
cigarettes and fluid (e-liquid) when inhaled or ingested, and the health risks 
in children and adolescents. The work explored the spectrum of injuries 
related to e-cigarette exposure among Canadian children and adolescents. A 
one-time survey was sent to all paediatricians in Canada. Information was 
collected on children and adolescents who presented with e-cigarette 
exposure (inhalation and ingestion cases) in the previous 12 months. 
Questions included the number of injuries and symptoms, in addition to age, 
sex, treatment setting, intentional e-cigarette use, and how the products 
were accessed. A total of 520 surveys were completed and returned, 
identifying 220 cases. Symptoms related to inhalation were present in 135 
inhalation cases (43 unintentional, 92 intentional) and in 85 ingestion cases 
(35 unintentional, 50 intentional). For inhalation cases, most were males 
aged 15–19 years who sought treatment in an outpatient clinic/office for 
nausea/vomiting, cough, throat irritation, or acute nicotine toxicity. Most 
inhalation cases reported e-cigarette use 2–3 days/week, and that e-
cigarettes were purchased from a mall kiosk/store. For ingestion cases, most 
were males aged 1–4 years presenting to an emergency department with 
nausea/vomiting, cough, or respiratory irritation. Younger cases accessed e-
liquid at home, whereas older cases purchased it in a mall kiosk/store. E-
liquid flavours reported to have been consumed were fruit, candy, and 
tobacco. The authors concluded that e-cigarettes, recently introduced into 
the North American market, are hazardous to children and adolescents.  
Choi et al.177 
2019 
Harm The authors conducted an observational case series study using records 
containing both coded fields and free-text narratives from the British 
Columbia Drug and Poison Information Centre for all calls involving exposure 
to ENDS (poisonings) received from 2012 to 2017. The authors described 
trends in exposures and exposed people, as well as clinical effects. A total of 
243 calls were recorded for 186 unique exposures to e-cigarette devices, e-
juice, e-cigarette cartridges, and other associated paraphernalia over the 
study period. Calls related to ENDS exposures increased nearly six-fold 
between 2013 and 2014 and did not subsequently decline. Exposures were 
most frequently documented in children aged 4 years or under (81 [43.5%]), 
with 58 cases (31.0%) occurring in 1- and 2-year-olds. 72 exposures (89%) in 
children aged 4 years or under were due to accidental ingestion. Adults aged 
25 years or older called the poison centre following ENDS malfunctions (7 
[23%]), spills (4 [13%]), and exposure to e-juice mistaken for other 
substances (4 [13%]). Of the 186 exposed people, 87 (46.8%) reported 
symptoms.  




Harm The authors reported on findings from 10 European Union member states on 
e-cigarette exposures from national poison centres between 2012 and 
March 2015. Of the 277 incidents reported, 71.3% were unintentional 
exposures (with e-cigarette refill vials responsible for 87.3% of the reported 
incidents). Two-thirds (67.5%) of all exposures occurred as ingestion of e-
liquids, which was more frequent among children (≤5 years, 6–18 years) 
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p<0.001); exposure via the respiratory tract (5.4% versus 22.2% versus 
22.2%, respectively; p<0.001) was more frequent among paediatric patients 
and adults, while ocular routes (2.2% versus 3.7% versus 11.4%, respectively; 
p=0.021) were more frequent among adults. Logistic regression analyses 
indicated that paediatric incidents (in children aged ≤5 years) were more 
likely to be through ingestion (adjusted odds ratio (AOR): 4.36; 95% CI: 1.87–
10.18), but less likely to have a reported clinical effect (AOR: 0.41; 95% CI: 
0.21–0.82).  
Spain   
de la Oliva et 
al.179 
2014 
Harm The authors reported on an audit of calls regarding cases of exposure to e-
cigarette-related poisons between 1 January 2013 and 30 April 2014. 
Information was obtained from the database of the Spanish poison centre 
(Servicio de Información Toxicológica). They found 64 cases in which the 
recorded product involved was an e-cigarette, and observed an increase 
from 3 to 23 cases in the last quarter of 2013. Two-thirds of the cases 
registered involved the ingestion of liquid contained in the refillable 
cartridge; 28.1% were children (and 77.7% of those were aged under 2 
years).  
UK   
Ang et al.180 
2018 
Harm The authors explored the effects of e-liquid exposure (poisoning) in the 
paediatric population from an analysis of all telephone enquiries to the UK’s 
National Poisons Information Service. Cases of childhood e-liquid exposure 
from April 2008 to March 2016 were evaluated from the UK National Poisons 
Information Service database. The National Poisons Information Service 
received 278 enquiries regarding e-liquid exposure in children aged under 16 
years between 2008 and 2016 involving 165 boys, 112 girls, and 1 of 
unknown sex. Most (222, 79.8%) were aged under 4 years. Most incidents 
were accidental and asymptomatic; no deaths occurred in this series, 
although complete follow-up data for individual cases are not available. Out 
of five intentional exposures, four involved male adolescents. When 
symptoms were present (63/278 cases), they were generally minor. The 
most common clinical features experienced by the children were vomiting 
(9.5%), tachycardia (2%), dysaesthesia (1%), irritation (1%), and increased 
creatine kinase (1%).  
USA   
Cantrell Clark et 
al.188 
2014a 
Harm The authors reported on findings from telephone calls to poison control 
centres in California between 2010 and 2013 on exposures to nicotine 
solution. There were 35 cases from 2010 to 2012, and 105 cases in 2013 
alone. In 2013, exposure to nicotine refill solution was involved in 18% of all 
cases. Exposure in 10 children resulted in hospital evaluation for 7. Five 
adults mistakenly instilled nicotine refill solution instead of eyedrops into 
their eyes, resulting in considerable but transient irritation in each case. In 
addition, systemic symptoms of nicotine poisoning developed in three adults 
after they spilled nicotine refill solution on their skin.  
Cantrell189 
2014b 
Harm The second paper from these authors reports on findings from a state-wide 
poison system from 2010 to 2012. A total of 35 cases of nicotine-related 
poisonings were identified: 4 in 2010, 12 in 2011, and 19 in 2012. The 
patients’ ages ranged from 8 months to 60 years. Reported symptoms were 
mild and transient. Five patients were evaluated in an emergency 
department and none were admitted. Product nicotine concentrations 
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Harm The authors reported on findings from USA poison centres about human e-
cigarette-related poisonings (exposure calls) from September 2010 (when 
new, unique codes were added specifically for capturing e-cigarette calls) 
through to February 2014. During the study period, poison centres reported 
2,405 e-cigarette and 16,248 cigarette exposure calls from across the USA 
and its territories. E-cigarettes accounted for an increasing proportion of 
combined monthly e-cigarette and cigarette exposure calls, increasing from 
0.3% in September 2010 to 41.7% in February 2014. A greater proportion of 
e-cigarette exposure calls than cigarette exposure calls came from 
healthcare facilities (12.8% versus 5.9%). Cigarette exposures were primarily 
among persons aged 0–5 years (94.9%); e-cigarette exposures, on the other 
hand, occurred among persons aged 0–5 years in 51.1% of cases and among 
persons aged over 20 years in 42.0% of cases. E-cigarette exposures were 
more likely than cigarette exposures to be reported as inhalations (16.8% 
versus 2.0%), eye exposures (8.5% versus 0.1%), and skin exposures (5.9% 
versus 0.1%), and less likely than cigarette exposures to be reported as 
ingestions (68.9% versus 97.8%). Among the 9,839 exposure calls with 
information about the severity of adverse health effects, e-cigarette 
exposure calls were more likely than cigarette exposure calls to report an 




Harm The authors reported on trends in e-cigarette-related poisonings reported to 
USA poison centres between 1 June 2010 and 30 September 2013. In 
addition to the trends in exposures over time, trends in demographics, 
geographic characteristics, clinical effects and outcomes, management site, 
and exposure route were also assessed. A total of 1,700 exposures were 
reported to poison centres during this time. The most frequently affected 
age groups were children aged under 5 years, with 717 (42.2%) exposures, 
and adults aged 20–39 years, with 466 (27.4%) exposures. Temporal trends 
showed an increase of 1.36 exposures per month (95% CI; 1.16–1.56) from 
June 2010 through December 2012, after which the average number of 
exposures increased by 9.6 per month (95% CI; 8.64–10.55) between January 
and September 2013. Most patients who were followed up on reported that 
they had only minor effects. The majority of exposures to e-cigarette devices 




Harm The author reported findings from Texas poison centres from January 2010 
to June 2014. Cases of e-cigarette-related poisonings among patients aged 5 
years or under were reported. Of 203 exposures, 2 cases were reported in 
2010, 5 in 2011, 20 in 2012, 70 in 2013, and 106 between January and June 
2014. 51% of the patients were male; 32% of the patients were aged 1 year, 
and 42% were aged 2 years. 96% of the exposures occurred at the patient’s 
own residence. The exposure routes were ingestion (93%), dermal (11%), 
ocular (3%), and inhalation (2%). 58% of the patients were managed on site. 
Of the patients seen at a healthcare facility, 69% were treated or evaluated 
and released. 11% of the exposures were serious. The most commonly 
reported clinical effects were vomiting (24%), drowsiness/lethargy (2%), and 
cough/choking (2%). The author found e-cigarette exposures involving young 
children reported to poison centres to be increasing, with exposures most 
likely to involve patients aged 2–3 years, occur at the child’s own residence, 




Harm The authors conducted a retrospective medical record review of e-cigarette-
related poisoning calls to the Arizona Poison Control Centre in order to 
evaluate trends in exposures over time and patient demographics, and to 
further characterise outcomes following e-cigarette exposure. Data from 
cases of e-cigarette exposures called into the Arizona Poison Control Centre 
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collected included case number, age, sex, vital signs, intent, offending 
agent(s), medication(s), dosage, laboratory values, interventions, and 
outcomes. All191 patients were followed until the cessation of symptoms or 
were evaluated via a 1-hour telephone follow-up if asymptomatic. During the 
study period, 100 patients met the inclusion criteria. E-cigarette exposure 
calls increased annually, with 10 total reported exposures in 2012, 24 in 
2013, and 66 in 2014. Children aged 5 years or under accounted for 52.0% of 
total exposure calls (range: 40.0%–54.2%). All patients were asymptomatic or 
reported mild symptoms, including vomiting, nausea, and dizziness. Poison 
dose information was not obtained, so the mild clinical symptoms may 
reflect low exposure doses.  
Ordonez et al.192  
2015 
Harm The authors reported on e-cigarette-related poisonings reported to Texas 
poison centres between 2009 and February 2014. Of 225 total exposures, 2 
were reported in January 2009, 6 in 2010, 11 in 2011, 43 in 2012, 123 in 
2013, and 40 through February 2014. 53% (n=119) occurred among 
individuals aged 5 years or under, 41% (n=93) occurred among individuals 
aged 20 years or over, and 6% (n=13) occurred among individuals aged 6–19 
years. 50% were female. The route of exposure was ingestion in 78% of 
cases. 87% of the exposures were unintentional, and 5% were intentional. 
The exposures occurred at the patient’s own residence in 95% of the cases. 
The clinical effects reported most often were vomiting (20%), nausea (10%), 




Harm The authors reported on findings from the Mississippi State University Social 
Science Research Center. Surveys assessed e-cigarette use among Mississippi 
adolescents and adults. The centre provided data on reported cases of e-
cigarette-related poisonings. From 2010 to 2014, current e-cigarette use 
increased from 0.6% to 6.7% among middle school students, from 1.2 % to 
10.1% among high school students, and from 0.2% to 6.8% among adults. 
There were no reported cases of e-cigarette-related poisonings in 2010, 





Harm The authors compared findings from poison centres from September 2010 
through December 2014, reporting data on monthly counts and 
demographics, exposure, and health effects from calls about e-cigarettes 
and conventional combustible tobacco cigarettes. Monthly e-cigarette calls 
increased from 1 in September 2010 to a peak of 401 in April 2014, and 
declined to 295 in December 2014. Monthly conventional combustible 
tobacco cigarette calls during the same period ranged from 302 to 514. E-
cigarette calls were more likely than conventional combustible tobacco 
cigarette calls to report adverse health effects, including vomiting, eye 
irritation, and nausea. Five e-cigarette calls reported major health effects, 
such as respiratory failure, and there were two deaths associated with e-
cigarette calls.  
Kamboj et al.185 
2016 
Harm The authors reported on poisonings associated with nicotine and tobacco 
products among children aged 6 years or under from the USA’s National 
Poison Data System data from January 2012 through April 2015. There were 
29,141 calls for nicotine and tobacco product exposures among children 
aged 6 years or under, averaging 729 child exposures per month. Tobacco 
cigarettes accounted for 60.1% of exposures, followed by other tobacco 
products (16.4%) and e-cigarettes (14.2%). The monthly number of 
exposures associated with e-cigarettes increased by 1,492, or 9%, over the 
study period. Children aged under 2 years accounted for 44.1% of e-cigarette 
exposures, 91.6% of cigarette exposures, and 75.4% of other tobacco 
exposures. Children exposed to e-cigarettes had 5.2 times higher odds of a 
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outcome than children exposed to cigarettes. One death occurred in 
association with a nicotine liquid exposure.  
Weiss et al.194 
2016 
Harm The authors reported on tobacco cigarette and e-cigarette-related 
poisoning calls to the Wisconsin Poison Center from 1 January 2010 through 
10 October 2015. The authors compared cigarette and e-cigarette exposure 
calls by several characteristics. During the study period, 98 e-cigarette 
exposure calls were reported, and the number of annual e-cigarette 
exposure calls increased approximately 17-fold, from 2 to 35. During the 
same period, 671 single-exposure cigarette calls were reported, with stable 
annual call volumes. The majority of e-cigarette exposure calls were 
associated with children aged 5 years or under (57/98, 58.2%) and adults 
aged 20 years or over (30/98, 30.6%). Cigarette exposure calls predominated 
among children aged 5 years or under (643/671, 95.8%). The authors 
concluded that the frequency of e-cigarette exposure calls had increased and 
was highest among children aged 5 years or under and adults aged 20 years 
or over.  
Wang et al.186 
2017 
Harm Using data from the National Poison Data System from 1 January 2001 to 31 
October 2016, the authors analysed data on tobacco-related poison 
exposure calls involving children aged under 5 years. From 2001 to 2016, 
there were 123,876 calls involving young children. During the study period, 
calls increased for most product types; e-cigarette-related calls increased 
from 7 in 2010 to 2,558 in 2015. In calls with information on level of care 
(92.2%), 278 children were admitted to an intensive care unit, 497 were 
admitted to a hospital non-critical care unit, and 19,834 were treated and 
released. The authors concluded that tobacco-related poison events 
commonly occur in the USA and have serious health consequences, and that 
this likely represents a small portion of actual tobacco-related poisoning 




Harm The authors reported on liquid nicotine poisoning data from the USA’s 
National Poison Data System for January 2012 to April 2017. Of the 8,269 
liquid nicotine exposures among children aged under 6 years, most (92.5%) 
were exposed through ingestion and 83.9% were aged under 3 years. Among 
children exposed to liquid nicotine, 35.1% were treated and released from a 
healthcare facility and 1.4% were admitted. The annual exposure rate per 
100,000 children increased substantially, from 0.7 in 2012 to 10.4 in 2015, 
and subsequently decreased to 8.3 in 2016. The authors reported that 
among states without a pre-existing law requiring child-resistant packaging 
for liquid nicotine containers, there was a significant decrease in the mean 
number of exposures during the 9 months before compared with during the 
9 months after the federal child-resistant packaging law went into effect, 
averaging 4.4 (95% CI: -7.1 to -1.7) fewer exposures per state after 
implementation of the law. The authors concluded that decreased paediatric 
exposures to liquid nicotine after January 2015 may, in part, be attributable 




Harm The authors reported on the number of adverse events related to smoking 
cessation treatments and e-cigarettes in the United States Food and Drug 
Administration’s Adverse Event Reporting System covering the period from 
April 2004 to December 2016. The total number of cases related to the 
administration of nicotine (after exclusion of duplicates) was 7,348,357. 
Adverse events were generated according to the preferred terms of MedDRA 
Version 19.0. The numbers of adverse events (specifically nausea, nicotine 
dependence, and dizziness) for all forms of NRT were 1,673 for transdermal, 
1,016 for buccal, 425 for oral, and 56 for respiratory administration. For e-
cigarettes, 27 cases of primary suspect adverse events were reported; these 
included 4 cases each for the adverse events of dizziness and dyspnoea. The 
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tremors, disorientation, cough, and wheezing were two for each category. 
The reported numbers of cases of thermal burn, pulmonary oedema, and 
throat irritation were one for each category. Other detected terms which 
were not currently included in MedDRA but which were observed included: 
altered visual depth perception (1), chills (1), device component issue (1), 
device deposit issue (1), device malfunction (2), device physical property 
issue (1), fear (1), headache (1), insomnia (1), lung disorder (1), malaise (1), 
migraine (1), pain (2), product label issue (1), productive cough (1), panic 
reaction (1), sensation of heaviness (1), and seventh nerve paralysis (1).  
Chang197 
2019a 
Harm The author used National Electronic Injury Surveillance System data from 
2013 to 2017 to calculate national estimates (95% CI) of poisoning incidents 
related to e-liquid nicotine exposure. From 2013 to 2017, an estimated 
4,745 poisoning cases related to e-liquids among children aged under 5 years 
were treated in USA hospital emergency departments; the number of cases 
increased from 181 (95% CI: 0–369) in 2013 to 1,736 (95% CI: 871–2,602) in 
2015, and then decreased to 411 (95% CI: 84–738) in 2017. Most of the cases 
were treated and released; 4.1% were admitted to the hospital. The most 
common route of exposure was through ingestion (96.9%), and 2.6% of the 
cases were through dermal exposure. The highest amount of e-liquids or 
nicotine ingested was difficult to assess as the measures assessed were not 
standardised. For example, 118.2 mL was the highest volume, and 100 mg 
was the highest weight. The most common symptoms related to nicotine 
poisoning were nausea and vomiting (63.6%). The author noted that at the 
time of reporting, since the National Electronic Injury Surveillance System 
data did not include product codes specific to e-cigarettes or provide 
information on poisoning severity, the author was required to use general 
keywords to capture these events, which might underestimate the 
population burden.  
Chang198 
2019b 
Harm The author used 2018 National Electronic Injury Surveillance System data to 
generate national estimates (95% CI) of ENDS liquid nicotine-related 
poisonings among children aged under 5 years who were treated in USA 
hospital emergency departments. In 2018, an estimated 885 (95% CI: 397–
1,374) poisoning cases that were related to liquid nicotine among children 
aged under 5 years were treated in USA hospital emergency departments, 
which was a non-statistically significant increase from 2017 (411 poisoning 
cases, 95% CI: 84–738). The most common route of exposure was through 
ingestion (99.4%). Most cases were treated and released from the hospital 
(90.0%), 8.9% of the cases left the hospital without being seen, and 1.1% of 
the cases were treated and admitted to the hospital. 
Hughes et al. 195 
2019b 
Harm The authors undertook an examination of records of calls to a single poison 
centre (in Oregon) from 1 July 2014 to 31 December 2017. For all calls that 
involved e-cigarette devices or e-liquid, a data collection instrument was 
filled out by the specialist in poison information; 265 cases were identified, 
including 193 children and 72 adults. The majority of both paediatric (72%; 
n=139) and adult (61%; n=44) exposures involved e-liquid refill containers or 
fluid. 56% (n=108) of paediatric exposures involved ingestion of e-liquid. 
Although children who ingested e-liquid received only a small amount, initial 
symptoms were evident in 32% (n=35) of cases. Children who did not ingest 
or inhale the products were less likely to develop toxicity. Only two children 
who were asymptomatic on initial call became symptomatic on follow-up. 
Most patients’ symptoms resolved within 4 hours. 71 specific 
products/brands were identified, with nicotine concentrations ranging from 
0 mg/mL to 60 mg/mL, and one product containing 3000 mg in a single 
bottle. A variety of flavours were identified, including several with names 
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to produce irritant effects from topical exposures and nicotine toxicity from 
ingestions, as well as from some dermal and “sucking” toddler exposures. 
Wang et al. 168 
2019a 
Harm The authors analysed poisoning exposure cases involving e-cigarettes and e-
liquids from the National Poison Data System from 2010 to 2018. The annual 
number of e-cigarette exposure cases increased greatly between 2010 and 
2014, reaching a peak of 3,742 in 2014, and then decreasing each year 
between 2015 and 2017. Between 2017 and 2018, the overall number of e-
cigarette exposure cases increased by 25.0% (from 2,320 to 2,901). 
Approximately two-thirds (64.8%) of all poisonings were in children aged 
under 5 years, 6.4% were in children aged 5–17 years, and 8.3% were in 
young adults aged 18–24 years. A small proportion of cases developed life-
threatening symptoms (0.1%); cases with more serious medical outcomes 
tended to be exposed to a higher quantity of e-liquid or nicotine. The 
authors concluded that annual declines in e-cigarette exposure cases 
between 2015 and 2017 did not continue in 2018 
4.2.3.2.8 Exposure to e-cigarette toxins: surveillance papers 
There was one surveillance paper on secondary exposure to e-cigarettes (Table 31). Notifications 
received by the United States Food and Drug Administration Center for Tobacco Products between 
January 2012 and December 2014 reported 40 events involving non-e-cigarette users.169 Thirty-five 
reports related to mainly indoor passive aerosol exposure. Respiratory symptoms, the most common 
adverse events, included asthma exacerbations, bronchitis, cough, difficulty breathing, and 
pneumonia. Additional symptoms included eye irritation, headache, nausea, throat irritation, 
dizziness, and racing or irregular heart rate. Of the reports providing information about pre-existing 
conditions, just under half indicated a history of respiratory disease or allergy. The four reports on 
children included an infant death, burns in a 3-year-old following an e-cigarette explosion, breathing 
problems in a 3-year-old, and ‘raspy’ voice in a 4-year-old after passive aerosol exposure. 
Table 31 Surveillance papers on exposure to e-cigarette toxins, benefits or harms 
Author(s), year Possible 
benefit 
or harm 




Harm The authors reported on notifications received by the United States Food and 
Drug Administration Center for Tobacco Products between 1 January 2012 
and 31 December 2014 associated with e-cigarettes, but only in non-users. Of 
the 136 reports related to e-cigarette adverse events, 40 involved non-users. 
35 reports were related to passive aerosol exposure (typically in indoor 
spaces). Respiratory symptoms (n=26, including 2 children) were most 
common and included asthma exacerbations, bronchitis, cough, difficulty 
breathing, and pneumonia. Additional passive aerosol exposure symptoms 
included eye irritation (n=8), headache (n=8), nausea (n=6), sore 
throat/irritation (n=6), dizziness (n=5), and racing/irregular heart rate (n=5). 
11 reports identified recurrent problems associated with repeat exposure, 
and 6 reports described adverse events in multiple individuals. Six cases 
reported seeking medical attention; three of these cases reported 
prescription of medications, two reported self-treatment, and one reported 
hospitalisation. Of 27 reports providing information about pre-existing 
conditions, 11 indicated a history of respiratory or allergic conditions and 9 of 
those adverse events may have been related to the underlying condition. The 
remaining five non-user reports included three reports of burns (due to 
contact with an overheated device [n=2] and to device explosion [n=1 child] 
while recharging), one report of lip cheilitis (after kissing an e-cigarette user), 
and one report of infant death after choking on an e-liquid cartridge. Most 





4.2.3.2.9 Other outcomes: surveillance papers  
There were no surveillance papers on the relationship between e-cigarettes and other outcomes. 
4.3 Observational epidemiological studies: e-cigarettes 
Incidents of mainly harms associated with e-cigarette devices or e-liquids were reported in 110 
papers. Stratification by research design allowed us to categorise the papers into 86 cross-sectional 
surveys, 2 case-control studies, and 22 longitudinal cohort studies. The sample sizes ranged from 20 
to 486,303. 
The authors of the 86 cross-sectional surveys described the association of e-cigarette devices or e-
liquids with mainly health-related harms.  
The authors of the two case-control studies identified two harms probably associated with either e-
cigarette devices or e-liquids.  
The 22 longitudinal cohort studies reported data on exposure to e-cigarette devices or e-liquids at 
baseline and followed up on the incidence of outcomes observed in the same individuals during 
subsequent timepoints.  
The summary tables for cross-sectional surveys, case-control studies, and longitudinal cohort studies 
are presented under the adapted Academies of Sciences’ headings in Sections 4.3.1, 4.3.2, and 4.3.3. 
These summary tables present details of the authors, study objectives, and concluding summary 
findings. For cross-sectional surveys and longitudinal cohort studies, tables with additional details are 
presented in Appendices 3 and 4.  
4.3.1 Cross-sectional surveys: e-cigarettes 
4.3.1.1 Study characterisation: e-cigarettes 
In the 86 cross-sectional surveys, the investigator measured the exposures (e-cigarette and/or e-
liquid) and the outcome (benefit or harm) in the study participants at the same timepoint.27 These 
surveys are very useful for describing the prevalence of an outcome such as a harm or benefit in the 
included population. However, cross-sectional surveys require adequate sample sizes in order to 
estimate prevalence. The limitations of cross-sectional surveys are that they cannot establish a 
temporal sequence and they have difficulty controlling for the influence of confounding factors on the 
outcome of interest. 
The cross-sectional surveys were completed on populations living in 17 countries, but the majority 
were from the USA. The countries were: Egypt (n=1), France (n=1), Greece (n=1), Hong Kong China 
(n=1), Hungary (n=1), Indonesia (n=1), Italy (n=1), South Korea (n=7), Malaysia (n=1), Poland (n=3), 
Saudi Arabia (n=8), Romania (n=1), Spain (n=1), Sweden (n=1) Turkey (n=1), the UK (n=1), and the USA 
(n=51). Two studies included populations from across Europe and another two studies included 
populations from across the world. The surveys were published between 2010 and 2019. The sample 
sizes ranged from 20 to 486,303. 
A significant minority of cross-sectional survey papers were on dependence and abuse liability (21 out 
of 86) and respiratory diseases (21 out of 86). The number of cross-sectional survey papers 
categorised under the adapted Academies of Sciences’ framework were: 21 under dependence and 
abuse liability, 5 under cardiovascular diseases, 5 under cancers, 21 under respiratory diseases, 14 
under oral diseases, 9 under exposure to e-cigarette toxins, and 11 under other outcomes, which 
reported on endocrine outcomes, ophthalmic outcomes, and passive exposure outcomes. There were 
no cross-sectional survey papers under the headings ‘developmental and reproductive effects’ or 
‘injuries and poisonings’. 
The summary tables for cross-sectional surveys are presented under the adapted Academies of 
Sciences’ headings in Sections 4.3.1.2.1 to 4.3.1.2.9. These summary tables present the authors, study 
objectives, and concluding summary findings. For cross-sectional surveys, tables with additional 





4.3.1.2 Harms, harm reduction, and benefits: e-cigarettes 
The harms associated with e-cigarette use identified under the dependence and abuse liability 
heading and investigated in cross-sectional surveys were: high level of dependence on e-cigarettes, 
depression, suicidality, sleep disturbance, and use by young people as a method of weight control. 
The harm identified under cardiovascular diseases was the higher level of activation of the 
inflammatory signaling network underlying acute cardiac ischaemia in e-cigarette users compared to 
non-users. The presence of carcinogens for lung, oral, and oesophageal cancers was identified in e-
cigarette users under the cancers heading. In support of the possible link between cancers and tissue 
damage in e-cigarette users, metals, volatile organic compounds, and other toxins were identified as 
contributing constituents. Some of the metals and volatile organic compounds identified in e-
cigarettes were not in conventional tobacco cigarette smoke. A number of respiratory conditions 
were associated with e-cigarettes, including lung injury, exacerbation of asthma in active and passive 
users, and exacerbation of chronic obstructive pulmonary disease. Signs of possible future respiratory 
diseases in e-cigarette users were also described; specifically, sputum abnormalities, and genes 
displaying decreased expression. Under the oral diseases heading, plaque, caries, periodontal 
diseases, and markers for oral infection were identified in e-cigarette users. Passive or third-hand 
nicotine intake was also identified among infants in neonatal units. 
A number of cross-sectional surveys identified that e-cigarettes were less harmful than conventional 
tobacco cigarettes. For example, one cross-sectional survey paper showed that individuals’ 
dependence level on e-cigarettes was lower than their dependence level on tobacco cigarettes. One 
other cross-sectional survey demonstrated that while there is inflammation of the signalling network 
underlying acute cardiac ischaemia in e-cigarette users, such inflammation is lower than that found in 
smokers. Additionally, while carcinogens are present in e-cigarette users’ body fluids, the levels are 
lower than those found in smokers, and e-cigarette users excrete lower levels of polycyclic aromatic 
hydrocarbon biomarkers in their urine than tobacco cigarette smokers. Two cross-sectional surveys 
showed that the extent of caries and periodontal disease was lower in e-cigarette users than in 
tobacco cigarette smokers, but this finding is not supported by other cross-sectional surveys. Finally, 
one cross-sectional survey paper found that the effects of e-cigarettes on the voice were mild when 
compared with voice effects in tobacco cigarette smokers.  
The only benefits of e-cigarettes identified in cross-sectional surveys was the possibility of e-cigarette 
use for smoking cessation or reduction.  
4.3.1.2.1 Dependence and abuse liability: cross-sectional surveys 
Twenty-one cross-sectional survey papers reported measures of illness, behaviours, and personality 
traits associated with dependence and abuse liability (Table 32). Some papers included measures of 
mental health and well-being, such as measures of anxiety sensitivity, depression, suicidality, and pain 
severity. The surveys also measured the prevalence of e-cigarette use among people with mental 
health conditions (such as anxiety, depression, emotional disorder, attention deficit disorder, bipolar 
disorder, and schizophrenia). Some cross-sectional survey papers measured e-cigarette-related 
behavioural outcomes (such as impact on sleeping patterns) and dependency (measure of frequency 
of e-cigarette use, patterns of use, assessment of dependence, and urinary cotinine levels in body 
fluids). Other outcomes examined in cross-sectional survey papers included tobacco cigarette use and 
marijuana use, weight status, and appetite control.  
Five cross-sectional survey papers found support for e-cigarette use in cigarette reduction, cessation, 
and dependence levels. The first paper concluded that experienced e-cigarette users stated that 
initiating e-cigarette use helped them to quit or reduce their conventional smoking, which they 
believe reduced their health risks.200 Survey respondents who used e-cigarettes acknowledged that 
more research is needed in order to understand the safety and long-term effects of e-cigarette use; 
they also reported that current effects experienced by them included dry mouth and lack of reliability 
of e-cigarette products. The second paper reported that e-cigarettes were mostly used by 
respondents to avoid the harm associated with smoking. In this survey, high levels of nicotine were 
used at initiation, and users subsequently tried to reduce nicotine consumption, with only a small 





play an important role in achieving and maintaining cessation of smoking conventional tobacco 
cigarettes in a group of motivated smokers.202 The fourth survey paper determined that some e-
cigarette users were dependent on nicotine-containing e-cigarettes, but that these products were less 
addictive than conventional tobacco cigarettes.203 The final paper reported that dual users smoked 
significantly fewer cigarettes and were more likely to have a psychiatric history.204 
By contrast, another four cross-sectional surveys questioned cigarette reduction, cessation, and 
dependence levels associated with e-cigarette use. The first cross-sectional survey paper reported 
that its results did not suggest that e-cigarette use was associated with a reduction in cigarette 
consumption to less than one pack per day.205 Current use of conventional tobacco cigarettes and e-
cigarettes was associated with quit attempts in the past 12 months, and a self-reported likelihood of 
future tobacco cessation. However, e-cigarette use was not associated with confidence to quit in the 
next month, cigarette packs smoked per day, or salivary cotinine levels. The second paper concluded 
that e-cigarette users had higher average nicotine dependence levels than conventional cigarette 
users; nicotine dependence levels were titrated to years of e-cigarette use and the concentration of 
nicotine in the e-liquid used.206 The third paper determined that adolescents who used pod products 
reported more signs of nicotine dependence than non-pod users.207 Positive responses to 
dependence questions were supported by higher urinary cotinine levels. The fourth paper reported 
that nicotine dependence levels, measured using the Fagerström Test for Nicotine Dependence, were 
more than two times higher among e-cigarette users compared to traditional tobacco smokers. 208 
Similarly, among dual users, nicotine dependence levels were higher when using an e-cigarette 
compared to when using conventional tobacco cigarettes. The final paper concluded that dual users 
(those who used both e-cigarettes and conventional tobacco cigarettes) were more likely to be white, 
be younger, have above a high school education, and have a psychiatric history. Dual users also 
smoked significantly fewer cigarettes and had lower levels (rather than none) of the carcinogen 4-
(Methylnitrosamino)-1-(3-pyridyl)-1-butanol. 
Six papers reported a harmful association between e-cigarettes and mental health. One paper 
concluded that, after controlling for covariates, having a chronic mental illness significantly increased 
the likelihood of both trying an e-cigarette and being an e-cigarette user.209 One study reported that, 
after adjusting for covariates, a nationally representative sample of adolescents who used e-
cigarettes only, marijuana only, or both e-cigarettes and marijuana had significantly poorer mental 
health outcomes (depression and suicidality) when compared with those who did not use such 
substances.210 A further three studies supported the association between e-cigarettes and suicidal 
behaviour and/or depression.211 212 One study reported that dual use of e-cigarettes with another 
product was associated with higher depressive symptoms.213 One paper concluded that there needs 
to be further investigation into anxiety sensitivity and pain severity in the context of e-cigarette use, 
as there may be a benefit to screening for and clinically addressing these factors in order to help 
offset the effects of e-cigarette use.214 
Two studies examined the topic of e-cigarettes and body weight. A single study concluded that the 
existing relationship between obesity and increased cigarette smoking may extend to e-cigarette use 
among young adults.215 Another paper described how a subset of adolescents had reported using 
flavoured e-liquids to lose weight, and that these adolescents reported vaping more frequently than 
their counterparts, raising concerns about increased nicotine exposure.216 
Three papers reported a harmful association between e-cigarettes and sleep patterns. The first paper 
found that dual use of e-cigarettes with conventional tobacco had the highest risk for causing sleep 
disruption; nicotine or coughing were considered the causal agent and mechanism, respectively. 217 
The second paper concluded that conventional cigarette and e-cigarette users reported significantly 
more sleep difficulties than never users, and that e-cigarette users reported greater use of sleep 
medication than did combustible cigarette users.218 The third paper concluded that e-cigarette and 
dual-product use are significantly associated with greater odds of reporting sleep-related complaints 
among adolescents.219 
One paper concluded that the findings of their research suggest that e-cigarette use increased as self-





Table 32 Cross-sectional survey papers on dependence and abuse liability, benefits or harms 
Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on dependence and abuse liability 
  Smoking reduction, smoking cessation, and nicotine levels 
Farsalinos et al. 
202 
2013b 
Benefit The authors described the nicotine levels used in order to achieve 
smoking cessation, as well as the reported benefits, associated side 
effects, and estimation of e-cigarette dependence, compared with tobacco 
cigarette dependence.  
Comparative groups 
E-cigarettes users themselves (former smokers) 
The authors concluded that nicotine levels appear to play an important 
role in achieving and maintaining smoking cessation in the group of 
motivated subjects studied. High-nicotine-containing liquids were used, 
but few mild and temporary side effects were reported. The authors 
concluded that regulatory proposals should consider the pragmatic use 
patterns of e-cigarettes, especially in consumers who have completely 
substituted tobacco cigarettes with e-cigarettes.  









The authors described the characteristics, perceived side effects, and 
benefits of e-cigarettes.  
Comparative groups 
E-cigarettes themselves (with detail on device type, as occasional users) 
Conventional combustible tobacco cigarette smokers 
• Former smokers 
• Never smokers 
• Current smokers 
They concluded that e-cigarettes are mostly used to avoid the harm 
associated with smoking. They noted that e-cigarettes can be effective 
even in highly dependent smokers, and that they are used as long-term 
substitutes for smoking. High levels of nicotine are used at initiation; 
subsequently, e-cigarette users try to reduce nicotine consumption, with 
only a small minority using non-nicotine liquids. Side effects are minor and 
health benefits are substantial, especially for those who completely 
substitute tobacco cigarettes with e-cigarettes.  








The authors reported on the dependence level in users of e-cigarettes, 
nicotine gum, and tobacco cigarettes.  
Comparative groups 
E-cigarettes themselves (former smokers) 
Conventional combustible tobacco cigarette smokers 
• Former smokers 
• Daily smokers 
• Occasional smokers 
Nicotine gum users History of other types of tobacco use (pipe smokers, cigar 
smokers, smokeless and chewing tobacco, hookah use) 
They concluded that some e-cigarette users were dependent on nicotine-
containing e-cigarettes, but that these products were less addictive than 
tobacco cigarettes. E-cigarettes may be as addictive as or less addictive 
than nicotine gums, which themselves are not very addictive.  
Baweja et al. 200 
2016 
 
Benefit  The authors reported on the experiences, satisfaction, opinions, and 
preferences of e-cigarette users. 
Comparative groups 
E-cigarettes themselves (former smokers)  
Conventional combustible tobacco cigarette smokers 
• Former smokers 
• Current smokers 
Smokers, who use other tobacco products They concluded that experienced e-
cigarette users stated that initiating e-cigarette use helped them to quit or 
reduce their conventional smoking, which they believed reduced their 
health risks. In comparison to cigarette smoking, e-cigarette users reported 
using their e-cigarette more times per day, but with fewer puffs than on 





Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on dependence and abuse liability 
users acknowledged that more research is needed in order to understand 
the safety and long-term effects of use. Finally, the e-cigarette users 
mentioned dry mouth as a common side effect and they also noted 
common problems with the reliability of e-cigarettes.  
Comiford et al. 
205 
2018 
Harm The authors reported on the relationship between e-cigarette use and 
smoking-related measures (salivary cotinine levels) among American 
Indians who smoked.  
Comparative groups 
E-cigarettes users themselves as former smokers  
E-cigarettes users themselves as never smokers  
E-cigarettes users themselves as dual or poly product uses (themselves and one or 
more tobacco product) 
Conventional combustible tobacco cigarette users (current) 
The results did not suggest that e-cigarette use is associated with a 
reduction of cigarette consumption to less than one pack per day. Current 
use of cigarettes and e-cigarettes was associated with quit attempts in the 
past 12 months and a self-reported likelihood of future tobacco cessation, 
and that this may be an indication that e-cigarette use may signify a 
greater interest in smoking cessation. However, e-cigarette use was not 
associated with confidence to quit in the next month, cigarette packs 
smoked per day, or salivary cotinine levels.  
Johnson et al. 
206 
2018 
Harm The authors reported on the relationship between characteristics of e-
cigarette usage and Fagerström Test for Nicotine Dependence outcome 
scores, specifically scores on nicotine dependence.  
Comparative groups 
E-cigarettes users themselves only (current)  
E-cigarette users themselves who were former smokers (current)  
E-cigarette users themselves who were conventional combustible tobacco cigarette 
smokers and/or water pipe users (current) 
The authors concluded that e-cigarette users can have higher average 
nicotine dependence levels than conventional combustible tobacco 
cigarette users. They noted that the length of e-cigarette use (<1 year 
versus >1 year) and the level of nicotine used in e-cigarette liquid (none 
versus any level of nicotine) were significantly associated with the 
Fagerström Test for Nicotine Dependence scores. They also noted that 
those who used e-cigarette fluid with no nicotine had lower scores than 
those who used fluids that contained nicotine.  








The authors reported on the relationship between completed baseline 
assessments of demographics, tobacco use, and dependence. They also 
provided details of breath samples for carbon monoxide (CO) assay and 
urine samples for cotinine, 3-hydroxycotinine (3HC), and 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL, a carcinogen) assays.  
Comparative groups 
E-cigarettes users themselves  
Conventional combustible tobacco cigarette smokers (current, ≥ 5 cigarettes per 
day for 6 months) 
Dual users (e-cigarettes and conventional combustible tobacco cigarette users)  
The authors concluded that dual users were more likely to have a 
psychiatric history. Dual users also smoked significantly fewer cigarettes 
and had lower levels of NNAL (a carcinogen), but they did not differ from 
exclusive smokers in terms of carbon monoxide or cotinine levels, 
suggesting that they supplemented their nicotine intake via e-cigarettes.  
Boykan et al.207 
2019 
Harm The authors reported on differences in urinary cotinine levels in pod versus 
non-pod e-cigarette users. In addition, they assessed dependence levels in 
a subset of the original population. 
Comparative groups 
E-cigarettes themselves (as past-week pod users) 





Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on dependence and abuse liability 
The authors concluded that adolescents who used pod products showed 
more signs of nicotine dependence than non-pod users. Positive responses 




Harm The authors assessed patterns of e-cigarette use and compared nicotine 
dependence among cigarette and e-cigarette users in a group of highly 
educated young adults. 
Comparative groups 
E-cigarettes themselves  
Conventional combustible tobacco cigarette users (current users) 
Dual users (e-cigarette and conventional combustible tobacco cigarette users) 
The authors concluded that the nicotine dependence levels measured with 
the Fagerström Test for Nicotine Dependence were more than two times 
higher among e-cigarette users than among traditional tobacco smokers. 
Similarly, among dual users, nicotine dependence levels were higher when 
using an e-cigarette compared to using conventional combustible tobacco 
cigarettes. Habits and behaviours associated with the use of e-cigarettes 
did not differ significantly between exclusive e-cigarette users and dual 
users of e-cigarettes and conventional combustible tobacco cigarettes. The 
findings suggest that e-cigarettes may have a higher addictive potential 
than smoked cigarettes among young adults.  




Harm The authors reported on the relationship between tobacco and nicotine 
product use and depressive symptoms. 
Comparative groups 
E-cigarettes themselves (current users) 
Conventional combustible tobacco cigarette users (current users) 
Other tobacco product current users (hookah, cigar, smokeless tobacco) 
The authors reported that e-cigarettes were the only alternative tobacco 
product that were uniquely associated with depressive symptoms, and that 
the association was significant even after controlling for current cigarette 
use, sociodemographic characteristics, and current use of three other 
three alternative tobacco products tested.  
Bianco et a.l209 
2019 
 
Harm The authors reported on the rates of e-cigarette use among adults with a 
chronic mental illness (classified as depression, anxiety, emotional 
disorder, or ADD, bipolar disorder, schizophrenia, other disorders). 
Comparative groups 
E-cigarettes themselves (ever to daily use) 
Conventional combustible tobacco cigarette users (current users with data on daily 
and some days use) 
Never-e-cigarette users  
The authors noted that previous trial of an e-cigarette is more likely in a 
person with depression, anxiety, or an emotional problem (odds ratio (OR): 
2.84). Trying an e-cigarette is more likely in a person with ADD, bipolar 
disorder, schizophrenia, or other disorder (OR: 2.47). Regular e-cigarette 
use is more likely in a person with depression, anxiety, or an emotional 
problem (OR: 2.69). Regular e-cigarette use is more likely in a person with 
ADD, bipolar disorder, schizophrenia, or other disorder (OR: 3.02). 
However, as the temporary path of mental health diagnosis and e-cigarette 
uptake was not specified, the reported relationship must be viewed as 
cross-sectional in nature. The authors concluded that logistic regressions 
suggested that having a chronic mental illness significantly increases the 
likelihood of both trying an e-cigarette and being an e-cigarette user.  
Chadi et al. 210 
2019 
Harm The authors reported on the relationship between e-cigarette and 
marijuana use and depressive symptoms and suicidality in a large sample 
of high school students.  
Comparative groups 
E-cigarettes themselves (current user, ≥ 1 per day for 30 days) 
Themselves (current marijuana user, ≥ 1 per day for 30 days) 





Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on dependence and abuse liability 
Non-nicotine product user 
The authors stated that adolescents who admitted e-cigarette-only use, 
marijuana-only use, or dual e-cigarette and marijuana use had poorer 
mental health outcomes compared to those who denied use, when 
adjusting for demographic factors, use of other substances, and other 
relevant confounders. The association between depression and use of e-
cigarettes has previously been reported in a nationally representative 
sample of adolescents, but the association between e-cigarette use and 
suicidality has not. The authors observed an increased likelihood of 
depressive symptoms and suicidal ideation in all three investigated 
substance use categories (e-cigarette-only, marijuana-only, and dual e-
cigarette/marijuana use).  
Kim212 
2019 
Harm The author investigated the association between the use of e-cigarettes 
and suicidal behaviours in adolescents.  
Comparative groups 
E-cigarettes themselves (current users) 
Conventional combustible tobacco cigarette users (ever users) 
Non-e-cigarette users in past 30 days 
The author concluded that suicidal behaviours are significantly higher 
among current adolescent e-cigarette users than adolescents who have not 
used an e-cigarette in the past 30 days.  
Lee et al. 213 
2019 
Harm The authors reported on the association of depression and suicidality with 
electronic and conventional combustible tobacco cigarette use in South 
Korean adolescents. 
Comparative groups 
E-cigarettes themselves (ever user) 
Conventional combustible tobacco cigarette users (ever user) 
Dual product users (e-cigarette and conventional combustible tobacco cigarette 
users) 
Never nicotine product users 
There were significant differences between tobacco cigarette and e-
cigarette users: dual users had a higher prevalence of depression and 
suicidality for both lifetime and current use; e-cigarette-only users had 
higher levels of depression and suicidality than non-users; and female 
adolescents who were conventional-cigarette-only users, e-cigarette-only 
users, or dual users had a higher prevalence of depression and suicidality 
than male adolescents in those user categories. The authors concluded 
that the findings suggest an urgent need for evaluation of, and 
intervention in, e-cigarette use by health professionals providing smoking 




Harm The authors reported on levels of pain severity and anxiety sensitivity 
interplay among exclusive e-cigarette users and dual e-cigarette and 
conventional combustible tobacco cigarette users.  
Comparative groups 
E-cigarettes themselves (daily users) 
Conventional combustible tobacco cigarette users (daily users) 
The authors concluded that the findings suggest that there needs to be 
further study of anxiety sensitivity and pain severity in the context of e-
cigarette use, as there may be a benefit to screening for and clinically 
addressing these factors in order to help offset e-cigarette use.  
  Body weight 
Lanza et al. 215 
2017 
Harm The authors reported on the relationship between e-cigarette and 
conventional combustible tobacco cigarette use and higher weight status 
(obesity). 
Comparative groups 
E-cigarettes themselves (ever users)  
E-cigarettes themselves (current users) 
Conventional combustible tobacco cigarette users (current users) 





Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on dependence and abuse liability 
Conventional combustible tobacco cigarette users (former users) 
The authors concluded that the relationship between obesity and cigarette 
smoking may extend to e-cigarette use among young adults. 
Morean et al. 
216 
2019 
Harm The authors reported on the relationship between use of flavoured e-
cigarettes and e-liquids with appetite control and weight loss. 
Comparative groups 
E-cigarette users themselves (using ≥ 1 per day for 30 days, data on flavours) 
Conventional combustible tobacco cigarette users (current users ≥ 1 per day for 30 
days) 
The authors concluded that a subset of adolescents reported using 
flavoured e-liquids for weight-related reasons. These adolescents reported 
vaping more frequently than their counterparts, raising concerns about 
increased nicotine exposure. Research is needed in order to understand 
where adolescents learn about weight-motivated vaping (e.g. friends, 
social media) and whether weight-related motives promote e-cigarette 
initiation among e-cigarette-naive individuals or continued/escalating use 
among current users. 
  Sleep pattern 
Boddu et al. 217 
2019 
Harm The authors reported on the effects of e-cigarettes on sleep. 
Comparative groups 
E-cigarettes users themselves  
Conventional combustible tobacco cigarette users  
Dual users (e-cigarettes and Conventional combustible tobacco cigarette users) 
The authors found that dual use of e-cigarettes with conventional tobacco 
has the highest risk for causing sleep disruption. They concluded that 
mechanistically, this finding is logical if nicotine is the causal agent of sleep 
disruption, as dual users are more likely to consume greater 
concentrations of nicotine than either smokers or vapers. This notion may 
reveal the underlying mechanism for poorer sleep quality and for increased 
odds and severity of cough in dual users. 
Brett et al. 218 
2019 
Harm The authors reported on the relationship between e-cigarette use and 
sleep health in young adults. 
Comparative groups 
E-cigarettes users themselves (daily)  
E-cigarettes users themselves (not daily but at least monthly) 
Conventional combustible tobacco cigarette users (daily or weekly) 
The authors concluded that current combustible and e-cigarette users 
reported significantly more sleep difficulties than never users. E-cigarette 
users reported greater use of sleep medication than combustible cigarette 
users. 
Riehm et al. 219 
2019 
Harm The authors reported on the relationship between e-cigarette use and 
sleep-related complaints. 
Comparative groups 
E-cigarettes users themselves (past year) 
E-cigarettes users themselves (ever use) 
Conventional combustible tobacco cigarette users (past year) 
Conventional combustible tobacco cigarette users (ever use) 
Dual product users (e-cigarette and conventional combustible tobacco cigarette 
users in past year) 
Non nicotine product users (in past year) 
The authors concluded that e-cigarette and dual-product use are 
significantly associated with greater odds of reporting sleep-related 
complaints among adolescents. 
  Perceived health 
Lequy et al. 220 
2019 
Harm The authors reported on perceived health and its association with current 
use of e-cigarettes in current and former smokers.  
Comparative groups 
E-cigarettes users themselves (ever, disposable)  





Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on dependence and abuse liability 
Conventional combustible tobacco cigarette (ever users)  
Conventional combustible tobacco cigarette users (former users who quit smoking 
within the last three years) 
The authors concluded that the findings suggest that the unhealthier 
current and former smokers felt, the more they tended to currently use e-
cigarettes.  
 
4.3.1.2.2 Cardiovascular diseases: cross-sectional surveys 
Five cross-sectional survey papers reported on the relationship between e-cigarettes and myocardial 
infarction, other cardiovascular diseases, and the inflammatory signalling network underlying acute 
cardiac ischaemia (known as the splenocardiac axis).  
The five cross-sectional survey papers reported mixed findings with respect to the association 
between e-cigarettes and cardiovascular diseases (Table 33).  
One paper concluded that the findings indicated activation of the splenocardiac axis in a graded 
manner, from lowest in non-users, healthy control subjects, to mid-level in habitual e-cigarette users, 
to highest in tobacco cigarette smokers.221 
One paper determined that e-cigarette use was independently associated with increased odds of 
having had a myocardial infarction, as was daily conventional cigarette smoking,222 whereas another 
paper concluded that the pooled analysis of the 2016 and 2017 National Health Interview Survey 
found no association between e-cigarette use and a self-reported recent medical diagnosis of 
myocardial infarction or coronary heart disease.223 
One paper reported that the SF-12 general health score, measuring 19 cardiopulmonary symptoms, 
was lower (worse) in e-cigarette users compared to non-users. E-cigarette users reported higher 
breathing difficulty scores, and greater proportions reported chest pain, palpitations, coronary heart 
disease, arrhythmia, chronic obstructive pulmonary disease, and asthma than non-users.224 
A large study reported that 10% of 449,092 participants had cardiovascular disease.225 The authors 
reported that dual use of e-cigarettes combined with conventional tobacco cigarettes was associated 
with significantly higher odds of cardiovascular disease compared with smoking tobacco cigarettes 
alone. They also found a graded increase in odds of cardiovascular disease with increasing frequency 
of e-cigarette exposure among current tobacco cigarette smokers. There was no significant 








Table 33 Cross-sectional survey papers on cardiovascular diseases, benefits or harms 
Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on cardiovascular diseases 








The authors reported on the relationship between electronic and tobacco 
cigarettes and the inflammatory signalling network underlying acute 
cardiac ischaemia (the Splenocardiac Axis). 
Comparative groups 
E-cigarettes users themselves (e-cigarettes for a minimum of 1 year) 
Conventional combustible tobacco cigarette users (for a minimum of 1 year) 
Healthy controls 
The authors reported that both hematopoietic tissue metabolic activity 
and aortic wall metabolic activity are increased in tobacco and e-cigarette 
users, and that plasma cotinine, an estimate of tobacco cigarette and e-
cigarette burden, was weakly correlated with bone marrow activity. The 
authors concluded that the findings indicated activation of the 
Splenocardiac Axis in a graded manner, from non-user, healthy control 
subjects, to habitual e-cigarette users, to tobacco cigarette smokers 
Alzahrani et al. 
222 
2018 
Harm The authors reported on the relationship between e-cigarette use and 
myocardial infarction.  
Comparative groups 
E-cigarettes users themselves (daily) 
E-cigarettes users themselves (some days) 
E-cigarettes users themselves (former) 
Conventional combustible tobacco cigarette users (daily) 
Conventional combustible tobacco cigarette users (some days) 
Conventional combustible tobacco cigarette users (former) 
Never smokers (conventional combustible tobacco cigarette) 
Never vapers (e-cigarette) 
The authors concluded that e-cigarette use was independently associated 
with increased odds of having had a myocardial infarction.  
Wang et al. 224 
2018 
Harm The authors reported on the relationship between cigarette and e-
cigarette dual use and risk of cardiopulmonary symptoms. 
Comparative groups 
E-cigarettes users themselves (current users) 
Conventional combustible tobacco cigarette users (ever) 
Dual users (e-cigarette and conventional combustible tobacco cigarette users) 
The SF-12 general health score, measuring 19 cardiopulmonary symptoms, 
was lower (worse) in dual users compared to cigarette-only users; this was 
specifically observed in the outcomes of breathing difficulties and a history 
of arrhythmia. E-cigarette-only use, compared to no product use, was 
associated with lower general health scores, higher breathing difficulty 
scores (typically and in the past month), and greater proportions of those 
who responded ‘yes’ to having chest pain, palpitations, coronary heart 
disease, arrhythmia, chronic obstructive pulmonary disease, and asthma. 
The authors suggested that the use of e-cigarettes alone may have 
contributed to cardiopulmonary health risks, particularly respiratory health 
risks.  





The authors reported on the relationship between e-cigarette use, 
coronary heart disease, and myocardial infarction.  
Comparative groups 
E-cigarettes users themselves (daily) 
E-cigarettes users themselves (some days) 
E-cigarettes users themselves (former) 
Conventional combustible tobacco cigarette users (daily) 
Conventional combustible tobacco cigarette users (some days) 
Conventional combustible tobacco cigarette users (former users who stopped 
between 6 and 10 years) 
Never smokers (conventional combustible tobacco cigarette) 





Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on cardiovascular diseases 
The authors concluded that the pooled analysis of the 2016 and 2017 
National Health Interview Survey showed no association between e-
cigarette use and myocardial infarction or coronary heart disease. The 
associations between established risk factors, including smoking, and both 
conditions were remarkably consistent. The inconsistent associations 
observed in single-year surveys and the cross-sectional design of the 
National Health Interview Survey cannot substantiate any link between e-
cigarette use and an elevated risk for myocardial infarction or coronary 
heart disease.  
Osei et al. 225 
2019a 
Harm The authors reported on the association between e-cigarette use and 
cardiovascular disease.  
Comparative groups 
E-cigarettes users themselves (ever use) 
E-cigarettes users themselves (daily) 
E-cigarettes users themselves (occasional) 
Conventional combustible tobacco cigarette users (current users) 
Conventional combustible tobacco cigarette users (ever) 
Dual users (e-cigarette and conventional combustible tobacco cigarette users) 
Never smokers (conventional combustible tobacco cigarette) 
Never vapers (e-cigarette) 
The authors concluded that their results suggest significantly higher odds 
of cardiovascular disease among dual users of e-cigarettes and combustible 
cigarettes compared with combustible tobacco cigarette-only users. They 
also queried whether the current lack of significant association between e-
cigarette use and cardiovascular disease among never combustible 
cigarette smokers may be due to the younger age of this group. 
 
4.3.1.2.3 Cancers: cross-sectional surveys 
Five cross-sectional survey papers reported on the relationship between e-cigarettes and a range of 
cancer-related risk markers and outcomes (Table 34). These included measuring the total nicotine 
equivalents or dose, and the nicotine metabolite ratio. A number of tobacco-specific smoking-related 
carcinogens are measured in the cross-sectional papers, namely: N’-Nitrosonornicotine (NNN), which 
is a risk marker for oral and oesophageal cancer; and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL) and its glucuronides, which are risk markers for lung cancer. Oral cavity cancer was assessed 
in the cross-sectional papers by cytologic examination of micronuclei in the oral mucosa. Salivary 
specimens were assayed for cotinine (a biomarker of nicotine exposure), and urine specimens for 
NNAL (a biomarker of the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)). 
Two of the five cross-sectional survey papers examined levels of tobacco-related carcinogens. The 
authors of one cross-sectional survey reported on the relationship between smokers of combustible 
cigarettes only, former smokers with long-term e-cigarette-only use, former smokers with long-term 
NRT-only use, long-term dual users of both combustible cigarettes and e-cigarettes, and long-term 
users of both combustible cigarettes and NRT with exposure to nicotine, tobacco-related carcinogens, 
and toxins.226 The authors concluded that e-cigarette-only users had significantly lower 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol levels levels (which is a risk marker for lung cancer) than 
all other groups. Combustible cigarette-only users, dual combustible cigarette and NRT users, and 
dual combustible cigarette and e-cigarette users had largely similar levels of tobacco specific N-
nitrosamines (most of which are carcinogenic) and volatile organic compounds (which are also 
carcinogenic). The second cross-sectional survey paper examined the relationship between smokeless 
tobacco and nicotine and carcinogen exposures.227 The authors concluded that adolescents who used 
smokeless tobacco products were exposed to substantial levels of nicotine and a specific carcinogen 
(4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, NNK); However, this paper indicated that exclusive 
e-cigarette users have non-detectable concentrations of salivary nicotine and very low concentrations 
of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol compared with smoking or smokeless. Although 





given the young age of the sample and the tendency for smokeless tobacco users to increase use 
intensity over time. 
Two survey papers measured markers for oral cancer or oesophageal cancer. One study reported that 
the highest prevalence of micronuclei (indicative elements of genomic instability which may have a 
clinical application in screening tests for risk categories of oral cavity carcinoma) was observed in 
smokers, followed by e-cigarette users, and then by non-users, who had the lowest prevalence of 
micronuclei among the three groups.228 One study reported that N'-nitrosonornicotine (marker for 
oral and oesophageal cancer) is formed endogenously by e-cigarette users, and exposure to it in e-
cigarette users’ saliva is lower than in smokers. 229  
Table 34 Cross-sectional survey papers on cancers, benefits or harms 
Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on cancers 








The authors reported on the relationship between e-cigarettes and 
micronuclei prevalence indicative of oral cavity cancer following cytologic 
examination of oral mucosa. 
Comparative groups 
E-cigarettes users themselves (current for ≥ 6 months) 
Conventional combustible tobacco cigarette users (current) 
Conventional combustible tobacco cigarette users (former) 
Never smokers (conventional combustible tobacco cigarette) 
A higher prevalence of micronuclei was observed in smokers relative to e-
cigarette smokers, and non-users had the lowest prevalence of micronuclei 
among the three groups. The authors stated that micronuclei are indicative 
elements of genomic instability and may have a clinical application in 
screening tests for risk categories of oral cavity carcinoma. They also 
suggested that e-cigarettes seem to be safe for oral cells and should be 
suggested as an aid for smoking cessation.  










The authors reported on the relationship between smokers of combustible 
cigarettes only, former smokers with long-term e-cigarette-only use, 
former smokers with long-term NRT-only use, long-term dual users of both 
combustible cigarettes and e-cigarettes, and long-term users of both 
combustible cigarettes and NRT with exposure to nicotine, tobacco-
related carcinogens, and toxins. 
Comparative groups 
E-cigarettes users themselves (former conventional combustible tobacco cigarette 
users) 
Conventional combustible tobacco cigarette users (users) 
Conventional combustible tobacco cigarette users (former users on nicotine 
replacement therapy) 
Dual users (e-cigarettes and conventional combustible tobacco cigarettes) 
Dual users (conventional combustible tobacco cigarettes and nicotine replacement 
therapy) 
Across the five groups (n=36–37 per group), nicotine, carcinogen, and toxin 
exposures were assessed using urine and saliva samples, which were 
analysed for biomarkers of nicotine, tobacco-specific N-nitrosamines 
(TSNAs), and volatile organic compounds. The authors concluded that e-
cigarette-only users had significantly lower 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol (NNAL) levels than all other groups. Combustible 
cigarette-only users, dual combustible cigarette and nicotine replacement 
therapy (NRT) users, and dual combustible cigarette and e-cigarette users 
had largely similar levels of tobacco-specific N-nitrosamines and volatile 










The authors reported on the relationship between e-cigarette use and the 
presence of N'-nitrosonornicotine (NNN) as a risk marker of oral and 
oesophageal cancer. 
Comparative groups 
E-cigarettes users themselves only (daily for 3 months) 






Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on cancers 
Never smokers (conventional combustible tobacco cigarette) 
The authors concluded that N'-nitrosonornicotine is formed endogenously 
in e-cigarette users, and while overall exposure to N'-nitrosonornicotine in 
e-cigarette users is lower than in smokers, the known carcinogenic potency 
of N'-nitrosonornicotine should be monitored (specifically salivary rather 
than urinary NNN) in order to assess the potential relationship of e-
cigarettes with oral and oesophageal cancers  
Carroll et al. 230 
2018 
Harm The authors reported on the relationship of cigarette smokers and 
electronic nicotine delivery system (ENDS) users with nicotine 
metabolism and nicotine and carcinogen exposure. 
Comparative groups 
E-cigarettes users themselves only (daily for three months) 
Conventional combustible tobacco cigarette users (exclusive, ≥ 5 per day for 3 
months) 
Dual users (not specified) 
Among smokers, there were inverse relationships between nicotine 
metabolite ratio and total nicotine equivalents (r=-0.45) and between 
nicotine metabolism nicotine metabolite ratio and (4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol and its glucuronides [NNAL] (r=-0.50). Among dual 
users, nicotine metabolism, nicotine metabolite ratio and total nicotine 
equivalents, and nicotine metabolite ratio and (4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanol and its glucuronides were not associated. Among 
ENDS users, nicotine metabolism, nicotine metabolite ratio and total 
nicotine equivalents were not associated.  








The authors assessed tobacco product use (smokeless, combustible, and 
electronic cigarettes) and nicotine and carcinogen exposures. 
Comparative groups 
E-cigarettes users themselves (last seven days) 
Conventional combustible tobacco cigarette users (last 7 days) 
E-cigarettes users themselves only 
Conventional combustible tobacco cigarette users only 
Smokeless tobacco users only 
Dual users (e-cigarettes and conventional combustible tobacco) 
Dual users (smokeless and conventional combustible tobacco) 
Poly users (e-cigarettes together with smokeless and/or combustible tobacco) 
The authors concluded that adolescents who use smokeless tobacco 
products (including e-cigarettes) are exposed to substantial levels of 
nicotine and to the biomarker of the carcinogen 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone (NNK). Although exposed to lower levels than adult 
smokeless tobacco product users, the findings are concerning given the 
young age of the sample and the tendency for smokeless tobacco product 
users to increase use intensity over time. However, the conclusion appears 
to be based on smokeless tobacco users of whom some were smokers, and 
some were e-cigarette users, so it is impossible to isolate the effect of e-
cigarette use in this group. In addition, Table 2 of Chaffee et al.’s paper 
indicates that exclusive e-cigarette users have non-detectable 
concentrations of salivary nicotine and very low concentrations of NNAL 
compared with smoking or smokeless.  
4.3.1.2.4 Respiratory diseases: cross-sectional surveys 
Twenty-one cross-sectional survey papers reported on the relationship between e-cigarettes and 
respiratory diseases (Table 35). The papers examined e-cigarettes and their effect on respiratory 
function, their association with signs and symptoms of respiratory diseases, their association with 
subjective symptoms of ill health, and their association with diagnosed respiratory diseases.  
The measures of respiratory function included: lung capacity, volume of air expired in a normal breath 
or a forced breath, and ratios between lung capacity and respiratory expiration. These were 





expiratory volume in the first second (FEV1), forced expiratory ratio (FEV1/FVC), and peak expiratory 
flow (PEF). A lower percentage forced expiratory flow is an indicator of lower lung function.  
The signs and symptoms of possible respiratory diseases assessed in e-cigarette users in the surveys 
included: dry or irritated mouth, dry or irritated throat, cough (dry or productive), sputum production, 
and wheezing or whistling. The subjective symptoms of ill health as a result of e-cigarette use 
assessed in the survey papers included: nose irritation (itchy nose, uncomfortable smell, and 
sneezing), eye irritation (watery eye, sore eye, and reddish eye), and throat irritation (sore throat, dry 
throat, cough, and choking sensation). 
The measures of propensity for respiratory diseases among e-cigarette users included assessment of 
immune gene expression profiles and lung function. 
One study reported that e-cigarette users had several negative changes in the content and 
consistency of their sputum.231 E-cigarette users exhibited significant increases in aldehyde 
detoxification and oxidative stress-related proteins in their sputum, normally observed in higher 
levels in conventional cigarette smokers than in non-smokers. The levels of innate defence proteins in 
sputum associated with chronic obstructive pulmonary disease, such as elastase and matrix 
metalloproteinase-9, were significantly elevated in e-cigarette users as well. E-cigarette users’ sputum 
also uniquely exhibited significant increases in neutrophil granulocyte-related and neutrophil 
extracellular trap-related proteins. Peripheral neutrophils from e-cigarette users showed increased 
susceptibility to phorbol 12-myristate 13-acetate-induced neutrophil extracellular traposis. Finally, a 
compositional change in the gel-forming building blocks of airway mucus (i.e. an elevated 
concentration of one mucin) was observed in both conventional cigarette smokers and e-cigarette 
users. 
One paper concluded that fractional exhaled nitric oxide (FeNO) was decreased in e-cigarette users, 
but the decrease was not statistically significant.232 Also, the use of e-cigarettes significantly impaired 
various lung function parameters, and the pattern of impairment exhibited a peripheral obstructive 
airway involvement. 
Six other papers reported respiratory symptoms in e-cigarette users. The first paper noted a strong 
association between respiratory symptoms (cough or phlegm) in adolescent e-cigarette users.233 The 
second paper determined that, after controlling for covariates, respiratory symptoms (such as cough, 
sputum production, or wheeze) were significantly associated with adult dual use, tobacco cigarette 
smoking only, and former tobacco smoking, but not with former vaping or e-cigarette use when 
compared to non-users (non-smokers and non-vapers).234 The third paper reported that self-reported 
health complaints among 20 adults who were mainly dual users mostly consisted of upper airway 
irritation with acute effect. 235 The fourth paper concluded that most e-cigarette users reported at 
least one symptom, most commonly a cough or a dry or irritated mouth or throat.236 The fifth paper 
reported that e-cigarette use was associated with increased risk of wheezing and related respiratory 
symptoms.237 The sixth paper concluded that adolescent e-cigarette users had increased rates of 
chronic bronchitic symptoms.238 
Seven papers reported a harmful association between e-cigarette use and asthma in adolescents, 
adults, and passive vapers. One paper concluded that e-cigarette use by adolescents was 
independently associated with an asthma diagnosis.239 Another paper concluded that recent e-
cigarette use by adolescents with asthma was associated with having an asthma attack in the 12 
months prior to the survey.240 The third paper reported that e-cigarette use had an increased 
association with asthma and that users were more likely to have had days absent from school due to 
severe asthma symptoms.241 The fourth paper found that active and passive vaping among 
adolescents was significantly associated with the onset of asthma symptoms.242 The fifth paper 
reported that adult asthmatic patients who continue to smoke conventional tobacco cigarettes or 
replace them with e-cigarettes have a significant decline in their pulmonary function and their asthma 
control test score in comparison with non-user asthmatic patients.243 The remaining two papers 
concluded that e-cigarette use may be associated with asthma among never-smokers.244 245 
One study found a significant independent association between e-cigarette use and chronic 





One study described an epidemiologic investigation into reports of several cases of lung injury in 
previously healthy persons in Illinois who reported e-cigarette use.247 Overall, 75 (87%) of 86 
interviewed patients reported using e-cigarette products containing tetrahydrocannabinol, and 61 
(71%) reported using nicotine-containing products. Nearly all (96%) tetrahydrocannabinol-containing 
products reported were packaged, prefilled cartridges, and 89% were acquired from informal 
sourcesOne paper reported that all genes displaying decreased expression in cigarette smokers 
(n=53) were also displaying decreased expression in e-cigarette smokers.248 Additionally, vaping e-
cigarettes was associated with suppression of many unique genes (n=305). Furthermore, the e-
cigarette users showed a greater suppression of genes commonly changed in cigarette smokers. 
One paper found that non-smokers who are passively exposed to e-cigarettes absorb nicotine.249 
One paper concluded that the effects of e-cigarettes on voice, using subjective and objective voice 
analysis, were mild compared with conventional tobacco cigarettes. 250 
Table 35 Cross-sectional survey papers on respiratory diseases, benefits or harms 
Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on respiratory diseases 
  Respiratory symptoms 
Wang et al. 233 
2016 
Harm The authors reported on the relationship between e-cigarette use and 
respiratory symptoms. 
Comparative groups 
E-cigarettes users themselves (current users) 
Conventional combustible tobacco cigarette users (experimental) 
Conventional combustible tobacco cigarette users (current users) 
Conventional combustible tobacco cigarette users (former users) 
Never smokers (conventional combustible tobacco cigarette) 
The authors noted that the strong association of respiratory symptoms 
(cough or phlegm for 3 consecutive months in the past 12 months) in 
adolescent e-cigarette users who never smoked tobacco cigarettes (AOR: 
2.06; 95% CI: 1.24–3.42) is comparable with that found in adolescent 
occasional smokers (AOR: 1.72; 95% CI: 1.01–2.93) in other Hong Kong 
study populations. 
McConnell et al. 
238 
2017 
Harm The authors reported on the relationship of e-cigarette use with chronic 
bronchitis symptoms and wheeze in an adolescent population. 
Comparative groups 
E-cigarettes users themselves (current) 
E-cigarettes users themselves (former users) 
Conventional combustible tobacco cigarette users (current) 
Never smokers (conventional combustible tobacco cigarette) 
Never vapers (e-cigarette) 
Never users (cigar) 
Never users (pipe) 
Never users (hookah) 
Former users (cigar) 
Former users (pipe) 
Former users (hookah users) 
The authors concluded that adolescent e-cigarette users had increased 
rates of chronic bronchitic symptoms. 









The authors reported on the association of e-cigarette use with smoking 
habits, demographic factors, and respiratory symptoms (such as sputum 
production, chronic productive cough, and wheeze). 
Comparative groups 
E-cigarettes users themselves (daily) 
E-cigarettes users themselves (sometimes) 
Conventional combustible tobacco cigarette users (current users) 
Conventional combustible tobacco cigarette users (former users) 
Dual users (e-cigarette and combustible tobacco cigarette) 
Never smokers (conventional combustible tobacco cigarette) 





Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on respiratory diseases 
Respiratory symptoms (long-standing cough, sputum production, chronic 
productive cough, any wheeze, recurrent wheeze, any respiratory 
symptoms) were most common among dual users of conventional 
combustible tobacco cigarettes and e-cigarettes, and among former 
smokers and non-smokers who used e-cigarettes. In a regression analysis 
adjusted for sex, age group, survey, and educational level, having any 
respiratory symptoms was significantly associated with dual use (OR: 4.03; 
95% CI: 3.23–5.02), smoking only (OR: 2.55; 95% CI: 2.36–2.77), and 
former smoking without e-cigarette use (OR: 1.27; 95% CI: 1.19–1.36), 
while former smoking with e-cigarette use (OR: 1.47; 95% CI: 0.91–2.37) 
and non-smoking with e-cigarette use (OR: 1.46; 95% CI: 0.93–2.29) did 
not reach statistical significance. Non-smokers without e-cigarette use 
were used as the reference in the regression analysis. 
Lestari et al. 235 
2018 
Harm The authors reported on the relationship between e-cigarette use, a range 
of subjective feelings of upper respiratory well-being, and formaldehyde 
vapour concentration. 
Comparative groups 
E-cigarettes users themselves (daily and number per day) 
The authors concluded that health complaints were mostly upper airway 
irritation with acute effect, and that cotinine in urine was mostly positive. 
Reidel et al. 231 
2018 
Harm The authors reported on the relationship between cigarette smokers, e-
cigarette users, and non-smokers with the profile of innate defence 
proteins in airway secretions of mucins MUC5AC and MUC5B, and of 
neutrophil extracellular trap formation rates. 
Comparative groups 
E-cigarettes users themselves (current) 
Conventional combustible tobacco cigarette users (current) 
Never smokers (conventional combustible tobacco cigarette) 
The authors concluded that e-cigarette use alters the profile of innate 
defence proteins in airway secretions, inducing similar and unique changes 
relative to cigarette smoking. These data challenge the concept that e-










The authors reported on the effects of e-cigarettes on voice performance 
compared with conventional combustible tobacco cigarettes.  
Comparative groups 
E-cigarettes users themselves (between 1 and 3years) 
Conventional combustible tobacco cigarette users (daily 10 to 20 cigarettes for 1 to 
5 years) 
Never smokers (conventional combustible tobacco cigarette) 
The authors concluded that the effects of e-cigarettes on voice were 
detected as mild compared with those of conventional combustible 
tobacco cigarettes, according to the subjective and objective voice analysis 
results in the study.  
King et al. 236 
2019 
Harm The authors reported on the adverse symptoms identified in e-cigarette 
users. 
Comparative groups 
E-cigarettes users themselves (ever and current) 
E-cigarettes users themselves (former users) 
Conventional combustible tobacco cigarette users (daily or some days) 
Conventional combustible tobacco cigarette users (former) 
Never smokers (conventional combustible tobacco cigarette) 
The authors concluded that most e-cigarette users reported at least one 
symptom, most commonly a cough or a dry or irritated mouth or throat. 
Former cigarette smokers who used e-cigarettes in the past 30 days were 
less likely than current or never-smokers to report adverse symptoms of e-
cigarette use.  
Li et al. 237 
2019 
Harm The authors reported on the association between smokers, dual users, and 






Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on respiratory diseases 
E-cigarettes users themselves (exclusive) 
E-cigarettes users themselves (ever and current) 
Conventional combustible tobacco cigarette users (exclusive users) 
Conventional combustible tobacco cigarette users (ever and current) 
Dual users (e-cigarette and combustible tobacco cigarette) 
The authors concluded that vaping was associated with increased risk of 
wheezing and related respiratory symptoms. Current vapers had a lower 
risk of wheezing and related respiratory symptoms than current smokers 
or dual users, but a higher risk than non-users. Both dual use and smoking 
significantly increased the risk of wheezing and related respiratory 
symptoms.  









The authors reported on the impact of e-cigarettes on lung function and 
fractional exhaled nitric oxide (FeNO) among 60 young healthy male 
adults. 
Comparative groups 
E-cigarettes users themselves (daily in past 6 months) 
Non-users (conventional tobacco cigarettes, shisha) 
Non-users (e-cigarettes) 
The authors concluded that fractional exhaled nitric oxide was decreased 
in e-cigarette users, but it did not reach the level of significance. Also, the 
use of e-cigarettes significantly impaired various lung function parameters, 
and the pattern of impairment exhibited a peripheral obstructive airway 
involvement. 
  Asthma 
Cho et al. 241 
2016 
Harm The authors reported on findings regarding the association between e-
cigarette use and asthma (students’ self-reported doctor diagnosis in past 
12 months).  
Comparative groups 
E-cigarettes users themselves (ever and current) 
E-cigarettes users themselves (former) 
Conventional combustible tobacco cigarette users (ever and current) 
Conventional combustible tobacco cigarette users (former) 
Never users (conventional combustible tobacco cigarette) 
The authors concluded that e-cigarette users have an increased 
association with asthma and are more likely to have had days absent from 
school due to severe asthma symptoms than non-users.  
Choi et al. 240 
2016 
Harm The authors reported findings on the association between e-cigarette use 
and asthma.  
Comparative groups 
E-cigarettes users themselves (ever) 
E-cigarettes users themselves (current) 
Conventional combustible tobacco cigarette users (current users grouped by 
number of days used) 
The authors concluded that e-cigarette use is more common among 
Florida high school youth with asthma and is associated with susceptibility 
to cigarette smoking.  
Kim et al. 242 
2017 
Harm The authors reported on the association of active and passive e-cigarette 
vaping with asthma. 
Comparative groups 
E-cigarettes users themselves (current) 
Conventional combustible tobacco cigarette users (current) 
Passive smokers 
The authors concluded that the study demonstrated a positive association 
between e-cigarette use and an asthmatic episode in the past 12 months, 
and that this association was observed when adjustments for active and 
passive vaping exposure were included in the analysis. However, e-
cigarette vaping in the past month was not significantly associated with 
lifetime asthma after adjusting for active and passive vaping. Active and 





Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on respiratory diseases 
asthma history than recent e-cigarette vaping. As a high proportion of e-
cigarette smokers are generally previous active smokers, the effects of 
previous active vaping were high in this group.  
Schweitzer et al. 
239 
2017 
Harm The authors reported on the association of e-cigarettes with asthma, 
controlling for cigarette smoking, marijuana use, and six demographic 
covariates. 
Comparative groups 
E-cigarettes users themselves (ever) 
E-cigarettes users themselves (current and data on device) 
Conventional combustible tobacco cigarette users (ever users)  
Conventional combustible tobacco cigarette users (current) 
Never smokers (conventional combustible tobacco cigarette) 
Current e-cigarette use was associated with currently having (versus never 
having) asthma (AOR: 1.48; CI: 1.26–1.74) and with previously having 
(versus never having) asthma (AOR: 1.22; CI: 1.07–1.40). The level of 
confidence for CI is not reported in paper. The authors concluded that e-
cigarette use by adolescents is independently associated with asthma.  
AboElNaga243 
2018 
Harm The author reported on the relationship between e-cigarettes and specific 
respiratory outcomes, including asthma control test, lung function, blood 
eosinophils, and airway immunoinflammatory phenotype.  
Comparative groups 
Conventional combustible tobacco cigarette users (ever and current) 
E-cigarettes users themselves (current) 
Dual users (e-cigarette and conventional combustible tobacco cigarette in past 12 
months) 
Non-smokers (conventional combustible tobacco cigarette) 
The asthmatic patients were reported to have significant differences in 
spirometry and distribution of sputum cell subtypes between non-
smokers, current conventional combustible tobacco cigarette smokers, 
and e-cigarette users. The author stated that asthmatic smoker patients 
who smoke e-cigarettes develop mixed sputum subtype; there was no 
difference in the pulmonary function or asthma control of patients who 
smoke e-cigarettes compared with that observed in conventional smokers. 
The author concluded that asthmatic patients who continue to smoke 
conventional combustible tobacco cigarettes or replace them with e-
cigarettes have a significant decline in their pulmonary function, as 
recorded by spirometry parameters (FVC, FEV1, FEV1/FVC, maximal mid 
expiratory flow, and peak expiratory flow rate), and asthma control test 
score, in comparison with non-smoking asthmatic patients.  
Osei et al. 244 
2019b 
Harm The authors reported on the relationship between e-cigarette use and 
asthma among never combustible cigarette smokers.  
Comparative groups 
E-cigarettes users themselves (ever) 
E-cigarettes users themselves (daily) 
E-cigarettes users themselves (occasional) 
Conventional combustible tobacco cigarette users (ever) 
Conventional combustible tobacco cigarette users (current) 
Never smokers (conventional combustible tobacco cigarette) 
Never vapers (e-cigarette) 
Dual user (e-cigarettes and combustible tobacco cigarettes) 
The authors concluded that there was an increased rate of asthma among 
never combustible cigarette smoker e-cigarette users, with 39% higher 
odds of self-reported asthma compared to never e-cigarette users (OR: 
1.39; 95% CI: 1.15–1.68).  
Perez et al. 245 
2019 
Harm The authors reported on the association of e-cigarette use and asthma in 
never- smokers. 
Comparative groups 
E-cigarettes users themselves (current)  
E-cigarettes users themselves (former)  





Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on respiratory diseases 
Never vapers (e-cigarette) 
Dual users (e-cigarettes and conventional combustible tobacco for ≥ 6 months) 
The authors concluded that e-cigarette use may be associated with asthma 
among never-smokers.  
  Other respiratory conditions 
Martin et al. 248 
2016 
Harm The authors reported on the relationship between non-smokers, cigarette 
smokers, and e-cigarette users and immune gene expression profiles 
assessed from nasal scrape biopsies, nasal lavage, urine, and serum.  
Comparative groups 
E-cigarettes users themselves (current for ≥ 6 months)  
E-cigarettes users who were former smokers (current for ≥ 6 months)  
Conventional combustible tobacco cigarette users  
Non-smokers (conventional combustible tobacco cigarette) 
The authors concluded that the data indicate that vaping e-cigarettes is 
associated with decreased expression of a large number of immune-
related genes, which are consistent with immune suppression at the level 
of the nasal mucosal.  
Wills et al. 246 
2019 
Harm The authors reported on the association of e-cigarette use with diagnosed 
respiratory disorders. 
Comparative groups 
E-cigarettes users themselves (ever) 
Conventional combustible tobacco cigarette users (ever and current)  
Non-smokers (conventional combustible tobacco cigarette) 
The authors concluded that the study showed a significant independent 
association between e-cigarette use and chronic respiratory disorders. The 
association was stronger among non-smokers than among smokers.  
  Lung injury 
Ghinai et al. 247 
2019 
Harm In July 2019, the Illinois Department of Public Health and the Wisconsin 
Department of Health Services launched a coordinated epidemiologic 
investigation after receiving reports of several cases of lung injury in 
previously healthy persons who reported using e-cigarettes or vaping.  
Comparative groups 
Tetrahydrocannabinol (THC) containing e-cigarette products users (exclusive) 
Nicotine containing products users (exclusive) 
Dual or poly user (tetrahydrocannabinol (THC) containing e-cigarette products and 
other nicotine products users)  
Dank vapes tetrahydrocannabinol (THC) containing products users (exclusive)  
The Centers for Disease Control and Prevention reported the precise 
source of the outbreak as currently unknown; however, the predominant 
use of prefilled tetrahydrocannabinol-containing cartridges among 
patients with lung injury associated with e-cigarette use suggested that 
these products played an important role.  
  Passive smoking 
Bayly et al. 249 
2019 
Harm The authors reported on the relationship between second-hand e-
cigarette aerosol exposure and asthma exacerbations among youth with 
asthma. 
Comparative groups 
E-cigarettes users themselves (current) 
E-cigarettes users themselves (former) 
Conventional combustible tobacco cigarette users (current) 
Conventional combustible tobacco cigarette users (former) 
Never smokers (conventional combustible tobacco cigarette) 
Never vapers (e-cigarette) 
Never users (cigar) 
Never users (hookah) 
Passive e-cigarette exposure (current) 
Cigar users (current) 





Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on respiratory diseases 
Hookah users (current) 
Hookah users (former) 
The results found that airborne markers were statistically higher in the 
homes of conventional combustible tobacco cigarette smokers (5.7 times 
higher) than in the homes of e-cigarette users. However, concentrations of 
both biomarkers among non-smokers exposed to conventional 
combustible tobacco cigarettes and to e-cigarette vapour were statistically 
similar (2 and 1.4 times higher, respectively). The authors concluded that 
non-smokers passively exposed to e-cigarettes absorb nicotine.  





The authors reported on a preliminary exploration of second-hand smoke 
or vapour exposure in youth with sickle cell disease through biochemical 
verification of cotinine, pulmonary functioning, and healthcare utilisation. 
Comparative groups 
E-cigarettes users themselves (current)  
E-cigarettes users themselves (former) 
Conventional tobacco cigarettes users (current) 
Conventional tobacco cigarettes users (former) 
Never smokers (conventional tobacco cigarettes users) 
Never vapers (e-cigarette) 
The authors concluded that most of the youth (88%) were exposed to 
second-hand smoke via salivary cotinine. Interestingly, no significant 
associations were observed between youth cotinine levels and emergency 
department utilisation, physician-reported sickle cell crises, or pulmonary 
functioning. Present findings indicate a need to assess for second-hand 
smoke using objective assessment measures. 
4.3.1.2.5 Oral diseases: cross-sectional surveys 
The 14 cross-sectional survey papers grouped under the ‘oral disease’ heading reported on clinically, 
radiographically, laboratory, and self-reported measures of oral health (Table 36). These included the 
clinical and radiographic peri-implant parameters that assess: cavities, gum disease, dental stains, 
extent of full-mouth and peri-implant plaque, and bleeding on probing. Probing depth was measured 
at different sites in each tooth, including maxillary and mandibular teeth. Peri-implant bone loss and 
marginal bone loss were measured. Levels of tumour necrosis factor-alpha (TNF-alpha), interleukin 6 
(IL-6), interleukin -1 beta, and matrix metalloproteinase-9 in peri-implant sulcular fluid were 
ascertained. Levels of immunoglobulin A (IgA), lysozyme, and lactoferrin levels in unstimulated saliva 
were also measured. Some papers measured outcomes such as gingival pain and/or bleeding, tongue 
and/or inside-cheek pain, cracked or broken teeth, number of permanent teeth removed due to non-
traumatic causes, and unstimulated whole salivary flow rate. One paper determined carrier status for 
oral Candida in survey participants.  
There were 11 studies on oral health; 9 reported that there was a harmful association between e-
cigarettes and oral health and 2 reported that e-cigarettes were less harmful than conventional 
tobacco cigarettes for oral health.  
One study reported that daily e-cigarette use among adolescents may be a risk factor for cracked or 
broken teeth and for tongue and/or inside-cheek pain.252 Seven studies concluded that periodontal 
inflammation and/or disease were poor among e-cigarette users when compared to non-users.253-255 
256 256-258 One study found that daily e-cigarette use was independently associated with 78% higher 
odds of permanent tooth extraction due to caries.259 Another study determined that use of 
conventional tobacco cigarettes and dual use of e-cigarettes and tobacco cigarettes were associated 
with adolescents self-reporting past-year diagnosis of dental problems.  
On the other hand, two studies reported that clinical and radiographic parameters of periodontal 
inflammation were poorer in tobacco cigarette users than in e-cigarette users and in never-
smokers.260 261 The papers’ abstracts implied that e-cigarette users and never-smokers have similar 





There were three papers on markers for oral infection in e-cigarette users. One paper examined the 
relationship of e-cigarettes with selected antibacterial properties of saliva (IgA, lysozyme, and 
lactoferrin levels) and concluded that the saliva of e-cigarette users showed negative changes in 
antibacterial properties compared with non-users and with tobacco cigarette smokers.262 Another 
paper reported that oral Candida albicans carriage was significantly higher among tobacco cigarette 
smokers, water pipe smokers, and e-cigarette users than among non-users.263 On the other hand, the 
third paper reported that people who regularly use e-cigarettes do not have measurably different oral 
or gut bacterial communities compared to non-smokers.264 
Table 36 Cross-sectional survey papers on oral diseases, benefits or harms 
Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on oral diseases 
  Oral health 
Cho252 
2017 
Harm The author reported on the relationship between e-cigarette use and oral 
health, measured as gingival pain and/or bleeding, tongue and/or inside-
cheek pain, and cracked or broken teeth. 
Comparative groups 
E-cigarettes users themselves (current) 
E-cigarettes users themselves (daily, nicotine-free) 
E-cigarettes users themselves (daily, nicotine use) 
E-cigarettes users themselves (former) 
Conventional combustible tobacco cigarette users (daily, nicotine free) 
Conventional combustible tobacco cigarette users (current) 
Conventional combustible tobacco cigarette users (former) 
Never smokers (conventional tobacco cigarettes users) 
Never vapers (e-cigarette) 
The author reported that former e-cigarette users had a significantly higher 
occurrence of cracked or broken teeth than never e-cigarette users, and 
that daily e-cigarette users had a significantly higher occurrence of tongue 
and/or inside-cheek pain than never e-cigarette users, concluding that 
daily e-cigarette use among adolescents may be a risk factor for cracked or 
broken teeth and for tongue and/or inside-cheek pain.  
Javed et al. 253 
2017 
Harm The authors reported on the relationship between cigarette smokers 
(group 1), individuals exclusively vaping e-cigarettes (group 2), and never-
smokers (group 3) with periodontal parameters and self-perceived oral 
symptoms.  
Comparative groups 
E-cigarettes users themselves who were never smokers (exclusive for ≥ 12 months, 
group 2) 
Conventional combustible tobacco cigarette users (≥ 5 daily for ≥ 12 months, group 
1)  
Never users (any type of nicotine product, group 3) 
Plaque index (p<0.01) and probing depth ≥4 mm (p<0.01) were significantly 
higher in groups 1 and 2 than in group 3. Bleeding on probing was 
significantly higher in group 3 than in groups 1 and 2 (p<0.01). There was 
no difference in the number of missing teeth, clinical attachment loss, or 
marginal bone loss between all groups. Gingival pain was more often 
reported by individuals in group 1 than by individuals in groups 2 or 3 
(p<0.01).  
Akinkugbe et al. 
254 
2018 
Harm The authors investigated associations between self-reported use of 
cigarettes and e-cigarettes with oral health status. 
Comparative groups 
E-cigarettes users themselves (current) 
E-cigarettes users themselves (ever) 
Conventional combustible tobacco cigarette users (ever)) 
Conventional combustible tobacco cigarette users (current) 
Current dual users (e-cigarette and conventional combustible tobacco cigarette) 
Ever dual users (e-cigarette and conventional combustible tobacco cigarette) 
The authors used adjusted logistic regression to estimate prevalence odds 





Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on oral diseases 
problems’ covariate-adjusted values were: POR: 1.50 (95% CI: 1.18–1.90) in 
current cigarette users and POR: 1.11 (95% CI: 0.79–1.55) in current e-
cigarette users. Ever use of cigarettes and e-cigarettes was likewise 
associated with increased prevalence odds of self-reported past-year 
diagnosis of dental problems, although to a lesser magnitude. The authors 
concluded that dual use of e-cigarettes and conventional combustible 
tobacco cigarettes is associated with poor oral health outcomes among 
adolescents.  
Al-Aali et al. 255 
2018 
Harm The authors reported on the relationship between vaping e-cigarettes and 
never smoking with clinical and radiographic peri-implant parameters and 
levels of tumour necrosis factor alpha (TNF-alpha) and interleukin (IL)-
1beta. 
Comparative groups 
E-cigarettes users themselves (using for ≥ 1 year) 
Never-smokers (conventional combustible tobacco cigarette) 
The authors concluded that clinical and radiographic peri-implant 
parameters were compromised among vaping individuals. The authors 
concluded that increased levels of proinflammatory cytokines in peri-
implant sulcular fluid may suggest greater local inflammatory response in 
vaping individuals for peri-implant inflammation and peri-implant bone 
loss (p=0.016). A significant positive correlation was found between IL-1 
beta and peri-implant bone loss (p=0.018) in e-cigarette users compared to 
non-users of e-cigarettes.  
AlQahtani et al. 
256 
2018 
Harm The authors reported on the relationship of water pipe smokers, e-
cigarette users, and cigarette smokers with peri-implant parameters and 
local levels of proinflammatory cytokines; specifically, periodontal and 
peri-implant plaque index, bleeding on probing, and probing depth (≥4 
mm) and levels of TNF-alpha, interleukin -6, and interleukin -1 beta in peri-
implant sulcular fluid. 
Comparative groups 
E-cigarettes users themselves (current, ≥ 10 per day use for ≥ 5 years)) 
Conventional combustible tobacco cigarette users (current daily use) 
Non-smokers (conventional combustible tobacco cigarette) 
Water pipe users (current daily use) 
Mean peri-implant plaque index (p<0.05), probing depth ≥4 mm (p<0.05), 
and total radiographic bone loss (p<0.01) were significantly higher among 
cigarette smokers, water pipe smokers, and subjects using e-cigarettes 
compared with non-smokers. Statistical differences in bleeding on probing 
were observed in non-smokers (p<0.01) compared to cigarette smokers, 
water pipe smokers, and subjects using e-cigarettes. Cigarette smokers and 
water pipe smokers showed significantly higher probing depth ≥4 mm and 
radiographic bone loss compared with subjects using e-cigarettes (p<0.05). 
Levels of TNF-alpha, IL-6, and IL-1 beta were significantly higher in cigarette 
smokers, water pipe smokers, and subjects using e-cigarettes compared to 
non-smokers. There were no statistical differences in the mean levels of all 
proinflammatory cytokines among individuals who were cigarette smokers 
or water pipe smokers.  









The authors reported on the relationship between cigarette smoking, 
water pipe smoking, e-cigarette using, and never smoking behaviours, and 
outcome oral health measures of clinical (plaque index, bleeding on 
probing, probing pocket depth, and clinical attachment loss), radiographic 
(marginal bone loss), and periodontal parameters, and of whole salivary 
cotinine, interleukin -1 beta, and interleukin -6 levels.  
Comparative groups 
E-cigarettes users themselves who never smoked (exclusive for ≥ 12 months) 
Conventional combustible tobacco cigarette users (daily for ≥ 12 months) 
Never smokers (conventional combustible tobacco cigarette) 





Author(s), year Possible 
benefit or 
harm 
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The authors reported that clinical and radiographic parameters of 
periodontal inflammation were poorer in cigarette and water pipe smokers 
than in e-cigarette users and never-smokers, and that whole salivary 
cotinine levels were similar in all groups. Whole salivary interleukin -1 beta 
and interleukin -6 levels were higher in cigarette and water pipe smokers 
than e-cigarette users and never-smokers.  
Alqahtani et al. 
265 
2019 
Harm The authors compared cotinine levels in the peri-implant sulcular fluid 
among cigarette and water pipe smokers, e-cigarette users, and non-
smokers. 
Comparative groups 
E-cigarettes users themselves (daily for ≥ 1 year) 
Conventional combustible tobacco cigarette users (current, daily for ≥ 1 year) 
Never smokers (conventional combustible tobacco cigarette users) 
Other product users (waterpipe users) 
The authors concluded that habitual use of nicotinic products enhances the 
expression of cotinine in the peri-implant sulcular fluid. Cotinine levels in 
the peri-implant sulcular fluid of cigarette and water pipe smokers and e-
cigarette users are comparable.  









The authors reported on the relationship between cigarette smokers’, e-
cigarette vaping individuals’, and non-smokers’ peri-implant health using 
clinical and radiographic peri-implant parameters (specifically peri-implant 
plaque index, bleeding on probing, probing depth, and marginal bone loss), 
levels of matrix metalloproteinase-9, and interleukin -1 beta levels. 
Comparative groups 
E-cigarettes users themselves (≥ 1 year) 
Conventional combustible tobacco cigarette users (smoking for at least ≥ 1 year) 
Never smokers (conventional combustible tobacco cigarette) 
The authors concluded that peri-implant health was more compromised 
among cigarette smokers than vaping individuals and non-smokers. 
Increased levels of proinflammatory cytokines in cigarette smokers and 
vaping individuals may suggest greater peri-implant inflammatory 
response.  
Huilgol et al. 259 
2019 
Harm The authors reported on the relationship between e-cigarette use, defined 
as daily or intermittent use within 30 days prior to survey administration, 
and poor oral health (the number of permanent teeth removed due to 
non-traumatic causes). 
Comparative groups 
E-cigarettes users themselves (daily, some days, intermittent use in last 30 days) 
Conventional combustible tobacco cigarette users (current daily, some days, 
intermittent use) 
Non-users (conventional combustible tobacco cigarettes in last 30 days) 
Non-users (e-cigarettes in last 30 days) 
In multivariable analysis, daily e-cigarette use was independently 
associated with 78% higher odds of poor oral health (AOR: 1.78; 95% CI: 
1.39–2.30; p<0.001). The authors concluded that daily, but not 
intermittent, use of e-cigarettes was independently associated with poor 
oral health.  
Jeong et al. 257 
2020 
Harm The authors reported on the association of conventional combustible 
tobacco cigarette smoking and e-cigarette vaping with periodontal 
disease. 
Comparative groups 
E-cigarettes users themselves  
E-cigarettes users themselves (former) 
Conventional tobacco cigarette users  
Non-users (e-cigarette) 
Non-users (any products) 
The authors concluded that e-cigarette and conventional combustible 
tobacco cigarette use were both significantly associated with increased 
periodontal disease rates. After adjusting for demographic, socioeconomic, 
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significant association with periodontal diseases. The authors suggested 
that vaping may not be a safe alternative to smoking.  
Vora et al. 258 
2019 
Harm The authors reported on the relationship between smoking behaviours – 
specifically cigarette smoking and using other types of tobacco products – 
and self-reported gingival disease. 
Comparative groups 
E-cigarettes users themselves who never smoked (current) 
Conventional combustible tobacco cigarette users (ever and current) 
Conventional combustible tobacco cigarette users (former stopped ≤12 months) 
Conventional combustible tobacco cigarette users (former stopped > 12 months) 
Cigar users (regular)  
Pipe users (regular)  
Hookah users (regular)  
Other tobacco product users (smokeless tobacco products, chewing tobacco, snuff, 
snus, or dissolvable tobacco) (regular)  
Poly product users (conventional combustible tobacco cigarette, cigar, pipe and/or 
hookah)  
Experimenters (currently using cigarettes, e-cigarettes, cigar products, pipes, 
hookah, or smokeless tobacco products, but used fewer than 100 times) 
The authors concluded that numerous tobacco use patterns were 
associated with worse periodontal health compared with tobacco never 
users.  
  Markers of infection 
Cichonska et al. 
262 
2019 
Harm The authors reported on the relationship between e-cigarettes and 
selected antibacterial properties of saliva (IgA, lysozyme, and lactoferrin 
levels). 
Comparative groups 
E-cigarettes users themselves (daily for ≥ 6 months) 
Conventional combustible tobacco cigarette users (≥ 10 per day for≥ 6 months) 
Non-smokers (conventional combustible tobacco cigarette) 
The authors concluded that the saliva of e-cigarette users showed changes 
in antibacterial properties in comparison with the control group and with 
conventional combustible tobacco cigarette smokers. More specifically, 
among e-cigarette users, statistically significant differences were observed 
in levels of lysozyme and lactoferrin; however, no statistically significant 
differences for the IgA levels were found.  
Mokeem et al. 
263 
2019 
Harm The authors reported on the relationship between oral Candida albicans 
carriage, number of missing teeth, and unstimulated whole salivary flow 
rate with smoking-related behaviours, specifically among cigarette and 
water pipe smokers, e-cigarette users, and never-smokers.  
Comparative groups 
E-cigarettes users themselves  
Conventional combustible tobacco cigarette users (daily) 
Never smokers (conventional combustible tobacco cigarette) 
Water pipe smokers ≥ 1 time per day for ≥12-months 
The authors concluded that oral Candida albicans carriage was significantly 
higher among cigarette and water pipe smokers and e-cigarette users than 
among never-smokers. No significant differences were identified among 
groups in the oral carriage of other Candida species.  






The author reported the effects of tobacco smoke and e-cigarette vapour 
exposure on the oral and gut microbiota in humans. 
Comparative groups 
E-cigarettes users themselves (daily) 
Conventional combustible tobacco cigarette users (daily) 
Matched controls (matching variables not reported) 
The author concluded that people who regularly use e-cigarettes do not 






4.3.1.2.6 Developmental and reproductive effects: cross-sectional surveys 
There were no cross-sectional surveys on the relationship between e-cigarettes and developmental 
and reproductive effects. 
4.3.1.2.7 Injuries and poisonings: cross-sectional surveys 
There were no cross-sectional surveys on the relationship between e-cigarettes and injuries or 
poisonings.  
4.3.1.2.8 Exposure to e-cigarette toxins: cross-sectional surveys 
There were nine cross-sectional survey papers grouped under exposure to e-cigarette toxins (Table 
37). They measured toxins in e-cigarettes alone, toxins and carcinogens in e-cigarettes compared to 
conventional tobacco cigarettes, organophosphates entering the body from e-cigarettes, and 
polycyclic aromatic hydrocarbons (which are environmental pollutants). Some of the categories of 
toxins measured were: urinary nicotine metabolites, minor tobacco alkaloids, arsenic and arsenic 
compounds, tobacco-specific nitrosamines, metals, polycyclic aromatic hydrocarbons, and volatile 
organic compounds. 
One study concluded that tobacco smoke was a source of toxic elements such as copper, zinc, 
antimony, strontium, and vanadium.266 E-cigarette aerosol seemed to be a new source for intake of 
other toxic elements, such as silver, tin, and rare earth elements such as cerium, erbium, and 
gadolinium.266 The outcomes assessed in this study were limited to participants blood toxin levels.  
Four studies examined the toxicity of conventional tobacco cigarettes compared with e-cigarettes. 
The first study concluded that compared with cigarette smokers, people using e-cigarettes have lower 
levels of the urinary toxicant and carcinogen metabolites measured in their study.267 The second 
study concluded that using conventional tobacco cigarettes alone or in combination with e-cigarettes 
is associated with higher concentrations of potentially harmful tobacco constituents in comparison 
with using e-cigarettes alone.268 However, the lowest levels of harmful tobacco constituents were in 
non-users. The third study concluded that smokers who completely switched to e-cigarettes and quit 
smoking tobacco cigarettes may significantly reduce their exposure to cadmium, and probably to 
lead.269 By contrast, the fourth study concluded that the observed levels of blood cadmium, lead, and 
mercury among USA participants aged 12 years or over did not differ among cigarette smokers only, 
e-cigarette users only, and dual users of both cigarettes and e-cigarettes.270 
One study reported that although e-cigarette vapour may be less hazardous than tobacco smoke, 
findings challenged the idea that e-cigarette vapour is safe, because many of the volatile organic 
compounds identified within the vapour are carcinogenic.271 
The authors of one study found nickel in urine and saliva, and chromium in saliva.272 Both were 
positively associated with concentrations of the corresponding metals in aerosol samples collected 
from the vapour of the participants’ personal vaping devices, providing strong evidence that metals 
present in the aerosol were inhaled by the users. 
One study reported that four organophosphate flame retardants were detected in a much higher 
proportion of smokeless tobacco users (including e-cigarette users) than in cigarette smokers and 
non-users.273  
Polycyclic aromatic hydrocarbons are associated with environmental pollution and their biomarkers 
were examined in one study.274 Cigarette users had the highest geometric mean levels of polycyclic 
aromatic hydrocarbons compared with other tobacco product users, and, not surprisingly, non-users 
had the lowest mean levels. Smokeless tobacco product users and e-cigarette users had levels of 
polycyclic aromatic hydrocarbon biomarkers that fell somewhere between the levels found in tobacco 







Table 37 Cross-sectional survey papers on exposure to e-cigarette toxins, benefits or harms 
Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on exposure to e-cigarette toxins 








The authors reported on the relationship between e-cigarette smokers 
who had not smoked tobacco cigarettes for at least 2 months and the 
presence of a suite of toxicant and carcinogen metabolites, including: 1-
hydroxypyrene (1-HOP), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
and its glucuronides (total NNAL), 3-hydroxypropylmercapturic acid (3-
HPMA), 2-hydroxypropylmercapturic acid (2-HPMA), 3-hydroxy-1-
methylpropylmercapturic acid (HMPMA), S-phenylmercapturic acid 
(SPMA), nicotine, and cotinine. 
Comparative groups 
E-cigarettes users themselves (exclusive for 2 months) (former) 
Conventional combustible tobacco cigarette users (exclusive)) 
Levels of 1-HOP, total NNAL, 3-HPMA, 2-HPMA, HMPMA, and SPMA were 
significantly lower in the urine of e-cigarette users compared with that of 
cigarette smokers. Levels of nicotine and cotinine were significantly lower 
in e-cigarette users compared with cigarette smokers. The authors 
concluded, with respect to the compounds analysed in this study, that e-
cigarettes have a more favourable toxicity profile than tobacco cigarettes.  
Aherrera et al. 
272 
2017 
Harm The authors reported on the relationship between e-cigarettes and the 
metals nickel and chromium, which are components of the devices’ 
heating coil. 
Comparative groups 
E-cigarettes users themselves (exclusive daily for ≥ 6 weeks in never smokers or 
quitters ≥ 3 months) 
Dual users (used combustible cigarettes at least weekly and e-cigarette users daily 
for ≥ 6 weeks) 
The authors concluded that the study of daily e-cigarette users indicates 
that metals in e-cigarette aerosol are inhaled and absorbed into the 
bodies of users, representing a relevant contributor to metal internal 
dose. As the first study to make direct comparisons between source and 
metal biomarkers from e-cigarette use, the authors found that nickel in 
urine and saliva and chromium in saliva were positively associated with 
concentrations of the corresponding metals in aerosol samples collected 
from users’ personal vaping devices, providing strong evidence that 
metals present in the aerosol are inhaled by the user. E-cigarette use 
patterns – such as more e-liquid consumed per week, a shorter time 
between waking and first vape, and a higher voltage used – were also 
associated with higher nickel biomarker levels.  
Badea et al. 266 
2018 
Harm The authors reported on the relationship between non-smokers, cigarette 
smokers, and e-cigarette users with the presence of a range of inorganic 
elements. Serum concentration levels of 43 elements, including trace 
elements and other rare earth elements and minor elements considered 
pollutants were measured. 
Comparative groups 
E-cigarettes users themselves (former smokers) 
Conventional combustible tobacco cigarette users (daily) 
Non-users (conventional combustible tobacco cigarette) 
The authors concluded that tobacco smoke is a source of toxic elements 
such as copper, zinc, antimony, strontium, and vanadium, and that e-
cigarettes seem to be a new source for intake of silver, tin, and rare earth 
elements such as cerium, erbium, and gadolinium.  







The authors reported on estimates of biomarker concentrations in 
combustible cigarette users, e-cigarette users, dual users, and never 
tobacco users of tobacco-related toxicant concentrations. 
Comparative groups 
E-cigarettes users themselves (exclusive, daily or someday) 
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tobacco 
cigarettes 
Dual users (e-cigarettes and conventional combustible tobacco cigarette users, 
exclusive, daily or someday) 
Never users (conventional combustible tobacco) 
The authors concluded that the findings provide evidence that using 
combustible tobacco cigarettes alone or in combination with e-cigarettes 
is associated with higher concentrations of potentially harmful tobacco 










The authors reported on the relationship between e-cigarettes and levels 
of cadmium and lead.  
Comparative groups 
E-cigarettes users themselves (≥ 6 months, and former smokers for ≥ 6 months,) 
Conventional combustible tobacco cigarette users (daily for ≥ 2 years) 
Dual users (e-cigarettes for ≥ 6 months and smoked conventional tobacco 
cigarettes for ≥ 2 years) 
Non-smokers 
The authors concluded that smokers who completely switched to e-
cigarettes and quit smoking conventional combustible tobacco cigarettes 
may significantly reduce their exposure to cadmium, and probably to lead.  









The authors reported on a range of chemical toxicants (metabolites of 
benzene, ethylene oxide, acrylonitrile, acrolein, propylene oxide, 
acrylamide, and crotonaldehyde) in two groups, e-cigarette-only users 
and never-using controls.  
Comparative groups 
E-cigarettes users themselves (current, ≥ 1 time past 30 days and ≥ 10 times in 
lifetime) 
Conventional combustible tobacco cigarette users (current) 
Dual users (e-cigarettes and smoked conventional tobacco cigarettes) 
Never-using controls 
The authors concluded that although e-cigarette vapour may be less 
hazardous than tobacco smoke, their findings challenged the idea that e-
cigarette vapour is safe, because many of the volatile organic compounds 
identified are carcinogenic.  
Wei et al. 273 
2018 
Harm The authors reported on the relationship between e-cigarette users and 
metabolite levels of flame retardants (and their urinary metabolites. 
Four metabolites had detection rates >60%, the authors observed higher 
adjusted geometric mean for (bis(2-chloroethyl) phosphate (BCEP)), a 
metabolite of tris(1-chloro-2-propyl) phosphate (bis(1-chloro-2-propyl) 
phosphate), tris(2-chloroethyl) phosphate (TCEP), in the users of e-
cigarettes than in both non-users and cigarette users, suggesting that 
using e-cigarettes could lead to elevated exposure to TCEP. In a similar 
fashion, cigar users may have a higher exposure to triphenyl phosphate 
(TPhP) while smokeless tobacco (including e-cigarette) users showed 
higher exposure to tributyl phosphate (TBUP), but lower exposure to 
triphenyl phosphate.  
Comparative groups 
E-cigarettes users themselves (exclusive, ≥ 1 in last 5 days) 
Conventional combustible tobacco cigarette users (exclusive, ≥ 1 in last 5 days) 
Non-user (any tobacco products)  
Cigar users (exclusive, frequency of use in last 5 days) 
Smokeless tobacco products users (exclusive, frequency of use in last 5 days) 
The authors concluded that while the results are preliminary, they 
indicate a need for a better examination of the types and levels of 
organophosphate flame retardants and their potential contamination 
sources in non-cigarette tobacco products, including e-cigarettes.  
Jain 270 
2019 
Harm The author reported on concentrations of cadmium, lead, and mercury in 
blood among cigarette, cigar, e-cigarette, and dual cigarette and e-
cigarette users in the USA. 
Comparative groups 
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Conventional combustible tobacco cigarette users (frequency of use in last 5 days)  
Dual users (e-cigarettes and conventional tobacco cigarettes) 
Non-smokers (for the last five days)  
Cigars users only (frequency of use in last 5 days) 
The author concluded that the observed levels of blood cadmium, lead, 
and mercury among persons in the USA aged 12 years or over were not 
found to differ among cigarette-only users, e-cigarette-only users, and 
dual users of both cigarettes and e-cigarettes.  
Wang et al. 274 
2019b 
Harm The authors reported on the relationship between smoking behaviours in 
adults and environmental pollutants of polycyclic aromatic 
hydrocarbons. 
Comparative groups 
E-cigarettes users themselves (exclusive, current)  
Conventional combustible tobacco cigarette users (exclusive, current)  
Smokeless product users (exclusive, current)  
Other single tobacco product users (exclusive, current) 
Dual users (combustible products users and non-combustible products users) 
Dual and poly users (any other dual or multiple product users) 
Never users (of any tobacco product) 
Geometric mean (GM) concentrations and evaluated associations 
between tobacco product user categories and polycyclic aromatic 
hydrocarbon biomarker concentrations were reported. For all biomarkers 
examined, cigarette users had the highest geometric means compared to 
other tobacco product users. Interestingly, geometric means of 2-
hydroxyfluorene, 3-hydroxyfluorene, and 2,3-hydroxyphenanthrene were 
significantly higher in exclusive smokeless product users than in e-
cigarette users; 3-hydroxyfluorene and 1-hydroxypyrene were also 
significantly higher in e-cigarette and exclusive smokeless product users 
than in never users. Everyday cigarette and exclusive smokeless product 
users had significantly higher geometric means for most biomarkers than 
sometimes users; cigarette and exclusive smokeless product users who 
had used the product in the last hour had significantly higher geometric 
means of most biomarkers than other occasional cigarette or exclusive 
smokeless product users. By contrast, everyday e-cigarette users’ 
geometric means of most biomarkers did not differ significantly from 
those in sometimes e-cigarette users.  
4.3.1.2.9 Other outcomes: cross-sectional surveys 
The 11 cross-sectional survey papers where the reported outcomes did not align with the adapted 
Academies of Sciences’ umbrella terms included papers on the endocrine system, sensory organs, 
metal contaminates, and adverse events (Table 38). The endocrine system papers examined e-
cigarette use and measures of self-reported diagnosis of prediabetes and clinically assessed glycated 
haemoglobin levels. One paper reported that there was an indirect association between e-cigarette 
smoking and glycated haemoglobin levels (HbA1c) levels in e-cigarette users and dual users, 
compared with levels among non-smokers.275 Physically inactive and overweight males who vaped 
had higher HbA1c levels. Another paper reported that current e-cigarette users had increased odds of 
reporting a diagnosis of prediabetes compared to never e-cigarette users.276 
The sensory organ system paper included an ophthalmic assessment of tear function.277 This study 
concluded that e-cigarette vapers were more likely to show moderate to severe symptomatic dry eye 
and poorer tear film quality compared with non-smokers. 
The papers on metal contaminates included secondary or subsequent exposure to e-cigarette 
contaminates among non-e-cigarette users. One paper concluded that non-users living in homes with 
e-cigarette users were passively exposed to, and absorbed, nicotine.278 Another paper concluded that 
almost four out of five neonatal intensive care unit medical staff had measurable finger nicotine, 





One paper examined any spending on e-cigarettes among e-cigarette users, and reported that, after 
controlling for confounding factors, the odds of negative health outcomes were similar and occurred 
whether the participant had purchased the e-cigarettes or not.280 
One paper concluded that dual users were significantly more likely to report adverse events of vaping 
than e-cigarette-only users.281 Experiencing health improvements was significantly more likely among 
e-cigarette-only users than among dual users for all surveyed physiological functions.  
Two papers reported that subjective experiences at first use differ by tobacco product, 282 and one 
paper reported that adolescents who had tried e-cigarettes reported fewer negative symptoms from 
their first e-cigarette than from their first conventional cigarette. 283  
One paper described experiences of e-cigarette-related adverse events (such as a ‘dry puff’) and 
undesirable events (such as leaking).284 
Table 38 Cross-sectional survey papers on other outcomes, benefits or harms 
Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on other outcomes 
Ballbe et al. 278 
2014 
Harm The authors reported on the relationship between passive exposure to 
nicotine in conventional combustible tobacco cigarettes and e-
cigarettes in 54 non-smoker volunteers from different homes. 
Comparative groups 
E-cigarettes users themselves ( 
Passive exposure (living at home with conventional combustible tobacco 
cigarette users) 
Passive exposure (living at home without conventional combustible tobacco 
cigarette users) 
The authors concluded that non-smokers passively exposed to e-
cigarettes absorb nicotine.  








The authors reported on how symptoms that adolescents experience 
during their first time using a cigarette predict their current use, but 
little is known about the symptoms experienced during first e-
cigarette use. 
Comparative groups 
E-cigarettes users themselves (current)  
Conventional combustible tobacco cigarette users (current) 
Dual users (e-cigarettes and conventional combustible tobacco cigarette) 
Non-users (not current)  
The symptoms were coded as negative (felt bad, coughing/chest pain, 
bad taste in mouth, upset stomach, and dizzy/lightheaded, with a 
range from 0 to 5) and positive (rush/buzz, and felt relaxed, with a 
range from 0 to 2) symptoms from their first cigarette and e-cigarette 
use. Of the 29 adolescents who had tried conventional combustible 
tobacco cigarettes, 28 had reported results, 22 (76%) reported 
experiencing negative symptoms only, 2 (7%) reported feeling neutral 
only, and 4 (14%) reported experiencing both positive and negative 
symptoms. No participants reported positive symptoms only. The 
negative symptoms that adolescents reported included feeling dizzy, 
sick, bad taste in their mouth, difficulty breathing, and headache. By 
contrast, of the 29 adolescents who had tried e-cigarettes, 9 (31%) 
reported experiencing negative symptoms only, 12 (41%) reported 
feeling neutral only, 6 (21%) reported experiencing positive symptoms 
only, and 2 (7%) reported experiencing both positive and negative 
symptoms. Twenty-five of the 29 adolescents (86%) reported that they 
felt ‘normal’, ‘no change’, or ‘the same’ after their first e-cigarette. 
Adolescents reported fewer negative symptoms from their first e-
cigarette than from their first cigarette, and e-cigarette symptoms did 
not influence use as they do for cigarettes.  





The authors reported on the relationship between cigarette, e-
cigarette, hookah, and cigar products and symptoms at first use 





Author(s), year Possible 
benefit or 
harm 





E-cigarettes users themselves  
Conventional combustible tobacco cigarette users 
Hookah users 
Cigar users  
The authors concluded that subjective experiences at first use differ by 
tobacco product.  
Yao et al. 280 
2017 
Harm The authors examined the relationship between spending on e-
cigarettes, 30-day e-cigarette use, and disease symptoms among 
current adult cigarette smokers. 
Comparative groups 
E-cigarettes users themselves (ever)  
E-cigarettes users themselves (current)  
Conventional combustible tobacco cigarette users (< 5 years ago) 
The authors reported that those who spent money on e-cigarettes 
were more likely to report chest pain (AOR: 1.25; 95% CI: 1.02–1.52), 
to notice blood when brushing their teeth (AOR: 1.23; 95% CI: 1.02–
1.49), to have sores or ulcers in their mouth (AOR: 1.36; 95% CI: 1.08–
1.72), and to have more than one cold (AOR: 1.36; 95% CI: 1.05–1.78) 
than those with no spending on e-cigarettes in the past 30 days in an 
adjusted analysis. After controlling for cigarettes smoked per day and 
other covariates, there were no significant relationships between 30-
day e-cigarette use and symptoms.  
Choi et al. 275 
2018 
Possible harm The authors reported on the relationship between smoking behaviour 
patterns and glycated haemoglobin levels.  
Comparative groups 
Conventional combustible tobacco cigarette users (current)  
Conventional combustible tobacco cigarette users (former)  
Dual users (e-cigarette and conventional combustible tobacco cigarette)  
Non-smoker (conventional combustible tobacco cigarette users) 
In the reported findings, elevated glycated haemoglobin levels 
(HbA1c) levels were observed among subjects who were dual users of 
e-cigarettes and conventional combustible tobacco cigarettes and who 
were e-cigarette-only or conventional combustible tobacco cigarette-
only users, compared with those among non-smokers; however, a 
direct association between e-cigarette use and HbA1c levels was not 
reported. In the analyses stratified by sex, men who were dual users 
and e-cigarette only or conventional combustible tobacco cigarette-
only users had higher HbA1c levels than non-smokers, whereas among 
women, there were no significant results. Among physically inactive 
subjects, dual users were more strongly associated with elevated 
HbA1c levels. However, it remains unclear whether e-cigarette use 
alone can induce an increase in HbA1c levels. According to body mass 
index, dual users had a strong association of elevated HbA1c levels 
among people who were obese and overweight compared with those 




Harm The authors reported on the characteristics and correlates of e-cigarette 
product attributes and undesirable events during use.  
Comparative groups 
E-cigarettes users themselves (ever)  
E-cigarettes users themselves (current, daily and weekly)  
E-cigarettes users themselves (current, less than weekly) 
The authors reported that current daily or weekly prevalence of e-
cigarette use among a sample of adult smokers was 7.5%. The most 
common attributes of e-cigarettes used included those that are 
flavoured, contain nicotine, and are of tank style. Use of e-liquid refill 
nozzle caps, described as easy for a child to open, was associated with 
spilling during refill. Participants who occasionally or regularly adjusted 





Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on other outcomes 
of ever experiencing a ‘dry puff’. Mixing different e-liquids was 
associated with leaking during use and spilling during refill. The authors 
concluded that ongoing evaluation of factors associated with e-cigarette 
attributes, and of the correlates of experiencing undesirable events 
during e-cigarette use to product design, is crucial to monitoring the 










The authors reported on the relationship between e-cigarette-only 
users and dual e-cigarette and conventional combustible tobacco 
cigarette users with a range of 16 adverse events and 10 physiological 
functions. 
Comparative groups 
E-cigarette users themselves (former smokers who had switched completely to 
e-cigarettes, with detail on daily past use of conventional combustible tobacco 
cigarette recorded; and detail on frequency and duration of e-cigarette use and 
nicotine content)  
Dual users (e-cigarettes, combustible tobacco cigarettes users) 
Excluded never smokers 
The authors concluded that the dual users were significantly more 
likely to report adverse events of vaping than e-cigarette-only users 
(26.2% versus 11.8%; p<0.001). Experiencing health improvements was 
significantly more likely among e-cigarette-only users than among dual 
users for all surveyed physiological functions. E-cigarette-only users 
reported larger effects of vaping on sensory, physical functioning, and 




Harm The authors reported on the association of e-cigarette use with a self-
reported diagnosis of prediabetes in never cigarette smokers. 
Comparative groups 
E-cigarettes users themselves (current) 
E-cigarettes users themselves (former) 
Smokeless tobacco products users (current) 
Never vapers (e-cigarettes) 
The authors concluded that e-cigarette use may be associated with 
self-reported prediabetes.  
Chang et al.285 
2019 
Harm The authors reported on the relationship between e-cigarette use and 
self-reported health outcomes. 
Comparative groups 
E-cigarettes users themselves (exclusive, current) 
E-cigarettes users themselves (with smokers, current) 
Conventional combustible tobacco cigarette users (exclusive, current) 
Conventional combustible tobacco cigarette users (with e-cigarette, current) 
*The sample was stratified into the smoking and non-smoking populations 
based on the status of current cigarette use.  
The authors concluded that some e-cigarette usage patterns were 
associated with poorer health conditions in smoking and non-smoking 
populations, but that they were cautious about making conclusive 
claims regarding e-cigarette usage patterns.  
Md Isa et al.277 
2019 
Harm The authors reported on the tear function in e-cigarette vapers. 
Comparative groups 
E-cigarettes users themselves (used ≥ 1-year, former combustible tobacco 
smokers ≥ 6 months, or e-cigarette daily users who occasionally use 
conventional combustible tobacco cigarette)  
Never smokers (with no history of smoking and smokers in their close family) 
The authors concluded that vapers showed moderate to severe 
symptomatic dry eye and poorer tear film quality compared with non-
smokers. High vaping voltage may have aggravated the dry eye 
syndrome because of hazardous by-products from pyrolysis of the e-
liquid constituents.  
Northrup et 
al.279 
Harm The authors reported on the contribution of medical staff to third-






Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on other outcomes 
2019 E-cigarettes users themselves (current) 
E-cigarettes users themselves (former) 
Conventional combustible tobacco cigarette users (current) 
Conventional combustible tobacco cigarette users (former) 
Never vapers (e-cigarette) 
Never smokers (conventional combustible tobacco cigarette) 
Passive exposure (living with a conventional combustible tobacco cigarette 
users or e-cigarette users) 
Passive exposure (living without a conventional combustible tobacco cigarette 
or e-cigarette users) 
The authors concluded that almost four in five neonatal intensive care 
unit medical staff had measurable finger nicotine, with finger surface 
area and frequency of reported exposure to tobacco smoke in friends’ 
or family members’ homes emerging as important correlates, leading 







4.3.2 Case-control studies: e-cigarettes 
4.3.2.1 Study characterisation: e-cigarettes 
There were two case-control studies that selected their cases based on the disease of interest and 
examined their history to identify exposures of interest.27 The controls did not have the disease of 
interest but were comparable with respect to other factors of interest. The limitations of case-control 
studies are that they suffer from recall bias, cannot establish a temporal sequence, and have difficulty 
controlling for all confounding factors.  
Both case-control studies were conducted in the USA and published between 2018 and 2019. Both 
reported harms of e-cigarette use. 
The number of case-control study papers on e-cigarette harms categorised under the adapted 
Academies of Sciences’ framework were: one under cancers (two markers for bladder cancer 
identified in e-cigarette users, n=23) and one under respiratory diseases (lung injury associated with 
tetrahydrocannabinol in e-liquid, n=585). There were no case-control study papers under the other 
reporting areas: ‘dependence and abuse liability’, ‘cardiovascular diseases’, ‘oral diseases’, 
‘developmental and reproductive effects’, ‘injuries and poisonings’, ‘exposure to e-cigarette toxins’, 
and ‘other outcomes’.  
4.3.2.2 Harms: e-cigarettes 
4.3.2.2.1 Dependence and abuse liability: case-control studies 
There were no case-control studies on the relationship between e-cigarettes and dependence and 
abuse liability outcomes.  
4.3.2.2.2 Cardiovascular diseases: case-control studies 
There were no case-control studies on the relationship between e-cigarettes and cardiovascular 
disease outcomes.  
4.3.2.2.3 Cancers: case-control studies  
There was one case-control study on the relationship between e-cigarettes and bladder cancer 
outcomes (Table 39). Bladder carcinogenic risk was assessed through a variety of measures, including 
aromatic amines and polyaromatic hydrocarbon metabolites, biomarkers of nicotine, tobacco-specific 
N-nitrosamines (TSNAs), and a range of volatile organic compounds.286 The specific volatile organic 
compounds measured were the compounds acrolein, acrylamide, acrylonitrile, 1,3-butadiene, and 
ethylene oxide. The authors of the study determined that e-cigarette users’ urine tested positive for 
the presence of two carcinogenic compounds, o-toluidine and 2-naphthylamine, at a mean 2.3-fold 
and 1.3-fold higher concentration, respectively, than that observed in the bladder cancer controls. 
According to the authors, this highlights the need to better understand the safety profile of e-






Table 39 Case-control study papers on cancers, benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case-control study papers on cancers 
Fuller et al. 286 
2018 
Harm The authors reported on the relationship between non-cigarette smoking e-
cigarette-only users and non-smoking, non-e-cigarette-using controls with 
known bladder carcinogenic aromatic amines and polyaromatic hydrocarbon 
metabolites in order to understand the risk profile of e-cigarette use and 
bladder cancer.  
Age: mean age of 39.4 years. Sex: male (69.2%). Country: USA.  
Data source: Not reported. Population size: 23.  
Comparative groups 
E-cigarettes users themselves (some former smokers >12 months) 
Non- conventional combustible tobacco cigarette users 
Outcomes: Participants were tested for urinary aromatic amines and 
polyaromatic hydrocarbon metabolites. Specifically, samples were analysed 
for the noncarcinogenic marker of polyaromatic hydrocarbon exposure 1-
hydroxypyrene; for carcinogenic polyaromatic hydrocarbons, including 
benz(a)anthracene and benzo(a)pyrene; and for the carcinogenic aromatic 
amines o-toluidine and 2-naphthylamine. 
Analysis of e-cigarette users’ urine revealed the presence of two carcinogenic 
compounds, o-toluidine and 2-naphthylamine, at a mean 2.3-fold and 1.3-fold 
higher concentration (p=0.0013 and p=0.014, respectively) than that 
observed in the controls.  
The authors identified the need to better understand the safety profile of e-
cigarettes and their contribution to the development of bladder cancer given 
the observed greater concentration of carcinogenic aromatic amines in the 
urine of e-cigarette users.  
Device and products: Not reported  
 
4.3.2.2.4 Respiratory diseases: case-control studies 
There was one case-control study on the relationship between e-cigarettes and respiratory disease 
outcomes, specifically lung injury (Table 40). The paper identified risk factors of e-cigarette products 
used by patients in Illinois and examined whether e-cigarette use behaviours differed between adult 
e-cigarette-associated lung injury patients (cases) and adults who used these products but did not 
develop lung injury (controls).287 The e-cigarette use behaviours of 66 e-cigarette-associated lung 
injury patients aged 18–44 years who were interviewed as part of the ongoing outbreak investigation 
were compared with a subset of 519 survey respondents aged 18–44 years who reported use of 
tetrahydrocannabinol-containing e-cigarettes. Compared with these survey respondents, e-cigarette-
associated lung injury patients had higher odds of reporting exclusive use of tetrahydrocannabinol-
containing products, using e-cigarettes frequently, and obtaining e-cigarettes from informal sources. 
The odds of using Dank Vapes, a class of largely counterfeit tetrahydrocannabinol-containing 






Table 40 Case-control study papers on respiratory diseases, benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case-control study papers on respiratory diseases 
Navon et al. 287 
2019 
 
Harm In the Morbidity and Mortality Weekly Report of the US Department of Health 
and Human Services and Centers for Disease Control and Prevention, first 
posted in November 2019, the authors reported on risk factors of e-cigarette, 
or vaping, products used by patients in Illinois.  
Comparative groups 
E-cigarettes users themselves (nicotine) 
E-cigarettes users themselves (tetrahydrocannabinol and nicotine). 
The Illinois Department of Public Health conducted an online public survey 
between September and October 2019 targeting e-cigarette, or vaping, 
product users in Illinois, examining whether e-cigarette, or vaping, product 
use behaviours differed between adult e-cigarette, or vaping, product use-
associated lung injury patients and adults who used these products but did 
not develop lung injury. Among 4,631 survey respondents, 94% reported 
using any nicotine-containing e-cigarette, or vaping, products in the past 3 
months; 21% had used any tetrahydrocannabinol-containing products; and 
11% had used both tetrahydrocannabinol-containing products and nicotine-
containing products. The prevalence of tetrahydrocannabinol-containing 
product use was highest among survey respondents aged 18–24 years (36%) 
and decreased with increasing age. E-cigarette, or vaping, product use 
behaviours of 66 e-cigarette, or vaping, product use-associated lung injury 
patients aged 18–44 years who were interviewed as part of the ongoing 
outbreak investigation were compared with a subset of 519 survey 
respondents aged 18–44 years who reported use of tetrahydrocannabinol-
containing e-cigarette, or vaping, products. Compared with these survey 
respondents, product use-associated lung injury patients had higher odds of 
reporting exclusive use of tetrahydrocannabinol-containing products (AOR: 
2.0; 95% CI: 1.1–3.6); frequent use (more than five times per day) of these 
products (AOR: 3.1; 95% CI: 1.6–6.0); and obtaining these products from 
informal sources, such as a dealer, off the street, or from a friend (AOR: 9.2; 
95% CI: 2.2–39.4). The odds of using Dank Vapes, a class of largely counterfeit 
tetrahydrocannabinol-containing products, was also higher among e-
cigarette, or vaping, product use-associated lung injury patients (AOR: 8.5; 
95% CI: 3.8–19.0).  
Device and products: Any nicotine-containing products. Only nicotine-
containing products. Any nicotine-containing product <1x/day§. Any nicotine-
containing product >5x/day. Any tetrahydrocannabinol-containing products. 
Only tetrahydrocannabinol-containing products. Any tetrahydrocannabinol-
containing product <1x/day§. Any tetrahydrocannabinol-containing product 
>5x/day§. Dank Vapes*. Obtained any tetrahydrocannabinol-containing 
product informally**. Both tetrahydrocannabinol- and nicotine-containing 
products. 
* Dank Vapes are a class of largely counterfeit THC-containing products of 
unknown provenance that are marketed under a common name and 
distributed through informal sources. 
** Obtaining any tetrahydrocannabinol-containing e-cigarette, or vaping, 
products from informal sources (a dealer, off the street, or from a friend) was 
compared with obtaining any tetrahydrocannabinol-containing products from 
a formal source (store or licensed dispensary). Because online sources might 
be formal (e.g. a licensed dispensary) or informal, persons who reported 
online purchases were excluded from this analysis. Fewer than 1% of public 







4.3.2.2.5 Oral diseases: case-control studies 
There were no case-control studies on the relationship between e-cigarettes and oral disease 
outcomes.  
4.3.2.2.6 Developmental and reproductive effects: case-control studies 
There were no case-control studies on the relationship between e-cigarettes and developmental and 
reproductive effect outcomes.  
4.3.2.2.7 Injuries and poisonings: case-control studies 
There were no case-control studies on the relationship between e-cigarettes and injury and poisoning 
outcomes.  
4.3.2.2.8 Exposure to e-cigarette toxins: case-control studies 
There were no case-control studies on the relationship between e-cigarettes and exposure to e-
cigarette toxins outcomes.  
4.3.2.2.9 Other outcomes: case-control studies 







4.3.3 Longitudinal cohort studies: e-cigarettes 
4.3.3.1 Study characterisation: e-cigarettes 
There were 22 papers categorised as longitudinal cohort studies. In these longitudinal studies, the 
investigators measured e-cigarette exposure(s) in the study participants at baseline and the 
outcome(s) (benefit or harm) at each follow-up.27 People with the outcome(s) of interest at baseline 
are excluded from the cohort. Cohort studies are useful for measuring incidence of outcomes in a 
population and comparing the incidence of outcomes by exposure status. However, incidence 
calculations require an adequate sample size in order to create a meaningful estimate. Cohort studies 
can establish a dose response and temporal sequence. However, they have difficulty controlling for 
the influence of confounding factors on the outcome of interest. 
The studies were completed on populations living in France (n=1), Italy (n=10), Saudi Arabia (n=1), the 
UK (n=1), and the USA (n=9). The longitudinal cohort study sample sizes for analysis ranged from 16 to 
30,818. The follow-up periods were between 4 and 48 months. The studies were published between 
2013 and 2019. 
Half of the longitudinal cohort studies (10 out of 22) were categorised under the Academies of 
Sciences’ framework heading dependence and abuse liability. The number of longitudinal cohort 
study papers categorised under the adapted Academies of Sciences’ framework were: 10 under 
dependence and abuse liability, 3 under cardiovascular diseases, 5 under respiratory diseases, 3 
under oral diseases, and 1 under developmental and reproductive effects. There were no longitudinal 
cohort study papers under the reporting areas ‘cancers’, ‘injuries and poisonings’, ‘exposure to e-
cigarette toxins’, or ‘other outcomes’.  
The summary tables for longitudinal cohort studies are presented under the adapted Academies of 
Sciences’ headings in Sections 4.3.3.2.1 to 4.3.3.2.9 These summary tables present the authors, study 
objectives, and concluding summary findings. For longitudinal cohort studies, tables with additional 
details are presented in Appendix 4.  
4.3.3.2 Harms, harm reduction, and benefits: e-cigarettes 
The harms associated with e-cigarette use identified under the heading dependence and abuse 
liability, and investigated in longitudinal cohort studies, were: dependence, depression, dual use of 
conventional tobacco cigarettes and e-cigarettes, and weight control. There were higher rates of 
chronic respiratory diseases in e-cigarette users than in non-users, and rates of chronic respiratory 
diseases in smokers, vapers, and dual users (of e-cigarettes and conventional tobacco cigarettes) 
were similar. Under the oral diseases heading, e-cigarette users had poorer dental and periodontal 
health compared with non-users. One paper under the developmental and reproductive effects 
heading identified that new-born infants of e-cigarette users were small for gestational age. A second 
paper based on prospective longitudinal study design and published after the mapping search period 
did not uphold the first longitudinal study findings.288 
A number of longitudinal cohort studies identified that e-cigarettes were less harmful than 
conventional tobacco cigarettes. For example, one study found that the use of e-cigarettes decreased 
cigarette consumption by 50% without causing significant nicotine withdrawal symptoms or 
increasing negative mental health symptoms in chronic schizophrenic patients who smoked and did 
not intend to quit. Another study reported that there was only a modest weight increase associated 
with switching from tobacco cigarettes to e-cigarettes. In addition, there was a reduction in asthma 
and chronic obstructive pulmonary disease symptoms after tobacco cigarette smokers switched to e-
cigarette vaping. Under the oral diseases heading, e-cigarette users had lower levels of dental and 
periodontal diseases compared with tobacco cigarette smokers. 
The authors of two longitudinal cohort studies proposed that e-cigarettes may be beneficial relative 
to conventional cigarette smoking. The first benefit was the possibility that their use may facilitate 
better blood pressure control than would be facilitated by continued tobacco cigarette smoking. The 
second benefit was described as a state of stable dependence, which other observers may classify as 





4.3.3.2.1 Dependence and abuse liability: longitudinal cohort studies 
There were 10 longitudinal cohort study papers reporting a range of measures of behaviours and 
personality traits among e-cigarette users associated with dependence and abuse (Table 41) These 
included mental health issues associated with e-cigarette use (such as depression), patterns of e-
cigarette use (such as populations using e-cigarettes, smoking cessation, and relapsing behaviours), 
and dependence (via self-reported behaviours and measures of urinary cotinine levels). Other 
outcomes measured were 3-hydroxycotinine level, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL) level, and changes in weight.  
The studies under this heading were grouped into three themes: e-cigarette use and conventional 
tobacco cigarette smoking status, e-cigarettes’ association with mental health, and e-cigarettes and 
weight gain.  
Two studies reported that e-cigarettes were strongly associated with conventional tobacco cigarette 
use and that many e-cigarette users were dual users (i.e. they used both e-cigarettes and tobacco 
cigarettes).289 290 Another two studies reported that nicotine e-cigarette use led to a state of stable 
dependence.291 One study found that e-cigarette use decreased conventional tobacco cigarette 
consumption by 50% without causing significant nicotine withdrawal symptoms or increasing negative 
mental health symptoms in chronic schizophrenic patients who smoked and did not intend to quit.292 
One study reported changed puffing topography to maintain nicotine levels. 293 
In three studies, e-cigarette use was associated with depression. Three studies reported that as 
depressive symptoms increased, so did e-cigarette use.294 295 296 One study reported that onset of 
depression was associated with onset of e-cigarette use.295  
In one study, the authors concluded that there was no evidence of post-cessation weight increase in 
those who substantially reduced cigarette consumption by switching to using both conventional 
tobacco cigarette use and e-cigarettes (dual users), and only modest post-cessation weight increase 
was reported in exclusive e-cigarette users at 12-month follow-up.297 
Table 41 Longitudinal cohort study papers on dependence and abuse liability, benefits or harms 
Author(s), year Possible 
benefit or 
harm 
Longitudinal cohort study papers on dependence and abuse liability 




Benefit The authors reported on the relationship of e-cigarette use with smoking 
reduction and smoking cessation. 
Comparative groups 
E-cigarettes users themselves (‘Categoria‘) 
Conventional combustible tobacco cigarette users (smoke ≥20 cigarettes per day for ≥10 
years and not intending to quit) 
The authors concluded that e-cigarette use substantially decreased cigarette 
consumption without causing significant side effects in chronic schizophrenic 
patients who smoked and did not intend to quit. This was achieved without 
negative impacts on the symptoms of schizophrenia as assessed by the Scale for 
the Assessment of Positive Symptoms and the Scale for the Assessment of 
Negative Symptoms.  




The authors reported on findings from a cohort study regarding e-cigarette use 
effectiveness and safety at 24 months. 
Comparative groups 
E-cigarettes users themselves (at least 50 puffs per week for at least 6 months) 
Conventional combustible tobacco cigarette users (1 tobacco cigarette per day for ≥6 
months) 
Dual users (smoked conventional tobacco cigarettes and used e-cigarettes for ≥6 months) 
The authors concluded that e-cigarette use alone might support tobacco quitters 
in remaining abstinent from smoking. However, dual use did not improve the 
likelihood of quitting tobacco or e-cigarette use, but may be helpful in reducing 






Author(s), year Possible 
benefit or 
harm 
Longitudinal cohort study papers on dependence and abuse liability 
Du et al. 291 
2019 
Benefit The authors reported on changes in e-cigarette use behaviours and dependence 
in long-term e-cigarette users. 
Comparative groups 
E-cigarettes users themselves (exclusive for past 7 days) 
Poly users (e-cigarettes, other nicotine products for past 7 days) 
The authors concluded that findings suggest that the risk of relapse to cigarette 
smoking is low, and that e-cigarette-related dependence remains stable in long-
term e-cigarette users.  
McMillen et al. 
290 
2019 
Harm The authors reported on the relationship between e-cigarette use and future 
cigarette initiation among never-smokers, and relapse among former smokers. 
Comparative groups 
E-cigarettes users themselves (ever user but not current) 
E-cigarettes users themselves (current)  
Conventional combustible tobacco cigarette users (former, quit ≥ 5 years) 
Never vapers (e-cigarettes) 
Never smokers (conventional combustible tobacco cigarette) 
Former combustible cigarette smokers who reported e-cigarette past-30-day 
users (9.3%) and e-cigarette ever users (6.7%) were significantly more likely than 
never users (1.3%) to have relapsed to current combustible cigarette smoking at 
follow-up (p<0.001). Baseline never-smokers who reported e-cigarette past-30-
day use at follow-up (25.6%) and ever use (13.9%) were significantly more likely 
than those who had never used e-cigarettes (2.1%) to have initiated combustible 
cigarette smoking (p<0.001). Adults who reported past-30-day e-cigarette use 
(7.0%) and ever e-cigarette use (1.7%) were more likely than those who had never 
used e-cigarettes (0.3%) to have transitioned from never-smokers to current 
combustible cigarette smokers (p<0.001). E-cigarette use predicted combustible 
cigarette smoking in multivariable analyses controlling for covariates.  
Soar et al. 293 
2019 
Harm The authors examined the relationship, in exclusive vapers, of levels of nicotine 
intake over time as nicotine e-liquid concentrations are reduced, i.e. nicotine 
absorption from e-cigarettes over a 12-month period. 
Comparative groups 
E-cigarettes users themselves (exclusive) 
The authors concluded that although the sample of experienced vapers reduced 
the concentration of nicotine in their e-liquid over time, they maintained their 
nicotine intake, possibly through self-titration via more intensive puffing. Findings 
suggest that there may be little benefit in reducing nicotine e-liquid 
concentration, since this appears to result in higher e-liquid consumption, which 
may incur both a financial and health cost.  
  Mental health issues 
Bandiera et al. 
294 
2017 
Potential harm The authors reported on the relationship between depressive symptoms and 
current e-cigarette use. 
Comparative groups 
E-cigarettes users themselves (current) 
Conventional combustible tobacco cigarette users (current) 
Other products users (smokeless snus, smokeless tobacco, large cigars, cigarillos/little cigars, 
or hookah) 
The authors concluded that elevated depressive symptoms predicted e-cigarette 
use 6 months later among a young adult college population, even after controlling 
for a variety of sociodemographic characteristics and the number of tobacco 
products used. However, they found no evidence that e-cigarette use predicted 
elevated depressive symptoms.  
Lechner et al. 295 
2017 
Harm The authors reported on the relationship between baseline depressive symptoms 
and onset of e-cigarette use, tobacco cigarette use, and dual use at follow-ups. 
Comparative groups 
Non-vapers (e-cigarettes) at baseline 
Non-smokers (conventional combustible tobacco cigarette) at baseline 
E-cigarettes users themselves (at 6-month follow-up)  
Conventional combustible tobacco cigarette users (at 6-month follow-up)  





Author(s), year Possible 
benefit or 
harm 
Longitudinal cohort study papers on dependence and abuse liability 
Higher baseline depressive symptoms predicted subsequent onset of tobacco 
cigarette use (OR: 1.024; 95% CI: 1.009−1.055), e-cigarette use (OR: 1.015; 95%CI: 
1.003−1.023), and dual use of both products (OR: 1.021; 95%CI: 1.003−1.043). 
Sustained use of e-cigarettes over the 12-month observation period (versus non-
use) was associated with a greater rate of increase in depressive symptoms over 
time (B=1.272; standard error [SE]=0.513; P=0.01). Among those who sustained 
use of e-cigarettes, higher frequency of use was associated with higher depressive 
symptoms at the final follow-up (B=1.611; p=0.04). The authors concluded that a 
bi-directional association of depressive symptoms with e-cigarette use onset 
across mid-adolescence was observed.  
Marsden et al. 
298 
2019 
Harm The authors reported on the association between frequency of cigarette and 
alternative tobacco product use and depressive symptoms. 
Comparative groups 
E-cigarettes users themselves (current, refillable devices) 
E-cigarettes users themselves (current, disposable devices) 
Conventional combustible tobacco cigarette users (current) 
Hookah product users (current) 
Smokeless tobacco products (current) 
Other product users (cigars cigarillos, little cigars) (current) 
The authors concluded, following separate examination of used refillable and 
disposable e-cigarettes, that the results did not provide evidence of a different 
association for each type of e-cigarette when cigarettes were not also used. Dual 
use of cigarettes with another product was associated with higher depressive 
symptoms for most product combinations. However, infrequent dual use of 
disposable e-cigarettes and cigarettes may not be associated with depressive 
symptoms.  
Wiernik et al. 296 
2019 
Harm The authors reported on the relationship between e-cigarette use and depressive 
symptoms in smokers and former smokers. 
Comparative groups 
E-cigarettes users themselves (current, nicotine levels) 
E-cigarettes users themselves (former, nicotine levels) 
Conventional combustible tobacco cigarette users (current, nicotine levels)  
Conventional combustible tobacco cigarettes users (former, nicotine levels)  
Never-smokers nicotine levels (conventional combustible tobacco cigarettes) 
Never-vapers nicotine levels (e-cigarette) 
The authors concluded that depressive symptoms were positively associated with 
e-cigarette use in both cross-sectional and longitudinal analyses with a dose-
dependent relationship. In addition, nicotine concentration and depressive 
symptoms were positively associated.  
  Weight control 
Russo et al. 297 
2018 
Benefit The authors reported on the relationship between e-cigarette use and post-
cessation weight increase.  
Comparative groups 
All conventional combustible tobacco cigarette users (smoked > 20 per day at baseline) who 
quit or reduced smoking related behaviours):  
Regular e-cigarettes users at follow-up (exclusive or dual) 
Regular conventional combustible tobacco cigarette users at follow up (exclusive);  
Sustained smoking or vaping abstinence at follow-up (quitters). 
The authors concluded that there was no evidence of post-cessation weight 
increase in those who substantially reduced tobacco cigarette consumption by 
switching to e-cigarettes (i.e. dual users), and only modest post-cessation weight 
increase was reported in exclusive e-cigarette users at 12-month follow-up. By 
reducing weight gain and tobacco consumption, e-cigarette-based interventions 
may promote an overall improvement in quality of life.297 
4.3.3.2.2 Cardiovascular diseases: longitudinal cohort studies 
Three longitudinal cohort study papers examined the relationship between e-cigarettes and 





pressure, levels of blood pressure control, oxygen perfusion of body tissues following surgery, heart 
rate, and body weight were analysed to determine cardiovascular health and its association with e-
cigarette use. In addition to cardiovascular measures, respiratory measures of lung function, 
respiratory symptoms, fractional exhaled breath nitric oxide (FeNO), exhaled carbon monoxide (eCO), 
and high-resolution computed tomography of the lungs were measured.  
In the first study, the authors stated that reducing cigarette smoking and taking up e-cigarettes 
resulted in improvements in systolic and diastolic blood pressure, as well as better blood pressure 
control at 6-month and 12-month follow-up.299 Of note, the patients in both groups (43 e-cigarette 
smokers and 46 non-users) were also receiving antihypertensive treatment, which may explain some 
of the blood pressure controls observed. The second study involved 16 young people who had never 
smoked tobacco but had initiated e-cigarette use. The authors reported that , they did not 
demonstrate any additional respiratory function, lung injury, blood pressure, or heart rate concerns 
associated with 3.5 years of e-cigarette use when compared with matched non-users.300 In the third 
study, the authors reported that the number of e-cigarette smokers were not adequate to enable 
measurement of the influence of e-cigarettes on cardiovascular complications following surgery, but 
they concluded that nicotine replacement using e-cigarettes carries similar risks as continued smoking 
and is not as safe as abstinence in the perioperative period in plastic surgery patients.301  
Table 42 Longitudinal cohort study papers on cardiovascular diseases, benefits or harms 
Author(s), year Possible 
benefit or 
harm 
Longitudinal cohort study papers on cardiovascular diseases 








The authors reported on the relationship between smokers with a 
diagnosis of hypertension and those who quit or reduced tobacco 
consumption by switching to e-cigarettes, and long-term improvement in 
resting blood pressure and in level of blood pressure control. 
Comparative groups 
E-cigarettes users themselves (daily for ≥10 months) 
Conventional combustible tobacco cigarette users (regular users)  
Dual users (e-cigarette and conventional combustible tobacco cigarette) 
The authors concluded that regular e-cigarette use may aid smokers with 
arterial hypertension in reducing or abstaining from cigarette smoking, 
with only trivial post-cessation weight gain (a finding reported on in the 
paper). The reduction in cigarette smoking and weight and the taking up of 
e-cigarettes resulted in improvements in systolic and diastolic blood 
pressure as well as better blood pressure control.  
Polosa et al. 300 
2017 
No harm or 
benefit 
Authors reported-on cardiovascular and respiratory health outcomes 
blood pressure, heart rate, body weight, lung function, respiratory 
symptoms, fractional exhaled breath nitric oxide (FeNO), exhaled carbon 
monoxide (eCO), and high-resolution computed tomography of the lungs. 
Comparative groups 
E-cigarettes users themselves (exclusive, daily for ≥ 3 months) (never smoked)  
Never smokers (conventional combustible tobacco cigarette) 
The authors concluded that although it cannot be excluded that some 
harm may occur from e-cigarettes at later stages of the e-cigarette user’s 
life, this study did not demonstrate any health concerns associated with 
long-term use of e-cigarettes in relatively young users who did not also 
smoke tobacco.  
Michaels et al. 
301 
2018 
Harm The authors examined nicotine replacement therapy (including e-
cigarettes) as a safe alternative to smoking in plastic surgery patients. 
Comparative groups 
Conventional combustible tobacco cigarette users (current) 
Conventional combustible tobacco cigarette users (former, negative urine test) 
Conventional combustible tobacco cigarette users (former, positive urine test) 
Never smokers (conventional combustible tobacco cigarette) 
The authors concluded that nicotine replacement using e-cigarettes carries 
similar risks as continued smoking and is not as safe as abstinence in the 





Author(s), year Possible 
benefit or 
harm 
Longitudinal cohort study papers on cardiovascular diseases 
stopped smoking for the surgery had equivalent risk for postoperative 
complications as patients who had never smoked.  
 
4.3.3.2.3 Cancers: longitudinal cohort studies 
There were no longitudinal cohort studies on the relationship between e-cigarettes and cancer 
outcomes.  
4.3.3.2.4 Respiratory diseases: longitudinal cohort studies 
The five longitudinal cohort study papers reporting on the association between e-cigarette use and 
respiratory disease outcomes examined the relationship between e-cigarettes and chronic obstructive 
pulmonary disease, airway hyperresponsiveness, and asthma exacerbation (Table 43). Signs and 
symptoms of respiratory diseases and a range of respiratory function measures were assessed. In 
addition, information on other outcomes, such as myocardial infarction and/or angina, congestive 
heart failure, stroke, and any cancer were reported. 
The studies on chronic respiratory diseases and symptoms indicate mixed findings as to whether e-
cigarette use is better than tobacco use and worse than no nicotine use. For example, the authors of 
two small studies (16–18 participants) reported improvements in asthma at 6-month and 1-year 
follow-up, although it appears that the samples in the two studies may overlap.302 303 In two studies 
examining chronic obstructive pulmonary disease and e-cigarettes, one study with 24 participants 
reported a benefit by switching from tobacco smoking to e-cigarettes at 6-month and 1-year follow-
up304 and the other study with 55 dual users reported harm at 1-year follow-up.305 One study 
examining smoking-related diseases by type of cigarette use reported that smoking-related diseases 
were observed in 73 participants (8.0%) at 4-year follow-up, and that the rates of smoking-related 
diseases were similar in e-cigarette users, dual users (those who used both e-cigarettes and 
conventional tobacco cigarettes), and conventional tobacco cigarette smokers. 306  
Table 43 Longitudinal cohort study papers on respiratory diseases, benefits or harms 
Author(s), year Possible 
benefit or 
harm 
Longitudinal cohort study papers on respiratory diseases 








The authors undertook a retrospective review of changes in spirometry 
data, airway hyperresponsiveness, asthma exacerbations, and subjective 
asthma control in smoking asthmatics who switched to regular e-cigarette 
use. 
Comparative groups 
E-cigarettes users themselves (former daily smokers) 
Dual users (e-cigarette and conventional combustible tobacco cigarette) 
The authors reported improvements in asthma control, airway 
hyperresponsiveness, and pulmonary function in 18 asthmatic smokers 
who quit or dramatically reduced their tobacco consumption by switching 
to e-cigarettes.  








The authors reported on the relationship between persisting long-term 
benefits of smoking abstinence and reduction in asthmatic smokers who 
have switched to e-cigarettes. 
Comparative groups 
E-cigarettes users themselves (exclusive) 
Dual users (e-cigarette and conventional combustible tobacco cigarette) 
The authors concluded that regular e-cigarette use ameliorates asthma 
outcomes, that these beneficial effects may persist in the long term, that 
similar benefits could also be noted in dual users, and that regular e-
cigarette use was well tolerated.  
Polosa et al. 304 Less harmful 
than 
The authors reported their evidence for harm reduction in smokers with 





Author(s), year Possible 
benefit or 
harm 






E-cigarettes users themselves (exclusive, daily) 
Dual users (e-cigarettes and conventional combustible tobacco cigarettes daily)  
Conventional combustible tobacco cigarette users (exclusive, daily) 
The authors concluded that a marked reduction in cigarette consumption 
was observed in e-cigarette users. A significant reduction in chronic 
obstructive pulmonary disease exacerbations was reported in the chronic 
obstructive pulmonary disease e-cigarette user group, with their mean 
(±standard deviation) decreasing from 2.3 (±1) at baseline to 1.8 (±1; 
p=0.002) and 1.4 (±0.9; p<0.001) at follow-up visit 1 and follow-up visit 2, 
respectively. A significant reduction in chronic obstructive pulmonary 
disease exacerbations was also observed in e-cigarette users who also 
smoked conventional combustible tobacco cigarettes (i.e. dual users). 
Chronic obstructive pulmonary disease symptoms and ability to perform 
physical activities improved statistically in the e-cigarettes group at both 
visits, with no change in the control group (those who continued smoking 
conventional tobacco cigarettes).  
Bowler et al. 305 
2017 
Harm The authors reported on the relationship between e-cigarette use in USA 
adults at risk for, or with, chronic obstructive pulmonary disease. 
Comparative groups 
E-cigarette users themselves (ever) 
E-cigarette users themselves (current) 
Conventional combustible tobacco cigarette users (current ≥10 pack years) and e-
cigarettes (current) 
Conventional combustible tobacco cigarette users (former, ≥10 pack years) and e-
cigarettes (current) 
Never users (conventional combustible tobacco cigarette or other tobacco products) 
The authors concluded that they could find no evidence supporting the use 
of e-cigarettes as a harm reduction strategy among current smokers with, 
or at risk for, chronic obstructive pulmonary disease.  
Flacco et al. 306 
2019 
Harm The authors reported on the relationship between e-cigarettes and a 
range of possibly smoking-related diseases – such as chronic obstructive 
pulmonary disease, myocardial infarction and/or angina, congestive heart 
failure, transitory cerebrovascular ischaemia or stroke, and any cancer – 
and changes in tobacco use. 
Comparative groups 
E-cigarettes users themselves (for≥ six months) 
Conventional combustible tobacco cigarette users (≥1 daily for ≥6 months) 
Dual users (e-cigarettes and conventional combustible tobacco cigarette for ≥ 6 
months) 
The authors concluded that after 4 years a non-significant harm reduction 
was observed among e-cigarette users and dual users of e-cigarettes and 
conventional tobacco cigarettes. The complete switch to e-cigarettes may 
help tobacco quitters remain abstinent, but e-cigarette use in addition to 
tobacco did not increase the likelihood of smoking cessation or reduction. 
The rates of smoking-related diseases were similar in e-cigarette users, 
dual users (those who used both e-cigarettes and conventional tobacco 
cigarettes), and conventional tobacco cigarette smokers 
4.3.3.2.5 Oral diseases: longitudinal cohort studies 
Three longitudinal cohort study papers reported on the association between e-cigarette use and oral 
health outcomes (Table 44). The papers examined the relationship between e-cigarettes and oral 
disease using the following measures: full-mouth plaque index, bleeding on probing, clinical 
attachment loss, probing depth, gum disease, and bone loss around teeth. 
The findings on dental health depended on the comparator, with two studies reporting improved 
dental health (reduced periodontal disease) following tobacco smoking cessation and moving to e-





poorer dental health (increased periodontal disease and bone loss) at 2-year follow-up in e-cigarette 
users compared with non-users.  
Table 44 Longitudinal cohort study papers on oral diseases, benefits or harms 
Author(s), year Possible 
benefit or 
harm 
Longitudinal cohort study papers on oral diseases 








The authors reported on the changes in periodontal health in individuals 
who had ceased tobacco cigarette consumption and had started to use e-
cigarettes, and a self-assessed need to smoke combustible cigarettes. 
Comparative groups 
E-cigarettes users themselves (for approximately 4 months, former daily smokers for 
< 10 years) 
E-cigarettes users themselves (for approximately 4 months, former daily smokers for 
≥ 10 years) 
The authors stated that their observations revealed an interesting, growing 
trend, relating to plaque index, periodontal bleeding index, and papillary 
bleeding index, in the 110 subjects considered in this study. They reported 
a constant reduction of bacterial plaque on teeth surfaces from baseline at 
T0 to the end of the observational period at T2. More precisely, group 1 
(less than 10 years smoking) subjects showed a homogeneous presence of 
a thin film of plaque at T0, which visibly decreased towards T1 until it 
completely disappeared in all of the group 1 subjects at T2. The result was 
more marked in group 2 subjects (more than 10 years smoking), and was 
characterised by a huge presence of plaque at T0. The authors also noted 
that many patients had reported an interesting reduction in the need to 
smoke. 









The authors reported on the impact of cigarette smoking, e-cigarette use, 
and non-smoking on dental and periodontal health: full-mouth plaque 
index, bleeding on probing, clinical attachment loss, and probing depth 
were measured at baseline and at 3 and 6 months after full-mouth 
ultrasonic scaling (without root surface debridement). The numbers of 
missing teeth were also recorded. 
Comparative groups 
E-cigarettes users themselves (exclusive, used for ≥1 year with) 
Conventional combustible tobacco cigarette users (≥ 5 daily)  
Never users (any tobacco product) 
The authors stated that a range of periodontal inflammatory parameters 
were worse in cigarette smokers than in individuals who vape e-cigarettes 
and in never-smokers following full-mouth ultrasonic scaling. 
Atuegwu et al. 
309 
2019b 
Harm The authors reported on the relationship between e-cigarettes and 
periodontal disease, specifically gum disease and bone loss around teeth.  
Comparative groups 
E-cigarettes users themselves (daily or some days) 
E-cigarettes users themselves (ever or any) 
Conventional combustible tobacco cigarette users (every or some days) 
Dual users (e-cigarettes with marijuana) 
The hypothesis in this study was that the use of electronic nicotine 
products would be associated with increased odds of gum disease and 
bone loss around teeth, even after controlling for use of conventional 
combustible tobacco cigarettes and other known risk factors. Sub-group 
analysis was performed to examine this association in participants who had 
a history of marijuana use and a history of illicit or non-prescribed drug 
use. The authors concluded that this was the case.  
 
4.3.3.2.6 Developmental and reproductive effects: longitudinal cohort studies 
One longitudinal cohort study paper reported on the association between e-cigarette use and 
developmental and reproductive effects (Table 45). The subject matter covered in the paper related 
to e-cigarettes and their effects on weight for gestational age at birth.310 The authors concluded that 





second paper based on prospective longitudinal study design and published after the mapping search 
period did not uphold the first longitudinal study findings.288 
Table 45 Longitudinal cohort study papers on developmental and reproductive effects, benefits or 
harms 
Author(s), year Possible 
benefit 
or harm 
Longitudinal cohort study papers on developmental and reproductive 
effects 
Cardenas et al. 
310 
2019 
Harm The authors reported on the relationship between e-cigarette use in 
pregnant women and risk of small-for-gestational-age births. 
Comparative groups 
E-cigarettes users themselves (current) 
Conventional combustible tobacco cigarette users (current) 
Conventional combustible tobacco cigarette users (former) 
Never vapers (e-cigarettes) 
Never smokers (conventional combustible tobacco cigarette) 
The authors concluded that e-cigarette use is associated with an increased 
risk of small-for-gestational-age births. 
4.3.3.2.7 Injuries and poisonings: longitudinal cohort studies 
There were no longitudinal cohort studies on the relationship between e-cigarettes and injuries or 
poisonings outcomes.  
4.3.3.2.8 Exposure to e-cigarette toxins: longitudinal cohort studies 
There were no longitudinal cohort studies on the relationship between e-cigarettes and exposure to 
e-cigarette toxins outcomes.  
4.3.3.2.9 Other outcomes: longitudinal cohort studies 







4.4 Interventional trials: e-cigarettes 
4.4.1 Study characterisation: e-cigarettes 
There were 86 papers grouped as interventional trials. Of these, eight (9%) were authored by the e-
cigarette industry (Appendix 7). In these trials, participants were assigned the intervention (e-
cigarette) by the investigator. The investigator then measured the impact of the exposure on one or 
more outcomes at a subsequent timepoint. Interventional trials allow quantification of the size and 
the direction of an intervention-outcome effect. There are several trial designs included in this 
mapping exercise. These are: randomised controlled trials, randomised crossover or Latin-square 
trials, non-randomised crossover or Latin-square trials, and non-randomised before and after studies. 
A proportion of the study papers which we grouped under interventional trials did not randomise 
participants to the intervention, or interventions to the participants. Rather, the investigator 
measured the factors of interest in the same individuals before and after intervention uptake similar 
to that of an observational study, but the difference was that the participant, once recruited, could 
not choose whether to be exposed or not as could be done in an observational study. These trials are 
better described as non-randomised before-and-after interventional trials. Another type of trial is a 
crossover before-and-after trials where participants are randomised to an intervention, and where 
comparisons are achieved through a crossover approach. Crossover trials with more than one 
crossover are referred to as Latin squares’ crossover trials. The ideal trial is a randomised control trial 
with intervention(s) and their comparators are randomly allocated to two or more groups and these 
provide the highest level of evidence, followed by randomised crossover or Latin square trials. The 
lowest level of trial evidence is provided by non-randomised before-and-after trials whether they 
have or do not have a crossover element. The trial designs were most often conducted across a short 
time span, usually hours, days, or, in some cases, weeks. 
Broadly speaking, trials on e-cigarettes were conducted in one of two settings: in a clinical laboratory 
setting or in a general community setting. Trials conducted in a laboratory setting followed a 
standardised protocol for determining aspects of the devices and nicotine levels to be assessed. This 
included issues such as the type of device (generation, battery power, voltage, coil resistance, carrier 
solution, and additives), the individuals’ puffing frequency, and duration of exposure, along with how 
and when outcome measures were to be assessed. The second location was a community setting, 
where more often the individuals’ general behaviours were observed. Here, participants were often 
allowed to vape in their customary manner. However, there was overlap in practices across the 
various trial settings with respect to the degree of fidelity or adherence to the standardised protocol – 
for example, with participants in a clinical laboratory setting being allowed to vape as desired, and 
participants in a general community setting following a specific set of e-cigarette vaping instructions. 
In general, in clinical laboratory-based trials, outcomes were assessed at various timepoints, starting 
with baseline and then a follow-up minutes, hours, or, in a small number of cases, days after exposure 
to e-cigarettes. These trials measured the acute impact that e-cigarette use had on a range of 
outcomes within the time frame of the trial. In trials where the intervention represented the 
participants’ e-cigarette behavioural habits, such as daily vaping as a lifestyle norm in a community 
setting, outcomes were assessed weeks, months, or up to 2 years after the trials commenced.  
We identified some information on the e-cigarette devices used in the interventional trials in 62 of 
the 86 trial papers identified (Table 46). The characteristics of e-cigarette devices included: brand, 
model, generation, nicotine content, battery energy measure, voltage, and coil resistance. The 
variations in e-cigarettes tested included: disposable e-cigarettes which were not refillable, e-
cigarettes which used replaceable prefilled cartridges, and tank models which were filled with liquids 
by the user. E-cigarettes which were disposable consisted of batteries with primary (not chargeable) 
cells, whereas e-cigarettes with secondary (rechargeable) cells used replaceable prefilled cartridges, 
or had refillable tanks. Information on charging capacity (how much charged, number of allowable 
times to be charged) and the battery energy (the charge a battery holds and time until recharging 
requirement, measured by milliampere hour [mAh]) was noted by some authors.  
The 62 trials that examined health benefits and harms in people and that provided information about 





produced,3 4 which gives a sense of the small range of e-cigarettes tested in trials involving people 
that are subsequently published in peer-reviewed papers. The nicotine concentration levels were 
reported in several ways. Specifically, a nicotine concentration level could be reported in mg/mL, as a 
percentage, as an upper concentration threshold level, or as an average concentration level. Some 
authors reported processes where nicotine levels noted on the manufacturer’s product label were 
independently assessed using peer-reviewed published laboratory methods, noting a difference 
between the concentration on the manufacturer’s label and laboratory-assessed nicotine 
concentration levels. An alternative method of assessing nicotine was by calculating the residual e-
liquid supplied to participants at specific timepoints during trial participation or at trial completion. 
The actual reported nicotine concentration level in supplied products varied from nicotine free (also 
referred to as a placebo) to a strength of 48 mg/mL. The variation in nicotine dosages is noteworthy, 
doubly so in trials seeking to assess issues around dependence and abuse liability, in light of reports 
that the higher nicotine levels, specifically reported as between 18 and 36 mg/mL in some trials, have 
been demonstrated to be the only doses resulting in a reliable increase in nicotine plasma 
concentrations. Battery energy measures varied from 90 to 5000 milliampere hour, voltage from 3.0 
to 4.4 volts and coil resistance from 0.2 to 1.8-ohm. Finally, reports on the carrier solution a mixture 
of propylene glycol and vegetable glycerine, varied from 40.0% to 72.5% for propylene glycol and 
18.8% to 40.8% for vegetable glycerine. A range of other products and their percentages in the carrier 
solution – such as <5% cadmium, <5% lead, <1% mercury, <5% chromium, 19.7% pyrazine, 0.13% 2,3-
dimethylpyrazine, 0.10% trimentyl, and 0.15% myosmine – was also noted. 
Nine (10%) of the 86 trials reported on an exposure outcome effect measured between 12 weeks and 
24 months. More specifically, two (2%) trials ran for 24 months; four (5%) trials ran for 12 months; 
two trials had 6 months’ duration, and one trial had a duration of 3 months.  
The remaining 77 (90%) trials reported on outcomes gathered within 8 weeks or less. Five trials of 
very short duration had time period intervals between the exposure and the outcome measurement 
point as short as during intervention administration, or 10, 20, 30, or 50 minutes after intervention 
initiation.  
Of the 77 short-term trials, 33 (43%) had several sessions (between two and five) with varying time 
periods between sessions (ranging from 24 hours to 1 week). Five trials reported a varying number of 
sessions (between two and four) with up to 4 weeks between the timepoints at which outcome 
measures were gathered. Such trials in general represented a crossover design. In many of the 
crossover trial designs, the time interval between the exposure and data collection of biochemical 
and biometric outcomes (in blood, urine, and exhaled breath) varied from being contemporaneous 
(i.e. measures were gathered at the same time as the exposure), to minutes after exposure (e.g. 5, 10, 
20, or 30 minutes), up to a 24-hour period after exposure. The remaining trials were in the main 
laboratory-based studies where assessment of outcomes was made over a consecutive number of 
days, usually between 3 and 5 days. For a small number of laboratory-based trials, the length of the 
break time in hours or days between interventions in crossover was not clear. The break time is 
known as the ‘washout’ period. 
The trials were completed on populations living in 13 countries. The countries were: Belgium (n=5), 
Canada (n=2), Germany (n=2), Greece (n=7), Hungary (n=1), Indonesia (n=1), Italy (n=13), Japan (n=1), 
Poland (n=2), South Africa (n=1), Sweden (n=3), Turkey (n=1), the UK (n=10), and the USA (n=37). The 
trial sample size ranged from 1 to 408. The trials were published between 2010 and 2019. 
The number of interventional trial papers grouped under the adapted Academies of Sciences’ 
framework were: 25 under dependence and abuse liability, 21 under cardiovascular diseases, 16 
under respiratory diseases, 3 under oral diseases, 13 under exposure to e-cigarette toxins, and 8 
under other outcomes. There were no interventional trial papers under the reporting areas of 
‘cancers’, ‘developmental and reproductive effects’, and ‘injuries and poisonings’.  
The summary tables for interventional trials are presented under the adapted Academies of Sciences’ 
headings in Sections 4.4.2.1 to 4.4.2.9. These summary tables present details of the authors, study 
objectives, and the concluding summary finding. For the interventional trials, tables with additional 





Table 46 E-cigarette brands, nicotine levels, battery characteristics, and carrier solutions 
Characteristics Details 
Brand names Aspire, American Heritage, Alien 220 box mod, Blu, CE4, Categoria model 401, Categoria model 501, 
DIPSE, ELIPS C Series, C, eGo, eGo-One, eGo-T, eGo-C 2, eGo XL, Ego-3, Giant, Greensmoke, eVic-VT, 
CE4 model, Hydro, iStick Pico, Giant, Joyetech, Kanger T2-CC, model Ego, myblu, NPRO, Nobacco, 
NJOY® King Bold, ONE original, ONEMint, SmokTech, SUR-VAPES, Tornado, TFV8 baby beast tank, V8 
Baby-Q2 Core, Vuse Solo, Vype, Vapor King (KR808 model), and White Super. 
Nicotine levels Examples of specific nicotine concentration levels: 
• 0 mg/mL, 0 mg (placebo), <0.001% nicotine  
• 1.2%, 1.5 mg/mL, 1.6%, 1.8 % nicotine 
• 2 mg/mL, 2.4% nicotine, 2.7 mg nicotine/capsule 
• 3 mg/mL 
• 11 mg/mL, 12 mg/mL, 14 mg/mL, 16mg/mL, 18 mg/mL 
• 24 mg/mL, 25 mg/mL, 26 mg/mL, 29 mg/mL 
• 36 mg/mL 
• 40 mg/mL, 48 mg/mL  
Examples of upper threshold levels, means, or nicotine concentration levels: 
• <10% nicotine 
• mean 0.6 mg  
• 0.5–1.8 mg/mL and 12–24 mg/mL 
A small number of papers reported on how nicotine content was determined. One specific example 
is: 
• The authors reported that nicotine was measured by ISO machine-smoking (ISO 
3308:2012) and printed on the package, or 
• The amount of nicotine consumed was calculated by converting the mass of solution 
consumed into volume by dividing the mass of solution by either the specific density of 
propylene glycol (1.032 g/cm3) or of vegetable glycerine (1.261 g/cm3) or, if the solu-
tion was a blend, by estimating it to be a 50:50 ratio and averaging the specific density 
to 1.147 g/cm3. The volume was multiplied by the measured nicotine concentration to 
yield the mass of nicotine consumed during the exposure. The unused e-cigarette car-
tridges and solutions were collected and sent to the Centers for Disease Control and 
Prevention for analysis of pH and nicotine concentrations, with analysis performed in a 
manner that aligned with a published reported methodology. 
Battery 
characteristics  
Energy measure  
• 90 milliampere hour 
• 350 milliampere hour  
• 650 milliampere hour 
• 900 milliampere hour 
• 1000 milliampere hour 
• 1100 milliampere hour 
• 1300 milliampere hour 
• 3000 milliampere hour 
• 5000 milliampere hour 
Voltage 
• 3.0 volts 
• 3.3 volts 
• 3.4 volts 
• 3.5 volts 
• 3.7 volts 
• 4.2 volts 
Coil resistance 
• 0.2 ohm  
• 0.4 ohm  
• 1.3 ohm  







Carrier solution • 70.0% propylene glycol and 30.0% vegetable glycerine 
• 70.8% propylene glycol and 21.2% vegetable glycerine 
• 72.5% propylene glycol and 18.8% vegetable glycerine 
• 40.0% propylene glycol and 40.8% vegetable glycerine 
4.4.2 Harms, harm reduction, and benefits: e-cigarettes 
The harms associated with e-cigarettes identified under the dependence and abuse liability heading 
and investigated in interventional trials were dependence and higher nicotine uptake than in 
smokers. The harms identified in e-cigarette users under the cardiovascular diseases heading were 
increased arterial stiffness and reduced local circulation to the right hand. There were no studies 
under the cancers heading, but under the exposure to e-cigarette toxins heading, the presence of 
carcinogens in e-cigarette users was identified. The presence of toxins (metals and volatile organic 
compounds) was also identified. Three respiratory system harms were identified: reduced vascular 
function to the lungs, damaged respiratory system organs and tissue, and reduced physiological 
function. Two harms under the oral diseases heading were identified in e-cigarette users: periodontal 
disease and increased gingival inflammation when tobacco smokers switched from smoking to vaping. 
The negative effect of passive nicotine intake through others’ vaping was examined in one study. 
A number of interventional trials identified that e-cigarettes were less harmful than conventional 
tobacco cigarettes. For example, some trials reported reduced craving-like sensations in e-cigarette 
users compared with smokers, and other trials reported lower nicotine uptake in e-cigarette users 
than in smokers. One trial reported steady progressive improvements in certain exhaled breath 
measurements and symptom scores when using e-cigarettes compared with smoking conventional 
tobacco cigarettes. Trials reported that the toxins in tobacco smoke were higher than in e-cigarette 
vapour.  
Two benefits of e-cigarettes were identified in interventional trials. Firstly, e-cigarettes may improve 
blood flow to the oral mucosa post operatively in non-smoker populations and secondly, smokers 
who quit smoking by switching to e-cigarettes may limit their post-smoking-cessation weight gain. 
4.4.2.1 Dependence and abuse liability: interventional trials 
There were 26 papers where participants received an intervention in the form of an e-cigarette 
and/or e-liquid grouped under dependence and abuse liability (Table 47). The outcomes assessed 
among e-cigarette users were cravings, desire to smoke, cognitive performance or memory, weight 
status, and blood or brain nicotine levels. Comparisons of outcomes took account of participants’ 
smoking-related behaviours. This included the difference in outcomes between two or more of the 
following groups: non-smokers, conventional cigarette smokers, e-cigarette users, and dual users of 
conventional tobacco cigarettes and e-cigarettes. Comparisons of outcomes also took account of e-
cigarette characteristics, including the different pharmacokinetic profiles of conventional tobacco 
cigarettes and e-cigarettes  
Eight trials reported that e-cigarettes reduced craving-like sensations in conventional cigarette 
users311-316 317 318 and four trials reported a reduction in the number of cigarettes smoked314-316 319 By 
contrast, four trials reported that e-cigarettes did not reduce cravings,320-323 of which, one trial found 
that cravings reduced in males but not in females.323  
One trial reported that former smokers who were daily e-cigarette users transferred their physical 
dependence to e-cigarettes.324 Two trials reported that e-cigarettes have potential for abuse 
liability325 326 and one trial reported that e-cigarettes maintained a nicotine addiction.327 Two trials 
reported that e-cigarettes created dependence and abuse liability among non-users (i.e. those who 
had never smoked conventional tobacco cigarettes)328 329 and another trial reported that exposure to 






Two trials reported that e-cigarettes had a positive association with cognitive performance or 
memory when compared with that of tobacco cigarette users.313 317  
One trial reported that switching to e-cigarettes may limit their post-cessation weight gain. 
Five trials reported that nicotine uptake varied among e-cigarette users. One trial reported brain 
nicotine uptake level, while the remaining four trials reported blood nicotine level. The findings of the 
trials were mixed, with two trials reporting that levels of nicotine were lower in e-cigarette users than 
in tobacco cigarette smokers.318 331 and three trials reporting equivalent nicotine levels in e-cigarette 
users and tobacco cigarette smokers.318 332 333  











No benefit The authors reported on the relationship between 
nicotine delivery and craving suppression, heart rate, 
and subjective effects. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
users (mean: 18.5 cigarettes per day and naïve to e-cigarettes 
at baseline) using: 
(1) own brand cigarette  
(2) sham smoking (puffing an unlit cigarette)  
(3) e-cigarette ‘NPRO’ with a 16mg nicotine cartridge (menthol 
or regular) 
(4) e-cigarette ’Hydro’ with a 16mg nicotine cartridge (menthol 
or regular) 
The authors concluded that relative to a tobacco 
cigarette, 10 puffs from an e-cigarette with a 16 mg 
nicotine cartridge delivered little to no nicotine and 
suppressed cravings less effectively. Results on heart 









Benefit The authors reported on the relationship between own-
brand cigarettes, two types of e-cigarette devices, and 
a sham (unlit cigarette) with plasma nicotine and 
carbon monoxide (CO) concentrations, heart rate, and 
a range of subjective effects. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
users (mean: 22 cigarettes per day at baseline) using: 
(1) own brand cigarette  
(2) sham smoking  
(3) ‘NPRO’ e-cigarette with a 18mg nicotine cartridge (menthol 
or regular) 
(4) ’Hydro’ e-cigarette with a 16mg nicotine cartridge (menthol 
or regular).  
The authors concluded that in acute testing conditions, 
neither of the e-cigarettes exposed users to measurable 
levels of nicotine or CO, although both suppressed 






Dawkins et al. 
323 
2012 
Benefit for men The authors reported on the relationship between e-
cigarettes and effects on desire to smoke, withdrawal 
symptoms, and cognition. The study aimed to explore 
whether e-cigarettes can reduce desire to smoke and 
also reduce abstinence-related withdrawal symptoms 
over a 20-minute period.  
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
users (naïve to e-cigarettes at baseline) using: 
(1) 18mg nicotine ‘Super While’ e-cigarette  
(2) 0mg nicotine ‘Super While’ e-cigarette  
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The authors concluded that desire to smoke and some 
aspects of nicotine withdrawal were significantly 
reduced 20 (but not 5) minutes after e-cigarette use; in 
this respect, the nicotine e-cigarette was superior to 
placebo in males but not in females. Nicotine derived 
via use of e-cigarettes also improved working memory 










The authors assessed the abuse liability of e-cigarettes. 
Comparative groups 
Conventional combustible tobacco cigarette users - 
comparison(s) (≥20 cigarettes per day at baseline) using:  
(1) e-cigarette users taking bouts of ‘Vapour king’. separated by 
30 minutes 
(2) e-cigarette users taking bouts of ‘Vapour king’. Own brand 
tobacco cigarettes 10 puffs and varying amounts of money 
(3) e-cigarette users taking bouts of ‘Vapour king’. Tobacco 
cigarettes 10 puffs and a varying number of own brand 
cigarette  
(4) e-cigarette users taking 1-10 own brand puffs and varying 
amounts of money using the multiple-choice procedure 
The authors concluded that e-cigarettes can deliver 
clinically significant amounts of nicotine and reduce 
cigarette abstinence symptoms. In addition, they appear 






Dawkins et al. 
313 
2013 
Benefit The authors reported on the relationship between 
nicotine derived from e-cigarettes and time-based 
prospective memory in abstinent smokers. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
users (smoked within 1 hour of waking and ≥10 cigarettes per 
day for ≥ 1 year at baseline) using: 
(1) Super While’ nicotine 18mg tobacco flavoured  
(2) Super While’ nicotine 0mg tobacco flavoured 
The authors concluded that compared with placebo, 
nicotine e-cigarettes reduced the desire to smoke and 
tobacco withdrawal symptoms, and improved time-
based but not event-based prospective memory. There 
was a moderate, marginally significant negative 
correlation between prospective memory performance 








Benefit The authors reported on the effectiveness of e-
cigarettes in an 8-week Flemish study with 6-month 
follow-up on smoking reduction, craving, and 
experienced benefits and complaints. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
users using: 
(1) ‘Joyetech eGo-C’ supplied with 30mL bottles of tobacco-
flavour e-liquid (Dekang ‘Turkish Blend’) containing 18mg/mL 
of nicotine  
(2) ’Kanger T2-CC’ supplied with 30mL bottles of tobacco-
flavour e-liquid (Dekang ‘Turkish Blend’) containing 18mg/mL 
of nicotine  
The authors concluded that in a series of controlled 
laboratory sessions with e-cigarette-naive tobacco 
smokers, second-generation e-cigarettes were shown to 
be immediately and highly effective in reducing 
abstinence-induced cigarette craving and withdrawal 
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carbon monoxide. Remarkable (>50%) 8-month 
reductions in, or complete abstinence from, tobacco 
smoking was achieved with e-cigarettes in almost half 
(44%) of the participants. 
Nides et al. 315 
2014 
Benefit The authors reported on the relationship between 
short-term smoking reduction with an electronic 
nicotine delivery system and nicotine blood levels, 
heart rate, and cravings. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
users (≥10 cigarettes per day for ≥ 1 year at baseline) with:  
(1) e-cigarette users using disposable NJOY King Bold device 
with a wad containing 0.5mL of nicotine solution, e-liquid 
nicotine solution with approximately 25 mg of nicotine and 
menthol flavoured 
The authors concluded that the NJOY® King Bold e-










Benefit The authors examined the effect of e-cigarettes as an 
aid for smokers to quit or reduce cigarette 
consumption. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
users (≥15 cigarettes per day for ≥ 10 years at baseline) with: 
(1) e-cigarette device ‘Categoria’ with nicotine cartridges 
The authors concluded that long-term e-cigarette use 
can substantially decrease cigarette consumption in 






Polosa et al. 
319 
2014c 
Benefit The authors reported on success rates with nicotine 
personal vaporisers in a prospective 6-month pilot 
study of smokers not intending to quit. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
users (≥15 cigarettes per day for ≥ 10 years at baseline) with:  
(1) e-cigarette device ‘EGO/CE4’ with e-liquid containing 
nicotine 9mg/ml  
The authors concluded that the use of second-
generation personal vaporisers substantially decreased 
cigarette consumption without causing significant 
adverse effects in smokers not intending to quit; in 
addition, participants’ perception and acceptance of the 





Russo et al.334 
2016 
Benefit The authors reported on the relationship between e-
cigarettes and weight gain. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
users (≥15 cigarettes per day for ≥ 10 years at baseline) with: 
(1) e-cigarette users using ‘Categoria’ ‘Original 2.4%’,  
(2) e-cigarette users using ‘Categoria’ ‘Original 1.8%’  
(3) e-cigarette users using ‘Categoria’ ‘Original 0%’. 
The authors concluded that smokers who quit smoking 
by switching to e-cigarettes may limit their post-
cessation weight gain, with substantial reversal in 





et al. 317 
2017 
Benefit The authors reported on cognitive performance, 
craving, and gesture (physical act of having a 
conventional combustible tobacco cigarette in hand) in 
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Comparison(s) of conventional combustible tobacco cigarette 
users (≥15 cigarettes per day for ≥ 10 years at baseline) using: 
(1) first generation rechargeable cigalike e-cigarette with 24mg 
nicotine and tobacco aroma  
(2) second generation disposable cigalike e-cigarette with 0mg 
nicotine mint aroma  
(3) second generation personal vaporizer model Ego C with 
liquid nicotine 24mg tobacco aroma, and  
(4) usual conventional combustible tobacco cigarette 
The authors concluded that the cognitive measures of 
attention, executive function, and working memory are 
not influenced by different e-cigarettes and sex, 
demonstrating that in general, e-cigarettes could 
become a strong support from a cognitive point of view 
for those who decide to quit smoking. It seems that not 
only cravings and other smoking withdrawal symptoms, 
but also cognitive performance, are linked to the 
presence of nicotine; this suggests that the reasons 
behind the dependence and the related difficulty in 
quitting smoking needs to be examined. The physical act 
of smoking conventional combustible tobacco cigarettes 
also needs to be studied. 
Hiler et al. 335 
2017 
Harm The authors looked at the relationship between nicotine 
delivery profile and cardiovascular and subjective 
effects. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
users (≥10 cigarettes per day and e-cigarette naive at baseline) 
with: 
(1) ’eGo’ e-cigarette 0 mg/ml nicotine  
(2) ’eGo’ e-cigarette 8 mg/ml nicotine,  
(3) ’eGo’ e-cigarette 18 mg/ml nicotine  
(4) ’eGo’ e-cigarette 36 mg/ml nicotine  
E-cigarette users themselves (≥ 3 months use with ≥ 1 ml of e-
cigarette solution daily containing nicotine concentration ≥ 8 
mg/ml and using ≤ 5 conventional tobacco cigarettes daily at 
baseline) with the same 4 interventions listed above.  
The authors concluded that participants’ plasma 
nicotine concentration was related directly to liquid 
nicotine concentration and was dependent on user 
experience, with significantly higher mean plasma 
nicotine increases observed in e-cigarette-experienced 
individuals relative to e-cigarette-naive smokers in each 













The authors evaluated the abuse liability of three Vuse 
Solo e-cigarettes with a nicotine content ranging from 
14 mg cartridge, to 29mg, and to 36 mg, relative to 
high- and low-abuse liability comparator products (usual 
brand combustible cigarettes and nicotine gum, 
respectively).  
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
users (≥10 king size filtered cigarettes per day for ≥ 6 months 
and e-cigarette and first cigarette within 30 minutes of waking 
at baseline) with: 
(1) e-cigarette device Vuse Solo  
(2) nicotine gum 
Participants could also use their own cigarette during the study 
The authors concluded that the use of Vuse Solo e-
cigarettes resulted in subjective measures (product 
liking, intent to use product again, product effects, urge 
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that were between those of combustible cigarettes and 
nicotine gum, although generally closer to nicotine gum. 
Compared with combustible cigarettes, use of Vuse Solo 
e-cigarettes resulted in significantly lower scores in 
measures of product liking, positive effects, and intent 
to use again. These pharmacodynamic findings were 
consistent with the pharmacokinetic data, showing that 
tobacco cigarettes produced substantially faster and 
higher levels of nicotine uptake when compared with 
Vuse Solo e-cigarettes and nicotine gum. Vuse Solo e-
cigarettes resulted in more rapid initial uptake of 
nicotine compared to nicotine gum, but peak 
concentration and long-term extent of uptake were not 
different or were lower with Vuse Solo e-cigarettes. 
Collectively, these findings suggest that Vuse Solo 
cigarettes likely have an abuse liability that is 





No benefit Authors reported on a three-day randomised crossover 
trial, focusing on the behavioural and experiential 
effects of the short-term use of the heat-not-burn 
product IQOSTM, versus an e-cigarette, and versus a 
regular cigarette, in current smokers who were novice 
users for both IQOSTM and e-cigarettes. To investigate 
the effect of using an IQOSTM on exhaled carbon 
monoxide, acute cigarette craving, withdrawal 
symptoms, and subjective positive and negative 
experiences after overnight smoking abstinence, 
compared to using an e-cigarette or a regular tobacco 
cigarette. And to investigate which product (e-cigarette 
or IQOSTM) would be preferred. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
users (≥10 cigarettes per day for ≥ 3 years at baseline) with: 
(1) own habitual regular brand of cigarettes 
(2) Eleaf iStick e-cigarette with 18mg/mL nicotine with either a 
tobacco or menthol flavour 
(3) IQOS heat-not-burn tobacco product 
The authors concluded that short-term use of a specific 
heat-not-burn product, IQOSTM, can be effective to 
momentarily reduce acute cigarette craving and 
withdrawal symptoms, while having a minimal impact 
on the exhaled carbon monoxide levels, and being 
slightly more liked by novice users than an e-cigarette. 
They stated however that this does not guarantee that 
craving/withdrawal symptom reduction will also be 
sustained over longer time spans or in case of repeated 
use, nor do they provide assurance that these effects 
are sufficient to lead to smoking reduction or cessation 








Harm The authors examined the relationship between e-
cigarette use and Beta2*-nicotinic acetylcholine 
receptors (β2*-nAChR) occupancy. 
Comparative groups 
E-cigarette users themselves (for ≥ 1 month at baseline) with  
(1) 0 mg/ml e-cigarette  
(2) 8 mg/ml e-cigarette  
(3) 36 mg/ml EC e-cigarette 
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Comparison(s) of conventional combustible tobacco cigarette 
users (≥11 cigarettes per day for ≥1 year and e-cigarette and 
first cigarette within 30 minutes of waking at baseline) with 
same four products 
The authors concluded that the e-cigarettes studied 
have abuse liability and may provide an adequate 
alternative nicotine delivery system for cigarette 
smokers. 
Hobkirk et al. 
332 
2018 
Harm The authors reported on changes in resting state 
functional brain connectivity and withdrawal 
symptoms associated with acute e-cigarette use. 
Comparative groups 
Comparison(s) of e-cigarette users themselves (≥20 days out of 
the last 28 days with a nicotine concentration of ≥12mg/mL at 
baseline) with: 
(1) their own e-cigarette after 14 hours of nicotine abstinence 
The authors concluded that the preliminary results 
suggest that the effects of e-cigarette use on resting 
state functional brain connectivity are like those seen 





Ruther et al. 
327 
2018 






The authors reported on the nicotine delivery efficiency 
of first- and second-generation e-cigarettes and their 
impact on relief of cravings during the acute phase of 
use. 
Comparative groups 
Comparison(s) of e-cigarette users themselves (regular users of 
nicotine-containing e-cigarettes for ≥ 3months and not smoked 
for ≥1 month at baseline) with: 
(1) Cigalike American Heritiage 18.0 mg/mL nicotine content,  
(2) Cigalike Vype 18.6 mg/mL nicotine content, 
(3) Blu 18.0 mg/mL nicotine content 
(4) Tank model Aspire/Joytech Upgrade Set 18.0 mg/mL 
nicotine content  
(5) conventional tobacco cigarette Marlboro Red 0.8mg 
nicotine per cigarette  
Comparison(s) of conventional combustible tobacco cigarette 
users (who smoked ≥ 5 cigarettes per day for ≥ 3 years at 
baseline) with the same five products: 
The authors concluded that the heart rate of tank mode 
users was markedly lower than that of the tobacco 
cigarette users. Unlike disposable cigalikes, tank mode 
e-cigarettes represent an effective source of nicotine 
and might be used as an alternative nicotine 
replacement product to aid smoking cessation. 
However, nicotine plasma levels observed in tank mode 
users after short-term vaping also have the potential to 





Cobb et al. 328 
2019 
Harm The authors reported on the influence of e-cigarette 
liquid flavours and nicotine concentration on 
subjective measures of abuse liability in young adult e-
cigarette vapers. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
users (who smoked mean of 10.1 cigarettes per day for a mean 
of 18.3 months at baseline) using: 
(1) own brand cigarette  
(2) e-cigarette combinations 1 ml of one of three liquid flavours 
(Food/Dessert/Spice) 0mg/ml nicotine concentration.  
(3) fruit 0mg/ml nicotine concentration.  
(4) tobacco/Menthol at either 0mg/ml nicotine concentration 
(5) e-cigarette combinations 1 ml of one of three liquid flavours 
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(6) fruit 36 mg/ml nicotine concentration 
(7) tobacco/Menthol at either 36 mg/ml nicotine concentration  
The authors concluded that among young adult vapers, 
e-cigarette containing nicotine were positively 
associated with several, but not all, subjective measures 
of abuse liability. Flavours did not consistently 
mask/enhance the effects observed. The results 
reinforce continued examination of e-cigarette-
delivered nicotine and liquid flavours in relation to 
abuse liability. 
De La Garza 
et al. 321 
2019 
Harm The authors reported on e-cigarette-naive cigarette 
smokers and the effects on cravings after acute 
exposure to e-cigarettes in the laboratory. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
users (who smoked ≥ 11 cigarettes per day for 1 years and 
were e-cigarette naïve at baseline) using: 
(1) participant’s own brand conventional tobacco cigarette  
(2) eGO with e-liquid Virginia Pure tobacco flavoured 
containing 0 mg/ml of nicotine 
(3) eGO with e-liquid Virginia Pure tobacco flavoured 
containing 18mg/ml nicotine 
(4) eGO with e-liquid Virginia Pure tobacco flavoured 
containing 36 mg/ml of nicotine 
The authors concluded that e-cigarettes did not reduce 





Hughes et al. 
324 
2019a 
Harm The authors reported on the symptoms of nicotine 
withdrawal in former smokers who were current daily 
e-cigarette users. 
Comparative groups 
Comparison(s) of e-cigarette users themselves (daily for ≥ 2 
months and using refillable tank, but not a JUUL. Former 
smoker for ≥1 year, and ≤6 tobacco cigarettes in the last year 
at baseline) with: 
(1) participants own e-cigarette. 
The authors concluded that former smokers who are 
daily e-cigarette users transfer physical dependence on 
tobacco cigarettes to dependence on e-cigarettes. The 
severity of withdrawal from e-cigarettes appears to be 






Hughes et al. 
329 
2019b 
Harm The authors reported on withdrawal symptoms from e-
cigarette abstinence among adult never-smokers. 
Comparative groups 
Comparison(s) of e-cigarette users themselves who were never 
smokers (daily at baseline) with: 
(1) participants own nicotine containing e-cigarette 
The authors concluded that withdrawal symptoms can 
occur in never-smokers who are daily e-cigarette users. 
However, the severity of withdrawal from e-cigarette 
abstinence in never-smokers appears to be small and 















The authors conducted an abuse liability assessment of 
an e-cigarette use in combustible cigarette smokers. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
users (who smoked ≥ 10 cigarettes per day for ≥1 year at 
baseline) using: 
(1) participants own brand cigarette  
(2) e-cigarette with nicotine 36mg  



















(4) Food and Drug Administration nicotine inhaler 
The authors concluded that the abuse liability of the e-
cigarette examined was higher than the Food and Drug 
Administration-approved nicotine inhaler but lower 




Benefit The authors evaluated the pharmacokinetic profiles of 
cigarettes and e-cigarettes with nicotine salt 
formulations in adult smokers in the USA. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
users (who smoked ≥ 10 cigarettes per day for ≥1 year at 
baseline) using: 
(1) myblu pod-system containing 25mg nicotine (‘freebase’) 
tobacco flavour  
(2) myblu pod-system containing 16 mg nicotine lactate 
tobacco flavour  
(3) myblu pod-system containing 25mg nicotine lactate 
tobacco flavour  
(4) myblu pod-system containing 40 mg lactate tobacco flavour  
(5) blu PRO open system containing 48 mg nicotine lactate 
tobacco flavour 
(6) own brand commercially available conventional tobacco 
cigarettes 
The authors concluded that the rate of nicotine 
absorption into the bloodstream was comparable 
among all e-cigarettes tested and was as rapid as that 
for conventional combustible tobacco cigarettes. 
However, in all cases, nicotine delivery did not exceed 
that of the conventional combustible tobacco cigarette. 
The pharmacokinetic profiles of nicotine salt emissions 
were also dependent upon the properties of the e-
cigarette device. Subjective scores were numerically 
highest after smoking a conventional combustible 
tobacco cigarette, followed by the Myblu 40 mg 
nicotine salt formulation per cigarette. The rise in 
nicotine blood levels following use of all tested e-
cigarettes was quantified as ‘a little’ to ‘modestly’ 
satisfying in terms of relieving the desire to smoke. All 
products were well tolerated with no notable adverse 
events reported. These results demonstrate that, while 
delivering less nicotine than a conventional combustible 
tobacco cigarette, the use of nicotine salts in e-
cigarettes enables cigarette-like pulmonary delivery of 





Sai et al.333 
2019 
Both benefit and 
harm 
The authors reported on the relationship between e-
cigarettes and brain nicotine kinetics. 
Comparative groups 
Comparison(s) of e-cigarette users themselves who were never 
smokers (exclusive, current users ≥ 4 times per month) and e-
cigarette users (current ≥ 4 times per month at baseline) who 
were former smokers (with a mean of 21 years smoking): 
(1) standardised puff of vapour from V2 Rede-liquid 1.2% 
nicotine  
(2) conventional combustible tobacco cigarette a shortened 
Basic Gold 100’s cigarette (Philip Morris) 
The authors concluded that e-cigarettes can deliver 
nicotine to the brain with similar rapidity as 
conventional tobacco cigarettes. Therefore, to the 
extent that rapid brain uptake promotes smoking 
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dependence and also serve as non-combustible 
substitutes for cigarettes.  
St. Helen et 
al.322 
2019 
Equally harmful  The authors reported on the relationship between e-
cigarettes and nicotine exposure in dual users of e-
cigarettes and conventional combustible tobacco 
cigarettes. 
Comparative groups 
Comparison(s) of dual users (conventional combustible tobacco 
cigarette users who smoked ≥5 cigarettes per day and e-
cigarette users who used the same device ≥1 time per day in 
the past month at baseline) with: 
(1) participants used their usual brand of conventional tobacco 
cigarette users  
(2) Cig-alike e-cigarette 
(3) pod type e-cigarette,  
(4) fixed-power e-cigarette  
(5) variable-power e-cigarette tank devices. 
The authors were not able to detect any differences in 
withdrawal symptoms, affective states, and urge to 
smoke cigarettes between e-cigarette and dual users of 






Vena et al.330 
2020 
Harm The authors reported on the relationship between 
passive exposure to the use of a female-marketed e-
cigarette with selectively enhanced smoking urge, 
cigarette and e-cigarette desire, and smoking behaviour 
among women (versus men) smokers. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
(who smoked ≥ 5 cigarettes per day and were not attempting 
to quit at baseline) with: 
(1) hot-pink coloured iStick Pico e-cigarette mod device 
adorned with a jewelled crown or bow charm (VaporDolls, 
Etsy) 
The authors concluded that both women and men were 
sensitive to the use of the female-marketed e-cigarettes 












4.4.2.2 Cardiovascular diseases: interventional trials 
There were 21 interventional trial papers examining the relationship between e-cigarettes and 
cardiovascular diseases (Table 48). 
The measures assessed in order to evaluate cardiovascular health included:  
• Blood counts 
• Myocardial function 
• Arterial stiffness and arterial pressure 
• Systolic and diastolic blood pressure and heart rate 
• Endothelial progenitor cells 
• Vagal and sympathetic activity 
• Microvascular endothelial function and oxidative stress 
• Vascular and haemodynamic measures (cardio-ankle vascular index, flow-mediated dilation), and 
• Oxidative stress levels. 
One 21-day crossover trial examined the relationship between e-cigarettes and blood count 
measures, gauging 15 markers at three timepoints in the first week, followed by a 1-week break, 
known as a washout period, before the process was repeated with conventional tobacco cigarettes in 
the third week.336 The authors concluded that the results suggest that active e-cigarette smoking in 
smokers and passive e-cigarette smoking in never-smokers did not affect markers of complete blood 
count. By contrast, active tobacco cigarette smoking in smokers and passive tobacco cigarette 
smoking in never-smokers increased white blood cell count, lymphocyte count, and granulocyte count 
for at least 1 hour. 
One trial assessed 11 markers of myocardial function following 7 minutes of e-cigarette use.337 The 
authors stated that e-cigarette use had no immediate effect on myocardial function.  
Four trials examined the effects of e-cigarettes on arterial stiffness. One trial reported no effect on 
arterial stiffness following 15 puffs of an e-cigarette during the intervention,338 while a second trial 
reported unfavourable effects on aortic stiffness in 20 participants after 30 minutes of e-cigarette 
use.339 A third trial examined the differential effects of e-cigarette carrier solvents (propylene glycol 
and glycerol) and of nicotine on micro- and macrovascular function, including arterial stiffness in an 
11-day crossover trial.340 The authors reported that the increased indices of arterial stiffness (harmful) 
were attributable to nicotine but not to other components in the vaporised inhalant. The fourth trial 
reported on the relationship between e-cigarette smoking and increases in aortic stiffness and blood 
pressure in young smokers and concluded that various patterns of e-cigarette smoking clearly 
demonstrated an unfavourable effect on aortic stiffness and blood pressure.341 The authors reported 
that using e-cigarettes for 30 minutes induces an unfavourable effect on aortic stiffness similar to 
tobacco cigarette smoking. The influence of e-cigarette smoking at 5 minutes on aortic stiffness is not 
as prompt (peak effect at 15 minutes) and is less potent compared with the effect of tobacco 
cigarette smoking.  
Four trials examined a combination of oxidative stress and vascular function. Three reported harms 
related to e-cigarettes and the fourth reported no harm. The first short-term crossover trial examined 
the acute impact of tobacco and e-cigarette smoking on oxidative stress and vascular function and 
concluded that smoking both e-cigarettes and conventional tobacco cigarettes led to a significant 
increase in the levels of soluble NOX2-derived peptide and 8-iso-prostaglandin F2α and a significant 
decrease in nitric oxide bioavailability, vitamin E levels, and flow mediated dilation 30 minutes after 
intervention.342 The second trial examined the role of nicotine versus non-nicotine constituents in e-
cigarette emissions in causing increased resting cardiac sympathetic nerve activity and increased 





acute sympathomimetic effect of e-cigarettes (measured 10 minutes after exposure) is attributable to 
the inhaled nicotine, not to non-nicotine constituents in e-cigarette aerosol, reproducing the same 
heart rate variability pattern associated with increased cardiac risk in multiple populations with and 
without known cardiac disease. However, evidence of oxidative stress, as estimated by plasma 
paraoxonase activity, was not uncovered following acute e-cigarette exposure. The third study, a 
short-term crossover trial, examined the relationship of conventional tobacco cigarettes and e-
cigarettes with oxidative stress and endothelial dysfunction and reported that absolute changes in 
oxidative stress and vascular features immediately after smoking a conventional cigarette and vaping 
an e-cigarette were significantly associated with oxidative stress and endothelial dysfunction, with 
one exception of 8-iso-prostaglandin F2α-III levels.344 One three-period 21-day crossover trial 
reported on the differential effects of e-cigarettes (specifically the differential effects of vehicles, 
propylene glycol and glycerol, and nicotine) on macro and microvascular function, arterial stiffness, 
and oxidative stress.345 The authors concluded that high-temperature e-cigarette vehicle vaporisation 
does not alter micro- and macrovascular function or oxidative stress at 15 and 30 minutes after 
vaping, and that these effects are solely attributable to nicotine. Since our mapping exercise another 
prospective study, with a non-randomised trial and cohort study combined, reported that 
conventional tobacco cigarette smokers, particularly females, demonstrate significant improvement 
in vascular health within 1 month of switching from a tobacco cigarette to an electronic cigarette.346 
One crossover trial reported on the relationship between e-cigarettes and an increase in the number 
of endothelial progenitor cells in the blood of healthy volunteers.347 The authors concluded that in 
healthy volunteers, 10 puffs of e-cigarette vapour inhalation caused an increase in endothelial 
progenitor cells up to 24 hours following use. This increase was of the same magnitude as that 
following smoking one conventional cigarette. Taken together, these results may represent signs of 
possible vascular changes after short e-cigarette inhalation. 
Six trials reported on the relationship between e-cigarettes and heart rate and/or blood pressure. 
Two trials reported no effect and four trials reported a harmful effect. The first trial was an RCT and 
reported on the effect of continuous smoking reduction and abstinence on blood pressure and heart 
rate in smokers switching to e-cigarettes over a 1-year period and concluded that quitting smoking 
with the use of e-cigarettes does not lead to higher blood pressure values.348 The second trial 
reported on the effects of e-cigarette use on vascular measures of health up to 2 hours after exposure 
and concluded that there were no significant changes in heart rate, systolic and diastolic blood 
pressure, endothelial function, or arterial stiffness throughout the experiment.349 By contrast, the 
third trial (a crossover trial) reported on the relationship of e-cigarettes and cigarettes with peripheral 
and central haemodynamics, as well as arterial stiffness measured for up to 2 hours after exposure 
and concluded that there were increases in peripheral and central blood pressure and also in pulse 
wave velocity after either smoking a conventional cigarette or after vaping a nicotine-containing e-
cigarette.350 The fourth trial investigated the effects of the e-cigarette liquid solvents propylene glycol 
and vegetable glycerine on user nicotine delivery, heart rate, subjective effects, and puff topography 
over 12 days; the authors concluded that participants’ heart rates increased significantly after e-
cigarette use.351 The fifth trial, a crossover 5-day trial, examined the exercise-induced heart rate 
response and heart rate variability in subjects caused by inhaling smoke from conventional tobacco 
cigarettes and aerosolised vapour from e-cigarettes and concluded that a significant acute autonomic 
cardiac modulation during exercise is induced by an acute episode of using either conventional 
tobacco cigarettes or e-cigarettes.352 The sixth trial consisted of two RCTs separated by at least 1 
week and tested a placebo e-cigarette and 18 mg per ml nicotine e-cigarette and reported on the 
acute cardiorespiratory and performance effects of vaporised nicotine delivered via e-cigarettes at 
rest and during cycle exercise in young, normotensive, non-smoking subjects.353 The authors 
concluded that acute vaporised nicotine inhalation via e-cigarettes increases resting and exercise 
diastolic blood pressure but does not affect resting metabolic rate or cycle aerobic power.  
One trial reported on the impact of conventional cigarette versus e-cigarette smoking on platelet 
function.354 Each participant smoked a conventional cigarette then returned 1 week later to vape a 
study e-cigarette with the same nominal nicotine content. Blood samples were drawn shortly before 





cigarettes have short-term effects on platelet activation, although in non-smokers the use of e-
cigarettes had a less important impact on platelet function. 
Two papers examined the relationship between e-cigarettes and cardio-respiratory function. One 
three-period 21 day crossover trial reported on the acute effects of vaping and their reversibility on 
biological/clinical cardio-respiratory parameters and concluded that short-term e-cigarette cessation 
by regular users decreases baseline heart rate and lung inflammation and increases forced expiratory 
flow by 25%, suggesting that high-wattage vaping alters airway function.355 In addition, acute nicotine 
vaping increased systolic blood pressure, diastolic blood pressure, and heart rate.355 The second trial, 
a three-period crossover trial, which was investigator-blinded and conducted over 21 days with 
former smokers who were exclusive nicotine e-cigarette users for a least 1 year at baseline, 
concluded that short-term e-cigarette cessation by regular users decreases baseline heart rate and 
lung inflammation and increases forced expiratory flow, suggesting that vaping negatively alters 
airway function.356  
One paper concluded that a 24 mg e-cigarette significantly reduced vapers’ hand microcirculation 
during and up to 20 minutes post intervention.357 
Table 48 Interventional trial papers on cardiovascular diseases, benefits or harms 
Author(s), year Possible 
benefit or 
harm 
Interventional trial papers on cardiovascular diseases Trial design 




The authors investigated the acute effects of electronic and 
tobacco cigarette smoking on complete blood count. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(who smoked ≥ 15 cigarettes per day and were e-cigarette naive at 
baseline) with: 
(1) control session (ASCON),  
(2) an active tobacco cigarette smoking session (ASTOB) 
(3) an active e-cigarette smoking session (ASE-CIG) 
Comparison(s) of never conventional combustible tobacco cigarette 
and never e-cigarette users at baseline) with the same 3 
interventions. 
The authors concluded that active e-cigarette smoking in 
smokers and passive e-cigarette smoking in never-smokers 
do not affect markers of complete blood count. By contrast, 
active tobacco cigarette smoking in smokers and passive 
tobacco cigarette smoking in never-smokers increase white 
blood cell count, lymphocyte count, and granulocyte count 









The authors reported on the acute effects of using an e-
cigarette on myocardial function. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(≥ 15 cigarettes per day for ≥5 years at baseline) with  
Electronic cigarette users who were former smokers (daily, 9-
12 mg/ml nicotine-containing liquid for ≥1 month) after both 
received: 
(1) one commercially available conventional combustible tobacco 
cigarette of the same nicotine (1.0 mg), tar (10 mg) and carbon 
monoxide (10 mg) yields. 
The authors concluded that although acute smoking causes 
a delay in myocardial relaxation, e-cigarette use has no 
immediate effects. E-cigarettes’ role in tobacco harm 
reduction should be studied intensively in order to 
determine whether switching to e-cigarette use may have 










The authors reported on the influence of inhaled nicotine 
from conventional combustible tobacco cigarettes versus 








Author(s), year Possible 
benefit or 
harm 
Interventional trial papers on cardiovascular diseases Trial design 
Comparison(s) of e-cigarette users themselves who were former 
smokers (current users of with nicotine-containing liquid for ≥1 
month at baseline) with conventional combustible tobacco 
cigarette users smoking ≥15 cigarettes per day for ≥5 years at 
baseline) after both received: 
(1) second-generation device eGo-T battery with liquid containing 
11 mg/ml nicotine concentration 
The authors concluded that in contrast to conventional 
combustible tobacco cigarette use, the use of e-cigarettes 
causes no changes in arterial stiffness. They suggested that 
this may indicate lower bioavailability of nicotine from the 
e-cigarette or an additional effect of other substances 




Cooke et al. 339 
2015 
Harm The authors reported on the effect of acute inhalation of 
vaporised nicotine on arterial pressure in young non-
smokers. 
Comparative groups 
Comparison(s) of non-conventional combustible tobacco cigarette 
users (never smokers at baseline) with: 
(1) e-cigarette containing nicotine (18 mg) 
(2) a placebo (0 mg nicotine) 













The authors reported on the effects of using e-cigarettes on 
nicotine delivery and cardiovascular function in comparison 
with conventional combustible tobacco cigarettes. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(who smoked mean of 10 cigarettes per day for ≥ 1 year at baseline) 
using: 
(1) blu e-cigs commercial products (Product D) that contain 16 
mg/mL (1.6%) nicotine and  
(2) blu e-cigs commercial products (Product E) that contain 16 
mg/mL (1.6%) nicotine and  
(3) non-commercial products (Product A) that contain 24 mg/mL 
(2.4%) nicotine 
(4) non-commercial products (Product B) that contain 24 mg/mL 
(2.4%) nicotine 
(5) non-commercial products (Product C) that contain 24 mg/mL 
(2.4%) nicotine  
(6) the market-leading conventional cigarette (Marlboro) with 
approximately 0.8 mg nicotine per cigarette (FTC 2007). 
The authors concluded that the nicotine plasma 
concentrations after 1.5 hours of e-cigarette product use 
were significantly lower in the users of e-cigarettes than in 
users of Marlboro cigarettes. The combination of glycerine 
and propylene glycol as the delivery vehicle facilitated 
delivery of more nicotine than the use of glycerine alone. 
Heart rate and systolic and diastolic blood pressure, were 
significantly elevated after use of Marlboro cigarettes, but 
the elevation was less after use of most of the e-cigarettes 
tested. Use of e-cigarettes had no impact on exhaled carbon 
monoxide levels, whereas the Marlboro cigarettes 
significantly increased exhaled carbon monoxide to more 






Harm The authors reported on the relationship between e-
cigarettes and an increase in the number of endothelial 









Author(s), year Possible 
benefit or 
harm 
Interventional trial papers on cardiovascular diseases Trial design 
2016 Comparison(s) of conventional combustible tobacco cigarette users 
(who smoked maximum 10 cigarettes per month at baseline) with: 
(1) second-generation electronic cigarette device (eGo XL) and an e-
liquid with nicotine 12 mg/ml 
The authors concluded that in healthy volunteers, 10 puffs 
of e-cigarette vapour inhalation caused an increase in 
endothelial progenitor cells. This increase was of the same 
magnitude as that following smoking one conventional 
combustible tobacco cigarette. Taken together, these 
results may represent signs of possible vascular changes 
after short e-cigarette inhalation. 
Carnevale et al. 
342 
2016 
Harm The authors examined the acute impact of tobacco and e-
cigarette smoking on oxidative stress and vascular 
function. 
Indicators of oxidative stress (serum levels of soluble NADPH 
oxidase 2 (NOX2)-derived peptide, nitric oxide 
bioavailability, 8-iso-prostaglandin F2α-III, and vitamin E) 
and endothelial dysfunction (flow-mediated dilation) were 
collected. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(who smoked a mean of 11.1 cigarettes per day for a mean of 6.4 
years at baseline) with: 
(1) conventional combustible tobacco cigarette with mean nicotine 
content of 0.6 mg 
(2) tobacco-flavoured e-cigarette with a nicotine content of 16mg 
per cartridge 
The authors concluded that smoking both e-cigarettes and 
conventional combustible tobacco cigarettes led to a 
significant increase in the levels of soluble NOX2-derived 
peptide and 8-iso-prostaglandin F2α and a significant 
decrease in nitric oxide bioavailability, vitamin E levels, and 










The authors reported on the effect of continuous smoking 
reduction and abstinence on blood pressure and heart rate 
in smokers switching to e-cigarettes. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(who smoked ≥ 5 cigarettes per day for ≥ 5 years and not intending 
to quit at baseline) with: 
(1) ‘Original’ 2.4% nicotine Categoria’; Arbi Group Srl, Italy 
(2) Categoria’1.8 % nicotine Categoria’; Arbi Group Srl, Italy 
(3) Original’ without nicotine and with ‘sweat tobacco’ aroma 
Categoria’; Arbi Group Srl, Italy 
The authors concluded that quitting smoking with the use of 
e-cigarettes does not lead to higher blood pressure values, 
and this is independently observed whether e-cigarettes are 




Fogt et al. 353 
2016 
Harm The authors reported on the acute cardiorespiratory and 
performance effects of vaporised nicotine delivered via e-
cigarettes at rest and during cycle exercise in young, 
normotensive, non-smoking subjects. 
Comparative groups 
Comparison(s) of non-smokers (conventional combustible tobacco 
cigarette) using: 
(1) e-cigarettes placebo (0 mg nicotine)  
(2) e-cigarettes types nicotine (18 mg nicotine) 
The authors concluded that acute vaporised nicotine 
inhalation via e-cigarettes increases resting and exercise 









Author(s), year Possible 
benefit or 
harm 
Interventional trial papers on cardiovascular diseases Trial design 
metabolic rate or cycle aerobic power in young, 
normotensive non-smokers. 
Vlachopoulos 








The authors reported on the relationship between e-
cigarette smoking and increases in aortic stiffness and 
blood pressure in young smokers. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
using: 
(1) conventional combustible tobacco cigarette  
(2) e-cigarette over a 5-minute period  
(3) e-cigarette over a 30-minute period  
(4) nothing (a sham) 
The authors concluded that various patterns of e-cigarette 
smoking on aortic stiffness and blood pressure clearly 
demonstrated an unfavourable effect. Using e-cigarettes for 
30 minutes induces an unfavourable effect on aortic 
stiffness similar to tobacco cigarette smoking. The influence 
of e-cigarette smoking for 5 minutes on aortic stiffness is 
not as prompt (peak effect at 15 minutes) and is less potent 








Harm The authors reported on the role of nicotine versus non-
nicotine constituents in e-cigarette emissions in causing 
increased resting cardiac sympathetic nerve activity and 
increased susceptibility to oxidative stress in otherwise 
healthy humans.  
Comparative groups 
Comparison(s) of not current conventional combustible tobacco 
cigarette or e-cigarette users (but could be former users for >1 year 
at baseline) using: 
(1) e-cigarette the Greensmoke cigalike device with tobacco-
flavoured liquid and 1.2% nicotine  
(2) e-cigarette the Greensmoke cigalike device with tobacco-
flavoured liquid and 0% nicotine  
(3) the second-generation penlike device (1.0 O, eGo-One by 
Joyetech) with strawberry flavouring and 1.2% nicotine  
(4) the second-generation penlike device (1.0 O, eGo-One by 
Joyetech) with strawberry flavouring and 0% nicotine  
(5) a sham  
The authors concluded that the acute sympathomimetic 
effect of e-cigarettes is attributable to the inhaled nicotine, 
not to non-nicotine constituents in e-cigarette aerosol, 
recapitulating the same heart rate variability pattern 
associated with increased cardiac risk in multiple 
populations with and without known cardiac disease. 
Evidence of oxidative stress, as estimated by plasma 








Harm The authors reported on the differential effects of e-
cigarettes (specifically the differential effects of vehicles, 
propylene glycol and glycerol, and nicotine) on macro and 
microvascular function, arterial stiffness, and oxidative 
stress. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
occasional users (median cumulative pack-years: 0.2) using: 
(1) e-cigarette with e-liquid which was nicotine free (0 mg.ml−1)  
(2) e-cigarette with e-liquid 3 mg/ml−1  
(3) sham vaping 
The authors concluded that high-temperature e-cigarette 








Author(s), year Possible 
benefit or 
harm 
Interventional trial papers on cardiovascular diseases Trial design 
macrovascular function or oxidative stress, and that these 
effects are solely attributable to nicotine. 
Franzen et al. 
350 
2018 
Harm The authors reported on the relationship of e-cigarettes and 
cigarettes with peripheral and central haemodynamics, as 
well as arterial stiffness. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(current, without a history of vaping or dual use) with: 
(1) e-cigarette with nicotine the eGo-T CE4 vaporizer (third 
generation) 24 mg/mL nicotine tobacco flavour  
(2) e-cigarette with 0 mg/mL nicotine tobacco flavour  
(3) conventional combustible tobacco cigarette (Philip & Morris) 
The authors concluded that there were changes in 
peripheral and central blood pressure and also in pulse 
wave velocity after smoking a conventional combustible 
tobacco cigarette as well as after vaping a nicotine-
containing e-cigarette. These findings may be associated 







Harm The authors reported on the relationship of conventional 
combustible tobacco cigarettes and e-cigarettes with 
oxidative stress and endothelial dysfunction. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(who smoked a mean of 11.1 cigarettes per day for a mean of 6.4 
years at baseline) using: 
(1) e-cigarette with a mean nicotine content of 16mg  
(2) conventional tobacco cigarette with a mean nicotine content of 
0.6mg  
The authors reported that absolute changes in oxidative 
stress and vascular features after smoking a conventional 
combustible tobacco cigarette and vaping an e-cigarette 
were significantly associated, with the notable exception of 
8-iso-prostaglandin F2α-III levels The authors also stated 
that this post hoc analysis of the SUR-VAPES 1 trial suggests 
that the comparative oxidative and vascular effects of e-
cigarettes versus conventional combustible tobacco 
cigarettes may be influenced by smoking status, with a 





Nocella et al. 
354 
2018 
Harm The authors reported on the impact of conventional 
combustible tobacco cigarette versus e-cigarette smoking 
on platelet function. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(who smoked a mean of 11.1 cigarettes per day for a mean of 6.4 
years at baseline) using: 
(1) conventional combustible tobacco cigarette users with a mean 
nicotine content of 0.6 mg  
(2) e-cigarette with a nicotine cartridge with a mean nicotine 
content of 16 mg 
The authors concluded that in smokers, there were no 
significant changes in sCD40L and sP-selectin, but there was 
a significant increase in platelet aggregation. In non-
smokers, there was a significant increase in all markers of 
platelet activation following both conventional combustible 
tobacco cigarette and e-cigarette use. Both conventional 
combustible tobacco cigarette and e-cigarettes have short-
term effects on platelet activation, although in non-smokers 










Author(s), year Possible 
benefit or 
harm 
Interventional trial papers on cardiovascular diseases Trial design 
Pywell et al.357 
2018 
Harm The authors reported on the effect of e-cigarettes on hand 
microcirculation. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(average consumption 1.5 packs per week at baseline) using: 
(1) e-cigarette nicotine 24 mg  
(2) e-cigarette with no nicotine 0 mg 
Comparison(s) of non-smokers using: 
(1) e-cigarette nicotine 24 mg  
(2) e-cigarette with no nicotine 0 mg 
The authors concluded that a 24 mg e-cigarette significantly 
reduced smokers’ hand microcirculation during and after 
smoking. Microcirculation increased in smokers after 
inhalation of a 0 mg e-cigarette. The authors advised 
smokers undergoing hand surgery to avoid high-dose e-







Spindle et al. 
351 
2018 
Harm The authors reported on the effects of the e-cigarette liquid 
solvents propylene glycol and vegetable glycerine on user 
nicotine delivery, heart rate, subjective effects, and puff 
topography. 
Comparative groups 
Comparison(s) of dual users (e-cigarette and conventional 
combustible tobacco cigarette) (who smoked < 5 cigarettes daily, 
and used their e-cigarette for ≥ 3 months and vaped ≥ 1 ml of ≥ 6 
mg/ml nicotine concentration liquid daily at baseline) with: 
(1) eGo Cartomizers filled with 1 ml of e-cigarette liquid containing 
18 mg/ml of nicotine where the difference was with the liquid 
propylene glycol: vegetable glycerine ratio 100:0 
(2) eGo Cartomizers filled with 1 ml of e-cigarette liquid containing 
18 mg/ml of nicotine where the difference was with the liquid 
propylene glycol: vegetable glycerine ratio 70:30  
(3) eGo Cartomizers filled with 1 ml of e-cigarette liquid containing 
18 mg/ml of nicotine where the difference was with the liquid 
propylene glycol: vegetable glycerine ratio 30:70  
(4) eGo Cartomizers filled with 1 ml of e-cigarette liquid containing 
18 mg/ml of nicotine where the difference was with the liquid 
propylene glycol: vegetable glycerine ratio 0:100 
The authors concluded that the ratio of liquid propylene 
glycol to vegetable glycerine influenced nicotine delivery, 
some subjective effects, and puff topography. Lower overall 
product satisfaction associated with the 100% propylene 
glycol liquid suggests that factors other than nicotine 
delivery (aerosol visibility) may play a role in maintaining e-
cigarette use. Regulating e-cigarette acute effects, such as 
nicotine delivery, and subjective effects may require 
simultaneous attention to the ratio of liquid propylene 
glycol to vegetable glycerine, as well as device, liquid, and 
behavioural factors known to influence these outcomes. The 









Harm The authors reported on the acute effects of e-cigarette 
inhalation on the vasculature and the conducting airways. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
occasional users (maximum 10 cigarettes per month at baseline) 
with: 
(1) e-cigarette with 19mg/ml nicotine  
(2) e-cigarette with 0mg/ml nicotine 
The authors concluded that inhaled e-cigarette aerosol with 








Author(s), year Possible 
benefit or 
harm 
Interventional trial papers on cardiovascular diseases Trial design 
pulmonary function, and that chronic usage may lead to 
long-term adverse health effects. 




The authors reported on the effects of a single bout of e-
cigarette use on vascular measures of health. 
Comparative groups 
Comparison(s) of e-cigarette themselves (in young healthy 
participants who were naive to any tobacco products) using: 
(1) e-cigarette with nicotine  
(2) e-cigarette without nicotine, and  
(3) placebo control (menthol flavoured cigarette-like pipe) 
The authors concluded that there were no significant 
changes in heart rate, systolic and diastolic blood pressure, 
endothelial function (via flow‐mediated dilation), or arterial 







et al. 352 
2019 
Harm The authors examined the exercise-induced heart rate 
response and heart rate variability in subjects caused by 
inhaling smoke from tobacco cigarettes and aerosolised 
vapour from e-cigarettes.  
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(regular, smoking a mean of 9.2 (SD ± 1.3) cigarette per day for a 
mean duration of 3.5 years) using: 
(1) 0 mg/mL nicotine e-cigarette  
(2) 3 mg/mL nicotine e-cigarette 
(3) Two tobacco cigarettes with 1.5 mg nicotine each which equals 3 
mg.  
The authors concluded that a significant acute autonomic 
cardiac modulation during exercise is induced by an acute 








Harm The authors reported on the acute effects of vaping and 
their reversibility on biological/clinical cardio-respiratory 
parameters (serum/urine pneumoproteins, haemodynamic 
parameters, lung function test and diffusing capacities, 
transcutaneous gas tensions (primary outcome), and skin 
microcirculatory blood flow). 
Comparative groups 
Comparison of e-cigarette users themselves exclusive nicotine e-
cigarette use for ≥ 1 year at baseline) using: 
(1) e-cigarette with nicotine  
(2) e-cigarette without nicotine 
(3) cessation of e-cigarette 
The authors concluded that short-term e-cigarette cessation 
by regular users decreases baseline heart rate and lung 
inflammation and increases forced expiratory flow by 25%, 
suggesting that high-wattage vaping alters airway function. 
Urine metabolomic signature was also slightly modified by 
this short-term e-cigarette cessation. Acute nicotine and 
nicotine-free vaping decreased transcutaneous oxygen 
tensions likely as a result of gas exchange disturbances. 
Finally, only acute nicotine vaping increased systolic blood 




4.4.2.3 Cancers: interventional trials 





4.4.2.4 Respiratory diseases: interventional trials 
There were 16 interventional trials reporting on the relationship between e-cigarette use and 
respiratory disease outcomes (Table 49). Broadly, the outcomes can be grouped as measures of tissue 
damage or stress; measures of respiratory function, including functional impairment; symptoms of ill 
health; and measures of toxicity in body tissue and exhaled breath. The outcomes assessed included: 
• Indices of endothelial activation in human pulmonary microvascular endothelial cells, oxidative 
stress, alveolar macrophages tissue, hypoxia and lower airway injury symptoms, inflammation pa-
rameters, and levels of C-reactive protein 
• Pulmonary function tests, such as forced expiratory volume in 1 second and forced vital capacity, 
and their ratio; forced expiratory flow and forced oscillation technique, resonant frequency, reac-
tance area, inspiratory capacity, tidal volume, and respiratory rate 
• Plasma endothelial microparticles 
• Signs and symptoms: cough; phlegm; urge-to-cough sensation, specifically the urge-to-cough 
threshold; cough reflex sensitivity; chest tightness; breathlessness; secretions; wheezing; sinona-
sal symptoms and nasal mucociliary clearance; and shortness of breathExhaled nitric oxide, frac-
tional concentration of carbon monoxide in exhaled breath, and oxygen saturation. 
Taken together, the 16 trials reported discordant findings. One paper concluded that smokers invited 
to switch to e-cigarettes who completely abstained from smoking showed steady progressive 
improvements in their exhaled breath measurements and symptom scores.359 Two papers concluded 
that e-cigarettes did not negatively affect lung function.360 361 Five papers reported that e-cigarettes 
were less harmful to lung function than conventional tobacco cigarettes,362-365 366 and one of these 
studies suggested that e-cigarette use may reverse negative respiratory outcomes in former 
smokers.364 However, nine papers suggest that e-cigarettes damage the respiratory system by 
reducing vascular function to the lungs and/or reducing physiological function.365 367-374 
Two of the trials reported on the relationship between e-cigarettes and measures of tissue damage 
which were assessed as oxidative stress, and indicated a discordance in the nature and direction of 
the relationship. The first study reported that even in the absence of nicotine, acute e-cigarette 
aerosol inhalation can lead to a transient increase in oxidative stress and inflammation.373 According 
to the trial authors, this can adversely affect the vascular endothelial network by promoting oxidative 
stress and immune cell adhesion; they concluded that e-cigarette inhalation has the potential to drive 
the onset of vascular pathologies. In the second study, the authors concluded that although 
endothelial microvascular function and oxidative stress remained unaffected, acute vaping of an 
aerosol of propylene glycol/glycerol at high wattage and in large quantities induced a sustained tissue 
hypoxia, airway epithelial injury, and small airway constriction.370  










Harm The authors reported on the short-term pulmonary effects 
of using an e-cigarette, including: impact on respiratory 
flow resistance, impedance, and exhaled nitric oxide. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(with a minimum pack-year index of 5 at baseline) using: 
(1) e-cigarette with a cartridge NOBACCO MLB-MED with a dose of 
11 mg nicotine  
(2) control group e-cigarette without a cartridge 
The authors concluded that the e-cigarettes assessed in the 
context of this study had immediate adverse physiological 
effects after short-term use comparable to some of the 























The authors conducted a comprehensive and standardised 
assessment of the acute impact of active and passive e-
cigarette smoking on serum cotinine and lung function 
(plus toxins). 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(smoking ≥15 cigarettes per day at baseline) using: 
(1) a control session (ACTIVECON)  
(2) an active tobacco cigarette smoking session (ACTIVETOB) 
smoking participant favourite brand  
(3) an active e-cigarette smoking session (ACTIVEE-CIG) using the 
model: Giant, Nobacco with a ‘‘tobacco taste’’ and containing 11 
mg/ml of nicotine 
Comparison(s) of never smokers using the same 3 interventions 
The authors concluded that, regarding short-term usage, 
the studied e-cigarettes generate smaller changes in lung 
function than, but a similar nicotinergic impact as, tobacco 
cigarettes. Future research should target the health effects 















The authors reported on the short-term effects of a 
nicotine-free e-cigarette compared to a conventional 
combustible tobacco cigarette in smokers and non-
smokers. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(with a minimum pack-year index of 5 at baseline) using: 
(1) nicotine free e-cigarette (ELIPS C Series)  
(2) traditional cigarettes (a commercial ’popular brand’ Marlboro 
Red Label Box 
Comparison(s) of non-smokers (not defined) using the same two 
interventions 
The authors concluded that the specific brand of nicotine-
free e-cigarettes used in this study was not associated with 
major acute physiological changes, causing only small 
(albeit statistically significant) decreases in forced 
expiratory flow (FEF) 25% and forced expiratory volume in 
the first second (FEV1) in the group of smokers. By contrast, 
smoking a conventional combustible tobacco cigarette 






Benefit The authors reported on changes in breathomics (breath-
based diagnostics) from a 1-year randomised smoking 
cessation trial of e-cigarettes fractional nitric oxide 
concentration in exhaled breath (FeNO), exhaled carbon 
monoxide, and symptom scores). 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(median cigarette per day 20.0 and median pack-years 24.9; smoke 
≥ 10 tobacco cigarettes per day for ≥ 5 years and not intending to 
quit at baseline) with: 
(1) first-generation cigarette-lookalike e-cigarette (‘Categoria’; Arbi 
Group Srl, Seregno, Italy ‘Original 2.4%’ (2.27% nicotine)  
(2) ‘Categoria 1.8%’ (1.71% nicotine)  
(3) ‘Categoria Original 0%’ nicotine (‘sweet tobacco’ aroma) 
The authors concluded that smokers who were invited to 
switch to e-cigarettes who completely abstained from 
smoking showed steady progressive improvements in their 
exhaled breath measurements and symptom scores. 
Fractional exhaled nitric oxide and exhaled carbon 













Interventional trial papers on respiratory diseases Trial design 
respiratory health outcomes and adds to the notion that 




Benefit The authors reported on lung function and respiratory 
symptoms in a randomised smoking cessation trial of e-
cigarettes, presented on the basis of participants’ pooled 
continuous smoking phenotype classification (quitters, 
reducers, or failures). 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(median cigarette per day 20.0 and median pack-years 24.9; smoke 
≥ 10 tobacco cigarettes per day, for ≥ 5 years and not intending to 
quit at baseline) using: 
(1) first-generation cigarette-lookalike EC (‘Categoria’; Arbi Group 
Srl, Seregno, Italy ‘Original 2.4%’ (2.27% nicotine)  
(2) ‘Categoria 1.8%’ (1.71% nicotine) 
(3) ‘Original 0%’ without nicotine (‘sweet tobacco’ aroma). 
The authors concluded that this 1-year prospective RCT 
shows improvements in spirometric indices of peripheral 
airways, as well as in respiratory symptoms in smokers who 
were invited to quit or reduce their cigarette consumption 
by switching to first-generation e-cigarettes. Specifically, 
the present study shows progressive and consistent 
improvement in forced expiratory flow (FEF) 25–75% among 
those who completely gave up cigarette smoking. 
Improvements in FEF 25–75% from baseline were no 
different in quitters who stopped using e-cigarettes 







Harm The authors reported on the effect of e-cigarette use on 
the urge-to-cough sensation, specifically the urge-to-cough 
threshold, and cough reflex sensitivity. 
Comparative groups 
Comparison(s) of never conventional combustible tobacco cigarette 
users using: 
(1) disposable e-cigarette (Blu, Classic Tobacco flavour, Lorillard 
Technologies, Greensboro) 
(2) disposable Blu e-cigarette contains 20–24 mg of nicotine 
The authors concluded that a single exposure to an e-
cigarette significantly inhibits the urge-to-cough threshold 
as measured by capsaicin cough challenge testing. These 
findings add to the growing body of evidence that e-
cigarette vapour is not a physiologically benign substance 
and support further investigation of the effects of repeated 










Harm The authors reported on the impact of e-cigarette smoking 
on sinonasal symptoms and nasal mucociliary clearance. 
Comparative groups 
Comparison of e-cigarette users themselves with: 
(1) e-cigarette with a medium density (11-12 mg/ml) liquid 
Comparison(s) of exclusive conventional combustible tobacco 
cigarette users (smoked 1 pack of cigarettes per day for ≥5 years 
(mean 9.7 years) and willing to quit smoking at baseline) and dual 
users (e-cigarettes and conventional combustible tobacco cigarette 
who smoked 1 pack of cigarettes per day for ≥5 years (mean 9.8 
years)using: 
(1) e-cigarette with a medium density (11-12 mg/ml) liquid 
The authors concluded that although e-cigarettes are widely 
used as a method of quitting smoking, they have negative 

















No harm or 
benefit 
The authors reported on the acute effects of nicotine-free 
and flavour-free e-cigarette use on lung functions in 
healthy and asthmatic individuals. 
Comparative groups 
Comparison(s) of never smokers (who were not active e-cigarette 
users at baseline) using: 
(1) e-cigarette with nicotine-free and flavour-free liquid  
(2) e-cigarette without liquid 
The authors concluded that a 1-hour inhalation session of a 
high-grade and contaminant-free mixture of propylene 
glycol and glycerol using a commercially available e-
cigarette, performed in a controlled environment, does not 
significantly impact pulmonary function or symptoms in 













The authors reported on the relationship between partial or 
complete substitution of cigarettes with e-cigarettes in 
adult smokers with measurements of cardiovascular and 
pulmonary function endpoints and other physiological 
effects. 
Comparative groups 
Comparison of dual users (conventional combustible tobacco 
cigarettes and e-cigarettes) using: 
1) close system rechargeable blu e-cigarette tobacco flavour 24 
mg/mL nicotine  
(2) close system rechargeable blu e-cigarette cherry flavour 24 
mg/mL nicotine  
(3) close system disposable blu e-cigarette cherry flavour 24 mg/mL 
nicotine 
Comparison of e-cigarette users themselves (exclusive at baseline) 
with: 
(1) close system rechargeable blu e-cigarette tobacco flavour 24 
mg/mL nicotine plus usual brand combustible tobacco cigarettes 
(2) close system rechargeable blu e-cigarette cherry flavour 24 
mg/mL nicotine plus usual brand combustible tobacco cigarettes  
(3) close system disposable blu e-cigarette cherry flavour 24 mg/mL 
nicotine plus usual brand combustible tobacco cigarettes 
The authors concluded that use of e-cigarettes for 5 days 
under the various study conditions did not lead to higher 
blood pressure or heart rate values, negative respiratory 
health outcomes, or serious adverse health events. 
Reductions in blood pressure and heart rate vital signs were 
observed in most of the participants who either ceased 
tobacco and nicotine product use altogether or switched 
completely to using e-cigarettes. Pulmonary function tests 
showed small but non-statistically significant improvements 
in forced vital capacity and forced expiratory volume in 
most usage groups. Statistically significant (p<0.05) benefits 
associated with smoking reduction were also noted in 
exhaled carbon monoxide and fractional nitric oxide 
concentration in exhaled breath. All studied products were 
well tolerated. The study findings suggest that there are 
potential cardiovascular and pulmonary function benefits 







Harm The authors reported on the relationship of high-wattage e-
cigarettes with tissue hypoxia and lower airway injury. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette 
occasional users (median cumulative pack years 0.25 at baseline) 
with: 
(1) e-cigarette with a propylene glycol and glycerol mix (50:50) mix 
Randomised 










Interventional trial papers on respiratory diseases Trial design 
The authors concluded that although endothelial 
microvascular function and oxidative stress remained 
unaffected, acute vaping of an aerosol of propylene 
glycol/glycerol at high wattage and in a large amount 
induced sustained tissue hypoxia, airway epithelial injury, 





















The authors examined whether the active use of e-
cigarettes in healthy subjects can cause short-term effects 
on lung function, and whether these effects are different 
from those associated with a similar exposure to tobacco 
smoke. 
Comparative groups 
Comparison(s) of non-smokers (who were healthy volunteers) with: 
(1) e-cigarette containing e-liquid 18mg/ml nicotine model EGO P(L)  
(2) tobacco cigarette (not specified in summary) 
The authors concluded that the active use of e-cigarettes 
for a short time caused similar, although less pronounced, 
effects as tobacco smoke on pulmonary function. Similarly, 
the particles released in the environment had a lower 
concentration and persistence than those of tobacco 
cigarettes. These data suggest that e-cigarettes may 









Harm The authors investigated the duration of immediate 
respiratory effects of e-cigarette smoking and tested the 
hypothesis that e-cigarette smoking has more prominent 
effects in asthmatics compared with healthy smokers. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(≥ 1 cigarette during the past 30 days) with e-cigarette users 
themselves using (≥ 1 ml of liquid per day with a nicotine 
concentration of ≥ 12 mg/mL and used their device for ≥ three 
months) with: 
(1) the new generation e-cigarette with nicotine 1.18% and tobacco 
essence 
The authors concluded that a single session of e-cigarette 
smoking had immediate mechanical and inflammatory 
respiratory effects in healthy smokers and in asymptomatic 
smokers with intermittent asthma. These actions persisted 
for 15 to 30 minutes (fractional nitric oxide concentration in 
exhaled breath). The intensity and duration of these 








Harm The authors reported on the altered lung biology of healthy 
never-smokers following acute inhalation of e-cigarettes. 
Comparative groups 
Comparison(s) of never smokers using: 
(1) the e-cigarette “Blu” with nicotine  
(2) the e-cigarette “Blu” without nicotine 
 The authors concluded that even limited, acute exposure to 
e-cigarette aerosols dysregulates the biology of the human 
lung in vivo. Whether or not chronic exposure to e-
cigarettes will result in lung disease is unknown and can 
only be evaluated by large-scale, long-term trials of 
individuals who are not former or current cigarette smokers 
who have used only e-cigarettes, a study that would be 
challenging to carry out at present, as most e-cigarette 














Interventional trial papers on respiratory diseases Trial design 
However, the observed changes in the biology of the small 
airway epithelium, alveolar macrophages, and (indirectly) 
lung capillary endothelium may signal that e-cigarette use 










The authors aimed to examine the effects of combustible 
and non-combustible methods of smoking on lung 
function based on functional respiratory tests and the 
degree of alveolocapillary membrane damage, measured by 
dynamic inhalation scintigraphy. 
Comparative groups 
Comparison of e-cigarette user (who currently using e-cigarettes 
with 10 mg nicotine/ml and were previously heavy conventional 
combustible tobacco cigarette smokers) with: 
(1) conventional combustible tobacco cigarettes with participants 
smoking 20 to 25 cigarettes per day for one week 
The authors concluded that e-cigarette smoking is less 
harmful to lung function than conventional combustible 
tobacco cigarette smoking, and that it can be recommended 









Harm The authors reported on the acute response to aerosol 
inhalation of non-nicotinised e-cigarettes in terms of 
oxidative stress and indices of endothelial activation in 
human pulmonary microvascular endothelial cells. 
Comparative groups 
Comparison(s) of non- smokers (conventional combustible tobacco 
cigarette) with: 
(1) e-cigarette E-puffer an eco-disposable nicotine device 
The authors concluded that the findings suggest that even 
in the absence of nicotine, acute e-cigarette aerosol 
inhalation leads to a transient increase in oxidative stress 
and inflammation. This can adversely affect the vascular 
endothelial network by promoting oxidative stress and 
immune cell adhesion. Thus, e-cigarette inhalation has the 





Kerr et al.374 
2019 
Harm The authors reported on the acute effects of electronic and 
tobacco cigarettes on vascular and respiratory function in 
healthy volunteers. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(Mean: 7 per day and ≥ 1 tobacco cigarettes per day) using: 
(1) the habitual conventional combustible tobacco cigarette of 
study participants (which comprised one of six brands)  
(2) second-generation e-cigarette device with 18 mg/ml nicotine 
and tobacco flavoured  
 The authors concluded that acute exposure to tobacco 
smoking as well as to e-cigarettes influences vascular and 
respiratory function. Where tobacco smoking significantly 
increased microparticle formation, indicative of possible 
endothelial injury, e-cigarette use induced vasoreactivity 
and decreased peak expiratory flow. These findings suggest 
that both e-cigarette and tobacco smoking negatively 
impact vascular and respiratory function. 
Randomised 
crossover trial 
4.4.2.5 Oral diseases: interventional trials 
Three interventional trial papers reported on the association between e-cigarette use and oral health 
outcomes (Table 50). Outcomes were perfusion of buccal mucosal tissue,375 gingival inflammation,376 





One trial reported that e-cigarettes may improve blood flow to the oral mucosa, although further 
trials are needed to show whether they improve healing time after surgery.375 The authors of another 
trial concluded that there was a statistically significant increase in gingival inflammation when 
tobacco smokers switched from smoking to vaping for 2 weeks.376  
 










Benefit The authors reported on the immediate effects of e-cigarettes on 
perfusion in buccal mucosal tissue in non-smokers. 
Comparative groups 
Comparison of volunteers (who were currently non-smokers, of note, 
other smoking and e-cigarette related behaviours were not described in 
summary) using: 
(1) e-cigarette containing no nicotine in e-liquid  
(2) e-cigarette continuing 16 mg nicotine in e-liquid  
The authors concluded that e-cigarettes may influence blood flow 
to the oral mucosa, although further trials are needed to show 








Harm The authors reported findings from a pilot study on gingival 
response when smokers switched from smoking to vaping. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users (≥ 10 
tobacco cigarettes per day, for ≥ 5 years and not intending to quit at 
baseline) with: 
(1) blu PRO e-cigarette with 18mg nicotine 
The authors concluded that there was a statistically significant 
increase in gingival inflammation when tobacco smokers 
switched from smoking to vaping for 2 weeks, but results should 












The authors reported on findings following the monitoring of 
nicotine intake from e-cigarettes; specifically, the measurement 
of parent drug and metabolites in oral fluid and plasma. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users (≥ 3 
tobacco cigarettes per day, for ≥ 1 year and not tried e-cigarettes at 
baseline) using: 
(1) a second-generation e-cigarette (Nhoss®, e-liquid 16 mg/mL nicotine, 
flavour “blond”, France)  
(2) tobacco cigarette (Marlboro®, 0.8 mg nicotine per cigarette, USA) 
The authors concluded that the obtained results support the 
measurement of nicotine and metabolites in oral fluid in the 
assessment of intake after e-cigarette use and appear to be a 
suitable alternative to plasma when monitoring nicotine delivery 




4.4.2.6 Developmental and reproductive effects: interventional trials 
There were no interventional trials on the association between e-cigarette use and developmental 
and reproductive effects outcomes. 
4.4.2.7 Injuries and poisonings: interventional trials 
There were no interventional trials on the relationship between e-cigarettes and injuries or 






4.4.2.8 Exposure to e-cigarette toxins: interventional trials 
There were 13 interventional trials reporting on the relationship between e-cigarettes and exposure 
to e-cigarette toxins outcomes (Table 51). The trials measured the toxicants – including nicotine 
equivalents, major nicotine metabolites, and a range of other volatile organic compounds – and 
assessed biomarkers of harmful and potentially harmful constituents of e-cigarette toxicants. A list of 
harmful and potentially harmful constituents is presented in Appendix 8. 
The outcomes assessed included:  
• Nicotine exposure, measured by the following nicotine metabolites: 3-hydroxycotinine, cotinine, 
nicotine, cotinine N-oxide, nicotine N-oxide, norcotinine, nornicotine, and nicotine equivalents 
• Tobacco exposure, measured by the following nitrosamine: 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)  
• Selected carcinogens and toxicants, measured as biomarkers of urine concentration 
• Toxic gases, including exhaled carbon monoxide and carboxyhaemoglobin 
Eight trials reported that toxin levels associated with smoking conventional tobacco cigarettes were 
lower in persons who had switched from using conventional tobacco cigarettes to using e-
cigarettes.378-385 Three studies examined e-cigarettes’ ability to deliver nicotine and concluded that it 
was not as good as the conventional cigarette,384 386 387 but two of these studies reported they was as 
good as or better than nicotine replacement therapy products.384 387 One paper reported that e-
cigarette users had higher concentrations of methylating agent metabolites388 and another paper 
reported that e-cigarettes negatively impacted psychomotor performance, and, in some instances, 
produced detectable levels of a urine alcohol metabolite.389 
















The authors reported on carboxyhaemoglobin levels, and on 
health and lifestyle perceptions in smokers converting from 
tobacco cigarettes to e-cigarettes. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(median cigarette per day 20.0 [range 10-30]and median spending on 
cigarettes R700 [range R400 - R1000] per month; heavy and 
longstanding smokers at baseline) with: 
(1) Twisp e-cigarette 
The authors concluded that smoking the Twisp e-cigarette may 













The authors reported on the nicotine intake from e-cigarettes 
following initial use and after 4 weeks of regular use. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(mean cigarettes per day 25, interested in quitting and not having 
previously used e-cigarettes for ≥1 week at baseline) with: 
(1) a first-generation Green Smoke e-cigarette with cartridges labelled 
2.4% nicotine tobacco flavoured 
The authors concluded that first-generation e-cigarettes 
provide faster nicotine absorption than nicotine replacement 
products, but to compete successfully with conventional 
combustible tobacco cigarettes, e-cigarettes may need to 
provide higher doses of nicotine. Nicotine intake from e-
cigarettes can increase with practice, but further trials are 
























The authors investigated exposure to carbon monoxide (CO), 
nicotine (by measuring cotinine in urine), and acrolein (by 
measuring its primary metabolite, S-(3-hydroxypropyl) 
mercapturic acid (3-HPMA) in urine) in smokers and e-
cigarette users. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(interested in quitting and not having previously used e-cigarettes for 
≥1 week at baseline) using: 
(1) a first-generation Green Smoke e-cigarette with cartridges labelled 
2.4% nicotine tobacco flavoured which was used exclusive for four 
weeks  
(2) a first-generation Green Smoke e-cigarette with cartridges labelled 
2.4% nicotine tobacco flavoured which was used in combination with 
conventional tobacco cigarettes for four weeks 
The authors concluded that a significant reduction in carbon 
monoxide was observed in e-cigarette users and dual users of 
e-cigarettes and conventional combustible tobacco cigarettes. 
Cotinine levels also declined, but to a lesser extent at 17% 
decrease compared to their baseline measure; and dual users 
at 44% decrease. Mean acrolein (3-HPMA) levels had 
decreased at 4 weeks, with a 79% decrease in e-cigarette-only 
users compared to their baseline measure and a 60% decrease 
in dual users. In dual users, e-cigarette use significantly 
reduced exposure to carbon monoxide and acrolein because of 
a reduction in smoke intake. E-cigarettes may reduce harm 
even in smokers who continue to smoke, but long-term follow-














The authors reported on reductions in biomarkers of 
exposure to harmful or potentially harmful constituents 
following partial or complete substitution of cigarettes with e-
cigarettes in adult smokers. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users (≥ 
10 tobacco cigarettes per day for ≥ 1 year and never previously used e-
cigarettes at baseline) using: 
(1) a closed system rechargeable blu e-cigarette with tobacco flavour  
(2) a closed system rechargeable blu e-cigarette with cherry flavour  
(3) a closed system disposable blu e-cigarette with to cherry tobacco 
flavour 
The authors concluded that the levels of urinary biomarkers in 
subjects who completely substituted their usual conventional 
combustible tobacco cigarettes with e-cigarettes were 
significantly lower (29–95%) after 5 days. Percentage 
reductions in eight of nine urinary biomarkers of exposure 
were indistinguishable from smokers who had quit smoking, 
except for nicotine equivalents, which declined by 25–40%. 
Dual users who halved self-reported daily cigarette 
consumption by replacing them with e-cigarettes exhibited 
reductions (7–38%) in eight of nine urinary biomarkers but had 
increased (1–20%) nicotine equivalents. Reductions were 
broadly proportional to the reduced numbers of cigarettes 
smoked. Dual user urinary nicotine equivalents were slightly 
higher when compared to other groups (e-cigarette only group 
and non-user or cessation group), but not statistically 
significant. After 5 days, blood nicotine biomarker levels were 
lower in the and non-user or cessation group (75–96%) and 
exclusive e-cigarette use group (11–83%), with dual users 
experiencing no significant reductions. All subjects 













Interventional trial papers on exposure to e-cigarette toxins Trial design 
monoxide; these decreases in the cessation and exclusive use 
groups ranged from 88–89%, and from 27–32% in dual users. 
Exhaled fractional nitric oxide concentration in exhaled breath 
(FeNO) increased in the cessation and exclusive use groups 
(46% and 63%, respectively), whereas the dual users 
experienced minimal changes. Overall, smokers who 
completely or partially substituted conventional combustible 
tobacco cigarettes with e-cigarettes over 5 days experienced 




Equal harm The authors reported on acute active and e-cigarette changes 
on antioxidant responses and subsequent pathologies 
measuring redox status. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(smoke ≥ 15 tobacco cigarettes per day at baseline) using: 
(1) a control session  
(2) an active tobacco cigarette smoking session (smoked 2 cigarettes 
within 30-min)  
Comparison(s) of non -smokers (conventional combustible tobacco 
cigarette) using: 
(1) a control session  
(2) a passive tobacco cigarette smoking session (exposure of 1 h to 23 
± 1ppm of CO in a 60m3 environmental chamber)  
(3) a passive e-cigarette smoking session (exposure of 1 h to air 
enriched with pre- determined number of puffs in a 60m3 
environmental chamber 
The authors concluded that tobacco and e-cigarette smoking 
exposure do not acutely alter the response of the antioxidant 
system, under either active or passive smoking conditions. 
Overall, there is no distinction between tobacco and e-








Harm The authors reported on the effects of alcohol-containing e-
cigarettes on young adult smokers. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(daily or sometimes use of cigarettes in the past six months [mean 
smoking years: 8.7 years] and use of an e-cigarette ≥ 1 in the previous 
year) using: 
(1) the Joyetech eGo-C without measurable levels of alcohol  
(2) the Joyetech eGo-C with 0.1 to 0.7% alcohol  
(3) the Joyetech eGo-C with 1.0 to 3.0% alcohol  
(4) the Joyetech eGo-C with 23.5% alcohol 
The authors concluded that brief use of a widely available type 
of e-cigarette containing an e-liquid purchased from an 
Internet vendor can negatively impact psychomotor 
performance and, in some instances, produce detectable 













The authors reported on the relationship of e-cigarettes with 
a range of carcinogens and toxicants. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users (≥ 
5 tobacco cigarettes per day for ≥ 1 year and able to use e-cigarettes 
safely at baseline) with: 
(1) a pen-style M201 e-cigarettes with 11.0mg of nicotine and 
tobacco-flavoured 
The authors concluded that the study showed that after 
switching from tobacco to e-cigarettes, nicotine exposure 
remains unchanged, while exposure to selected carcinogens 
and toxicants is substantially reduced. These findings suggest 
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carcinogenic substances among smokers who switched to e-










The authors reported on the nicotine delivery profiles and 
harmful constituent exposures of second-generation and 
third-generation e-cigarette users. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(mean cigarette per day 18.4; exclusive smoker for ≥ 3 months) using: 
(1) e-cigarette users used their own device and e-liquid with their 
preferred flavour and nicotine concentration. 
(2) third- (G3) e-cigarette device 
(3) second-generation (G2) e-cigarette devices 
Comparison of e-cigarette users themselves (who were exclusive, 
using same style of e-cigarette non-modified G2 device for ≥ 3 
months) or (who were exclusive, using same style of e-cigarette non-
modified G3 device for ≥ 3 months) using: 
(1) e-cigarette users used their own device and e-liquid with their 
preferred flavour and nicotine concentration. 
(2) third- (G3) e-cigarette device 
(3) second-generation (G2) e-cigarette devices 
The authors concluded that while baseline cotinine 
concentration levels among exclusive smokers, second-
generation e-cigarette users, and third-generation e-cigarette 
users are similar (which may have implications for addiction 
and e-cigarettes’ viability as a substitute for smoking), second-
generation and third-generation e-cigarette users had 
significantly lower levels of exposure to a potent lung 





Yuki et al.386 
2017 
Harm The authors reported on the pharmacokinetics of nicotine 
following the use of a prototype novel tobacco vapour 
product in comparison to a conventional combustible tobacco 
cigarette. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(mean cigarette per day 18.1 and mean smoking history of 18.9 years; 
smoke ≥ 11 tobacco cigarettes per day for ≥ 1 year at baseline) using: 
(1) a prototype novel tobacco vapor (PNTV) product described as a 
power supply unit, a cartridge with a heater and liquid, a capsule filled 
with tobacco blend which generate a nicotine free vapour  
(2) commercially available conventional cigarette (1 mg tar and 0.1 mg 
nicotine) 
The authors concluded that the results suggest that the 
prototype novel tobacco vapour product shows a similar 
pharmacokinetic profile to conventional combustible tobacco 














The authors reported on the relationship between tobacco 
and e-cigarette use with a range of biomarkers including 
carbon monoxide (CO), 1-hydroxypyrene (1-HOP), and 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL). 
Comparative groups 
Comparison of dual users (conventional combustible tobacco cigarette 
[≥5] daily and e-cigarettes daily [previous 7 days]) using: 
(1) dual users’ session  
(2) tobacco cigarette users’ session  
(3) e-cigarette users’ session  
(4) no product user session 
Comparison of e-cigarettes users themselves (daily for previous 7 
days) using the same four interventions.  
The authors concluded that although dual use may reduce 













Interventional trial papers on exposure to e-cigarette toxins Trial design 
abstaining from smoking is the most effective way to reduce 
such exposure. They also stated that public health authorities 
should clearly communicate the relative risk of e-cigarettes 










The authors reported on the outcome levels of a range of 
biomarkers of tobacco exposure after smokers switch to an 
e-cigarette or nicotine gum. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(who smoke ≥ 10 tobacco filtered cigarettes per day and smoke first 
cigarette within 30 minutes of waking at baseline) with: 
(1) Vuse Solo Digital Vapor Cigarettes (Original - tobacco flavour)  
(2) Vuse Solo Digital Vapor Cigarettes (Menthol)  
(3) Nicorette 4 mg nicotine gum 
The authors concluded that exposure to toxicants when using 
Vuse Solo is significantly reduced compared with combustible 
cigarette smoking, and these reductions are similar to those 
observed with use of nicotine gum. Although nicotine 
exposure is significantly reduced, Vuse Solo maintained closer 
to conventional combustible tobacco cigarette smoking 
compared with nicotine gum use. This research suggests that 
use of Vuse Solo exposes consumers to fewer and lower levels 
of smoke toxicants than combustible cigarettes, while still 













The authors reported on exhaled carbon monoxide levels in 
smokers after fully switching to e-cigarettes or to a tobacco 
heating system. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(mean cigarette per day 21.7 and mean smoking history of 31 years 
either unwilling or unable to stop smoking at baseline and requesting 
a switch to reduced risk products) using: 
(1) a low potential e-cigarette (disposable, pre-filled cartridge, low–
medium supply power, nicotine 18mg/ml)  
(2) tobacco heating system 2.2 (sticks with mean nicotine content of 
0.50 mg per stick 
The authors concluded that reduced levels of percentage 
carboxyhaemoglobin did not significantly differ between the 
two groups, while the tobacco heating system group had a 
significantly greater reduction in levels of carbon monoxide 
versus the e-cigarette group. Both e-cigarettes and tobacco 
heating systems are capable of significantly reducing exhaled 
carbon monoxide at least in the medium term, hence 
constituting a viable tobacco harm-reduction approach in 





St. Helen et 
al.388 
2020 
Harm The authors reported on the relationship between e-cigarette 
use, conventional combustible tobacco cigarette use, and 
abstention from smoking with a range of volatile organic 
compounds (specifically 10 mercapturic acid metabolites of 
volatile organic compounds). 
Comparative groups 
Comparisons of dual users (e cigarettes [mean times per day 8.1 and 
mean days used in previous month was 22.6 days] and conventional 
combustible tobacco cigarettes [mean per day 12.9] using: 
(1) ad libitum vaping using cig-a-like e-cigarette  
(2) ad libitum vaping using fixed-power tanks  
(3) ad libitum vaping using variable-power tanks  
(4) pod e-cigarettes all JUULs  
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The authors concluded that concentrations of volatile organic 
compound metabolites were higher during smoking compared 
with during vaping, except for the methylating agents’ 
metabolite. Metabolites of acrylamide were higher during 
vaping compared with abstention. The 1,3-butadiene and 
propylene oxide metabolites were higher in variable-power 
tank users compared with users of cigalikes. E-cigarettes 
expose users to lower levels of toxic volatile organic 
compounds compared with cigarette smoking. However, some 
e-cigarettes expose users to volatile organic compounds such 
as acrylamide, benzene, and propylene oxide, and may pose 
health risks to non-smoking users. 
 
4.4.2.9 Other outcomes: interventional trials 
Seven interventional trials reported on in other outcomes (Table 52). The outcomes measured were 
puffing topography, adverse events associated with two e-cigarette brands, weight status, other 
disease-related outcomes, and second-hand vaping.  
One paper concluded that puff topography adapted to maximise nicotine intake from e-cigarettes. 391 
Two papers reported the safety profiles of two e-cigarettes. One paper reported that in the short 
term, e-cigarette users had lower toxin levels (benzene, acrolein, and NNK) than those found in 
tobacco cigarette smokers.392 The second paper concluded that there were few serious adverse 
events during the 24 months of Puritane™ use, and none were related to use of the vaping product.393 
A single paper concluded that smokers who quit smoking by switching to e-cigarettes may limit their 
post-smoking cessation weight gain, with reversal in any weight gain at later timepoints. 394 
A trial with one person reported that nicotine administered via e-cigarettes may reduce levodopa-
induced dyskinesia in patients with Parkinson’s disease.395 
There were two papers on second-hand smoking. Two papers reported that non-users absorbed 
nicotine from e-cigarettes, 396 397 and one of these papers reported negative cardiac autonomic effects 
by measuring heart rate variability. 396  










Harm The authors reported on how initial puffing behaviours and 
subjective responses differ between an electronic nicotine 
delivery system (ENDS) and conventional combustible 
tobacco cigarettes. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(exclusive in the previous 30 days, smoke ≥ 10 tobacco filtered 
cigarettes per day and did not intend to quit at baseline) using: 
(1) smoking own cigarette using the portable CReSS* device  
(2) e-cigarette TRIO-3 first generation with 11mg nicotine using the 
portable CReSS* device. 
*The CReSS device was used to record smoking topography 
The authors concluded that ENDS were smoked more 
intensively than own brand cigarettes, but delivered 
significantly less nicotine and were less satisfying. These 
findings have implications for the viability of certain ENDS as 
























The authors undertook a randomised, parallel group study in 
order to evaluate the safety profile of an e-vapour product 
over 12 weeks. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(smoke between 5 and 30 tobacco cigarettes daily at baseline) using: 
(1) e-vapour protype 2.0% nicotine  
(2) conventional cigarette 
From this trial, the authors reported the safety profile of an e-
vapour product (2.0% nicotine) in smokers of conventional 
combustible tobacco cigarettes switching to using an e-vapour 
product for 12 weeks. During the study, no clinically significant 
product-related findings were observed in terms of vital signs, 
electrocardiogram, lung function tests, and standard clinical 
laboratory parameters. Adverse events reported by e-vapour 
product subjects were more frequent during the first week 
after switching to the e-vapour product. Only 6% of 1515 
adverse events were judged as being probably or definitely 
related to an e-vapour product. Additional observations in e-
vapour product subjects included a decrease in the level of 
urine nicotine equivalents by up to 33.8%, and decreases in the 
level of three biomarkers of exposure to toxicants known to be 
present in tobacco cigarette smokers (benzene, acrolein, and 
NNK). The decrease in nicotine equivalents coincided with an 
increase in nicotine withdrawal symptoms, measured by a 
questionnaire, which subsided after 2 weeks. The data 
presented here show the potential that e-vapour products may 












The authors reported on the sensory effects of menthol and 
nicotine in an e-cigarette. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(smoke menthol flavoured tobacco cigarettes daily for ≥ 1 year at 
baseline) with e-cigarettes containing: 
(1) 0 mg/ml nicotine and 0% menthol  
(2 0 mg/ml nicotine and 0.5% menthol  
(3) 0 mg/ml nicotine and 3.5% menthol  
(4) 6 mg/ml nicotine and 0% menthol  
(5) 6 mg/ml nicotine and 0.5% menthol  
(6) 6 mg/ml nicotine and 3.5% menthol  
(7 12 mg/ml nicotine and 0% menthol  
(8) 12 mg/ml nicotine and 0.5% menthol  
(9) 12 mg/ml nicotine and 3.5% menthol  
(10) 18 mg/ml nicotine and 0% menthol  
(11) 18 mg/ml nicotine 0.5% menthol  
(12) 18 mg/ml nicotine 3.5% menthol  
(13) 24 mg/ml nicotine and 0% menthol  
(14) 24 mg/ml nicotine and 0.5% menthol 
The authors concluded that menthol can potentially improve 
the appeal of e-cigarettes not only via its coolness and minty 
flavour, but also by reducing the harshness from high 







Benefit The authors investigated the effectiveness of nicotine delivered 
through e-cigarettes for managing levodopa-induced 
dyskinesia, associated with Parkinson’s disease, with nicotine  
The authors used the term ‘patient-driven N-of-1’ for self-
tracking the effect, in this instance, managing levodopa-
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Comparison(s) of never-smoker (conventional combustible tobacco 
cigarette) using: 
(1) e-cigarette with nicotine 3 mg/ml  
(2) e-cigarette without nicotine 
The authors concluded that nicotine administered via e-
cigarettes may have a reducing effect on levodopa-induced 
dyskinesia in individual patients with Parkinson’s disease. 
Lee et al.396 
2018 
Harm The authors reported on the effects of second-hand exposure 
to nicotine from e-cigarettes. 
Comparative groups 
Comparison(s) of never smokers (conventional combustible tobacco 
cigarette) with: 
(1) e-cigarette with 1.8% nicotine exposure sessions 
The authors concluded that there are cardiac autonomic 
effects of short-term second-hand exposure to nicotine from e-







Harm The authors measured the systemic absorption of nicotine 
following acute second-hand exposure to e-cigarette aerosol 
in a realistic social setting. 
Never users of combustible tobacco products (never smoked more 
than 100 cigarettes in their lifetime), no use in the past year of non-
combustible tobacco products (smokeless tobacco) or nicotine 
replacement therapies. Nonusers agreed to abstain from exposure to 
secondhand tobacco smoke or e-cigarette aerosol for 6 days before 
each exposure. 
Comparative groups 
The 3 e-cigarette users were the intervention itself. They vaped in front 
of the 3 never smokers who were the participants: 
The e-cigarettes used were: 
(1) iTaste variable voltage tank java with a mean nicotine content of 
15.1 mg/ml  
(2) iTaste variable voltage tank swiss cherry with a mean nicotine 
content of 15.1 mg/ml  
(3) iTaste variable voltage tank peach with a mean nicotine content of 
15.1 mg/ml  
(4) blu disposable e-cigarette classic tobacco with a mean nicotine 
content of 15.1 mg/ml  
(5) blu disposable e-cigarette cherry crush with a mean nicotine 
content of 15.1 mg/ml  
(6) Fling ice berry disposable e-cigarette with a mean nicotine content 
of 15.1 mg/ml (java, swiss cherry and peach) 
The authors concluded that although exposures may vary 
considerably, non-users can systemically absorb nicotine 















The authors reported on the safety profile of Puritane™, a 
closed-system e-vapour product, when used by smokers of 
conventional combustible tobacco cigarettes in a real-life 
setting over a 24-month period.  
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(smoke between 5 and 30 tobacco cigarettes daily for ≥ 1 year) using: 
(1) Puritane, a closed system electronic vapour product  
(2) usual own brand conventional combustible tobacco cigarette 
The authors concluded that few serious adverse events, or 
withdrawals due to adverse events, occurred during the 24 
months of Puritane™ use, none of which were related to use of 
the e-vaping product. The authors concluded that the use of 
the e-vaping product for up to 2 years in this study appears to 
be an acceptable alternative for smokers, with the advantage 









5 Findings: heat-not-burn harms and benefits 
5.1 Introduction 
We categorised the papers on the possible benefits and harms of heat-not-burn products according 
to epidemiological study design in order to assign a notional hierarchy of evidence to the literature. 
We firstly present descriptive studies (case series, case reports, and surveillance studies) that are 
deemed to provide the lowest level of epidemiological evidence. We then present observational 
studies (cross-sectional surveys, case-control studies, and longitudinal cohort studies), and end with 
interventional trials, that are deemed to provide the highest level of epidemiological evidence. The 
hierarchy of evidence does not include surveillance reports; additionally, only some of its depictions 
include cross-sectional surveys. However, we included these studies to present a comprehensive map 
of heat-not-burn products’ harms and benefits. There were 28 peer-reviewed papers on the harms 
and benefits of heat-not-burn products; these comprised 2 case reports, 1 cross-sectional survey, and 
25 interventional trials. 
Within each study design, the possible benefits and harms outcomes that were identified through this 
mapping exercise are presented under nine headings. Seven of the headings were identified by the 
United States National Academies of Sciences, Engineering, and Medicine for classifying health 
research on tobacco products: (i) dependence and abuse liability; (ii) cardiovascular diseases; (iii) 
cancers; (iv) respiratory diseases; (v) oral diseases; (vi) developmental and reproductive effects; and 
(vii) injuries and poisonings. We added two further categories for outcomes that did not align with the 
Academies of Sciences’ framework; these were: (viii) exposure to heat-not-burn toxins; and (ix) other 
outcomes.6 
The heat-not-burn papers are categorised under the following adapted Academies of Sciences’ 
umbrella terms: dependence and abuse liability (5 papers), cardiovascular diseases (8 papers), 
respiratory diseases (3 papers), and exposure to heat-not-burn toxins (12 papers). There are no peer-
reviewed papers reporting on outcomes of cancers, oral diseases, developmental and reproductive 
effects, or injuries and poisonings. However, it should be noted that many of the papers grouped 
under the heading ‘exposure to heat-not-burn toxins’ report on outcomes which have been identified 
as definite or probable causes of a range of carcinogenic or neurological pathologies. 
Summaries of the included heat-not-burn articles are presented in tables, which are organised by the 
nine outcome categories and by study design. We observed that the trial papers included in Section 5 
of the report were written by either industry- or academic-based authors, and we have organised the 
tables to reflect the authors’ place of work. In addition, we observed in several instances that the 
same lead trial author reported on studies employing a very similar design and frequently testing the 
same product, or a close variation of it, in different geographical populations. Therefore, in order to 
ensure a better understanding of the relationship pattern between the exposure and the outcome, 
the papers by the same team of authors are grouped by team, then by product, and then listed in 
chronological order.  









Figure 5 PRISMA flow chart 
Records included after title and 
abstract screening: n=551 
(e-cigarettes: n=526;  
heat-not-burn devices: n=25) 
Records excluded: n=5,675 
Duplicate records excluded 
n=8,163 
Records assigned to other review 
questions: n=284 
Records reassigned from e-cigarettes to 
heat-not-burn devices: n=5 
Records included after full-text 
screening: n=369 
(e-cigarettes: n=339;  
heat-not-burn devices: n=30) 
Records excluded from e-cigarettes: 
n=182 
Records after duplicates removed 
n=6,510 
Papers included in final analysis 
n=388 
(e-cigarettes: n=361; 
 heat-not-burn devices: n= 28) 
(Note: One paper is included in both 
e-cigarettes and heat-not-burn 
devices: (Adriaens, 2018)1 
Records included from supplemental 
results: n=96 (e-cigarettes: n=96) 
Records excluded from final analysis: 
n=76 (e-cigarettes: n=74; heat-not-burn 
devices: n=2) 
Records reassigned from e-cigarettes to 
both e-cigarettes and heat-not-burn 
devices: n=1 
Records identified through database, search engine and repository searches (n=14,673) 
(Databases: MEDLINE: n=3,874; Embase: n=4,212; PsycINFO: n=1,519; Cochrane Central Register of 
Controlled Trials: n=527; Cochrane Database of Systematic Reviews: n=14; LILACS: n=4,042; PROSPERO: 
n=93) 






5.1.1 Outcomes assessed in the heat-not-burn papers 
We categorised the papers’ outcome indicators of harms or benefits of heat-not-burn products under 
the adapted Academies of Sciences framework headings. The indicators included psychological and 
physical measures of health and well-being. Broadly speaking, psychological measures were assessed 
using validated questionnaires. Biological measures were evaluated through assessment of organ and 
tissue functionality, or through other biological measures such as breath, blood, or urine levels of 
toxic or potentially toxic substances. The papers’ authors reported toxic substances by acronym, the 
biomarker of exposure, or as a group titled ‘harmful or potentially harmful smoke constituents’. We 
have reported the terms used by the papers’ authors in the tabulated summaries. Some indicators did 
not exclusively align with individual adapted Academies of Sciences’ umbrella terms. For example, 
measures of nicotine were regarded as indicators of dependence and abuse liability, but they also 
fitted under the umbrella term ‘exposure to heat-not-burn toxins’. Similarly, assessments of organ 
and tissue functionality – for example, symptom-limited spiroergometry, which includes measures 
such as oxygen uptake – can be employed to assess aspects of both respiratory and cardiovascular 
function.  
5.1.2 Harms or benefits 
The principal focus of this mapping exercise was on mapping the harms and the benefits of heat-not-
burn products. However, a determination of whether an outcome was considered a harm or a benefit 
was made by taking account of the relative or absolute nature of the relationship being examined. In 
other words, the effect of the heat-not-burn product(s) was assessed relative to whether the 
comparison group comprised non-smokers, smokers currently abstaining from smoking, smokers of 
conventional [combustible] tobacco cigarettes, vapers of e-cigarettes, or poly (or dual) users of two or 
more smoking-related products. For the trial papers, we have reported the authors’ conclusions 
regarding their assessment of the effect of the heat-not-burn products on damage or injury to 
biological tissue, or on levels of toxicants measured. Therefore, in order to contextualise the harm or 
benefit of the reported exposure-outcome relationship, we have also provided details on the smoking 
and vaping behaviours of study participants with whom the comparisons have been made.  
5.1.3 Paper characteristics 
Possible harms and benefits associated with heat-not-burn products are reported in 28 peer-reviewed 
papers. Stratification by the research study design identified 2 case reports, 1 cross-sectional survey, 
and 25 interventional trials. 
Five papers were authored by persons who were based in, or affiliated with, a university or hospital. 
Of these, two were case reports that presented findings on respiratory outcomes, one was a cross-
sectional survey that reported on dependence and abuse liability, and two were interventional trials. 
One of these trials reported on dependence and abuse liability and the other reported on 
cardiovascular outcomes.  
The remaining 23 papers were reporting the results of trials and authored by employees of the 
tobacco industry, including companies such as Philip Morris and Altria Client Services, R. J. Reynolds 
Tobacco Company, and Japan Tobacco International. Three papers were authored by Philip Morris 
employees, including employees with both tobacco industry and university affiliations. Industry-
authored papers on trial results focused on the following areas: dependence and abuse liability, 
cardiovascular diseases, respiratory diseases, and exposure to heat-not-burn toxins. Several trial 
papers reported findings which could be placed under two or more umbrella terms (for example, 
‘cardiovascular diseases’ and ‘exposure to heat-not-burn toxins’). Where this occurred, papers were 
placed under the umbrella term that best reflected the principal focus of the trial.  
Overall, outcomes were rarely clinical diseases or pathological features considered collectively to 
reflect the typical behaviour of a disease. A rare exception was the diagnosis of acute eosinophilic 
pneumonia in two case reports. More frequently, study outcomes represented a laboratory-based 
examination of body tissue to assess body system, organ, or tissue health or function, or toxicity 





5.2 Descriptive epidemiological studies: heat-not-burn products 
We grouped three papers within this section: two case reports and one paper reporting findings from 
a cross-sectional survey. The authors of the case reports described two individual cases of hospital 
admissions due to adverse respiratory outcomes (specifically acute eosinophilic pneumonia). The 
cross-sectional survey reported on psychological measures of well-being – specifically perceived 
stress – in addition to other behavioural outcomes. 
5.2.1 Case reports: heat-not-burn products 
There were two case reports on the relationship between heat-not-burn products and any of the 
adapted Academies of Sciences’ framework headings. Both case reports described harms associated 
with respiratory disease outcomes (acute eosinophilic pneumonia) in young males living in Japan. One 
case occurred in 2016 and the other in 2018. Both cases recovered following hospital-based 
treatment.  
5.2.1.1 Dependence and abuse liability: case reports 
There were no case reports on the relationship between heat-not-burn products and dependence and 
abuse liability outcomes. 
5.2.1.2 Cardiovascular diseases: case reports  
There were no case reports on the relationship between heat-not-burn products and cardiovascular 
disease outcomes. 
5.2.1.3 Cancers: case reports  
There were no case reports on the relationship between heat-not-burn products and cancer 
outcomes. 
5.2.1.4 Respiratory diseases: case reports 
There were two case reports on the relationship between heat-not-burn products and respiratory 
disease outcomes (Table 53). Both case report papers described a diagnosis of acute eosinophilic 
pneumonia: one case occurred immediately after first use of a heat-not-burn product by a 16-year-
old male,398 and the other occurred after a 6-month period of use by a 20-year-old male.399 Both cases 
recovered following hospital-based treatment. In both cases, the authors, who were clinical 
practitioners, concluded that the use of heat-not-burn products was the likely causal agent. 
Table 53 Case reports on respiratory diseases, benefits or harms 
Author(s), year Possible 
benefit 
or harm 
Case reports on respiratory diseases, benefits or harms 
Kamada et al. 
399 
2016 
Harm Product: Unidentified device for smoking heat-not-burn cigarettes 
Dose taken or reported relevant behaviour: 20 heat-not-burn cigarettes per 
day over the previous 6 months, and who had recently purchased a second 
device for smoking heat-not-burn cigarettes. As a result of purchasing this 
second device, he had increased his smoking to 40 cigarettes per day 2 weeks 
Outcome: Acute eosinophilic pneumonia  
Aokage et al. 398 
2018 
Harm  
Product: Heat-not-burn tobacco product 
Dose taken or reported relevant behaviour: First smoking heat-not-burn 
cigarettes 
Outcome: Acute eosinophilic pneumonia 
5.2.1.5 Oral diseases: case reports 






5.2.1.6 Developmental and reproductive effects: case reports  
There were no case reports on the relationship between heat-not-burn products and developmental 
and reproductive effects outcomes. 
5.2.1.7 Injuries and poisonings: case reports  
There were no case reports on the relationship between heat-not-burn products and injuries and 
poisonings outcomes. 
5.2.1.8 Exposure to heat-not-burn toxins: case reports 
There were no case reports on the relationship between heat-not-burn products and exposure to 
heat-not-burn toxins outcomes. 
5.2.1.9 Other outcomes: case reports 
There were no case reports on the relationship between heat-not-burn products and other outcomes. 
5.2.2 Case series: heat-not-burn products 
There were no case series papers on the relationship between heat-not-burn products and any of the 
adapted Academies of Sciences’ framework headings. 
5.2.2.1 Dependence and abuse liability: case series  
There were no case series papers on the relationship between heat-not-burn products and 
dependence and abuse liability outcomes. 
5.2.2.2 Cardiovascular diseases: case series  
There were no case series papers on the relationship between heat-not-burn products and 
cardiovascular disease outcomes. 
5.2.2.3 Cancers: case series  
There were no case series papers on the relationship between heat-not-burn products and cancer 
outcomes.  
5.2.2.4 Respiratory diseases: case series papers 
There were no case series papers on the relationship between heat-not-burn products and 
respiratory disease outcomes. 
5.2.2.5 Oral diseases: case series  
There were no case series papers on the relationship between heat-not-burn products and oral 
disease outcomes. 
5.2.2.6 Developmental and reproductive effects: case series  
There were no case series papers on the relationship between heat-not-burn products and 
developmental and reproductive effects outcomes.  
5.2.2.7 Injuries and poisonings: case series  
There were no case series papers on the relationship between heat-not-burn products and injuries 
and poisonings outcomes. 
5.2.2.8 Exposure to heat-not-burn toxins: case series 
There were no case series papers on the relationship between heat-not-burn products and exposure 





5.2.2.9 Other outcomes: case series  
There were no case series papers on the relationship between heat-not-burn products and other 
outcomes. 
5.2.3 Information or surveillance system reports: heat-not-burn products 
There were no information or surveillance systems papers on the relationship between heat-not-burn 
products and any of the adapted Academies of Sciences’ framework headings. 
5.2.3.1 Dependence and abuse liability: surveillance system reports  
There were no information or surveillance systems papers on the relationship between heat-not-burn 
products and dependence and abuse liability outcomes. 
5.2.3.2 Cardiovascular diseases: surveillance system reports 
There were no information or surveillance systems papers on the relationship between heat-not-burn 
products and cardiovascular disease outcomes.  
5.2.3.3 Cancers: surveillance system reports 
There were no information or surveillance systems papers on the relationship between heat-not-burn 
products and cancer outcomes.  
5.2.3.4 Respiratory diseases: surveillance system reports 
There were no information or surveillance systems papers on the relationship between heat-not-burn 
products and respiratory disease outcomes.  
5.2.3.5 Oral diseases: surveillance system reports 
There were no information or surveillance systems papers on the relationship between heat-not-burn 
products and oral disease outcomes.  
5.2.3.6 Developmental and reproductive effects: surveillance system reports 
There were no information or surveillance systems papers on the relationship between heat-not-burn 
products and developmental and reproductive effects outcomes. 
5.2.3.7 Injuries and poisonings: surveillance system reports 
There were no information or surveillance systems papers on the relationship between heat-not-burn 
products and injuries and poisonings outcomes. 
5.2.3.8 Exposure to heat-not-burn toxins surveillance system reports 
There were no information or surveillance systems papers on the relationship between heat-not-burn 
products and exposure to heat-not-burn toxins outcomes. 
5.2.3.9 Other outcomes: surveillance system reports 
There were no information or surveillance systems papers on the relationship between heat-not-burn 






5.3 Observational epidemiological studies: heat-not-burn products 
5.3.1 Cross-sectional surveys: heat-not-burn products 
There was one cross-sectional survey paper on the relationship between heat-not-burn products and 
any of the adapted Academies of Sciences’ framework headings. This was under the ‘dependence and 
abuse liability’ framework heading. The survey was completed in 2018 by 60,040 schoolchildren aged 
12–18 years in South Korea, and was published in 2019. It examined the association of heat-not-burn 
tobacco products with perceived stress, frequency of physical activity, and Internet usage time, and 
the authors found an association between these variables 
5.3.1.1 Dependence and abuse liability: cross-sectional surveys 
There was one cross-sectional survey paper on the relationship between heat-not-burn products and 
dependence and abuse liability outcomes (Table 54). In the 2018 national survey of teenaged 
schoolchildren in South Korea, a series of questions on cigarettes, e-cigarettes, and heat-not-burn 
products were asked in order to assess the prevalence of use of these products and the factors 
associated with their use.400 Using odds ratios, the authors measured the associations of perceived 
stress, and other behavioural outcomes such as frequency of physical activity, with use of a range of 
tobacco-related products, including heat-not-burn tobacco products. Of 60,040 teenaged 
schoolchildren, 50,778 (85%) reported never smoking, 7,694 (13%) used cigarettes or e-cigarettes 
alone or in combination, and the remaining 1,569 (3%) schoolchildren reported using a heat-not-burn 
tobacco product alone or in combination with other tobacco-related products. The odds of 
experiencing perceived stress was greater in users who reported simultaneous use of all tobacco-
related products than in non-product users. With regard to perceived stress, frequency of physical 
activity, and Internet usage time, the authors reported that there were significant associations 
between high levels of perceived stress and cigarette-only use, dual use of cigarettes with e-
cigarettes, and triple use of cigarettes with both e-cigarettes and heat-not-burn tobacco products. An 
association between higher heat-not-burn tobacco product use and higher perceived stress was 
reported. However, the cross-sectional nature of the findings prohibited assessment of a causal 






Table 54 Cross-sectional survey papers on dependence and abuse liability, benefits or harms  
Author(s), year Possible 
benefit or 
harm 
Cross-sectional survey papers on dependence and abuse liability 




The authors reported on current tobacco product use, including heat-not-
burn tobacco products, in teenaged schoolchildren in South Korea and 
whether the use of heat-not-burn tobacco products is associated with 
perceived stress, frequency of physical activity, and Internet usage time. 
Age: 12–18 years. Sex: 30,463 males, 29,577 females. Country: South Korea 
Data source: Korean Youth Risk Behavior Web-based Survey 
Population size: 60,040 schoolchildren from a total of 800 schools (400 
middle schools and 400 high schools) participated in the survey, which had a 
response rate of 95.6%. 
Data collection period: 2018 
E-cigarettes, smoking, and other related status: The experience of the use of 
tobacco products during the participants’ lifetime to evaluate the smoking 
patterns of adolescents was assessed through questionnaires.  
Comparative exposure 
(1) Never smoker or vaper 
(2) Conventional tobacco cigarette smoker only 
(3) E-cigarettes vaper only 
(4) Heat-not-burn tobacco products user only 
(5) Conventional combustible tobacco cigarettes and e-cigarettes dual user 
(6) Conventional combustible tobacco cigarettes and heat-not-burn tobacco products 
dual user 
(7) E-cigarettes and heat-not-burn tobacco products dual user 
(8) Conventional combustible tobacco cigarettes as well as e-cigarettes and heat-not-
burn tobacco products dual user 
A single use of a tobacco product was defined as reporting the use of only 
one among the three tobacco products. Dual use refers to the use of two 
products. The tobacco ever use categories (and numbers of schoolchildren 
in each) were: never smoke (50,778); cigarettes only (4,690); e-cigarettes 
only (571); heat-not-burn tobacco products only (59); cigarettes and e-
cigarettes (2,433); cigarettes and heat-not-burn tobacco products (147); e-
cigarettes and heat-not-burn tobacco products (92); cigarettes as well as e-
cigarettes and heat-not-burn tobacco products (1,270).  
Outcomes: The association of tobacco ever use with perceived stress and 
frequency of physical activity. Students with high perceived stress had 
higher odds of using cigarettes only, dual use of cigarettes and e-cigarettes, 
and triple use of cigarettes, e-cigarettes, and heat-not-burn tobacco 
products (odds ratio [OR]: 1.11, 1.17, and 1.34, respectively). Moderate 
perceived stress was negatively associated with the use of heat-not-burn 
tobacco products only compared to low perceived stress (OR: 0.47; 95% 
confidence interval [CI]: 0.24–0.93) and Internet usage time. The prevalence 
of lifetime heat-not-burn tobacco product use was 2.9%, including single use 
(0.1%), dual use (0.5%), and triple use (2.3%). 
The authors concluded that the findings indicated that adolescents with 
high perceived stress, a high frequency of physical activity, and who spent 
less time using the Internet were more likely to engage in the use of tobacco 
products. However, the strength and direction of the relationship varied 
according to smoking product type. 







5.3.1.2 Cardiovascular diseases: cross-sectional surveys 
There were no cross-sectional surveys on the relationship between heat-not-burn products and 
cardiovascular disease outcomes. 
5.3.1.3 Cancers: cross-sectional surveys 
There were no cross-sectional surveys on the relationship between heat-not-burn products and 
cancer outcomes. 
5.3.1.4 Respiratory diseases: cross-sectional surveys 
There were no cross-sectional surveys on the relationship between heat-not-burn products and 
respiratory disease outcomes. 
5.3.1.5 Oral diseases: cross-sectional surveys 
There were no cross-sectional surveys on the relationship between heat-not-burn products and oral 
disease outcomes. 
5.3.1.6 Developmental and reproductive effects: cross-sectional surveys 
There were no cross-sectional surveys on the relationship between heat-not-burn products and 
developmental and reproductive effects outcomes. 
5.3.1.7 Injuries and poisonings: cross-sectional surveys 
There were no cross-sectional surveys on the relationship between heat-not-burn products and 
injuries and poisonings outcomes.  
5.3.1.8 Exposure to heat-not-burn toxins: cross-sectional surveys 
There were no cross-sectional surveys on the relationship between heat-not-burn products and 
exposure to heat-not-burn toxins outcomes.  
5.3.1.9 Other outcomes: cross-sectional surveys 







5.3.2 Case-control studies: heat-not-burn products 
There were no case-control studies on the relationship between heat-not-burn products and any of 
the adapted Academies of Sciences’ framework headings. 
5.3.2.1 Dependence and abuse liability: case-control studies 
There were no case-control studies on the relationship between heat-not-burn products and 
dependence and abuse liability outcomes. 
5.3.2.2 Cardiovascular diseases: case-control studies 
There were no case-control studies on the relationship between heat-not-burn products and 
cardiovascular disease outcomes. 
5.3.2.3 Cancers: case-control studies 
There were no case-control studies on the relationship between heat-not-burn products and cancer 
outcomes. 
5.3.2.4 Respiratory diseases: case-control studies 
There were no case-control studies on the relationship between heat-not-burn products and 
respiratory disease outcomes. 
5.3.2.5 Oral diseases: case-control studies 
There were no case-control studies on the relationship between heat-not-burn products and oral 
disease outcomes. 
5.3.2.6 Developmental and reproductive effects: case-control studies 
There were no case-control studies on the relationship between heat-not-burn products and 
developmental and reproductive effects outcomes. 
5.3.2.7 Injuries and poisonings: case-control studies 
There were no case-control studies on the relationship between heat-not-burn products and injuries 
and poisonings outcomes.  
5.3.2.8 Exposure to heat-not-burn toxins: case-control studies 
There were no case-control studies on the relationship between heat-not-burn products and 
exposure to heat-not-burn toxins outcomes.  
5.3.2.9 Other outcomes: case-control studies 







5.3.3 Longitudinal cohort studies: heat-not-burn products 
There were no longitudinal cohort studies on the relationship between heat-not-burn products and 
any of the adapted Academies of Sciences’ framework headings. 
5.3.3.1 Dependence and abuse liability: longitudinal cohort studies 
There were no longitudinal cohort studies on the relationship between heat-not-burn products and 
dependence and abuse liability outcomes. 
5.3.3.2 Cardiovascular diseases: longitudinal cohort studies 
There were no longitudinal cohort studies on the relationship between heat-not-burn products and 
cardiovascular disease outcomes. 
5.3.3.3 Cancers: longitudinal cohort studies 
There were no longitudinal cohort studies on the relationship between heat-not-burn products and 
cancer outcomes. 
5.3.3.4 Respiratory diseases: longitudinal cohort studies 
There were no longitudinal cohort studies on the relationship between heat-not-burn products and 
respiratory disease outcomes. 
5.3.3.5 Oral diseases: longitudinal cohort studies 
There were no longitudinal cohort studies on the relationship between heat-not-burn products and 
oral disease outcomes. 
5.3.3.6 Developmental and reproductive effects: longitudinal cohort studies 
There were no longitudinal cohort studies on the relationship between heat-not-burn products and 
developmental and reproductive effects outcomes. 
5.3.3.7 Injuries and poisonings: longitudinal cohort studies 
There were no longitudinal cohort studies on the relationship between heat-not-burn products and 
injuries and poisonings outcomes.  
5.3.3.8 Exposure to heat-not-burn toxins: longitudinal cohort studies 
There were no longitudinal cohort studies on the relationship between heat-not-burn products and 
exposure to heat-not-burn toxins outcomes.  
5.3.3.9 Other outcomes: longitudinal cohort studies 







5.4 Interventional trials: heat-not-burn products 
5.4.1 Study characterisation: heat-not-burn products 
5.4.1.1 Trial design characteristics 
There were 25 papers categorised as interventional trials (Tables 55–58). In these trials, participants 
were assigned to a heat-not-burn product(s) intervention, or control intervention(s), by the 
investigator. The investigator then measured the impact of the exposure on one or more outcomes at 
baseline and at subsequent timepoint(s). In general, in clinical laboratory-based trials, outcomes were 
assessed at specific timepoints and over a time range; in other words, data on exposure outcomes 
could be gathered near the timepoint of intervention, i.e. minutes or hours after intervention, and 
consecutively over several days. For example, data on nicotine levels (as its metabolite cotinine in 
blood) could be gathered 5 minutes post intervention, at four timepoints during each trial day, and 
for each day of the trial duration period. The laboratory trial papers included in our map of possible 
harms and benefits measured the acute impact of heat-not-burn product use on a range of outcomes 
within the time frame of the trials. Interventional trials allow quantification of the size and the 
direction of an intervention outcome effect. In the trial papers included in the map the time between 
assignment of the intervention and measurement of outcome(s) varied from hours to days. The 
interventional trial designs were controlled trials, and included randomised controlled trials and 
crossover trials. In the crossover trials, the participants were assigned to each of the interventions 
under investigation, often with a washout period before switching to the alternative intervention. 
Almost all trials were conducted in clinical laboratory settings following a standardised protocol of 
determining the device(s) and the heat-not-burn chemical compound(s) being assessed, and 
describing how to use the devices. This included issues such as tar and nicotine content, puffing 
frequency, and duration of exposure, along with how and when outcome measures were to be 
assessed.  
5.4.1.2 Heat-not-burn products  
There are different kinds of heat-not-burn tobacco products available, and the effect of each product 
varies. The authors reported on several products, and descriptions of three products are summarised 
in Sections 5.4.1.2.1, 5.4.1.2.2, and 5.4.1.2.3 in order to allow an understanding of the nature of 
products reported as part of the heat-not-burn mapping exercise. The products include, but are not 
limited to, the electrically heated cigarette smoking system (EHCSS), the tobacco heating system 
(THS), and the carbon-heated tobacco product prototype. More details on these products are 
available in the tables in Section 5.4.2.  
5.4.1.2.1 Electrically heated cigarette smoking system products 
The following examples of electrically heated cigarette smoking system products were identified in 
the interventional trial papers: the EHCSS series-K, EHCSS-K3, EHCSS-K6, EHCSS series-K lighter, and 
EHCSS series JLI.  
Broadly, the products have been described by the trial authors as follows: the electrically heated 
cigarette smoking system consists of a cigarette containing a column of standard cigarette tobacco 
filler, wrapped in a tobacco mat with a paper overwrap, which is inserted into an e-cigarette lighter 
(or puff-activated lighter). The lighter’s eight blades heat the cigarette only when the smoker takes a 
puff, thereby avoiding smouldering of the cigarette between puffs. Using this design, the tobacco 
reaches a peak temperature of approximately 500 °C during puffing. This contrasts with the burning 
cone of a lit-end the lit end of a conventional cigarette, which can reach approximately 900 °C during 
puffing. Some electrically heated cigarette smoking system devices differ in the construction of the 
filter, with later versions having a more efficient filter. The trial authors assessed that the more 
efficient filter results in reduced delivery of harmful or potentially harmful constituents in cigarette 
smoke when product versions were tested according to International Organization for 
Standardization methods. The electrically heated cigarette smoking system heater cannot be used to 
smoke conventional tobacco cigarettes. The third-generation EHCSS series-K puff-activated electrical 





It should be noted that the authors of some of the papers evaluating electrically heated cigarette 
smoking system heater products reported that the product being evaluated was not intended for sale 
on the market.  
5.4.1.2.2 Tobacco heating system products 
The following examples of tobacco heating system products were identified from the interventional 
trial papers: the THS 1.0, THS 2.1, and THS 2.2. 
The trial authors reported that the tobacco heating system is made up of three components: the 
tobacco heating system tobacco stick, the holder, and the charger. The tobacco heating system 
tobacco stick has a tobacco plug containing processed tobacco cast leaf, which is covered by a paper 
wrap. The holder includes a battery, controlling electronics, and the heater element. The tobacco 
heating system tobacco stick is inserted into the holder and heats the tobacco via an electronically 
controlled heating blade. The charger recharges the holder. The tobacco heating system tobacco 
sticks are preheated for 30 seconds in the tobacco heating system holder, and the energy capacity of 
the holder is enough to maintain a product user session of 6 minutes. At the end of each product use 
session, the tobacco heating system holder requires recharging. The trial authors reported that the 
later versions of the tobacco heating system (THS 2.1 and THS 2.2) have evolved to become slimmer 
and less bulky than the THS 1.0, with the heating blade inserted directly into the tobacco heating 
system tobacco stick rather than heating the tobacco stick from the outside. This results in a more 
consistent heating of the tobacco at lower temperatures (<400 °C). Consequently, the trial authors 
reported that lower levels of harmful or potentially harmful smoke constituents were achieved in the 
THS 2.1 aerosol compared with the THS 1.0, as well as an improved sensorial experience, which 
addressed consumer feedback on the previous version. By design, the use of the THS 1.0 was limited 
to eight puffs per cigarette, while the THS 2.1 offers an operating window of 6 minutes and 14 puffs 
per cigarette, which is more in line with the smoking ritual observed with conventional tobacco 
cigarettes. The trial authors reported that the evolution of the electronic device from THS 1.0 to THS 
2.1, in addition to lowering the operating temperature from 550 °C with the THS 1.0 to under 400 °C 
with the THS 2.1, decreased the emission of harmful or potentially harmful smoke constituents 
generated at temperatures above 400 °C. The trial authors concluded that the lowering of the 
operating temperature represented a significant improvement of the product. The heating of the 
tobacco heating system tobacco stick is initiated by pressing the button on the holder, and a light-
emitting diode (LED) indicates when the initial heating process is complete. Like the third-generation 
electrically heated cigarette smoking system products, the tobacco heating system products were 
developed to smoke either non-menthol or menthol cigarettes.  
5.4.1.2.3 Carbon-heated tobacco product  
The trial authors reported that the carbon-heated tobacco product prototype MD2-E7 consists of a 
carbon heat source, a tobacco plug wrapped in paper, an empty tube (to allow aerosol transfer), and 
a filter (a strip of aluminium foil that attaches the carbon heat source to the tobacco plug). The trial 
authors stated that it looked like a conventional cigarette, and that the carbon-heated tobacco 
product was based on technology that avoided pyrolysis or combustion of tobacco. The heat-not-burn 
tobacco product prepared by Japan Tobacco International was described as an electrically heated 
cigarette consisting of four consecutive functional parts: a heat source assembly, comprising a carbon 
heat source; the film substrate, filled with tobacco leaf; a tobacco rod; and a filter. The trial authors 
stated that this makes the electrically heated cigarette structurally different from a conventional 
cigarette. After igniting the heat source assembly, a hot air flow generated by puffing warmed the 
film substrate and passed through the tobacco rod to generate smoke, and then the generated smoke 
was passed through a filter and inhaled by puffing.  
5.4.1.2.4 Comparison of heat-not-burn products with conventional tobacco cigarettes 
The trial authors provided some information on the chemical composition yield of heat-not-burn 
products and their comparison with conventional tobacco cigarettes. For example, the authors of one 
trial paper reported on the electrically heated cigarette smoking system compared with the 





the EHCSS-K3 were 3 mg tar, 0.2 mg nicotine, and 0.6 mg carbon monoxide, and for the EHCSS-K6 
were 5 mg tar, 0.3 mg nicotine, and 0.6 mg carbon monoxide. These are lower than yields reported on 
the cigarette packaging for Marlboro (M6UK) (for which the yield was 6 mg tar, 0.5 mg nicotine, and 7 
mg carbon monoxide), and lower than the carbon monoxide yield for Philip Morris One (PM1), which 
has 1 mg tar, 0.1 mg nicotine, and 2 mg carbon monoxide. The trial authors found that the carbon-
heated tobacco product prototype MD2-E7 (which is another heat-not-burn product) yields were 3 
mg tar, 2 mg glycerol, 0.4 mg nicotine, and 1 mg carbon monoxide. 
5.4.1.3 Comparisons made in the heat-not-burn trial papers 
In the 25 trials presented in Section 5.4.2, comparisons are made between the many smoking/vaping 
behavioural practices of the study population, as well as between various product types. In brief, 
comparisons of behaviours included contrasting between use of: 
• Heat-not-burn products and e-cigarettes alone 
• Heat-not-burn products, e-cigarettes, and conventional tobacco cigarettes  
• Heat-not-burn products and conventional tobacco cigarettes  
• Heat-not-burn products, conventional tobacco cigarettes, and smoking abstinence; and 
• Conventional cigarette smokers and non-smokers at baseline.  
The observed heterogeneity in comparison groups (i.e. non-smokers, smoking abstainers, smokers, e-
cigarette users, and heat-not-burn users) was further compounded by assessment of a wide range of 
heat-not-burn products. These included: the electrically heated cigarette smoking system, the 
tobacco heating system, and other products such as the carbon-heated tobacco product prototype 
MD2-E7. In addition to the various heat-not-burn product types, various versions of the products 
were tested. For example, the EHCSS-K3 and EHCSS-K6 versions of an electrically heated cigarette 
smoking system, and the THS 2.1 and THS 2.2 versions of the tobacco heating system, were 
compared.  
5.4.1.4 Study characteristics 
The trials were completed on populations living in eight countries including Belgium (1 trial), Italy (1 
trial), Japan (8 trials), Poland (3 trials), South Africa (3 trials), South Korea (1 trial), the UK (2 trials), 
and the USA (4 trials). Two trial papers did not report the country where it was based. The trial 
sample sizes ranged from 18 to 316. Twelve trials had fewer than 100 participants. The age range of 
trial participants was 19–65 years. Most trial participants were men. The trials were published 
between 2005 and 2019. 
The number of interventional trial papers grouped by the adapted Academies of Sciences’ framework 
headings were: 4 under dependence and abuse liability, 8 under cardiovascular diseases, 1 under 
respiratory diseases, and 12 under exposure to heat-not-burn toxins. There were no interventional 
trial papers under the following reporting areas: ‘cancers’, ‘oral diseases’, ‘developmental and 
reproductive effects’, ‘injuries and poisonings’, and other outcomes  
5.4.2 Harms, harm reduction, and benefits: heat-not-burn products 
The possible harms and benefit outcomes measured for heat-not-burn users under the ‘dependence 
and abuse liability’ heading included cigarette craving/urge to smoke, withdrawal symptoms, nicotine 
and its metabolites, and various forms of carbon monoxide. The outcomes measured under the 
‘cardiovascular diseases’ heading included antioxidant status and oxidative stress, platelet activity, 
blood functions, endothelial function and dysfunction, lipid risk markers, cardiac risk markers, heart 
rate variability, cardiovascular risk and function, and factors related to oxygen uptake. The reported 
outcomes under the ‘respiratory diseases’ heading included measures of lung resistance, function, 
and volume. The outcomes measured under the ‘exposure to heat-not-burn toxins’ heading were an 
extensive array of harmful or potentially harmful constituents of tobacco smoke (see listing in 





Persons who abstained from smoking any products during the trial period had the best biomarkers of 
health when compared with those who used heat-not-burn products, vaped e-cigarettes, and/or 
smoked conventional tobacco cigarettes. The overarching conclusion by the trial authors was that 
heat-not-burn tobacco products had lower levels of the biomarkers, which are risk markers for 
adverse health outcomes, compared to levels observed in persons smoking conventional tobacco 
cigarettes.  
5.4.2.1 Dependence and abuse liability: interventional trials 
Four interventional trial papers reported the relationship between heat-not-burn products and 
dependence and abuse liability outcomes (Table 55 and Appendix 6). The authors of one trial, 
Adriaens et al. (2018), were university based;1 the authors of the remaining three trials were industry 
based. The number of trial participants were 24, 28, 30, and 110. The duration of the trials varied 
according to the degree to which pre-data collection phase (to standardise behaviours and product 
use) was undertaken; the pre-data collection period ranged from 3 to 8 days. However, the actual 
period over which data assessing the effect of the intervention were collected ranged from 2 to 5 
days, which illustrates the short-term nature of the intervention and measurement process. The 
outcomes included, but were not limited to:  
• Cigarette craving/urge to smoke 
• Withdrawal symptoms  
• Urine nicotine, its metabolites, and nicotine concentration curves 
• Exhaled carbon monoxide and carboxyhaemoglobin, and 
• Cough assessment. 
Other outcomes reported in these papers included product evaluation, participants’ product 
preferences, and the assessment of adverse events (respiratory symptoms such as cough assessment; 
changes in vital signs; body mass index; spirometry findings; electrocardiography; clinical chemistry; 
haematology; urinalysis; and physical examinations).  
Roethig et al.401 (2005) reported findings from 110 participants in a controlled, parallel-group design 
trial with forced switching. Here, two electrically heated cigarette smoking systems (first-generation 
EHCSS1 and EHCSS2), two forms of conventional tobacco cigarettes (CC1 and CC2), and a smoking 
abstinence group were assessed over 3 days. The authors measured several biomarkers of exposure 
under controlled smoking conditions and reported that lowering the temperature during tobacco 
combustion resulted in a substantial reduction in exposure to carbon monoxide, 
carboxyhaemoglobin, and nicotine and urine mutagenicity (specifically urine nicotine and five of its 
metabolites) in those using the EHCSS1 and EHCSS2 devices when compared to exposures in persons 
using conventional tobacco cigarettes. 
The other three papers reported on findings from open-label randomised trials. Picavet et al.402 (2016) 
reported findings from 28 participants participating in a 2-day, two-period, two-sequence crossover 
study. The authors assessed outcomes after single and ad libitum use of the THS 2.1 or conventional 
tobacco cigarettes. The authors concluded that the THS 2.1 effectively delivered nicotine and 
achieved similar pharmacokinetic profiles (measured as nicotine blood levels) as conventional 
tobacco cigarettes while reducing the urge to smoke. Adriaens et al.1 (2018) reported findings from 30 
subjects who participated in a 3-day randomised crossover trial evaluating cigarette craving, 
withdrawal symptoms, and exhaled carbon monoxide among users of the heat-not-burn product 
IQOS™, e-cigarette users, and conventional cigarette users. The authors concluded that cravings were 
reduced in the heat-not-burn product users following short-term use. Yuki et al.386 (2017) reported 
findings from 24 participants participating in a 3-day, two-period, two-sequence crossover study. The 
authors assessed outcomes after use of a prototype novel tobacco vapour product or conventional 
tobacco cigarettes. The authors concluded that the pharmacokinetics of nicotine following prototype 
novel tobacco vapour product use were not markedly different from those following conventional 
cigarette use, while the prototype novel tobacco vapour product provided less nicotine following a 











Interventional trial papers on dependence and abuse liability Trial design 










The authors reported on levels of carbon monoxide, 
carboxyhaemoglobin, nicotine, and urine mutagenicity 
(specifically urine nicotine and five of its metabolites (nicotine-
N-glucuronide, cotinine, cotinine-N-glucuronide, trans-3′-
hydroxycotinine, and trans-3′-hydroxycotinine-O-glucuronide)) 
in conventional combustible tobacco cigarette brand users, 
electrically heated cigarette smoking system users, and low-tar 
conventional combustible tobacco cigarette users.  
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(smoke between 5 and 25 Marlboro Lights per day at baseline) using: 
(1) electrically heated cigarette smoking system (EHCSS 1) 
(2) electrically heated cigarette smoking system (EHCSS 2) 
(3) no smoking 
(4) low-tar combustible conventional cigarette (Marlboro Ultra) 
The authors concluded that lowering the temperature during 
tobacco combustion results in a substantial reduction in 











The authors reported on the relationship between use of the 
THS 2.1 or conventional combustible tobacco cigarettes, and 
the pharmacokinetics of nicotine, specifically a range of mean 
nicotine concentration curves. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(smoke ≥ 10 commercially available non-menthol cigarettes per day for ≥ 
4 weeks, with ≤1 mg nicotine per cigarette, at baseline) with: 
(1) Tobacco Heating System 2.1 (THS 2.1)  
The authors concluded that the THS 2.1 effectively delivers 
nicotine and achieves similar pharmacokinetic profiles as 
conventional combustible tobacco cigarettes. The THS 2.1 also 
reduced the urge to smoke to a similar degree as conventional 
combustible tobacco cigarettes. 
Randomised 
crossover trial 
Yuki et al. 
386 
2017 





The authors reported on the pharmacokinetics of nicotine 
following the use of a prototype novel tobacco vapour product 
in comparison to a conventional combustible tobacco 
cigarette. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(smoke ≥11 tobacco cigarettes per day for ≥ 1 year at baseline) using: 
(1) prototype novel tobacco vapor product 
(2) conventional cigarette 
The authors concluded that under the conditions of the present 
study, the pharmacokinetics of nicotine following prototype 
novel tobacco vapour product use were not markedly different 
from those following conventional combustible tobacco 
cigarette use, while the prototype novel tobacco vapour product 
provided less nicotine following a controlled single use.  
Randomised 
crossover trial 









The authors reported on a 3-day randomised crossover trial, 
focusing on the behavioural and experiential effects of the 
short-term use of the heat-not-burn product IQOS™, versus an 
e-cigarette and versus a conventional combustible tobacco 












Interventional trial papers on dependence and abuse liability Trial design 
IQOS™ and of e-cigarettes. The purpose was to investigate the 
effect of using IQOS™ on exhaled carbon monoxide, acute 
cigarette craving, withdrawal symptoms, and subjective 
positive and negative experiences after overnight smoking 
abstinence, compared to using an e-cigarette or a conventional 
combustible tobacco cigarette, and to investigate which product 
(the e-cigarette or IQOS™) would be preferred. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users (≥10 
cigarettes per day for ≥ 3 years and no intention to quit at baseline) 
using: 
(1) a regular tobacco cigarette, 
(2) an e-cigarette  
(3) the IQOSTM HnB tobacco product 
The authors concluded that short-term use of a specific heat-
not-burn product, IQOS™, can be effective in momentarily 
reducing acute conventional combustible tobacco cigarette 
craving and withdrawal symptoms, while having a minimal 
impact on exhaled carbon monoxide levels and being slightly 
more liked by novice users than an e-cigarette. They stated, 
however, that this does not guarantee that craving/withdrawal 
symptom reduction will also be sustained over longer time spans 
or in cases of repeated use, nor do they provide assurance that 
these effects are sufficient to lead to smoking reduction or 
cessation in smokers willing to quit or cut down on conventional 
combustible tobacco cigarettes. 
5.4.2.2 Cardiovascular diseases: interventional trials 
Eight interventional trial papers reported on the relationship between heat-not-burn products and a 
range of cardiovascular disease risk markers (Table 56 and Appendix 6). Risk markers included 
indicators of oxidative stress, damage and inflammation, endothelial dysfunction, coagulation, heart 
function, measures of metabolic syndrome, and indicators of a hypercoagulable state. An overview of 
the study characteristics of cardiovascular-related measures, trial design, sample size, and specifics on 
intervention devices and products is provided here, with more detail reported in Table 56. The toxins 
reported included measures of toxic gases (such as carbon monoxide and biomarkers of nicotine 
exposure). More specific examples of the cardiovascular (and toxin) outcomes included, but were not 
limited to: 
• Antioxidant status and oxidative stress: levels of vitamin E and serum hydrogen peroxide (H2O2) 
breakdown activity, and 8-epi-prostaglandin F2α (8-epi-PGF2α) 
• Oxidative damage and inflammation: isoprostane, isomers and metabolites iPF2a-III, 2,3-di-
noriPF2a- III, iPF2a-VI, 8,12-isoiPF2a- VI, and PGF2a 
• Platelet activation/activity: soluble CD40 ligand (sCD40L) and soluble P-selectin, and 11-DTXB2 
• Endothelial dysfunction/function: flow-mediated dilation, and soluble intracellular adhesion mol-
ecule-1 (sICAM-1) 
• Lipid metabolism: high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cho-
lesterol, triglycerides, and total cholesterol 
• Specific markers of inflammation: total white blood cells (WBC), soluble intercellular adhesion 
molecule-1 (sICAM-1), C-reactive protein 
• Cardiovascular risk/function: homocysteine, high-sensitivity C-reactive protein (hs-CRP), fibrino-
gen, and blood pressure (systolic, diastolic) 
• Metabolic syndrome, including insulin resistance: blood glucose, haemoglobin A1c (HbA1c), body 





• Serum levels of soluble NOX2-derived peptide, a marker of NADPH (nicotinamide adenine dinu-
cleotide phosphate oxidase) oxidase activation 
• Heart rate variability derived from the 24-hour electrocardiogram: NN interval (i.e. normal-to-
normal heart beat interval), SDNN (i.e. standard deviation of all NN intervals), SDANN (i.e. stand-
ard deviation of all 5-minute averaged normal-to-normal heart beat interval), NN intervals in a 
24-hour period, and the square root of the mean of all squared differences between adjacent NN 
intervals in a 24-hour period 
• Hypercoagulable state: fibrinogen, homocysteine, hematocrit, haemoglobin (HgB), and platelets 
• Lipid/cardiac risk markers: high-density lipoprotein (HDL), low-density lipoprotein (LDL), HDL/LDL 
ratio, oxidised LDL (OxLDL), and triglycerides 
• Endothelial function: circulating endothelial precursor (CEP) cells 
• DNA damage: sister chromatid exchange (SCE) in peripheral lymphocytes 
• Full blood cell count, serum nicotine and cotinine 
• Symptom-limited spiroergometry (spiroergometric parameters included oxygen uptake, carbon 
monoxide exhalation, heart rate, and systolic and diastolic blood pressure 12-lead electrocardio-
gram) 
• Blood carboxyhaemoglobin (COHb), nitric oxide (NO), and concentrations of thiocyanate (plasma 
SCN) a biomarker of exposure for hydrogen cyanide 
• Nicotine and five major metabolites (nicotineglucuronide, cotinine and its glucuronide, trans-3′-
hydroxycotinine and its glucuronide) 
• Cigarette smoke constituents (biomarkers of exposure): NNK (3-hydroxy-1-methylpropyl-mercap-
turic acid), 4-ABP (4-ABP: 4-aminobiphenyl), pyrene (PAH: polycyclic aromatic hydrocarbon) (1-
OHP: 1-hydroxypyrene), benzene, 1,3-butadiene (MHBMA: monohydroxybutenyl mercapturic 
acid), acrolein (3-HPMA: 3-hydroxypropylmercapturic acid) 
• Adenosine diphosphate (ADP)-induced platelet aggregation, and 8-epi-PGF2α; and 
• 11-dehydro-thromboxane B2 (11-DTXB2). 
 
The authors of one paper reporting on outcomes for cardiovascular disease, Biondi-Zoccai et al.22 
(2019), were university based, while the authors of the remaining papers were employees of Philip 
Morris, R. J. Reynolds Tobacco Company, or Japan Tobacco International. The trial from Biondi-Zoccai 
et al. is reported first, followed by the remaining seven trials, which are listed chronologically, and 
those published within the same year are listed alphabetically by the first author’s name. 
Biondi-Zoccai et al.22 (2019) conducted a randomised crossover study over 4 weeks on 20 subjects. 
Participants were allocated to six different cycles undertaking a single use of each product: a heat-
not-burn cigarette, an e-cigarette, and a conventional cigarette. The 20 participants underwent a 1-
week washout period between exposures. Participants used all three products assessed in the trial. 
Outcomes of oxidative stress, antioxidant reserve, platelet activation, flow-mediated dilation, blood 
pressure, and satisfaction scores show adverse effects following a single use of each product. 
However, the adverse effects observed for measures of oxidative activation (NOX2-derived peptide) 
and potent agonists of platelet and vascular thromboxane 8-isoprostaglandin vitamin E) following use 
of the new-generation heat-not-burn cigarette were less extreme than those observed following use 
of the other products. The effects of heat-not-burn cigarettes and e-cigarettes on flow-mediated 
dilation (soluble CD40 ligand and soluble P-selectin) were less damaging than that of the conventional 
tobacco cigarettes. The heat-not-burn cigarette, and, to a lesser extent, the e-cigarette, exhibited 
lower impacts on raising blood pressure than the conventional tobacco cigarettes.  
The remaining seven trials were by industry-based authors and included some form of randomisation. 
In many, control was achieved by a crossover study design, where findings were assessed in the same 
individuals at different timepoints and following exposure to the different interventions. In some 
trials, a washout period between exposures was reported. Some trials were conducted where 
individuals were allocated to one intervention only. These randomised controlled trials without 





participants nor the investigators were blinded to the intervention(s)). In crossover trials, the number 
of periods from which outcomes were assessed ranged from two to four. In several cases, the trial 
period was preceded by a preparatory period of up to 40 days, wherein participants were instructed 
in standardised behavioural regimes, including dietary intake and product use. In two trials, a 
subsequent follow-up period of up to 80 days was undertaken in order to assess the incidence of 
adverse events post exposure.  
The data collection period assessing the exposure-outcome relationship varied. In five of the six trials 
conducted by Philip Morris data were gathered over 3 to 5 days; in the sixth trial data were gathered 
over a 12-month period. The R. J. Reynolds Tobacco Company trial gathered data over a 24-week 
period. Reported outcomes reflected outcomes gathered during these quantified periods. Trials were 
mainly conducted in a controlled situation with trained observers. 
The number of participants in the industry-based trials ranged from 18 to 316. The six Philip Morris 
trials were conducted in Japan, South Africa (two trials), Poland, the USA and at one unidentified 
location. Participants numbered: 316 (Poland), 160 (Japan), 82 (USA), 34 (unidentified location), and 
18 (in both South Africa trials). The R. J. Reynolds Tobacco Company trial in the USA consisted of 150 
participants 
Unverdorben et al. 403 (2007) reported on improved exercise performance assessed by symptom-
limited spiroergometry parameters in 18 study participants. They found that persons who did not 
smoke or who used second-generation electrically heated cigarette smoking systems showed 
improved outcome measures relative to conventional cigarette users. A second paper by 
Unverdorben et al.404 (2008), on 18 participants in a crossover trial that switched between three 
interventions (smoking conventional tobacco cigarettes, using an electrically heated cigarette 
smoking system, or smoking abstinence) over a 7-day period, found improvements in heart rate and 
rate-pressure-product parameters in persons switching to an electrically heated cigarette smoking 
system, and noted even greater improvements in participants who stopped smoking.  
Roethig et al405 analysed a range of biomarkers of tobacco smoke exposure and cardiovascular risk 
factors in 97 tobacco cigarette smokers who were either switched to a second‐generation electrically 
heated cigarette smoking system or continued smoking conventional tobacco cigarettes for 12 
months following baseline measurements. The authors concluded that there was a rapid and 
sustained reduction in all biomarkers of exposure after switching to the electronic heated cigarette 
smoking system, with statistically significant reductions in several cardiovascular risk factors from the 
baseline levels. 
Munjal et al.406 (2009) measured heart rate variability in 30 of 34 participants randomly assigned to 
either a conventional cigarette or an electrically heated cigarette smoking system over a 3-day trial 
period. The authors concluded that after 3 days, adult smokers tended to show increased heart rate 
variability with reduced exposure to conventional cigarette smoke, indicating a physiologically 
favourable change in the autonomous nervous system.+ However, it should be noted that the heat-
not-burn device was solely a research tool and was not commercially available.  
Martin Leroy et al.407 (2012) reported a per-protocol analysis at 8 weeks, including 309 of 316 study 
participants, which measured blood health biomarkers and selected harmful and potentially harmful 
constituents of tobacco in two study groups (EHCSS-K6 users, and conventional cigarette users). The 
findings indicated an increase in high-density lipoprotein (HDL) cholesterol, and reductions in red 
blood cell count, haemoglobin, and haematocrit levels in the EHCSS-K6 group. All biomarkers of 
exposure to the selected harmful and potentially harmful constituents in conventional cigarette 
smoke decreased in the EHCSS-K6 group, despite an increase in EHCSS-K6 cigarette consumption, 
when compared to the conventional cigarette group. A list of harmful and potentially harmful 
constituents is presented in Appendix 8. 
Ogden et al 408 (2015) measured oxidative damage, lipids, indicators of a hypercoagulable state, 
insulin resistance, endothelial function, and DNA damage in a 24-week trial of 150 smokers 
randomised to use of tobacco-heating systems, snus, or ultra-low machine yield tobacco-burning 
cigarettes. The authors reported improvements in some but not all biomarkers for each of the three 





consistent and statistically significant differences in pairwise comparisons between product groups 
were not observed. 
Lüdicke et al.409 (2018) reported findings for 104 of 160 trial participants in Japan who switched from 
conventional tobacco cigarettes to the menthol THS 2.2, assessing a range of outcomes including 
oxidative stress, endothelial function, lipid metabolism, cardiovascular risk/function (including systolic 
and diastolic blood pressure), and measures of metabolic syndrome. The authors concluded that 
switching from conventional tobacco cigarettes to the menthol THS 2.2 was associated with 
reductions in biomarkers of exposure to conventional cigarette smoke, and changes were observed in 
clinically relevant biomarkers of oxidative stress (8-epi-prostaglandin F2α), platelet activity (11-
dehydro-thromboxane B2), endothelial function (soluble intracellular adhesion molecule-1), lipid 
metabolism (high-density lipoprotein (HDL) cholesterol), and lung function (forced expiratory volume 
in 1 second) that were similar to the smoking abstinence group.  
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  University-based trials  
Biondi-Zoccai 










The authors reported on the acute effects of a single use of heat-
not-burn cigarettes, electronic vaping cigarettes, and conventional 
combustible tobacco cigarettes in healthy smokers. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users (mean 
years smoking: 15±SD 12 at baseline) using: 
(1) heat-not-burn cigarettes 
(2) e-cigarettes  
(3) conventional combustible tobacco cigarettes 
 The authors concluded that the acute effects of heat-not-burn 
cigarettes, electronic vaping cigarettes, and conventional 
combustible tobacco cigarettes are different on several oxidative 
stress, antioxidant reserve, platelet function, cardiovascular, and 
satisfaction dimensions, with conventional combustible tobacco 
cigarettes showing the most detrimental changes in clinically 
relevant features, thus suggesting that these modified-risk products 
may prove useful as tools to quit smoking conventional combustible 
tobacco cigarettes.  
Randomised 
crossover trial 
  Industry-based trials  
Unverdorben 










The authors reported on exercise performance following reduced 
exposure to conventional combustible tobacco cigarette smoke 
and no smoking in adult smokers switching from conventional 
combustible tobacco cigarettes to an electrically heated cigarette 
smoking system or smoking abstinence.  
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users (smoke 
20 to 40 cigarettes per day for ≥10 years, with brand and cigarettes per day 
stable for ≥3 months, at baseline) with: 
(1) conventional combustible tobacco cigarette 
(2) second-generation EHCSS series JLI 
They found that persons who did not smoke or who used second-
generation electrically heated cigarette smoking systems showed 
improved outcome measures relative to conventional combustible 












The authors reported on the prognostic parameters of heart rate 
(HR) and rate-pressure-product (RPP) on exercise performance in 
adult smokers switching from a conventional combustible tobacco 
cigarette to a potential exposure-reduced electrically heated 
















Comparison(s) of conventional combustible tobacco cigarette users (smoke 
20 to 40 cigarettes per day for ≥10 years, with brand and cigarettes per day 
stable for ≥3 months, at baseline) with: 
(1) "Controlled smoking" conditions 
(2) EHCSS smoking system (EHCSS series JLI 
(3) conventional combustible tobacco cigarette 
The authors concluded that reduced exposure to tobacco smoke or 
not smoking for 3 days may translate into improvements in heart 
rate and rate-pressure-product parameters that are associated with 
cardiovascular prognosis. These improvements seem to be more 
pronounced during smoking abstinence than during the use of the 









Authors reported on cardiovascular risk factors in adults’ smokers 
switching from conventional tobacco cigarettes to a second-
generation electronic heated cigarette smoking system 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users (smoke 
20 to 40 cigarettes, with 1–7 mg tar, per day for ≥10 years, with brand and 
cigarettes per day stable for ≥3 months, at baseline) using: 
(1) EHCSS1 (Accord first-generation EHCSS series E4) 
(2) EHCSS2 (Oasis first-generation EHCSS series E4) 
(3) conventional cigarette brand (CC1, Marlboro Lights) 
(4) low-tar conventional cigarette (CC2, Marlboro Ultra) 
The authors concluded that there was a rapid and sustained 
reduction in all biomarkers of exposure after switching to the 
electronic heated cigarette smoking system, with statistically 
significant reductions from baseline 
Randomised 
crossover trial 











The authors reported on heart rate variability among users of 
different tobacco products. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users (smoke 
20 to 40 cigarettes per day for ≥10 years at baseline) using: 
(1) conventional cigarette 
(2) third generation, electrically heated cigarette smoking system (EHCSS 
series K) 
The authors concluded that adult smokers tend to show increased 
heart rate variability with reduced exposure to conventional 
combustible tobacco cigarette smoke after 3 days, indicating a 






















The authors reported on biomarkers associated with cardiovascular 
risk and biomarkers of exposure to 10 selected harmful and 
potentially harmful constituents in conventional combustible 
tobacco cigarette smoke, comparing findings with those smoking 
the the EHCSS-K6. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users (smoke 
20 to 40 cigarettes, with 3–10 mg tar, per day for ≥10 years at baseline) 
using: 
(1) EHCSS-K6  
(2) conventional tobacco cigarettes 
The authors concluded that there were no statistically significant 
differences in the two primary biomarkers between the study 
groups at the end of the study. End-of-study comparisons of 
secondary biomarkers between study groups indicated an increase 

















blood cell count, haemoglobin, and haematocrit levels in the EHCSS-
K6 group. All biomarkers of exposure to the selected harmful and 
potentially harmful constituents in conventional combustible 
tobacco cigarette smoke were decreased in the EHCSS-K6 group, 
despite an increase in product consumption, compared to the levels 
found in the conventional combustible tobacco cigarette group. 
There were no apparent differences in any of the safety assessment 
parameters between the groups, and the overall incidence of study-
related adverse events was low.  










The authors reported on changes in biomarkers of biological effect 
among adult conventional combustible tobacco cigarette smokers 
who switched to tobacco-heating systems, snus, or ultra-low 
machine yield tobacco-burning cigarettes for 24 weeks. 
Comparisons were made between smokers and a group of never-
smokers at baseline, and among the three tobacco-using groups 
over time and in comparison, with each other. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users 
(exclusive for 6 months, ≥15 cigarettes per day for ≥10 years and did not 
intend to quit at baseline) using: 
(1) tobacco-heating cigarette (Eclipse brand cigarette, non-menthol (2) 
tobacco-heating cigarette (Eclipse brand cigarette, menthol  
(3) snus (Camel SNUS, subject choice of Frost, Spice and Mellow varieties)  
(4) an ultra-low machine yield tobacco-burning cigarette 
(5) Cambridge Filter Method ‘‘tar’’ Camel non-menthol or Salem, 
(6) Cambridge Filter Method ‘‘tar’’ menthol 
(7) never smokers (baseline comparison) 
The authors concluded that half of the biomarkers of biological 
effect evaluated were statistically significantly different in the 
baseline comparisons between smokers and never-smokers. 
Differences in C-reactive proteins, high-density lipoproteins (HDL), 
low-density lipoproteins (LDL), HDL/LDL, triglycerides, fibrinogen, 
and platelets between smokers and non-smokers, were not 
observed in this study. They noted that consistent and statistically 
significant differences in pairwise comparisons between product 
groups were not observed. 
Randomised 
controlled trial 











The authors reported on the risk profile of a new tobacco product, 
the menthol THS 2.2, an alternative to conventional combustible 
tobacco cigarettes. 
Comparative groups  
Comparison(s) of conventional combustible tobacco cigarette users (smoke 
≥10 menthol cigarettes per day, with ≤1 mg of nicotine, for the previous 4 
weeks, and had smoked for ≥3 years with no plan to quit at baseline) using: 
(1) menthol Tobacco Heating System 2.2 (mTHS) 
(2) conventional combustible tobacco cigarette 
(3) smoking abstinence  
The authors concluded that switching from conventional combustible 
tobacco cigarettes to the menthol THS 2.2 was associated with reductions 
in biomarkers of exposure to conventional combustible tobacco 
cigarette smoke, and changes were observed in clinically relevant 
biomarkers of oxidative stress (8-epi-prostaglandin F2α), platelet 
activity (11-dehydro-thromboxane B2), endothelial function (soluble 
intracellular adhesion molecule-1), lipid metabolism (high-density 
lipoprotein (HDL) cholesterol), and lung function (forced expiratory 
volume in 1 second) which were similar to the smoking abstinent 












Interventional trial papers on cardiovascular diseases Trial design 
the potential to reduce the adverse health effects of using 
conventional combustible tobacco cigarettes. 
5.4.2.3 Cancers: interventional trials 
There were no interventional trials on the relationship between heat-not-burn products and cancer 
outcomes. 
5.4.2.4 Respiratory diseases: interventional trials 
There was one interventional trial on the relationship between heat-not-burn products and 
respiratory disease outcomes (Table 57 and Appendix 6). The trial’s reported respiratory outcomes 
included the following measures of lung resistance, function, and volume:  
• Airway resistance – measured by specific airway conductance, airway conductance, specific re-
sistance, and raw resistance 
• Spirometry – measured by forced expiratory volume after 1 second, forced expiratory flow after 
the first 25% of the vital capacity, forced expiratory flow after the first 50% of the vital capacity, 
forced mid-expiratory flow, peak expiratory flow, and peak inspiratory flow; and 
• Lung volumes – measured by vital capacity, forced inspiratory vital capacity, and thoracic gas vol-
ume. 
• Respiratory rate, tidal volume, and expiratory time  
Unverdorben et al.410 (2010) reported on respiratory outcomes from a single-blind (technicians and 
laboratory staff), randomised, controlled, three-period crossover study with 49 male participants. The 
intervention was conducted over 3 days. Comparisons were made between outcomes following 
conventional cigarette use, third-generation electrically heated cigarette smoking system use, and 
smoking abstinence. The authors concluded that acute and reversible effects of different cigarette 
smoke exposures and no smoking on mid- to small-size pulmonary airways occurs in a dose-
dependent manner, with the damage occurring in a decreasing stepwise manner from conventional 
cigarette users, to third-generation electrically heated cigarette smoking system users, to the least 
damage in smoking abstainers. 
Table 57 Interventional trial papers on respiratory diseases, benefits or harms 
Author(s), year Possible 
benefit or 
harm 
Interventional trial papers on respiratory diseases Study design 












The authors reported on the extent and potential reversibility of 
changes in pulmonary function in adult smokers of conventional 
combustible tobacco cigarettes after 3 days of either smoking 
conventional combustible tobacco cigarettes, using an electrically 
heated cigarette smoking system, or smoking abstinence. 
Comparative groups 
Comparison(s) of conventional combustible tobacco cigarette users (smoke 
20 to 40 cigarettes per day for ≥10 years, with brand and cigarettes per day 
stable for ≥3 months, at baseline) with: 
(1) conventional cigarette 
(2) electrically heated smoking system (EHCSS series K) 
(3) did not smoke 
Characteristics of baseline group: (1) conventional combustible tobacco 
cigarette users 
The authors concluded that acute and reversible effects of different 
cigarette smoke exposures and no smoking on mid- to small-size 







5.4.2.5 Oral diseases: interventional trials 
There were no interventional trials on the relationship between heat-not-burn products and oral 
disease outcomes.  
5.4.2.6 Developmental and reproductive effects: interventional trials 
There were no interventional trials on the relationship between heat-not-burn products and 
developmental and reproductive effects outcomes.  
5.4.2.7 Injuries and poisonings: interventional trials 
There were no interventional trials on the relationship between heat-not-burn products and injuries 
and poisonings outcomes.  
5.4.2.8 Exposure to heat-not-burn toxins: interventional trials 
There were 12 interventional trial papers reporting on the relationship between heat-not-burn 
products and toxin-related outcomes (Table 58 and Appendix 6). The intervention portions of the 
trials were short term, usually of 2–3 days’ duration, but an intervention assessment period of up to 4 
weeks was reported. In some studies, a pre-trial monitoring period of between 7 and 40 days was 
conducted. During this time, participants were instructed to undertake standardised dietary and 
lifestyle behaviours, including protocol-agreed smoking-related behaviours. A post-trial period of 
between 7 and 80 days, where participants were asked about subsequent effects or any adverse 
events, was also conducted in a small number of trials. 
All interventional trial papers except for one provided information on the chemical composition of the 
intervention. From the reported data, it was clear that the term ‘heat-not-burn products’ was an 
umbrella term for a range of products which shared specific characteristics but also exhibited 
differences regarding features such as nicotine strength; glycerine, glycerol, and tar content; 
flavourings; and heating temperature. Different generations of heat-not-burn products, heat-not-
burn products with and without menthol, and carbon-heated tobacco products were assessed. 
Comparisons were made between a range of conventional tobacco cigarettes with and without 
menthol. In addition, some studies’ outcomes were contrasted not only in persons who were 
randomised to using a heat-not-burn product or a conventional cigarette, but also with persons 
randomised to abstain from smoking during the trial period. Hence, two-, three-, or four-way 
comparisons of heat-not-burn, conventional tobacco cigarettes, and smoking abstention were 
reported.  
Examples of heat-not-burn products studied included, but were not limited to, the following:  
• A 7 mg/cigarette (according to International Organization for Standardization conditions) tar com-
bustible tobacco non-menthol cigarette, the glo™ THP 1.0 with non-menthol NeoStiks, or the 
menthol-containing cigarette equivalent, the glo™ THP 1.0 with menthol NeoStiks 
• The heat-not-burn THS 2.2 test product, containing 0.5 mg nicotine (as determined under Inter-
national Organization for Standardization conditions) and 56.4 mg/stick of glycerine, or the men-
thol-containing equivalent, the menthol THS 2.2; and 
• The carbon-heated tobacco product prototype MD2-E7, containing 3 mg tar, 2 mg glycerol, and 
0.4 mg nicotine, and with a 1 mg carbon monoxide (CO) yield. 
Each of these products was compared with a nationally available cigarette brand from the country in 
which the study was being conducted with varying values of reported tar and nicotine content. For 
example, packaging of a conventional tobacco cigarette in one of the studies conducted in Japan 
reported 10 mg tar and 0.8 mg nicotine in the conventional cigarette. Alternatively, in other studies, 
participants supplied their own conventional tobacco cigarettes, the chemical composition of which 
was not documented. The study countries were Japan, Poland, the UK, and the USA.  
A wide range of potentially harmful constituents, biomarkers, and/or toxins; known risk markers; or 





using the nomenclatures as reported in the individual papers. Where possible we have expanded the 
abbreviations employed in tables within the papers using the details provide at the end of the 
reporting table or within the body of the text. However, on a small number of occasions the papers 
authors did not provide a more complete name. We have not extrapolated beyond the reporting 
authors text. Some toxins have been classified as Group 1 (the agent is carcinogenic to humans), 
Group 2A (the agent is probably carcinogenic to humans), or Group 2B (the agent is possibly 
carcinogenic to humans) by the International Agency for Research on Cancer.411 The toxins drive 
metabolic activation that results in a range of pathogenic changes, including, but not limited to: 
binding of reactive metabolites to DNA and proteins, mutagenicity, oxidative DNA damage, 
chromosomal damage, and cytotoxicity. Many of the toxins have been identified as determinants in 
the development of lung and bladder cancers, or potential severe neurological harm. However, it 
should be noted that the clinical consequences of their presence in human body tissue in these trials 
requires a longer follow-up time period in order to more fully assess their effect.  
The most common toxin outcomes assessed in the interventional trial papers (biomarker and harmful 
or potentially harmful constituent terms provided) were:  
• 1-NA (1-aminonaphthalene) 
• 1-OHP (1-hydroxypyrene) 
• 2-NA (2-aminonaphthalene)  
• 3-HPMA (3-hydroxypropylmercapturic acid): acrolein  
• 3-OH-B[a]P (3-hydroxy(a)benzopyrene) 
• 3-HMPMA (3-hydroxy-1-methylpropylmercapturic acid): crotonaldehyde  
• 4-ABP (4-aminobiphenyl) 
• AAMA (acrylamide mercapturic acid): acrylamide 
• B[a]P (benzo[a]pyrene)  
• CEMA (2-cyanoethylmercapturic acid): acrylonitrile  
• GAMA (glycidamide mercapturic acid)  
• HEMA (2-hydroxyethyl mercapturic acid): ethylene oxide 
• Mutagens Salmonella mutagenicity (YG1024) with S9  
• MHBMA (monohydroxybutenyl mercapturic acid): 1,3-butadiene  
• NNAL (total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol): NNK (4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone) 
• o-tol (o-toluidine): o-toluidine  
• S-PMA (S-phenylmercapturic acid): benzene  
• Total NNAL (total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol): 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK) 
• Total NNN (total N-nitrosonornicotine): N-nitrosonornicotine  
• Total 1-OHP (total 1-hydroxypyrene): pyrene 
• Total 3-OH-B[a]P (3-hydroxy-benzo(a)pyrene): benzo(a)pyrene  
• TMA (trans, trans-muconic acid) 
• S-BMA (S-benzylmercapturic acid): toluene, and 
• SCN: thiocyanate a biomarker of exposure for hydrogen cyanide. 
 
All 12 papers in this section were from trials conducted by the industry. The trial undertaken by 
British American Tobacco was based in Japan (3 papers), and the nine papers from Philip Morris 
reported on trials conducted in Japan (3), Poland (2), South Korea (1), the UK (1), and the USA (1). The 
location of one trial was not reported.  
Tricker et al. published four papers in 2012 from trials conducted in Japan, South Korea, and the 





160 across the four trials, so all analyses were per protocol and therefore did not include trial 
dropouts. Subjects were randomised into one of three or parallel groups, where the following heat-
not-burn products with or without menthol (indicated by ‘M’) and conventional tobacco cigarettes 
were evaluated in comparison with smoking abstinence:  
• The electrically heated cigarette smoking system with and without menthol, specifically the 
EHCSS series-K cigarette, the EHCSS-K3 cigarette, the EHCSS-K6 cigarette, and the EHCSS-K6M cig-
arette 
• The following tobacco cigarettes: Marlboro non-menthol cigarettes with 6 mg tar and 0.5 mg nic-
otine delivery (M6J), the M4J(M), the Marlboro non-menthol cigarette United Kingdom (M6UK), 
the Philip Morris One cigarette (PM1), the Lark1 (1.0 mg tar, 0.1 mg nicotine, and 1.5 mg CO), and 
the Lark1M; and 
• Smoking abstinence.  
The Marlboro non-menthol cigarettes (M6J and M6UK) were chosen to represent the Japanese and 
UK cigarette markets, and the Lark1 was chosen to represent the South Korean cigarette market. 
Biomarkers of exposure to between 9 and 12 selected harmful and potentially harmful constituents of 
tobacco, as well as urinary excretion of mutagenic material, were assessed. The findings across Tricker 
et al.’s412 413-415 (2012) industry-based trials were reasonably consistent. The authors concluded that 
the trials showed statistically significant mean reductions in biomarkers of selected harmful and 
potentially harmful constituents of tobacco smoke, and reductions in excretion of mutagenic material 
in urine, of smokers who smoked their own cigarettes when they switched to use the EHCSS series-K 
lighter and smoked any of the EHCSS series heat-not-burn products at the final day of the trial, 
compared to baseline. In smokers who switched to smoking conventional tobacco cigarettes 
representative of the low-tar cigarette market, smaller mean reductions were observed, most of 
which were statistically significant. The largest mean reductions occurred in smokers who switched to 
smoking abstinence. Changes in serum concentrations of Clara cell 16-kDa protein could not be 
meaningfully interpreted. 
In an industry-based trial, Sakaguchi et al.416 (2014) examined the impact of a prototype electrically 
heated cigarette in a population of 70 healthy Japanese male smokers. The trial authors concluded 
that exposure to most tobacco cigarette smoke constituents, except carbon monoxide, can be 
reduced by switching from the conventional cigarette (10 mg tar and 0.8 mg nicotine) to the 
prototype electrically heated cigarette. However, it should be noted that the test cigarette prototype 
was prepared by Japan Tobacco International for the study and was never commercially available.  
Haziza et al.417-419 published three industry-based trial papers between 2016 and 2020 reporting on 
the relationship between heat-not-burn products (with and without menthol), conventional tobacco 
cigarettes, and abstaining from smoking in trials conducted in Japan, Poland and the USA. In each 
trial, 160 subjects were assigned to one of three products (albeit with differences in the number of 
participants in each of the study arms), and a range of biomarkers of exposure to harmful and 
potentially harmful constituents in tobacco were assessed. In general, biomarker levels were reduced 
following use of heat-not-burn products compared with conventional cigarette use, and in some 
instances, biomarker levels were reported as approaching the levels observed in the smoking 
abstinence group.  
Lüdicke et al. 420-422 published one trial paper in 2016, one in 2017 and one in 2018. The 2017 trial 
paper measured the impact of switching from smoking conventional tobacco cigarettes to the THS 2.1 
on biomarkers of exposure to harmful and potentially harmful tobacco constituents in 42 people in a 
5-day trial. In the 2018 paper, the authors reported on findings from 160 participants comparing the 
menthol THS 2.2, conventional tobacco cigarettes, and smoking abstention. In the 2016 paper, the 
authors reported on findings from 112 participants comparing carbon-heated tobacco products, 
conventional tobacco cigarettes, and smoking abstention. A similar array of biomarkers of exposure 
was examined in the studies. In the three papers, the authors reported decreasing levels of 





compared with conventional cigarette use and these approached the levels of biomarkers observed in 
the smoking abstinence group.  
Gale et al.423 of British American Tobacco conducted a randomised, controlled, parallel group open-
label trial with clinical confinement and product exposure of 5 days’ duration. Participants were 
randomised to one of six groups (non-menthol cigarette group, non-menthol glo™ THP 1.0 group, 
menthol cigarette group, menthol glo™ THP 1.0 group, iQOS THP group, and abstinence group) for 5 
days of exposure, with approximately 30 participants in each group. More than 15 urinary biomarkers 
of toxicant exposure were assessed in this trial. Participants trialling the new-generation heat-not-
burn cigarette, compared with participants using conventional cigarette products, showed fewer 
adverse effects on NOX2-derived peptide and 8-isoprostaglandin vitamin E. The heat-not-burn 
cigarette and the electronic vaping cigarette were associated with less damage than conventional 
tobacco cigarettes on flow-mediated dilation, hydrogen peroxide breakdown activity F2a-III, and on 
soluble CD40 ligand and soluble P-selectin. The heat-not-burn cigarette, and, to a lesser extent, the e-
cigarette, exhibited a less evident impact on raising blood pressure than the conventional cigarette.  
Table 58 Interventional trial papers on exposure to heat-not-burn toxins, benefits or harms 
Author(s), 
year 
Possible benefit or 
harm 
Interventional trial papers on exposure to heat-
not-burn toxins 
Trial design 
  Industry-based trials  
  Electrically heated cigarette smoking system  
Tricker et al. 
412 
2012a 




The authors reported on levels of biomarkers of 
exposure to nine selected harmful and potentially 
harmful constituents in conventional combustible 
tobacco cigarette smoke (Marlboro cigarettes 
containing 6 mg tar, 0.5 mg nicotine, and 7.0 mg 
carbon monoxide (CO)) and levels of urinary 
excretion of mutagenic material in smokers and in 
users of one of two EHCSS series-K cigarettes, the 
EHCSS-K3 cigarette or the EHCSS-K6 cigarette. 
Comparative groups 
Comparison(s) of conventional combustible tobacco 
cigarette users (smoke 10–25 Marlboro non-menthol 
cigarettes per day for ≥4 weeks, with 6 mg tar, 0.5 mg 
nicotine, and 7.0 mg carbon monoxide per cigarette, at 
baseline) using: 
(1) Marlboro cigarettes  
(2) Electrically Heated Cigarette Smoking System EHCSS‐
K6 (0.3mg nicotine) 
(3) Electrically Heated Cigarette Smoking System EHCSS‐
K6 (0.3mg nicotine) 
(4) Philip Morris One cigarettes 
The authors concluded that the study showed 
strong mean reductions in uptake of selected 
harmful and potentially harmful constituents in 
cigarette smoke, and reductions in excretion of 
mutagenic material in urine, from baseline to day 8 
in M6UK non-menthol cigarette smokers who 
switched to smoking either the EHCSS-K3 or the 
EHCSS-K6 non-menthol cigarettes. Smokers who 
switched to smoking PM1, a conventional 
combustible tobacco non-menthol cigarette 
representative of the low-tar cigarette market, 
showed smaller reductions. The largest mean 




Tricker et al. 
413 
Less harmful than 
conventional 
The authors reported on levels of biomarkers of 









Possible benefit or 
harm 





harmful constituents in conventional combustible 
tobacco cigarette smoke (Lark1 cigarettes 
containing 1.0 mg tar, 0.1 mg nicotine, and 1.5 mg 
carbon monoxide (CO)), and levels of urinary 
excretion of mutagenic material. The study involved 
the following three groups: smokers of Lark1 
cigarettes; users of EHCSS-K3 cigarettes (3 mg tar, 
0.2 mg nicotine, and 0.6 mg carbon monoxide (CO)); 
and non-smokers.  
Comparative groups 
Comparison(s) of conventional combustible tobacco 
cigarette users (smoke 10–30 cigarettes with 1.0–3.0 mg 
tar daily and smoke 10-30 Lark1 for ≥ 2 weeks at baseline) 
using: 
(1) Lark One cigarettes  
(2) Electrically Heated Cigarette Smoking System EHCSS‐
K3  
(3) smoking abstinence 
The authors concluded that the study showed mean 
reductions in biomarkers of exposure to 10 of 12 
selected harmful and potentially harmful 
constituents of conventional combustible tobacco 
cigarette smoke (1,3-butadiene, 2-naphthylamine, 
4-aminobiphenyl, acrylamide, benzene, carbon 
monoxide (CO), nicotine, Total 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), 
pyrene, and o-toluidine) from baseline to day 8 in 
Lark1 smokers who switched to smoking EHCSS-K3 
cigarettes. No change was determined for 
biomarkers of exposure to crotonaldehyde and 
acrolein. In smokers who continued to smoke Lark1 
cigarettes, exposure to the majority of the harmful 
and potentially harmful constituents of 
conventional combustible tobacco cigarette smoke 
(1,3-butadiene, 2-naphthylamine, 4-aminobiphenyl, 
acrylamide, benzene, carbon monoxide (CO), 
crotonaldehyde, nicotine, Total 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) 
and o-toluidine) increased, while biomarkers of 
exposure to acrolein and pyrene decreased. With 
the exception of 1,3-butadiene, 2-naphthylamine, 
benzene, carbon monoxide (CO), nicotine, and 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK), few of the changes reached the level of 
statistical significance. The largest mean reductions 
in all harmful and potentially harmful constituents 
of conventional combustible tobacco cigarette 
smoke occurred in smokers who switched to no 
smoking. Excretion of mutagenic material in urine 
was significantly decreased in the EHCSS-K3 and no-
smoking groups, and was significantly increased in 
the Lark1 group.  
Tricker et al. 
414 
2012c 




The authors reported on levels of biomarkers of 
exposure to 12 selected harmful and potentially 
harmful constituents of tobacco smoke (in 
Marlboro cigarettes containing 6 mg tar, 0.5 mg 
nicotine, and 7.0 mg carbon monoxide (CO)), and on 
levels of urinary excretion of mutagenic material. 









Possible benefit or 
harm 
Interventional trial papers on exposure to heat-
not-burn toxins 
Trial design 
of the EHCSS-K6 (5 mg tar, 0.3 mg nicotine, and 0.6 
mg carbon monoxide (CO)); users of the EHCSS-K3 
(3 mg tar, 0.2 mg nicotine, and 0.6 mg carbon 
monoxide (CO)); smokers who switched to smoking 
Lark1 cigarettes (1 mg tar, 0.1 mg nicotine, and 2.0 
mg carbon monoxide (CO)); and non-smokers.  
Comparative groups 
Comparison(s) of conventional combustible tobacco 
cigarette users (smoke 10–30 Marlboro non-menthol 
cigarettes per day for ≥2 weeks, with 6 mg tar, 0.5 mg 
nicotine, and 7.0 mg carbon monoxide per cigarette, at 
baseline) using: 
(1) Marlboro cigarettes  
(2) Electrically Heated Cigarette Smoking System (EHCSS ‐
K6 0.3mg nicotine)  
(2) Electrically Heated Cigarette Smoking System (EHCSS ‐
K6 0.2mg nicotine)  
(4) Lark One cigarettes 
The authors concluded that this study showed 
statistically significant mean reductions in 
biomarkers of exposure to selected harmful and 
potentially harmful constituents in tobacco cigarette 
smoke and in excretion of mutagenic material in 
urine of smokers who smoke the M6J cigarette and 
switched to using the EHCSS K lighter and smoking 
either the EHCSS-K3 or the EHCSS-K6 cigarette at 
day 8, compared to baseline. In smokers who 
switched to smoking the Lark1 cigarette, a 
conventional combustible tobacco cigarette 
representative of the low-tar cigarette market, 
smaller mean reductions were observed, most of 
which were statistically significant. The largest mean 
reductions occurred in smokers who switched to no 
smoking. 
Tricker et al. 
415 
2012d 




The authors reported on levels of biomarkers of 
exposure to 12 selected harmful and potentially 
harmful constituents in conventional combustible 
tobacco cigarette smoke (Marlboro Ultra Lights 
Menthol cigarettes, the M4J(M) (4 mg tar and 0.3 
mg nicotine)), and on levels of urinary excretion of 
mutagenic material and serum Clara cell 16-kDa 
protein (CC16) in the following four groups: smokers 
of conventional combustible tobacco cigarettes; 
users of the M4J(M) cigarettes; participants who 
switched to smoking either the EHCSS-K6M 
cigarette (5 mg tar and 0.3 mg nicotine) or the Lark1 
menthol cigarette (Lark1M) (1 mg tar and 0.1 mg 
nicotine); and non-smokers. 
Comparative groups 
Comparison(s) of conventional combustible tobacco 
cigarette users (smoke 10–30 menthol cigarettes per day 
for ≥2 months, with 3–6 mg tar, at baseline) using: 
(1) Marlboro Ultra Lights Menthol cigarettes  
(2) Electrically Heated Cigarette Smoking System menthol 
cigarette (EHCSS‐K6(M)) 
(3) Lark One menthol cigarette (Lark1(M)) 
(4) smoking abstinence 
The authors concluded that this study showed 









Possible benefit or 
harm 
Interventional trial papers on exposure to heat-
not-burn toxins 
Trial design 
biomarkers of exposure to selected harmful and 
potentially harmful constituents in tobacco cigarette 
smoke from baseline to day 5 or 6 in smokers of the 
M4J(M) cigarette who switched to using the EHCSS 
series-K lighter and smoking the EHCSS-K6M 
menthol cigarette. In smokers who switched to 
smoking the Lark1M menthol cigarette, a 
conventional combustible tobacco cigarette 
representative of the low-tar menthol cigarette 
market, reductions in exposure to individual 
harmful and potentially harmful constituents in 
tobacco cigarette smoke were smaller. The largest 
reductions in individual harmful and potentially 
harmful constituents in tobacco cigarette smoke 
occurred in smokers who switched to no smoking. 
Reductions in the mean excretion of mutagenic 
material in urine occurred in the EHCSS-K6M and 
no-smoking groups, but not in the M4J(M) and 
Lark1M groups. Changes in serum concentrations of 
Clara cell 16-kDa protein could not be meaningfully 
interpreted. 








The authors reported on changes in levels of 
biomarkers of exposure in healthy smokers who 
switched to a prototype heated cigarette. Measures 
on 10 biomarkers of exposure (nicotine, carbon 
monoxide (CO), benzene, 1,3-butadiene, acrolein, 
hydrogen cyanide, crotonaldehyde, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK), pyrene, and 4-aminobiphenyl), and urine 
mutagenicity, were recorded 
Comparative groups 
Comparison(s) of conventional combustible tobacco 
cigarette users (smoke ≥ 20 cigarettes per day for ≥1 year, 
with 10–15 mg tar, and same brand for ≥ 8 weeks, at 
baseline) using: 
(1) prototype heated cigarette  
(2) 10 mg tar conventional cigarette 
The authors concluded that exposure to most 
tobacco cigarette smoke constituents, except 
carbon monoxide (CO), can be reduced by switching 
from a conventional combustible tobacco cigarette 





  Tobacco heating system  
Haziza et al. 
417 
2016a 




The authors reported on levels of harmful and 
potentially harmful constituents in smokers 
continuing to smoke conventional combustible 
tobacco cigarettes, smokers switching to the THS 
2.2, and smokers abstaining from smoking for 5 
days. 
Comparative groups 
Comparison(s) of conventional combustible tobacco 
cigarette users (smoke ≥ 10 non-menthol cigarettes per 
day for ≥4 weeks, with a maximum yield of 1 mg nicotine 
per cigarette, and smoked ≥ 3 years, at baseline) using: 









Possible benefit or 
harm 
Interventional trial papers on exposure to heat-
not-burn toxins 
Trial design 
(2) conventional combustible tobacco cigarettes  
(3) smoking abstinence 
The authors concluded that switching from smoking 
conventional combustible tobacco cigarettes to 
using the THS 2.2 resulted in substantial reductions 
in exposure to 15 selected harmful and potentially 
harmful constituents of tobacco smoke. The kinetics 
and the magnitude of the decrease in levels of 
biomarkers of exposure observed in the THS 2.2 
group were approaching the levels observed in the 
smoking abstention group for the majority of the 
biomarkers of exposure. Nicotine uptake was similar 
between the THS 2.2 and conventional combustible 
tobacco cigarette groups at the end of the 5-day 
exposure period; after users had started to adapt to 
a new product, and with a transitional period of 
changing puffing behaviour, users were able to 
achieve their desired nicotine level. The 
combination of the results of nicotine exposure and 
subjective effect measures indicated that the THS 
2.2 offered comparable satisfaction, with regard to 
taste and sensorial experience, to that which was 
observed in conventional combustible tobacco 
cigarette smokers. No adverse event or severe 
adverse events were reported during this study, 
with the total number of adverse events being very 








The authors reported on levels of harmful and 
potentially harmful constituents in smokers 
continuing to smoke conventional combustible 
tobacco cigarettes, smokers switching to the THS 
2.2, and smokers abstaining from smoking for 5 
days. 
Comparative groups 
Comparison(s) of conventional combustible tobacco 
cigarette users with (smoke ≥ 10 non-menthol cigarettes 
per day for ≥4 weeks, with a maximum yield of 1 mg 
nicotine per cigarette, and smoked ≥ 3 years, at baseline) 
using: 
(1) ad libitum use of THS 2.2  
(2) conventional combustible tobacco cigarette use 
(3) smoking abstinence, 
The authors concluded that biomarkers of exposure, 
except those associated with nicotine exposure, 
were significantly reduced in the THS 2.2 group 
compared with the conventional combustible 
tobacco cigarette group, and approached the levels 
observed in the smoking abstinence group. 
Increased product consumption and total puff 
volume were reported in the THS 2.2 group. 
However, exposure to nicotine was similar to that in 
the conventional combustible tobacco cigarette 
group at the end of the confinement period. 
Reduction in the urge to smoke was comparable 
between the THS 2.2 and conventional combustible 
tobacco cigarette groups, and the THS 2.2 product 





Less harmful than 
conventional 
The authors reported on levels of biomarkers of 









Possible benefit or 
harm 





conventional combustible tobacco cigarettes, 
smokers switching to the menthol THS 2.2, and 
smokers abstaining from smoking for 5 days in a 
confined setting, followed by an 86-day ambulatory 
period. 
Comparative groups 
Comparison(s) of conventional combustible tobacco 
cigarette users (smoke ≥ 10 non-menthol cigarettes per 
day for 4 weeks, with a maximum yield of 1 mg nicotine 
per cigarette, and smoked ≥ 3 years, and did not plan to 
quit, at baseline) with: 
(1) menthol Tobacco Heating System (mTHS) 2.2  
(2) menthol cigarettes  
(3) smoking abstinence 
The authors concluded that switching to the 
menthol THS 2.2 led to significant reductions in 
exposure to Total NNAL the molar sum of 4-
(methylnitrosamino)-1-(3-pyridy1)-1-butanol and its 
O-glucuronide conjugate, Total NNN the molar sum 
of free and conjugated NNN i.e.N-
nitrosonornicotine, carboxyhemoglobin, 





Cyanoethylmercapturic Acid, Hydroxybutyl 
Mercapturic Acid, HMPMA, and benzo[a]pyren after 
5 days in confinement, which were maintained 
throughout the subsequent ambulatory period of 86 
days. The reductions were comparable to those 








The authors reported on the impact of switching to 
the THS 2.1 on biomarkers of exposure to harmful 
and potentially harmful constituents. 
Comparative groups 
Comparison(s) of conventional combustible tobacco 
cigarette users (smoke ≥ 10 non-menthol cigarettes per 
day for 4 weeks, with a maximum yield of 1 mg nicotine 
per cigarette, and smoked ≥ 3 years, at baseline) using: 
(1) conventional combustible tobacco cigarette 
(2) Tobacco Heating System THS 2.1 
The authors concluded that the THS 2.1 is a 
promising alternative to smoking conventional 
combustible tobacco cigarettes. Notwithstanding 
possible use adaption through consumption or 
puffing behaviour, the exposure to harmful smoke 
constituents was markedly reduced following use of 










The authors reported on the impact of switching to 
the menthol THS 2.2 on biomarkers of exposure to 
harmful and potentially harmful constituents 
relative to smoking menthol conventional 
combustible tobacco cigarettes and smoking 
abstinence. 
Comparative groups 
Comparison(s) of conventional combustible tobacco 









Possible benefit or 
harm 
Interventional trial papers on exposure to heat-
not-burn toxins 
Trial design 
4 weeks, with a maximum yield of 1 mg nicotine per 
cigarette, and smoked ≥ 3 years, at baseline) using: 
(1) menthol Tobacco Heating System 2.2 (mTHS)  
(2) conventional combustible tobacco cigarettes 
The authors concluded that switching from menthol 
conventional combustible tobacco cigarettes to the 
menthol THS 2.2 significantly reduced exposure to 
harmful and potentially harmful constituents 
relative to continuing smoking menthol 
conventional combustible tobacco cigarettes, with 
concentrations in those who switched being similar 
to the concentrations observed following smoking 
abstinence in Japanese adult smokers. 









The authors aimed to investigate the effects of 
exposure to selected harmful and potentially 
harmful constituents of conventional combustible 
tobacco cigarette smoke in adult smokers who 
switched to a carbon-heated tobacco product, 
compared with adult smokers who continued to 
smoke conventional combustible tobacco cigarettes 
and those who abstained from smoking for 5 days. 
Comparative groups 
Comparison(s) of conventional combustible tobacco 
cigarette users (smoke 10−30 cigarettes per day for 4 
weeks, with a maximum tar yield of 10 mg per cigarette, 
and smoked ≥ 5 years, at baseline) using: 
(1) conventional combustible tobacco cigarette smoking ad 
libitum  
(2) carbon-heated tobacco product (CHTP) 
version MD2-E7 ad libitum 
The authors concluded that the results provide clear 
evidence supporting a reduction in the level of 
exposure to harmful and potentially harmful 
constituents of tobacco cigarette smoke in smokers 
who switched to a carbon-heated tobacco product 
under controlled conditions, and that the reduction 




  glo™ THP 1.0 versus IQOS/THS  




products equal  
The authors reported on the relationship of using 
two tobacco heating products (the glo™ THP 1.0 or 
the in-market comparator, the IQOS/THS) with 
biomarkers of toxicant exposure. 
Comparative groups 
Comparison(s) of conventional combustible tobacco 
cigarette users (smoke 10−30 menthol cigarettes per day 
for ≥ 3 years, at baseline) using: 
(1) a 7-mg/cig ISO tar combustible tobacco non-menthol 
cigarette  
(2) glo™/THP1.0 with non-menthol Neostiks  
(3) a 7-mg/cig ISO tar combustible tobacco menthol 
Cigarette  
(4) glo™/THP1.0 with menthol Neostiks 
Note: The iQOS/THS product with non-menthol tobacco 
consumables was also studied as an in-market comparator 









Possible benefit or 
harm 
Interventional trial papers on exposure to heat-
not-burn toxins 
Trial design 
mentholated cigarettes were randomized to use 
mentholated products during the study 
The authors concluded that switching from smoking 
to using THPs resulted in significant reductions in 
biomarkers of exposure for selected smoke 
constituents. For most of these biomarkers, the 
speed and magnitude of the reductions were 
comparable to those observed during smoking 
cessation. In this clinical study, the use of the study 
THPs was safe and well tolerated with a small 
number of AEs reported that were not attributed to 
study product use. Together with pre-clinical data 
on glo™/THP1.0 showing reduced emissions and 
toxicological endpoints relative to cigarettes, glo™ 
has the potential to be a reduced exposure and/or 
reduced risk tobacco product when used by 
smokers whose cigarette consumption is displaced 
completely. 
5.4.2.9 Other outcomes: interventional trials 








6.1 Summary of findings 
This mapping exercise describes findings from published peer-reviewed journal articles and organises 
the information in a way that enables discussion and decision-making by researchers, policy makers, 
and practitioners. This mapping exercise allows examination of the relationship between two 
nicotine-related products and their impact on health. Specifically, it addresses two questions posed 
by the Irish Department of Health. The first ‘What are the public health benefits and harms of e-
cigarettes?’ and the second ‘What are the public health benefits and harms of heat-not-burn tobacco 
products?’ The HRB identified 388 papers eligible for inclusion in the report, 361 reporting the harms 
and benefits of e-cigarettes, and 28 reporting the harms and benefits of heat-not-burn tobacco 
products, with one paper reporting both exposures. The outcomes measured were clinically 
diagnosed diseases or injuries, biological risk markers for disease, measures of organ function, 
presence of toxins and toxicants, and self-reported signs and symptoms. These biological risk markers 
were: measures within the normally accepted clinical range indicative of health and well-being, and 
measures outside the normally accepted clinical range which are regarded as indicative of current or 
later disease (Tables 60 and 64). 
6.1.1 E-cigarette summary map 
6.1.1.1 Study design by United States National Academies of Sciences, Engineer-
ing, and Medicine (Academies of Sciences) umbrella terms: e-cigarettes 
The 361 included studies on possible harms and benefits of e-cigarettes were mapped by study design 
and by the adapted Academies of Sciences’ umbrella terms.6 The number of study papers in each 
group is presented in Table 59. All types of epidemiological study designs are used to investigate the 
recent e-cigarette phenomenon. The highest number of studies are case reports, followed by 
interventional trials and cross-sectional surveys. Papers reporting surveillance data are also presented 
as they characterise clinical presentation of the harms and benefits of e-cigarettes at a community-
level. Most of the observational and interventional studies identify associations between e-cigarettes 
and the outcomes of interest, but these associations do not prove causality. A well-conducted RCT 
adequately controls for confounding and the observed direction of effect may indicate a causal 
beneficial or harmful effect where the other essential criteria for causality are met. However, care 
must be taken in the area of e-cigarettes when generalising findings from the studied populations to 
other populations with different characteristics, and when generalising findings from populations 
where different kinds of interventions were used. In addition, the included studies have short follow-
up periods and small sample sizes. Overall, it is difficult to generalise any e-cigarette trial findings to 
the general population. A total of 9% of the interventional trials were completed by the e-cigarette 
industry. The highest and second-highest number of studies by scientific heading and study design are 
shown in navy blue, and light blue shading, respectively, in Table 59. The majority of studies were 
completed on the acute effects of e-cigarettes, specifically on acute respiratory conditions and on 
injuries and poisonings. Relatively little research was published on e-cigarettes and cancers, on e-
cigarettes and developmental and reproductive effects, or on e-cigarettes and the effects of passive 







Table 59 Study papers on e-cigarettes, mapped by study design and by adapted Academies of 





umbrella terms  






















60 0 2 1 21* 0 10 26* 
Cardiovascular 
diseases 
32 2 1 0 5 0 3 21 
Cancers 7 0 1 0 5 1 0 0 
Respiratory 
diseases 
78 23 8 4 21 1 5 16 





2 0 0 1 0 0 1 0 
Injuries and 
poisonings 




28 4 1 1 9 0 0 13 
Other 
outcomes 
30 12 0 0 11 0 0 7 
*The highest and second-highest number of studies by scientific heading and study design are shown in navy blue, and light 






6.1.1.2 Study characteristics: e-cigarettes 
The peer-reviewed published studies were drawn from all over the globe, with the highest number 
from the USA, followed by Italy. The study participants were mainly adults. However, young children 
were common in studies examining injuries and poisonings. Never-smokers were also observed to use 
e-cigarettes.  
The outcomes measured were clinically diagnosed diseases or injuries, biological risk markers for 
disease, measures of organ function, toxins and toxicants, and self-reported signs and symptoms. The 
follow-up periods in the mapped studies ranged from minutes to 24 months and did not have a 
sufficient timeframe to detect chronic disease outcomes such as cardiovascular diseases, cancers, or 
chronic respiratory diseases. A total of 8 (9%) of the 86 interventional trials reported on an exposure 
outcome effect measured between 12 weeks and 24 months, while the remaining 78 trials reported 
on outcomes measured within 8 weeks or less. The study designs were a mix of randomised 
controlled trials, randomised and non-randomised crossover trials including Latin square trials, and 
non-randomised before and after studies. 
It is important to note that e-cigarettes and their e-liquids were not a standard intervention in the 
included studies; rather, they are an umbrella term for a device that delivers nicotine and other 
products including flavourings. By 2017, more than 611 e-cigarette brands were available, and to 
generalise findings from the randomised trial of one specific e-cigarette as an assessment of the 
expected impact of all e-cigarette types discounts the differences in the chemical composition of 
various e-cigarette brands and types. The content of the e-liquids was another confounding factor 
due to the variation in nicotine dosages and other contents. To date, of the 86 trials examining health 
benefits and harms in people included in the map, only 62 trials identified the device used and only 
39 e-cigarette devices were tested out of 611 ever available on the market or 433 believed to be 
currently available, which gives a sense of the small number of e-cigarette devices that have been 
tested in trials involving people, and the small number of corresponding research papers published in 
peer-reviewed literature.  
The variations in e-cigarettes tested included: disposable e-cigarettes which were not refillable, e-
cigarettes which used replaceable prefilled cartridges, and tank models which were filled with liquids 
by the user. Disposable e-cigarettes consisted of batteries with primary (not chargeable) cells, 
whereas e-cigarettes with rechargeable cells used replaceable prefilled cartridges or had refillable 
tanks.  
The content of the e-liquids was another confounding factor. The variation in nicotine dosages is 
noteworthy, specifically in trials seeking to assess issues around dependence and abuse liability. This 
is particularly relevant given that the higher nicotine levels, specifically reported as between 18 and 
36 mg/mL, have been demonstrated to be the only doses resulting in a reliable increase in nicotine 
plasma concentrations. Reports on the carrier solution, a mixture of propylene glycol and vegetable 
glycerine, varied from 40.0% to 72.5% for propylene glycol and from 18.8% to 40.8% for vegetable 
glycerine. A range of other products was found in the carrier solution, for example, the presence of 
metals (cadmium, lead, mercury, and chromium), volatile organic compounds (pyrazine and 2,3-






Table 60 Study characterisation  
Characteristic Descriptor 
Study design Case report, case series, information or surveillance system report, cross-sectional survey, case-
control study, longitudinal cohort study, and interventional trials to test interventions (which included 
randomised controlled, randomised and non-randomised crossover, non-randomised before and 
after, or Latin square) 
Age All age groups, but a high proportion of young adults 
Young children were associated with poisonings 
Sex Both sexes, but more males than females 
Continent or 
country 
Africa (Egypt, South Africa), Americas (Canada, the USA), Asia (Hong Kong, China, Indonesia, Japan, 
Malaysia, South Korea, Saudi Arabia, Turkey), Australia, and Europe (Belgium, Denmark, France, 
Greece, Germany, Hungary, Italy, Poland, Romania, Russia, Spain, Sweden, and the UK)). There were 
two worldwide surveys and two cross-European studies. 
Population size Wide variation in study numbers, ranging from 1 to 486,303 
Study duration Minutes to 24 months. Varied by study design. 
Case report, case series, and information or surveillance system report consisted of one event per 
case where the exposure was followed in a short period of time by the outcome 
Case-control studies looking back from disease to exposure 
Cross-sectional survey through a single point in time interview 
Cohort studies with at least one follow-up. The longest follow-up period was 24 months. 




E-cigarettes are not standard interventions. 
E-cigarette users were grouped as never, former, occasional, and daily users. 
Each of the four groups was further subdivided according to e-cigarette use (such as nicotine and non-
nicotine) and dual use. 
Outcomes The dependence and abuse liability outcomes assessed were: patterns of e-cigarette use, cravings, 
desire to smoke, dependence, sleeping patterns, appetite control, cognitive performance or memory, 
depression, suicidality, and blood or brain nicotine levels.  
The measures assessed in order to evaluate cardiovascular health included: blood pressure, blood 
counts, heart rate, body weight, myocardial function, arterial stiffness and arterial pressure, 
endothelial progenitor cells, vagal and sympathetic nerve activity, antioxidant parameters, 
microvascular endothelial function and oxidative stress, and vascular and haemodynamic measures. 
Carcinogenic risk was assessed through a variety of measures, including the total nicotine equivalents 
or dose; the nicotine metabolite ratio; tobacco-specific smoking-related carcinogens for oral, 
oesophageal, lung, and bladder cancers; and cytologic examination of micronuclei in the oral mucosa. 
The measures used to assess respiratory diseases were: signs and symptoms of possible respiratory 
diseases, respiratory function tests, measures of tissue damage or stress, measures of toxicity in body 
tissue and exhaled breath, and the propensity for respiratory diseases.  
The measures of oral diseases were: full-mouth plaque index, bleeding on probing, clinical attachment 
loss, probing depth, gum disease, bone loss around teeth, gingival inflammation, perfusion of buccal 
mucosal tissue, infection markers, tumour markers, and parent drug and metabolites in oral fluid. 
The developmental and reproductive effects measured were: prevalence of e-cigarette use during 
pregnancy and the lactating period, and the effects of e-cigarettes on weight for gestational age at 
birth. 
Injuries and poisonings were measured using chemical laboratory analysis and were classified using 






The toxins and toxicants measured were urinary nicotine metabolites, minor tobacco alkaloids, arsenic 
and arsenic compounds, tobacco-specific nitrosamines, metals, polycyclic aromatic hydrocarbons, 
volatile organic compounds, and toxic gases. 
6.1.1.3 Absolute health-related harms associated with e-cigarettes 
Most observed clinical harms were due to acute events associated with the use of e-cigarettes and 
were reported in descriptive case studies, surveillance system papers, and cross-sectional survey 
papers (Table 61).  
The acute effects included poisonings (mainly nicotine and some e-liquid constituents), injuries 
(mainly burns and some fractures), and respiratory diseases (mainly injuries to the lungs and 
exacerbation of asthma). There were fatalities among the poisonings and respiratory disease cases, 
and long-term disability among some burn cases. Twelve papers reported on the outbreak of lung 
injury associated with e-cigarettes or vaping between June and October 2019 across a range of 
American states. These papers presented acute effects of e-cigarette use that in some cases resulted 
in fatalities. Both the poisoning cases and the respiratory disease cases highlighted a possible 
association between e-cigarettes and the use of other drugs such as alcohol, synthetic cannabinoids, 
and opiates. The categories ‘injuries and poisonings’ and ‘exposure to e-cigarette toxins’ were closely 
linked. Poisonings resulted in acute adverse events, while exposure to toxins covered the detection of 
the slow build-up of toxins and toxicants (such as metals and volatile organic compounds) in the body, 
which are biomarkers for future disease and can cause tissue damage or cancer. In addition, hand and 
mouth contact with e-cigarettes was associated with harms such as dermatitis (five cases) and 
reduced blood circulation (and delayed wound healing in three case reports).  
Seven studies identified an association between e-cigarettes and depression, and three studies 
identified an association with suicidality. Two trials reported that e-cigarettes have potential for 
abuse liability and another two trials reported that e-cigarettes created dependence and abuse 
liability among never smokers.  
There was some early evidence of damage to cardiovascular and respiratory tissue, mainly due to 
metals and volatile organic compounds. Four cross-sectional surveys on cancers identified the 
presence of carcinogens for lung, oral, and oesophageal cancer, and one identified biomarkers for 
bladder cancers. In addition, two case report papers described two e-cigarette users with oral cancer 
that could not be attributed to another exposure or factor. With respect to dental and periodontal 
health, seven papers found that e-cigarette users are prone to developing plaque, caries, or 
periodontal disease. Three cross-sectional survey papers identified markers for oral infection in e-
cigarette users. One surveillance system paper reported on cases of e-cigarette vaping during 
pregnancy, and there was evidence from one longitudinal study that e-cigarettes may be associated 
with newborns being small for gestational age. A second paper based on prospective longitudinal 
study design and published after the mapping search period did not uphold the first longitudinal 
study findings.288  Five studies identified that passive nicotine intake had occurred in the participants 
involved in these studies, and the authors of these studies reported that negative effects of passive 






Table 61 Possible e-cigarette-related negative outcomes, mapped by study design and by adapted 
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 Depression    5  4  
 Suicidality    4    
 Sleep 
disturbance    3    
 Weight control    2    
 Dual use      ● 1 
 Higher nicotine 









fibrillation 1  .  .   
 Coronary artery 
dissection 1       
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 Increased heart 
rate       3 
 Increased 
blood pressure       4 
 Platelet activity 
or clotting       1 
 Arterial 
stiffness       2 
Associated with smoking initiation in adolescents 
Indicator of tissue damage 

































stress       3 
 Reduced local 
circulation       2 
Cancers Oral carcinoma  1      
 Presence of 
carcinogens for 
lung, oral, and 
oesophageal 
cancers 
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 Bladder cancer 
biomarkers     1   
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Respiratory 
diseases 
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chronic 
respiratory 
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non-users  
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Injuries  Blast injuries 8 13 3  .   
 Burns 10 6 1     
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Poisonings Nicotine/e-
































 Opiate 1 1      
 Synthetic 
cannabinoids 1       
Exposure to e-
cigarette toxins 




1       
 Second- or 
third-hand 
nicotine intake 
  1    1 
 Metals    3    
 Volatile organic 
compounds    2   3 
 Other toxins    1   1 
 
6.1.1.4 Relative health-related harms associated with e-cigarettes 
Due to the mapping nature of the work undertaken here, we have stated the direction of effect for 
the observed relationships in observational and interventional studies, but not quantified the 
direction of effect. It is important to consider if harms or benefits from e-cigarettes or heat-not-burn 
tobacco products are greater or less than harms or benefits arising from the use of conventional 
tobacco cigarettes or other nicotine products which is defined as a relative effect.  
As this is an evolving research area, it is too early to identify definitive chronic disease outcomes 
comparable to disease outcomes attributable to conventional cigarette use. There was variation in 
the direction of the impact of e-cigarettes on respiratory, cardiovascular, and oral disease outcomes, 
sometimes of a discordant nature. Some respiratory, cardiovascular, and oral diseases were noted to 
be less harmful in e-cigarette users than in conventional cigarette smokers but were as harmful in 
dual users (i.e. users of both conventional tobacco cigarettes and e-cigarettes) (Table 62). For 
example, with respect to respiratory diseases, one trial reported steady, progressive improvements in 
certain exhaled breath measurements and symptom scores following the switch from conventional 
tobacco cigarettes to e-cigarettes. Five trials reported that e-cigarettes were less harmful to lung 
function than conventional tobacco cigarettes. However, nine trials suggested that e-cigarettes 
damage the respiratory system by reducing vascular function to the lungs and/or reducing 
physiological function. Some examples of the findings for cardiovascular diseases are: four trials 
examined the effects of e-cigarettes on arterial stiffness, one trial reported no effect on arterial 
stiffness and three trials reported an increase in arterial stiffness. Four trials plus a fifth post-review 
non-randomised prospective study examined a combination of oxidative stress and vascular function; 
one trial reported a benefit was identified and one trial reported no harm was identified while three 
trials reported increased oxidative stress related to e-cigarettes. Six trials reported on the relationship 
between e-cigarettes and heart rate and/or blood pressure; two trials reported no effect and four 
trials reported a harmful effect. With respect to oral diseases, one trial concluded that e-cigarettes 
may improve blood flow to the oral mucosa while another trial concluded that there was a 
Indicator of tissue damage 





statistically significant increase in gingival inflammation when tobacco smokers switched from 
smoking to vaping for 2 weeks. 
Some biomarkers for lung, oral, and oesophageal cancers were noted to be lower in e-cigarette users 
than in conventional cigarette smokers. For example, four cross-sectional surveys examined the 
toxicity of conventional tobacco cigarettes and e-cigarettes when taken together or alone. These 
surveys showed that conventional cigarette smokers and dual users of conventional tobacco 
cigarettes and e-cigarettes had similar levels of urinary toxicants and carcinogen metabolites, 
whereas exclusive e-cigarette users had lower levels and non-users had the lowest levels. In addition, 
nine trial papers reported that toxin levels associated with smoking conventional tobacco cigarettes 
were lower in persons who had switched from using conventional tobacco cigarettes to using e-
cigarettes. Smokeless tobacco product users and e-cigarette users had polycyclic aromatic 
hydrocarbon biomarkers somewhere between the levels found in conventional cigarette smokers and 
in non-smokers.  
One study found that participants who were users of both e-cigarettes and conventional tobacco 
cigarettes had a lower level of dependence on e-cigarettes than on conventional tobacco cigarettes; 
however, this finding was not consistent across other studies. One trial found that use of e-cigarettes 
decreased cigarette consumption by 50% without causing significant nicotine withdrawal symptoms 
or increasing negative mental health symptoms in patients with chronic schizophrenia who smoked 
and did not intend to quit. Eight trials reported that using e-cigarettes reduced craving-like sensations 
in conventional cigarette smokers, whereas five trials reported that e-cigarettes did not reduce 
craving-like sensations. Two trials reported lower nicotine uptake in e-cigarette vapers than in 
conventional cigarette smokers, but another three trials reported similar nicotine uptake in vapers 
when compared to smokers. 
Table 61 Possible e-cigarette-related harms, but less harmful than those related to conventional 
tobacco cigarettes, mapped by study design and by adapted Academies of Sciences’ umbrella terms 
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6.1.1.5 Health-related benefits associated with e-cigarettes 
The evidence map featured few benefits of e-cigarettes reported in the examined studies (Table 63). 
The most common relative benefits, reported by a small number of heavy smokers of conventional 
tobacco cigarettes, were smoking cessation and smoking reduction. A state of stable dependence was 
categorised as a benefit in one paper. In a few studies, e-cigarette vaping was used as a way to 
minimise weight gain post-cessation of conventional cigarette smoking. One study claimed that e-
cigarettes may better facilitate control of blood pressure (compared with smoking cigarettes), but all 
of these study participants were also prescribed personally titrated antihypertensive regimes. E-
cigarettes may improve blood flow to the oral mucosa postoperatively in the non-smoker population, 
but only one small trial paper reported better blood circulation while three case studies reported 
reduced blood circulation and delayed wound healing. Four case report participants reported 
improvement in chronic disease symptoms and associated the improvement with the initiation of e-
cigarette use (reduction of ulcerative colitis symptoms in one case, reversal of a blood condition in 
one case, recovery from chronic tonsillitis in one case, resolution of chronic nasal infection in one 
case, and reduction of Parkinson’s disease symptoms in one case).  
6.1.1.6 Summary statement on e-cigarette health-related harms, harm reduction, 
and benefits 
The e-cigarette-related health harms, harm reduction, and benefits known to date are presented in 
this mapping exercise. However, there may be unknown harms. Most of the observed clinical harms 
were due to acute harmful events associated with the use of e-cigarettes and were reported in 
descriptive case studies, surveillance system papers, and cross-sectional survey papers.  
The acute harms included poisonings (mainly nicotine and some e-liquid constituents), injuries 
(mainly burns and some fractures), and respiratory diseases (mainly injuries to the lungs and 
exacerbation of asthma). There were fatalities among the poisonings and respiratory disease cases, 
and long-term disability among some burn cases. Both the poisoning cases and the respiratory 
disease cases highlighted a possible association between e-cigarettes and the use of other drugs such 
as alcohol, synthetic cannabinoids, and opiates. There was some early evidence of damage to 
cardiovascular and respiratory tissue, mainly due to metals and volatile organic compounds. Four 
cross-sectional surveys on cancers identified the presence of carcinogens for lung, oral, and 
oesophageal cancer, and one identified biomarkers for bladder cancers. Some respiratory, 
cardiovascular, and oral diseases were noted to be less harmful in e-cigarette users than in 
conventional cigarette smokers, but were as harmful in dual users (i.e. users of both conventional 
tobacco cigarettes and e-cigarettes). However, these respiratory, cardiovascular, and oral disease 
findings were not consistent across all studies. The evidence map featured few reported benefits. The 
most common benefits, which were reported by a small number of heavy smokers of conventional 
tobacco cigarettes, were smoking cessation and smoking reduction.  
Alongside this map, two systematic reviews 424 425 on e-cigarettes were completed by the HRB. In the 
first review, we found that e-cigarettes were not more effective than approved nicotine replacement 
therapies (NRTs), which questions the need for e-cigarettes as a smoking cessation intervention. In 
the second review, we found that e-cigarettes were associated with initiation of conventional 
cigarette smoking among adolescents, which identifies a potentially serious harm. In addition, we 
note that many studies showed that dual use (of both e-cigarettes and conventional tobacco 
cigarettes) was not less harmful than smoking conventional tobacco cigarettes alone, thereby raising 
questions about the smoking reduction benefit of e-cigarettes. However, long-term longitudinal 
cohort studies with detailed measures of exposure, specifically frequency of use and the chemical 
nature of the product used, are required in order to better understand if changes in the use of 
smoking-related products, such as the use of heat-not-burn tobacco products and e-cigarettes, have a 
positive or negative impact on later life health outcomes. Generally, our thematic findings align with 
the high-level findings of six reviews and has some contrasting findings with one systematic review. 
Given the time gap between the existing systematic reviews and our mapping exercise, we identified 
additional recent papers covering oral diseases as well as developmental and reproductive effects 





Table 62 Possible e-cigarette-related beneficial outcomes, mapped by study design and by adapted 
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6.1.2 Heat-not-burn tobacco products summary map 
6.1.2.1 Study design by adapted Academies of Sciences’ umbrella terms: heat-not-
burn tobacco products 
The 28 included published, peer-reviewed studies on possible harms and benefits of heat-not-burn 
tobacco products have been mapped by study design and by the adapted Academies of Sciences’ 
umbrella terms (Table 64).6 There were two case reports and one cross-sectional survey covering 
these products. There were 25 interventional trials, 23 of which were completed by authors working 
in the tobacco industry and 2 of which were completed by authors in universities, indicating a dearth 
of independent research on heat-not-burn tobacco products. Among the 25 published interventional 
trial papers, just under one-half (12) reported biomarkers of exposure to harmful or potentially 
harmful smoke constituents (see listing on Appendix 8). Eight interventional trial papers reported 
outcomes of cardiovascular health, and this represented the second most reported area of interest. 
One crossover interventional trial paper reported on measures of respiratory function, and four 
interventional trial papers reported on measures of dependence and abuse liability. The mapped 
interventional trials’ follow-up periods ranged from minutes to 24 weeks and were not long enough 
to detect heat-not-burn chronic disease outcomes such as cardiovascular diseases, cancers, or chronic 
respiratory diseases. No peer-reviewed studies on humans were published on cancers, oral diseases, 
or developmental and reproductive effects up to mid-November 2019. There were no acute 
poisonings or injuries as a result of heat-not-burn tobacco products, but the subject of toxicity is 







Table 63 Study papers on heat-not-burn tobacco products, mapped by study design and by adapted 
Academies of Sciences’ umbrella terms 





























5 0 0 0 1* 0 0 4* 
Cardiovascular 
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8 0 0 0 0 0 0 8 
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Respiratory 
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12 0 0 0 0 0 0 12 
Other 
outcomes 
0 0 0 0 0 0 0 0 
*The highest and second-highest number of studies by scientific heading and study design are shown in navy blue, and light 
blue shading, respectively. 
6.1.2.2 Study characteristics: heat-not-burn tobacco products 
In general, study participants were adults. However, there were some exceptions: adolescents were 
the subject of one cross-sectional study, and a 16-year-old male was the subject of one case report. 
Approximately one-half of the studies were conducted in Belgium, Italy, Poland, South Africa, the UK, 
and the USA, and approximately the same number were conducted in Asia (Japan and South Korea) 
(Table 65). The two case reports each described one individual’s history of acute eosinophilic 
pneumonia; the cross-sectional survey reported findings from 60,040 participants, and the sample 
sizes in the remaining papers (all interventional trials) varied from 18 to 316 participants. 
The majority of trials were classified as randomised controlled trials, or crossover trials; such designs, 
when well-designed and implemented, control for confounding. The time frames of 24 of the 25 
interventional trials were short; outcomes were gathered within a 10-day period or less. For the 
remaining trial, outcomes were gathered for 24 weeks. Biological measures were frequently gathered 
minutes or hours after exposure. The data collection time frames were adequate to report on 
transient effects following short-term heat-not-burn tobacco product use, but not the possible 
deleterious effects arising from long-term exposure. In general, the impact of heat-not-burn tobacco 
product use on outcomes beyond the short trial time frame parameters was not quantified.  
It is important to note that heat-not-burn tobacco products were not standardised interventions (i.e. 
products), but rather that ‘heat-not-burn tobacco products’ is an umbrella term for devices with 
similar but not identical yields of tar, nicotine, and other products, such as carbon monoxide. There 
was variation in the types of devices examined, the chemical yield of the devices, and the trial 





prototypes which are well described in Section 5.4.1.2. Data on tar, nicotine, glycerine, and glycerol 
content levels were reported; sticks of heat-not-burn tobacco products had values ranging from 3 to 5 
mg tar, 0.3 to 1.21 mg nicotine, 3.94 to 5.4 mg glycerine, and 2 to 50 mg glycerol per stick. Products 
with and without menthol flavouring were tested. Data on the chemical yield of the comparator 
conventional cigarette were not always available, as in several trials, participants were asked to bring 
and smoke their own preferred brand of conventional tobacco cigarettes. The available comparator 
data indicated that conventional tobacco cigarettes’ tar levels varied from 1 to 11 mg, nicotine levels 
varied from 0.1 to 0.8 mg, and a carbon monoxide yield varied from 1.5 mg to 11 mg. In addition, 
comparisons with e-cigarette devices (blu PRO, Fontem, Netherlands) and snus (Camel Snus) were 
also reported. 
Individual outcomes under the umbrella terms of ‘dependence and abuse liability’, ‘cardiovascular 
diseases’, ‘respiratory diseases’, and ‘exposure to heat-not-burn toxins’ were reported. The possible 
harm and benefit outcomes measured under the ‘dependence and abuse liability’ heading included 
cigarette craving/urge to smoke, withdrawal symptoms, nicotine and its metabolites, and various 
measures of carbon monoxide. The outcomes measured under the ‘cardiovascular diseases’ heading 
included a wide range of biomarkers that indicate organ and tissue damage. The reported respiratory 
outcomes included measures of airway resistance, lung function, and lung volume. The outcomes 
measured under the ‘exposure to heat-not-burn toxins’ heading were an extensive array of harmful 






Table 64 Study characterisation 
Characteristic Descriptor 
Study design Case report, cross-sectional survey, and interventional trials to test interventions 
(randomised and crossover) 
Age 16–65 years 
Sex Both sexes, but more males than females 
Continent or country Belgium, Italy, Japan, Poland, South Africa, South Korea, the UK, and the USA. Two 
studies did not report the geographical location of the study. 
Population size Wide variation in study numbers, ranging from 1 to 60,040 (interventional trials 
ranged from 18 to 316) 
Study duration Days to 24 weeks. 
Cross-sectional survey consisting of one interview 
Case report consisting of one event per case where the exposure was followed in a 
short period of time by the outcome 
Interventional trials vary in follow-up time, ranging from minutes to days or weeks 
Intervention or 
exposure 
Heat-not-burn tobacco products are not standard interventions. 
A range of heat-not-burn devices were used by study participants. Various editions 
of electrically heated cigarette smoking systems (e.g. EHCSS series-K), tobacco 
heating systems (e.g. THS 2.1), and a carbon-heated tobacco product prototype 
were tested in the interventional trials. 
Outcomes Clinically diagnosed harms, a wide range of biological risk markers for disease, 
measures of body function, and self-reported signs and symptoms associated with 
heat-not-burn product use. 
The possible harm and benefit outcomes measured for heat-not-burn product users 
under the ‘dependence and abuse liability’ heading included cigarette craving/urge 
to smoke, withdrawal symptoms, nicotine and its metabolites, and various 
measures of carbon monoxide.  
The outcomes measured under the ‘cardiovascular diseases’ heading included 
antioxidant status and oxidative stress, platelet activity, blood functions, endothelial 
function and dysfunction, lipid risk markers, cardiac risk markers, heart rate 
variability, cardiovascular risk and function, and factors related to oxygen uptake.  
The reported outcomes under the ‘respiratory diseases’ heading included measures 
of airway resistance, lung function, and lung volume.  
The outcomes measured under the ‘exposure to heat-not-burn toxins’ heading were 
an extensive array of harmful or potentially harmful constituents of tobacco smoke. 
6.1.2.3 Absolute and relative health-related harms associated with heat-not-burn 
tobacco products 
Three epidemiological study designs were used to investigate the impact of heat-not-burn tobacco 
products. These were case reports, one cross-sectional study, and interventional trials. The two case 
report papers described clinical diagnoses of acute eosinophilic pneumonia in a hospital setting (Table 
65). The cross-sectional survey paper reported an increased odds ratio of perceived stress among ad-
olescent heat-not-burn product users relative to non-tobacco users from a national-level survey in 
South Korea. Both study designs report associations between heat-not-burn tobacco products and the 
measured outcomes, but these study designs are not sufficient to determine a causal relationship.  
Four of the 25 interventional trials reported on dependence and abuse liability outcomes, and on 
related data measures that were gathered over an intervention period of between 2 and 8 days. The 
authors of the four papers concluded that substantial reductions in exposure to smoke constituents; 





following conventional cigarette smoking; and momentary reduction of acute cigarette craving and 
withdrawal symptoms were observed among persons using heat-not-burn tobacco products.  
Eight interventional trial papers reported on cardiovascular disease outcomes. Aside from one trial 
which lasted 24 weeks, outcome measures for the remaining trials were gathered over a period of 
between 2 and 10 days. The authors of the seven cardiovascular trial papers concluded that, 
compared with smoking conventional tobacco cigarettes or vaping e-cigarettes, cardiovascular 
disease outcome measures were less detrimental in heat-not-burn product users. However, adverse 
levels for all indicators were greater in heat-not-burn product users compared with non-smokers or 
persons who abstained from smoking during the trial period. 
One interventional trial paper focused on measures of respiratory disease outcomes. This crossover 
trial paper reported on measures of respiratory function and found that using heat-not-burn products 
was less harmful to mid- to small-size pulmonary airways than smoking conventional tobacco 
cigarettes, but that it was more harmful than smoking abstinence. 
The remaining 12 interventional trial papers examined in the heat-not-burn tobacco product section 
focused on a range of outcomes grouped within the ‘exposure to heat-not-burn toxins’ heading of the 
adapted Academies of Sciences’ framework. In general, the reported direction of effect regarding the 
relationship between heat-not-burn tobacco products and measures of harmful or potentially harmful 
smoke constituents indicated lower levels of many of these constituents in heat-not-burn product 
users relative to smokers of conventional tobacco cigarettes, but the lowest levels of these 
constituents were observed among smoking abstainers. For example, in some papers, strong mean 
reductions in the uptake of selected harmful and potentially harmful constituents of cigarette smoke 
and in the excretion of mutagenic material in urine were noted. This change in levels from baseline to 
the timepoint of outcome measurement was observed in cigarette smokers who switched from 
smoking high-tar conventional tobacco cigarettes to smoking heat-not-burn tobacco products. 
Reductions were also reported in smokers who switched to smoking conventional tobacco cigarettes 
representative of the low-tar cigarette market; however, the magnitude of the reduction was lower. 
The largest mean reductions occurred in smokers who completely abstained from smoking, though 
this reducing effect was not true in all instances. For some studies, reports on the direction of effect 
were mixed. One interventional trial paper specifically reported no change in biomarker levels of 
exposure to crotonaldehyde and acrolein. One interventional trial paper reported that changes in 
serum concentrations of Clara cell 16-kDa protein could not be meaningfully interpreted in 
participants who switched from smoking conventional tobacco cigarettes to using heat-not-burn 
tobacco products. 
6.1.2.4 Relative health-related benefits associated with heat-not-burn tobacco 
products 
The authors of the mapped studies reported no absolute benefits associated with heat-not-burn 
tobacco products, but did report relative benefits (Table 66). For example, cardiovascular disease 
outcome indicators reflected more clinically favourable levels in heat-not-burn tobacco product users 
than those observed in conventional cigarette smokers, but less favourable than those observed in 
smoking abstainers. A similar picture emerged for outcomes of harmful and potentially harmful 
constituents in cigarette smoke. For example, lower levels of harmful and potentially harmful 
constituents (see listing on page 8) in cigarette smoke were observed in the urinary, plasma, or blood 
tissue tested after use of heat-not-burn tobacco products than in the results of comparable tests 
carried out on conventional cigarette smokers, but the lowest levels of these constituents were 
observed in persons abstaining from smoking. However, it is important to remember that this 
mapping exercise has not examined the long-term consequences of changes in cardiovascular 
indicators or the impact of exposure to various toxins in harmful and potentially harmful constituents 
of tobacco smoke; these measures of exposure to toxins were collected over a period of 10 days or 
less.  
Table 65 Possible heat-not-burn tobacco product-related negative outcomes, mapped by study 
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6.1.2.5 Summary statement on heat-not-burn tobacco product harms and bene-
fits 
The map of the peer-reviewed literature on heat-not-burn tobacco products reported a range of 
health-related outcomes covering dependence and abuse liability, two body systems (cardiovascular 
and respiratory), and toxicology measures arising from exposure to harmful and potentially harmful 
constituents in tobacco smoke. We note that the majority of trials reporting on this area have 
compared a small number of commercially available heat-not-burn tobacco products with a range of 
conventional tobacco cigarettes, both releasing varying chemical yields. In a number of trials, 
comparisons have also been made with persons who have abstained from smoking for the trial 
duration or for a period during a crossover trial. The overall conclusions of the primary study authors 
were that the impacts of heat-not-burn tobacco constituents measured for cardiovascular and 
respiratory health and well-being were less harmful than those of conventional tobacco cigarettes, 
but more harmful than those observed in study participants who abstained from smoking. In a similar 
fashion, lower levels of the measured harmful and potentially harmful constituents in cigarette smoke 
were present in heat-not-burn tobacco product users than in smokers of conventional tobacco 
cigarettes, but the lowest levels of these harmful and potentially harmful constituents were observed 
in study participants who abstained from smoking. However, the long-term consequences of these 
outcomes cannot be addressed by the study designs examined in this mapping exercise. Our findings 





harmful and potentially harmful constituent levels were lower in heat-not-burn tobacco product users 
relative to the conventional cigarette user and that most research on heat-not burn tobacco products 
was industry funded.23 426 The review by the World Health Organization concluded the there is 
insufficient evidence to conclude that heat-not-burn tobacco products are less harmful than 
conventional tobacco cigarettes. In fact, the Organization concluded that the there is insufficient 
evidence to deem that heat-not-burn tobacco products are less harmful than conventional tobacco 
cigarettes.427 The Organization goes on to say that there are reservations, as heat-not-burn tobacco 
products may expose users to lower levels of some toxicants than conventional tobacco cigarettes, 
but they may also expose users to higher levels of other toxicants, and it is not clear how this 
toxicological profile transforms into short- and long-term health effects.427 
 
6.2 Comparison with systematic reviews 
6.2.1 E-cigarettes 
We compared our findings to published reviews on the health effects of e-cigarettes. We located 
seven reviews that covered the general health effects of e-cigarettes.428 429 430 431 6 426 432 Pisinger and 
Døssing (2014) completed a systematic review of the health effects of e-cigarettes and e-liquids based 
on 76 studies published before 14 August 2014 and concluded that despite the limitations of existing 
research, e-cigarettes cannot be considered harmless.433 The Canadian Agency for Drugs and 
Technologies in Health (CADTH) completed a rapid response report in 2017 based on article 
summaries, titled Electronic Cigarettes for the Reduction or Cessation of Smoking: Clinical Utility, 
Safety, and Guidelines, and reported that the long-term safety of e-cigarettes is unknown.429 The 
Commonwealth Scientific and Industrial Research Organisation (2018) reviewed the impacts of the 
use of e-cigarettes, personal vaporisers, and nicotine on individual and population health, and 
reported that the evidence available suggested that regular use of e-cigarettes was likely to have 
adverse health consequences, going on to say that there was a lack of clarity about the magnitude of 
adverse health effects and the quantity of e-cigarette use required to trigger adverse health 
effects.430 The Electronic Cigarettes – Task Force report from the European Respiratory Society (2018) 
concluded that e-cigarette aerosol contained potentially toxic chemicals.431 The 2018 Academies of 
Sciences’ publication, Public Health Consequences of E-Cigarettes, concluded that the absolute risks of 
these products cannot be unambiguously determined at this time, and that the long-term health 
effects were not yet clear.6 McNeil et al. published an evidence review of e-cigarettes and heated 
tobacco products in 2018; the report was commissioned by Public Health England.426 The authors 
made a number of conclusions generally in favour of e-cigarettes 426 The World Health Organization’s 
brief on e-cigarettes concluded with our findings that e-cigarettes are not harmless though the long-
term effects such as disease causation and death are not studied adequately. The Organization stated 
that e-cigarettes “are not safe for young people, pregnant women, and adults who have never 
smoked.”432(p10) They stated that “non-pregnant adult smokers who completely switch from 
combustible tobacco cigarettes to use of unadulterated and appropriately regulated e-cigarettes 
alone might reduce their health risks”.432(p10) The complete switch is consistent with the concept that 
e-cigarettes have no place in smoking reduction and dual use is not beneficial to health status. 
We found studies that identified an association between e-cigarette use and depression. Byrne et al. 
also highlighted the association between e-cigarette use and depression, which it stated was not 
thought to be causal but that it identified a population subgroup (i.e. people suffering from 
depression) that was vulnerable to the uptake and continued use of e-cigarettes.430 
We found that there appears to be early evidence of e-cigarette use causing damage to 
cardiovascular and respiratory organs and tissue, mainly due to exposure to metals and volatile 
organic compounds. Byrne et al. reported that there was no evidence that e-cigarette use was 
associated with clinical cardiovascular disease, although they stated that this conclusion was mainly 
due to a lack of long-term studies.430 However, Byrne et al. also found in vitro studies on e-cigarette 
vapour, liquid, and extracts that strongly indicated potential health risks, including cell death, 





expression, and increased cellular risk factors for cardiovascular disease. The World Health 
Organization reported that there is insufficient research to determine with certainty whether 
unadulterated and appropriately regulated e-cigarette use is associated with cardiovascular or lung 
diseases.432 The Organization found that the main substances in the e-cigarette aerosol that raise 
health concern are metals and carbonyls. The types and concentrations of metals depended on the 
product features and inhaling patterns of use. Exposure to certain levels of some metals may cause 
diseases of the cardiovascular and respiratory systems in the future.432 These findings concur with the 
findings presented in our research map. 
We found that a small number of studies identified the presence of carcinogens for lung, oral, and 
oesophageal cancers, and identified biomarkers for bladder cancers. In addition, we found two case 
report papers describing two e-cigarette users with oral cancer that could not be attributed to 
another exposure. Pisinger and Døssing found that e-cigarettes contained fine or ultrafine particles, 
harmful metals, carcinogenic tobacco-specific nitrosamines, volatile organic compounds, and 
carcinogenic carbonyls; were cytotoxic; and changed gene expressions.433 Byrne et al. also reported 
that e-cigarettes contained carcinogenic compounds, and that carcinogenic metabolites arising from 
e-cigarette use were present in e-cigarette users.430 However, Byrne et al. stated that the risk of 
developing cancer or other health effects from the levels of carcinogenic compounds and 
carcinogenic metabolites detected was not yet known.430 The Electronic Cigarettes – Task Force report 
from the European Respiratory Society reported that when compared to conventional tobacco 
cigarettes, e-cigarettes had fewer toxins and generally contained these toxins in lower 
concentrations.431 However, the report’s authors also stated that the long-term effects of e-cigarette 
use were unknown, and there was therefore no evidence that e-cigarettes were safer than 
conventional tobacco cigarettes in the long term and negative health effects could not be ruled out. 
The Academies of Sciences also reported that e-cigarette aerosol contained fewer numbers and lower 
levels of most toxicants than were found in smoke from conventional tobacco cigarettes.6 The 
Academies of Sciences reported that laboratory tests of e-cigarette ingredients, in vitro toxicological 
tests, and short-term human studies suggest that e-cigarettes are likely to be less harmful than 
conventional tobacco cigarettes, but cautioned that the long-term health effects of e-cigarettes were 
not yet clear; the World Health Organization used this evidence in their conclusions on cancer.432 The 
World Health Organization shared our and other reviewers the concerns on carbonyl compounds and 
it concluded that they are hazardous to users.432 For example, formaldehyde is a human carcinogen, 
acetaldehyde is possibly carcinogenic to humans, acrolein is a strong irritant of the respiratory system 
and glyoxal shows mutagenicity. However, the Organization acknowledges that the number and levels 
of carbonyls detected in the aerosol were lower than in smoke from combustible tobacco, but even 
these levels raised health concerns.432 McNeill et al. reported that one assessment of the published 
data on emissions from conventional tobacco cigarettes and e-cigarettes calculated the lifetime 
cancer risks of e-cigarettes were largely under 0.5% of the risk associated with smoking cigarettes.426 
McNeil et al. reported that biomarkers of exposure assessed were consistent with significant 
reductions in harmful constituents, and for a few biomarkers, similar levels to smokers abstaining 
from smoking or non-smokers were observed.426 
We reported that a small number of studies demonstrated that dual use of e-cigarettes and were 
more harmful than conventional tobacco cigarettes alone. McNeill et al. reported found one study 
showed no reductions across a range of biomarkers for dual users.426 The World Health 
Organization432 and Academies of Sciences6 also addressed the issue of dual or poly use. The 
Academies of Sciences review concluded that there is no available evidence on whether long-term e-
cigarette use among smokers (dual use) changes morbidity or mortality compared with those who 
only smoke conventional tobacco cigarettes. The World Health Organization found recent evidence 
that suggested that dual users have a greater level of oxidative stress than smokers and that adding 
use of e-cigarettes to smoking may contribute to cardiac and respiratory disease health risks.432 The 
organization pointed to another study that concluded dual users were not reducing exposure to 
harmful toxicants compared to exclusive cigarette smokers due to their continued smoking.432  
We found that respiratory diseases (mainly injuries to the lungs and exacerbation of asthma) were 
associated with e-cigarette use. Pisinger and Døssing reported that experimental studies found 





cigarettes impaired lung function, although it notes that the independent effect of e-cigarette vaping 
was unclear because of potential confounding by conventional cigarette smoking.430 McNeill et al. 
reported that there have been some studies with adolescents suggesting respiratory symptoms 
among e-cigarette experimenters, but one small scale study which examined the effect of switching 
from smoking to vaping demonstrated some respiratory improvements.426 The World Health 
Organization supports the assertions of Pisinger and Døssing and Byrne and conclude that there is 
moderate evidence that e-cigarette use increases cough and wheeze in adolescents and is associated 
with an increase in asthma exacerbations; this evidence applies to non-smokers as well as smokers.432  
We found a large number of studies detailing poisonings (mainly nicotine and some e-liquid 
constituents) and injuries (mainly burns and some fractures); there were fatalities among the 
poisonings and respiratory disease cases, as well as long-term disability among some burn cases. 
Byrne et al. also reported that intentional or accidental ingestion of e-liquids can cause serious injury 
or death.430 On the other hand, CADTH reported that potential harms occurred from acute nicotine 
poisoning through ingestion of the nicotine cartridge, especially in young children, but that this was 
uncommon. CADTH reported that the most prominent acute safety concern was from the potential 
for lithium battery-powered e-cigarettes to explode, causing thermal burns to the user.429 Byrne et 
al., like us, identified several case studies and case series reporting blast and thermal injuries that 
were attributed directly to e-cigarettes.430 McNeill et al. also found that e-cigarettes were associated 
with injuries and poisonings. The World Health Organization reported that there was conclusive 
evidence that e-cigarette devices can explode and cause burns and blast injuries when batteries are 
of poor quality, stored improperly or modified by users.432 The World Health Organization found 
conclusive evidence that intentional or accidental exposure to e-liquids can result in adverse health 
effects including death.432 
Pisinger and Døssing raised the issue of compounds not found in conventional tobacco cigarettes, 
such as propylene glycol, and said that these compounds merit special attention.433 The Academies of 
Sciences reported that exposure to nicotine and to toxicants from the aerosolisation of e-cigarette 
ingredients was dependent on user and device characteristics.6 McNeill et al. reported that levels of 
metals identified in e-cigarette aerosol do not give rise to any significant safety concerns to date, but 
metal emissions, however small, are unnecessary.426 McNeill et al. also reported that two studies of 
biomarker data for acrolein, a potent respiratory irritant, found levels consistent with non-smoking 
levels in e-cigarette user and that e-cigarettes can release aldehydes if e-liquids are overheated.426  
We found that hand and mouth contact with e-cigarettes was associated with harms such as 
dermatitis and reduced blood circulation. Byrne et al. also reported that case studies suggested that 
e-cigarette use interferes with, or delays, wound healing.430 
We found five studies that identified the occurrence of passive nicotine intake. The Electronic 
Cigarettes – Task Force report from the European Respiratory Society identified that second-hand 
exposures to chemicals in e-cigarettes may represent a potential risk, especially to vulnerable 
populations.431 On the contrary, McNeill et al. reported there were no identified health risks of 
passive vaping to bystanders to date.426 The World Health Organization reported that some studies 
indicate that a selection of volatile organic compounds were also exhaled into the environment 
during e-cigarette use.432 The Organization went on to say that passive exposure to nicotine and 
particulates is lower from e-cigarette aerosol compared with conventional tobacco cigarettes, but are 
higher than the smoke-free level recommended by the WHO Framework Convention on Tobacco 
Control.432 
We identified 12 papers that covered the outbreak of lung injury associated with e-cigarettes or 
vaping. The World Health Organization was the only review recent enough to cover this issue and 
reported that up to 7 January 2020, more than 2,500 cases had been reported to CDC from 50 states 
in the USA, and just under 60 deaths had been confirmed in 27 states.432 The World Health 
Organization stated that CDC identified the causal agent as Vitamin E acetate which is used as an 






Generally, our thematic findings align with the high-level findings of six reviews and has some 
contrasting findings with one systematic review. Given the time gap between the existing systematic 
reviews and our mapping exercise, we identified additional recent papers covering oral diseases as 
well as developmental and reproductive effects associated with e-cigarettes. 
6.2.2 Heat-not-burn tobacco products 
We compared our findings to three recent systematic reviews on heat-not-burn tobacco products.23 
426 427 Simonavicius et al.’s focus was to appraise the peer-reviewed evidence on heat-not-burn 
tobacco products, their second-hand emissions, and their use by humans, and to identify differences 
between independent and industry-funded studies. There were points of accord between their 
review and our mapping exercise, but also points of difference. Like Simonavicius et al., we examined 
papers reporting on heat-not-burn tobacco products in humans; however, we excluded laboratory 
comparison studies on heat-not-burn tobacco product mainstream smoke emission, which is the 
smoke a user draws in and is measured in the laboratory using standardised machine smoking 
regimes. Our findings aligned with those of Simonavicius et al. in several ways.23 We both found that 
the majority of papers examined were affiliated with the tobacco industry, and we both identified a 
range of harmful and potentially harmful smoking-related constituents arising from the use of heat-
not-burn tobacco products. We also both observed that heat-not-burn tobacco products provided 
similar cigarette craving-related measures to conventional tobacco cigarettes. While Simonavicius et 
al. quantified the relative levels of harmful and potentially harmful constituents in heat-not-burn 
tobacco product users in comparison to the levels observed among conventional cigarette smokers, 
we provided a narrative summary assessment.23 Simonavicius et al.’s quantification of comparisons 
for carbon monoxide levels and of harmful and potentially harmful smoking-related constituents did, 
however, align with our statements that these levels were lower in heat-not-burn tobacco product 
users relative to those in conventional cigarette smokers. The main points of difference were that we 
identified an additional nine papers for consideration, and we reported on cardiovascular and 
respiratory outcomes. We were unable to undertake further comparisons between our two reviews, 
as the focus of our mapping exercise – reporting on possible harms and benefits under the Academies 
of Sciences’ umbrella terms – deviated from the focus of Simonavicius et al.’s systematic review.23  
McNeil et al. published an evidence review of heated tobacco products in 2018.426 McNeill et al. 
concluded that heated tobacco products were commercially available in 27 countries in 2018. Out of 
20 studies that were included in their review, 12 were funded by manufacturing companies so and so 
the authors stated there is a lack of independent research. We also reported a lack of independent 
research, but we found that 23 out of 25 trials were industry funded. Similar to our findings, McNeill 
et al. reported that studies that compared use of heated tobacco products with smoking cigarettes as 
per the smokers wishes consistently reported lower nicotine levels in heated tobacco product 
smokers relative to conventional tobacco cigarette smokers. McNeill et al. reported that heated 
tobacco product use reduced urges to smoke conventional tobacco cigarettes, but smokers 
consistently reported smoking heated tobacco product was less rewarding compared with smoking a 
cigarette, and this finding is similar to our findings.426 
The World Health Organization concluded “there is insufficient evidence to conclude that heat-not-
burn tobacco products are less harmful than conventional tobacco cigarettes. In fact, there are 
concerns that while they may expose users to lower levels of some toxicants than conventional 
tobacco cigarettes, they also expose users to higher levels of other toxicants. It is not clear how this 
toxicological profile translates into short- and long-term health effects.”427(p8) The World Health 
Organization found that the nicotine delivery profile of some IQOS heat-not-burn tobacco products 
approximated to that of conventional tobacco cigarettes.427 The Organization reported, like our 
findings, that satisfaction is reported to be lower than for conventional tobacco products.427 
The World Health Organization concluded that there is no available evidence as to whether heat-not-
burn tobacco products use is associated with any long-term clinical outcome, positive or negative, 
from exposure to the mainstream emission. One Philip Morris International study claimed to the FDA 
that IQOS, compared to smoking a conventional cigarette, reduced biomarkers associated with 





counts, but the World Health Organization stated that these findings were not supported in their own 
paper.427 
6.3 Research gaps 
The reporting framework used in this mapping exercise allows a clear view of the published, peer-
reviewed, English-language research which has been undertaken to assess the impacts of e-cigarettes 
and heat-not-burn tobacco products on human health. The evidence map will serve as a framework 
for developing questions for scientific appraisal of the nature and direction of the observed 
relationship within different population groups and different clinical areas. The combination of the 
hierarchy of evidence and the adapted Academies of Sciences’ umbrella terms was a very useful 
method for categorising the retrieved papers. Presenting the papers in this way highlights that some 
areas are well described using epidemiological studies, but that there is a dearth of longitudinal 
cohort studies with well-designed protocols that capture the true effects of e-cigarettes and heat-not-
burn tobacco products. Long-term longitudinal cohort studies with detailed measures of exposure, 
specifically frequency of use and the chemical nature of the product used, are required in order to 
better understand if changes in the use of smoking-related products, such as the use of e-cigarettes 
and heat-not-burn tobacco products, have a positive or negative impact on later life health outcomes. 
The multitude of possible outcomes require targeted long-term cohort studies to answer research 
questions under all of the adapted Academies of Sciences’ umbrella terms in order to quantify 
outcome-specific differences between conventional cigarette smokers, e-cigarette users, heat-not-
burn tobacco product users, dual users of any combination of these product types, and non-users of 
any type of cigarette. In the absence of long-term studies, modelling of levels of biological markers for 
exposure to harmful or potentially harmful constituents in cigarette smoke may allow us to gain a 
preliminary understanding of some adverse effects of e-cigarettes and heat-not-burn tobacco 
products. At present, the USA, among other countries, is identifying the research needs, solutions, 
and funding requirements to progress an understanding of the health effects of e-cigarettes and heat-
not-burn tobacco products. It should be noted that there may be unknown harms which are yet to be 
identified. Some specific research areas that need to be examined thoroughly are the effects of 
deposits and accumulation of toxins from e-cigarettes and heat-not-burn tobacco products on 
respiratory, cardiovascular, neurological, and other body tissues; this will also require long-term 
studies examining the incidence of degenerative diseases and cancers among e-cigarette and heat-
not-burn tobacco product users. In addition, preliminary data indicate that a thorough examination of 
the effects of e-cigarettes and heat-not-burn tobacco products on embryos and newborns is required.  
There are four areas which we believe would enhance our understanding of the impacts not only of e-
cigarettes and heat-not-burn tobacco products, but also of other tobacco-related products that 
people can smoke, chew, or sniff.  
First, the comparison populations regarding smoking-related behaviours must be clearly defined. We 
identified a variety of potential comparison populations, ranging from never-smokers to current non-
smokers, current smokers, current e-cigarette users, or current dual or poly users of two or more 
tobacco-related products, but in some cases the populations for comparison were not clearly defined. 
The comparison study population parameters will depend on whether evidence on the absolute or 
relative effects of an e-cigarette or heat-not-burn tobacco product are being measured.  
Second, heterogeneity in the chemical yields and in the temperature at which the tobacco is heated 
for both the heat-not-burn tobacco products and the comparison conventional tobacco cigarettes 
needs to be closely examined and more clearly delineated in order to detect meaningful findings. 
There is a wide range of heat-not-burn tobacco products on the market. In general, these are known 
by their trade name and version (for example, THS 1.0 or THS 2.1). However, differences in chemical 
composition and even in certain design aspects can potentially mean that intra-brand differences 
between products may be similar to or even greater than inter-brand differences. In order to better 
assess the differences, if any, between the various heat-not-burn tobacco products and the 
comparison conventional tobacco cigarettes, research should take account of each product’s chemical 
composition and levels rather than simply the brands and versions, as this would represent a more 





comparison more closely aligns with a robust scientific evaluation of the products’ impact on health. 
From this mapping exercise, it appeared that marketing techniques were employed to suggest that 
differences in product type affected the harms and benefits arising from the use of the various 
tobacco products tested. This may indeed be the case; however, without a rigorous profiling of the 
chemical yield of each product, differences in the products tested and their mode of use will 
confound any true differences in effect. The current variety of e-cigarette devices and the chemical 
composition of the various e-liquids available on the market needs to be documented and evaluated 
in order to determine the safety of these products. The use of e-liquids as a carrier substance for 
psychoactive drugs, both licit and illicit, also needs to be investigated. In addition, the overlap 
between e-cigarette use and the use of other psychoactive drugs, including alcohol, requires 
examination. When considering young people, the use of flavourings to entice non-smokers to initiate 
e-cigarette use and the issue of flavourings approved for ingestion, but not for inhalation, requires 
investigation.  
Third, what, if any, difference changes in levels of biomarkers of exposure to harmful or potentially 
harmful vapour or smoke constituents have on the subsequent development of associated 
deleterious outcomes needs to be understood. Heat-not-burn tobacco products and e-cigarettes have 
been reported to deliver lower levels of the measured chemical toxicants than conventional tobacco 
cigarettes, while at the same time effectively delivering comparable levels of nicotine. This duality has 
been purported to offer a more benign exposure to the adverse health effects of conventional 
tobacco cigarettes and, in some way, to represent a less harmful nicotine addiction behaviour. 
However, the chemical components of all tobacco-related products represent an array of harmful and 
potentially harmful substances linked to adverse health outcomes for a range of body systems, such 
as cardiovascular, respiratory, and even neurological systems, as well as an array of diseases, such as 
cancers of the mouth, lungs, and bladder. A better understanding of the direct, mechanistic, and 
parallel effects of these toxins is required before assertions can be made that lower levels of exposure 
translate into reductions in the incidence of specific or overall disease outcomes. In addition, other 
harmful materials (e.g. metals) not currently in conventional tobacco cigarettes are present in the 
promoted tobacco-consumption substitutes, including e-cigarettes and heat-not-burn products. 
Furthermore, regarding nicotine uptake, what, if any, benefit arises from substituting one mode of 
delivery (conventional tobacco cigarettes) with another (e-cigarettes or heat-not-burn tobacco 
products) requires consideration, especially if the nicotine dependence habit remains unchanged or a 
dual habit develops. 
Fourth, there is a dearth of longitudinal information on specific populations where evidence on the 
impact of e-cigarettes could clearly contribute to public health policy formation. These populations 
include: adolescents, pregnant and lactating women and pregnancy itself (embryos and newborns), 
people with mental health problems, as well as patients with cancer, cardiovascular disease, or 
diabetes. 
6.4 Strengths and limitations  
The combination of the hierarchy of evidence and the adapted Academies of Sciences’ framework 
was a very useful method for categorising the existing literature. We have categorised 388 studies 
examining the possible harms and benefits of e-cigarettes and heat-not-burn tobacco products on 
human health. This mapping exercise allows us to identify the indicative benefits and harms, but does 
not allow us to explore any subject area in depth. While we can describe heterogenous findings, this 
exercise does not allow us to investigate the potential underlying reasons for the heterogeneity. Due 
to time and other resource limitations, we concentrated on human studies as these were the priority 
for this brief and excluded papers examining the effects of e-cigarettes and heat-not-burn tobacco 
products in animal studies and environmental studies. We suggest that an updated mapping exercise 
be completed in these areas in the near future, as systematic reviews identified that e-cigarettes are 
associated with some harms in animals.430 431 6 We anticipate that this mapping exercise will help 
subject-specific researchers determine what was known by November 2019 in their area of study and 
move quickly to address primary research gaps. With the exception of the trials, the observational 





cigarettes and heat-not-burn tobacco products with adverse health effects, rather than demonstrate 
causal links, and this is indicative of low levels of evidence. 
A limitation of all mapping exercises is that quality assessment of each primary paper is not required 
which prohibits critical examination of the primary authors’ study findings. While we did not do a 
quality assessment of each paper, we did categorise the studies by study design as rated on a 
hierarchy of evidence. Furthermore, we presented the study definition and purpose with respect to 
causal inferences in the findings’ chapters. Validity was also assessed by highlighting small sample 
sizes, loss to follow-up, lack of clarity with respect to exposures or interventions, lack of clarity with 
respect to comparison groups, and lack of independence with respect to tobacco industry funding. In 
addition, we have classified intervention trials by their level of randomisation. However, it is 
important to note that inclusion of a study in this or any other mapping exercise does not indicate 
that the identified relationship or the reported primary papers authors’ assertions are valid, as we 
have not critically appraised the individual studies. In addition, we cannot comment on the the 
strength of the reported evidence.  
A serious limitation of any systematic review of these products is that ‘e-cigarettes’, ‘e-liquids’, and 
‘heat-not-burn tobacco products’ are broad terms for a miscellaneous group of products that change 
over time and between brands, and the research is not generalisable beyond the specific products 
tested. In addition, very few heat-not-burn tobacco products and e-cigarettes have published, peer-
reviewed test results, and new products are being developed as we write. The predominance of the 
tobacco industry in leading the research on heat-not-burn tobacco products, and its influence on 
research on e-cigarettes, are also concerns, as are the focus, the nature, and the very short time span 
over which such products have been studied. In the short-term trials, heat-not-burn tobacco product 
use and e-cigarette use were reported to result in disturbances to health, e.g. cardiovascular and 
respiratory markers of well-being, and raised levels of biomarkers of exposure to harmful or 
potentially harmful smoke constituents. Such constituents were observed in studies of conventional 
tobacco cigarettes and were known to be harmful to health.411 However, several factors (listed in 
Section 6.3) must be accounted for before evidence regarding the harmful or beneficial nature of 
heat-not-burn tobacco products or e-cigarettes and their longer-term impact can be fully evaluated. 
The health-related outcomes grouped as harms and benefits spanned a wide range of biological 
measures, from transient indicators of changes in biological cells and tissue to full blown pathological 
diseases. However, whether the observed outcome associated with the exposure represented a harm 
or a benefit depended not only on consideration of the temporal exposure-outcome relationship, but 
on the health-related behaviours of the study population.This project has identified numerous 
morbidities, possibly associated with exposure to e-cigarettes or heat-not-burn tobacco products. 
However, an important point of note is that the effect, whether an absolute or relative harm or 
benefit of e-cigarette exposure, differed not only according to the underlying conventional tobacco 
smoking-related characteristics of the study populations, but also according to the product and the 
outcomes being assessed. Interpretation of the effect of e-cigarettes requires findings from not just a 
range of individual questions on specific exposure-outcome relationships, but also aggregation of the 
range exposure-outcome relationships. For instance, examining the impact of nicotine in relation to 
issues of dependence and abuse represents one potential exposure-outcome relationship of interest. 
In a well-designed and conducted study, findings will inform understanding of nicotine dependency, 
but these findings will not necessarily inform understanding of other pathologies arising from e-
cigarette use. Understanding harms or benefits arising from nicotine uptake requires not just framing 
findings taking account of the baseline smoking-related behaviours of the population, but also taking 
account of the relationships between e-cigarette exposure and each of the other human body 
systems be it at the level of genes, cellular tissues, or organs.  
An area touched on in the mapping exercise is the varying levels of detail by which e-cigarette or 
heat-not-burn product use was recorded. Study authors used a variety of questions to gather data on 
the use of e-cigarettes, conventional tobacco cigarettes, and other tobacco-related products. The 
depth of reporting varied ranging from binary (yes, no) variables recording current use to composite 
variables recording the best practice variable ‘pack years’ (number of units used per day- and number 
of years of product use). In some cases, one of the following data measures were collected: type of 





setting, is commonly used to assess nicotine self-administration in cigarette smokers, and involves 
measuring variables such as puff volume, duration, number of puffs per product, and interval 
between puffs. Puff length in e-cigarette users varies with experience, more experienced users usually 
take longer puffs. The more detailed measures of use provide a more accurate assessment of 
exposure and thus reduce the level of residual confounding arising from inadequate assessment of 
exposure. However, heterogeneity in data gathering practices reduces comparability of findings even 
among studies addressing the same scientific question and weakens the accuracy of statistical 
quantification of effect.  
Information system coding processes have been expanded to include e-cigarette-related health 
conditions, although they need further expansion in order to code the newly observed harms arising 
from e-cigarette and heat-not-burn tobacco product use. Authors from some of the included papers 
note that adverse events may be under-reported due to surveillance system coding deficiencies. The 
number of cases categorised under ‘other outcomes’ highlights that the Academies of Sciences’ 
framework headings will need to be expanded as we learn more about the harms and benefits of e-
cigarettes and heat-not-burn tobacco products. It may be useful to add five new headings to the 
Academies of Sciences’ framework headings: ‘endocrine diseases’, ‘neurological diseases’, 
‘ophthalmic diseases’, ‘exposure to e-cigarette toxins’ and ‘second- and third-hand effects of e-
cigarette toxin and toxicant uptake’; second- and third-hand effects of e-cigarette toxin would outline 






The e-cigarette-related health harms, harm reduction, and benefits known to date are presented in 
this mapping exercise. However, there may be unknown harms. Most of the observed clinical harms 
were due to acute harmful events associated with the use of e-cigarettes and were reported in 
descriptive case studies, surveillance system papers, and cross-sectional survey papers.  
The acute harms included poisonings (mainly nicotine and some e-liquid constituents), injuries 
(mainly burns and some fractures), and respiratory diseases (mainly injuries to the lungs and 
exacerbation of asthma). There were fatalities among the poisonings and respiratory disease cases, 
and long-term disability among some burn cases. Both the poisoning cases and the respiratory 
disease cases highlighted a possible association between e-cigarettes and the use of other drugs such 
as alcohol, synthetic cannabinoids, and opiates.  
There was some early evidence of damage to cardiovascular and respiratory tissue, mainly due to 
metals and volatile organic compounds. Four cross-sectional surveys on cancers identified the 
presence of carcinogens for lung, oral, and oesophageal cancer, and one identified biomarkers for 
bladder cancers. Some respiratory, cardiovascular, and oral diseases were noted to be less harmful in 
e-cigarette users than in conventional cigarette smokers, but were as harmful as in dual users (i.e. 
users of both conventional tobacco cigarettes and e-cigarettes). However, these respiratory, 
cardiovascular, and oral diseases findings were not consistent across all studies.  
The evidence map featured few benefits reported in the examined studies on the harms and benefits 
associated with e-cigarettes. The most common benefits reported by a small number of heavy 
smokers of conventional tobacco cigarettes was smoking cessation or reduction in smoking. We note 
that many studies showed that dual use (of both e-cigarettes and conventional tobacco cigarettes) 
was not less harmful than smoking conventional tobacco cigarettes alone, thereby raising questions 
about the smoking reduction benefit of e-cigarettes. Alongside this map, two systematic reviews 424 
425 on e-cigarettes were completed by the HRB. In the first review, we found that e-cigarettes were 
not more effective for smoking cessation than approved nicotine replacement therapies (NRTs), 
which questions the need for e-cigarettes as a smoking cessation intervention. In the second review, 
we found that e-cigarettes were associated with initiation of conventional cigarette smoking among 
adolescents, which identifies a potentially serious harm. 
Generally, our thematic findings align with the high-level findings of six reviews and have some 
contrasting findings with one systematic review. Given the time gap between the existing systematic 
reviews and our mapping exercise, we identified additional recent papers covering oral diseases, and 
developmental and reproductive effects associated with e-cigarettes.  
Long-term longitudinal cohort studies with detailed measures of exposure, specifically frequency of 
use and the chemical nature of the product used, are required in order to better understand if 
changes in the use of smoking-related products, such as the use of heat-not-burn tobacco products 
and e-cigarettes, have a positive or negative impact on later life health outcomes.  
The map of the peer-reviewed literature on heat-not-burn tobacco products reported a range of 
health-related outcomes covering dependence and abuse liability, two body systems (cardiovascular 
and respiratory), and toxicology measures arising from exposure to harmful and potentially harmful 
constituents in tobacco smoke.  
We note that the majority of trials reporting on this area have compared a small number of 
commercially available heat-not-burn tobacco products with a range of conventional tobacco 
cigarettes, both releasing varying chemical yields. In a number of trials, comparisons have also been 
made with persons who have abstained from smoking for the trial duration or for a period during a 
crossover trial. This mapping project has identified that the overall conclusion of the study authors 
was that the impacts of heat-not-burn tobacco constituents measured for cardiovascular and 
respiratory health and well-being were less harmful than those of conventional tobacco cigarettes, 
but more harmful than those observed in study participants who abstained from smoking. In a similar 
fashion, lower levels of the measured harmful and potentially harmful constituents in cigarette smoke 





cigarettes, but the lowest levels of these harmful and potentially harmful constituents were observed 
in study participants who abstained from smoking. However, the long-term consequences of these 
outcomes cannot be addressed by the study designs examined in this mapping exercise.  
Our findings on heat-not-burn tobacco products agreed with two recent systematic reviews, in that, 
the measured harmful and potentially harmful constituent levels were lower in heat-not-burn 
tobacco product users relative to the conventional cigarette user and that most research on heat-not 
burn tobacco products was industry funded. The review by the World Health Organization concluded 
the there is insufficient evidence to conclude that heat-not-burn tobacco products are less harmful 
than conventional tobacco cigarettes. In fact, the Organization concluded that the there is insufficient 
evidence to deem that heat-not-burn tobacco products are less harmful than conventional tobacco 
cigarettes. The Organization goes on to say that there are reservations, as heat-not-burn tobacco 
products may expose users to lower levels of some toxicants than conventional tobacco cigarettes, 
but they may also expose users to higher levels of other toxicants, and it is not clear how this 
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Appendix 1: Literature search strategies and results 
List of databases and resources used 
1. Ovid MEDLINE 
2. Cochrane Library: Cochrane CENTRAL and Cochrane Reviews 
3. Ovid PsycINFO 
4. Elsevier Embase 
5. NHS NIHR PROSPERO 
6. PAHO/WHO/Bireme LILACS 
7. Google Scholar 
8. CORE.ac.uk (Open University/JISC) 
9. List of reviews and reports used for citation searching 
 
Results from each database 




Duplicates excluded from each 
database  
Total 14,676 6,510 8,166 
Ovid MEDLINE 3,874 3,690 184 
Wiley Cochrane Central 527 274 253 
Wiley Cochrane Database 
of Systematic Reviews  
14 12 2 
Ovid PsycINFO 1,519 369 1,150 
Elsevier Embase 4,212 1,391 2,821 
NHS NIHR PROSPERO 93 93 0 
PAHO/WHO/Bireme LILACS 4,042 558 3,506 
Google Scholar 200 43 157 
CORE.ac.uk 192 80 112 
 
1. Ovid MEDLINE search strategy and results  
 
Ovid MEDLINE: E-cigarettes and heat-not-burn tobacco products  
Database Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, 
Daily and Versions(R) 1946 to April 12, 2019  
Date of Search 15.04.2019 




Language limits None used in the search 
Date limits None, apart from the limits set by the invention of e-cigarettes (2003-4) and heat-not-burn 
tobacco products (approximately 1988 in their current forms) 
Study types Exclude animal models, cell lines 
Publication 
types 
Exclude commentary, editorials, replies. Letters are not outright excluded as research 








Search term Results 
E-cigarettes 1 Vaping/ 291 
2 Electronic Nicotine Delivery Systems/ 2293 
3 "Nebulizers and Vaporizers"/ and (nicotine or tobacco).mp. 155 
4 e-cig$.mp. 3087 
5 Ecig$.mp. 80 
6 (Vape or vaping or vaper or vapers).mp. 853 
7 (Vapori#e$ adj3 (cigarette$ or nicotine)).mp. 77 
8 ((electric or electronic) adj2 (cig$ or nicotine or tobacco or 
smoking)).mp. 
3496 
9 (e-sigaret$ or "e-sígarett$" or een sigaret$ or E-Zigarette$ or 
"cigarette$ électronique$" or "L'e-cigarette" or vapoteuse$ or 
"cigarrill$ electrónico$" or sigarett$ elettronic$ or sigarett$ 
elettronik$ or sigarett$ elettroniche$ or elektronik$ sigar$ or e-
savuke$ or e-rokok$ or rokok$ elektronik$ or e-papieros$ or e-
ugwayi).mp. 
55 
10 (mods adj5 (tobacco or nicotine)).mp. 2 
11 Juul$.mp. 40 
12 (e-juice$ or e-liquid$).mp. 392 
13 (cig-a-like$ or cigalike$ or ciga-like$).mp. 36 
14 (e-hookah$ or electronic hookah$ or "hookah pens").mp. 19 
15 (ENNDS or electronic non-nicotine delivery).mp. 3 
16 ((NMNDS and nicotin$) or non-medicinal nicotine delivery 
system$).mp. 
0 




18 (Heated tobacco product$ or tobacco heating product$ or 
tobacco heating system$).mp. 
118 
19 ("heat-not-burn" or "heat not burn" or "heat notburn" or 
"heatnot burn").mp. 
83 
20 (Heatsticks or heat-sticks or tobacco sticks or Neosticks).mp. 13 
21 ((HEETS or Fiit or glo) adj3 (tobacco or nicotine or smok$)).mp. 2 
22 (IQOS or iFuse or Ploom).mp. 70 
23 (electrically-heated smoking system and (nicotin$ or 
tobacco$)).mp. 
1 
24 (Vapotage or "tabac chauffé" or "verhitte tabak" or "riscaldatori 
di tabacco" or "tabacco riscaldato" or "erhitzter Tabak" or 
"verhit tabak" or "zahřátý tabák" or "opvarmet tobak" or 
"oppvarmet tobakk" or "uppvärmd tobak" or "kuumutatud 
tubakas" or "pinainit na tabako" or "lämmitetty tupakka" or 
"shan taba mai tsanani" or "hitað tóbak" or "apsildāmā tabaka" 
or "tembakau dipanaskan" or "šildomas tabakas" or "tembakau 
yang dipanaskan" or "te taakapa" or "podgrzewany tytoń" or 
"tabaco aquecido" or "încălzit tutunul" or "zahriaty tabak" or 
"ogrevani tobak" or "tabaco caliente" or "ısıtılmış tütün" or 
"ugwayi ovuthayo" or "thuốc lá nóng").mp. 
11 





26 17 or 25 4645 






and cell studies 
search 
28 exp animals, laboratory/ or exp Animal experimentation/ or exp 
Models, animal/ or Disease Models, Animal/ or exp Animal 
Diseases/ 
1563266 
29 (animal adj2 (model$ or stud$ or experiment$ or 
laboratory)).ti,ab,kf. 
231870 
30 (Cat or cats or feline or dog or dogs or canine or rat or rats or 
Wistar or Sprague-Dawley or rodent$ or mouse or mice or 
murine or zebrafish or fish or chicken$ or horse$ or rabbit$ or 
"C. elegans" or caenorhabditis elegans or nematod$ or Xenopus 
or bird or birds or reptil$ or livestock or larva$).ti,ab,kf. 
3615741 
31 exp In Vitro Techniques/ or exp Biological Assays/ or exp cells, 
cultured/ or exp clinical laboratory techniques/ or Chemistry 
techniques, analytical/ or chemistry techniques, synthetic/ 
4144439 
32 ("in vitro" or biological assay$ or cell culture or cultured cells or 
cell lines or cell transformation assay$).ti,ab,kf. 
1414252 





cell or animal 
studies 
34 26 not 33 4284 
Publication type 35 (comment or editorial or note).pt. 1105825 
36 (reply or commentary or comment or editorial).ti. 135049 









38 34 not 37 3874 
 
2. Cochrane Database of Systematic Reviews and Cochrane Central search 
strategy and results 
Cochrane Library: E-cigarettes and HeatNotBurn devices 
Database John Wiley & Sons Cochrane Library including Cochrane Database of Systematic Reviews 
and Cochrane CENTRAL 
Date of Search 15.04.2019 




Language limits None used in the search 
Date limits None, apart from the limits set by the invention of e-cigarettes (2003-4) and HeatNotBurn 










Search terms Results 
E-
cigarettes 
#1 MeSH descriptor: [Vaping] explode all trees 10 
#2 MeSH descriptor: [Electronic Nicotine Delivery Systems] explode all 
trees 
72 
#3 MeSH descriptor: [Nebulizers and Vaporizers] explode all trees 2218 
#4 ((nicotine OR tobacco)):ti,ab,kw 10856 
#5 #3 AND #4 31 
#6 (e-cig*):ti,ab,kw 309 
#7 (ecig*):ti,ab,kw 309 
#8 ((vape OR vaping OR vaper OR vapers)):ti,ab,kw 66 
#9 (((vaporise OR vaporised OR vaporiser OR vaporize OR vaporized OR 
vaporizer) NEAR/3 (cigarette* OR nicotine))):ti,ab,kw 
18 
#10 (((electric or electronic) NEAR/2 (nicotine or tobacco or smoking or 
cig*))):ti,ab,kw 
321 
#11 ((e-sigaret* OR "e-sígarett*" OR E-Zigarette* OR "cigarette* 
électronique*" OR "L'e-cigarette" OR vapoteuse* OR "cigarrill* 
electrónico*" OR sigarett* elettronic* OR sigarett* elettronik* OR 
sigarett* elettroniche* OR elektronik* sigar* OR e-savuke* OR e-rokok* 
OR rokok* elektronik* OR e-papieros* OR e-ugwayi)):ti,ab,kw 
9 
#12 ((mods NEAR/5 (nicotine OR tobacco))):ti,ab,kw 0 
#13 (Juul*):ti,ab,kw 11 
#14 (e-juic* OR e-liquid*):ti,ab,kw 48 
#15 ((cig-a-like* OR cigalike* OR ciga-like*)):ti,ab,kw 4 
#16 (e-hookah* OR "electronic hookah" OR "electronic hookahs" OR 
"hookah pen" OR "hookah pens"):ti,ab,kw 
2 
#17 (ENNDS OR "electronic non-nicotine delivery"):ti,ab,kw 0 
#18 ((NMNDS AND nicotin*)):ti,ab,kw 0 
#19 (non-medicinal nicotine delivery system*):ti,ab,kw 0 
#20 #1 OR #2 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR 






#21 ("heated tobacco" OR "tobacco heating"):ti,ab,kw 43 
#22 (Heated tobacco product* OR tobacco heating product* OR tobacco 
heating system*):ti,ab,kw 
70 
#23 ("heat-not-burn" OR "heat not burn" OR "heat notburn" OR "heatnot 
burn" OR "heatnotburn"):ti,ab,kw 
6 
#24 (Heatsticks OR heat-sticks OR "heat sticks" OR tobacco sticks OR 
Neosticks):ti,ab,kw 
9 
#25 (IQOS or iFuse or Ploom):ti,ab,kw 17 
#26 ((Vapotage OR "tabac chauffé" OR "verhitte tabak" OR "riscaldatori di 
tabacco" OR "tabacco riscaldato" OR "erhitzter Tabak" OR "verhit 
tabak" OR "zahřátý tabák" OR "opvarmet tobak" OR "oppvarmet 
tobakk" OR "uppvärmd tobak" OR "kuumutatud tubakas" OR "pinainit 
na tabako" OR "lämmitetty tupakka" OR "shan taba mai tsanani" OR 
"hitað tóbak" OR "apsildāmā tabaka" OR "tembakau dipanaskan" OR 
"šildomas tabakas" OR "tembakau yang dipanaskan" OR "te taakapa" 
OR "podgrzewany tytoń" OR "tabaco aquecido" OR "încălzit tutunul" or 
"zahriaty tabak" OR "ogrevani tobak" OR "tabaco caliente" OR "ısıtılmış 
tütün" OR "ugwayi ovuthayo" OR "thuốc lá nóng")):ti,ab,kw 
7 
#27 ((HEETS or Fiit or glo) NEAR/3 (tobacco or nicotine or smok*)):ti,ab,kw 1 
#28 (("electrically-heated smoking system" AND (nicotin* OR 
tobacco*))):ti,ab,kw 
1 


















3. Ovid PsycINFO search strategy and results 
Ovid PsycINFO: E-cigarettes and HeatNotBurn devices 
Database Ovid PsycINFO 
Date of Search 15.04.2019 
Age limits None used in the search 
Geographic limits None 
Language limits None used in the search 
Date limits None, apart from the limits set by the invention of e-cigarettes (2003-4) and HeatNotBurn 
(approximately 1988 in their current forms) 
Study types NOTE: did not remove animal or publication type items from PsycINFO as after testing, very few 
animal studies, and publication types filter removed useful items also. 





Search terms Results 
E-
cigarettes 
1 exp Electronic cigarettes/ 897 
2 ((Nebulizer$ or Vaporizer$) adj5 (nicotine or tobacco)).mp. 14 
3 e-cig$.mp. 1188 
4 Ecig$.mp. 59 
5 (Vape or vaping or vaper or vapers).mp. 252 
6 (Vapori#e$ adj3 (cigarette$ or nicotine)).mp. 33 
7 ((electric or electronic) adj2 (cig$ or nicotine or tobacco or smoking)).mp. 1215 
8 (e-sigaret$ or "e-sígarett$" or een sigaret$ or E-Zigarette$ or "cigarette$ 
électronique$" or "L'e-cigarette" or vapoteuse$ or "cigarrill$ electrónico$" or 
sigarett$ elettronic$ or sigarett$ elettronik$ or sigarett$ elettroniche$ or 
elektronik$ sigar$ or e-savuke$ or e-rokok$ or rokok$ elektronik$ or e-
papieros$ or e-ugwayi).mp. 
1 
9 (mods adj5 (tobacco or nicotine)).mp. 1 
10 Juul$.mp. 27 
11 (e-juice$ or e-liquid$).mp. 76 
12 (cig-a-like$ or cigalike$ or ciga-like$).mp. 21 
13 (e-hookah$ or electronic hookah$ or "hookah pens").mp. 6 
14 (ENNDS or electronic non-nicotine delivery).mp. 0 
15 ((NMNDS and nicotin$) or non-medicinal nicotine delivery system$).mp. 0 





17 (Heated tobacco product$ or tobacco heating product$ or tobacco heating 
system$).mp. 
6 
18 ("heat-not-burn" or "heat not burn" or "heat notburn" or "heatnot 
burn").mp. 
14 
19 (Heatsticks or heat-sticks or tobacco sticks or Neosticks).mp. 2 
20 ((HEETS or Fiit or glo) adj3 (tobacco or nicotine or smok$)).mp. 0 
21 (IQOS or iFuse or Ploom).mp. 6 
22 (electrically-heated smoking system and (nicotin$ or tobacco$)).mp. 0 
23 (Vapotage or "tabac chauffé" or "verhitte tabak" or "riscaldatori di tabacco" 
or "tabacco riscaldato" or "erhitzter Tabak" or "verhit tabak" or "zahřátý 
tabák" or "opvarmet tobak" or "oppvarmet tobakk" or "uppvärmd tobak" or 






"lämmitetty tupakka" or "shan taba mai tsanani" or "hitað tóbak" or 
"apsildāmā tabaka" or "tembakau dipanaskan" or "šildomas tabakas" or 
"tembakau yang dipanaskan" or "te taakapa" or "podgrzewany tytoń" or 
"tabaco aquecido" or "încălzit tutunul" or "zahriaty tabak" or "ogrevani 
tobak" or "tabaco caliente" or "ısıtılmış tütün" or "ugwayi ovuthayo" or 
"thuốc lá nóng").mp. 







25 16 or 24 1518 
 
4. Elsevier Embase search strategy and results 
Elsevier Embase: E-cigarettes and HeatNotBurn devices 
Database Elsevier Embase 
Date of Search 15.04.2019 




Language limits None used in the search 
Date limits None, apart from the limits set by the invention of e-cigarettes (2003-4) and HeatNotBurn 
(approximately 1988 in their current forms) 
Study types Exclude animal models, cell lines 
Publication 
types 





Search terms Results 
E-cigarettes #1 'vaping'/exp OR 'vaping'  1,014 
#2 'electronic cigarette'/exp  4,468 
#3 'e cig*':ti,ab,kw  3,604 
#4 ecig*:ti,ab,kw  212 
#5 vape:ti,ab,kw OR vaping:ti,ab,kw OR vaper:ti,ab,kw OR vapers:ti,ab,kw   803 
#6 vapori?e$ NEAR/3 (cigarette* OR nicotine)  79 
#7  ((electric OR electronic) NEAR/2 (cig* OR nicotine OR tobacco OR 
smoking)):ti,ab,kw  
3,046 
#8 'e sigaret*':ti,ab,kw OR 'e sígarett*':ti,ab,kw OR 'e zigarette*':ti,ab,kw 
OR 'cigarette* électronique*':ti,ab,kw OR 'l e cigarette':ti,ab,kw OR 
vapoteuse*:ti,ab,kw OR 'cigarrill* electrónico*':ti,ab,kw OR 'sigarett* 
elettronic*':ti,ab,kw OR 'sigarett* elettronik*':ti,ab,kw OR 'sigarett* 
elettroniche*':ti,ab,kw OR 'elektronik* sigar*':ti,ab,kw OR 'e 
savuke*':ti,ab,kw OR 'e rokok*':ti,ab,kw OR 'rokok* 
elektronik*':ti,ab,kw OR 'e papieros*':ti,ab,kw OR 'e ugwayi':ti,ab,kw  
9 
#9  (mods NEAR/5 (tobacco OR nicotin* OR smoking OR 
cigarette)):ti,ab,kw  
2 





#11 'e juice*':ti,ab,kw OR 'e liquid*':ti,ab,kw  548 
#12 'cig-a-like*':ti,ab,kw OR 'cigalike*':ti,ab,kw OR 'ciga-like*':ti,ab,kw OR 
'cig-alike':ti,ab,kw  
86 
#13 'e hookah*':ti,ab,kw OR 'electronic hookah*':ti,ab,kw OR 'electric 
hookah*':ti,ab,kw OR 'hookah pen*':ti,ab,kw OR 'e-shisha':ti,ab,kw OR 
'electronic shisha':ti,ab,kw OR 'electric shisha':ti,ab,kw  
17 
#14 'ennds':ti,ab,kw OR 'electronic non-nicotine delivery':ti,ab,kw  6 
#15 nmnds:ti,ab,kw AND nicotine:ti,ab,kw 0 
 #16 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR 




#17 'heated tobacco':ti,ab,kw OR 'tobacco heating':ti,ab,kw  183 
#18 'heat-not-burn':ti,ab,kw OR 'heat not burn':ti,ab,kw OR 'heat 
notburn':ti,ab,kw OR 'heatnot burn':ti,ab,kw  
104 
#19 'heatsticks':ti,ab,kw OR 'heatstick':ti,ab,kw OR 'heat-stick':ti,ab,kw OR 
'heat-sticks':ti,ab,kw OR 'tobacco sticks':ti,ab,kw OR 'tobacco 
stick':ti,ab,kw OR 'neostick':ti,ab,kw OR neosticks:ti,ab,kw  
17 
#20  ((heets OR fiit OR glo OR ifuse) NEAR/3 (tobacco OR nicotine OR 
smok*)):ti,ab,kw  
5 
#21 iqos:ti,ab,kw OR ploom:ti,ab,kw  55 
#22 'electrically-heated smoking system':ti,ab,kw AND (nicotin*:ti,ab,kw 
OR tobacco*:ti,ab,kw)  
1 
#23 vapotage:ti,ab,kw OR 'tabac chauffé':ti,ab,kw OR 'verhitte 
tabak':ti,ab,kw OR 'riscaldatori di tabacco':ti,ab,kw OR 'tabacco 
riscaldato':ti,ab,kw OR 'erhitzter tabak':ti,ab,kw OR 'verhit 
tabak':ti,ab,kw OR 'zahřátý tabák':ti,ab,kw OR 'opvarmet 
tobak':ti,ab,kw OR 'oppvarmet tobakk':ti,ab,kw OR 'uppvärmd 
tobak':ti,ab,kw OR 'kuumutatud tubakas':ti,ab,kw OR 'pinainit na 
tabako':ti,ab,kw OR 'lämmitetty tupakka':ti,ab,kw OR 'shan taba mai 
tsanani':ti,ab,kw OR 'hitað tóbak':ti,ab,kw OR 'apsildāmā 
tabaka':ti,ab,kw OR 'tembakau dipanaskan':ti,ab,kw OR 'šildomas 
tabakas':ti,ab,kw OR 'tembakau yang dipanaskan':ti,ab,kw OR 'te 
taakapa':ti,ab,kw OR 'podgrzewany tytoń':ti,ab,kw OR 'tabaco 
aquecido':ti,ab,kw OR 'încălzit tutunul':ti,ab,kw OR 'zahriaty 
tabak':ti,ab,kw OR 'ogrevani tobak':ti,ab,kw OR 'tabaco 
caliente':ti,ab,kw OR 'ısıtılmış tütün':ti,ab,kw OR 'ugwayi 
ovuthayo':ti,ab,kw OR 'thuốc lá nóng':ti,ab,kw  
1 






#25 #16 OR #24  5,850 
Animal, in 
vitro or cell 
line studies 
#26 'animal'/exp NOT 'human'/exp  5,227,7
28 
#27 'experimental animal'/exp  623,633 
#28 'animal experiment'/exp  2,359,9
62 






#30 'animal model'/exp  1,244,8
03 
#31 'animal tissue, cells or cell components'/exp  3,618,5
29 
#32 'veterinary clinical trial'/exp  2 
#33 animal NEAR/2 (model* OR stud* OR experiment* OR laboratory)  2,716,1
11 
#34 cat:ti,ab,kw OR cats:ti,ab,kw OR feline:ti,ab,kw OR dog:ti,ab,kw OR 
dogs:ti,ab,kw OR canine:ti,ab,kw OR rat:ti,ab,kw OR rats:ti,ab,kw OR 
wistar:ti,ab,kw OR 'sprague dawley':ti,ab,kw OR rodent*:ti,ab,kw OR 
mouse:ti,ab,kw OR mice:ti,ab,kw OR murine:ti,ab,kw OR 
zebrafish:ti,ab,kw OR fish:ti,ab,kw OR chicken*:ti,ab,kw OR 
horse*:ti,ab,kw OR rabbit*:ti,ab,kw OR 'c. elegans':ti,ab,kw OR 
'caenorhabditis elegans':ti,ab,kw OR nematod*:ti,ab,kw OR 
xenopus:ti,ab,kw OR bird:ti,ab,kw OR birds:ti,ab,kw OR reptil*:ti,ab,kw 
OR livestock:ti,ab,kw OR larva*:ti,ab,kw  
4,327,8
95 
#35 'human tissue, cells or cell components'/exp  2,434,6
43 
#36 'bioassay'/exp  250,786 
#37 'in vitro study'/exp  5,605,0
74 
#38 'in vitro':ti,ab,kw OR 'biological assay*':ti,ab,kw OR 'cell 
culture':ti,ab,kw OR 'cultured cells':ti,ab,kw OR 'cell lines':ti,ab,kw OR 
'cell transformation assay*':ti,ab,kw  
1,769,3
94 
#39 #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR 









in vitro or 
Cell lines 





#41 'editorial'/exp  603,392 
 #42 'note'/exp  706,258 
#43  ('editorial'/it OR 'note'/it) AND ([editorial]/lim OR [note]/lim)  1,337,1
86 
#44 'reply':ti  77,815 
#45 commentary:ti  51,142 
#46 editorial:ti  72,014 
#47 note:ti  28,805 






in vitro or 
Cell lines) 
NOT 










5. NHS NIHR PROSPERO  
NHS NIHR PROSPERO E-cigarettes and heat-not-burn tobacco products 
Database NHS NIHR PROSPERO https://www.crd.york.ac.uk/prospero/#searchadvanced 
Date of Search 15.04.2019 
Note “All status reviews, All fields” used 




Language limits None used in the search 
Date limits None, apart from the limits set by the invention of e-cigarettes (2003-4) and HeatNotBurn 
(approximately 1988 in their current forms) 







Search terms Search 
results 
E-cigarettes #1 e-cig* 62 
#2 ecig* 3 
#3 MeSH DESCRIPTOR Vaping EXPLODE ALL TREES 6 
#4 e-juic* 2 
#5 e-liquid* 4 
#6 cig-a-like OR cigalike OR cig-alike OR ciga-like 0 
#7 e-hookah 5 
#8 juul 26 
#9 vape 11 
#10 vaping 22 
#11 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR 
#8 OR #9 OR #10 
92 
HnB #12 "heated tobacco" OR "tobacco heating" 2 
#13 "heat-not-burn" OR "heat not burn" OR "heat 
notburn" OR "heatnot burn" 
2 
#14 heatsticks OR "heat-sticks" OR "tobacco sticks" 
OR neosticks 
0 
#15 iqos OR ploom OR iFuse 1 
#16 "electrically heated smoking system" AND 
tobacco 
0 
#17 #16 OR #15 OR #14 OR #13 OR #12 4 
E-cigarettes OR heat-not-burn 
tobacco products 







6. LILACS (Latin American and Caribbean Health Sciences Literature) 
LILACS: E-cigarettes and heat-not-burn tobacco products devices 
Database PAHO/WHO/Bireme LILACS (Including databases: (LILACS, IBECS, CUMED, BDENF – 
Nursing, BBO – Dentistry, WHO IRIS, PAHO-IRIS, Index Psychology - Scientific journals, 
MedCarib) 
Date of Search 15.04.2019 




Language limits None used in the search 
Date limits None, apart from the limits set by the invention of e-cigarettes (2003-4) and HeatNotBurn 
(approximately 1988 in their current forms) 
Study types Exclude animal models, cell lines 
Publication 
types 
Exclude commentary, editorials, replies. Letters are not outright excluded as research 
letters are in scope. 
Search number Search terms Search results 
1 (tw:(("E-cigarette" OR "E-cigarettes" OR “ecigarette” or 
“ecigarettes” OR vaping OR vape OR "electronic 
nicotine" OR "cig-a-like" OR "e-hookah" OR "E-liquid" OR 
"E-juice"))) 
 
2 “cigarrillo electrónico” OR “cigarrillo electrónico” OR OR 
“e-cigarros” OR “e-cigarro” OR "cigarette électronique" 
OR "cigarettes électroniques" OR “e-sigaretten” OR “een 
sigaret” OR “sigaretta elettronica” OR “sigarette 
elettroniche” 
 
3 "heated tobacco" OR "tobacco heating" OR "heat-not-
burn" OR "heat not burn" OR IQOS OR heatsticks OR 
"heat-sticks" OR "tobacco sticks" 
 
4 Vapotage OR "tabac chauffé" OR "verhitte tabak" OR 
"riscaldatori di tabacco" OR "tabacco riscaldato" OR 




Database results Show in 
graphical form:  
  total n=4061 
MEDLINE (4019) 
  IBECS (21) 
  LILACS (14) 
  DeCS - Descriptors in Health 
Sciences (2) 
  WHO IRIS (2) 
  BRISA/RedTESA (1) 
  LIS -Health Information 
Locator (1) 








7. Google scholar 
 
Google Scholar: E-cigarettes and heat-not-burn tobacco products 
Search Engine 
and Browser 
Google Scholar on Firefox 66 
Date of Search 15.04.2019 
Note Due to the simple search interface, reduced searches were used for the two research 
concepts. Limitation of using Google Scholar include limited search faceting and the 
unknown algorithm sorting the results.  




Language limits None used in the search 
Date limits None, apart from the limits set by the invention of e-cigarettes (2003-4) and heat-not-burn 
tobacco products (approximately 1988 in their current forms) 





Concept Search terms Results Results considered 
E-cigarettes (E-cigarette OR ecigarette OR Vape OR 
Vaping OR Vaper OR e-juice OR e-liquid 
OR e-hookah) 
About 28,700 results 
(0.56 sec) 
First 100 results (first 





"heated tobacco" OR "tobacco heating" 
OR "heat-not-burn" OR "heat not burn" 
OR "IQOS" OR "heatsticks" OR "heat-
sticks" OR "tobacco sticks" 
About 4,140 results (0.34 
sec) 
First 100 results (first 









CORE.ac.uk E-cigarettes and heat-not-burn tobacco products 
Repository  CORE.ac.uk (The Open University and JISC) 
Date of Search 15.04.2019 
Note Due to the simple search interface, reduced searches were used. Search terms were 
limited to e-cigarette and vaping terms. 




Language limits None used in the search.  
Date limits None  
Study types None excluded in the search 
Publication 
types 
None excluded in the search 
Search terms Results Selected After deduplication 
title:((E-cigarette OR 
ecigarette OR Vape OR 
Vaping OR Vaper)) 




OR "tobacco heating" OR 
"heated tobacco" OR 
"heat not burn" OR IQOS 
OR heatnotburn)  









9. List of reviews and reports used for citation searching in supplemental 
searches  
Reviews 
1. El Dib R, Suzumura EA, Akl EA, et al.434 Electronic nicotine delivery systems and/or electronic non-nicotine 
delivery systems for tobacco smoking cessation or reduction: a systematic review and meta-analysis. 
BMJ Open 2017;7(2):e012680. doi: 10.1136/bmjopen-2016-012680 [published Online First: 
2017/02/27] 
2. Evans SE, Hoffman AC.435 Electronic cigarettes: abuse liability, topography and subjective effects. Tob Control 
2014;23 Suppl 2:ii23-9. doi: 10.1136/tobaccocontrol-2013-051489 [published Online First: 2014/04/16] 
3. Glasser A, Abudayyeh H, Cantrell J, et al.436 Patterns of e-cigarette use among youth and young adults: review 
of the impact of e-cigarettes on cigarette smoking. Nicotine & Tobacco Research 2018;21(10):1320-30. 
doi: 10.1093/ntr/nty103 
4. Glasser AM, Collins L, Pearson JL, et al.437 Overview of electronic nicotine delivery systems: a systematic 
review. Am J Prev Med 2017;52(2):e33-e66. doi: 10.1016/j.amepre.2016.10.036  
5. Hartmann-Boyce J, McRobbie H, Bullen C, et al.438 Electronic cigarettes for smoking cessation. Cochrane 
Database Syst Rev 2016;9:Cd010216. doi: 10.1002/14651858.CD010216.pub3  
6. Kalkhoran S, Glantz SA.439 E-cigarettes and smoking cessation in real-world and clinical settings: a systematic 
review and meta-analysis. Lancet Respir Med 2016;4(2):116-28. doi: 10.1016/s2213-2600(15)00521-4  
7. Khoudigian S, Devji T, Lytvyn L, et al.440 The efficacy and short-term effects of electronic cigarettes as a method 
for smoking cessation: a systematic review and a meta-analysis. Int J Public Health 2016;61(2):257-67. 
doi: 10.1007/s00038-016-0786-z  
8. Knight-West O, Bullen C.441 E-cigarettes for the management of nicotine addiction. Subst Abuse Rehabil 
2016;7:111-8. doi: 10.2147/sar.S94264  
9. Liu X, Lu W, Liao S, et al.442 Efficiency and adverse events of electronic cigarettes: A systematic review and 
meta-analysis (PRISMA-compliant article). Medicine (Baltimore) 2018;97(19):e0324. doi: 
10.1097/md.0000000000010324  
10. Livingston CJ, Freeman RJ, Costales VC, et al.443 Electronic nicotine delivery systems or e-cigarettes: American 
College of Preventive Medicine's Practice Statement. Am J Prev Med 2019;56(1):167-78. doi: 
10.1016/j.amepre.2018.09.010  
11. Malas M, van der Tempel J, Schwartz R, et al.444 Electronic cigarettes for smoking cessation: A Systematic 
Review. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and 
Tobacco 2016;18(10):1926-36. doi: 10.1093/ntr/ntw119  
12. O'Leary R, MacDonald M, Stockwell T, et al.445 Clearing the air: A systematic review on the harms and benefits 
of e-cigarettes and vapour devices Victoria, Canada: Canadian Institute for Substance Use Research, 
University of Victoria, 2017. 
13. Rahman MA, Hann N, Wilson A, et al.446 E-cigarettes and smoking cessation: evidence from a systematic 
review and meta-analysis. PloS one 2015;10(3):e0122544. doi: 10.1371/journal.pone.0122544  
 
Reports 
1. Bals R, Boyd J, Esposito S, et al.431 Electronic cigarettes: a task force report from the European Respiratory 
Society. Eur Resp J 2019;53:1801151. doi: 10.1183/13993003.01151-2018 
2. Health Information and Quality Authority, (HIQA).447 Health technology assessment (HTA) of smoking cessation 
interventions [Internet] Dublin, Ireland: Health Information and Quality Authority (HIQA); 2017 
[Available from: https://www.hiqa.ie/sites/default/files/2017-04/Smoking%20Cessation%20HTA.pdf  
3. McNeill A, Brose L, Calder R, et al.426 Evidence review of e-cigarettes and heated tobacco products 2018 A 
report commissioned by Public Health England London, England: Public Health England; 2018 [Available 
from: https://www.gov.uk/government/publications/e-cigarettes-and-heated-tobacco-products-
evidence-review . 
4. National Academies of Sciences, Engineering, Medicine, Health and Medicine Division, Board on Population 
Health and Public Health Practice, Committee on the Review of the Health Effects of Electronic Nicotine 
Delivery Systems.6 Public health consequences of e-cigarettes. Washington (DC): National Academies of 
Sciences, Engineering, Medicine; 2018 [Available from: 
http://nationalacademies.org/hmd/Reports/2018/public-health-consequences-of-e-cigarettes.aspx. 
5. Wells C, Farrah K.448 Electronic cigarettes for the reduction or cessation of smoking: clinical utility, safety, and 
guidelines [Rapid response]. Ottowa, Canada: Canadian Agency for Drugs and Technologies in Health 






Appendix 2: E-cigarette and vaping associated lung injury  
 
Twelve papers132 134 136 137 138 135 139 166 171 172 247 287 reported on the outbreak of lung injury associated 
with e-cigarettes or vaping, a phenomena known as e-cigarette and vaping associated lung injury (E-
VALI or VALI). The papers represented findings which occurred between June and October 2019 
across a range of American states. The papers focused on one or more of the following areas: case 
presentation and clinical signs and symptoms, including hospital stay and treatments, diagnostic 
criteria and associated technologies, development of algorithms or guidelines as diagnostic aids, and 
pathogenesis and disease aetiology. Five of the papers summarised findings from Centers for Disease 
Control and Prevention’s (CDC) news alerts on the topic, the Morbidity and Mortality Weekly Report 
Early Release (MMWR). The news alerts summarised report clinical findings, survey data estimating 
prevalence of e-cigarette use and EVALI, and laboratory findings. 166 171 172 247 287 
The team of authors represented a large number of disciplines investigating the phenomenon that 
included: clinical practitioners, radiologists, histopathologists, haematologists, microbiologists, public 
health specialists, epidemiologists, and surveillance information systems officers.  
The geographical distribution identified cases from 20 of the 50 states. Specifically Utah, 132 166 172 
Arizona, Florida and Minnesota,134 California and Wisconsin,136 New York,137 Georgia,138 Ohio, 
Tennessee,135 Pennsylvania,139 California, Connecticut, Hawaii, Illinois,166 247 287 Maryland, Michigan, 
Minnesota, Texas, Wisconsin,166 and North Carolina171. Apart from the CDC survey data papers the 
number of subjects reported on ranged from 5 to 83. Where detailed, the age of presenting patients 
ranged from 14 to 66 years with an average ages of 19 to 35 years reported (three did not report on 
age). Two papers did not report sex, three papers reporting findings on males only and the 
percentage of females in the study population varied from 17% to 41%. 
The World Health Organization was the only review recent enough to cover lung injury and reported 
that up to 7 January 2020, more than 2,500 cases had been reported to Centers for Disease Control 
and Prevention from 50 states in the USA, and just under 60 deaths had been confirmed in 27 
states.432 The World Health Organization stated that the Centers identified the causal agent as 
Vitamin E acetate which is used as an additive, most notably as a thickening agent in 
tetrahydrocannabinol-containing e-cigarette, or vaping, products.432   
Clinical presentation 
The E-VALI presenting constitutional symptoms were predominantly respiratory and or 
gastrointestinal132 in nature; but other non-specific symptoms were also reported. Respiratory 
morbidity presented both as acute and subacute134 but most frequently demonstrated a rapid 
development with subsequent acute lung injuries.136 Episodes of subacute organising pneumonia 
(inflammation of the bronchioles and surrounding tissue in the lungs) developing over a period of 
days to weeks and arising from hard metals in e-cigarette use was also reported.136 The main 
respiratory signs and symptoms included: features of dyspnoea, fever, cough,137 pleuritic pain,135 
sputum, haemoptysis (the coughing of blood the respiratory tract below the level of the larynx),138 
shortness of breath,135 and non-productive cough and chest pain.166 The main gastrointestinal 
symptoms included emesis (vomiting),137 138 135 nausea, diarrhoea,138 135 166 and abdominal pain.138 166 
135 The range of systemic symptoms reported included: fever (subjunctive),166 sweats, chills and 
myalgias (pain in a muscle or group of muscles), weight loss, fatigue or malaise,138 and headache.135 In 
addition, a range of miscellaneous complaints where patients had made previous health-care visit(s) 
for symptoms suggested to be potentially related to the use of e-cigarettes were noted. These 
included: sore throat, nasal congestion, headache, epistaxis (nosebleed), odynophagia (painful 
swallowing) and leg and back pain.138  A number of presenting cases required hospital admission and 
a sub-set of these required intensive case treatment and intubation. The majority of cases recovered, 





Diagnostic criteria and technologies  
A range of imaging chest imaging techniques were employed in the diagnostic process: including 
computed tomography (CT) and X-ray. One paper, from Wisconsin and California, reported four 
imaging patterns that correlated with pathological findings attributable to vaping.136 These included: 
acute eosinophilic pneumonia (accumulation of eosinophils, one type of white blood cell, in the 
lungs), diffuse alveolar damage, organizing pneumonia, and lipoid pneumonia (a form of lung 
inflammation that develops when lipids enter the bronchial tree).136 Most of the patterns had basilar-
predominant consolidation and ground-glass opacity, often with areas of lobular or subpleural 
sparing.136  
A second paper, from Wisconsin and Illinois, which reported the CT results of 48 of 53 cases found 
findings were abnormal in 100% of patients. Opacities in both lungs were reported as present, with 
the ground-glass opacities in both lungs and subpleural sparing.138 In eight of the patients with CT 
imaging, there were four cases of pneumomediastinum, five cases of pleural effusions, and one case 
of pneumothorax. One patient had both a pneumomediastinum and a pneumothorax, and one 
patient had both a pneumomediastinum and pleural effusion.138  
Patients with EVALI in Pennsylvania has similar chest X-ray results that is their X-ray films showed 
bilateral, multifocal alveolar opacifications.139 CT scans supported these finding revealing multi-lobar 
ground glass opacities with subpleural sparing.139 CT and X-ray imaging techniques were 
complemented by other imaging techniques such as bronchoscopy which allowed the biopsy of tissue 
samples for histological examination. 
Finding from clinics spanning four states, Minnesota, Florida, Illinois and Arizona, reviewed lung 
biopsies from patients whom had a history of vaping (71% with marijuana or cannabis oils) and were 
clinically suspected to have EVALI.134 Histopathological findings showed patterns of acute lung injury, 
including acute fibrinous pneumonitis, diffuse alveolar damage, and/or organizing pneumonia, usually 
bronchiolocentric accompanied by bronchiolitis. No histologic findings were specific, but foamy 
macrophages and pneumocyte vacuolization were seen in all cases.134  
A coordinated public health investigation, in Wisconsin and Illinois, following reports of pulmonary 
disease associated with the use of e-cigarettes examined the data of 24 patients who underwent 
bronchoalveolar lavage.138 A total of seven cytology reports on bronchoalveolar-lavage specimens 
stained with oil red O noted lipid-laden macrophages. Patients reported having used 
tetrahydrocannabinol products in e-cigarette devices, although a wide variety of products and devices 
was reported. Although the features of e-cigarette use that were responsible for injury were not 
identified, the cluster of illnesses was deemed to represent an emerging clinical syndrome or 
syndromes.138 
Algorithms development or guidelines as diagnostic aids 
The Wisconsin Department of Health Services and the Illinois Department of Public Health released 
their first health alert notices on 25 July 2019 and 2 August 2019, respectively, to inform clinicians of 
the initial cases and to request reporting of possible cases to their local health departments.138 Their 
original outbreak case definition accompanying this report was further refined in coordination with 
the CDC and the Council for State and Territorial Epidemiologists.135  
The criteria for a ’confirmed case’ were as follows:  
1. Using an e-cigarette or dabbing during the 90 days before symptom onset 
2. Pulmonary infiltrate on chest radiograph or ground glass opacities on chest CT 
3. Absence of pulmonary infection on initial workup. Minimum criteria include negative respiratory 
viral panel, influenza polymerase chain reaction, or rapid test if local epidemiology supports test-
ing. All other clinically indicated respiratory infectious disease testing (e.g., urine antigen for 
Streptococcus pneumoniae and Legionella, sputum culture if productive cough, bronchoalveolar 
lavage culture if done, blood culture, human immunodeficiency virus (HIV)–related opportunistic 





4. No evidence in medical record of alternative plausible diagnoses (e.g., cardiac, rheumatologic, or 
neoplastic process).135 
Pathogenesis and disease aetiology 
The authors of several papers investigated potential causal factors for E-VALI and mechanisms of 
disease. The report from Blount et al.166 was the first to identify a potential toxicant of concern 
(vitamin E acetate) in biologic specimens obtained from EVALI patients. The authors stated findings 
provided direct evidence of vitamin E acetate at the primary site of injury among EVALI patients and 
are consistent with Food and Drug Administration product testing and media reports of state public 
health laboratory testing documenting vitamin E acetate in product samples used by EVALI patients. 
Other diluents and additives of concern (e.g., plant oils, medium chain triglyceride oil, petroleum 
distillates, and diluent terpenes) were not detected in bronchoalveolar lavage fluid specimens from 
EVALI patients. Vitamin E acetate was detected in all specimens in their analysis of a convenience 
sample of 29 EVALI case associated bronchoalveolar lavage specimens. However, the authors stated 
that additional studies are needed, including comparison with bronchoalveolar lavage fluid specimens 
from healthy volunteers and animal studies using controlled exposures to establish whether a causal 
link exists between this exposure and EVALI. They also suggest however, it is possible that more than 
one compound or ingredient could be a cause of lung injury, and evidence is not yet sufficient to rule 
out the contribution of other toxicants to EVALI.166 Navon et al. noted from their survey findings that 
EVALI patients had higher odds of reporting exclusive and more frequent use of THC-containing 
products including Dank Vales (a class of largely counterfeit THC-containing products) and of 
obtaining these products from informal sources, such as a dealer, off the street, or from a friend.287  
Table 66 E-cigarette and vaping associated lung injury (EVALI) extracted from surveillance papers 
Author(s), year Possible 
benefit 
or harm 
Surveillance papers on respiratory diseases 
  EVALI 
Blagev et al.132 
2019 
Harm In this multicentre, prospective, observational, cohort study the authors 
reported on risk factors of e-cigarette, or vaping, and products used by 
patients presenting at the Intermountain Healthcare, an integrated health 
system in Utah, USA, between June 27 and Oct 4, 2019. Telecritical care, 
based in Salt Lake City, Utah, USA, was used as the central repository for case 
validation, public reporting, and system-wide dissemination of expertise, 
which included a proposed diagnosis and treatment guideline for lung injury 
associated with e-cigarettes or vaping 
In total, 60 patients presented with lung injury associated with e-cigarettes or 
vaping at 13 hospitals or outpatient clinics in the integrated health system. 33 
(55%) of 60 were admitted to an intensive care unit (ICU). 53 (88%) of 60 
patients presented with constitutional symptoms, 59 (98%) with respiratory 
symptoms, and 54 (90%) with gastrointestinal symptoms. 54 (90%) of 60 
were given antibiotics and 57 (95%) were given steroids. Six (10%) of 60 
patients were readmitted to an ICU or hospital within 2 weeks, three (50%) of 
whom had relapsed with vaping or e-cigarette use. Of 26 patients who were 
followed up within 2 weeks, despite clinical and radiographic improvement in 
all, many had residual abnormalities on chest radiographs (ten [67%] of 15) 
and pulmonary function tests (six [67%] of nine). Two patients died and lung 
injury associated with e-cigarettes or vaping was thought to be a contributing 
factor, but not the cause of death, for both. 
The authors concluded that lung injury associated with e-cigarettes or 
vaping is an emerging illness associated with severe lung injury as well as 
with constitutional and gastrointestinal symptoms. Increased awareness has 
led to identification of a broad spectrum of severity of illness in patients who 
were treated with antibiotics and steroids. Despite improvement, at short-





Device and products: Length of use: <1 year 10/23 (43%), 1–<2 years 4/23 
(17%), 2–<3 years 6/23 (26%) and ≥3 years 3/23 (13%) 
Type of device used: Disposable e-cigarette 5/23 (22%), Reusable device for 
liquids 16/22 (73%), Reusable device for wax or dry herbs 9/23 (39%), Vape 
rig (for competitive vaping and stronger 
vape) 5/22 (23%), Vaping salts 3/23 (13%) 
Reported inhalation device: Juul (nicotine) 7 (26%), Smok (nicotine) 2 (7%), 
Nicotine E-Juice (various brands) 7 (26%), Golden Gorilla 
(tetrahydrocannabinol) 4 (15%), Smart Cart (tetrahydrocannabinol) 3 (11%), 
Cereal (tetrahydrocannabinol) 1 (4%), Dank Vapes (tetrahydrocannabinol) 6 
(22%), Rove (tetrahydrocannabinol) 6 (22%) 
Other brands of inhalation device: (tetrahydrocannabinol), 11 (41%) 
Where vape liquid purchased: A Utah vape shop 4 (15%), Dealer 4 (15%), 
Online dealer or social media app 7 (26%), Out of state dispensary 2 (7%), 
Friend 5 (19%), Convenience store 2 (7%) 
Vape liquid or e-liquid used: Prefilled cartridges 18/23 (78%), Dank Vapes 
10/22 (45%), A variety of liquids 16/20 (80%), Premade liquid 13/22 (59%), 
Nicotine 17/25 (68%), Tetrahydrocannabinol oil 22/25 (88%), Marijuana 
10/21 (48%), Cannabidiol oil 10/23 (44%), Synthetic marijuana 18/21 (86%), 
Mixed own vape liquid 1/21 (5%) 
If using tetrahydrocannabinol, using for medicinal reasons 7/11 (64%). 
Butt et al. 134 
2019 
Harm The authors reviewed lung biopsies from 17 patients (13 men; median 
age=35 years [range: 19–67 years]), all of whom had a history of vaping (71% 
with marijuana or cannabis oils) and were clinically suspected to have 
vaping-associated lung injury. Presentation was acute or subacute in all 
cases, with bilateral pulmonary opacities; all but two patients presented in 
2019. 11 met the criteria for a ‘confirmed’ diagnosis of vaping-related lung 
injury; the remaining 6 met the criteria for a ‘probable’ designation. In all 
cases, histopathological findings showed patterns of acute lung injury, 
including acute fibrinous pneumonitis, diffuse alveolar damage, or organising 
pneumonia. No histological findings were specific, but foamy macrophages 
and pneumocyte vacuolisation were seen in all cases and may be useful 
diagnostic clues in an appropriate clinical context. Pigmented macrophages 
were sometimes present but were never a dominant feature. Neutrophils 
were often prominent, but eosinophils were rare, and granulomas were not 
seen. In two cases, bronchioloalveolar lavage fluid was available and 
contained abundant foamy macrophages. Despite treatment with 
glucocorticoids and maximum supportive care, two patients with diffuse 
alveolar damage died 
Device and products: Not reported 
Henry et al.136 
2019 
Harm The authors reported imaging patterns that they had identified from 19 cases 
of vaping-associated lung disease which they had seen in a clinical setting. All 
met the case definition of vaping-associated lung injury, which includes 
“abnormalities on chest imaging”. The authors identified four imaging 
patterns that correlated with pathological findings attributable to vaping, 
including acute eosinophilic pneumonia, diffuse alveolar damage, organising 
pneumonia, and lipoid pneumonia. In addition, some cases were associated 
with variegated imaging patterns. Through clinical and pathological 
investigations, patterns of giant cell interstitial pneumonia, hypersensitivity 
pneumonitis, and diffuse alveolar haemorrhage were identified. Although the 
variety of imaging patterns suggests different mechanisms of injury, and 
more patterns will probably be reported, most of the patterns have basilar-
predominant consolidation and ground glass opacity, often with areas of 
lobular or subpleural sparing. The authors noted that rapidly developing 
acute lung injuries are associated with inhalational injuries, have overlapping 
pathological and imaging findings, and have been reported to occur with 
vaping. Hypersensitivity pneumonitis is an immune response to an 
environmental antigen, but the antigens related to vaping are unknown. 
Lipoid pneumonia is an inflammatory response to the presence of lipids 





hydrocarbons or oil-based products, but it has now been seen with vaping. 
The authors have not observed the computed tomographic finding of fat 
attenuation in the lung, which is a hallmark of lipoid pneumonia, in these 
cases of vaping-associated lung injury. Not all cases are acute; organising 
pneumonia often develops sub-acutely, over a period of days to weeks, and 
the one case of giant cell interstitial pneumonia that was correlated with hard 
metals in e-cigarettes developed over a period of 6 months. 
Device and products: Not reported 
Kalininskiy et al. 
137 
2019 
Harm The authors reported on 12 cases treated for suspected e-cigarette, or 
vaping, product use associated with lung injury at their medical centre 
between 6 June and 15 September 2019. 10 (83%) patients had dyspnoea, 
fever, and vomiting, and 9 (75%) had cough. 11 (92%) patients reported the 
use of e-cigarette cartridges containing tetrahydrocannabinol oil. Although 
eight (67%) patients required admission to the intensive care unit for 
hypoxaemic respiratory failure, no deaths occurred. The median 
hospitalisation duration was 7 days. All patients completing follow-up (6 
[50%]) had resolution of previous chest abnormalities. The authors 
highlighted the importance of ruling out infection and other cardiopulmonary 
conditions before making a presumptive diagnosis of e-cigarette, or vaping, 
product use-associated lung injury. 11 patients reported vaping a 
tetrahydrocannabinol product. 
Device and products specifically substance use: Tetrahydrocannabinol vaping 
11 (92%), Nicotine vaping 7 (58%), Cannabis use (non-vape) 5 (42%), 
Cannabidiol vaping 1 (8%), Nicotine vaping only 1 (8%), Tobacco cigarettes 1 
(8%) 




The authors reported on work commenced in July 2019 by the Wisconsin 
Department of Health Services and the Illinois Department of Public Health 
which receive, and process reports of pulmonary disease associated with the 
use of e-cigarettes (vaping). The authors defined cases as persons who 
reported use of e-cigarette devices and related products in the 90 days 
before symptom onset and who had pulmonary infiltrates on imaging, and 
whose illnesses were not attributed to other causes. Medical record 
abstraction and case patient interviews were conducted with the use of 
standardised tools. There were 53 cases, 83% of whom were male; the 
median age of the patients was 19 years. The majority of the patients 
presented with respiratory symptoms (98%), gastrointestinal symptoms 
(81%), and constitutional symptoms (100%). All case patients had bilateral 
infiltrates on chest imaging. A total of 94% of the patients were hospitalised, 
and 32% underwent intubation and mechanical ventilation; one death was 
reported. A total of 84% of the patients reported having used 
tetrahydrocannabinol products in e-cigarette devices, although a wide variety 
of products and devices was reported. 
Device and products specifically substance use: All patients had a history of 
use of e-cigarettes and related products within the 90 days before symptom 
onset, and 94% of those with data (32 of 34 patients) regarding the date of 
last use reported vaping in the week before symptom onset. Most patients 
(29 of 33 patients [88%]) reported at least daily e-cigarette use. Of the 41 
patients who were extensively interviewed, 61% reported use of nicotine 
products, 80% reported use of tetrahydrocannabinol products, and 7% 
reported use of cannabidiol products. A total of 37% of the patients reported 
using tetrahydrocannabinol products only, whereas 17% reported using 
nicotine-containing products only. A total of 44% of the patients reported 
using both nicotine and tetrahydrocannabinol products. Patients reported 
using 14 distinct brands of tetrahydrocannabinol products and 13 brands of 
nicotine products in a wide range of flavours. The most common 
tetrahydrocannabinol product that was reported was marketed under the 
“Dank Vape” label (reported by 24 of 41 interviewed patients [59%]). Patients 





products. Of the 41 patients who were extensively interviewed, seven 
reported smoking combustible cigarettes as well. 
Mukhopadhyay 
et al 135 
2020 
Harm The authors described findings from the lung biopsies of eight male patients 
(aged 19–61 years) who had a vaping-associated pulmonary illness. The 
biopsies were negative for infection in all cases, and there was no evidence 
for other aetiologies. Imaging showed diffuse bilateral ground glass opacities 
in all patients. Seven of the patients recovered with corticosteroid therapy 
and one died. Lung biopsies (seven transbronchial, one surgical) showed 
acute lung injury, including organising pneumonia and/or diffuse alveolar 
damage. Common features were fibroblast plugs, hyaline membranes, 
fibrinous exudates, type 2 pneumocyte hyperplasia, and interstitial 
organisation. Some cases featured a sparse interstitial chronic inflammatory 
infiltrate. Although macrophages were present within the airspaces in all 
cases, this feature was not prominent, and findings typical of exogenous 
lipoid pneumonia were absent. The authors concluded that the 
histopathology of acute pulmonary illness was related to e-cigarette use 
(vaping) and was characterised by acute lung injury patterns, supporting the 
contention that vaping can cause severe lung damage 
Device and products specifically substance use: (individual practices 
reported): 90% tetrahydrocannabinol, tetrahydrocannabinol (brand: “Dank”) 
and nicotine; recent refill of cartridge with 90% tetrahydrocannabinol, 
tetrahydrocannabinol /marijuana (vaping) and marijuana wax (dabbing), 
tetrahydrocannabinol (cannabis oil), Purified tetrahydrocannabinol 





Harm The authors reported on six young men who presented with high fever and a 
variety of respiratory and gastrointestinal symptoms, including dyspnoea, 
non-productive cough, chest and abdominal pain, nausea, vomiting, and 
watery diarrhoea. All patients reported regular use of vaporised cannabis 
and nicotine products, and the most recent exposure ranged between 3 and 
9 days prior to presentation. Four of the patients used the same type of 
cannabis solution. Chest radiographs demonstrated bilateral, multifocal 
alveolar opacifications. Computed tomography scans revealed multilobar 
ground glass opacities with subpleural sparing. Two patients underwent 
bronchoscopy with bronchoalveolar lavage. Microbial cultures were negative 
in the bronchoalveolar lavage. Extensive infectious workup came back 
negative for every patient, and most received corticosteroid treatment. No 
fatalities occurred. 
Device and products: Not described 
Blount et al.168 
2019 
Harm The authors investigated a national outbreak of lung injury associated with e-
cigarette, or vaping, product use. Based on data collected as of 15 October 
2019, 86% of 867 e-cigarette, or vaping, product use-associated lung injury 
patients reported using tetrahydrocannabinol-containing products in the 3 
months preceding symptom onset. Analyses of tetrahydrocannabinol-
containing product samples by Food and Drug Administration and state public 
health laboratories have identified potentially harmful constituents in these 
products, such as vitamin E acetate, medium-chain triglyceride oil, and other 
products. Vitamin E acetate, in particular, might be used as an additive in the 
production of e-cigarette, or vaping, products; it can also be used as a 
thickening agent in tetrahydrocannabinol products. Inhalation of vitamin E 
acetate might impair lung function. 
The Centers for Disease Control and Prevention, the Food and Drug 
Administration, state and local health departments, and multiple public 
health and clinical partners investigated a national outbreak of e-cigarette, or 
vaping, product use–associated lung injury. Findings here are (lower case b 





Based on data collected as of 15 October 2019, 86% of 867 e-cigarette, or 
vaping, product use-associated lung injury patients reported using 
tetrahydrocannabinol-containing products in the 3 months preceding 
symptom onset. Analyses of tetrahydrocannabinol-containing product 
samples by Food and Drug Administration and state public health 
laboratories have identified potentially harmful constituents in these 
products, such as vitamin E acetate, medium-chain triglyceride oil, and other 
products. Vitamin E acetate, in particular, might be used as an additive in the 
production of e-cigarette, or vaping, products; it can also be used as a 
thickening agent in tetrahydrocannabinol products. Inhalation of vitamin E 
acetate might impair lung function. 
Device and products: Among 23 patients for whom self-reported 
tetrahydrocannabinol use information was available,20 reported using 
tetrahydrocannabinol-containing products. Tetrahydrocannabinol or its 
metabolites were detected in 23 of 28 patient bronchoscopy and 
bronchoalveolar lavage samples, including in those of three patients who said 
they did not use tetrahydrocannabinol products. Nicotine metabolites were 
detected in 16 of 26 patient bronchoscopy and bronchoalveolar lavage 
specimens. Results for plant oils, medium chain triglyceride oil, petroleum 
distillates, and diluent terpenes were all below analyte-specific levels of 




Harm The authors reported on more than 200 possible cases of acute lung injury 
potentially associated with vaping reported from 25 states. During July and 
August 2019, five patients were identified at two hospitals in North Carolina 
with acute lung injury potentially associated with e-cigarette use. The 
patients were adults aged 18–35 years, and all experienced several days of 
worsening dyspnoea, nausea, vomiting, abdominal discomfort, and fever. All 
patients demonstrated tachypnoea with increased difficulty with breathing 
on examination, hypoxaemia (pulse oximetry <90% on room air), and bilateral 
lung infiltrates on chest X-ray. All five patients shared a history of recent use 
of marijuana oils or concentrates in e-cigarettes. All of the products used 
were electronic vaping pens/e-cigarettes that had refillable chambers or 
interchangeable cartridges with tetrahydrocannabinol vaping concentrates or 
oils, which were all purchased on the street. Three of the patients also used 
nicotine-containing e-cigarettes, and two of the patients smoked marijuana 
or conventional combustible tobacco cigarettes, although none used other 
illicit drugs. All five patients were hospitalised for hypoxaemic respiratory 
failure. All of the patients survived. 
Device and products: Not reported 
Lewis et al.174 
2019 
Harm The Utah Department of Health (UDOH) detailed medical abstractions for a 
subset of 83 patients in Utah who presented with lung injury. 
Detailed medical abstractions were completed for 79 patients (95%). Of the 
79 patients, 70 (89%) were hospitalised, 39 (49%) required breathing 
assistance, and many reported pre-existing respiratory and mental health 
conditions. Among 53 interviewed patients, all of whom reported using e-
cigarette, or vaping, products within 3 months of the acute lung injury, 49 
(92%) reported using any products containing tetrahydrocannabinol, 35 (66%) 
reported using any nicotine-containing products, and 32 (60%) reported using 
both. Product sample testing at the Utah Public Health Laboratory showed 
evidence of vitamin E acetate in 17 of 20 (89%) tetrahydrocannabinol-
containing cartridges, which were provided by 6 of the 53 interviewed 
patients. 
Device and products: Among 53 interviewed patients, all of whom reported 
using e-cigarette, or vaping, products within 3 months of acute lung injury, 49 
(92%) reported using any products containing tetrohydrocannabinol, the 
principal psychoactive component of cannabis; 35 (66%) reported using any 
nicotine-containing products, and 32 (60%) reported using both. Most 





sources such as friends or illicit in-person and online dealers. 
Tetrohydrocannabinol containing products were most commonly used one to 
five times per day, whereas nicotine-containing products were most 
commonly used >25 times per day. 
Ghinai et al.247  
2019 
 
Harm In July 2019, the Illinois Department of Public Health and the Wisconsin 
Department of Health Services launched a coordinated epidemiologic 
investigation after receiving reports of several cases of lung injury in 
previously healthy persons who reported using e-cigarettes or vaping.  
The Centers for Disease Control and Prevention reported the precise source 
of the outbreak as currently unknown; however, the predominant use of 
prefilled tetrahydrocannabinol-containing cartridges among patients with 
lung injury associated with e-cigarette use suggested that these products 
played an important role.  
Device and products: Detailed patient interviews were conducted. Numerous 
products and brand names were identified by patients. Among the 86 
interviewed patients, 75 (87%) reported using e-cigarette products containing 
tetrahydrocannabinol, the principal psychoactive component of cannabis, 
during the 3 months preceding illness; 61 (71%) reported using nicotine-
containing products; 50 (58%) reported using both tetrahydrocannabinol- and 
nicotine-containing products. Twenty-five (29%) patients reported exclusive 
use of tetrahydrocannabinol-containing products, whereas 11 (13%) reported 
exclusive use of nicotine-containing products. In total 234 unique e-cigarette, 
or vaping, products labelled with 87 different brand names were reported. 
Nicotine-containing product users reported a mean of 1.3 different nicotine 
brands, and tetrahydrocannabinol containing product users reported a mean 
of 2.1 different tetrahydrocannabinol brands. Nearly all (96%) 
tetrahydrocannabinol -containing products reported were packaged, prefilled 
cartridges, and 89% were primarily acquired from informal sources (e.g., 
friends, family members, illicit dealers, or off the street). In contrast, 77% of 
nicotine-containing products were sold as prefilled cartridges, and 83% were 
obtained from commercial vendors. 




Harm In the Morbidity and Mortality Weekly Report of the US Department of 
Health and Human Services and Centers for Disease Control and Prevention, 
first posted in November 2019, the authors reported on risk factors of e-
cigarette, or vaping, products used by patients in Illinois.  
The Illinois Department of Public Health conducted an online public survey 
between September and October 2019 targeting e-cigarette, or vaping, 
product users in Illinois, examining whether e-cigarette, or vaping, product 
use behaviours differed between adult e-cigarette, or vaping, product use-
associated lung injury patients and adults who used these products but did 
not develop lung injury. Among 4,631 survey respondents, 94% reported 
using any nicotine-containing e-cigarette, or vaping, products in the past 3 
months; 21% had used any tetrahydrocannabinol-containing products; and 
11% had used both tetrahydrocannabinol-containing products and nicotine-
containing products. The prevalence of tetrahydrocannabinol-containing 
product use was highest among survey respondents aged 18–24 years (36%), 
and decreased with increasing age. E-cigarette, or vaping, product use 
behaviours of 66 e-cigarette, or vaping, product use-associated lung injury 
patients aged 18–44 years who were interviewed as part of the ongoing 
outbreak investigation were compared with a subset of 519 survey 
respondents aged 18–44 years who reported use of tetrahydrocannabinol-
containing e-cigarette, or vaping, products. Compared with these survey 
respondents, product use-associated lung injury patients had higher odds of 
reporting exclusive use of tetrahydrocannabinol-containing products (AOR: 
2.0; 95% CI: 1.1–3.6); frequent use (more than five times per day) of these 
products (AOR: 3.1; 95% CI: 1.6–6.0); and obtaining these products from 
informal sources, such as a dealer, off the street, or from a friend (AOR: 9.2; 





tetrahydrocannabinol-containing products, was also higher among e-
cigarette, or vaping, product use-associated lung injury patients (AOR: 8.5; 
95% CI: 3.8–19.0).  
Device and products: Any nicotine-containing products. Only nicotine-
containing products. Any nicotine-containing product <1x/day§. Any nicotine-
containing product >5x/day§. Any tetrahydrocannabinol-containing products. 
Only tetrahydrocannabinol-containing products. Any tetrahydrocannabinol-
containing product <1x/day§. Any tetrahydrocannabinol-containing product 
>5x/day§. Dank Vapes*. Obtained any tetrahydrocannabinol-containing 







Appendix 3: Cross-sectional survey papers by adapted Academies of 
Sciences framework headings for e-cigarettes 
Table 67: Cross-sectional surveys papers on dependence and abuse lability, benefits or harms 
Author(s) year Possible 
benefit or 
harm 
Cross-sectional surveys papers dependence and abuse liability 




Benefit The authors described the nicotine levels used in order to achieve smoking 
cessation, as well as the reported benefits, associated side effects, and 
estimation of e-cigarette dependence, compared with tobacco cigarette 
dependence.  
Age: 20 to 55 years. Sex: Most participants (84%) were male. Country: 
Greece 
Data source: Participants were recruited for research protocols evaluating 
the clinical effects of e-cigarette use, which were implemented in 2012 and 
early 2013 
Population size: One hundred and thirteen vapers participate (32 hospital 
visitors and 81 members of consumers’ Internet forum). 
Data collection period: 2012, 2013 
E-cigarette, smoking and other related status: A significant proportion of the 
study sample consisted of formerly heavy smokers (smoking more than 20 
cigarettes per day). Forty-eight of them (42%) quit smoking during the first 
month of using e-cigarette; 22 (19.8% of the whole group) quit on the first 
day. All participants achieved smoking abstinence by using second-
generation (eGo-type batteries, 90.9%) or third-generation (variable voltage, 
often called “Mod”) devices (9.1%). Thirty-five participants (31.5%) reported 
that they initiated e-cigarette use with a first-generation cigarette-like 
device. 
Outcomes: Smoking abstinence and dependency  
The authors concluded that nicotine levels appear to play an important role 
in achieving and maintaining smoking cessation in the group of motivated 
subjects studied. High-nicotine-containing liquids were used, but few mild 
and temporary side effects were reported. The authors concluded that 
regulatory proposals should consider the pragmatic use patterns of e-
cigarettes, especially in consumers who have completely substituted 
tobacco cigarettes with e-cigarettes.  
Device and products: Subjects were included in the analysis irrespective of 




Benefit The authors described the characteristics, perceived side effects, and 
benefits of e-cigarettes. 
Age (median) years: 39. Sex: a significantly higher proportion were males 
Country: worldwide survey 74.7% from Europe, 20.7% from America, 1.8% 
from Asia, 1.1% from Australia, and 0.2% from Africa 
Data source: A questionnaire was developed and uploaded in an online 
survey tool (www.surveymonkey.com). The questionnaire was available 
in 10 languages (Czech, English, French, German, Greek, Hungarian, Italian, 
Polish, Russian, and Spanish). 





Author(s) year Possible 
benefit or 
harm 
Cross-sectional surveys papers dependence and abuse liability 
E-cigarette, smoking and other related status: former smokers and current 
smokers: current smokers 3682, former smokers 15,671, all e-cigarette 
users but 244 no longer current users 
Outcomes: characteristics and experiences of e-cigarette users and the 
differences between those who partially and completely substituted 
smoking with e-cigarette use 
They concluded that e-cigarettes are mostly used to avoid the harm 
associated with smoking. They noted that e-cigarettes can be effective even 
in highly dependent smokers, and that they are used as long-term 
substitutes for smoking. High levels of nicotine are used at initiation; 
subsequently, e-cigarette users try to reduce nicotine consumption, with 
only a small minority using non-nicotine liquids. Side effects are minor and 
health benefits are substantial, especially for those who completely 
substitute tobacco cigarettes with e-cigarettes. 
Device and products: E-cigarette device most often used: Cigarette-like, eGo 
batteries “Mods”; e-cigarette liquid use: prefilled cartomisers , ready-to-use 
liquids, do-it-yourself liquids; e-cigarette daily consumption mL liquid per 
day, nr of cartridges per day; Current nicotine levels in e-cigarette, and 
Nicotine levels at initiation of e-cigarette use 
Etter et al.203 
2015 
Benefit The authors reported on the dependence level in users of e-cigarettes, 
nicotine gum, and tobacco cigarettes. 
Age (mean) years: Former smokers 44.7, Daily e-cigarette users 40.9, Daily 
e-cigarette users 44.6, internet population 37.8 General population 40.1 
Sex (males %): Former smokers 38.6, Daily e-cigarette users 68.9, Daily e-
cigarette users 57.1, internet population 36.8 General population 58.4 
Country: Respondence to the smoking cessation website Stop-tabac.ch 
Data source: Internet and mail surveys 
Population size: 4,781. Data collection period: October 2012 to October 
2013 
E-cigarette, smoking and other related status: 766 daily users of nicotine-
containing e-cigarettes with 30 daily users of nicotine-free e-cigarettes; (b) 
911 former smokers who used the e-cigarette daily with 451 former 
smokers who used the nicotine gum daily (but no e-cigarette); (c) 125 daily 
e-cigarette users who smoked daily (dual users) with two samples of daily 
smokers who did not use e-cigarettes (2206 enrolled on the Internet and 
292 enrolled by mail from the general population of Geneva 
Outcomes: Dependence ratings 
They concluded that some e-cigarette users were dependent on nicotine-
containing e-cigarettes, but that these products were less addictive than 
tobacco cigarettes. E-cigarettes may be as addictive as or less addictive than 
nicotine gums, which themselves are not very addictive.203. 
Device and products: Not reported 
Baweja et al.200 
2016 
 
Benefit  The authors reported on the experiences, satisfaction, opinions, and 
preferences of e-cigarette users. 
Age: 30 to 50 years. Sex: 146 males. Country: 175/200 USA. Ethnicity: 177 
white 





Author(s) year Possible 
benefit or 
harm 
Cross-sectional surveys papers dependence and abuse liability 
Population size: 200 participants randomly selected from a sample of 1,177 
persons who completed an online survey about their electronic cigarette 
preferences 
Data collection period: December 2012 to May 2014  
E-cigarette, smoking and other related status: Cigarette smoking status - 
Past user (166) Current occasional user (13) Current daily user (21) Days 
Since quit Smoking (Past cigarette users only) 90–730, Quit smoking (166) 
Long before started using e-cigarettes (13) After started using e-cigarettes 
(153) History of other types of tobacco use Pipe smoker (43) Cigar smoker 
(80) Smokeless/chewing tobacco (69) Hookah user (49)  
Outcomes: Multiple see subsequent text. 
The sample was selected from a group of electronic cigarette users invited 
to complete an online survey aiming to improve understanding of the use of 
e-cigarettes, including the types of e-cigarettes being used, how frequently 
they are used and whether or not they are replacing other types of tobacco 
among e-cigarette users aged ≥18 years old. Participation in this study was 
voluntary and respondents could remain anonymous, although individuals 
who wished to volunteer for additional research on e-cigarettes were 
invited to enter their contact details at the end of the survey. The survey 
was administered, and responses were stored on REDCap (Research 
Electronic Data Capture). Information on a range of variables was gathered 
include information on: electronic cigarette use times per day (one ‘‘TIME’’ 
consists of around 15 puffs, or lasts around 10 minutes), number of models 
of e-cigarettes have been used prior to the current one, electronic cigarette 
contains button to press just prior to inhalation/puffing, type of liquid used 
in e-cigarette (Propylene glycol, Vegetable glycerine (VG), Both propylene 
glycol and VG). 
A 158-item questionnaire was administered with questions on the use of the 
electronic cigarette, differences in use between e-cigarettes and 
conventional combustible tobacco cigarettes, important characteristics of e-
cigarettes and effects associated with e-cigarette use. In this latter area, 
effects associated with e-cigarettes use 14 themes were identified. Here, 
approximately one-fourth of responses were related to experiencing no 
undesirable effects (25 comments, ‘‘No negative effects, they have all been 
positive’’). The most common negative effects were: symptoms related to 
dehydration including dry mouth, chapped lips and bad breath (25 
comments, ‘‘Dry mouth occurred more when I first started using the e-
cigarette and was every time I used it’’); worsening respiratory symptoms 
(10 comments, ‘‘Exacerbation of asthma symptoms’’); side effects possibly 
related to nicotine effects (8 comments, ‘‘headaches are from high 
nicotine’’); followed by throat and nasal irritations (8 comments), transient 
headache (6 comments), increased heart rate (5 comments). A number of 
other symptoms were mentioned by only one respondent. Of the 
participants who reported undesirable effects, 13 spontaneously mentioned 
the transient nature of the undesirable effects (‘‘In the first few months 
when I was trying all those new kinds, I did have dry mouth & other 
symptoms but not with what I use now’’). The physical health related 
outcome on which data were gathered included the experienced effects as a 
result of e-cigarettes (quite often/once a week): dry mouth, dry cough, 
throat irritation.  
There were 15 positive themes identified from responses. The most 
frequently cited positive aspects of e-cigarette use were: assisted in smoking 
cessation and reduced cigarette consumption (81 comments, ‘‘As far as 
Nicotine Replacement Devices go, e-cigarettes are fantastic. Both my wife 
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comments, ‘‘My blood pressure has stabilized and have, under doctors [sic] 
orders, quit taking some of my medications for it’’); improved breathing, 
decreased cough, fewer sore throats (70 comments, ‘‘Breathing is easier. No 
hacking cough at any time of the day’’); safe way to use nicotine (42 
comments, ‘‘I’m still on nicotine, but much less. I’m avoiding close to 4000 
chemicals in a conventional combustible tobacco cigarette’’); followed by 
pleasure of inhaling and smoking-related actions (34 comments); 
comparatively less toxic than smoking tobacco (33 comments); 
improvement in sense of smell and taste (32 comments); less expensive 
than cigarettes (28 comments); feasibility to use e-cigarettes (23 
comments); similar gestures or action of smoking cigarette (21 comments); 
not associated with unpleasant odours and ash or dirt (21 comments); taste 
and variety of flavours (12 comments); safe for others or bystander with no 
second hand smoke (10 comments); helped relieve the craving for tobacco 
(10 comments), and improvement in dental health (4 comments). 
They concluded that experienced e-cigarette users stated that initiating e-
cigarette use helped them to quit or reduce their conventional smoking, 
which they believed reduced their health risks. In comparison to cigarette 
smoking, e-cigarette users reported using their e-cigarette more times per 
day, but with fewer puffs than on conventional combustible tobacco 
cigarettes at each use time. E-cigarette users acknowledged that more 
research is needed in order to understand the safety and long-term effects 
of use. Finally, the e-cigarette users mentioned dry mouth as a common side 
effect and they also noted common problems with the reliability of e-
cigarettes.200 
Device and products: Most e-cigarette users had tried at least three 
different models prior to the one they were using currently. Almost half of 
the users spent more than 50 U.S. dollars on their current e-cigarette with a 
weekly maintenance cost of approximately 10 U.S. dollars. The most 
frequently used e-cigarette contained a button to press prior to 
inhalation/puffing (79.5%), had a tank to hold the liquid (58.5%), and used 




Harm The authors reported on the relationship between e-cigarette use and 
smoking-related measures (salivary cotinine levels) among American 
Indians who smoked.  
Age: Age groupings were categorized as years 18-44 and 45+.  
Sex: 145 males, 230 females  
Country: USA. Ethnicity: Cherokee citizens reside in the area under tribal 
administration 
Data source: Research staff recruited study participants from a high-traffic 
waiting area within the W.W. Hastings primary care outpatient facility in 
Tahlequah, Oklahoma. 
Population size: 375. Data collection period: Not reported 
E-cigarette, smoking and other related status: Status of e-cigarette use was 
assessed with the following questions: “Have you ever vaped or used an e-
cig, even one or 2 times?” and, “On how many of the past 30 days did you 
use an e-cigarette or vape even one or 2 times?” Individuals were 
considered current e-cigarette users if they reported e-cigarette use within 
the past 30 days. Individuals were considered past e-cigarette users if they 
ever used e-cigarettes but did not use within the past 30 days. Individuals 
were considered never e-cigarette users if they had never used e-cigarettes, 
even one or 2 times. The sample consider of 375 smokers of which 137 





Author(s) year Possible 
benefit or 
harm 
Cross-sectional surveys papers dependence and abuse liability 
current e-cigarette users.  Other tobacco use (current, past, or never) was 
based on use of smokeless tobacco, cigars, cigarillos, filtered cigars, 
hookahs, or dissolvable tobacco. Never use was defined as having never 
tried any of the identified tobacco products. Past use was defined as either 
having tried or yearly use of any of the identified tobacco products. Current 
use was defined as daily, weekly, or monthly use of any of these or other 
tobacco products. Individuals were considered current e-cigarette users if 
they reported e-cigarette use within the past 30 days. Individuals were 
considered past e-cigarette users if they ever used e-cigarettes but did not 
use within the past 30 days. Individuals were considered never e-cigarette 
users if they had never used e-cigarettes, even one or 2 times. 
Outcomes: Salivary cotinine levels and measures of intention to quit 
smoking. More than 63% of the study population reported use of e-
cigarettes either currently or in the past.  
The results did not suggest that e-cigarette use is associated with a 
reduction of cigarette consumption to less than one pack per day. Current 
use of cigarettes and e-cigarettes was associated with quit attempts in the 
past 12 months and a self-reported likelihood of future tobacco cessation, 
and that this may be an indication that e-cigarette use may signify a greater 
interest in smoking cessation. However, e-cigarette use was not associated 
with confidence to quit in the next month, cigarette packs smoked per day, 
or salivary cotinine levels.205 




Harm The authors reported on the relationship between characteristics of e-
cigarette usage and Fagerström Test for Nicotine Dependence outcome 
scores, specifically scores on nicotine dependence.  
Age: males were 31 years old (range 18–68, standard deviation (SD) = 11.1) 
and females were 35 years old (range 18–56, SD = 11.5)  
Sex: 72% were male and 28% female. Country: USA.  
Data source: A convenient sample of e-cigarette users attending a large 
South-eastern e-cigarette convention in Fall 2015. Surveys were placed on a 
table manned by a researcher in the convention centre entrance lobby. 
Subjects were able to approach the table and receive a paper survey to 
complete. 
Population size: 131. Data collection period: October 2015.  
E-cigarette, smoking and other related status: Low dependence, low to 
moderate dependence, moderate dependence, high dependence 
Outcomes: All questions from the Fagerstrom Test for Nicotine Dependence 
were included as well as select questions from the Penn State Electronic 
Cigarette Dependence Index. In total 25 questions were used to derived 
measures of addictive and behavioural characteristics and nicotine 
dependence rankings.  
The authors concluded that e-cigarette users can have higher average 
nicotine dependence levels than conventional combustible tobacco 
cigarette users. They noted that the length of e-cigarette use (<1 year versus 
>1 year) and the level of nicotine used in e-cigarette liquid (none versus any 
level of nicotine) were significantly associated with the Fagerström Test for 
Nicotine Dependence scores. They also noted that those who used e-
cigarette fluid with no nicotine had lower scores than those who used fluids 
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Device and products: This study surveyed 131 adult attendees at the 
“Orlando Vape Convention” on October 17, 2015. An estimated 1000 people 
attended to socialize and purchase e-cigarette liquids and supplies from 
approximately 40 vendors. An e-cigarette convention was chosen as the 
venue because it attracted many intense e-cigarette users over a short 
amount of time. Only current e-cigarette users were eligible to complete the 
survey. However, information on the type of device used by participants was 
not reported.206 








The authors reported on the relationship between completed baseline 
assessments of demographics, tobacco use, and dependence. They also 
provided details of breath samples for carbon monoxide (CO) assay and 
urine samples for cotinine, 3-hydroxycotinine (3HC), and 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL, a carcinogen) assays.  
Age in years: (Mean [SD]) Total 40.4 (14.1), Smokers 42.6 (14.4), Dual user 
39.0 (13.8). Sex: Slightly more than half were men (53.1%). Country USA 
Data source: Participants were recruited from the greater Madison and 
Milwaukee, WI areas via television and social media (e.g., Facebook) 
advertisements seeking adults who smoke or use e-cigarettes to participate 
in a study that tracks tobacco use. Interested callers completed a telephone 
screen, and eligible participants attended an initial study visit where they 
learned about the study and provided written informed consent. The 
authors initially set a minimum of 5 cigarettes/day for dual users, but this 
created difficulty with recruitment (i.e., 28% [57 of the 560] of the e-
cigarette users were disqualified for smoking fewer than 5 cigarettes/day). 
Therefore, approximately 6 months into the 2-year recruitment the authors 
changed the dual use criteria to require that dual users merely needed to 
have smoked daily for the last 3 months. The authors thus determined this 
to be an examination of an observational cohort (smokers, n = 166, ≥5 
cigarettes/day for 6 months and no e-cigarette use in 3 months; dual users, 
n = 256, smoked daily for 3 months and used e-cigarettes at least 
once/week for the past 3 months). This longitudinal observational cohort 
study explores use patterns and health indices over a 2-year period. The 
data reported here are from the baseline assessments. 
Population size: Total N = 422, Smokers (n = 166), Dual users (n = 256) 
Data collection period: Year not reported 
E-cigarette, smoking and other related status: compared smokers and dual 
users on indices of dependence and smoke exposure, including biomarkers 
Outcomes: baseline assessments of demographics, tobacco use, and 
dependence. Breath samples for carbon monoxide (CO) assay and urine 
samples for cotinine, 3-hydroxycotinine, and 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol (NNAL) assays. Smoking dependence measures: 
Cigarettes/day, Expired carbon monoxide (CO), Fagerstrom Test for 
Cigarette Dependence (FTCD), Smoke in first 30 minutes, Wisconsin 
Inventory of Smoking Dependence Motives Primary Dependence Motives 
(WISDM PDM), Wisconsin Inventory of Smoking Dependence Motives 
Secondary Dependence Motives (WISDM SDM), WISMD total.  
The authors concluded that dual users were more likely to be white, be 
younger, have more than a high school education, and have a psychiatric 
history. Dual users also smoked significantly fewer cigarettes and had lower 
levels of NNAL (a carcinogen), but they did not differ from exclusive smokers 
in terms of carbon monoxide or cotinine levels, suggesting that they 
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Device and products: Among the dual users, the most common type of 
device used was a refillable tank (65.3%), followed by replaceable cartridges 
(19.2%), and disposables (11.4%). The most commonly used e-liquid flavours 
were fruit (42.3%) and menthol (19.9%); 9% had no preference, 6.6% 
preferred candy flavours, and 6.6% used tobacco flavoured liquid. The 
preferred nicotine content in the e-liquid (listed in order of prevalence) was 
high nicotine (18–24 mg; 27.8%), very low nicotine (1–6 mg; 26.9%), low-to-
medium nicotine (7–12 mg; 23.3%), medium-to-high nicotine (13–17 mg; 
14.8%), very high nicotine (>24 mg; 4.5%), and no nicotine (2.7%). 
Boykan et al.207 
2019 
Harm The authors reported on differences in urinary cotinine levels in pod versus 
non-pod e-cigarette users. In addition, they assessed dependence levels in a 
subset of the original population. 
Age: 12-21 year. Sex: Not reported. County: USA 
Data source: Stony Brook Children outpatient office attendees 
Population size: 92 (of which 42 were considered in the secondary analysis 
of the following groups: past week pod users n=21, past week e-cigarette 
users who did not use pods n=27 (combustible pod users were excluded) 
Data collection period: April 2017 to April 2018 
E-cigarette, smoking and other related status: reported as past week pod 
users n=21, or past week e-cigarette users who did not use pods n=27 and 
2.9% (n = 18) were past-week tobacco smokers. 
Outcomes: early onset of nicotine addiction 
The authors concluded that adolescents who used pod products showed 
more signs of nicotine dependence than non-pod users. Positive responses 
to dependence questions were reflected in higher urinary cotinine levels207 




Harm The authors reported on levels of pain severity and anxiety sensitivity 
interplay among exclusive e-cigarette users and dual e-cigarette and 
conventional combustible tobacco cigarette users.  
Age (mean) (SD) years: 22.4 (2.2). Sex:60% males, 40% females. Country: 
Poland 
Data source: survey-based and multicentred international project, the 
Young People E-Smoking Study 
Population size: 93, 39 exclusive e-cigarette users and 54 dual users 
Data collection period: January and March 2018 
E-cigarette, smoking and other related status: exclusive e-cigarette users 
and dual users 
Outcomes: nicotine dependence levels 
The authors concluded that the findings suggest that there needs to be 
further study of anxiety sensitivity and pain severity in the context of e-
cigarette use, as there may be a benefit to screening for and clinically 
addressing these factors in order to help offset e-cigarette use..208 
Device and products: Not specifically reported. But the following 
information was provided: nicotine content in the e-liquid, e-liquid 
consumption, type of e-liquid used, and the number of e-cigarettes used, 
did not differ significantly between e-cigarette users and dual users. Users of 
e-cigarettes consumed an average of 4.2 mL of e-liquid per day, with the 
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mL of e-liquid. None of the subjects used nicotine free e-liquids. The study 
population was dominated by individuals who prepared e-liquids 
themselves. Over half of the e-cigarette users of exclusive e-cigarette users 
and dual users; had chosen devices that allow technical modifications of the 
e-cigarette such as voltage, power, and resistance of the heater.208 




Harm The authors reported on the relationship between tobacco and nicotine 
product use and depressive symptoms. 
Age: 18 to 29 years. Participants were required to be 18–26 years old if they 
were a lifetime non-tobacco user or 18–29 years old if they were a lifetime 
tobacco user 
Sex: 63.8% were female. Country: USA 
Data source: convenience sample of college students in 24 colleges and 
universities in Texas  
Population size: 5,438. Data collection period: November 2014 to February 
2015.  
E-cigarette, smoking and other related status: Lifetime tobacco use was 
defined by having ever smoked at least 100 cigarettes, or at least 20 cigars, 
or having ever used smokeless/spit/chewing tobacco at least 20 times. Use 
of five types of tobacco/nicotine products were examined in the study, 
current or past 30-day use of cigarettes, smokeless/snus tobacco, large 
cigars/cigarillos/little cigars, hookah, and e-cigarettes. Current use of 
cigarettes, smokeless tobacco, and hookah were assessed with the 
questions “During the past 30 days, on how many days did you 
smoke/use____?” Current use of large cigars/cigarillos/little cigars and 
hookah were assessed with questions “During the past 30 days, how many 
days did you smoke as intended (i.e. with tobacco)?” Current use of e-
cigarettes was assessed with the question “During the past 30 days, have 
you used any ENDS product (i.e., an e-cigarette, vape pen, or e-hookah), 
even one or two puffs, as intended (i.e. with nicotine cartridges and/or e-
liquid/e-juice)?” 
Outcomes: Depressive symptoms were assessed with the 10-item short-
form Centre for Epidemiologic Studies Depression 10 Scale (CES-D 10). 
Specifically, low depressive symptoms = CES-D score > 10; High depressive 
symptoms = CES-D score ≥ 10 
The authors reported that e-cigarettes were the only alternative tobacco 
product that were uniquely associated with depressive symptoms, and that 
the association was significant even after controlling for current cigarette 
use, sociodemographic characteristics, and current use of three other three 
alternative tobacco products tested.211 
Device and products: Not reported 
Bianco et al.209 
2019 
Harm The authors reported on the rates of e-cigarette use among adults with a 
chronic mental illness (classified as depression, anxiety, emotional disorder, 
or ADD, bipolar disorder, schizophrenia, other disorders). 
Age: 50.77 (SD=18.61; range 18–85). Sex: 54.6% female. Country: USA.  
Ethnicity 80.3% white. 
Data source: National Health Interview Survey 





Author(s) year Possible 
benefit or 
harm 
Cross-sectional surveys papers dependence and abuse liability 
E-cigarette, smoking and other related status: The majority of the sample 
did not have a chronic mental illness (97.1%, n=32,081), 2.7% (n=886) had 
chronic depression, anxiety, or an emotional problem, and 0.2% (n=61) had 
chronic ADD, bipolar, schizophrenia, or other disorder. Weighted 
percentages found 15.1% of the total sample tried an e-cigarette at least 
once and 3.1% were current e-cigarette users. 
Outcomes: Chronic mental illness (classified as depression, anxiety, 
emotional disorder, or attention deficit disorder (ADD), bipolar, 
schizophrenia, other disorder) 
The authors’ paper included the following findings: approximately 14% of 
the adult population in the USA has tried an e-cigarette, or is trying an e-
cigarette. Previous trial of an e-cigarette is more likely in a person with 
depression, anxiety, or an emotional problem (odds ratio (OR): 2.84). Trying 
an e-cigarette is more likely in a person with ADD, bipolar disorder, 
schizophrenia, or other disorder (OR: 2.47). Regular e-cigarette use is more 
likely in a person with depression, anxiety, or an emotional problem (OR: 
2.69). Regular e-cigarette use is more likely in a person with ADD, bipolar 
disorder, schizophrenia, or other disorder (OR: 3.02). However, as the 
temporary path of mental health diagnosis and e-cigarette uptake was not 
specified, the reported relationship must be viewed as cross-sectional in 
nature. The authors concluded that logistic regressions suggested that 
having a chronic mental illness significantly increases the likelihood of both 
trying an e-cigarette and being an e-cigarette user.209 
Device and products: Not reported 
Chadi et al.210 
2019 
Harm The authors reported on the relationship between e-cigarette and 
marijuana use and depressive symptoms and suicidality in a large sample 
of high school students.  
Age: high school students. Sex: 51.3% were female. Country: USA,  
Ethnicity: half of the sample participants (26,821) were white. 
Data source: Youth Risk Behaviour Survey 
Population size: 26,821 
Data collection period: 2015 and 2017  
E-cigarette, smoking and other related status: Four exposure groups for 
current e-cigarette and marijuana use: no use, e-cigarette-only use, 
marijuana-only use, and dual use. E-cigarette-only use was reported by 9.1% 
of participants, marijuana-only use in 9.7%, and dual e-cigarette/marijuana 
use in 10.2%. No Use (n=19047) E-Cigarettes Only (n=2431) Marijuana Only 
n=259 Dual Use n=2749 
Outcomes: Responses to the following questions: During the past 12 
months, did you ever seriously consider attempting suicide? Yes, no, 
unknown and During the past 12 months, did you ever feel so sad or 
hopeless almost every day for 2 weeks or more in a row that you stopped 
doing some usual activities? Answers were assessed to establish is 
participants had seriously considered suicide in the past 12 months, or 
endorsed symptoms of major depression for a 2-week period in the past 12 
months 
Almost one-third of participants (30.7%) reported experiencing depressive 
symptoms for more than 2 weeks and 17.3% reported seriously considering 
attempting suicide in the past year. E-cigarette-only use (vs no use) was 
associated with higher odds of reporting seriously considering attempting 
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which was also observed with marijuana-only use (vs no use) (AOR: 1.25, 
95%CI 1.04–1.50), and dual use (vs no use) (AOR: 1.28, 95% CI 1.06–1.54), 
Similarly, e-cigarette-only use (vs no use) was associated with higher odds of 
reporting depressive symptoms (AOR: 1.37, 95% CI 1.19–1.57), which was 
also observed with marijuana-only use (AOR: 1.49, 95% CI 1.27–1.75) and 
dual use (AOR: 1.62, 95%CI: 1.39–1.88). Finally, there was a non-significant 
trend towards higher odds of reporting suicidality and depressive symptoms 
among participants with dual e-cigarette and marijuana use vs single e-
cigarette or marijuana use.  
The authors stated that adolescents who admitted e-cigarette-only use, 
marijuana-only use, or dual e-cigarette and marijuana use had poorer 
mental health outcomes compared to those who denied use, when 
adjusting for demographic factors, use of other substances, and other 
relevant confounders. The association between depression and use of e-
cigarettes has previously been reported in a nationally representative 
sample of adolescents, but the association between e-cigarette use and 
suicidality has not. The authors observed an increased likelihood of 
depressive symptoms and suicidal ideation in all three investigated 
substance use categories (e-cigarette-only, marijuana-only, and dual e-
cigarette/marijuana use).210  
Device and products: The study sample included only participants with 
complete information for exposure to e-cigarettes and marijuana (89.5% of 
survey respondents). Participants were divided into 4 exposure groups for 
current e-cigarette and marijuana use: no use, e-cigarette-only use, 
marijuana-only use, and dual use. Current use was defined as use of the 
specified substance at least once in the past 30 days210 
Lee et al.213 
2019a 
Harm The authors reported on the association of depression and suicidality with 
electronic and conventional combustible tobacco cigarette use in South 
Korean adolescents. 
Age: 13–18 years old. Sex: Not reported. Mixed. Country: South Korea 
Data source: Korean Youth Risk Behaviour Web-based Survey 
Population size: 62,276. Data collection period: April 2017  
E-cigarette, smoking and other related status: Participants were categorized 
into four groups: current non-use, conventional-cigarette-only use, e-
cigarette only use, and dual use. Participants were assessed by asking “Have 
you ever used cigarettes in the past 30 days?” (yes/no) and “Have you ever 
used e-cigarettes in the past 30 days?” (yes/no). 
Outcomes: This web-based survey comprised 123 questions and 15 areas of 
health-related behaviours, including smoking behaviour and mental health. 
A multivariate logistic regression was performed to assess the association of 
depression and suicidality with electronic and conventional cigarette use.  
There were significant differences between tobacco cigarette and e-
cigarette users: dual users had a higher prevalence of depression and 
suicidality for both lifetime and current use; e-cigarette-only users had 
higher levels of depression and suicidality than non-users; and female 
adolescents who were conventional-cigarette-only users, e-cigarette-only 
users, or dual users had a higher prevalence of depression and suicidality 
than male adolescents in those user categories. The authors concluded that 
the findings suggest an urgent need for evaluation of, and intervention in, e-
cigarette use by health professionals providing smoking cessation 
programmes for adolescents.213 
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Kim212 
2019 
Harm The author investigated the association of the use of e-cigarettes with 
suicidal behaviours in adolescents 
Age: 13 to 18 years. Sex: 4,380 males, 1,024 females 
Country: South Korea  
Data source: Korean Youth Risk Behaviour Web-Based Survey 
Population size: 5405. Data collection period: 2016 
E-cigarette, smoking and other related status: E-cigarette use was assessed 
by the item, ‘How many days did you use e-cigarettes in the past 30 days?’ 
Response options were ‘None,’ ‘1–2 days,’ ‘3–5 days,’ ‘6–9 days,’ ‘10–19 
days,’ ‘20–29 days’ and ‘Every day.’ This study categorized e-cigarette users 
into two categories: ‘0 days in the past 30 days,’ which included those who 
answered ‘None,’ and ‘1–30 days in the past 30 days,’ which included those 
who answered ‘1–2 days,’ ‘3–5 days,’ ‘6–9 days,’ ‘10–19 days,’ ‘20–29 days’ 
and ‘Every day.’ 
Outcomes: suicidal ideation, suicidal attempts and serious suicidal attempts 
The author concluded suicidal behaviours are significantly higher among 
current adolescent e-cigarette smokers than adolescents who have not used 
an e-cigarette in the past 30 days212 




Harm The authors reported-on levels of pain severity and anxiety sensitivity 
interplay among exclusive and dual e-cigarette user 
Age mean (SD) years = 36.8 (10.6). Sex: 126 males, 193 females Country: 
USA.  
Ethnicity: White (78.1%) individuals, followed by 14.4% Black/African 
American, 9.7% Hispanic, 3.4% Asian, 2.2% other, and 1.9% Native 
American/Alaska Native 
Data source: Participants were recruited nationally via Qualtrics Inc. 
Interested participants were screened for eligibility and directed to the 
online, anonymous survey. 
Population size: 319. Data collection period: Not reported 
E-cigarette, smoking and other related status: e-cigarette users: The study 
included 319 current e-cigarette users 
Outcomes: anxiety sensitivity and pain severity. The interaction between 
anxiety sensitivity and pain severity was significantly related to increased e-
cigarette dependence, perceived risks of e-cigarette use, and perceived 
benefits of e-cigarette use. The form of the significant interaction indicated 
that participants reporting co-occurring higher levels of anxiety sensitivity 
and pain severity evinced greater e-cigarette dependence, perceived risks of 
e-cigarette use, and perceived benefits of e-cigarette use. 
The authors concluded that the findings suggest there needs to be further 
study of anxiety sensitivity and pain severity in the context of e-cigarette 
use, as there may be benefit to screening for and clinically addressing these 
factors to help offset e-cigarette use214 
Device and products: Not reported 
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Lanza et al.215 
2017 
Harm The authors reported on the relationship between e-cigarette and 
conventional combustible tobacco cigarette use and higher weight status 
(obesity). 
Age: The average age of participants was 21.3 years ± 2.6 (median = 21.0 
years) 
Sex: 59.1% (56.2%) female. Country: USA,  
Ethnicity: 36.9% (39.0%) Hispanic/Latino, 26.3% (23.4%) Asian/Pacific 
Islander, 17.9% (18.7%) Caucasian/White, 4.9% (3.8%) African 
American/Black, 5.1% (4.8%) Multiracial; 2.1% (3.6%) other, 0.2% (0.2%) 
Native American, and 6.6% declined to respond 
Data source: convenience sample of 452 undergraduates attending a 
California State University 
Population size: 452. Data collection period: 2015-2016 
E-cigarette, smoking and other related status: Participants were then asked 
questions related to cigarette smoking and electronic tobacco use: (1) “Have 
you ever smoked a cigarette?” (1 = yes, 0 = no); (2) “In the past month, have 
you smoked cigarettes regularly (at least 5 times in the last 30-day period)?” 
(1 = yes, 0 = no); and (3) “Have you ever smoked cigarettes regularly (at least 
5 times in a 30-day period)?” which was used to create a former cigarette 
smoker variable (1 = yes, 0 = no) by comparing responses from question 3 to 
question 2. Because there was no available validated questionnaire on 
young adult electronic tobacco use at the time of survey development and 
implementation, questions on electronic tobacco use were developed for 
this specific study. Two questions on prevalence included: (1) “Have you 
ever tried an electronic tobacco product (like e-cigarettes, vaporizers, e-
hookahs)?” (1 = yes, 0 = no); and (2) “Would you consider yourself a regular 
user of any electronic tobacco product, like e-cigarettes, vaporizers, or e-
hookahs?” (1 = yes, 0 = no). Almost 40% (39.8%) of the sample had engaged 
in electronic tobacco use, and 5% self-identified as a regular electronic 
tobacco user. 
Outcomes: weight status as a correlate of substance use patterns reflecting 
electronic tobacco use. Data on 118 questions pertaining to electronic 
tobacco use, alcohol use, cigarette smoking, nutrition and physical activity, 
and psychosocial adjustment. Participants self-reported height and weight, 
which was used to calculate body mass index (BMI; weight(lbs)/[height(in)2 
x 703). Those with a BMI score > 30 were identified as obese (1 = obese, 0 = 
non-obese). indicators of weight status, obesity and deviation from the 
group BMI norm, were generally associated with membership in the 
Cigarette/Electronic Tobacco class. Obese participants had a higher 
likelihood of belonging to the Cigarette/Electronic Tobacco class compared 
to the High Substance Use (β =1.48, OR = 4.40, p < .05) and Risky Alcohol 
Use (β =1.94, OR = 6.97, p < .05) classes; however, higher likelihood of being 
classified into the Cigarette/Electronic Tobacco class compared to the Low 
Substance Use class was only marginally significant (β =1.29, OR = 3.63, p = 
.07). Greater deviation from the group BMI norm significantly predicted 
higher likelihood of belonging to the Cigarette/Electronic Tobacco class 
compared to the Low Substance Use (β =.11, OR = 1.11, p <.05) and High 
Substance Use (β =.11, OR = 1.12, p < .05) classes; but a higher likelihood of 
belonging to the Cigarette/Electronic Tobacco class compared to the Risky 
Alcohol Use class was only marginally significant (β =.11, OR = 1.11, p = .06). 
Both obesity status and greater deviation from one’s group body mass index 
(BMI) norm were associated with a higher likelihood of belonging to the 
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The authors concluded that the relationship between obesity and cigarette 
smoking may extend to e-cigarette use among young adults.215 
Device and products: Not reported 
Morean et al.216 
2019 
Harm The authors reported on the relationship between use of flavoured e-
cigarettes and e-liquids with appetite control and weight loss. 
The authors concluded that a subset of adolescents reported using 
flavoured e-liquids for weight-related reasons. These adolescents reported 
vaping more frequently than their counterparts, raising concerns about 
increased nicotine exposure. Research is needed in order to understand 
where adolescents learn about weight-motivated vaping (e.g. friends, social 
media) and whether weight-related motives promote e-cigarette initiation 
among e-cigarette-naive individuals or continued/escalating use among 
current users. 
Age mean (SD) (range) years: 16.3 (1.2) (13 to 19).  
Sex: 49.4% males, 50.6% females. Country: USA 
Data source: school-based survey 
Population size: 529. Data collection period: Spring 2017 
E-cigarette, smoking and other related status: students with positive 
answers to the following questions: approximately how many days out of 
the past 30 days did you vape an e-cigarette/smoke a cigarette?” (0–30 
days). Participants who vaped/smoked on ≥1 day in the past 30 days were 
considered past-month e-cigarette users and/or smokers, respectively 
Outcomes: assessment of aadolescent e-cigarette users (past 30-days) who 
reported vaping flavoured e-liquids for appetite control and weight loss. 
The authors concluded that a subset of adolescents reported using 
flavoured e-liquids for weight-related reasons. These adolescents reported 
vaping more frequently than their counterparts, raising concerns about 
increased nicotine exposure. Research is needed in order to understand 
where adolescents learn about weight-motivated vaping (e.g. friends, social 
media) and whether weight-related motives promote e-cigarette initiation 
among e-cigarette-naive individuals or continued/escalating use among 
current users.216 
Device and products: Information on whether participants had “vaped e-
cigarettes with nicotine in the past 30 days” (no/yes), “which flavours [they 
had] used in the past 30 days” (response options: tobacco, menthol, mint, 
fruit, candy, vanilla, alcohol, coffee, spice, other, and I don’t know), and 
“Why do you use flavoured e-liquids?” (select all that apply from they taste 
better than regular cigarettes, they help me to cut down on smoking regular 
cigarettes, they help me to quit smoking, they freshen my breath, they 
provide a throat hit, they taste good, they help me control my appetite, they 
help me lose weight, and other (write-in)  
  Sleep pattern 
Boddu et al.217 
2019 
Harm The authors reported on the effects of e-cigarettes on sleep. 
Age: 30.2 (12.3). Sex: 134 males, 139 females 
Country: 20 USA states, 12 countries (not named) 
Data source: online social media advertisement  
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E-cigarette, smoking and other related status: Non-smokers (n=126) 
conventional cigarette users (n=25) e-cigarettes users (n=79) Dual users 
(n=44) 
Outcomes: Sleep disturbance associated with e-cigarette assessed by 
clinically validated sleep and cough questionnaires – Pittsburgh Sleep 
Quality Index and Leicester Cough Questionnaire assessment of the impact 
of cough severity on health-related quality of life, across physical, 
psychological and social domains) 
The authors found that dual use of e-cigarettes with conventional tobacco 
has the highest risk for causing sleep disruption. They concluded that 
mechanistically, this finding is logical if nicotine is the causal agent of sleep 
disruption, as dual users are more likely to consume greater concentrations 
of nicotine than either smokers or vapers. This notion may reveal the 
underlying mechanism for poorer sleep quality and for increased odds and 
severity of cough in dual users.dual.217 
Device and products: Not reported but the authors noted that JUULTM, 
which contains higher concentration of nicotine compared to conventional 
tobacco cigarettes (up to 60mg/mL)is used by >50% of current e-cigarettes 
vapers since 2017217 
Brett et al.218 
2019 
Harm The authors reported on the relationship between e-cigarette use and sleep 
health in young adults. 
Age:19.7 (2.5). Sex: 44% males, 66% females. Country: USA 
Data source: Undergraduates from a midwestern university self-selected 
into the study through the university online research recruitment system 
Population size: 1,664 college students. Data collection period: Not reported  
E-cigarette, smoking and other related status: Nine hundred and eighty‐four 
participants (59%) reported never using an e-cigarette. Five hundred and 
forty-six participants (33%) reported ever trying an e-cigarette, and 134 (8%) 
reported e-cigarette use at least once each month.   
Outcomes: Questionnaires assessed demographic information, sleep health 
(assessed using the Pittsburgh Sleep Quality Index) and e-cigarette use 
status and patterns. 
The authors concluded that current combustible and e-cigarette users 
reported significantly more sleep difficulties than never users. E-cigarette 
users reported greater use of sleep medication than combustible cigarette 
users.218 
Device and products: Not reported 218 
Riehm et al.219 
2019 
Harm The authors reported on the relationship between e-cigarette use and 
sleep-related complaints 
Age: 12 to 17. Sex: 4,914 males, 4,674 females, Country: USA  
Ethnicity: White only, Black only, other [American Indian or Alaska Native, 
Asian Indian, Chinese, Filipino, Japanese, Korean, Vietnamese, other Asian, 
Native Hawaiian, Guamanian or Chamorro, Samoan, and Pacific Islanders) 
Data source: Population Assessment of Tobacco and Health Study, a 
nationally representative cohort 
Population size: 9,588. Data collection period: 2013 to 2015 
E-cigarette, smoking and other related status: Participants were grouped in 
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past-year e-cigarette or combusted cigarette use at Wave 2: 1) exclusive e- 
cigarette use; 2) exclusive combusted cigarette use; 3) dual-product use; or 
4) no use of either product. E-cigarette use was assessed by first asking 
adolescents “Which of the following electronic nicotine products have you 
ever used?” and presenting a list of products. Those who selected “E-
cigarette (including vape pens and personal vaporizers)” were then asked, 
“When was the last time you used an e-cigarette, even one or two times?” 
Adolescents were considered to have used e-cigarettes if they selected a 
response that fell within the past year. Combustion cigarette use was 
assessed by asking “In the past 12 months, have you smoked a cigarette, 
even one or two puffs?” Adolescents were categorized as dual-product 
users if criteria for past-year use were met for both e-cigarettes and 
combusted cigarettes. 
Outcomes: adolescents who reported past-year e-cigarette and dual-
product use had 29% and 57% higher odds of reporting sleep-related 
complaints, respectively, compared to no use of either product 
The authors concluded e-cigarette and dual-product use are significantly 
associated with greater odds of reporting sleep-related complaints among 
adolescents  
Device and products: Respondence were asked the following e-cigarette 
device related questions: For lifetime e-cigarette use (yes/no), adolescents 
were considered lifetime users if they responded “yes” to the question, 
“Have you ever used an e-cigarette, such as NJOY, Blu, or Smoking 
Everywhere, even one or two times?” For lifetime combusted cigarette use, 
adolescents were considered lifetime users if they responded “yes” to the 
question, “Have you ever tried cigarette smoking, even one or two puffs?”. 
Have you ever used marijuana, hash, THC, grass, pot or weed?” or if they 
responded “yes” to the question, “Have you ever smoked part or all of a 
cigar, cigarillo or filtered cigar with marijuana in it?”219 
  Perceived health 
Lequy et al.220 
2019 
Harm The authors reported on perceived health and its association with current 
use of e-cigarettes in current and former smokers.  
The authors concluded that the findings suggest that the unhealthier 
current and former smokers felt, the more they tended to currently use e-
cigarettes. Authors reported on the perceived health and its association 
with current use of e-cigarettes in current and former vapers.  
Age: 18–69 years at baseline 
Current smokers – never n=4,805, current n=1,010. Former smokers - never 
n=11,986, current n=499 
Sex: 8,778 males. County: France 
Data source: participants included in the French CONSTANCES cohort (a 
large general-purpose national population-based cohort)  
Population size: 18,300 ever tobacco smokers with data on their e-cigarette 
use 
Data collection period: 2015 to 2017  
E-cigarette, smoking and other related status: Assessment of e-cigarette use 
as follows: “Have you ever smoked an electronic cigarette?” We defined 
participants answering yes as ever e-cigarette users. Among them, we 
distinguished between “Current e-cigarette user” and “Former e-cigarette 
user” through the following 2 questions: “Are you currently using disposable 
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who responded yes to at least one of these questions were classified as 
“Current e-cigarette user.” Since we had no data about how many and how 
long former users had used e-cigarettes or why they had stopped, we 
excluded former e-cigarette users. 
Outcomes: global and respiratory perceived health. Specifically, answers to 
the following questions “How do you describe your general health?” and 
Any self-reported personal history of respiratory disease (at least 1 positive 
answer to asthma, chronic obstructive pulmonary disease, or emphysema) 
and the existence of an obstructive syndrome measured by spirometry at a 
screening health centre (defined as the ratio of forced expiratory volume in 
1 second to forced vital capacity, or an forced expiratory volume in 1 
second/forced vital capacity ratio < 0.7). 
The authors concluded that the findings suggest that the unhealthier 
current and former smokers felt, the more they tended to currently use e-
cigarettes. Authors reported on the perceived health and its association 
with current use of e-cigarettes in current and former vapers.220 
Device and products: Not reported 
Table 68: Cross-sectional surveys papers on cardiovascular disease, benefits or harms 
Author(s) year Possible 
benefit or 
harm 
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The authors reported on the relationship between electronic and tobacco 
cigarettes and the inflammatory signalling network underlying acute cardiac 
ischaemia (the Splenocardiac Axis). 
Age: 21 to 45 years. Sex: 20 males, 7 females. Country: USA.  
Ethnicity: African American n=1, Asian n=4, Hispanic n=3, White (non-
Hispanic) n=19 
Data source: healthy habitual tobacco cigarette smokers or habitual e-
cigarette users (not dual users) who had used tobacco cigarettes or e-
cigarettes, respectively, most days for a minimum of 1 year, in whom plasma 
cotinine levels were elevated, were eligible for the study if they met the 
study criteria: no known health problems, nonobese (≤30 kg/m2 BMI), not 
taking prescription medications except oral contraceptive pills, alcoholic 
intake ≤2 drinks per day and no illicit drug use, not exposed to second-hand 
smoke, or using licensed nicotine replacement therapies. 
Population size: 31. Data collection period: Not reported 
E-cigarette, smoking and other related status: 10 habitual tobacco cigarette 
users, 11 habitual e-cigarette users, and 10 healthy control subjects. Nine in 
each group were included in the final analysis 
Outcomes: F-flurorodeoxyglucose positron emission tomography/computer 
tomography (FDG-PET/CT) imaging, cotinine (t1/2 20 h), carboxyhemoglobin 
(COHb) marker for tobacco cigarette, but not e-cigarette use; inflammatory 
markers, including C-reactive protein (CRP) and fibrinogen; the following 
antioxidant parameters: paraoxonase-1 activity, ((PON-1 activity) a protective 
ester hydrolase enzyme associated with HDL in blood that prevents the 
formation of oxidized LDL, LDL Oxidizability ((LDL-Ox) indicative of 
susceptibility of apoB-containing lipoproteins to oxidation and HDL 
antioxidant/anti-inflammatory capacity, expressed as a HDL antioxidant index 
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The authors reported that both hematopoietic tissue metabolic activity and 
aortic wall metabolic activity are increased in tobacco and e-cigarette users, 
and that plasma cotinine, an estimate of tobacco cigarette and e-cigarette 
burden, was weakly correlated with bone marrow activity. The authors 
concluded that the findings indicated activation of the Splenocardiac Axis in a 
graded manner, from non-user, healthy control subjects, to habitual e-
cigarette users, to tobacco cigarette smokers.221 




Harm The authors reported on the relationship between e-cigarette use and 
myocardial infarction.  
Age: 18 plus years. Sex: 38,209 females. Country: USA.  
Ethnicity: Hispanic 9826 White 46242 Black 8667 Asian 3769 Other 948 
Data source: National Health Interview Survey 
Population size: 36,697 (2014) 33,028 (2016) 
Data collection period: 2014 and 2016 
E-cigarette, smoking and other related status: E-cigarette use were grouped 
as never, former, some days and daily. Each of the four groups were further 
sub-grouped according to cigarette use status. Thus the 16 groups were: 
never electronic use never cigarette smoker, never electronic use former 
cigarette smoker, never electronic use someday cigarette smoker, never 
electronic use daily cigarette smoker; former electronic use never cigarette 
smoker, former electronic use former cigarette smoker, former electronic use 
someday cigarette smoker, former electronic use daily cigarette smoker; 
some days electronic use never cigarette smoker, some days electronic use 
former cigarette smoker, some days electronic use someday cigarette 
smoker, some days electronic use daily cigarette smoker; and daily electronic 
use never cigarette smoker, daily electronic use former cigarette smoker, 
daily electronic use someday cigarette smoker, daily electronic use daily 
cigarette smoker. 25.8% of current (some days or daily) e-cigarette users 
were former smokers and 66.2% of current e-cigarette users were current 
(some days or daily) cigarette smokers; current e-cigarette users were less 
likely to be daily users (34.4% or 776/2,259) than were current cigarette 
smokers (76.5% or 8,969/11,718, p<0.001). 
Outcomes: Myocardial infarction. Controlling for the demographic 
characteristics of age, gender, Body Mass Index (BMI) and several health 
characteristics (hypertension, diabetes, and hypercholesterolemia) e-
cigarette use was independently associated with increased odds of having 
had a myocardial infarction (OR=1.79, 95% CI=1.20, 2.66, p=0.004) as was 
daily conventional cigarette smoking (OR=2.72, 95% CI=2.29, 3.24, p<0.001)  
The authors concluded that e-cigarette use was independently associated 
with increased odds of having had a myocardial infarction.222 
Device and products: Not reported 
Wang et al.224 
2018 
Harm The authors reported on the relationship between cigarette and e-cigarette 
dual use and risk of cardiopulmonary symptoms.  
Age: median 41.4 years (E-cigarette use only), median 45 years cigarette use 
only, 46 years dual user 
Sex: 27,600 females, 12,047 males. Country: Mostly USA  
Ethnicity: Non-Hispanic White 32,302, Hispanic 2,761, Black/African-
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Data source: Health e-Heart Study. Population size: 39,747 
Data collection period: March 8, 2013 to March 1, 2017  
E-cigarette, smoking and other related status: 573 (1.4%) reported e-
cigarette only use, 1,693 (4.3%) reported cigarette only use, and 514 (1.3%) 
dual use. 
Outcomes: Nineteen cardiopulmonary symptoms: breathing difficulty, chest 
pain, palpitations, loss of consciousness or syncope, high blood pressure or 
hypertension, high cholesterol, diabetes, coronary artery disease/ angina, 
heart attack, blocked arteries (legs), blood clots (veins or lungs), congestive 
heart failure, stroke or TIA (transient ischemic attack), enlarged heart, atrial 
fibrillation, arrhythmia, sleep apnoea, COPD, asthma, or cardiac arrest. 
The SF-12 general health score, measuring 19 cardiopulmonary symptoms, 
was lower (worse) in dual users compared to cigarette-only users; this was 
specifically observed in the outcomes of breathing difficulties and a history of 
arrhythmia. E-cigarette-only use, compared to no product use, was 
associated with lower general health scores, higher breathing difficulty scores 
(typically and in the past month), and greater proportions of those who 
responded ‘yes’ to having chest pain, palpitations, coronary heart disease, 
arrhythmia, chronic obstructive pulmonary disease, and asthma. The authors 
suggested that the use of e-cigarettes alone may have contributed to 
cardiopulmonary health risks, particularly respiratory health risks.224 






The authors reported on the relationship between e-cigarette use, coronary 
heart disease, and myocardial infarction.  
Age (SD): Daily 43.3(15.7), Some days 41.2(15.5), Former 41.0 (15.6), Never 
52.2(18.6) 
Sex: 58.2% males, 41.8% females. Country: USA. Ethnicity: White, Black or 
African American, American Indian or Alaska Native (AIAN), Asian, and 
Multiple Race 
Data source: National Health Interview Surveys 
Population size: 33,028 (2016) and 26,742. Data collection period: 2016 and 
2017  
E-cigarette, smoking and other related status: Daily (714), Some days (1,009), 
Former (7,026), Never (50,830)  
Outcomes: participants informed reporting of receiving a diagnosis of 
coronary heart disease and myocardial infraction from a doctor 
The authors concluded that the pooled analysis of the 2016 and 2017 
National Health Interview Survey showed no association between e-cigarette 
use and myocardial infarction or coronary heart disease. The associations 
between established risk factors, including smoking, and both conditions 
were remarkably consistent. The inconsistent associations observed in single-
year surveys and the cross-sectional design of the National Health Interview 
Survey cannot substantiate any link between e-cigarette use and an elevated 
risk for myocardial infarction or coronary heart disease.223 
Device and products: Never smokers were defined in the survey based on a 
cut-off point of using 100 cigarettes in their life (participants were asked 
‘Have you smoked at least 100 cigarettes in your entire life?’). Those 
responding ‘no’ were classified as never smokers. Those responding ‘yes’ 
were subsequently asked about current smoking (participants were asked ‘Do 
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question was used to define daily and some days smokers, while former 
smokers were defined as those responding ‘yes’ to the question about ever 
smoking and ‘not anymore’ to the question about current smoking. Ever e-
cigarette use was determined by asking: ‘Have you ever used an e-cigarette 
even one time?’. Those responding ‘no’ were classified as never users. Those 
responding ‘yes’ were subsequently asked about current e-cigarette use 
(participants were asked ‘Do you now use e-cigarettes every day, some days, 
or not at all?’). This question was used to define daily and some days e-
cigarette users, while former e-cigarette users were defined as those 
responding ‘yes’ to the question about ever e-cigarette use and ‘not 
anymore’ to the question about current e-cigarette use. No other device or 
product specific information was gathered223 




The authors reported on the association between e-cigarette use and 
cardiovascular disease. 
Age: Median age group of current users 30 to 34 median age group of current 
never users 45 to 49 years 
Sex: 41.2% female in the current users, 55.2% female in the never users 
Country: USA. Ethnicity: White 69.7%, Black 9.1%, Asian 3.7%, Hispanic 
12.1%, Others 5.4 % in the current users, White 60.5%, Black 12.4%, Asian 
6.5%, Hispanic 17.9%, Others 2.7 % in the never users 
Data source: Behavioural Risk Factor Surveillance System 
Population size: 449,092. Data collection period: 2016 and 2017 
E-cigarette, smoking and other related status: 15,863 (3.5%) current e-
cigarette users, 12,908 (2.9%) dual users of e-cigarettes + combustible 
cigarettes,  
Outcomes: Cardiovascular Disease and Premature Cardiovascular Disease  
Of the 449,092 participants, 44,852 (10.0%) had cardiovascular disease. The 
authors reported that dual use of e-cigarettes + combustible cigarettes was 
associated with significantly higher odds of cardiovascular disease compared 
with smoking alone. They also found a graded increase in odds of 
cardiovascular disease with increasing frequency of e-cigarette exposure 
among current combustible-cigarette smokers. No significant association 
between e-cigarette use and cardiovascular disease among never 
combustible cigarette smokers. However, current combustible cigarette 
smokers who never used e-cigarettes, dual use of e-cigarettes plus 
combustible cigarettes was associated with 36% higher odds of 
cardiovascular disease (Odds Ratio [OR], 1.36; 95% CI, 1.18-1.56); with 
consistent results in subgroup analyses of premature cardiovascular disease 
in women less than 65years and men less than 55years old. That is higher 
odds of cardiovascular disease among dual users of e-cigarettes + 
combustible cigarettes compared to smoking alone.  
The authors concluded that their results suggest significantly higher odds of 
cardiovascular disease among dual users of e-cigarettes and combustible 
cigarettes compared with combustible tobacco cigarette-only users. They 
also queried whether the current lack of significant association between e-
cigarette use and cardiovascular disease among never combustible cigarette 
smokers may be due to the younger age of this group.225 
Device and products: Not reported 
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The authors reported on the relationship between e-cigarettes and 
micronuclei prevalence indicative of oral cavity cancer following cytologic 
examination of oral mucosa. 
Age: average years (range) smokers 47.6 (23–73), 57.8 (27–65), 46.7 (23–74) 
Sex: males 10 smokers, 12 e-cigarette smokers and 11 non-smokers, females 
13 smokers, 10 e-cigarette smokers and 9 non-smokers 
Country: Italy. Data source: Hospital outpatient attendees  
Population size: 65 
Data collection period: January and June 2015  
E-cigarette, smoking and other related status: smokers (n=23), e-cigarette 
smokers (n=22) and non-smokers (n=20). Smokers only subjects who 
consumed a single type of cigarette were included in the study, cigarettes 
were classified according to the average content of nicotine and tar, e-
cigarette smokers used different e-cigarette devices and various types of 
charging liquid. The e-cigarette smokers considered did not use the 
conventional combustible tobacco cigarette in the last six months. Thus, e-
cigarettes were classified according to the nicotine content of the charging 
liquid: light (0.4–0.9 mg), medium (0.10–0.12 mg), and heavy (0.13–0.16 mg). 
Outcomes: Micronuclei  
A higher prevalence of micronuclei was observed in smokers relative to e-
cigarette smokers, and non-users had the lowest prevalence of micronuclei 
among the three groups. The authors stated that micronuclei are indicative 
elements of genomic instability and may have a clinical application in 
screening tests for risk categories of oral cavity carcinoma. They also 
suggested that e-cigarettes seem to be safe for oral cells and should be 
suggested as an aid for smoking cessation.228 
Device and products: Group B (e-cigarette users) included subjects who used 
different e-cigarette devices and various types of charging liquid. The e-
cigarette smokers whom we have considered did not use the conventional 
combustible tobacco cigarette in the last six months. Thus, e-cigarettes were 
classified according to the nicotine content of the charging liquid: light (0.4–
0.9 mg), medium (0.10–0.12 mg), and heavy (0.13–0.16 mg). For each 
consumer, the content (mL) of the reservoir of the device and the number of 
daily refills were evaluated. Group A (Conventional cigarette users), specific 
data on cigarette consumption were collected from each subject, including 
daily and yearly consumption, type of cigarette, possible side effects, and 
period of consumption or withdrawal. Cigarette consumption was calculated 
according to the number of cigarettes smoked in 24 hours and the number of 
packs consumed yearly by using the formula: packages/year = (number of 
cigarettes smoked per day: 20) × year of consumption. Only subjects who 
consumed a single type of cigarette were included in the study. Cigarettes 
were classified according to the average content of nicotine and tar 










The authors reported on the relationship between smokers of combustible 
cigarettes only, former smokers with long-term e-cigarette-only use, former 
smokers with long-term NRT-only use, long-term dual users of both 
combustible cigarettes and e-cigarettes, and long-term users of both 
combustible cigarettes and NRT with exposure to nicotine, tobacco-related 
carcinogens, and toxins. 
Age: Mean age years 37.8. Sex: 100 males 71 females. Country: United 
Kingdom Ethnicity: White 131 
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Population size: 171. Data collection period: January 2014 to June 2014  
E-cigarette, smoking and other related status: combustible cigarette-only 
users, former smokers with long-term (≥6 months) e-cigarette-only or 
nicotine replacement therapy--only use, and long-term dual combustible 
cigarette-e-cigarette or combustible cigarette-nicotine replacement therapy 
users. Smokers: Cigarette-Only Users (n _ 37) Dual Cigarette–NRT Users (n _ 
36) Dual Cigarette–e-cigarette Users (n _ 36) Former Smokers: NRT–Only 
Users (n _ 36) e-cigarette-Only Users (n _ 36) 
Outcomes: biomarkers of nicotine, tobacco specific N-nitrosamines (TSNAs), 
and volatile organic compounds specifically the parent Compound 
(biomarker/metabolite) Acrolein (N-acetyl-S-(3-hydroxypropyl)-L-cysteine), 
Acrylamide (N-acetyl-S-(2-carbamoylethyl)-L-cysteine), Acrylonitrile (N-acetyl-
S-(2-cyanoethyl)-L-cysteine), 1,3-butadiene (N-acetyl-S-(4-hydroxy-2-buten-1-
yl)-L-cysteine), Ethylene oxide (N-acetyl-S-(2-hydroxyethyl)-L-cysteine). 
Across the five groups (n=36–37 per group), nicotine, carcinogen, and toxin 
exposure was assessed using urine and saliva samples, which were analysed 
for biomarkers of nicotine, tobacco-specific N-nitrosamines (TSNAs), and 
volatile organic compounds. The authors concluded that e-cigarette-only 
users had significantly lower 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL) levels than all other groups. Combustible cigarette-only users, dual 
combustible cigarette and NRT users, and dual combustible cigarette and e-
cigarette users had largely similar levels of tobacco-specific N-nitrosamines 
and volatile organic compounds metabolites. 
Device and products: Product use was verified by asking participants to bring 
in the NRT or e-cigarette that they were currently using, and smoking status 









The authors reported on the relationship between e-cigarette use and the 
presence of N'-nitrosonornicotine (NNN) as a risk marker of oral and 
oesophageal cancer. 
Age: mean 31.3 years e-cigarette users 41.9 years non-smokers 40.6 years 
smokers 
Sex: 8 e-cigarette users 12 years non-smokers 14 years smokers 
Country: USA. Ethnicity: White 20 e-cigarette users 10 non-smokers 16 
smokers, Other 10 smokers 3 non-smokers, Non-Hispanic 20 cig users 20 non-
smokers 19 smokers 
Data source: E-cigarette users, smokers, and non-smokers were recruited by 
the University of Minnesota Tobacco Research Programs 
Population size: 59. Data collection period: Not reported 
E-cigarette, smoking and other related status: 20 e-cigarette users, 20 
smokers, and 19 non-smokers. E-cigarette users were daily users who 
reported at least three months of exclusive e-cigarette use and no other 
tobacco use in the past 6 months. A smoker was classified as such if he/she 
smoked at least 10 cigarettes per day and had no regular use of nicotine 
replacement therapy products and no other tobacco or e-cigarette use in the 
last 6 months, participants were classified as non-smokers if they smoked less 
than 100 cigarettes in their lifetime and had no tobacco or e-cigarette use in 
the last 6 months. 
Outcomes: N'-nitrosonornicotine (NNN), nornicotine, and nicotine in saliva 
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The mean of N'-nitrosonornicotine (NNN) in saliva of e-cigarette users was 
14.6 (+/-23.1) pg/mL, ranging from nonquantifiable (below the limit of 
quantitation, LOQ) to 76.0 pg/mL. In smokers, salivary NNN ranged from 
below LOQ to 739 pg/mL, with 80% of smokers having salivary NNN in the 
range of levels found in e-cigarette users. Very low levels of urinary total N'-
nitrosonornicotine (NNN) were present in only 5 out of 20 e-cigarette users 
(ranging from 0.001 to 0.01 pmol/mL urine).  
The authors concluded that N'-nitrosonornicotine is formed endogenously in 
e-cigarette users, and while overall exposure to N'-nitrosonornicotine in e-
cigarette users is lower than in smokers, the known carcinogenic potency of 
N'-nitrosonornicotine should be monitored (specifically salivary rather than 
urinary NNN) in order to assess the potential relationship of e-cigarettes with 
oral and oesophageal cancers.229 
Device and products: Not reported 
Carroll et al.230 
2018 
Harm The authors reported on the relationship of cigarette smokers and electronic 
nicotine delivery system (ENDS) users with nicotine metabolism and 
nicotine and carcinogen exposure. 
Age: Median age 46 years cigarette smokers, 33 ENDS users, 40 Dual users 
Sex: Females 33/73 Cigarette smokers 16 ENDS users 17 Dual users 
Country: USA, adults of American Indian descent 
Data source: Community-based recruitment of adults of American Indian 
descent 
Population size: 73. Data collection period: USA.  
E-cigarette, smoking and other related status: smokers (n=27), electronic 
nicotine delivery system (ENDS) users (n=21), and dual users (n=25). A regular 
cigarette smoker was defined as an individual who smoked at least 5 
cigarettes per day for the past 3 months and in the past 24 h and had not 
used tobacco products other than cigarettes in the past 3 months. A regular 
ENDS user was defined as an individual who used an ENDS daily for the past 3 
months and in the past 24 h and had not used tobacco products other than 
ENDS in the past 3 months. A dual user was defined as an individual who 
smoked at least 5 cigarettes per day in the past 3 months and in the past 24 
h, used an ENDS product daily for the past 3 months and in the past 24 h, and 
not used tobacco products other than cigarettes and ENDS in the past 3 
months.230 
Outcomes: nicotine metabolism (nicotine metabolite ratio [NMR]), nicotine 
dose (total nicotine equivalents [TNE]), and a tobacco-specific lung 
carcinogen (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its 
glucuronides [total NNAL] 
Among smokers, there were inverse relationships between nicotine 
metabolite ratio and total nicotine equivalents (r=-0.45) and between 
nicotine metabolism nicotine metabolite ratio and (4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanol and its glucuronides [NNAL] (r=-0.50). Among dual 
users, nicotine metabolism, nicotine metabolite ratio and total nicotine 
equivalents, and nicotine metabolite ratio and (4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol and its glucuronides were not associated. Among ENDS 
users, nicotine metabolism, nicotine metabolite ratio and total nicotine 
equivalents were not associated.  
The authors concluded that the high prevalence of smoking and ENDS use 
among American Indians in the southern plains may not be related to 
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important role in light tobacco users, and this may be particularly true among 
American Indian light tobacco users who have strong cultural ties.230 
Device and products: Participants were asked to complete the following: You 
said you currently use an electronic nicotine product. These products are 
battery-powered, use nicotine fluid rather than tobacco leaves, and produce 
vapor instead of smoke. There are many different names for these devices. 
Some common brands include Fin, NJOY, Blu, e-Go and Vuse.’ Then, generic 
photos of commonly used ENDS (‘cig-a-like’; tank or vapor system; e-cigar; e-
pipe; e-hookah) were displayed and participants were asked to choose the 
photo(s) which best resembled the ENDS they currently used. Participants 
had the option of selecting more than one ENDS. Information on Type of 
ENDS: tank/mod or vapor system, and, ENDS nicotine concentration was 
reported. 
Chaffee et al.227 
2019 
Harm The authors examined assessed tobacco product use (smokeless, 
combustible, and electronic cigarettes) and nicotine and carcinogen 
exposures. 
Age: Mean age years 15.8. Sex: All males. Country: USA 
Data source: study participants were male baseball players at 36 rural 
California high schools 
Population size: 594. Data collection period: 2014 to 2016  
E-cigarette, smoking and other related status: Representative images and 
brief descriptions were shown for seven tobacco products: cigarettes, cigars, 
e-cigarettes (including cigarette-like disposable, rechargeable, and larger 
refillable devices), waterpipe (hookah), snus, dissolvable tobacco, and 
smokeless tobacco (moist snuff and chewing tobacco, listed in surveys as dip 
and chew, respectively). For each tobacco product, questions included: “Have 
you ever tried [tobacco product]? “During the past 30 days, on how many 
days did you use [tobacco product]?”; and “During the past 7 days, on how 
many days did you use [tobacco product]?” Individuals reporting past 30-day 
use of smokeless tobacco were asked to indicate the type (moist snuff, 
chewing tobacco, or both), the “brand of smokeless tobacco you use most 
often” (choose from a list or “other”), and the flavour (if any) of the 
smokeless tobacco usually used (choose from a list or “other”). 
Outcomes: Salivary specimens were assayed for cotinine (a biomarker of 
nicotine exposure) and urine specimens for 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol (NNAL, a biomarker of the carcinogen 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)  
The authors concluded that adolescents who use smokeless tobacco 
products (including e-cigarettes) are exposed to substantial levels of nicotine 
and to the biomarker of the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNK). Although exposed to lower levels than adult smokeless 
tobacco product users, the findings are concerning given the young age of the 
sample and the tendency for smokeless tobacco product users to increase 
use intensity over time.227 
Device and products: Not reported 
Table 70: Cross-sectional surveys papers on respiratory diseases, benefits or harms 
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Wang et al.233 
2016 
Harm The authors reported on the relationship between e-cigarette use and 
respiratory symptoms. 
Age: mean (SD) age was 14.6 (1.9) years. Sex: 51.1% males 
Country: Hong Kong. Ethnicity: Chinese 
Data source: Secondary students. Population size: 44,662.  
Data collection period: 2012 -2013  
E-cigarette, smoking and other related status: Smoking status was defined as 
never-smoking (36 915), ever-smokers (7048) experimental smoking (smoked 
once or a few times) (3576), ex-smoking (smoked in the past but not now) 
(1812), and current smoking (smoked on ≥1 day in the past 30 days) (1660). 
Use of e-cigarettes in the past 30 days (yes or no), respiratory symptoms 
(cough or phlegm) for 3 consecutive months in the past 12 months (yes or 
no), sociodemographic characteristics (sex, age, and perceived family 
affluence), and second-hand smoke exposure were recorded.  
Outcomes: respiratory symptoms (cough or phlegm) for 3 consecutive 
months in the past 12months (yes or no) 
Adjusted odds ratios (AORs) of respiratory symptoms - cough or phlegm. E-
cigarette use was significantly associated with respiratory symptoms (AOR, 
1.28; 95% CI, 1.06-1.56). The corresponding AORs (95% CIs) were 2.06 (1.24-
3.42) in never-smokers, 1.39 (1.14-1.70) in ever-smokers, and 1.40 (1.02-1.91) 
in ex-smokers. Positive but nonsignificant associations were observed in 
experimenters (AOR, 1.09; 95% CI, 0.66-1.80) and current smokers (AOR, 
1.15; 95% CI, 0.81-1.62).  
The authors noted that the strong association of respiratory symptoms 
(cough or phlegm for 3 consecutive months in the past 12 months) in 
adolescent e-cigarette users who never smoked tobacco cigarettes (AOR: 
2.06; 95% CI: 1.24–3.42) is comparable with that found in adolescent 
occasional smokers (AOR: 1.72; 95% CI: 1.01–2.93) in other Hong Kong study 
populations.233 




Harm The authors reported on the relationship of e-cigarette use with chronic 
bronchitis symptoms and wheeze in an adolescent population. 
Age: Mean age 17.3 years (SD, 0.6). Sex: Not reported. Country: USA  
Data source: Southern California Children’s Health Study 
Population size: n = 2,097; 87% of 2,412 members of the cohort attending 
schools in the study communities. 2,086 provided information on e-cigarette 
use and either wheeze or bronchitic symptoms. 
Data collection period: 2014. 
E-cigarette, smoking and other related status: Ever e-cigarette use was 
reported by 502 (24.0%), of whom 201 (9.6%) used e-cigarettes during the 
last 30 days (current users) 
Outcomes: Risk of bronchitic symptoms was increased by almost twofold 
among past users of e-cigarettes (odds ratio [OR], 1.85; 95% confidence 
interval [CI], 1.37–2.49), compared with never-users of e-cigarettes, and by 
2.02-fold (95% CI, 1.42–2.88) among current users of e-cigarettes. Risk 
increased with frequency of current use (OR, 1.66; 95% CI, 1.02–2.68) for 1–2 
days and 2.52 (95% CI, 1.56–4.08) for 3 or more days in past 30 days 
compared with never-users. Associations were attenuated by adjustment for 
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However, risk of bronchitic symptoms among past of e-cigarettes users 
remained elevated after adjustment for relevant potential confounders and 
was also observed among never–cigarette users (OR, 1.70; 95% CI, 1.11–
2.59). There were no statistically significant associations of e-cigarette use 
with wheeze after adjustment for cigarette use. Examination of interactions 
of e-cigarette use with sex, ethnicity (Hispanic and non-Hispanic white), and 
asthma and with a dog or cat in the home, was also undertake none of which 
was statistically significant.  
The authors concluded that adolescent e-cigarette users had increased rates 
of chronic bronchitic symptoms.238 
Device and products: Not reported 








The authors reported on the association of e-cigarette use with smoking 
habits, demographic factors, and respiratory symptoms (such as sputum 
production, chronic productive cough, and wheeze).  
Age: 20 to 75 years, Sex: 13,947 males, 16,325 females. Country: Sweden 
Data source: Obstructive Lung Disease in Northern Sweden study 
Population size: 30 272. Data collection period: 2016  
E-cigarette, smoking and other related status: The number of current smokers 
was 3694 (12.3%), and 7305 (24.4%) were former smokers. 
Outcomes: Respiratory symptoms were defined by affirmative answers to the 
following questions: for long-standing cough, “Have you had long-standing 
cough during the last year?”; for sputum production, “Do you usually have 
phlegm when coughing, or do you have phlegm in your chest that is difficult 
to bring up?”; for chronic productive cough, “Do you bring up phlegm on 
most days during periods of at least 3 months?” and “Have you had such 
periods during at least 2 successive years?”; for any wheeze, “Have you at any 
time during the last 12 months had wheezing or whistling in your chest?”; for 
recurrent wheeze, “Do you usually have wheezing, whistling, or a noisy sound 
in your chest when breathing?”; and for any respiratory symptoms, an 
affirmative answer to any of Respiratory symptoms (long-standing cough, 
sputum production, chronic productive cough, any wheeze, recurrent 
wheeze, any respiratory symptoms) were most common among dual users of 
conventional combustible tobacco cigarettes and e-cigarettes, and among 
former smokers and non-smokers who used e-cigarettes. In a regression 
analysis adjusted for sex, age group, survey, and educational level, having any 
respiratory symptoms was significantly associated with dual use (OR: 4.03; 
95% CI: 3.23–5.02), smoking only (OR: 2.55; 95% CI: 2.36–2.77), and former 
smoking without e-cigarette use (OR: 1.27; 95% CI: 1.19–1.36), while former 
smoking with e-cigarette use (OR: 1.47; 95% CI: 0.91–2.37) and non-smoking 
with e-cigarette use (OR: 1.46; 95% CI: 0.93–2.29) did not reach statistical 
significance. Non-smokers without e-cigarette use were used as the reference 
in the regression analysis.234 
Device and products: Not reported 
Lestari et al.235 
2018 
Harm The authors reported on the relationship between e-cigarette use, a range of 
subjective feelings of upper respiratory well-being, and formaldehyde 
vapour concentration. 
Age: 18 to 25 years. Sex: Not reported. Country: Indonesia.  
Data source: Purpose sampling. Population size: 20 
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E-cigarette, smoking and other related status: The sample consisted of active 
e-cigarettes smokers who have been smoking for at least 2 months as 
members of electronic cigarette community. 
Outcomes: Subjective feelings during smoking e-cigarettes such as irritation 
in nose, eye, and throat. Nose irritation - itchy nose, uncomfortable smell, 
and sneezing. Eye irritation - watery eye, sore eye, and reddish eye. Upper 
airway irritation - sore throat, dry throat, cough, and asphyxia. 
Health complaints were obtained by interviews using questionnaires. The 
specific health complaints irritation and number reporting the condition 
were: irritation in nose (Itchy nose n=3, sneezing n=4, uncomforted smell 
n=1), eye, (reddish n=0, sore=1 watery n=1) and throat (upper airway 
irritation – asphyxia n=1, cough n=5, dried throat n=13, sore throat n=2). 
Cotinine urine was positive in 88.0% of participants. A variety of vapours were 
assessed: vapor 1 (local vapor) contained 90% glycerine and 10% propylene 
glycol, vapor 2 (USA) contained 60% glycerine and 40% propylene glycol, 
vapor 3 (Malay) contained 60% glycerine and 40% propylene glycol, vapor 4 
(local vapor) contained 60% glycerine and 40% propylene glycol, vapor 5 
(Malay) contained 30% glycerine and 70% propylene glycol, vapor 6 
contained 70% glycerine and 30% propylene glycol in e-cigarettes. The 
duration of formaldehyde measurement was 60 minutes within the same 
smoking period in each measurement. Formaldehyde concentration varied 
from 0.0345 ppm to 0.1490 ppm. The health complaints were mostly upper 
airway irritation with acute effect and mostly cotinine urine was positive. 
The authors concluded that health complaints were mostly upper airway 
irritation with acute effect, and that cotinine in urine was mostly positive.235 
Device and products: The measurement of e-cigarettes brand was done to 
identify the formaldehyde concentration vapor in six brands of e-cigarettes 
that are liquid local 90(VG)/10 propylene glycol, liquid USA 60 propylene 
glycol)/40(VG), liquid Malay 60 propylene glycol/40(VG), liquid local 60 
propylene glycol/40(VG), liquid Malay 30 propylene glycol/70(VG), and liquid 
USA 70 propylene glycol)/30(VG). Before measuring six vapours, in the 
beginning formaldehyde concentration was measured in empty glass 
container as a control. Formaldehyde vapor concentration was analysed at 
Occupational Safety and Health Laboratory 
Reidel et al.231 
2018 
Harm The authors reported on the relationship between cigarette smokers, e-
cigarette users, and non-smokers with the profile of innate defence proteins 
in airway secretions of mucins MUC5AC and MUC5B, and of neutrophil 
extracellular trap formation rates. 
Age: Not reported. Sex: Not reported. Country: USA. 
Data source: Not reported 
Population size: 44. Data collection period: Not reported 
E-cigarette, smoking and other related status: 14 current cigarette smokers, 
15 current e-cigarette users, and 15 never-smokers. The average number of 
cigarettes smoked per day in the cigarette smoker group was approximately 
11. E-cigarette users had been using e-cigarettes actively and exclusively or 
predominantly for at least 6 months. In the e-cigarette user category, the 
average number of puffs inhaled per day was approximately 280. Of the 15 e-
cigarette users, 12 identified themselves as having previously smoked 
cigarettes, and three indicated no prior cigarette smoking history. In addition, 
five of the subjects reported occasionally smoking cigarettes  
Outcomes: mucins MUC5AC and MUC5B, and neutrophil extracellular trap 
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Using induced sputum samples from cigarette smokers, e-cigarette users, and 
non-smokers total and individual concentrations of mucins MUC5AC and 
MUC5B and neutrophil extracellular trap (NET) formation rates were 
determined. E-cigarette users exhibited significant increases in aldehyde-
detoxification and oxidative stress-related proteins associated with cigarette 
smoke compared with non-smokers. The levels of innate defence proteins 
associated with chronic obstructive pulmonary disease, such as elastase and 
matrix metalloproteinase-9, were significantly elevated in e-cigarette users as 
well. E-cigarette users' sputum also uniquely exhibited significant increases in 
neutrophil granulocyte-related and NET-related proteins, such as 
myeloperoxidase, azurocidin, and protein-arginine deiminase 4, despite no 
significant elevation in neutrophil cell counts. Peripheral neutrophils from e-
cigarette users showed increased susceptibility to phorbol 12-myristate 13-
acetate-induced NETosis. Finally, a compositional change in the gel-forming 
building blocks of airway mucus (i.e., an elevated concentration of mucin 
MUC5AC) was observed in both cigarette smokers and e-cigarette users.  
The authors concluded that e-cigarette use alters the profile of innate 
defence proteins in airway secretions, inducing similar and unique changes 
relative to cigarette smoking. These data challenge the concept that e-
cigarettes are a healthier alternative to cigarettes.231 










The authors reported on the effects of e-cigarettes on voice performance 
compared with conventional combustible tobacco cigarettes.  
Age: 18 to 54 years. Sex: Males. Country: Turkey 
Data source: Adana City Hospital otolaryngology clinic volunteers 
Population size: 81. Data collection period: Not reported 
E-cigarette, smoking and other related status: Three groups: e-cigarette users 
passed smoker of conventional tobacco cigarettes and electronic cigarette 
user for 1 to 3 years (group 1, n = 21), conventional cigarette users (group 2, n 
= 30), and non-smokers who had never smoked (group 3, n = 30).  
Outcomes: Fundamental frequency, jitter %, shimmer %, shimmer dB, 
harmonics-to-noise ratio (HNR) values, and Voice Handicap Index 10 
The nicotine content of the e-cigarettes was 9 and 12 mg/mL and these 
smokers inhale 1–2 mL/d. Group 2 consisted of men who smoked 10–20 
conventional tobacco cigarettes per day and had done so for 1–5 years. 
Volunteers in groups 1 and 2 were selected who were using 10–20 mg of 
nicotine per day. 
No significant difference regarding the Fundamental frequency, jitter %, and 
shimmer % values between the groups was detected. A significant difference 
was detected regarding the shimmer dB and harmonics-to-noise ratio values 
between the groups. The mean Voice Handicap Index 10 values of the 
conventional cigarette users were higher than those of the e-cigarette users 
and the control group (P < 0.05).  
The authors concluded that the effects of e-cigarettes on voice were detected 
as mild compared with those of conventional combustible tobacco cigarettes, 
according to the subjective and objective voice analysis results in the study.250  
Device and products: The nicotine content of the e-cigarettes was 9 and 12 
mg/mL and these smokers inhale 1–2 mL/d. 
King et al.236 
2019 
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Age: mean age years (SD) 37.9. Sex: 802 males, 820 females 
Country: USA. Ethnicity:1,140 white, 477 non-white 
Data source: nationally representative cross-sectional telephone survey of 
4,964 US adults 
Population size: 1,624. Data collection period: August 2016 to May 2017 
E-cigarette, smoking and other related status: ever e-cigarette users 
Outcomes: Cough, Dry Mouth or Throat, Dizziness or light-headedness, 
Headache or Migraine, Shortness of breath, Change in or loss of taste 
The authors concluded that most e-cigarette users reported at least one 
symptom, most commonly a cough or a dry or irritated mouth or throat. 
Former cigarette smokers who used e-cigarettes in the past 30 days were less 
likely than current or never-smokers to report adverse symptoms of e-
cigarette use.  
Device and products: All participants were read this statement: “The next few 
questions are about electronic or e-cigarettes and other vaping devices, such 
as vape pens. Popular brands include Blu, Vuse, NJOY, and Flavour Vapes.” 
Then, we asked participants whether they ever used an e-cigarette or other 
vaping devices, even one or two times. The authors asked participants who 
reported ever using e-cigarettes on how many of the past 30 days they used 
e-cigarettes. No further information on device or product was reported.236 
Li et al.237 
2019 
Harm The authors reported on the association between smokers, dual users, and 
vapers with wheezing and related respiratory symptoms. 
Age: Not reported. Sex: Not reported. Country: USA 
Data source: U. S. Population Assessment of Tobacco and Health 
Population size: 28,171 adults 
Data collection period: October 2014 to October 2015 
E-cigarette, smoking and other related status: 641 (1.2%) were current vapers 
who used e-cigarettes exclusively, 8525 (16.6%) were current exclusive 
smokers, 1106 (2.0%) were dual users and 17 899 (80.2%) were non-users 
Outcomes: wheezing and related respiratory symptoms; specifically, ever had 
wheezing or whistling in chest at any time in past, wheezing or whistling in 
chest in past 12 months, number of wheezing attacks more than 12 in past 12 
months, one or more nights per week had sleep disturbed due to wheezing, 
speech limited to only one or two words between breaths due to wheezing in 
past 12 months, chest has sounded wheezy during or after exercise and dry 
cough at night not associated with a cold or chest infection. 
Compared with non-users, risks of wheezing and related respiratory 
symptoms were significantly increased in current vapers (adjusted OR 
(aOR)=1.67, 95% CI: 1.23 to 2.15). Current vapers had significantly lower risk 
in wheezing and related respiratory symptoms compared with current 
smokers (aOR=0.68, 95% CI: 0.53 to 0.87). No significant differences were 
found between dual users and current smokers in risk of wheezing and 
related respiratory symptoms (aOR=1.06, 95% CI: 0.91 to 1.24). The authors 
concluded that vaping was associated with increased risk of wheezing and 
related respiratory symptoms. Current vapers had lower risk in wheezing and 
related respiratory symptoms than current smokers or dual users but higher 
than non-users. Both dual use and smoking significantly increased the risk of 
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The authors concluded that vaping was associated with increased risk of 
wheezing and related respiratory symptoms. Current vapers had a lower risk 
of wheezing and related respiratory symptoms than current smokers or dual 
users, but a higher risk than non-users. Both dual use and smoking 
significantly increased the risk of wheezing and related respiratory symptoms. 
Age: 18 to 65 year plus. Most current vapers were aged 18–34 years 
(52.06%). Most current smokers were aged 35–64 (56.63%).237 
Device and products: Not reported 








The authors reported on the impact of e-cigarettes on lung function and 
fractional exhaled nitric oxide (FeNO) among 60 young healthy male adults. 
Age: The mean age of the exposed group (ENDS users) and control group 
(non-e-smokers) was 27.07 ± 6.00 (mean ± SD) and 25.90 ± 7.72 years, 
respectively.  
Sex: All young healthy male adults. Country: Saudi Arabia 
Data source: participants from the various suburbs in the city of Riyadh 
Population size: 60. Data collection period: September 2016–September 2017  
E-cigarette, smoking and other related status: 30 e-cigarette users, who were 
using nicotine containing e-liquid daily for at least the past 6 months and 30 
male matched controls who had never tried e-cigarettes, regular cigarettes, 
or shisha  
Outcomes: Spirometry to assess lung function test parameters including 
forced vital capacity (FVC), forced expiratory volume in the first second 
(FEV1), forced expiratory ratio (FEV1/FVC), peak expiratory flow (PEF), forced 
expiratory flow—25% (FEF25%), forced expiratory flow—50% (FEF50%), 
forced expiratory flow—75% (FEF75%), forced expiratory flow 25%–75% 
(FEF25%–75%), and forced expiratory flow 75%–85% (FEF75%–85%). 
The study population was divided into two groups: group 1 (e-cigarette-
exposed group) 30 daily e-cigarette users (age 27.07 +/- 6.00 [mean +/- SD] 
years), group 2 (control group) 30 who were not e-cigarette users (age 25.90 
+/- 7.72 [mean +/- SD] years). The study population were neither current nor 
former traditional tobacco users.  
The lung function test parameters that were found to be significantly 
decreased in e-cigarette users compared to their control group were forced 
expiratory volume in the first second (FEV1), forced expiratory ratio 
(FEV1/FVC), forced expiratory flow-25% (FEF25%), forced expiratory flow-50% 
(FEF50%), forced expiratory flow-75% (FEF75%), forced expiratory flow-25%-
75% (FEF25%-75%), and forced expiratory flow-75%-85% (FEF75%-85%). 
Fractional nitric oxide concentration in exhaled breath (FeNO) was also 
decreased in e-cigarette users, but it did not reach the level of significance. 
The authors concluded that e-cigarettes significantly impaired various lung 
function parameters and the pattern of impairment exhibited a peripheral 
obstructive airway involvement 232 
The authors concluded that fractional exhaled nitric oxide was decreased in 
e-cigarette users, but it did not reach the level of significance. Also, the use of 
e-cigarettes significantly impaired various lung function parameters, and the 
pattern of impairment exhibited a peripheral obstructive airway 
involvement.232  
Device and products: Not reported 
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Cho et al.241 
2016 
Harm The authors reported on findings regarding the association between e-
cigarette use and asthma (students’ self-reported doctor diagnosis in past 12 
months).  
Age: mean age years (SD) 16.4 ±0.9. Sex: 17,997 females, 17,902 males.  
Country: South Korea 
Data source: The Tenth Korean Youth Risk Behaviour Web-based Survey from 
800 middle and high schools in 2014 
Population size: 35,904. Data collection period: 2014 
E-cigarette, smoking and other related status: 'current e-cigarette users' (n = 
2,513), 'former e-cigarette users' (n = 2,078), and 'never e-cigarette users' (n 
= 31,313). e-cigarette use was assessed by the question ‘Have you ever used 
an e-cigarette in your life?’ (yes/no). Answering no was classified as ‘never 
user’. Respondents who answered in the affirmative were asked a follow-up 
question ‘Have you used e-cigarettes in the past 30 days?’(yes/no). 
Answering yes was classified as ‘current user’ and answering no was classified 
as ‘former user’. Similarly, cigarette smoking was assessed by the question 
‘Have you ever smoked, even one puff in your life?’ (yes/no). Answering no 
was classified as ‘never smoker’. Respondents who answered in the 
affirmative were asked a follow-up question ‘In the past 30 days, how many 
days did you smoke?’ Answering ‘one or more days’ was classified as ‘current 
smoker’, and answering ‘none’ was classified as ‘former smoker.’ 
Outcomes: asthma (self-reported doctor diagnosis) 
The authors compared 'current e-cigarette' users with 'never e-cigarette' 
users, the unadjusted OR for asthma was 2.36 (95% CI: 1.89-2.94). In order to 
control for the effect of conventional cigarette (CC) smoking, after stratifying 
the subjects by the three CC smoking categories (never CC, former CC, and 
current CC), within the 'never CC' category, the unadjusted OR for asthma for 
'current e-cigarette' users was 3.41 (95% CI: 1.79-6.49), and the adjusted OR 
was 2.74 (95% CI: 1.30-5.78).  
The authors concluded that e-cigarette users have an increased association 
with asthma and are more likely to have had days absent from school due to 
severe asthma symptoms 241 
Device and products: Not reported  
Choi et al.240 
2016 
Harm The authors reported findings on the association between e-cigarette use 
and asthma.  
Age: 16 years. Sex: Not reported for the subsection of the population 
examined in this paper. Country: USA  
Ethnicity: Non-Hispanic White Hispanic Native American Non-Hispanic Asian 
Non-Hispanic Black Other  
Data source: Florida Youth Tobacco Survey 
Population size: 36,085. Data collection period: 2012  
E-cigarette, smoking and other related status: E-cigarette use was assessed by 
asking the participants if they had ever tried using an electronic cigarette 
(yes/no), and if they had used an electronic cigarette during the past 30 days 
(yes/no). E-cigarettes were described to the participants as “battery-operated 
devices that look, feel, and taste like a tobacco cigarette.” Participants 
reported the number of days they had smoked cigarettes during the 30 days 
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Among students with asthma, e-cigarette use was more common among 
those in non-metropolitan and rural counties than those in metropolitan 
counties (p<0.05). Ever and past 30-day e-cigarette use was associated with 
cigarette smoking susceptibility among participants with asthma and those 
who never tried cigarettes (n=2,410; ever use, AOR=3.96, 95% CI=1.49, 10.56; 
past 30-day use, AOR=422.10, 95% CI=50.29, >999.99). Past 30-day e-
cigarette use was associated with having an asthma attack in the past 12 
months among participants with asthma (n=5,865, p<0.01).  
The authors concluded that e-cigarette use is more common among Florida 
high school youth with asthma and is associated with susceptibility to 
cigarette smoking.240 
Device and products: Not reported 
Kim et al.242 
2017 
Harm The authors reported on the association of active and passive e-cigarette 
vaping with asthma. 
Age: 12 to 18 years (deduced from other studies using same dataset) 
adolescents. Sex: 106497 females. Country: South Korea 
Data source: Korea Youth Risk Behaviour Web-based Survey 
Population size: 216,956 
Data collection period: 2011, 2012 and 2013  
E-cigarette, smoking and other related status: Active smoking was classified 
into 4 groups (0 days, 1-5 days, 6-19 days, and >=20 days a month). Passive 
smoking was also categorized into 4 groups (0 days, 1-2 days, 3-4 days, and 
>=5 days a week). E-cigarette was defined as yes or no in the last 30 days 
Outcomes: asthma 
Active vaping was significantly associated with asthma (AOR [95% CI] of 
smoking >=20 days/month = 1.57 [1.38-1.77], P < 0.001). Passive vaping was 
also related with asthma (AOR [95% CI] of smoking >=5 days/week = 1.40 
[1.28-1.53], P < 0.001).  
E-cigarette showed positive relation with asthma, although the effects of past 
smoking history could not be excluded (AOR [95% CI] = 1.12 [1.01-1.26], P = 
0.027). Age, sex, obesity, region of residence, exhaled carbon monoxidenomic 
level, and parental educational level were adjusted for as confounders.  
The authors concluded that the study demonstrated a positive association 
between e-cigarette use and an asthmatic episode in the past 12 months, and 
that this association was observed when adjustments for active and passive 
vaping exposure were included in the analysis. However, e-cigarette vaping in 
the past month was not significantly associated with lifetime asthma after 
adjusting for active and passive vaping. Active and passive vaping were thus 
considered to be more influential on previous asthma history than recent e-
cigarette vaping. As a high proportion of e-cigarette smokers are generally 
previous active smokers, the effects of previous active vaping were high in 
this group.242 




Harm Authors reported on the association of e-cigarette with asthma, controlling 
for cigarette smoking, marijuana use, and six demographic covariates. 
Age: mean age was 15.8 (SD = 1.2) years. Sex: 50% female  
Country: Hawaii USA. Ethnicity: 2% of the participants were American Indian 
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were Native Hawaiian or Other Pacific Islander, 16% were Japanese or Other 
Asian, and 11% were Caucasian. 
Data source: Hawaii Youth Risk Behaviour Survey (HYRBS) 
Population size: 6,089. Data collection period: 2015  
E-cigarette, smoking and other related status: Cigarette smoking was 
assessed by “Have you ever tried cigarette smoking, even a few puffs?” 
(No/Yes) and “During the past 30 days, on how many days did you smoke 
cigarettes?” (7 response options: 0 days to all 30 days). E-cigarette use had 
the lead-in instruction, “The next two questions ask about electronic vapor 
products, such as blu, NJOY, or Starbuzz. Electronic vapor products include e-
cigarettes, e-cigars, vape pipes, e-hookahs, and hookah pens.” The items 
were “Have you ever used an electronic vapor product?” (No/Yes) and 
“During the past 30 days, on how many days did you use an electronic vapor 
product?” (7 response options, same as for cigarettes). Marijuana use was 
assessed with “How old were you when you tried marijuana for the first 
time?” (7 responses: Never tried to 17 years or older) and “During the past 30 
days, how many times did you use marijuana?” (6 response options: 0 times 
to 40 or more times). The item on age of first marijuana use was recoded to 
never tried vs. tried at any age, providing an index for ever use of marijuana. 
Outcomes: asthma 
Current e-cigarette use was associated with currently having (vs. never 
having) asthma (adjusted odds ratio [aOR]=1.48, CI 1.26-1.74) and with 
previously having (vs. never having) asthma (aOR=1.22, CI 1.07-1.40).  
The authors concluded that e-cigarette use by adolescents is independently 
associated with asthma.239 
Device and products: Nothing in addition reporting above 
AboElNaga 243 
2018 
Harm The author reported on the relationship between e-cigarettes and specific 
respiratory outcomes, including asthma control test, lung function, blood 
eosinophils, and airway immunoinflammatory phenotype.  
Age: Mean 30.07±4.97 years. Sex: 63 males and 67 females. Country: Egypt  
Data source: Outpatient Clinic of Chest Department of the October 6 
University Hospital 
Population size: 130. Data collection period: Not reported 
E-cigarette, smoking and other related status: non-smokers (48 patients), 
current conventional combustible tobacco cigarette smokers (41 patients), 
and e-cigarette smokers (41 patients). 
Outcomes: Spirometry parameters [forced vital capacity (FVC), forced 
expiratory volume in 1 s (FEV1), FEV1/FVC ratio, maximal mid expiratory flow, 
and peak expiratory flow rate (PEFR)] and asthma control test (ACT) score 
airways immunoinflammatory (Eosinophilic, Neutrophilic, Paucigranulocytic) 
phenotype and blood eosinophilic count. 
The asthmatic patients were reported to have significant differences in 
spirometry and distribution of sputum cell subtypes between non-smokers, 
current conventional combustible tobacco cigarette smokers, and e-cigarette 
users. The author stated that asthmatic smoker patients who smoke e-
cigarettes develop mixed sputum subtype; there was no difference in the 
pulmonary function or asthma control of patients who smoke e-cigarettes 
compared with that observed in conventional smokers. The author concluded 
that asthmatic patients who continue to smoke conventional combustible 
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in their pulmonary function, as recorded by spirometry parameters (FVC, 
FEV1, FEV1/FVC, maximal mid expiratory flow, and peak expiratory flow rate), 
and asthma control test score, in comparison with non-smoking asthmatic 
patients.243 
Device and products: Not reported 
Osei et al.244 
2019b 
Harm The authors reported on the relationship between e-cigarette use and 
asthma among never combustible cigarette smokers.  
Age: median age group of current e-cigarette users 18–24 years 
Sex: 224,774 males, 178,042 females. Country: USA 
Data source: Behavioral Risk Factor Surveillance System 
Population size: 402,822 
Data collection period: 2016 and 2017 
E-cigarette, smoking and other related status: 402,822 never combustible 
cigarette smokers, 3,103 (0.8%) current e-cigarette users  
Outcomes: odds of asthma among never combustible smoking e-cigarette 
users 
The authors concluded that there was an increased rate of asthma among 
never combustible cigarette smoker e-cigarette users, with 39% higher odds 
of self-reported asthma compared to never e-cigarette users (OR: 1.39; 95% 
CI: 1.15–1.68).244 
Device and products: Not reported  
Perez et al.245 
2019 
Harm The authors reported on the association of e-cigarette use and asthma in 
never- smokers. 
Age: Not reported. Sex: Not reported. Country: USA 
Data source: Behavioral Risk Factor Surveillance System 
Population size: 486,303 (2016) and 450,016 
Data collection period: 2016 and 2017 
E-cigarette, smoking and other related status: Defining e-cigarette users and 
never-smokers. Respondents were first asked, “Have you ever used an e-
cigarette or other electronic ‘vaping’ product, even just one time, in your 
entire life?” Those who responded “no” were considered never e-cigarette 
users. Those who answered “yes” were categorized as ever e-cigarette users, 
and then asked: “Do you now use e-cigarettes or other electronic ‘vaping’ 
products every day, some days, or not at all?” Ever e-cigarette users who 
responded “every day” were characterized as current e-cigarette daily users 
and those who reported “some days” were categorized as current e-cigarette 
someday users, while those who answered "not at all" were categorized as 
former e-cigarette users. Participants were considered never smokers of 
conventional tobacco cigarettes if they answered "no" to "Have you smoked 
at least 100 cigarettes in your entire life?” 
Outcomes: medical diagnosis of asthma as reported by participant 
The authors concluded that their findings suggest that e-cigarette use may be 
associated with asthma among never-smokers.245  
Device and products: Not reported 
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Martin et al.248 
2016 
Harm The authors reported on the relationship between non-smokers, cigarette 
smokers, and e-cigarette users and immune gene expression profiles 
assessed from nasal scrape biopsies, nasal lavage, urine, and serum.  
Age: 18 to 50 years of age. Sex: 18 males, 21 females. Country: USA 
Data source: USA. Population size: 39. Data collection period: Not reported 
E-cigarette, smoking and other related status: non-smokers not regularly 
exposed to second-hand smoke (control group) (13), self-described active 
cigarette smokers (smoker group) (14) and self-described, active e-cigarette 
users/vapers (12) who had been using e-cigarettes regularly for at least 6 mo. 
Dual users smoking more than 5 cigarettes/week in addition to using e-
cigarettes were excluded from these studies 
Outcomes: Serum cotinine and urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanol (NNAL) levels. Epithelial RNA was isolated and analysed for 
differential cell to quantify neutrophils. 
All genes with decreased expression in cigarette smokers (n = 53) were also 
decreased in e-cigarette smokers. Additionally, vaping e-cigarettes was 
associated with suppression of many unique genes (n = 305). Furthermore, 
the e-cigarette users showed a greater suppression of genes common with 
those changed in cigarette smokers especially suppressed expression of 
transcription factors, such as EGR1, which was functionally associated with 
decreased expression of 5 target genes in cigarette smokers and 18 target 
genes in e-cigarette users.  
The authors concluded that the data indicate that vaping e-cigarettes is 
associated with decreased expression of a large number of immune-related 
genes, which are consistent with immune suppression at the level of the nasal 
mucosal.248 
Device and products: Not reported  
Wills et al.246 
2019 
Harm The authors reported on the association of e-cigarette use with diagnosed 
respiratory disorders. 
Age: mean age of 55 year 
Sex: 4,314 female, 3,772 male, 1 missing 
Country: Hawaii, USA. Ethnicity: Hawaiian 1,096, Filipino 1,026, Japanese 
1,518, Chinese 379, Pac. Islander 185, Other Asian 160, Caucasian 3,374, 
Black 104, missing 245. 
Data source: Behavioural Risk Factor Surveillance Survey (BRFSS) 
Population size: 8,087. Data collection period: 2016  
E-cigarette, smoking and other related status: A clarifying instruction prior to 
asking the e-cigarette items stated: “Electronic-cigarettes and other ‘vaping’ 
products include electronic hookahs (e-hookahs), vape pens, e-cigars, and 
others. These products are battery powered and usually contain nicotine and 
flavours such as fruit, mint, or candy.” The item on ever e-cigarette use asked, 
“Have you ever used an electronic cigarette or other electronic ‘vaping’ 
product in your entire life.” (Yes/No/Not Sure). The item on current use 
asked, “Do you now use e-cigarettes or other electronic ‘vaping’ products 
every day, some days, or not at all.” A clarifying instruction prior to the 
cigarette items stated: “For cigarettes do not include e-cigarettes (e-
cigarettes, NJOY, Bluetip), herbal cigarettes, cigars, cigarillos, little cigars, 
pipes, bidis, kreteks, water pipes (hookahs), or marijuana.” The basic item on 
cigarette smoking asked, “Have you smoked at least 100 cigarettes in your 
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were then asked about current smoking: “Do you now smoke cigarettes every 
day, some days, or not at all.” Persons who indicated current smoking (some 
days or every day) were asked, “During the past 12 months, have you 
stopped smoking for one day or longer because you were trying to quit 
smoking” (Yes/No). Persons answering Yes to lifetime smoking but No to 
current smoking were asked, “How long has it been since you last smoked a 
cigarette?” (7 options, within past month to 10 years or more). 
Outcomes: diagnosed respiratory disorder (asthma, chronic obstructive 
pulmonary disease). 
The adjusted Odd Ratio of e-cigarette use with chronic pulmonary disorder 
was adjusted Odd Ratio = 2.58, CI 1.36-4.89, p < 0.01 in the total sample and 
adjusted Odd Ratio = 1.33, CI 1.00-1.77, p < 0.05 in non-smokers. The 
associations were stronger among non-smokers than among smokers.  
The authors concluded that the study showed a significant independent 
association between e-cigarette use and chronic respiratory disorders. The 
association was stronger among non-smokers than among smokers.  
Device and products: Not reported 
  Lung injury 
Ghinai et al.247 
2019 
Harm In July 2019, the Illinois Department of Public Health and the Wisconsin 
Department of Health Services launched a coordinated epidemiologic 
investigation after receiving reports of several cases of lung injury in 
previously healthy persons who reported using e-cigarettes or vaping.  
The Centers for Disease Control and Prevention reported the precise source 
of the outbreak as currently unknown; however, the predominant use of 
prefilled tetrahydrocannabinol-containing cartridges among patients with 
lung injury associated with e-cigarette use suggested that these products 
played an important role.  
Centrers for Disease Control and Prevention recommended that persons 
consider refraining from using e-cigarette, or vaping, products, particularly 
those containing tetrahydrocannabinol. Given the diversity of products 
reported and frequency of patients using both tetrahydrocannabinol - and 
nicotine-containing e-cigarette products, additional methods such as product 
testing and traceback could help identify the specific cause of this outbreak247 
Device and products: Numerous products and brand names were identified 
by patients 
  Passive smoking 
Bayly et al.249 
2019 
Harm The authors reported on the relationship between second-hand e-cigarette 
aerosol exposure and asthma exacerbations among youth with asthma. 
Age: 11-17 years. Two-thirds were aged 11 to 13 years. Sex: 50% female 
Country: USA. Data source: Florida Youth Tobacco survey 
Population size: N = 11,830. Data collection period: 2016  
E-cigarette, smoking and other related status: second-hand exposer to ENDS 
Outcomes: salivary cotinine 
Youth who participated in the 2016 Florida Youth Tobacco survey (aged 11-17 
years) with a self-reported diagnosis of asthma (N = 11,830) reported asthma 
attacks in the past 12 months, demographic characteristics, cigarette use, 
cigar use, hookah use, ENDS use, past 30-day second-hand smoke exposure, 
and past 30-day second-hand ENDS aerosol exposure were assessed for 
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mug/m(3) (GSD=4.05) in the smokers' homes, 0.13 mug/m(3) (GSD=2.4) in 
the e-cigarettes users' homes, and 0.02 mug/m(3) (GSD=3.51) in the control 
homes. The geometric means of salivary cotinine were 0.38 ng/ml (GSD=2.34) 
in the smokers' homes, 0.19 ng/ml (GSD=2.17) in the e-cigarette’s users' 
homes, and 0.07 ng/ml (GSD=1.79) in the control homes. Salivary cotinine 
concentrations of the non-smokers exposed to e-cigarette's vapour at home 
(all exposed >= 2 h/day) were statistically significant different that those 
found in non-smokers exposed to second-hand smoke >= 2 h/day and in non-
smokers from control homes.  
The results found that airborne markers were statistically higher in the homes 
of conventional combustible tobacco cigarette smokers (5.7 times higher) 
than in the homes of e-cigarette users. However, concentrations of both 
biomarkers among non-smokers exposed to conventional combustible 
tobacco cigarettes and to e-cigarette vapour were statistically similar (2 and 
1.4 times higher, respectively). The authors concluded that non-smokers 
passively exposed to e-cigarettes absorb nicotine.249 
Device and products: Participants were considered exposed to aerosols from 
ENDS if they answered yes to one or both of the following questions: “During 
the past 30 days, were you in the same room with someone who was using 
electronic vapor products?”; “During the past 30 days, did you ride in a car 
with someone smoking electronic vapor products?” 





The authors reported on a preliminary exploration of second-hand smoke or 
vapour exposure in youth with sickle cell disease through biochemical 
verification of cotinine, pulmonary functioning, and healthcare utilisation. 
Age: Thirty-one youth with Sex Sickle Cell (SC Type SS = 45.2%, mean age = 
9.0 years; SD = 4.5 years) and their caregivers (mean age = 37.6 years; SD = 
8.5 years) 
Sex: Child Gender Male 42% Female 58% Relationship to Child Mother 87% 
Country: USA 
Data source: Midwestern children’s hospital. Population size: 31 parent-child 
dyads 
Data collection period: Not reported  
E-cigarette, smoking and other related status: Current and previous 
nicotine/tobacco use was assessed via self-report surveys. Caregivers 
reported past 30-day and previous or ever-use of tobacco. Caregivers who 
denied current cigarette use, but indicated past use were categorized as 
‘former smokers’; caregivers who reported current cigarette use were 
categorized as current smokers. Caregivers who answered ‘no’ to both 
questions were categorized as ‘never smokers.’ To assess household second-
hand smoke exposure or second-hand ‘vapor’, caregivers reported how many 
individuals in the household smoked and/or used an electronic cigarette. A 
household SHS/SHVe variable was created by dichotomizing exposure as ‘yes’ 
or ‘no.’ 
Outcomes: pulmonary functioning, children over the age of six (N = 24) 
completed 5 trials of forced spirometry, all provided saliva for assessment of 
cotinine levels. Cotinine analyses indicated that 24 of the 27 participants 
(88%) were exposed, in some capacity, to second-hand smoke exposure 
(SHS)/ second-hand ‘vapor’(SHVe). Interestingly, no childexhaled carbon 
monoxide values were elevated and only two caregivers (both self-identified 
as current smokers) were elevated, highlighting the variability of two 
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utilizing salivary cotinine to measure second-hand smoke exposure / second-
hand ‘vapor’ among children.251 
The authors concluded that the majority of youth (88%) were exposed to 
second-hand smoke via salivary cotinine. Interestingly, no significant 
associations were observed between youth cotinine levels and emergency 
department utilisation, physician-reported sickle cell crises, or pulmonary 
functioning. Present findings indicate a need to assess for second-hand 
smoke using objective assessment measures.251 
Device and products: Not reported 
Table 71: Cross-sectional surveys papers on oral diseases, benefits or harms 
Author(s) year Possible 
benefit 
or harm 
Cross-sectional surveys papers oral diseases 
  Oral health 
Cho252 
2017 
Harm The author reported on the relationship between e-cigarette use and oral 
health, measured as gingival pain and/or bleeding, tongue and/or inside-
cheek pain, and cracked or broken teeth. 
Age: mean 15.0 (SD: 1.7).  
Sex: not reported for the subgroup reported in this paper. Country: South 
Korea 
Data source: Twelfth Korean Youth Risk Behaviour Web-based Survey 
Population size: 5,404 of 65,528 study participants. Data collection period: 
2016 
E-cigarette, smoking and other related status: E-cigarette users were grouped 
as use daily users, 0.5% (n = 297), '1 to 29 days past month users '1.9% (n = 
1259) and former users 5.9% (n = 3848).  
Outcomes: 'gingival pain and/or bleeding', 'tongue and/or inside-cheek pain', 
and 'cracked or broken teeth' 
Outcome within the past 12 months were considered for analysis. Comparing 
'daily e-cigarette users', '1 to 29 days past month e-cigarette users', and 
'former e-cigarette users' with 'never e-cigarette users', the adjusted ORs for 
'cracked or broken tooth' were 1.65 (95% CI: 1.19-2.27), 1.26 (95% CI: 1.06-
1.51), and 1.16 (95% CI: 1.04-1.30) respectively. Comparing 'daily e-cigarette 
users' with 'never e-cigarette users', the adjusted OR for 'tongue and/or 
inside-cheek pain' was 1.54 (1.05-2.26). e-cigarette use among adolescents 
was not associated with 'gingival pain and/or bleeding' when adjusted for the 
potential confounders.  
The author reported that former e-cigarette users had a significantly higher 
occurrence of cracked or broken teeth than never e-cigarette users, and that 
daily e-cigarette users had a significantly higher occurrence of tongue and/or 
inside-cheek pain than never e-cigarette users, concluding that daily e-
cigarette use among adolescents may be a risk factor for cracked or broken 
teeth and for tongue and/or inside-cheek pain.252 
Device and products: Not reported 
Javed et al.253 
2017 
Harm The authors reported on the relationship between cigarette smokers (group 
1), individuals exclusively vaping e-cigarettes (group 2), and never-smokers 
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Age: mean ages of 41.3 +/- 2.8 (former cigarette smokers), 37.6 +/- 2.1 (e-
cigarette users), and 40.7 +/- 1.6 never-smokers)  
Sex: All male. Country: Saudi Arabia.  
Data source: participants were recruited from the outpatient department of 
the College of Dentistry, King Saud University, Riyadh, Saudi Arabia 
Population size: 94. Data collection period: June 2016 and February 2017. 
E-cigarette, smoking and other related status: Ninety-four male participants 
(N=33 group 1, N=31 group 2, and N=30 group 3). Group 1 Individuals who 
reported to have been smoking up to five cigarettes daily for at least 12 
months were defined as former cigarette smokers. Group 2 e-cigarette users 
defined as individuals who were exclusively e-cigarette vaping at least once 
daily (one session) for 12 months. Group 3 participants who reported to have 
never used tobacco in any form were categorized as never-smokers  
Outcomes: Periodontal parameters: full-mouth plaque index, bleeding on 
probing, clinical attachment loss and probing depth >=4 mm measured at six 
sites per tooth (mesio-buccal, mid-buccal, disto-buccal, disto-lingual/palatal, 
mid-lingual/palatal, and mesio-lingual/palatal) on all maxillary and 
mandibular teeth, number of missing teeth, marginal bone loss. Self-
perceived oral symptoms 
Plaque index (p<0.01) and probing depth ≥4 mm (p<0.01) were significantly 
higher in groups 1 and 2 than in group 3. Bleeding on probing was 
significantly higher in group 3 than in groups 1 and 2 (p<0.01). There was no 
difference in the number of missing teeth, clinical attachment loss, or 
marginal bone loss between all groups. Gingival pain was more often 
reported by individuals in group 1 than by individuals in groups 2 or 3 
(p<0.01).253 




Harm The authors investigated associations between self-reported use of cigarettes 
and e-cigarettes with oral health status. 
Age: 6,997 aged 12 to 14 years and 6,653 aged 15 to 17 years 
Sex: 6,993 males, 6,657 females  
Country: USA. Ethnicity: 9,471. white, 2,086 Black 2,093 Other 
Data source: Population Assessment of Tobacco and Health study 
Population size: 13,650. Data collection period: 2013-2014 
E-cigarette, smoking and other related status: Ever cigarette use, ever e-
cigarette use. Adolescents were asked if they have ever tried cigarette 
smoking (i.e., conventional cigarette smoking), even 1 or 2 puffs (yes vs. no; 
defined in this study as ever use) or at least 1 or 2 puffs in the last 30 days 
(yes vs. no; defined in this study as current use). Past 30-day use of tobacco 
products among adolescents is a standard measure to indicate current use. 
Similar questions were elicited for e-cigarette use and defined in this study as 
ever use, if they have ever tried vaping e-cigarettes, and current use if they 
had used e-cigarettes in the past 30 days.  
Outcomes: past-year diagnoses with dental problems by a doctor, dentist, or 
other health professional (self-reported by parent or emancipated youth). 
Specifically, such as dental health issues such as cavities, gum disease or 
dental stains.  
The authors used adjusted logistic regression to estimate prevalence odds 
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covariate-adjusted values were: POR: 1.50 (95% CI: 1.18–1.90) in current 
cigarette users and POR: 1.11 (95% CI: 0.79–1.55) in current e-cigarette users. 
Ever use of cigarettes and e-cigarettes was likewise associated with increased 
prevalence odds of self-reported past-year diagnosis of dental problems, 
although to a lesser magnitude. The authors concluded that dual use of e-
cigarettes and conventional combustible tobacco cigarettes is associated with 
poor oral health outcomes among adolescents.254 
Device and products: Not reported 
Al-Aali et al.255 
2018 
Harm The authors reported on the relationship between vaping e-cigarettes and 
never smoking with clinical and radiographic peri-implant parameters and 
levels of tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-1beta. 
Age: Mean age SD (in years) Vaping Individuals 35.8+/-6.2 Never Smokers 
42.6+/-2.7. Sex: 92 males. Country: Saudi Arabia 
Data source: recruited from specialist prosthodontic private practice 
Population size: 92. Data collection period: January 2016 and March 2017  
E-cigarette, smoking and other related status: The study population consisted 
of 47 individuals vaping e-cigarettes (group-1) and 45 non-smokers (group-2). 
Group 1: current vapers who reported vaping e-cigarettes for at least the past 
year; (b) group 2: participants who never consumed tobacco in any form 
during their life time 
Outcomes: peri-implant plaque index (PI), bleeding on probing (BOP), probing 
depth (PD) and peri-implant bone loss (PIBL), in addition to levels of TNF-
alpha and IL-1beta in peri-implant sulcular fluid 
Bleeding on probing showed statistically significantly higher values in group-2 
patients as compared to group-1 patients (P < .01). Probing depth >= 4 mm 
and peri-implant bone was statistically significantly higher in group-1 patients 
as compared to group-2 patients (P < .05). Mean concentrations of TNF-alpha 
(P < .001) and IL-1beta (P < .01) were statistically significantly increased in 
individuals in group 1 as compared with group 2. There was a significant 
positive correlation between TNF-alpha levels and bleeding on probing (P = 
.02)  
The authors concluded that clinical and radiographic peri-implant parameters 
were compromised among vaping individuals. The authors concluded that 
increased levels of proinflammatory cytokines in peri-implant sulcular fluid 
may suggest greater local inflammatory response in vaping individuals for 
peri-implant inflammation and peri-implant bone loss (p=0.016). A significant 
positive correlation was found between IL-1 beta and peri-implant bone loss 
(p=0.018) in e-cigarette users compared to non-users of e-cigarettes and 
conventional combustible tobacco cigarettes.255 




Harm The authors reported on the relationship of water pipe smokers, e-cigarette 
users, and cigarette smokers with peri-implant parameters and local levels 
of proinflammatory cytokines; specifically, periodontal and peri-implant 
plaque index, bleeding on probing, and probing depth (≥4 mm) and levels of 
TNF-alpha, interleukin -6, and interleukin -1 beta in peri-implant sulcular 
fluid. 
Age: mean age 41.8 (34-53 years). Sex: All male. Country: Saudi Arabia 
Data source:  
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E-cigarette, smoking and other related status: 40 cigarette smokers, 40 
waterpipe smokers (aka hookah, sheesha), 40 subjects using e-cigarettes , 
and 40 non-smokers who reported to smoke at least 10 cigarettes daily for at 
least more than 5 years; (c) non-smokers who never smoked tobacco; and (d) 
≥1 dental implant(s) in service for ≥3 years Cigarette smoking was smoked at 
an average of 15 times daily with a mean duration of 8 minutes, 6 times daily 
for waterpipe smokers at a mean duration of 31.6 minutes, and 6.5 times 
daily for subjects using e-cigarettes at an average of 37.7 minutes 
Outcomes: peri-implant parameters and local levels of proinflammatory 
cytokines, specifically periodontal and peri-implant plaque index (PI), 
bleeding on probing (BOP), and probing depth (PD >= 4 mm) and levels of 
tumour necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, and IL-1beta in 
peri-implant sulcular fluid 
Mean peri-implant plaque index (p<0.05), probing depth ≥4 mm (p<0.05), and 
total radiographic bone loss (p<0.01) were significantly higher among 
cigarette smokers, water pipe smokers, and subjects using e-cigarettes 
compared with non-smokers. Statistical differences in bleeding on probing 
were observed in non-smokers (p<0.01) compared to cigarette smokers, 
water pipe smokers, and subjects using e-cigarettes. Cigarette smokers and 
water pipe smokers showed significantly higher probing depth ≥4 mm and 
radiographic bone loss compared with subjects using e-cigarettes (p<0.05). 
Levels of TNF-alpha, IL-6, and IL-1 beta were significantly higher in cigarette 
smokers, water pipe smokers, and subjects using e-cigarettes compared to 
non-smokers. There were no statistical differences in the mean levels of all 
proinflammatory cytokines among individuals who were cigarette smokers or 
water pipe smokers.256 










The authors reported on the relationship between cigarette smoking, water 
pipe smoking, e-cigarette using, and never smoking behaviours, and outcome 
oral health measures of clinical (plaque index, bleeding on probing, probing 
pocket depth, and clinical attachment loss), radiographic (marginal bone 
loss), and periodontal parameters, and of whole salivary cotinine, interleukin 
-1 beta, and interleukin -6 levels.  
Age: (mean ± SD) 42.4 ± 5.6 Cigarette -smokers 44.7 ± 4.5 Waterpipe-smokers 
28.3 ± 3.5 e-cigarette users 40.6 ± 4.5 Never-smokers 
Sex: All males. Country: Saudi Arabia. Data source: Not specified 
Population size: 154. Data collection period: Not specified  
E-cigarette, smoking and other related status: 39 cigarette-smokers, 40 
waterpipe-smokers, 37 e-cigarette users and 38 never-smokers. Individuals 
that reported to be smoking at least 5 cigarettes daily for at least 12 months 
were defined as “cigarette-smokers”. “Waterpipe smokers” were defined as 
individuals who reported smoking waterpipe at least once a day for a 
minimum duration of 12-months. “E-cigarette users” were defined as 
individuals vaping exclusively e-cigarettes for at least 12 months and had 
never used smoked tobacco in the past. Individuals who reported to have 
never smoked tobacco and/or consumed smokeless tobacco products were 
defined as “Never-smokers” 
Outcomes: clinical (plaque index [PI], bleeding on probing [BOP], probing 
pocket depth [PPD], clinical attachment loss [CAL]), radiographic (marginal 
bone loss [MBL]) periodontal parameters, whole salivary cotinine, interleukin 
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Full mouth plaque index, bleeding on probing, probing pocket depth and 
clinical attachment loss were measured on all teeth (excluding third molars); 
and marginal bone loss was measured in digital intra-oral radiographs. 
Unstimulated whole salivary flow rate (UWSFR) and whole salivary cotinine, 
IL-1beta and IL-6 levels were also measured. Group comparisons were 
performed using one-way analysis of variance and Bonferroni post-hoc tests. 
There was no difference in unstimulated whole salivary flow rate among the 
groups. Cotinine levels were significantly higher among cigarette- (P<0.001) 
and waterpipe-smokers (P<0.001) and E-cigarette users (P<0.001) than never-
smokers. IL-1beta (P<0.01) and IL-6 (P<0.01) levels were significantly higher 
among cigarette- and waterpipe-smokers than e-cigarette users and never-
smokers. There was no difference in PPD, CAL, mesial and distal MBL and 
whole salivary IL-1beta and IL-6 levels among e-cigarette users and never-
smokers.  
The authors reported that clinical and radiographic parameters of periodontal 
inflammation were poorer in cigarette and water pipe smokers than in e-
cigarette users and never-smokers, and that whole salivary cotinine levels 
were similar in all groups. Whole salivary interleukin -1 beta and interleukin -
6 levels were higher in cigarette and water pipe smokers than e-cigarette 
users and never-smokers.260 
Device and Products: Not reported 
Alqahtani et al. 
265 
2019 
Harm The authors compared cotinine levels in the peri-implant sulcular fluid 
among cigarette and water pipe smokers, e-cigarette users, and non-
smokers. 
Age mean (SD) years: Cigarette smokers 36.3 ± 1.2 Waterpipe smokers 34.1 ± 
1.4 Electronic-cigarette users 33.5 ± 0.7 Nonsmokers 32.2 ± 0.6 
Sex: All males. Country: Saudi Arabia 
Data source: Partially edentulous adults rehabilitated with dental implant 
were included. Every individual among the study groups had one dental 
implant placed in the region of a missing maxillary or mandibular premolar or 
molar. The dental implants were in function since 1.6 ± 0.4, 1.3 ± 0.2, 1.4 ± 
0.2, and 1.3 ± 0.2 years in cigarette smokers, waterpipe smokers, electronic 
cigarette users, and nonsmokers, respectively. 
Population size: One hundred two male individuals 35 cigarette smokers, 33 
waterpipe smokers, 34 e-cigarette users, and 35 non-smokers265 
Data collection period: Not reported  
E-cigarette, smoking and other related status: 35 cigarette smokers, 33 
waterpipe smokers, 34 e-cigarette users, and 35 non-smokers. Cigarette 
smokers, waterpipe smokers, and e-cigarette users were using their nicotinic 
products for 10.2 ± 4.1, 8.3 ± 0.4, and 3.5 ± 0.6 years, respectively. Cigarette 
smokers were smoking 9.2 ± 0.6 cigarettes daily, and waterpipe smokers were 
using waterpipe 5.1 ± 0.3 times daily. Electronic-cigarette users were vaping 
14.3 ± 1.2 times daily. Cigarette and waterpipe smokers were unaware of the 
amount of nicotine present in their respective tobacco products; and the 
amount of nicotine present in the e-liquids used by electronic cigarette users 
was 8.4 ± 0.6 mg. The mean duration of each session of cigarette and 
waterpipe smoking among the representative groups were 6.6 ± 0.5 and 16.3 
± 2.4 minutes, respectively. Electronic-cigarette users were vaping for a mean 
duration of 5.1 ± 0.6 minutes during each session of vaping. All waterpipe 
smokers and e-cigarette users were former cigarette smokers who had quit 
smoking cigarettes 8.3 ± 0.4 and 3.5 ± 0.6 years ago, respectively. 
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The authors concluded that habitual use of nicotinic products enhances the 
expression of cotinine in the peri-implant sulcular fluid. Cotinine levels in the 
peri-implant sulcular fluid of cigarette and water pipe smokers and e-
cigarette users are comparable.256 
Device and products: Not reported 








The authors reported on the relationship between cigarette smokers’, e-
cigarette vaping individuals’, and non-smokers’ peri-implant health using 
clinical and radiographic peri-implant parameters (specifically peri-implant 
plaque index, bleeding on probing, probing depth, and marginal bone loss), 
levels of matrix metalloproteinase-9, and interleukin -1 beta levels. 
Age: Cigarette smokers 40.4 ± 3.5 Vaping individuals 35.8 ± 6.2 Non-smokers 
42.6 ± 2.7. Sex: All male. Country: Saudi Arabia 
Data source: Attendees at the Department of Prosthetic Dental Sciences, King 
Saud University 
Population size: 95. Data collection period: June 2016 to September 2017.  
E-cigarette, smoking and other related status: Thirty-two cigarette smokers 
(group 1), 31 individuals vaping e-cigarettes (group 2), and 32 non-smokers 
(group 3) were included 
Outcomes: clinical and radiographic peri-implant parameters (specifically 
peri-implant plaque index (PI), bleeding on probing (BOP), probing depth (PD) 
and marginal bone loss (MBL)), levels of matrix metalloproteinase (MMP)-9 
and interleukin (IL)-1beta levels. 
Bleeding on probing showed significantly higher values in non-smokers (group 
3) as compared with cigarette smokers (group 1) and vaping e-cigarettes 
(group 2) (P < 0.01). Peri-implant plaque index (P < 0.01), probing depth >= 4 
mm (P < 0.01), and mean concentrations of matrix metalloproteinase -9 (P < 
0.001) and IL-1beta (P < 0.01) were significantly higher in groups 1 and 2 than 
group 3. Marginal bone loss was significantly higher in group 1 as compared 
with group 2 and group 3 (P < 0.01). Significant positive correlations were 
found between matrix metalloproteinase-9 (P = 0.0198) and IL-1beta (P = 
0.0047) levels and Marginal bone loss in group 1; and a significant positive 
correlation between IL-1beta and MBL in group 2 (P = 0.0031).  
The authors concluded that peri-implant health was more compromised 
among cigarette smokers than vaping individuals and non-smokers. Increased 
levels of proinflammatory cytokines in cigarette smokers and vaping 
individuals may suggest greater peri-implant inflammatory response. 
response261 
Device and products: Not reported  
Huilgol et al.259 
2019 
Harm The authors reported on the relationship between e-cigarette use, defined as 
daily or intermittent use within 30 days prior to survey administration, and 
poor oral health (the number of permanent teeth removed due to non-
traumatic causes). 
Age: 18 to 65 years plus 
Sex: Male and Female. Numbers for total survey population only reported 
Country: USA. Ethnicity: White Black Asian Other.  
Data source: Behavioural Risk Factor Surveillance System  
Population size: 67 003 (14.8%) of the original sample (456 343) reported 
current smoking within the previous 30 days, only 4957 (1.1%) reported 
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cigarettes, and 14 948 (3.3%) reported current use of smokeless tobacco. 
Numbers for total survey population only reported. 
Data collection period: 2016  
E-cigarette, smoking and other related status: e-cigarette use, was 
determined on a 4-level smoker status within 30 days prior to survey 
administration (everyday e-cigarette user, someday e-cigarette user, former 
e-cigarette user and non-e-cigarette user). Cigarette smoking status was 
categorized into current smokers and non/former smokers. Smokeless 
tobacco use was defined by chewing tobacco, snuff or snus, and was 
classified into everyday/intermittent users and non-users. 
Outcomes: number of permanent teeth removed due to non-traumatic 
causes 
In multivariable analysis, daily e-cigarette use was independently associated 
with 78% higher odds of poor oral health (AOR: 1.78; 95% CI: 1.39–2.30; 
p<0.001). The authors concluded that daily, but not intermittent, use of e-
cigarettes was independently associated with poor oral health.259 
Device and products: Not reported 
Jeong et al.257 
2020 
Harm The authors reported on the association of conventional combustible tobacco 
cigarette smoking and e-cigarette vaping with periodontal disease. 
Age mean (SD) years: 19 years of age plus. Sex: 5,715 males, 7,836 females. 
Country: South Korea 
Data source: Korean National Health and Nutrition Examination Survey 
Population size: 13,551. Data collection period: 2013 to 2015  
E-cigarette, smoking and other related status: e-cigarettes vapers, 
conventional tobacco cigarettes smokers, ex-users, and non-users 
Outcomes: Periodontal status was measured by the Community Periodontal 
Index. 187 men and 35 women who vape electronic cigarette, 67 (35.8%) men 
and 10 (28.6%) women had periodontal diseases. Out of 1,957 men and 363 
women who smoke conventional tobacco cigarettes, 861 (44.0%) men and 
121 (35.3%) women had periodontal diseases. Periodontal disease was more 
prevalent in each vapers and smokers than non-users in men (e-cigarettes: 
odds ratio [OR] = 2.34, 95% confidence interval [CI] = 1.52 to 3.59, 
conventional tobacco cigarettes: OR = 2.17, 95% CI = 1.76 to 2.68) 
The authors concluded that e-cigarette and conventional combustible 
tobacco cigarette use were both significantly associated with increased 
periodontal disease rates. After adjusting for demographic, socioeconomic, 
and health-related characteristics, both vaping and smoking had a significant 
association with periodontal diseases. The authors suggested that vaping may 
not be a safe alternative to smoking.257 
Device and products: Not reported 
Vora et al.258 
2019 
Harm The authors reported on the relationship between smoking behaviours – 
specifically cigarette smoking and using other types of tobacco products – 
and self-reported gingival disease. 
Age: > 18 years of age. Sex: male and females. Country: USA   
Data source: Population Assessment of Tobacco and Health study 
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E-cigarette, smoking and other related status: tobacco never users, pipe 
users, -cigarette users, multiple tobacco product users, recent quitters,  
Outcomes: Self-reported gingival disease diagnosis.  
Groups with the highest adjusted relative odds for diagnosis (reference, 
lifetime tobacco never users) were pipe users (2.7; 95% confidence interval 
[CI], 1.3 to 5.3), e-cigarette users (2.9; 95% CI, 1.9 to 4.5), multiple tobacco 
product users (2.8; 95% CI, 2.4 to 3.4), and recent (< 12 months) quitters (2.8; 
95% CI, 2.0 to 3.8).  
The authors concluded that numerous tobacco use patterns were associated 
with worse periodontal health compared with tobacco never users.258 
Device and products: Not reported 






The author reported the effects of tobacco smoke and e-cigarette vapour 
exposure on the oral and gut microbiota in humans. 
Age median (interquartile range): Controls 31 (28–36), E-cigarette 29 (24–37), 
Tobacco smoke 35 (30–45). Sex: 29 males, 2 females. 
Country: USA. Ethnicity: varied by group but included White Hispanic Asian 
Black.  
Data source: All participants were recruited from the Houston area 
Population size: 30 individuals in three distinct exposure groups; e-cigarette 
users (n = 10), tobacco smokers (n = 10), and matched controls (n = 10).  
Data collection period: Not reported 
E-cigarette, smoking and other related status: E-cigarettes users Nicotine 
concentration (mg), median (interquartile range) 9 (6–12) 
Outcomes: DNA was extracted from 125 mg of fresh faecal sample, DNA from 
buccal swabs and saliva samples was also assessed, The bacterial 16S rRNA 
gene V4 region. Faces had a distinct bacterial profile compared to the oral 
samples (buccal swab and saliva). 
The author concluded that people who regularly use e-cigarettes do not have 
measurably different oral or gut bacterial communities compared to non-
smokers.264 




Harm The authors reported on the relationship between e-cigarettes and selected 
antibacterial properties of saliva (IgA, lysozyme, and lactoferrin levels). 
Age mean (SD) years: 20 to 30 years. Sex: Not reported Country: Poland 
Data source: students of Medical University of Gdansk and young patients, 
who volunteered for a follow-up examination of periodontium and oral 
mucosa at the Department of Periodontology and Oral Mucosa Diseases 
Population size: 120 patients. 40 users of e-cigarettes, 40 smokers of 
conventional combustible tobacco cigarettes and 40 non-smokers 
Data collection period:  
E-cigarette, smoking and other related status: 40 users of e-cigarettes, 40 
smokers of conventional combustible tobacco cigarettes and 40 non-smokers. 
E-cigarette users were using e-cigarettes with small nicotine concentration 
for minimum 6 months vaping at least 50 times per day. Conventional 
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per day for a minimum of 6 months. There were no group of patients smoking 
both traditional and e-cigarettes. 
Outcomes: IgA, lysozyme and lactoferrin levels on unstimulated saliva 
The authors concluded that the saliva of e-cigarette users showed changes in 
antibacterial properties in comparison with the control group and with 
conventional combustible tobacco cigarette smokers. More specifically, 
among e-cigarette users, statistically significant differences were observed in 
levels of lysozyme and lactoferrin; however, no statistically significant 
differences for the IgA levels were found.262 




Harm The authors reported on the relationship between oral Candida albicans 
carriage, number of missing teeth, and unstimulated whole salivary flow rate 
with smoking-related behaviours, specifically among cigarette and water pipe 
smokers, e-cigarette users, and never-smokers.  
Age: Mean age in years (SD) Group-1 33.2 ± 8.6 Group-2 36.3 ± 6.9 Group-3 
29.4 ± 4.5 Group-4 32.5 ± 5.4 
Sex: All male. Country: Saudi Arabia 
Data source: The outpatient department of a local University-based dental 
clinic in Riyadh, Saudi Arabia  
Population size: 129 male individuals (34, 33, 30, and 32 in groups 1, 2, 3, and 
4, respectively) were included.  
Data collection period: April 2017 and January 2018  
E-cigarette, smoking and other related status: 34 cigarette-smokers (Group-
1), 33 waterpipe-smokers (Group-2), 30 e-cigarette users (Group-3), and 32 
never-smokers (Group-4). In groups 1 and 2, mean durations of cigarette and 
waterpipe smoking were comparable. 
Outcomes: Oral Candida carriage, number of missing teeth and unstimulated 
whole salivary flow rate (UWSFR) 
The authors concluded that oral Candida albicans carriage was significantly 
higher among cigarette and water pipe smokers and e-cigarette users than 
among never-smokers. No significant differences were identified among 
groups in the oral carriage of other Candida species.263 
Device and Products: Not reported 
Table 72: Cross-sectional surveys papers on exposure to e-cigarette toxins, benefits or harms 
Author(s) year Possible 
benefit 
or harm 
Cross-sectional surveys papers toxicology of e-cigarette constituents 








The authors reported on the relationship between e-cigarette smokers who 
had not smoked tobacco cigarettes for at least 2 months and the presence of 
a suite of toxicant and carcinogen metabolites, including: 1-hydroxypyrene 
(1-HOP), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides 
(total NNAL), 3-hydroxypropylmercapturic acid (3-HPMA), 2-
hydroxypropylmercapturic acid (2-HPMA), 3-hydroxy-1-
methylpropylmercapturic acid (HMPMA), S-phenylmercapturic acid (SPMA), 
nicotine, and cotinine. 
Age: years (SD) e-cigarette users 34.0 ± 12.7 Cigarette smokers: Carmella et al 





Author(s) year Possible 
benefit 
or harm 
Cross-sectional surveys papers toxicology of e-cigarette constituents 
Sex: Female percentages in each study group were: 42.9% Carmella et al 
64.7%, Hatsukami et al. 47.3%, Zarth et al 57.5% 
Country: USA 
Data source: Subjects were recruited by a member of the research staff of the 
University of Minnesota Tobacco Research Programs and initially screened 
over the telephone. 
Population size: 28. Data collection period: Not reported  
E-cigarette, smoking and other related status: Of the 28 participants eligible 
for this analysis, e-cigarette use was for a median of 9 months (range 3–36) 
and they quit smoking 9 months (range 2–36) before study entry. Most used 
e-cigarettes daily (96.2%) and the average nicotine concentrations were 12.5 
± 7.0 mg/ml. All e-cigarette users used refillable e-cigarettes and refilled an 
average of one time (range 0.3–5) per day. The brands of e-cigarettes used 
(number) are: Aqua (2) Aspire (2) Buck Naked Express (1) eGo (8) eQ (1) 
Green Smoke (1) Green Smart Living (1) Hades (1) iGo (1) Itazte (5) JDTech (1) 
Kanger (7) MyVape (1) Origin (1) Provari (4) Sigelei (1) SMOKTech (2) V2 (1) 
Vapor4Life (1) Vision Spinner (3) Vmax (1). aSome users used more than one 
brand. bTwo subjects used cartridges (Green Smoke, V2, and Green Smart 
Living); all others used tank systems. The 222-comparison group consisted of 
smokers who wanted to quit and represented, 17 smokers, 165 smokers of 
“light” cigarettes, and 40 cigarette smokers from three different study 
groups.  
Outcomes: the authors quantified urinary toxicant and carcinogen 
metabolites in people using e-cigarettes and compared their levels to those 
found in cigarette smokers. The compounds quantified were 1-
hydroxypyrene (1-HOP), a biomarker of carcinogenic PAH exposure; 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides (total 
NNAL), metabolites of the tobacco-specific nitrosamine and lung carcinogen 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK); 3-
hydroxypropylmercapturic acid (3-HPMA), a metabolite of the toxicant 
acrolein; 2-hydroxypropylmercapturic acid (2-HPMA), a metabolite of the 
carcinogen propylene oxide; 3-hydroxy-1-methylpropylmercapturic acid 
(HMPMA), a metabolite of the carcinogen crotonaldehyde; S-
phenylmercapturic acid, a metabolite of the carcinogen benzene; and 
nicotine and cotinine. 
Comparisons of findings in the primary studies e-cigarette smokers were 
made with findings obtained from previous analyses of cigarette smokers’ 
urine using essentially identical assay methods in three previous studies. In 
one study, 17 smokers who wanted to quit were recruited and provided urine 
samples at baseline prior to 8 weeks of refraining from smoking; baseline 
data were used here. A second study recruited 165 smokers of “light” 
cigarettes who were interested in quitting smoking and were assigned to 
either low nicotine cigarettes or nicotine lozenges; their baseline first 
morning urine samples were analysed for the data reported here. The third 
study analysed 40 samples from cigarette smokers who provided spot urine 
samples to the Tobacco Research Programs Repository. 
Levels of 1-HOP, total NNAL, 3-HPMA, 2-HPMA, HMPMA, and SPMA were 
significantly lower in the urine of e-cigarette users compared with that of 
cigarette smokers. Levels of nicotine and cotinine were significantly lower in 
e-cigarette users compared with cigarette smokers in one study, but not in 
another. The authors concluded, with respect to the compounds analysed in 






Author(s) year Possible 
benefit 
or harm 
Cross-sectional surveys papers toxicology of e-cigarette constituents 
Device and products: All e-cigarette users used refillable e-cigarettes and 
refilled an average of one time (range 0.3–5) per day. The brands of e-
cigarettes used are: Aqua, Aspire, Buck Naked Express, eGo, eQ, Green 
Smoke*, Green Smart Living*, Hades, iGo, Itazte, JDTech, Kanger, MyVape, 
Origin, Provari, Sigelei, SMOKTech, V2*, Vapor4Life, Vision Spinner and Vmax. 
Two subjects used cartridges (*Green Smoke, *V2, and *Green Smart Living); 




Harm The authors reported on the relationship between e-cigarettes and the 
metals nickel and chromium, which are components of the devices’ heating 
coil. 
Age: 18 years of age or older. Sex: Not reported. Country: USA.  
Data source: E-cigarette users were recruited through vaping conventions, 
flyers posted in universities, and e-cigarette shops 
Population size: 59 of 64. Data collection period: December 2015 and March 
2016  
E-cigarette, smoking and other related status: 50 sole users (never smokers or 
had quit smoking at least 3 months prior) and 14 dual users (used 
combustible cigarettes at least weekly) participants were daily e-cigarette 
users, and users for at least 6 weeks. 
Outcomes: Urine, saliva, exhaled breath condensate levels of nickel (Ni) and 
chromium 
The authors concluded that the study of daily e-cigarette users indicates that 
metals in e-cigarette aerosol are inhaled and absorbed into the bodies of 
users, representing a relevant contributor to metal internal dose. As the first 
study to make direct comparisons between source and metal biomarkers 
from e-cigarette use, the authors found that nickel in urine and saliva and 
chromium in saliva were positively associated with concentrations of the 
corresponding metals in aerosol samples collected from users’ personal 
vaping devices, providing strong evidence that metals present in the aerosol 
are inhaled by the user. E-cigarette use patterns – such as more e-liquid 
consumed per week, a shorter time between waking and first vape, and a 
higher voltage used – were also associated with higher nickel biomarker 
levels. 
Device and products: According to device type, 5 participants used first-
generation devices (cigalikes), while 59 used 2nd or 3rd generation devices 
that operate using a customizable tank-like system and/or mechanical mods 
(modified e-cigarettes). Data on e-liquid consumed per week, time to first 
vape from waking in the morning, preferred voltage, heating coil used 
(Kanthal/Nichrome/other), coil change per month, and nicotine 
concentrations in e-liquid was gathered. Data on e-liquid consumption per 
week (tertiles), time to first vape from waking (within 15 / more than 15 min), 
preferred voltage for e-cigarette use (tertiles), coil change per month (1–2 / 3 
times or more per month), and urinary cotinine (tertiles), as well as the 
corresponding metal levels in samples obtained from the dispenser, aerosol, 
and tank (tertiles) were gathered. Analyses were restricted to users of tank-
style/mods devices (n = 59), as information on coil change and e-liquid 
consumed, and collection of e-liquid from the dispenser and/or tank did not 
apply to cigalike devices. Median Nickel and chromium level were 0.73 and 
0.39mug/g in urine, 2.25 and 1.53mug/L in saliva, and 1.25 and 0.29mug/L in 
exhaled breath condensate. Increasing tertiles of e-liquid consumption per 
week tended to be associated with higher urinary, saliva and EBC Ni levels. In 
fully adjusted models the association was only statistically significant for the 
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Participants who vaped within 15 min from waking had 79% (95%CI 1.14, 
2.82) higher urine Ni levels compared to those taking longer to vape. By self-
reported voltage, there was a non-statistically significant trend with higher 
urine Ni levels (p for trend 0.14); with saliva, the association was only 
observed for the second tertile (4.06–4.47 V) (GMR 3.65, 95%CI 1.47, 9.07). 
Changing coils ≥3 times per month was associated with 91% (95%CI 1.23, 
2.98) higher urinary Ni levels. Tertiles 2 and 3 of urinary cotinine were 
associated with 38% and 80% higher urinary Ni levels (p-trend 0.04), 
respectively. Ni levels in e-cigarette dispenser samples were not associated 
with any of the Ni biomarkers. For Cr biomarkers, the two highest compared 
to the lowest tertile of liquid consumption per week were associated with 
28% and 71% higher levels in EBC (p-trend 0.08), 21% and 56% higher levels 
in saliva (p-trend 0.26), and 14% and 30% higher levels in urine (p-trend 0.29). 
Cr levels in dispenser samples were not associated with Cr biomarkers.272 
Badea et al.266 
2018 
Harm The authors reported on the relationship between non-smokers, cigarette 
smokers, and e-cigarette users with the presence of a range of inorganic 
elements. Serum concentration levels of 43 elements, including trace 
elements and other rare earth elements and minor elements considered 
pollutants were measured. 
Age: years (SD) Non-smokers 24.5+/- 6.7, Cigarette smokers 28.4 +/- 10.8, E-
cigarette users male 35.2 +/- 9.4 
Sex: Non-smokers male n= 10 female n=48, Cigarette smokers male n= 17 
female, n=41 E-cigarette users male n=8 female n=26 
Country: Brasov (Romania) 
Data source: convenience sample 
Population size: 150 
Data collection period: December 2017 and February 2018  
E-cigarette, smoking and other related status: 58 non-smokers, 58 
conventional cigarette smokers, and 34 e-cigarette users 
Outcomes: concentration of 42 of the (current) 275 elements, including trace 
elements, in the Agency for Toxic Substances and Disease Registry (ATSDR's) 
priority pollutant list and rare earth elements were measured by ICP-MS in 
the blood serum of participants. 
The full list consisted of: six trace elements (Chromium was excluded from 
the analyses): u (copper), Fe (iron), Mn (manganese), Mo (molybdenum), Se 
(selenium), Zn (zinc); 17 ATSDR's priority pollutant list elements: Ag (silver), 
As (arsenic), Ba (barium), Be (beryllium), Cd (cadmium), Co (cobalt), Hg 
(mercury), Ni (nickel), Pb (lead), Pd (palladium), Sb (antimony), Sn (tin), Sr 
(strontium), Th (thorium), Tl (thallium), U (uranium),V (vanadium), and 29 
lanthanides and other rare earth elements (REE): Ce (cerium), Dy 
(dysprosium), Er (erbium), Eu (europium), Ga (gallium), Gd (gadolinium), Ho 
(holmium), In (indium), La (lanthanum), Lu (lutetium), Nb (niobium),Nd 
(neodymium), Pr (praseodymium), Sm (samarium), Ta (tantalum),Tb 
(terbium), Tm (thulium), Y (yttrium),Yb (ytterbium), Ʃ lanthanides.  
The authors concluded that tobacco smoke is a source of toxic elements such 
as copper, zinc, antimony, strontium, and vanadium, and that e-cigarettes 
seem to be a new source for intake of silver, tin, and rare earth elements 
such as cerium, erbium, and gadolinium.266 
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The authors reported on estimates of biomarker concentrations in 
combustible cigarette users, e-cigarette users, dual users, and never tobacco 
users of tobacco-related toxicant concentrations. 
Age: most were aged 35 to 54 years. Sex: women (weighted percentage, 60%; 
95%CI, 59%-62%), 
Country: USA. Data source: Population Assessment of Tobacco and Health 
study 
Population size: 5,105. Data collection period: November 2016 to October 
2017  
E-cigarette, smoking and other related status: (n = 247) current exclusive e-
cigarette users, (n = 2,411) current exclusive cigarette smokers, (n = 792) 
users of both products (dual users) compared with (n = 1655) never tobacco 
users. The analysis consisted of current product users, all of whom reported 
(1) current every day or some-days use of cigarettes, e-cigarettes, or both 
products; (2) no current (every day or some-days use) use of any other 
tobacco products; and (3) no use of nicotine replacement therapies in the 
past 3 days. In addition, cigarette-only smokers and dual users had to report 
smoking at least 100 cigarettes in their lifetime to be included. Comparison 
were made between current cigarette and e-cigarette users with never users 
who reported no lifetime tobacco use. 
Outcomes: 50 individual biomarkers from 5 major classes of tobacco product 
constituents were measured. Specifically, nicotine, tobacco-specific 
nitrosamines (TSNAs), metals, polycyclic aromatic hydrocarbons (PAHs), and 
volatile organic compounds (VOCs). urinary nicotine metabolites specifically 
nicotine (internal biomarker tne2); tobacco-specific nitrosamines (tsnas) 4-
(methylnitros-amino)- 1-(3-pyridyl)- 1-butanone; metals, lead cadmium; 
polycyclic aromatic hydrocarbons (pahs) naphthalene, pyrene, and volatile 
organic compounds (vocs) acrylonitrile, acrolein acrylamide. 
The complete list of biomarkers are:  
Urinary Nicotine Metabolites: trans‐3’‐Hydroxycotinine (HCTT), Cotinine 
(COTT), Nicotine (NICT), Cotinine N‐oxide (COXT), Nicotine 1’‐oxide 
(NOXT), Norcotinine (NCCT), Nornicotine (NNCT)  
Minor Tobacco Alkaloids: Anabasine (ANBT), Anatabine (ANTT);  
Arsenic and Arsenic Compounds: Arsenous Acid, Arsenic Acid, Dimethylarsinic 
acid, Monomethylarsonic acid 
Tobacco Specific Nitrosamines: 4‐methylnitrosamino)‐4‐(3‐pyridyl)‐
1‐butanol (NNAL), N’‐nitrosonornicotine (NNN), N’‐nitrosoanatabine 
(NAT), N’‐nitrosoanabasine (NAB)  
Metals: Beryllium (UBE), Cadmium (UCD), Cobalt (UCO), Manganese (UMN), 
Lead (UPB), Strontium (USR), Thallium (UTL), Uranium (UUR);  
Polycyclic Aromatic Hydrocarbons: 1‐Naphthol or 1‐hydroxynaphthalene 
(1‐NAP), 2‐Naphthol or 2‐hydroxynaphthalene (2‐NAP), 3‐
Hydroxyfluorene (3‐FLU), 2‐Hydroxyfluorene (2‐FLU), 1‐
Hydroxyphenanthrene (1‐PHE), 1‐Hydroxypyrene (1‐PYR), 2‐
Hydroxyphenanthrene and 3‐Hydroxyphenanthrene (2‐3PHE)  
Volatile Organic Compounds (VOCs): 2‐Methylhippuric acid (2MHA) 
(Xylene), 3, 4‐Methylhippuric acid (34MH) (Xylene), N‐Acetyl‐S‐(2‐
carbamoylethyl)‐L‐cysteine (AAMA) (Acrylamide), N‐Acetyl‐S‐(N‐
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(BMA) (Toluene), N‐Acetyl‐S‐(2‐carboxyethyl)‐L‐cysteine (CEMA) 
(Acrolein), N‐Acetyl‐S‐(1‐cyano‐2‐hydroxyethyl)‐L‐cysteine 
(CYHA) (Acrylonitrile), N‐Acetyl‐S‐(2‐cyanoethyl)‐L‐cysteine (CYMA) 
(Acrylonitrile), N‐Acetyl‐S‐(3,4‐dihydroxybutyl)‐L‐cysteine (DHBM) 
(1,3‐Butadiene), N‐Acetyl‐S‐(2‐carbamoyl‐2‐hydroxyethyl)‐L‐
cysteine (GAMA) (Acrylamide), N‐Acetyl‐S‐(2‐hydroxyethyl)‐L‐
cysteine (HEMA) (Acrylonitrile, vinyl chloride, ethylene oxide), N‐Acetyl‐
S‐(2‐hydroxypropyl)‐L‐cysteine (HPM2) (Propylene Oxide), N‐
Acetyl‐S‐(3‐hydroxypropyl)‐L‐cysteine (HPMA) (Acrolein), N‐
Acetyl‐S‐(3‐hydroxypropyl‐1‐methyl)‐L‐cysteine (HPMM) 
(Crotonaldehyde), N‐Acetyl‐S‐(4‐hydroxy‐2‐methyl‐2‐buten‐
1‐yl)‐L‐cysteine (IPM3) (Isoprene), Mandelic acid (MADA), N‐Acetyl‐
S‐(4‐hydroxy‐2‐buten‐1‐yl)‐L‐cysteine (MHB3) (1,3 Butadiene), 
Phenylglyoxylic acid (PGHA) (Ethylbenzene, styrene), N‐Acetyl‐S‐
(phenyl)‐L‐cysteine (PMA) (Benzene), 2‐Thioxothiazolidine‐4‐
carboxylic acid (TTCA) (Carbon Disulfide). 
This study examined 50 biomarkers associated with exposure to tobacco. 
Participants included adults who provided a urine sample and data on 
tobacco use. Geometric mean concentrations of 50 individual biomarkers 
from 5 major classes of tobacco product constituents were measured: 
specifically, nicotine, tobacco-specific nitrosamines (TSNAs), metals, 
polycyclic aromatic hydrocarbons (PAHs), and volatile organic compounds 
(VOCs). Compared with exclusive e-cigarette users, never users had 19% to 
81% significantly lower concentrations of biomarkers of exposure to nicotine, 
tobacco-specific nitrosamines, some metals (e.g., cadmium and lead), and 
some volatile organic compounds (including acrylonitrile). Exclusive e-
cigarette users showed 10% to 98% significantly lower concentrations of 
biomarkers of exposure, including TSNAs, PAHs, most Volatile Organic 
Compounds, and nicotine, compared with exclusive cigarette smokers; 
concentrations were comparable for metals and 3 Volatile Organic 
Compounds. Exclusive cigarette users showed 10% to 36% lower 
concentrations of several biomarkers than dual users. Frequency of cigarette 
use among dual users was positively correlated with nicotine and toxicant 
exposure. Exclusive use of e-cigarettes appears to result in measurable 
exposure to known tobacco-related toxicants, generally at lower levels than 
cigarette smoking. Toxicant exposure is greatest among dual users, and 
frequency of combustible cigarette use is positively correlated with tobacco 
toxicant concentration. 
The authors concluded that the findings provide evidence that using 
combustible tobacco cigarettes alone or in combination with e-cigarettes is 
associated with higher concentrations of potentially harmful tobacco 
constituents in comparison with compared to e-cigarettes alone.268 










The authors reported on the relationship between e-cigarettes and levels of 
cadmium and lead.  
Age: 19 and 39 years. Sex: 77 men and 79 women. Country: Poland. 
Data source: Volunteers. Population size: 156. Data collection period: Not 
reported 
E-cigarette, smoking and other related status: four groups: smokers who 
smoked cigarettes for at least 2 years, dual users who smoked conventional 
tobacco cigarettes for at least 2 years and used e-cigarette for at least 6 
months, e-cigarette users who used e-cigarette for at least 6 months and 
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months and who directly switched from combustible cigarettes to e-cigarette 
after smoking for at least 2 years, and never-smokers. Non-smokers (n = 51), 
e-cigarette users (n = 48), Dual e-cigarette users-cigarette smokers (n = 29) 
and Cigarette-only smokers (n = 28).  
Outcomes: concentration of Cadmium and Lead in Nicotine Liquids and 
Electronic Cigarette Aerosols/Smoke. Tank system/cigarette: CE4(1), Pb 
(mg/L) 0.22‒29.26 CE5(2), CE4(3), CE5(4), 3R4f 
Participants from the e-cigarette group used 12 different brands of second-
generation (44 individuals) and third-generation (four individuals) e-
cigarettes. The nicotine concentrations of e-liquid used were as follows: 
0.1%–0.4% (two individuals); 0.6%–0.9% (15 individuals); 1.0%–1.5% (14 
individuals); 1.6%–2.4% (15 individuals); and greater than 2.4% (two 
individuals). Among the six groups of flavourings, most of the individuals used 
fruit taste (21 individuals) followed by tobacco taste (11 individuals), menthol 
taste (eight individuals), and tea/coffee taste (six individuals). Participants 
from the dual-user group used eight different brands of second-generation 
(26 individuals) and third-generation (three individuals) e-cigarettes. The 
nicotine concentrations of e-liquid used were as follows: 0.1%–0.4% (two 
individuals); 0.6%–0.9% (13 individuals); 1.0%–1.5% (15 individuals); 1.6%–
2.4% (15 individuals); and greater than 2.4% (one individual). Among the 
seven groups of flavourings, most of the individuals used fruit taste (11 
individuals) followed by tobacco taste (seven individuals) and menthol taste 
(seven individuals). 
The authors concluded that smokers who completely switched to e-cigarettes 
and quit smoking conventional combustible tobacco cigarettes may 
significantly reduce their exposure to cadmium, and probably to lead.269 
Device and products: The second-generation Ego-3 battery (3.4 V with 
voltage stabilization) was used most popularly among the participants in this 
study. The authors examined four tank systems (two CE4 systems with a top 
atomizer and two CE5 systems with a bottom atomizer) and convenience 
samples of 18 e-liquids. Each e-cigarette tank was filled, rotated a few times 
to ensure the homogeneous distribution of the contents, and stored for at 
least 24 hours in the dark at room temperature at a horizontal position 
before the experiment. Each was used for a single brand of e-liquid. The 
batteries were fully charged before the experiment and were replaced after 
the charge level reached half of the maximum value, which was signalled by 
the red diode on the battery. Participants from the dual-user group used 
eight different brands of second-generation (26 individuals) and third-
generation (three individuals) e-cigarettes. The nicotine concentrations of e-
liquid used were as follows: 0.1%–0.4% (two individuals); 0.6%–0.9% (13 
individuals); 1.0%–1.5% (15 individuals); 1.6%–2.4% (15 individuals); and 
greater than 2.4% (one individual). Among the seven groups of flavourings, 
most of the individuals used fruit taste (11 individuals) followed by tobacco 










The authors reported on a range of chemical toxicants (metabolites of 
benzene, ethylene oxide, acrylonitrile, acrolein, propylene oxide, acrylamide, 
and crotonaldehyde) in two groups, e-cigarette-only users and never-using 
controls.  
Age: 13–18 years. Sex: 68 males 35 females Country: USA.  
Ethnicity: E-Cigarette–Only Users: Non-Hispanic white 36/67 (54%) Asian 
American or Pacific Islander 12/67 (19%) Multiracial 10/67 (15%) Hispanic 
7/67 (10%) Dual Users: Non-Hispanic white 9/16 (67%) Asian American or 





Author(s) year Possible 
benefit 
or harm 
Cross-sectional surveys papers toxicology of e-cigarette constituents 
Controls: Non-Hispanic white 0 Asian American or Pacific Islander 2/20 (10%) 
Multiracial 0 Hispanic 18/20 (90%) 
Data source: recruited from the San Francisco Bay area by using fliers and 
online advertising. 
Population size: 103 E-Cigarette–Only users n=67 Dual Users n=16 Controls n 
= 20. 
Data collection period: Not reported 
E-cigarette, smoking and other related status: e-cigarette-only users (i.e. >=1 
use within the past 30 days, >=10 lifetime e-cigarette use episodes) 
specifically n= 67 e-cigarette-only users (no cigarettes in the past 30 days) and 
n = 16 (use of cigarettes in the past 30 days in addition to e-cigarettes); along 
with N = 20 never-using control 
Outcomes: Biomarkers of Nicotine, Tobacco-Specific Nitrosamine, and 
Volatile Organic Toxicants. Biomarkers of Nicotine Saliva cotinine, Urine NNAL 
(metabolite of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-
specific nitrosamine that is a potent carcinogen). Volatile Organic Toxicants 
metabolites of benzene (PMA), ethylene oxide (HEMA), acrylonitrile 
(CNEMA), acrolein (3-HPMA), and acrylamide (AAMA) 
Two groups of e-cigarette-only users specifically n= 67 e-cigarette-only users 
(no cigarettes in the past 30 days) and n = 16 (use of cigarettes in the past 30 
days in addition to e-cigarettes), along with N = 20 never-using controls were 
assessed. Metabolites of benzene, ethylene oxide, acrylonitrile, acrolein, and 
acrylamide was significantly higher in dual users versus e-cigarette-only users 
(all P < .05). Excretion of metabolites of acrylonitrile, acrolein, propylene 
oxide, acrylamide, and crotonaldehyde were significantly higher in e-
cigarette-only users compared with controls (all P < .05).  
The authors concluded that although e-cigarette vapour may be less 
hazardous than tobacco smoke, their findings challenged the idea that e-
cigarette vapour is safe, because many of the volatile organic compounds 
identified are carcinogenic271 
Device and products: The following characteristics were reported: Usual type 
of device - Vape pen, Modified, Juul, Other or unsure; E-cigarettes contain – 
nicotine (Always, Sometimes, Unsure, Never); Usual flavour of e-cigarette 
(Fruit, Candy, Menthol Tobacco) 
Wei et al.273 
2018 
Harm The authors reported on the relationship between e-cigarette users and 
metabolite levels of flame retardants (and their urinary metabolites. 
Age: Age (year), Non-user 20–45 years N = 511 >46 years N = 690, Cigarette 
User 20–45 years N = 142 >46 years N = 156, Cigar User 20–45 years N = 12 
>46 years N = 10, E-Cigarette User 20–45 years N = 10 >46 years N = 4 , User 
of Smokeless Tobacco Products 20–45 years N = 6 >46 years N = 9. 
Sex: Non-user male = 534, female 667; Cigarette User male = 170, female 
128; Cigar User male = 18, female 4; E-Cigarette User male = 8, female 6; User 
of Smokeless Tobacco Products male = 15, female=0 
Country: USA. Data source: National Health and Nutrition Examination 
Surveys 
Population size: 1,550. Data collection period: 2013-2014.  
E-cigarette, smoking and other related status: Exclusive e-cigarette users, 
exclusive cigarette smokers, exclusive cigar smokers, and exclusive users of 
smokeless tobacco products were identified if they self-reported use of e-
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within the five days prior to examination but never used any other tobacco 
products Non-user N = 1201, Cigarette User N = 298, Cigar User N = 22 E-
Cigarette User N = 14 User of Smokeless Tobacco Products N = 15 
Outcomes: Flame retardants and their (urinary metabolites): Triphenyl 
phosphate (TPhP), (Diphenyl phosphate (DPhP)); Tris(1,3-dichloro-2-propyl) 
phosphate (TDCPP) (Bis(1,3-dichloro-2-propyl) phosphate (BDCPP); Tris(1-
chloro-2-propyl) phosphate (TCPP) (Bis(1-chloro-2-propyl) phosphate (BCPP)); 
Tris(2-chloroethyl) phosphate (TCEP) (Bis(2-chloroethyl) phosphate (BCEP)); 
Tri-p-cresyl phosphate (TpCP) (Di-p-cresyl phosphate (DpCP)); Tri-o-cresyl 
phosphate (ToCP) (Di-o-cresyl phosphate (DoCP)); Tributyl phosphate (TBUP) 
(Dibutyl phosphate (DBUP)); Tribenzyl phosphate (TBzP) (Dibenzyl phosphate 
(DBzP)); 2-ethylhexyl-2,3,4,5-tetrabromobenzoate (TBB) (2,3,4,5-
tetrabromobenzoic acid (TBBA)). 
Four metabolites had detection rates >60%, the authors observed higher 
adjusted geometric mean for (bis(2-chloroethyl) phosphate (BCEP)), a 
metabolite of tris(1-chloro-2-propyl) phosphate (bis(1-chloro-2-propyl) 
phosphate), tris(2-chloroethyl) phosphate (TCEP), in the users of e-cigarettes 
than in both non-users and cigarette users, suggesting that using e-cigarettes 
could lead to elevated exposure to TCEP. In a similar fashion, cigar users may 
have a higher exposure to triphenyl phosphate (TPhP) while smokeless 
tobacco (including e-cigarette) users showed higher exposure to tributyl 
phosphate (TBUP), but lower exposure to triphenyl phosphate.  
The authors concluded that while the results are preliminary, they indicate a 
need for a better examination of the types and levels of organophosphate 
flame retardants and their potential contamination sources in non-cigarette 
tobacco products, including e-cigarettes.273 
Device and products: Not reported 
Jain.270 
2019 
Harm The authors reported on concentrations of cadmium, lead, and mercury in 
blood among cigarette, cigar, e-cigarette, and dual cigarette and e-cigarette 
users in the USA. 
Age mean (SD) years: 12 years of age or older. Sex: Not reported Country: 
USA. 
Data source: National Health and Nutrition Examination Survey 
Population size: 1,139 smokers. Data collection period: 2013 to 2016 
E-cigarette, smoking and other related status: Smokers were categorized as 
smokers of cigarettes only, cigars only, cigars and cigarettes, e-cigarettes 
only, and those who used both cigarettes and e-cigarettes. All other smokers 
were excluded from the database. 
Outcomes: concentrations of metals in blood: cadmium, lead and mercury 
The authors concluded that the observed levels of blood cadmium, lead, and 
mercury among adults in the USA aged 12 years or over were not found to 
differ among cigarette-only users, e-cigarette-only users, and dual users of 
both cigarettes and e- cigarettes.270 
Device and products: Not reported 
Wang et al.274 
2019 
Harm The authors reported on the relationship between smoking behaviours in 
adults and environmental pollutants of polycyclic aromatic hydrocarbons. 
Age: Recruitment employed address-based, area-probability sampling, using 
an in-person household screener to select youth (ages 12–17) and adults. 
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relative to population proportions. Specifically, 18–24 years, 25–34 years, 35–
54 years, and 55 years and older. 
Sex: Not specifically reported. Country: USA. Ethnicity: African Americans 
Data source: Population Assessment of Tobacco and Health study 
Population size: 8,327/11,519. Data collection period: 2013-2014  
E-cigarette, smoking and other related status: Participants smoking-related 
behaviours were grouped as follows: participants based on their use of 
tobacco products as never-tobacco user (never user, n=1700), exclusive 
current established combustible products user (combustible products user, 
n=5767), and exclusive current established non-combustible products user 
(non-combustible products user, n=860). Tobacco users were further 
classified as exclusive cigarette user (cigarette user, n=3964), exclusive 
smokeless product user (SLT user, n=509), and exclusive e-cigarette user (e-
cigarette user, n=280). In addition, categorization on the frequency of 
product use (everyday vs some days) and time since use (last hour, within 3 
days, over 3days) was also assessed. 
Outcomes: Seven urinary OH-PAH metabolites: biomarkers, 1-
Hydroxynaphthalene, 2-Hydroxynaphthalene, 2-Hydroxyfluorene, 3-
Hydroxyfluorene, 1-Hydroxyphenanthrene, Σ2,3-Hydroxyphenanthrene and 
1-Hydroxypyrene 
Geometric mean (GM) concentrations and evaluated associations between 
tobacco product user categories and polycyclic aromatic hydrocarbon 
biomarker concentrations were reported. For all biomarkers examined, 
cigarette users had the highest geometric means compared to other tobacco 
product users. Interestingly, geometric means of 2-hydroxyfluorene, 3-
hydroxyfluorene, and 2,3-hydroxyphenanthrene were significantly higher in 
exclusive smokeless product users than in e-cigarette users; 3-
hydroxyfluorene and 1-hydroxypyrene were also significantly higher in e-
cigarette and exclusive smokeless product users than in never users. Everyday 
cigarette and exclusive smokeless product users had significantly higher 
geometric means for most biomarkers than sometimes users; cigarette and 
exclusive smokeless product users who had used the product in the last hour 
had significantly higher geometric means of most biomarkers than other 
occasional cigarette or exclusive smokeless product users. By contrast, 
everyday e-cigarette users’ geometric means of most biomarkers did not 
differ significantly from those in sometimes e-cigarette users.274 
Device and products: Not reported 
Table 73: Cross-sectional surveys papers on other outcomes, benefits or harms 
Author(s) year Possible 
benefit 
or harm 
Cross-sectional surveys papers other outcomes 
Ballbè et al.278 
2014 
Harm The authors reported on the relationship between passive exposure to 
nicotine in conventional combustible tobacco cigarettes and e-cigarettes in 
54 non-smoker volunteers from different homes. 
Age: Not reported. Sex: Not reported. Country: Spain 
Data source: convenience sample. Population size: 54  
Data collection period: November 2011 and February 2012 
E-cigarette, smoking and other related status: 54 non-smoker volunteers 





with nicotine e-cigarette users, and 24 from control homes (not using 
conventional tobacco cigarettes neither e-cigarettes). The study group of 25 
persons lived at home with conventional smokers, of 5 persons lived with 
nicotine e-cigarette users, and 24 persons were from a control homes (not 
using conventional tobacco cigarettes neither e-cigarettes). 
Outcomes: airborne nicotine at home and biomarkers (cotinine in saliva and 
urine). Salivary and urinary cotinine were highly correlated (Spearman's 
rank correlation coefficient (rsp)=0.855, p>0.01) and both biomarkers were 
highly correlated with air nicotine concentration measured at the 
volunteers’ home for one week (rsp=0.731for salivary cotinine and 
rsp=0.710 for urinary cotinine p-values p<0.001). 
The authors concluded that non-smokers passively exposed to e-cigarettes 
absorb nicotine.278 
Device and products: Thee-cigarette devices (all tank system) and the e-
cigarette liquid brands (propylene glycol-based liquids) were of different 
brands (Totally Wickeds, Puffs, and FreeLifes). 








The authors reported on how symptoms that adolescents experience during 
their first time using a cigarette predict their current use, but little is known 
about the symptoms experienced during first e-cigarette use. 
Age: 13 to 17 years. Sex: Male 54 Female 57 Transgender 1. Country USA 
Data source: adolescents between ages 13–17 residing in North Carolina or 
California with a parent or guardian who participated in a randomized trial 
of pictorial cigarette pack warnings. The parents or guardians who 
participated in the randomized trial were recruited through advertisements 
posted on social media and in retail outlets, buses, and local newspapers. 
Population size: 112 participants, 41 of which had tried a cigarette or 
electronic cigarette 
Data collection period: December 2014 and September 2016 
E-cigarette, smoking and other related status: 12 had tried cigarettes only, 
12 had tried e-cigarettes, and 17 had tried both. Sixteen percent of 
adolescents who tried e-cigarettes only and 33% of adolescents who tried 
cigarettes only report smoking/vaping in the last 30 days. Among the 17 
participants who tried both cigarettes and e-cigarettes, 76% reported being 
a current user: 3 currently smoked cigarettes, 3 currently used e-cigarettes 
only, and 7 continued to use both. 
Outcomes: symptoms that adolescents experienced during their first-time 
using cigarettes and e-cigarettes.  
The symptoms were coded as negative (felt bad, coughing/chest pain, bad 
taste in mouth, upset stomach, and dizzy/lightheaded, with a range from 0 
to 5) and positive (rush/buzz, and felt relaxed, with a range from 0 to 2) 
symptoms from their first cigarette and e-cigarette use. Of the 29 
adolescents who had tried conventional combustible tobacco cigarettes, 28 
had reported results, 22 (76%) reported experiencing negative symptoms 
only, 2 (7%) reported feeling neutral only, and 4 (14%) reported 
experiencing both positive and negative symptoms. No participants 
reported positive symptoms only. The negative symptoms that adolescents 
reported included feeling dizzy, sick, bad taste in their mouth, difficulty 
breathing, and headache. By contrast, of the 29 adolescents who had tried 
e-cigarettes, 9 (31%) reported experiencing negative symptoms only, 12 
(41%) reported feeling neutral only, 6 (21%) reported experiencing positive 
symptoms only, and 2 (7%) reported experiencing both positive and 
negative symptoms. Twenty-five of the 29 adolescents (86%) reported that 
they felt ‘normal’, ‘no change’, or ‘the same’ after their first e-cigarette. 





than from their first cigarette, and e-cigarette symptoms did not influence 
use as they do for cigarettes.283 
Device and product: Not reported 








The authors reported on the relationship between cigarette, e-cigarette, 
hookah, and cigar products and symptoms at first use (nausea, coughing, 
relaxation, rush/buzz, and dizziness). 
Age of Initiation years mean (sd) E-Cigarettes 13.78 (1.43), Cigarettes 12.35 
(2.41) Hookah 13.69 (1.77) Large Cigar/Cigarillo/LFCs 12.97 (2.16). 6th, 8th 
and 10th grade students in four metropolitan areas of Texas 
(n=3,907/N=461,069) 
Sex: 49% female. Country: Four metropolitan areas, Texas USA.  
Data source: Texas Adolescent Tobacco and Marketing Surveillance System  
Population size: n=3,907/N=461,069  
Data collection period: October 2014 to June 2015  
E-cigarette, smoking and other related status: Subjective experiences of first 
use were assessed among ever users of any nicotine product. Ever use was 
assessed by the question “Have you EVER tried [product], even once? 
Remember, marijuana DOES NOT count.” with those responding “yes” 
defined as “ever users.” Participants who reported ever use of cigarettes, e-
cigarettes, hookah, large cigars, or little filtered cigars (LFC) or cigarillos, 
were asked if they experienced five different subjective experiences at first 
use. 
Outcomes: Nausea, coughing, relaxation, rush/buzz, and dizziness at first 
use were assessed for cigarettes, e-cigarettes, hookah, and cigar product 
The authors concluded that subjective experiences at first use differ by 
tobacco product.282 
Device and products: Not reported 
Yao et al.280 
2017 
Harm The authors examined the relationship between spending on e-cigarettes, 
30-day e-cigarette use, and disease symptoms among current adult 
cigarette smokers. 
Age: 2 to 44 years n= 199, 45 to 64 years n= 295, >=65 years n=39  
Sex: 217 males, 316 females. Country: USA 
Ethnicity: Non-Hispanic African American n=35 Non-Hispanic Asian n=9 Non-
Hispanic Others n=15 Non-Hispanic White n=429 Hispanic n=45 
Data source: Tobacco and Attitudes Beliefs Survey 
Population size: 539. Of whom, 262 of them were current (last 30 days) e-
cigarette users. After excluding 6 participants with missing information on 
CPD (N = 3, 0.6%) or race/ethnicity (N = 3, 0.6%), the final study sample 
consisted of 533 participants. 
Data collection period: August 2015  
E-cigarette, smoking and other related status: current cigarette smokers and 
e-cigarette ever users current (last 30 days) e-cigarette use. Current e-
cigarette use was measured by a dichotomous (yes/no) variable based on 
the answer to the question: Have you used e-cigarettes in the last 30 days? 
Outcomes: Fifteen disease symptoms were examined: coughing, wheezing, 
shortness of breath, chest tightness, headache, sore throat, waking up 
feeling tired, chest pain, having trouble falling asleep or staying asleep, 
toothache, sensitive teeth, noticing blood when brushing their teeth, having 






The authors reported that those who spent money on e-cigarettes were 
more likely to report chest pain (AOR: 1.25; 95% CI: 1.02–1.52), to notice 
blood when brushing their teeth (AOR: 1.23; 95% CI: 1.02–1.49), to have 
sores or ulcers in their mouth (AOR: 1.36; 95% CI: 1.08–1.72), and to have 
more than one cold (AOR: 1.36; 95% CI: 1.05–1.78) than those with no 
spending on e-cigarettes in the past 30 days in an adjusted analysis. After 
controlling for cigarettes smoked per day and other covariates, there were 
no significant relationships between 30-day e-cigarette use and 
symptoms.280  
Device and products: Not reported 




The authors reported on the relationship between smoking behaviour 
patterns and glycated haemoglobin levels.  
Age: 20 to >=70 years  
Sex: Men and women comprised 39.99% (n = 3523) and 60.01% (n = 5286) 
of the sample, respectively. 
Country: South Korea 
Data source: Korea National Health and Nutrition Examination Survey 
(KNHANES) 
Population size: 8,809 of 23,080 participants in the nationwide survey 
database study were assessed in the study 
Data collection period: 2014-2016 
E-cigarette, smoking and other related status: Regarding smoking 
behaviours, dual smokers, single smokers, ex-smokers, and non-smokers 
accounted for 1.61% (n = 142), 15.43% (n = 1359), 18.78% (n = 1654), and 
64.18% (n = 5654) of the sample, respectively 
Outcomes: and glycated haemoglobin (HbA1c) levels 
In the study, persons with a diabetes related diagnosis or missing data 
(smoking behaviour, HbA1c level, age, sex, occupation, household income, 
educational level, physical activity, body mass index (BMI), alcoholic 
behaviour, pack-years of smoking, anaemia status, family history of diabetes 
mellitus, and caloric intake) were excluded. Participant were classified into 
four categories: dual smokers (both cigarettes and e-cigarette), single 
smokers (cigarettes smokers), former smokers (ex-smokers), and non-
smokers. Normal weight/underweight, overweight, and obese subjects 
comprised 46.48% (n = 4094), 22.90% (n = 2017), and 30.63% (n = 2698) of 
the sample, respectively. The overall mean HbA1c level was 5.48 +/- 0.27%. 
In the reported findings, elevated glycated haemoglobin levels (HbA1c) 
levels were observed among subjects who were dual users of e-cigarettes 
and conventional combustible tobacco cigarettes and who were e-cigarette-
only or conventional combustible tobacco cigarette-only users, compared 
with those among non-smokers; however, a direct association between e-
cigarette use and HbA1c levels was not reported. In the analyses stratified 
by sex, men who were dual users and e-cigarette only or conventional 
combustible tobacco cigarette-only users had higher HbA1c levels than non-
smokers, whereas among women, there were no significant results. Among 
physically inactive subjects, dual users were more strongly associated with 
elevated HbA1c levels. However, it remains unclear whether e-cigarette use 
alone can induce an increase in HbA1c levels. According to body mass index, 
dual users had a strong association of elevated HbA1c levels among people 
who were obese and overweight compared with those who were average 
weight and underweight.275 
Device and products: The authors reported a limit to the study was they 
were not able to consider the type of e-cigarette, frequency of vaping, or 





behaviour, and socioeconomic status were collected via self-report surveys 
and thus might have been subject to recall bias and underestimated 
smoking behaviours. Finally, they could not consider each single e-cigarette 
smoking behaviour because the number of single e-cigarette smokers was 
very small. It should be noted that the relationship of e-cigarette alone with 
the outcome not examined. 
Kyriakos284 
2018 
Harm The author reported on the characteristics and correlates of e-cigarette 
product attributes and undesirable events during use.  
Age: 15 to 55+ years. Sex: Reported numbers were for a larger population 
group than those reported on in this paper Country: Germany, Greece, 
Hungary, Poland, Romania, Spain 
Data source: cross-sectional survey with a nationally representative sample 
of adult cigarette smokers 
Population size: 6,011, 1,178 reported ever use of e-cigarette (at least once 
in their life-time) 
Data collection period: June to September 2016  
E-cigarette, smoking and other related status: adult cigarette smokers 
reporting e-cigarette use  
Outcomes: characteristics and correlates associated with e-cigarette 
product attributes and identified correlates of experiencing undesirable 
events during e-cigarette use 
The author reported that current daily or weekly prevalence of e-cigarette 
use among a sample of adult smokers was 7.5%. The most common 
attributes of e-cigarettes used included those that are flavoured, contain 
nicotine, and are of tank style. Use of e-liquid refill nozzle caps, described as 
easy for a child to open, was associated with spilling during refill. 
Participants who occasionally or regularly adjusted the power (voltage) or 
temperature of their e-cigarette had greater odds of ever experiencing a 
‘dry puff’. Mixing different e-liquids was associated with leaking during use 
and spilling during refill. The author concluded that ongoing evaluation of 
factors associated with e-cigarette attributes, and of the correlates of 
experiencing undesirable events during e-cigarette use to product design, is 
crucial to monitoring the impact of the implementing Acts of the EU 
Tobacco Products Directive.284 
Device and products: The types of devices and products were not 
specifically reported but data using the following question was collected. 
What type of e-cigarettes is your usual/current brand? It is disposable, not 
refillable (non-rechargeable). It uses replaceable pre-filled cartridges 
(rechargeable). It has a tank that you fill with liquids (rechargeable). What 
flavours of e-cigarette or e-liquid have you used in the last 30 days? What is 
the nicotine strength (mg/mL) of current/last e-liquid? Do you ever mixed e-
liquids? Does the e-cigarette or vaping device you use most frequently 
contain settings to adjust the power (voltage) or temperature? 








The authors reported on the relationship between e-cigarette-only users 
and dual e-cigarette and conventional combustible tobacco cigarette users 
with a range of 16 adverse events and 10 physiological functions. 
Age: 18 to 75 years. Sex: 859 males 177 females. Country: Hungary. 
Data source: Convenience sample. Population size: 1042 
Data collection period: September–December 2015 
E-cigarette, smoking and other related status: E-cigarette-only user n=859, 
Dual users n=183. E-cigarette-only versus dual use was assessed by a 
question “Do you use e-cigarette or combustible cigarette?” (combustible 
cigarettes only, e-cigarettes only, both of them). Only persons who were e-





combustible cigarette use was measured by the number of tobacco 
cigarettes smoked per day before initiating e-cigarette use. Response 
options were categorized into: ≤10 CPD – light smoker, 11–19 CPD –
moderate smoker, ≥20 CPD – heavy smoker. Current e-cigarette use 
characteristics variables included in this study were (1) time since 
respondent started using e-cigarettes (< 6 month ago, 6–12 months ago, 1–
2 years ago, > 2 years ago), (2) frequency of e-cigarette use per day (non-
daily, 1–10 times a day, 11–19 times a day, ≥20 times a day), and (3) 
nicotine concentration of the e-liquid (0 mg/ml – 18 mg/ml or more) 
Outcomes: adverse events: sore/dry mouth and throat, cough, mouth or 
tongue sores/inflammation, gingivitis, gum bleeding, headache, dizziness, 
heart palpitation, breathing difficulties, chest pain, sleepiness, 
sleeplessness, allergy, black tongue, nose bleeding, any adverse event 
physiological functions: breathing, smell, taste, physical status in general, 
stamina, mood, quality of sleep, appetite, sexual performance and memory 
The convenience sample was obtained by posting the survey on Hungarian 
e-cigarette forum websites and an e-cigarette web shop inviting website 
visitors to participate. Participants reported the occurrence of adverse 
events and changes in physiological functions since they switched from 
smoking to e-cigarette use or while dually using e-cigarettes and 
combustible cigarettes. Confirmatory factor analysis with covariates was 
applied to explain perceived health changes due to e-cigarette-only use and 
dual use. Of the 1,584 initial respondents 1,042 unique respondents who 
ever smoked and were current e-cigarette users (only or dual users) were 
included in the study.  
The authors concluded that the dual users were significantly more likely to 
report adverse events of vaping than e-cigarette-only users (26.2% versus 
11.8%; p<0.001). Experiencing health improvements was significantly more 
likely among e-cigarette-only users than among dual users for all surveyed 
physiological functions. E-cigarette-only users reported larger effects of 
vaping on sensory, physical functioning, and mental health factors 
compared with dual users281 
Device and product: Information on ‘Frequency of e-cigarette use’, 
‘Combustible cigarettes smoked per day (before started using e-cigarette’, 
and ‘Nicotine concentration of e-liquid’ was gathered and reported. No 




Harm The authors reported on the association of e-cigarette use with a self-
reported diagnosis of prediabetes in never cigarette smokers. 
Age mean (SD) years: 18 to 55 years. Sex: 56% males, 44% females 
Country: USA.  
Ethnicity:White only, Non-Hispanic, Black only, Non-Hispanic, Other race or 
multiracial, Non-Hispanic and Hispanic 
Data source: Behavioral Risk Factor Surveillance System 
Population size: 154,404. Data collection period: 2017 
E-cigarette, smoking and other related status: 143,952 never, 1,339 current 
and 7,625 former e-cigarette users 
Outcomes: diagnosis of prediabetes. Current e-cigarette users had an 
increased odds of reporting a diagnosis of prediabetes 1.97 (95% CI 1.25–
3.10) compared to never e-cigarette users. After stratifying by gender, men 
and women had an increased odds ratio of reporting a diagnosis of 
prediabetes 2.36 (95% CI 1.26–4.40) and 1.88 (95% CI 1.00–3.53) 
respectively when compared to never e-cigarette users. There was no 






The authors concluded that e-cigarette use may be associated with self-
reported prediabetes276 
Device and products: Not reported 
Chang et al.285 
2019 
Harm The authors reported on the relationship between e-cigarette use and self-
reported health outcomes. 
Age: 18 to 75 years plus, the majority, 5844, were under 35 years of age 
Sex: 5182 males 4870 females. Country: USA Ethnicity: 7771 while, 1177 
black alone, 1104 other  
Data source: Population Assessment of Tobacco data  
Population size: 10,052 - 6,311 current smokers and 3,741 non-smokers 
Data collection period: 2013-2014 
E-cigarette, smoking and other related status: six variables were selected to 
describe subject’s patterns of e-cigarette use - own an e-cigarette. number 
of e-cigarette cartridges used in entire life, ever smoked e-cigarettes fairly 
regularly, used flavoured e-cigarettes, e-cigarettes used usually contain 
nicotine and concentration of nicotine in e-cigarette cartridge 
Outcomes: Four self-reported categorical variables to assess respondents’ 
health conditions including overall health, mental health, physical health, 
and quality of life. The categories include self-rated measurements on each 
variable: excellent, very good, good, fair, and poor.  
Chang et al reported-on findings from a nationally representative sample. 
They reported measures of physical and mental health and quality of life 
using relative risk ratio (RRR) and 95% confidence interval (95% CI) for self-
reported health outcomes between reference and comparison groups, 
estimated by multinomial logistic regression in non-smoking population (n = 
3,741); stratified by the categories of: Own an e-cigarette, Number of 
cartridges used in entire life, Ever smoked e-cigarettes fairly regularly, Used 
flavoured e-cigarettes and E-cigarettes used usually contain nicotine and 
Concentration of nicotine in e-cigarette cartridges. The reported statistical 
assessment, of relative risk ratio (RRR) found non-cigarette smoker who 
used e-cigarettes had lower levels of mental health in comparison to non-
smoking non e-cigarette users – RRR 0.66. When the respondents used e-
cigarette products containing nicotine, the risk for reporting poor mental 
health was higher (RRR = 1.87). Among cigarette smokers, more use of e-
cigarette cartridges was associated with higher risk of mental health (RRR = 
1.12). Poor quality of life was associated with regular e-cigarette use. If 
smokers used e-cigarette products with nicotine, the risk of reporting poor 
quality of life was lower than individuals who did not use such products 
(RRR = 0.49). Higher concentration of nicotine in e-cigarette cartridges was 
associated with higher risks of poor physical and poor overall health, and 
with lower chance of excellent mental health. 
The authors concluded that some e-cigarette usage patterns were 
associated with poorer health conditions in smoking and non-smoking 
populations, but that they were cautious about making conclusive claims 
regarding e-cigarette usage patterns.285 
Device and products: The authors stated among respondents the questions 
on “E-cigarettes used usually contain nicotine” and 
“Concentration of nicotine in e-cigarette cartridge” had many skipped 
responses, they therefore classified those inapplicable responses to 
“unknown” or “I don’t know the concentration.” 
Md Isa et al.277 
2019 
Harm The authors reported on the tear function in e-cigarette vapers. 





Data source: cross-sectional, single-visit, pilot study carried out at the 
National Institute of Ophthalmic Sciences Optometry Clinic 
Population size: 42. Data collection period: 2017 
E-cigarette, smoking and other related status: 21 vapers and 21 healthy 
non-smokers 
Outcomes: dry eye and tear film quality 
The authors concluded that vapers showed moderate to severe 
symptomatic dry eye and poorer tear film quality compared with non-
smokers. High vaping voltage may have aggravated the dry eye syndrome 
because of hazardous by-products from pyrolysis of the e-liquid 
constituents.277 




Harm The authors reported on the contribution of medical staff to third-hand 
smoke contamination in a neonatal intensive care unit. 
Age mean (SD) years: 36.0 (10.4). Sex: 215 females. Country: USA 
Data source: medical staff recruited from a large, urban children’s hospital 
in Houston, Texas with a 144-bed neonatal intensive care unit and over 
1000 admissions per year. 
Population size: 246. Data collection period: 2017 
E-cigarette, smoking and other related status: The authors explored 
contamination routes by characterizing nicotine levels (THS proxy) found on 
the fingers of neonatal intensive care units medical staff and assessed 
finger-nicotine correlates 
Outcomes: measurable finger nicotine 
The authors concluded that almost four in five neonatal intensive care unit 
medical staff had measurable finger nicotine, with finger surface area and 
frequency of reported exposure to tobacco smoke in friends’ or family 
members’ homes emerging as important correlates, leading to third-hand 
nicotine contamination in a neonatal intensive care unit.279 







Appendix 4: Longitudinal cohort study papers by adapted Academies of 
Sciences framework headings for e-cigarettes 
Table 74: Longitudinal cohort study papers on dependency and abuse liability, benefits or harms 
Author(s) year Possible 
benefit 
or harm 










The authors reported on the relationship of e-cigarette use with smoking 
reduction and smoking cessation. 
Age: 44.6 (±12.5) years), Sex: 6 male, 8 females. Country: Italy 
Data source: Chronic schizophrenic in-patients, who smoked ≥20 factory-
made cigarettes per day (cig/day) for at least the past 10 years, able to 
understand the assessment procedures, and to provide written informed 
consent were recruited from the “C.T.A, Villa Chiara-Psichiatrica Riabilitativa e 
Ricerca”, Mascalucia (in Catania). 
Population size: 14 
Data collection period: Year not reported. Study participants were invited to 
attend six study visits: at baseline, week-4, week-8, week-12 week-24 and 
week 52. The follow up period was 52-weeks. 
E-cigarette, smoking and other related status: Pack Years mean (SD) 28.8 
(±12.9). Level of nicotine dependence by using Fagerstrom Test of Nicotine 
Dependence 
Outcomes: The primary efficacy measure was sustained 50% reduction in the 
number of cigarettes/day at week-52 from baseline (reducers); defined as 
sustained self-reported 50% reduction in the number of cigarette/day 
compared to baseline for the 30 days period prior to week-52 study visit. 
Carbon monoxide levels in exhaled breath were measured to objectively 
verify smoking status and to document a reduction compared to baseline). An 
additional secondary efficacy measure of the study was sustained smoking 
abstinence at week-52 (quitters); defined as complete self-reported 
abstinence from tobacco smoking (not even a puff) for the 30 days period 
prior to week-52 study visit carbon monoxide levels in exhaled breath levels 
were measured to objectively verify smoking status with an carbon monoxide 
levels in exhaled breath concentration of ≤10 ppm). Those smokers who 
failed to meet the above criteria at the final week-52 follow-up visit (study 
visit 6) were categorized as reduction/cessation failures (failures). Sustained 
50% reduction in the number of cigarettes/day at week-52 was shown in 7/14 
(50%) participants; their median of 30 cigarettes/day decreasing significantly 
to 15 cigarettes/day (p = 0.018). Sustained smoking abstinence at week-52 
was observed in 2/14 (14.3%) participants. Combined sustained 50% 
reduction and smoking abstinence was shown in 9/14 (64.3%) participants. 
Nausea was observed in 2/14 (14.4%) of participants, throat irritation in 2/14 
(14.4%) of participants, headache in 2/14 (14.4%) of participants, and dry 
cough in 4/14 (28.6%) of participants. However, these adverse events 
diminished substantially by week-24.  
The authors concluded that e-cigarette use substantially decreased cigarette 
consumption without causing significant side effects in chronic schizophrenic 
patients who smoked and did not intend to quit. This was achieved without 
negative impacts on the symptoms of schizophrenia as assessed by the Scale 
for the Assessment of Positive Symptoms and the Scale for the Assessment of 
Negative Symptoms.292 
Device and products: an e-cigarette (“Categoria” e-Cigarette, Arbi Group Srl, 
Milano, Italy). A full 4-weeks supply of 7.4 mg nicotine cartridges (“Original” 
cartridges, Arbi Group Srl, Milano, Italy) was also provided and participants 





Author(s) year Possible 
benefit 
or harm 
Longitudinal cohort study papers dependency and abuse liability 
checks confirmed that the nicotine content per cartridge was 7.25 mg. 
Detailed toxicology and nicotine content analyses of “Original” cartridges had 




Harm The authors reported on the relationship between depressive symptoms and 
current e-cigarette use. 
Age: 18 to 29-year-old. Sex: ~64% female. Country USA.  
Ethnicity: Hispanic, Asian, White, Bi-ethnic or Bi-racial, African-American, 
Native-American/Pacific-Islander, other 
Data source: Participants were recruited from 24 colleges located in the five 
counties surrounding Austin, Dallas/Fort Worth, Houston, and San Antonio, 
Texas. A three-panel cross-lagged panel analysis was used to examine the 
bidirectional associations between current e-cigarette use and depressive 
symptoms across three study waves. Cross-lagged associations were assessed 
with direct paths from e-cigarette use to depression in the subsequent wave 
(6 months later) and from depression to e-cigarette use in the subsequent 
wave (6 months later). Four stability paths from each variable to their 
respective subsequent follow-up outcome variables (e.g., wave 1 depressive 
symptoms to wave 2 depressive symptoms) were also included. Thus, findings 
for the cross-lagged paths can be interpreted as being over and above the 
influence of the stability paths. 
Population size: 5,482 wave 1, 4,303 wave 2, 4,293 wave 3 
Data collection period: Initial assessment was from November 2014–February 
2015 and every 6 months thereafter for two subsequent waves (waves 2 and 
3). This was a 12-month follow-up study 
E-cigarette, smoking and other related status: Use of four types of tobacco 
products at wave 1, besides e-cigarettes, was included as covariates. Current 
or past 30-day use of cigarettes, smokeless/snus tobacco, large 
cigars/cigarillos/little cigars, and hookah was assessed. Participants reporting 
use of a product on one or more days in the past 30 days were given a score 
of 1 for that product. Scores for the four items were summed to create an 
index of the number of other tobacco products used in past 30 days (range = 
0–4). Current use of e-cigarette use was assessed with the question “During 
the past 30 days, have you used any ENDS product (i.e., an e-cigarette, vape 
pen, or e-hookah), even one or two puffs, as intended (i.e., with nicotine 
cartridges and/or e-liquid/e-juice)?” The item was scored 0 (used on 0 days in 
the past 30 days) or 1 (used on 1 or more days in the past 30 days).  
Outcomes: e-cigarette use and depression were predictive of their respective 
constructs after six months 
The authors concluded that elevated depressive symptoms predicted e-
cigarette use 6 months later among a young adult college population, even 
after controlling for a variety of sociodemographic characteristics and the 
number of tobacco products used. However, they found no evidence that e-
cigarette use predicted elevated depressive symptoms.294 
Device and products: Not reported 
Lechner et al.295 
2017 
Harm The authors reported on the relationship between baseline depressive 
symptoms and onset of e-cigarette use, tobacco cigarette use, and dual use 
at follow-ups. 





Author(s) year Possible 
benefit 
or harm 
Longitudinal cohort study papers dependency and abuse liability 
Ethnicity: Country USA. 44.1% Hispanic, 19.0% Asian, 16.2%White, 5.6% Bi-
ethnic or Bi-racial, 4.8% African-American, 4.1% Native-American/Pacific-
Islander, 5.5% other 
Data source: Data were drawn from a longitudinal study (baseline [wave 1], 
6-month follow-up [wave 2], and 12-month follow-up [wave 3]) of substance 
use and mental health among high school students in the Los Angeles, CA 
metropolitan area. 
Population size: data was collected for 3,383 (99.6%), 3,293 (97.0%), and 
3,282 (96.6%) participants, at baseline and 6- and 12-month follow-ups, 
respectively 
Data collection period: 2013 and 2014. Baseline [wave 1], a 6-month follow-
up [wave 2] and 12-month follow-up 
E-cigarette, smoking and other related status: lifetime and past 6-month use 
of e-cigarettes (described as “e-cigarettes, personal vaporizers”) and 
combustible cigarettes were measured at each wave (yes/no). Frequency of 
e-cigarette use, and cigarette use within the last 30 days (scored as a 6-level 
variable: 0 = 0 days, 1 = 1−2 days, 2 = 3−5 days, 3 = 6−9 days, 4 = 10−14 days, 
5 = 30 days) was assessed only at wave 3. 
Outcomes: Higher baseline depressive symptoms predicted subsequent onset 
of tobacco cigarette use (OR: 1.024; 95% CI: 1.009−1.055), e-cigarette use 
(OR: 1.015; 95%CI: 1.003−1.023), and dual use of both products (OR: 1.021; 
95%CI: 1.003−1.043). Sustained use of e-cigarettes over the 12-month 
observation period (versus non-use) was associated with a greater rate of 
increase in depressive symptoms over time (B=1.272; standard error 
[SE]=0.513; P=0.01). Among those who sustained use of e-cigarettes, higher 
frequency of use was associated with higher depressive symptoms at the final 
follow-up (B=1.611; p=0.04).  
The authors concluded that a bi-directional association of depressive 
symptoms with e-cigarette use onset across mid-adolescence was 
observed.295 
Device and products: Not reported 








The authors reported on findings from a cohort study regarding e-cigarette 
use effectiveness and safety at 24 months. 
Age: 30 to 75 years. Sex: Not reported. Country Italy 
Data source: Participants were recruited through direct contact with general 
practitioners and e-cigarette shops, via internet advertisement and social 
networks 
Population size: 1,355 subject provided baseline data: 343 users of e-
cigarettes only, 319 users of both cigarettes (dual users), 369 smokers of 
tobacco cigarettes only  
Data collection period: recruitment was June to November 2013. The study 
updated previous 12-month findings and report the results of the 24-month 
follow-up 
E-cigarette, smoking and other related status: Participants were classified as 
tobacco smokers, if they smoked ≥1 tobacco cigarette/day (2) e-cigarette 
users, if they inhaled ≥50 puffs/week of any type of e-cigarette and (3) dual 
users, if they smoked tobacco cigarettes and used e-cigarettes 
Outcomes: Sustained abstinence from tobacco cigarettes and/or e-cigarettes 
after 24 months, the difference in the number of tobacco cigarettes smoked 





Author(s) year Possible 
benefit 
or harm 
Longitudinal cohort study papers dependency and abuse liability 
events. Data at 24 months were available for 229 e-cigarette users, 480 
tobacco smokers and 223 dual users (overall response rate 68.8%). Of the e-
cigarette users, 61.1% remained abstinent from tobacco (while 23.1% and 
26.0% of tobacco-only smokers and dual users achieved tobacco abstinence). 
The rate (18.8%) of stopping use of either product (tobacco and/or e-
cigarettes) was not higher for e-cigarette users compared with tobacco 
smokers or dual users. Self-rated health and adverse events were similar 
between all groups. Among those continuing to smoke, there were no 
differences in the proportion of participants reducing tobacco cigarette 
consumption by 50% or more, the average daily number of cigarettes and the 
average self-rated health by baseline group. Most dual users at baseline 
abandoned e-cigarettes and continued to smoke tobacco. Those who 
continued dual using or converted from tobacco smoking to dual use during 
follow-up experienced significant improvements in the 3 outcomes compared 
with those who continued or switched to only smoking tobacco (p<0.001).  
The authors concluded that e-cigarette use alone might support tobacco 
quitters in remaining abstinent from smoking. However, dual use did not 
improve the likelihood of quitting tobacco or e-cigarette use, but may be 
helpful in reducing tobacco consumption. Adverse event data were scarce 
and must be considered preliminary.289 
Device and products: Not reported 
Russo et al.297 
2018 
Benefit The authors reported on the relationship between e-cigarette use and post-
cessation weight increase.  
The authors concluded that there was no evidence of post-cessation weight 
increase in those who substantially reduced tobacco cigarette consumption 
by switching to e-cigarettes (i.e. dual users), and only modest post-cessation 
weight increase was reported in exclusive e-cigarette users at 12-month 
follow-up. By reducing weight gain and tobacco consumption, e-cigarette-
based interventions may promote an overall improvement in quality of life 
Age: E-cigarette users study group n=86, Cigarette smokers study group n= 
93, Quitters study group n= 44 
Sex (male/female): E-cigarette users study group 58 males 28 females 
Cigarette smokers study group 59 males 34 females Quitters study group 29 
males 15 females 
Country: Italy  
Data source: medical records review of patients with cardiorespiratory 
conditions regularly followed-up at the outpatient clinics of four Italian 
hospitals. Baseline and follow-up data were extracted from patients’ medical 
records over a period of approx. 3.5 years 
Population size: 223 
Data collection period: March 2012 to December 2015  
E-cigarette, smoking and other related status: Patients reporting regular daily 
use of e-cigarettes (and if at all conventional tobacco cigarettes) on at least 
two consecutive follow-up visits (timed at approx. 6 and 12 months) were 
eligible for inclusion (e-cigarette users study group). Datasets from chart 
review of a second group of age-, sex-matched patients reporting to be 
regular smokers (and not using e-cigarettes) over the same observation 
period from the same participating clinics were selected as reference 
(cigarette smokers study group). Consecutive follow-up visits were timed as 
for the e-cigarette’s users study group (at approx. 6 and 12 months from 
baseline). Data from age-, sex-matched smokers in good general health who 





Author(s) year Possible 
benefit 
or harm 
Longitudinal cohort study papers dependency and abuse liability 
after successfully completing a cessation program based on licensed 
medications (nicotine patch, bupropion, or varenicline) in combination with 
counselling at the local smoking cessation centre was also collected. Baseline 
and follow-up data were extracted from clinic records of patients regularly 
followed-up at the smoking cessation centre over a period of approx. 3 years 
(February 2013 to January 2016). Their baseline measures were obtained 
before enrolling in the smoking cessation intervention (when they were 
smoking). For those who achieved documented sustained abstinence, 
consecutive follow-up visits were timed at approx. 6 and 12 months from 
baseline. 
Outcomes: change in body weight from baseline to the final follow-up visit at 
about 1 year 
The authors concluded that there was no evidence of post-cessation weight 
increase in those who substantially reduced tobacco cigarette consumption 
by switching to e-cigarettes (i.e. dual users), and only modest post-cessation 
weight increase was reported in exclusive e-cigarette users at 12-month 
follow-up. By reducing weight gain and tobacco consumption, e-cigarette-
based interventions may promote an overall improvement in quality of life.297 
Device and products: The authors reported details of e-cigarette devices and 
e-liquid nicotine strengths were gathered at the 12-month visit, however 
information was not recorded in the paper 








The authors reported on changes in e-cigarette use behaviours and 
dependence in long-term e-cigarette users. 
Age mean (SD) years: Exclusive e-cigarette users at follow-up: Baseline 41.2 
(11.9) Follow-up 44.9 (11.9) Poly users (e-cigarette and other tobacco 
products) at follow-up: Baseline 36.5 (11.9) Follow-up 40.1 (11.9) 
Sex: Exclusive e-cigarette users at follow-up -baseline - 278 (67.5) males, 
Follow-up 38 (64.4) males 
Country: USA 
Data source: study subjects were recruit through various online sources and 
were invited to complete an online survey of e-cigarette use. 
Population size: 494 
Data collection period: 2014-2014 with a follow-up online survey in 2017-
2018. A mean follow-up time of 3.7 years (SD=0.7; range, 2−6 years) for the 
analyses  
E-cigarette, smoking and other related status: The authors reported at 
baseline, 402 subjects (81.4%) were exclusive e-cigarette users, and 71 
subjects (14.4%) were poly users. Among baseline exclusive e-cigarette users, 
the majority (88.3%) continued using e-cigarettes exclusively, but 37 users 
(9.2%) became poly users and 1 returned to cigarette smoking at follow-up. 
Among baseline poly users, 60.6% became exclusive e-cigarette users at 
follow-up. The mean Penn State Electronic Cigarette Dependence Index score 
remained similar over time (8.4 at baseline vs 8.3 at follow-up. To evaluate 
changes in e-cigarette-use behaviours, repeated 7-day point prevalence 
measures were used to categorize study subjects as exclusive e-cigarette 
users, poly users, and ex-e-cigarette users at baseline and follow-up. Study 
subjects were classified into 5 groups according to their past-7-day use of e-
cigarettes and other tobacco or nicotine products (including any cigarettes, 
chewing tobacco, snuff/dipping tobacco, snus, pipe tobacco, or other nicotine 
products such as patch, gum, lozenge, inhaler, or nasal spray). “Exclusive e-
cigarette users” were subjects who had used only e-cigarettes, “poly users 





Author(s) year Possible 
benefit 
or harm 
Longitudinal cohort study papers dependency and abuse liability 
any other nicotine product, “poly users with other tobacco products” were 
those who had used both e-cigarettes and any other tobacco product, “ex−e-
cigarette users with cigarettes” were subjects who did not use an e-cigarette 
but consumed cigarettes, and “other ex−e-cigarette users” were subjects who 
did not use an e-cigarette or any cigarettes. The e-cigarette use behaviour at 
baseline was compared with the follow-up behaviour to evaluate if an 
individual’s e-cigarette use behaviour persisted or changed over time. 
Outcomes: changes in e-cigarette use behaviours and e-cigarette−related 
dependence measured using the Penn State Electronic Cigarette Dependence 
Index 
The authors concluded that findings suggest that the risk of relapse to 
cigarette smoking is low, and that e-cigarette-related dependence remains 
stable, in long-term e-cigarette users.291 




Harm The authors reported on the association between frequency of cigarette and 
alternative tobacco product use and depressive symptoms. 
Age mean (SD) years: 21 (2.3). Sex: 1919 males, 3,317 females 
Country: USA 
Data source; Texas college students. First six waves of the Marketing and 
Promotions across Colleges in Texas project (M-PACT). M-PACT is a 
prospective cohort study of Texas college students. M-PACT began in 
November 2014 with follow up at six-month intervals through May 2017 
Population size: 5,236 
Data collection period: 2014 to 2017 
E-cigarette, smoking and other related status: Past 30-day use of each 
product (cigarettes, refillable e-cigarettes, disposable e-cigarettes, hookah, 
cigars [including cigarillos and little cigars], and smokeless tobacco) was 
measured by the question, “During the past 30 days, have you used 
[product]?” Past 30-day use was a dichotomous measure (Yes/No coded as 
1/0 respectively). The survey included pictures of the tobacco products. To 
measure frequency of use, participants were asked, “On how many of the last 
30 days have you used such a product?” Frequency of use was modelled per 
every five days; i.e., the number of days used (range: 0–30) was divided by 
five to create a scaled variable (range: 0–6) and each unit of the scaled 
variable represented five days of use in the past 30 days 
Outcomes: Depressive symptoms were measured with the Center for 
Epidemiologic Studies Depression 10 scale (CES-D-10), a 10-item measure. 
Eight items asked about the frequency of a depressive symptom within the 
past seven days and were scored from 0 “rarely (less than 1 day)” to 3 “most 
of the time (5-7 days).” Two items asked about feeling hopeful or happy and 
were reverse coded. The scores were added to form a summary score with 
higher scores indicating greater frequency of depressive symptoms. The 
association between frequency of tobacco product use (cigarettes, e-
cigarettes, hookah, cigars, and smokeless) and depressive symptoms based 
on within-person comparisons from a young adult cohort with six waves of 
data from October 2014 through June 2017. Further, the association between 
e-cigarette type (i.e., refillable and disposable e-cigarettes) and depressive 
symptoms is examined, as well as dual use of cigarettes with another tobacco 
product. 
The authors concluded, following separate examination of used refillable and 
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different association for each type of e-cigarette when cigarettes were not 
also used. Dual use of cigarettes with another product was associated with 
higher depressive symptoms for most product combinations. However, 
infrequent dual use of disposable e-cigarettes and cigarettes may not be 
associated with depressive symptoms.298 




Harm The authors reported on the relationship between e-cigarette use and future 
cigarette initiation among never-smokers, and relapse among former 
smokers. 
Distant former combustible cigarette smokers who reported e-cigarette past-
30- 
Age mean (SD): 18 to 35 plus. Sex: 3,737 males, 4,348 females. Country: USA 
Data source: Population Assessment of Tobacco and Health Study 
Population size: 26,446 (Subpopulation 8085 reported on in this paper) 
Data collection period: 2 waves: 2013-2014 (baseline) and 2014-2015 (1-year 
follow-up) 
E-cigarette, smoking and other related status: In wave 1, respondents were 
asked, “Have you ever smoked a cigarette, even 1 or 2 puffs?” Respondents 
who replied yes were asked, “Do you now smoke cigarettes every day, some 
days, or not at all?” and “How many cigarettes have you smoked in your 
entire life?” Then all respondents who reported having ever smoked a 
combustible cigarette and who no longer smoked at all were asked, “About 
how long has it been since you completely quit smoking cigarettes?”. The 
authors defined distant former combustible cigarette smokers as adults who 
reported having ever smoked a combustible cigarette, having smoked equal 
to or more than 100 combustible cigarettes in their lifetime, no longer 
smoking combustible cigarettes, and having quit smoking combustible 
cigarettes equal to more than 5 years before completing the survey (n = 
2322). The authors defined never combustible cigarette smokers as adults 
who had never smoked a combustible cigarette, even 1 or 2 puffs 
Outcomes: day use (9.3%) and e-cigarette ever users (6.7%) were significantly 
more likely than never users (1.3%) to have relapsed to current combustible 
cigarette smoking at follow-up (p<0.001). Baseline never-smokers who 
reported e-cigarette past-30-day use at follow-up (25.6%) and ever use 
(13.9%) were significantly more likely than those who had never used e-
cigarettes (2.1%) to have initiated combustible cigarette smoking (p<0.001). 
Adults who reported past-30-day e-cigarette use (7.0%) and ever e-cigarette 
use (1.7%) were more likely than those who had never used e-cigarettes 
(0.3%) to have transitioned from never-smokers to current combustible 
cigarette smokers (p<0.001). E-cigarette use predicted combustible cigarette 
smoking in multivariable analyses controlling for covariates.290 
Device and products: Not reported 
Soar et al.293 
2019 
Harm The authors examined the relationship, in exclusive vapers, of levels of 
nicotine intake over time as nicotine e-liquid concentrations are reduced, i.e. 
nicotine absorption from e-cigarettes over a 12-month period. 
Age: the mean age was 43.81 (SD=9.19) years, Sex: 70% were male (n=19) 
Country UK. Ethnicity: 85% (n=23) were white British 
Data source: Recruited via social media (e.g. Twitter, Facebook) or were 





Author(s) year Possible 
benefit 
or harm 
Longitudinal cohort study papers dependency and abuse liability 
Population size: 32 
Data collection period: Baseline and a 12 month follow up point (between 
June 2015 and March 2017) 
E-cigarette, smoking and other related status: 32 exclusive electronic 
cigarette users (i.e. did not also smoke or use nicotine in any other form) 
Outcomes: Paired samples t-test indicated a significant reduction in the 
strength of e-liquid (mg/mL consumed over the 12 month period [t(26)=2.32, 
p=.03 95% CI [0.45,7.38] and a significant increase in daily e-liquid 
consumption (mL), [t(22)=−2.51, p=.02] 95% CI[−4.38,2.51]. Cotinine levels 
increased slightly over the 12 month period but this change was not 
statistically significant [t(24)=−1.21, p=.24], [CI -121.76-31.96]. self-reported 
nicotine concentrations in e-liquid declined significantly over time whilst 
volume of e-liquid consumed significantly increased. There was no change 
(and even a slight increase over time) in salivary cotinine levels. it therefore 
appears that whilst vapers reduce the nicotine concentration of their e-liquid, 
this has no effect on their nicotine intake since levels of nicotine absorption 
remain stable  
The authors concluded that although the sample of experienced vapers 
reduced the concentration of nicotine in their e-liquid over time, they 
maintained their nicotine intake, possibly through self-titration via more 
intensive puffing. Findings suggest that there may be little benefit in reducing 
nicotine e-liquid concentration, since this appears to result in higher e-liquid 
consumption, which may incur both a financial and health cost.293  
Device and products: Nicotine e-liquid concentration (mg/mL) mean (SD): 
Baseline: 13.83 (8.53); 12 months: 9.91 (6.48) 
Daily liquid consumption (mL) mean (SD): Baseline: 4.44 (2.86); 12 months: 
6.84 (6.45) 
Device Type mean (SD): Baseline: 2nd Generation n=1 (3.7), 3rd Generation 
n=17 (63.0), 3rd Generation & Sub-ohming n=8 (29.6). 12 months: 2nd 
Generation n=2 (7.4), 3rd Generation n=13 (48.1), 3rd Generation & Sub-
ohming n=11 (44.4). 
Wiernik et al.296 
2019 
Harm The authors reported on the relationship between e-cigarette use and 
depressive symptoms in smokers and former smokers. 
Age: 18 to 69 years at cohort inception. For the longitudinal analysis mean 
age (SD) was 49.3 (13.1) years. 
Sex: For the longitudinal analysis 45.4% of subjects who were included were 
male 
Country: France 
Data source: French Constances cohort. The Constances cohort includes 
volunteers randomly selected from French adults who are covered by 
CNAMTS (Caisse nationale d'assurance maladie des travailleurs salaries), 
which is the national health insurance of>85% of the French population. 
Recruitment of participants began mid-2012 and is still ongoing. Questions 
about e-cigarette were first introduced in the 2013 follow-up questionnaire, 
then every year and in the inclusion questionnaire from 2015 onwards. For 
cross-sectional analyses, the study population was composed of all subjects 
included from January 2015 to December 2016, without missing data for 
selected variables. For longitudinal analyses, the study population consisted 
of all subjects included from February 2012 to December 2014, with at least 
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as well as for depressive symptoms, age, sex, years of education and tobacco 
smoking status at baseline. 
Population size: 35,337 for cross sectional analysis, 30,818 for longitudinal 
analysis  
Data collection period: February 2012 to December 2016. For the longitudinal 
analysis the mean (SD) follow-up duration was 1.88 (0.65) years  
E-cigarette, smoking and other related status: ever and current e-cigarette 
use as well as the type of device used (i.e. disposable or rechargeable) were 
reported at study baseline. Participants were categorized into the following 
categories: never users, ex-users and current users of e-cig. Furthermore, 
nicotine concentration in mg/mL was collected at baseline in four categories: 
0 (i.e. e-liquid without nicotine) ;<6; 6–12; ≥13. Current e-cigarette use was 
also reported at follow-up, regardless of the date of inclusion. 
Outcomes: Cross-sectional and longitudinal associations were examined in 
this study group. Depressive symptoms were positively associated with e-
cigarette use in both cross-sectional and longitudinal analyses with a dose-
dependent relationship. In addition, nicotine concentration and depressive 
symptoms were positively associated. In longitudinal analyses (n=30,818), 
depressive symptoms at baseline were associated with current e-cigarette 
use at follow-up (2.02 [1.72–2.37]) with a similar dose-dependent 
relationship. These associations were mainly significant among smokers or 
former smokers at baseline. Furthermore, among smokers at baseline, 
depressive symptoms were associated with dual consumption at follow-up 
(1.58 [1.41–1.77]), whereas among former smokers, they were associated 
with either smoking only (1.52 [1.34–1.73]) or e-cigarette use only (2.02 
[1.64–2.49]), but not with dual consumption (1.11 [0.73–1.68]) at follow-up 
The authors concluded that depressive symptoms were positively associated 
with e-cigarette use in both cross-sectional and longitudinal analyses with a 
dose-dependent relationship. In addition, nicotine concentration and 
depressive symptoms were positively associated.296 
Device and products: For participants included from January 2015 to 
December 2016, ever and current e-cigarette use as well as the type of device 
used (i.e. disposable or rechargeable) were reported at study baseline. 
Participants were categorized into the following categories: never users, ex-
users and current users of e-cig. Furthermore, nicotine concentration in 
mg/mL was collected at baseline in four categories: 0 (i.e. e-liquid without 
nicotine);<6; 6–12;≥13. Current e-cigarette use was also reported at follow-
up, regardless of the date of inclusion. 
Table 75: Longitudinal cohort study papers on cardiovascular disease, benefits or harms 
Author(s) year Possible 
benefit 
or harm 
Longitudinal cohort study papers cardiovascular disease 








The authors reported on the relationship between smokers with a diagnosis 
of hypertension and those who quit or reduced tobacco consumption by 
switching to e-cigarettes, and long-term improvement in resting blood 
pressure and in level of blood pressure control. 
Age years (SD): E-Cigarette Group 53.5 (+/-6.3) Control Group 54.2 (+/-7.5) 
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Data source: A medical records review of patients with hypertension was 
conducted to identify patients reporting regular daily use of e-cigarettes on at 
least two consecutive follow-up visits. Data from a second group of age-, sex-
matched patients who reported to be regular smokers on at least two 
consecutives follow-up visits was included as a reference group. Patients in 
both study groups had to have similar weight (<5 kg) and systolic BP (<10 
mmHg) fluctuations between pre-baseline and baseline visits. Data from four 
visits were collected and analysed. At outpatient clinic visit patients were 
assessed for smoking history, systolic and diastolic blood pressure, heart rate, 
and body weight. Any patients with a known cause of secondary hypertension 
were excluded. The forty-three patients in the electronic cigarette group (26 
male, 17 females) reported regular daily use of e-cigarettes at two 
consecutive follow-ups. E-cigarette use ranged from 10 to 14 months, with 
36/43 (83.7%) patients using them for more than a year.  
Population size: A total of 89 regular smokers with a diagnosis of 
hypertension and on anti-hypertensive drugs at baseline. E-Cigarette Group 
(n = 43). Control Group (n = 46).  
Data collection period: Year not reported. Data from four visits were collected 
and analysed: specifically, data from chart review immediately preceding 
baseline visit, baseline visit and two consecutive follow-up visits (follow-up 
visit 1 and 2). Pre-baseline visits were carried out at 6–12 months prior to 
baseline visits. Follow-up visit 1 and 2 were carried out at 6 (+/-1) and 12 (+/-
2) months after baseline visit 
E-cigarette, smoking and other related status: hypertensive smokers who quit 
or reduced substantially their tobacco consumption by switching to e-
cigarettes. Patients reporting regular daily use of e-cigarettes on at least two 
consecutive follow-up visits were eligible to be included in the study 
Outcomes: The routine approach to anti-hypertensive treatment was 
employed and included a combination of drugs that work on different 
pathophysiological pathways in order to maximize blood pressure control. 
Where appropriate diuretics, vasodilators, sympatholytics, and renin-
angiotensin-aldosterone system blockers are prescribed. Changes to 
medications were made after review of both blood pressure office 
measurements and blood pressure home readings and were recorded. Self-
reported adherence to medications was assessed at each visit. Changes in 
smoking behaviour and patterns of e-cigarette use: A marked reduction in 
conventional cigarette consumption was observed in regular daily e-cigarette 
users, their mean (+/-SD) cigarettes/day use decreasing from 20.2 (+/-5.0) at 
baseline to 2.6 (+/-2.9) at follow-up visit 1 and to 1.8 (+/-2.0) at follow-up visit 
2, respectively (p < 0.001 for both visits). No significant reduction in 
conventional cigarette consumption was observed in the reference group. 
Dual usage was reported by 23/43 (53.5%) patients at follow-up visit 1 and 
22/43 (51.2%) at follow-up visit 2, respectively. A significant reduction in 
conventional cigarette consumption was also observed in dual users, with 
their mean (+/-SD) cigarettes/day use decreasing from 21.5 (+/-6.9) at 
baseline to 4.8 (+/-2.3) at follow-up visit 1 and to 3.7 (+/-1.1) at follow-up visit 
2, respectively (p < 0.001 for both visits). More than a 75% reduction from 
baseline in cigarettes/day consumption was reported by 14/23 (60.9%) dual 
users at follow-up visit 1 and by 17/22 (77.3%) at follow-up visit 2, 
respectively. A significant reduction in median systolic blood pressure (p < 
0.001) and diastolic blood pressure (p = 0.006) from baseline was observed at 
follow-up visit 2 in the e-cigarette group. In contrast, no significant change in 
blood pressure was observed in the reference group. The observed 
reductions in systolic blood pressure and diastolic blpod pressure were 
significant (p < 0.001, both for both measures) when comparing the e-
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subgroup analysis) apart from reduced cigarette consumption and systolic 
blood pressure at 12 months—no significant changes from baseline measures 
were observed299 
The authors concluded that regular e-cigarette use may aid smokers with 
arterial hypertension in reducing or abstaining from cigarette smoking, with 
only trivial post-cessation weight gain (a finding reported on in the paper). 
The reduction in cigarette smoking and weight and the taking up of e-
cigarettes resulted in improvements in systolic and diastolic blood pressure as 
well as better blood pressure control.299 
Device and products: Not reported 




The authors reported-on cardiovascular and respiratory health outcomes 
blood pressure, heart rate, body weight, lung function, respiratory symptoms, 
fractional exhaled breath nitric oxide (FeNO), exhaled carbon monoxide 
(eCO), and high-resolution computed tomography of the lungs. 
Age: mean (+/-SD) age of 29.7 (+/-6.1) years. Sex: Male 11; Female 5. Country: 
Italy 
Data source: Adult e-cigarette users (≥18 years old) were identified amongst a 
pool of regular vape shops customers. Vape shop owners who helped in a 
previous study were instructed to ask their regular clients a few questions 
about smoking history and e-cigarette use patterns. 
Population size: 16 
Data collection period: June 2013 to September 2013 and data collection 
completed in March 2017. Aside from the baseline visit three additional 
follow-up visits were scheduled yearly for up to 3.5 years; follow-up visits 1 
(F/up1), 2 (F/up2) and 3 (F/up3) were carried out at 12 (+/-1), 24 (+/-2) and 
42 (+/-2) months after baseline visits, respectively 
E-cigarette, smoking and other related status: Customers who had never 
smoked or who reported having smoked less than 100 cigarettes in their 
lifetime were defined as never smokers and considered for inclusion. They 
also had to be daily e-cigarette users of ≥3 months. Age- and sex-matched 
non-smoking controls (and not using e-cigarettes) were selected from 
hospital staff and included as a reference (control) group. Vapers recruited 
into the study had generally a short duration of regular e-cigarette use prior 
to entering the study (on average 8 months) and vaporized, on average, only 
a modest amount of e-liquid (about 4 ml/die),  
Outcomes: No impairment in the health measures evaluated in any of the e-
cigarette users in the study were reported. In a small sample of young-adult 
never-smoking, daily e-cigarette users who were carefully followed for 
approximately 3½ years, the authors found no decrements in spirometric 
indices, development of respiratory symptoms, changes in markers of lung 
inflammation in exhaled air or findings of early lung damage on high-
resolution computed tomography, when compared with a carefully matched 
group of never-smoking non-e-cigarette users. Even the heaviest e-cigarette 
users failed to exhibit any evidence of emerging lung injury as reflected in 
these physiologic, clinical or inflammatory measures. Moreover, no changes 
were noted in blood pressure or heart rate. Since the e-cigarette users who 
we studied were never smokers, potential confounding by inhalation of 
combustion products of tobacco were obviated. 
The authors concluded that although it cannot be excluded that some harm 
may occur from e-cigarettes at later stages of the e-cigarette users life, this 
study did not demonstrate any health concerns associated with long-term use 
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Harm The authors examined nicotine replacement therapy (including e-cigarettes) 
as a safe alternative to smoking in plastic surgery patients. 
Age: Average age in years was: non-nicotine users (48.5), smokers remaining 
abstinent (48.5), smokers (49.2), and non-smoker nicotine users 
Sex: Not reported. Country: USA  
Data source: All patients undergoing major surgery at a single outpatient 
ambulatory day surgery centre for a 5-year period. 
Population size: Four hundred seventy patients were included in the study. 
Patient count in each group was group A n = 380, group B n = 48, group C n = 
32, and group D n = 10.  
Data collection period: 1/1/2012-12/2016. Data were compiled in 2017. 
Patients were followed by the surgeons for 6 weeks to monitor for 
postoperative complications. 
E-cigarette, smoking and other related status: Patients were divided into 4 
groups: never smoked (group A), quit smoking with negative urine test (group 
B), continued to smoke (group C), and quit smoking with positive urine test 
(group D). Patient count in each group was group A n = 380, group B n = 48, 
group C n = 32, and group D. tobacco usage and nicotine replacement 
methods were self-reported and individual usage habits and doses of the 
patients were not captured. 
Outcomes: The complications found were wound dehiscence, flap loss (both 
major and minor), capsule formation (Baker 3 or 4), hematoma, and seroma. 
Measures of urine cotinine, a nicotine metabolite were assessed. Nicotine 
replacement carries similar risks as continued smoking and is not as safe as 
abstinence in the perioperative period in plastic surgery patients. 
Importantly, patients who stopped smoking for the surgery had equivalent 
risk for postoperative complications as patients who had never smoked. 
However, it should be noted that differentiation between the various nicotine 
replacement therapies, specifically e-cigarettes could not be assessed.  
The authors concluded that nicotine replacement using e-cigarettes carries 
similar risks as continued smoking and is not as safe as abstinence in the 
perioperative period in plastic surgery patients. Importantly, patients who 
stopped smoking for the surgery had equivalent risk for postoperative 
complications as patients who had never smoked.301 
Device and products: Not reported 
Table 76: Longitudinal cohort study papers on respiratory diseases, benefits or harms 
Author(s) year Possible 
benefit 
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The authors undertook a retrospective review of changes in spirometry data, 
airway hyperresponsiveness, asthma exacerbations, and subjective asthma 
control in smoking asthmatics who switched to regular e-cigarette use. 
Age: years 37.8 (±12.3) Sex: 11 male, 7 females Country: Italy 
Data source: A medical records review of patients with hypertension was 
conducted to identify patients reporting regular daily use of e-cigarettes on at 
least two consecutive follow-up visits. Data from four visits were collected 
and analysed: data from chart review immediately preceding baseline visit, 
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were carried out at 6–12 months prior to baseline visits. Follow-up visit 1 and 
2 were carried out at 6 (+/-1) and 12 (+/-2) months after baseline visit.  
Population size: 18. Data collection period: September 2012 to December 
2013 
E-cigarette, smoking and other related status: At outpatient clinic visit 
patients were assessed for smoking history, systolic (SBP) and diastolic blood 
pressure, heart rate, and body weight. Any patients with a known cause of 
secondary hypertension were excluded. The patients in the electronic 
cigarette group reported regular daily use of e-cigarettes at two consecutive 
follow-ups. E-cigarette use ranged from 10 to 14 months, with patients using 
them for more than a year. Of the 18 electronic cigarette users identified all 
were former tobacco smokers of about 20 conventional tobacco 
cigarettes/day. There were 10 single and eight dual users by the time of their 
most recent follow-up visit (follow-up visit 2). All dual users smoked ≤5 
conventional tobacco cigarettes/day. All patients initially switched to a 
cigarette-like model, but the majority went on to adopt a personal vaporizer. 
Duration of regular electronic cigarette use ranged from 10 to 14 months, 
with twelve patients using them for more than a year. All patients took a 
stable dose of inhaled corticosteroids, long-acting (LABA) and on-demand 
short-acting β2 agonist as well as on-demand short-acting β2 agonist 
throughout the observation period. None of the patients included had ever 
received a significant modification in anti-asthma therapy from their pre-
baseline visit. 
Outcomes: lung function, bronchial hyperresponsiveness (BHR) or Juniper’s 
Asthma Control Questionnaire scores, spirometry with parameters of forced 
expiratory flow in 1 second (FEV1), forced vital capacity (FVC), expiratory ratio 
(%FEV1/FVC) and forced expiratory flow at the middle half of the FVC 
(FEF25%-75%); and (iv) in some subjects bronchial provocation tests assessing 
Airway Hyperresponsiveness (AHR) with methacholine were also conducted 
as previously described  
The authors reported improvements in asthma control, airway 
hyperresponsiveness, and pulmonary function in 18 asthmatic smokers who 
quit or dramatically reduced their tobacco consumption by switching to e-
cigarettes.302 
Device and products: All patients initially switched to a cigarette-like model, 
but the majority went on to adopt a personal vaporizer 








The authors reported on the relationship between persisting long-term 
benefits of smoking abstinence and reduction in asthmatic smokers who 
have switched to e-cigarettes. 
Age: 38.0 (+/- 12.3). Sex: 10 males, 6 females. Country: Italy 
Data source: A medical records review of patients with hypertension was 
conducted to identify patients reporting regular daily use of e-cigarettes on at 
least two consecutive follow-up visits. An asthma cohort of adult daily 
electronic cigarette users was identified. Data from four visits were collected 
and analysed: data from chart review immediately preceding baseline visit, 
baseline visit and two consecutive follow-up visits (follow-up visit 1 and 2). 
Pre-baseline visits were carried out at 6–12 months prior to baseline visits. 
Follow-up visit 1 and 2 were carried out at 6 (+/-1) and 12 (+/-2) months after 
baseline visit.  
Population size: 16. Data collection period: October 2013 to January 2015 
E-cigarette, smoking and other related status: Before switching to e-
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dual users n=6 reported smoking pack years 29.8 (SD +/- 11.1). At 24-month 
follow-up all patients reported using 1.5 (SD +/-1.95) cigarettes per day.  
Outcomes: Juniper’s Asthma Control Questionnaire (ACQ) score, number of 
exacerbations from the previous follow up visit (an asthma exacerbation was 
defined as an increase in respiratory symptoms requiring a short course of 
oral or parenteral corticosteroids), simple spirometry with parameters of 
forced expiratory flow in 1 second (FEV1), forced vital capacity (FVC), and 
forced expiratory flow at the middle half of the FVC (FEF25%-75%); and in 
some subjects bronchial provocation tests assessing airway 
hyperresponsiveness (AHR) with methacholine. Smoking abstinence was 
defined as complete self-reported abstinence from tobacco smoking (not 
even a puff) since the previous study visit. This was biochemically verified at 
F/up 3 byexhaled carbon monoxide levels of ≤7 ppm. Asthmatic e-cigarette 
users in this category are classified as Quitters (Single users). Smoking 
reduction was defined as sustained self-reported reduction (at least >50%) in 
the number of cigarettes per day from baseline. Asthmatic electronic 
cigarette users in this category are classified as Reducers (Dual users). E-
cigarette users who were not categorized in the above categories were 
classified as Relapsers.  
The authors concluded that regular e-cigarette use ameliorates asthma 
outcomes, that these beneficial effects may persist in the long term, that 
similar benefits could also be noted in dual users, and that regular e-cigarette 
use was well tolerated.303 
Device and products: For all patients, first-time purchase was a “cig-alike” e-
cigarette model, but the majority went on to adopt refillable “pen-like” e-
cigarettes. Duration of regular e-cigarette use ranged from 20 to 26 months, 
with ten patients using them for at least 2 years. All participants were using 
standard refillable e-cigarettes by the end the study. The preferred nicotine 
strength of their e-liquid was 9 mg/ml and 18 mg/ml, which was consumed by 
62.5% (10/16) and 18.8% (3/16) of e-cigarette users respectively. Most of the 
participants consistently preferred tobacco flavours over other flavours at 
final follow up visit. 








The authors reported their evidence for harm reduction in smokers with 
chronic obstructive pulmonary disease who switch to using e-cigarettes. 
Sex: Electronic-cigarettes cases 20 males, 4 females comparable controls 21 
males, 3 females. Country: Italy 
Data source: A medical records review of patients with hypertension was 
conducted to identify patients reporting regular daily use of e-cigarettes on at 
least two consecutive follow-up visits. Data from four visits were collected 
and analysed: data from chart review immediately preceding baseline visit, 
data from the baseline visit and two consecutive follow-up visits (follow-up 
visit 1 and 2). Pre-baseline visits were carried out at 6 to 12 months prior to 
baseline visits. Follow-up visit 1 and 2 were carried out at 6 (+/-1) and 12 (+/-
2) months after baseline visit.  
Population size: Chronic obstructive pulmonary disease e-cigarettes users 
n=24 and comparable controls n=24 Total 48 
Data collection period: September 2013 to December 2015 
E-cigarette, smoking and other related status: Patients reporting regular daily 
use of e-cigarettes (and if at all conventional tobacco cigarettes) at least two 
follow-up visits over a 24-months period were eligible for inclusion. A second 
group of age- and sex-matched chronic obstructive pulmonary disease control 
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same observation period was selected from four participating clinics as a 
reference (control) group. 
Outcomes: The primary outcomes of interest were: a) reduction in cig/day 
consumption; and b) number of exacerbations in the previous 12 months at 
each of the visits and how they may have changed over the 24-month period 
in the e-cigarettes group compared to the control group. Secondary 
outcomes of interest were changes from baseline to the final follow-up visit 
in: lung function; chronic obstructive pulmonary disease Assessment Test 
(CAT) scores, and 6-minute walk distance (6MWD). In addition, changes in the 
relative proportion of chronic obstructive pulmonary disease GOLD stages 
throughout the 24-months observation period were reported for both study 
groups as well as the change in mean FEV1 from baseline to F/up2.  
The authors concluded that a marked reduction in cigarette consumption was 
observed in e-cigarette users. A significant reduction in chronic obstructive 
pulmonary disease exacerbations was reported in the chronic obstructive 
pulmonary disease e-cigarette user group, with their mean (±standard 
deviation) decreasing from 2.3 (±1) at baseline to 1.8 (±1; p=0.002) and 1.4 
(±0.9; p<0.001) at follow-up visit 1 and follow-up visit 2, respectively. A 
significant reduction in chronic obstructive pulmonary disease exacerbations 
was also observed in e-cigarette users who also smoked conventional 
combustible tobacco cigarettes (i.e. dual users). Chronic obstructive 
pulmonary disease symptoms and ability to perform physical activities 
improved statistically in the e-cigarettes group at both visits, with no change 
in the control group. Age: Electronic-cigarettes users 66.9 (±6.7) chronic 
obstructive pulmonary disease controls 65.3 (±5.5)304 
Device and products: Not reported 
Bowler et al.305 
2017 
Harm The authors reported on the relationship between e-cigarette use in USA 
adults at risk for, or with, chronic obstructive pulmonary disease. 
Age: COPD Gene group aged 45 to 80 years, SPIROMICS group age 40 to 80 
years.  
Sex: COPD Gene: Never e-cigarette use (N = 3,117) Current e-cigarette use (N 
= 127) Former e-cigarette use (N = 291) SPIROMICS Never e-cigarette use (N = 
888) Current e-cigarette use (N = 55) Former e-cigarette use (N = 117) 
Country USA  
Data source: The NIH-sponsored multicentre COPD Gene study includes 
10,294 subjects enrolled from 2008 to 2011 who were self-reported non-
Hispanic white or African-American, and with a history of at least 10 pack-
years of conventional cigarette smoking (N = 10,192) or no conventional 
cigarette smoking (≤ 1 pack-year lifetime; N = 102). The NIH-sponsored 
multicentre SPIROMICS is a cohort study that enrolled 2,982 subjects 
between November 2011 and January 2015. Inclusion criteria included age 40 
to 80 years and at least 20 pack-years of conventional cigarette smoking (N = 
2,780) or never tobacco smokers (N = 202). 
Population size: COPD Gene (N = 3,536) and SPIROMICS (N = 1,060). In COPD 
Gene, conventional cigarette smoking was assessed at both baseline and 5-
year follow-up visit. In SPIROMICS there was not a sufficient number of 
subjects who had both long-term follow-up visits (> 1 year) and e-cigarette 
questionnaire data; thus data from these subjects was cross-sectional and not 
reported here. 
Data collection period: 2010 to 2016 
E-cigarette, smoking and other related status: A total of 419 (12%) subjects in 
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Longitudinal cohort study papers respiratory diseases 
cigarettes. However, only 128 of 3536 (4%) and 55 of 1060 (5%) were 
currently using e-cigarettes at the time of study visits, with no significant 
difference in the percentage of subjects currently using e-cigarettes at the 
time of the survey 2014 to 2016. The duration of e-cigarette use in current 
smokers was longer in former e-cigarette users, but this difference was 
significant only in the SPIROMICS cohort.  
Outcomes: In both cohorts, COPD was defined as post-bronchodilator ratio of 
forced expiratory volume in one second (FEV1) to forced expiratory volume 
(FVC) < 0.70. Electronic-cigarette use was associated with worse pulmonary-
related health outcomes, but not with cessation of smoking conventional 
tobacco cigarettes. 
The authors concluded that they could find no evidence supporting the use of 
e-cigarettes as a harm reduction strategy among current smokers with, or at 
risk for, chronic obstructive pulmonary disease.305 
Device and products: Not reported 
Flacco et al.306 
2019 
Harm The authors reported on the relationship between e-cigarettes and a range 
of possibly smoking-related diseases – such as chronic obstructive 
pulmonary disease, myocardial infarction and/or angina, congestive heart 
failure, transitory cerebrovascular ischaemia or stroke, and any cancer – and 
changes in tobacco use. 
Age: 30-75 years. Sex: 56 >3% males. County: Italy 
Data source: Potential participants were recruited via general practitioners, e-
cigarette shops, internet advertisements, and social networks 
Population size: 228 e-cigarette users (all ex-smokers), 471 tobacco smokers, 
216 dual users.  
Data collection period: 2013 to 2017. The follow-up period was proposed to 
continue up to 72 months. The results reported here are after four years 
follow-up. 
E-cigarette, smoking and other related status: smokers of >=1 tobacco 
cigarette/day (tobacco smokers); users of any type of e-cigarette inhaling 
>=50 puffs weekly (e-cigarette users); users of both tobacco and e-cigarette 
(dual users). At recruitment (2013) recruited adults (30-75 years) who were: 
(a) smokers of ≥ 1 tobacco (only) cigarette daily for ≥ 6 months (tobacco 
smokers); (b) users of any type of e-cigarette for ≥ 6 months (e-cigarette 
users); (c) users of both tobacco and e-cigarette for ≥ 6 months (dual users). 
Outcomes: possibly smoking-related diseases (i.e. chronic obstructive 
pulmonary disease, myocardial infarction and/or angina, congestive heart 
failure, transitory cerebrovascular ischemia or stroke, any cancer.; validated 
through hospital discharge data or visit in 62.6% of the sample); 4-year 
tobacco abstinence; number of tobacco cigarettes/day. More specifically 
effectiveness outcomes were: (a) the rate of quitting of all products (either 
tobacco and/or e-cig, for >30 days); (b) the rate of abstinence/cessation from 
tobacco smoking at 48 months; and (c) the change in the daily number of 
tobacco cigarettes. Health outcomes were: (a) the rate of possibly smoking-
related diseases; and (b) the change in self-reported health (assessed through 
the final item of the Italian version of the EuroQol EQ-D5L). 
Data were collected by phone and/or internet, and carbon monoxide levels 
tested in 50% of those declaring tobacco abstinence. A possibly smoking-
related diseases was observed in 73 subjects (8.0%). No differences emerged 
across groups in possibly smoking-related diseases rates, with negligible 
variations in self-reported health. Of e-cigarette users, 63.6% remained 
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different rates of tobacco (33.8% vs. 26.8%) and all-product (20.2% vs. 19.4%) 
cessation, and a similar decrease in cigarettes/day. Almost 40% of the sample 
switched at least once (tobacco smokers: 17.2%; dual users: 81.9%).  
The authors concluded that after 4 years, a scarce, non-significant harm 
reduction was observed among e-cigarette users and dual users of e-
cigarettes and conventional tobacco cigarettes. The complete switch to e-
cigarettes may help tobacco quitters remain abstinent, but e-cigarette use in 
addition to tobacco did not increase the likelihood of smoking cessation or 
reduction. The rates of smoking-related diseases were similar in e-cigarette 
users, dual users (those who used both e-cigarettes and conventional tobacco 
cigarettes), and conventional tobacco cigarette smokers.306 
Device and products: Not reported 
Table 77: Longitudinal cohort study papers on oral diseases, benefits or harms 
Author(s) year Possible 
benefit 
or harm 
Longitudinal cohort study papers oral diseases 








The authors reported on the changes in periodontal health in individuals 
who had ceased tobacco cigarette consumption and had started to use e-
cigarettes, and a self-assessed need to smoke combustible cigarettes. 
Age: average age 31± 9. Sex: 89 men and 21 women. Country Italy 
Data source: Clinical observational study at the Unit of Periodontology and 
Oral Hygiene of Calabrodental Clinic. Population size: n=110 
Data collection period: This study was conducted for 120 days on each 
patient. Clinical examinations were performed at 3 different check-points: T0 
(baseline), T1 (after 60 day), and T2 (after 120 days). The 1st selection was 
performed by choosing those subjects which started to use e-cigarette 
approximately from 4±1 month, before the start of the study. Smokers were 
divided into 2 groups, according to the number of years of smoking by each of 
them: group 1 (less than 10 years of tobacco smoking), group 2 (more than 10 
years of tobacco smoking). All subjects were asked to abstain from tobacco 
cigarettes for the entire duration of the study. No year of study provided. 
E-cigarette, smoking and other related status: All the recruited patients, who 
switched to the e-cigarettes, reported that they have previously smoked only 
combustible cigarettes with high amount of nicotine (among 0.8–1mg per 
cigarette). All patients included in the study stated that they use e-cigarettes 
with an average content of 0.25mL of liquid containing a total amount of 
nicotine equivalent to 18mg: each cycle of use of the e-cigarette contains on 
average 4.5mg of nicotine, although the calculation should not consider the 
dispersed nicotine part, equal to about half of the basic content. The subjects 
enrolled in the study said they had smoked in the past an average of 20 
cigarettes a day, absorbing an average of 16mg of nicotine per. day. With the 
e-cigarette, if subject smokes the same number of cigarettes in a day it would 
be absorbed approximately 7mg of nicotine. 
Outcomes: The oral cavity was divided in 4 areas: upper right and upper left 
jaw, lower right and lower left jaw. Each patient underwent an oral 
examination to investigate the following parameters: plaque index, 
periodontal bleeding index, and papillary bleeding index. Patients also 
completed a self-assessment on: general health status; smell perception; 
taste perception; frequency of respiratory diseases; and need to smoke.  
The authors stated that their observations revealed an interesting, growing 
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bleeding index, in the 110 subjects considered in this study. They reported a 
constant reduction of bacterial plaque on teeth surfaces from baseline at T0 
to the end of the observational period at T2. More precisely, group 1 (less 
than 10 years smoking) subjects showed a homogeneous presence of a thin 
film of plaque at T0, which visibly decreased towards T1 until it completely 
disappeared in all of the group 1 subjects at T2. The result was more marked 
in group 2 subjects (more than 10 years smoking), and was characterised by a 
huge presence of plaque at T0. The authors also noted that many patients 
had reported an interesting reduction in the need to smoke.307 










The authors reported on the impact of cigarette smoking, e-cigarette use, 
and non-smoking on dental and periodontal health: full-mouth plaque index, 
bleeding on probing, clinical attachment loss, and probing depth were 
measured at baseline and at 3 and 6 months after full-mouth ultrasonic 
scaling (without root surface debridement). The numbers of missing teeth 
were also recorded. 
Age (range) years: 25 to 60 years mean (SD) cigarette smokers 36.4 ± 2.8, e-
cigarette vaping participants 32.5 ± 4.8, non-smoking individuals 32.6 ± 3.5 
Sex: All males. Country: Saudi Arabia. Data source: Clinic attendees 
Population size: cigarette smokers n=30, e-cigarette vaping participants n=28 
non-smoking individuals n=31 
Data collection period: June 2016 and February 2017 
E-cigarette, smoking and other related status: Cigarette smokers: individuals 
who were smoking at least five cigarettes daily since at least 12 months, e-
cigarette vaping participants: individuals without a previous history of 
tobacco usage who had been vaping exclusively e-cigarettes for at least 1-
year, non-smoking individuals who reported to have never used any form of 
tobacco product 
Outcomes: full-mouth plaque index, bleeding on probing, clinical attachment 
loss, and probing depth and number of missing teeth 
The authors stated that a range of periodontal inflammatory parameters 
were worse in cigarette smokers than in individuals who vape e-cigarettes 
and in never-smokers following full-mouth ultrasonic scaling.308 
Device and products: Not reported 
Atuegwu et al. 
309 
2019b 
Harm The authors reported on the relationship between e-cigarettes and 
periodontal disease, specifically gum disease and bone loss around teeth.  
Age: 18 years of age or older. Sex: 8,791 males, 9,468 females. Country USA 
Data source: Population Assessment of Tobacco and Health study  
Population size: 18,259 persons with no history of gum disease at baseline 
and with full relevant data. 329 participants who reported longitudinal 
electronic nicotine product use, 8298 participants who reported non-
longitudinal electronic nicotine product use and 9632 participants who 
reported never electronic nicotine product use. 
Data collection period: 12 September 2013 to 14 December 2014 (wave 1), 23 
October 2014 to 30 October 2015 (wave 2), and 19 October 2015 to 23 
October 2016 (wave 3). Three year follow up.  
E-cigarette, smoking and other related status: Regular electronic nicotine 
product users were participants who said yes to using “electronic nicotine 
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cigars, e-pipes, e-hookahs and hookah pens) fairly regularly every day or 
some days. Longitudinal electronic nicotine product users were participants 
who were regular electronic nicotine product users in all the three waves of 
the PATH survey. Longitudinal conventional cigarette users were participants 
who have smoked more than 100 cigarettes in their lifetime and smoked 
every day or someday in all the three waves of the PATH survey. 
Outcomes: Participants with no history of gum disease who used electronic 
nicotine products regularly every day or some days for a year or more had 
increased odds of being diagnosed with gum disease, even after controlling 
for conventional cigarette smoking and other known risk factors. The 
participants who used electronic nicotine products also had an increased 
odds of reporting bone loss around teeth which is indicative of advanced 
periodontal disease. The odds were higher for participants who had a history 
of marijuana use or any illicit and non-prescribed drug use. 
The hypothesis in this study was that the use of electronic nicotine products 
would be associated with increased odds of gum disease and bone loss 
around teeth, even after controlling for use of conventional combustible 
tobacco cigarettes and other known risk factors. Sub-group analysis was 
performed to examine this association in participants who had a history of 
marijuana use and a history of illicit or non-prescribed drug use. The authors 
concluded that this was the case.309 
Device and products: Not reported 
Table 78: Longitudinal cohort study papers on developmental and reproductive effects, benefits or 
harms 
Author(s) year Possible 
benefit 
or harm 




Harm The authors reported on the relationship between e-cigarette use in 
pregnant women and risk of small-for-gestational-age births. 
Age (range) years: 18 to over 28 years. Sex: All females. Ethnicity: Country: 
USA 
Data source: volunteers among patients seen at a prenatal clinic serving low-
risk pregnant women (those without underlying medical conditions or co-
morbidities and without antenatal complications)  
Population size: 248 pregnant women. Data collection period: April 2015 to 
May 2017  
E-cigarette, smoking and other related status: current e-cigarette use among 
pregnant women most (75%) of which were also concurrent cigarette 
smokers. Status was assessed by self-report exposure to tobacco products 
and non-invasive biomarker assays  
Outcomes: birth weight and risk of small-for-gestational-age in 232 
participants 
The authors concluded that e-cigarette use is associated with an increased 
risk of small-for-gestational-age births.310 







Appendix 5: Interventional trials papers by adapted Academies of 
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Interventional trial papers dependency and abuse liability 
Eissenberg320 
2010 
No benefit The authors reported on the relationship between nicotine delivery and craving 
suppression, heart rate, and subjective effects. 
Age mean years (SD): 29.8 (10.7). Sex: 11 males, 5 females  
Country: USA. Ethnicity: 8 non-white 
Duration of trial: Two hours Population size: 16  
Year of data collection: Not reported 
E-cigarette, smoking and other related status: Smokers naïve to e-cigarette. 
Mean cigarettes/day=18.5, SD=2.2 
Intervention and research design: Participants were instructed to puff normally 
and then puffed ad libitum 10 times (30-s inter puff interval) from the product 
of the day (bout 1). At 5, 15, 30 and 45 minutes after the first puff, subjective 
measures were completed, and blood sampled. At time +60 minutes 
assessments were repeated, product was administered (bout 2), and identical 
subsequent assessments completed 
Outcomes: Plasma nicotine and ‘craving for a cigarette/nicotine’, heart rate 
The authors concluded that relative to a tobacco cigarette, 10 puffs from an e-
cigarette with a 16 mg nicotine cartridge delivered little to no nicotine and 
suppressed cravings less effectively. Results on heart rate were not reported.320 
Device and products: Own brand cigarettes, sham smoking (puffing an unlit 
cigarette), ‘NPRO’ (NJOY, Scottsdale, Arizona, USA) with a 16 mg nicotine 
cartridge, or ‘Hydro’ (Crown Seven, Scottsdale, Arizona, USA) with a 16 mg 
nicotine cartridge. Cartridge flavour (menthol or regular) was chosen to match 
participant’s preferred cigarette flavour. A new cartridge (within its expiration 




Benefit The authors reported on the relationship between own-brand cigarettes, two 
types of e-cigarette devices, and a sham (unlit cigarette) with plasma nicotine 
and carbon monoxide (CO) concentrations, heart rate, and a range of subjective 
effects. 
Age years (SD): 18 to 55 years. Sex: Not reported. Country: USA 
Duration of trial: Four sessions. Eight-day interval between sessions 
Data source: men and women recruited from the Richmond, Virginia area USA 
Population size: 32. Year of data collection: Not reported 
E-cigarette, smoking and other related status: Participants smoked at least 15 
cigarettes per day (mean, 22 cigarettes per day; SD, 8.8) 
Outcomes: Plasma nicotine and carbon monoxide concentration, heart rate, and 
subjective effects – from the Hughes and Hatsukami questionnaire were 
assessed. Subjective effects included anxious craving a cigarette 
depression/feeling blue, difficulty concentrating, drowsy, hunger, impatient, 
irritability/frustration/anger, restless, desire for sweets, urge to smoke). Direct 
effects of nicotine (confused, dizzy, headache, heart pounding, lightheaded, 
nausea, nervous, salivation, sweaty, weak). Direct effects of tobacco (satisfying, 










Interventional trial papers dependency and abuse liability 
like own brand, feel like own brand, harsh as own brand, mild as own brand, 
smoke another cigarette RIGHT NOW) 
Own brand significantly increased plasma nicotine and CO concentration and 
heart rate within the first five minutes of administration whereas the devices 
tested (NPRO e-cigarette, Hydro e-cigarette, and sham smoking) did not 
Intervention and research design: four independent Latin-square ordered 
conditions that differed by product. Participants took 10 puffs at two separate 
times during each session 
The authors concluded that in acute testing conditions, neither of the e-
cigarettes exposed users to measurable levels of nicotine or carbon monoxide, 
although both suppressed nicotine/tobacco abstinence symptom ratings.311 
Device and products: own brand cigarette, “NPRO” electronic cigarettes (NPRO 
e-cigarette; 18 mg cartridge), “Hydro”e-cigarettes (Hydro e-cigarette; 16 mg 






The authors reported on the relationship between e-cigarettes and effects on 
desire to smoke, withdrawal symptoms, and cognition. The study aimed to 
explore whether e-cigarettes can reduce desire to smoke and also reduce 
abstinence-related withdrawal symptoms over a 20-minute period.  
Age mean years (range): 28.8 (18 to 52). Sex: 43 males, 43 females. Country: UK 
Duration of trial: 20 minutes. Following abstinence from smoking for at least 1 
hour, participants completed the Fagerstrom Test of Nicotine Dependence to 
assess six nicotine withdrawal symptoms: depression, irritability, anxiety, 
restlessness, hunger, poor concentration at baseline (T1), 5 (T2) and 20 (T3) 
minutes after using (or just holding) the electronic cigarette ad libitum for 5 
minutes. 
Data source: Not reported. Population size: 86. Data collection year: Not 
reported  
E-cigarette, smoking and other related status: e-cigarette naive smokers 
Intervention and research design: Subjects were randomly allocated to either 
18mg nicotine e-cigarette (nicotine), 0 mg e-cigarette (placebo; nicotine and 
placebo conditions administered single-blind) or just hold the e-cigarette (just 
hold) condition. Outcomes were assessed 20 minutes after exposure.  
Outcomes: Desire to smoke, Mood and Physical Symptoms Scale (MPSS) 
(depression, irritability, anxiety, restlessness, hunger, poor concentration), 
Letter Cancellation Task (a quick measure of attention/speed of processing and 
visual–spatial scanning ability) and the Brown–Peterson Working Memory.  
The authors concluded that desire to smoke and some aspects of nicotine 
withdrawal were significantly reduced 20 (but not 5) minutes after e-cigarette 
use; in this respect, the nicotine e-cigarette was superior to placebo in males 
but not in females. Nicotine derived via use of e-cigarettes also improved 
working memory performance, particularly at the longer interference 
intervals.323 
Device and product: The ‘White Super’ electronic cigarette was used (devices 
and cartridges supplied by The Electronic Cigarette Company) with a new 




Benefit The authors assessed the abuse liability of e-cigarettes. 










Interventional trial papers dependency and abuse liability 
Duration of trial: Four sessions. Eight-day interval between sessions. Measures 
were assessed up to 30 minutes post intervention 
Data source: Not reported Population size: 20. Year of data collection Not 
reported:  
E-cigarette, smoking and other related status: Current tobacco cigarette 
smokers >=15 cigarettes per day. 
Intervention and research design: Latin square. Participants completed four 4-
hour-long sessions that were separated by at least 48 hours and were preceded 
by at least 12 hours of objectively verified cigarette abstinence. The first session 
was a ‘sampling’ session that familiarized participants with the e-cigarette. The 
remaining three sessions were randomly ordered ‘choice’ sessions that differed 
by the options provided. 
Outcomes: Plasma nicotine, cardiovascular measures, questionnaire of smoking 
urges brief, nicotine/tobacco abstinence symptoms 
The authors concluded that e-cigarettes can deliver clinically significant amounts 
of nicotine and reduce cigarette abstinence symptoms. In addition, they appear 
to have lower potential for abuse relative to traditional tobacco cigarettes.312 
Device and product: The ‘Vapor King’ (KR808 model) automatic e-cigarette was 
used in this study450 It was chosen based on suggestions from experienced EC 
users who reported that this model would be acceptable to new users as it 
resembles a cigarette and would produce a consistent vapor. The ‘Vapor King’ 
consists of a rechargeable 3.7-volt battery and air flow sensor with a lighted 
display end; a disposable cartridge (‘cartomizer’) consisting of a metal threading 
(to fit securely onto the battery), heating element and wicking that is saturated 
with nicotine solution. ‘WOWCowboy’ or ‘WOWCowboy Menthol’ tobacco-
flavoured cartomizers (18 mg/ml nicotine; commonly used nicotine strength 
Vapor4Life) were matched to participants’ tobacco cigarette flavour preference 
(i.e. non-menthol or menthol). A new ‘cartomizer’ and fully charged battery 
were used for each session. Participants’ usual brand of tobacco cigarette was 
used in the own brand conditions. 




Benefit The authors reported on the relationship between nicotine derived from e-
cigarettes and time-based prospective memory in abstinent smokers. 
Age mean years (SD): 31.85 (8.7). Sex: 7 males, 13 females 
Country: UK. Ethnicity: Caucasian  
Duration of trial: Two sessions. Conducted on consecutive days. Each testing 
session lasted approximately 1 hour, outcomes were assessed 15 minutes after 
each intervention. The trial was conducted over four days, interventions were 
evaluated on day two and three of the trial 
Data source: recruited via advertisements, social network forums, e-mail and 
word of mouth 
Population size: 20. Year of data collection: Not reported 
E-cigarette, smoking and other related status: Smokers. All smoked within an 
hour of waking, smoked more than ten cigarettes a day and had done so for at 
least 1 year 
Intervention and research design: This study was employed an open-label, two-
sequence, two period, randomized crossover design, that is a within-subjects 
design was employed; each participant was tested on two occasions after 
overnight abstinence, with e-cigarette type (nicotine vs. placebo; order 










Interventional trial papers dependency and abuse liability 
used nicotine (18 mg) and placebo (0 mg) e-cigarette conditions. The placebo 
condition, therefore, represents the ‘abstinent’ state. The experimenter 
introduced the participant to the e-cigarette, explaining and demonstrating how 
to use it before allowing the participant to use it ad libitum for 10 minutes. 
Participants were then asked to wait for 15 minutes (to allow time for the 
nicotine to reach maximum plasma concentration; during which time they 
completed basic demographic information and the Fagerström Test of Nicotine 
Dependence (time 1 only). After 15 minutes, participants then completed the 
Mood and Physical Symptoms Scale and desire-to-smoke scales followed by the 
Cambridge Prospective Memory Test. Testing at time 2 followed the same 
procedural format using the parallel version of the Cambridge Prospective 
Memory Test (order counterbalanced), the demographic questionnaire and the 
Fagerström Test of Nicotine Dependence were not repeated. At the end of the 
second session, the participants were debriefed and asked to guess on which 
occasion they had received nicotine and placebo and then informed accordingly. 
Each testing session lasted approximately 1 hour. 
Outcomes: The Cambridge Prospective Memory Test, desire to smoke and 
tobacco withdrawal symptom specifically measure of depressed, irritable, 
anxious, drowsy, restless, hungry, unable to concentrate, the calculated 
outcomes from these measures are Mood and Physical Symptoms Scale (MPSS) 
total and desire to smoke as assed by the Mood and Physical Symptoms Scale.  
The authors concluded that compared with placebo, nicotine e-cigarettes 
reduced the desire to smoke and tobacco withdrawal symptoms, and improved 
time-based but not event-based prospective memory. There was a moderate, 
marginally significant negative correlation between prospective memory 
performance during abstinence and nicotine dependence.313 
Device and product: The ‘Tornado’ e-cigarette was supplied by Totally Wicked E-
Liquid. E-cigarettes were fully charged prior to each assessment session and 
fitted with either an 18 mg (nicotine) or 0 mg (placebo) cartridge, both of which 




Benefit The authors reported on the effectiveness of e-cigarettes in an 8-week Flemish 
study with 6-month follow-up on smoking reduction, craving, and experienced 
benefits and complaints. 
Age mean years (SD): 43.71 (13.13). Sex: 23 males, 27 females. Country: Belgium 
Duration of trial: During an eight-week period, participants were asked to come 
three times (Session 1 in week one, Session 2 in week four, Session 3 in week 
eight) to a lab session; each session lasted approximately one hour. Three 
months after the last lab session (FU1), the authors asked all participants to fill 
out an online questionnaire assessing any changes in terms of smoking or vaping 
behaviour. Six months after the last lab session (FU2), participants were invited 
to a follow-up session in which the authors provided some global information 
about the obtained preliminary results 
Data source: Participants from the area around Leuven Belgium were recruited 
through various channels 
Population size: 51 persons consented to participate, 50 participated and were 
randomised to one of three groups: E-cigarette 1 n=16, E-cigarette 2 n=17 and 
Control n=17. At eight weeks laboratory data was available on n=47 (E-cigarette 
1 n=15, E-cigarette 2 n=16 Control n=16). At 32-week laboratory data was 
available on n=36 (cig 1 n=11, E-cigarette 2 n=12 Control n=13) 
Year of data collection: December 2012 and February 2013 
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Intervention and research design: Two different kinds of second-generation e-
cigarettes (see below) 
Outcomes: breath carbon monoxide measurements, saliva samples to 
determine cotinine levels, craving for cigarettes, withdrawal symptoms, and 
number of cigarettes per day (assessed via online questionnaires) assessing any 
changes in terms of smoking or vaping behaviour, Tobacco Craving 
Questionnaire, the Minnesota Nicotine Withdrawal Scale and a visual analog 
scale assessing cigarette craving. Complaints and Benefits of cigarette or e-
cigarette. E-cigarette Use, Mood 
The authors concluded that in a series of controlled laboratory sessions with e-
cigarette-naive tobacco smokers, second-generation e-cigarettes were shown to 
be immediately and highly effective in reducing abstinence-induced cigarette 
craving and withdrawal symptoms, while not resulting in increases in exhaled 
carbon monoxide. Remarkable (>50%) 8-month reductions in, or complete 
abstinence from, tobacco smoking was achieved with e-cigarettes in almost half 
(44%) of the participants.314 
Device and product: Two different kinds of second-generation e-cigarettes, 
namely the “Joyetech eGo-C” and the “Kanger T2-CC”, referred to as 
respectively type one and type two e-cigarettes. The Joyetech eGo-C consists of 
a rechargeable 1000 milliampere hour 3.3 V lithium-ion battery, an atomizer 
body (cover cone and atomizer base) holding a refillable 1 mL cartridge serving 
as mouthpiece, and a replaceable 2.2-ohm atomizer head. The Kanger T2-CC 
consists of a replaceable mouthpiece, a 2.4 mL clearomizer, a 2.5-ohm coil and a 
rechargeable 650 milliampere hour 3.7 V lithium-ion battery. For both types of 
e-cigarettes the authors used 30 mL bottles of tobacco-flavoured e-liquid 
(Dekang “Turkish Blend”), containing 18 mg/mL of nicotine. Participants were 
encouraged to only use this type of e-liquid for reasons of standardization. The 
e-cigarette groups received the e-cigarette and four bottles of e-liquid at Session 
1 (group E-cigarette1 received the Joyetech eGo-C and group E-cigarette2 
received the Kanger T2-CC); at Session 2, participants’ empty bottles were 
replenished up to again four bottles and at Session 3, they were allowed to keep 
the remaining bottles. For these groups, we performed multiple weightings, 
with a calibrated scale, of the 30 mL bottles containing the e-liquid to derive the 
average consumption of liquid per day in mL. The control group received the e-
cigarette and e-liquid (six bottles) for two months at the end of Session 3 (eight 
of the 16 participants of the control group received the Joyetech eGo-C and the 
remaining eight participants received the Kanger T2-CC). All participants 
received their material for free. All devices and e-liquids for two months were 
provided by the experimenter 
Nides et al.315 
 2014 
Benefit The authors reported on the relationship between short-term smoking 
reduction with an electronic nicotine delivery system and nicotine blood 
levels, heart rate, and cravings. 
Age mean years (range): 43 (18 to 63) baseline assessment. Sex: 66% male.  
Country USA. Duration of trial: Three sessions. One-week intervals 
Data source: Subjects were recruited from the study site’s database and from 
the community through advertisements. 
Population size: 25. Year of data collection: Not reported 
E-cigarette, smoking and other related status: smoking at least 10 factory-
produced cigarette per day for the previous year 
Intervention and research design: The study consisted of 3 clinic visits at one-
week intervals. It was an open-label, noncomparative study. At the end of visit 
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conventional tobacco cigarettes they smoked each day over the following week, 
providing a more accurate baseline measure than the retrospective data 
collected at visit 1. At visit 2, the diary was returned, and the subjects were 
instructed on the use of the e-cigarettes, after which they could use the product 
on an ad libitum basis for 20 minutes while in the clinic. Subjects were given a 
10-day supply of the e-cigarettes. This supply was intended to last until visit 3, 
which was scheduled for 7 days later but could occur up to 10 days later. 
Depending on preference, subjects received either menthol or nonmentholated 
e-cigarettes. The subjects were instructed to start using the e-cigarettes on the 
day after visit 2 and to use them as often as they like (ad libitum) during the 
following week. No specific instructions on reducing conventional combustible 
tobacco cigarettes were given. Visit 3 was scheduled for 7 days after visit 2 and 
data recorded by participant during the study was collect, and 
pharmacokinetic/pharmacodynamic assessment data were gathered 
Outcomes: Craving assessment, withdrawal assessment, perception of e-
cigarettes, nicotine extraction from product. After 5 minutes of use, blood 
nicotine levels increased, heart rate increased, and craving was reduced by 55%. 
Cigarettes per day were reduced by 39% during the test week, and perceptions 
of use for reduction or cessation were positive.  
The authors concluded that the NJOY® King Bold e-cigarette delivered nicotine 
and led to short-term smoking reduction.315 
Device and product: The e-cigarettes used were NJOY® King Bold (NJOY, Inc., 
Scottsdale, AZ) and were provided to the subjects free of charge by the 
manufacturer. Externally, these e-cigarettes resemble conventional tobacco 
cigarettes; but internally, they contain a lithium battery, a surrounded by a 
cotton wad containing 0.5 mL of nicotine solution These e-cigarettes are neither 
rechargeable nor refillable; rather, they are disposable. The nicotine solution 
contains approximately 26 mg of nicotine. The nicotine is dissolved in 2 
excipients, namely propylene glycol and glycerol, both present at approximately 
40%. The balance of the solution consists of a variety of flavouring agents, each 
of which is present at less than 0.2% and has received the Flavour Extracts and 
Manufacturers Association classification as Generally Recognized as Safe for use 
in food products although their safety in inhaled products has not been 
confirmed. In addition, one NJOY® King Bold style contained menthol. 
Polosa et al. 
316 
2014b 
Benefit The authors examined the effect of e-cigarettes as an aid for smokers to quit or 
reduce cigarette consumption. 
The authors concluded that long-term e-cigarette use can substantially decrease 
cigarette consumption in smokers not willing to quit; in addition, it is well 
tolerated. 
Age mean years (SD): 42.3 (±8.6). Sex: 17 males, 6 females 
Country: Italy. Duration of trial: 24 months  
Data source: Adult smokers of >=15 cigarettes per day for at least 10 years who 
were not keen to quit smoking at the time of recruitment or in the forthcoming 
30 days, were recruited from the local hospital staff in Catania, Italy. 
Population size: 40 at baseline 23 completed the study at 24 months  
Year of data collection: Not reported 
E-cigarette, smoking and other related status: Adult smokers of >=15 cigarettes 
per day for at least 10 years who were not keen to quit smoking.  
Intervention and research design: This study was described by the authors as an 
observational prospective study following a cohort of smokers in a naturalistic 
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issued with Categoria e-Cigarettes. Specifically, eligible participants were invited 
to use a ‘Categoria’ e-Cigarette (Arbi Group Srl, Italy) for a period of 6 months 
and followed up prospectively for 2 years. After an initial 6-month intervention 
phase using the e-Cigarette, participants attended two follow-up visits, at 18 
and 24 months, at a smoking cessation clinic. As participants were issued with 
the intervention, Categoria e-Cigarettes, it has been included in the trial 
category in this review. After an intervention phase of 6 months, during which e-
Cigarette use was provided on a regular basis, cigarettes per day and exhaled 
carbon monoxide (eCO) levels were measured participants were followed up in 
an observation phase at 18 and 24 months. 
Outcomes: Efficacy measures included: 50 % reduction in the number of 
cigarettes per day from baseline, defined as self-reported reduction in the 
number of cigarettes per day 50 % reduction compared to baseline; 80 % 
reduction in the number of number of cigarettes from baseline, defined as self-
reported reduction in the number of number of cigarettes 80 % reduction 
compared to baseline; abstinence from smoking, defined as complete self-
reported abstinence from tobacco smoking (together with an exhaled carbon 
monoxide concentration of B10 ppm). Smoking reduction and abstinence rates 
were computed, and adverse events (throat irritation, mouth irritation, dry 
cough, dry mouth, dizziness, headache and nausea) reviewed. Of the 40 
subjects, 17 were lost to follow-up at 24 months. A 50 % reduction in the 
number of cigarettes per day at 24 months was shown in 11/40 (27.5 %) 
participants with a median of 24 cigarettes per day use at baseline decreasing 
significantly to 4 cig/day (p = 0.003). Smoking abstinence was reported in 5/40 
(12.5 %) participants while combined 50 % reduction and smoking abstinence 
was observed in 16/40 (40 %) participants at 24 months. Five subjects stopped 
e-Cigarette use (and remined abstinent), three relapsed back to tobacco 
smoking and four upgraded to more performing products by 24 months. Some 
mouth irritation, throat irritation, and dry cough were reported. Withdrawal 
symptoms were uncommon.  
The authors concluded that long-term e-cigarette use can substantially decrease 
cigarette consumption in smokers not willing to quit; in addition, it is well 
tolerated.316 
Device not reported 
Polosa et al. 
319 
2014c 
Benefit The authors reported on success rates with nicotine personal vaporisers in a 
prospective 6-month pilot study of smokers not intending to quit. 
Age range: 18 to 60 years. Sex: 44 males, 26 females. Country: Italy 
Duration of trial: 24 weeks  
Data source: Healthy smokers, smoking ≥15 conventional tobacco cigarettes per 
day for at least 10 years were recruited using anti-smoking leaflets and by an 
approved kiosk located in the atrium of the university hospital (‘Policlinico-
V.Emanuele’) promoting smoking cessation services at Centro per la 
Prevenzione e Cura del Tabagismo, Università di Catania, Italy 
Population size: 38. Initially, 72 persons were recruited within the hospital 
setting, 50 subjects were eligible for inclusion in the study at baseline, 38 
completed the study at 24 weeks 
Year of data collection: Not specified 
E-cigarette, smoking and other related status: Healthy smokers 18 to 60 years 
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Intervention and research design: as participants were issued with the 
intervention, it has been included in the trial category in this review.  
Outcomes: Sustained 50% and 80% reduction in cigarettes per day at week-24 
was reported in 15/50 (30%) and 7/50 (14%) participants with a reduction from 
25 cigarettes per day to 6 cigarettes per day (p < 0.001) and 3 cigarettes per day 
(p < 0.001), respectively. Smoking abstinence (self-reported abstinence from 
cigarette smoking verified by an exhaled carbon monoxide ≤10 ppm) at week-24 
was observed in 18/50 (36%) participants, with 15/18 (83.3%) still using their 
personal vaporiser at the end of the study. Combined 50% reduction and 
smoking abstinence was shown in 33/50 (66%) participants. Throat/mouth 
irritation (35.6%), dry throat/mouth (28.9%), headache (26.7%) and dry cough 
(22.2%) were frequently reported early in the study but waned substantially by 
week-24.  
The authors concluded that the use of second-generation personal vaporisers 
substantially decreased cigarette consumption without causing significant 
adverse effects in smokers not intending to quit; in addition, participants’ 
perception and acceptance of the products was very good.319 
Device and product: Participants were given a second-generation personal 
vaporiser, EGO/CE4 model, and a full supply of tobacco aroma e-Liquid 
containing 9 mg/ml nicotine for 4 weeks (14 vials in total). Commercially 
available PV kits (EGO/CE4 model with a rechargeable 3.7 V - 650mAh lithium-
ion battery, charger, and CE4 atomizer) and e-Liquids (Tuscan Reserve; 
FlavourArt –Italy, www.flavourart.it, and Calliope; DEA Flavour – Italy, 
www.flavourart.it; both consisting of a similar propylene glycol/VG base) were 
purchased from local vape shops out of a generous grant by LIAF (Lega Italiana 
Anti Fumo) 
Caponnetto 
et al.317  
2017 
Benefit The authors reported on cognitive performance, craving, and gesture (physical 
act of having a conventional combustible tobacco cigarette in hand) in subjects 
using e-cigarettes and their usual cigarettes. 
Age mean years (SD): 34.8 (11.4). Sex: 20 males, 4 females. Country: Italy 
Duration of trial: Five days. On the first study day, participants were randomized 
to use one of five different products: first generation rechargeable cigalike, e-
cigarettes, loaded with cartridges 24mg nicotine, tobacco aroma; second 
generation, disposable cigalike e-cigarette loaded with cartridges with 24mg 
nicotine, tobacco aroma; second generation disposable cigalike e-cigarette 
loaded with cartridges with 0mg nicotine, mint aroma; second generation 
electronic, personal vaporizer, model Ego C (tank cartomizer), loaded with liquid 
nicotine 24 mg, tobacco aroma; with their usual classic cigarettes. Allocation 
was performed using a random sequence of five codes, each corresponding to 
one product, prepared in advance by the study statistician using the Latin-
square method to control for time effects. 
Data source: Thirty-four regular smokers were recruited. Population size: 34 
Year of data collection: May 2015 to September 2015  
E-cigarette, smoking and other related status:  
Intervention and research design: randomized crossover trial designed to 
compare cognitive performances, craving, and gesture in subjects who used first 
generation e-cigarettes, second generation electronic-cigarettes with their usual 
cigarettes. Craving: in T1,T2,T3,T4,T5,T6. Participants rated their current desire 
for a cigarette using single item visual analog scale number between 0 and 10, 
where 0 = “not at all” and 10 =“extremely.” Carbon monoxide in exhaled breath 
(eCO) was measured at T1,T2,T3,T4,T5, T6. Gesture: at minute 2 during the 15 
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single item visual analog scale number between 0 and 10 (“Right now, how 
much do you want a cigarette in your hand or in your mouth?”), where 0 = 
“completely unsatisfying,” 10 = “fully satisfying.” 
Outcomes: cognitive performances, craving, and gesture in subjects who used 
first generation e-cigarettes, second generation e-cigarettes with their usual 
cigarettes 
The authors concluded that the cognitive measures of attention, executive 
function, and working memory are not influenced by different e-cigarettes and 
sex, demonstrating that in general e-cigarettes could become a strong support 
from a cognitive point of view for those who decide to quit smoking. It seems 
that not only cravings and other smoking withdrawal symptoms, but also 
cognitive performance, are linked to the presence of nicotine; this suggests that 
the reasons behind the dependence and the related difficulty in quitting 
smoking needs to be examined. The physical act of smoking conventional 
combustible tobacco cigarettes also needs to be studied.317 
Device and products: first generation rechargeable cigalike, e-cigarette, loaded 
with cartridges 24mg nicotine, tobacco aroma, second generation, disposable 
cigalike e-cigarette loaded with cartridges with 24mg nicotine, tobacco aroma, 
second generation disposable cigalike e-cigarette loaded with cartridges with 
0mg nicotine, mint aroma, second generation electronic, personal vaporizer, 
model Ego C (tank cartomizer), loaded with liquid nicotine 24 mg, tobacco 
aroma, and usual cigarettes.  
(a) First generation rechargeable cigalike, e-cigarettes, loaded with cartridges 
24mg nicotine (model “401”). The e-Cigarette “Categoria” model “401” was 
supplied by the manufacturer, Arbi Group Srl (Milano, Italy). It is a three-piece 
model that closely resembles a tobacco cigarette. Its heating element in the 
atomizer is activated by a rechargeable 3.7 V–90 milliampere hour lithium-ion 
battery. A fully charged battery can last up to the equivalent of 50–70 puffs. 
Disposable cartridges used in this study looked like tobacco cigarette’s filters 
containing an absorbent material saturated with a liquid solution of propylene 
glycol and vegetable glycerine in which nicotine or an aroma was dissolved. 
Disposable cartridges had to fit securely onto the heating element of the 
atomizer in order to produce a consistent vapor. One type of cartridges was 
provided for this study day; “Original” 24mg nicotine. Detailed toxicology and 
nicotine content analyses of these cartridges had been carried in a laboratory 
certified by the Italian Institute of Health and can be found at: 
http://www.categoriacigarette.com/. The cartridge labelled “Original 24 mg” 
contains liquid comprising 1.4% water, 2.37% nicotine, 75.6% propylene glycol, 
ethanol 0.16, glycerine 19.7%, pyrazine, trimentyl 0.10%, 2,3-dimethylpyrazine 
0.13%, myosmine 0.15%.  
(b) Second generation, disposable cigalike e-cigarette loaded with cartridges 
with 24mg nicotine, (model 501 “ONE original”). This is a single use electronic 
cigarette. Compared to “Categoria” E-cigarette (model “501”), the model ONE 
high original has a new filter technology that comprises an integrated atomizer 
and a new long-life battery, which guarantee high performance. Externally, 
these electronic cigarettes resemble conventional tobacco cigarettes; but 
internally, they contain a lithium battery, a heater unit, an integrated circuit, 
and a wick surrounded by a cotton wad containing 0.5 mL of nicotine solution. 
These electronic cigarettes are neither rechargeable nor refillable; rather, they 
are disposable. The nicotine solution contains approximately 24mg of nicotine. 
Detailed toxicology and nicotine content analyses of these cartridges had been 
carried in a laboratory certified by the Italian Institute of Health and can be 
found at: http://www.categoriacigarette.com/it/studi-e-ricerche/analisi/analisi-
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70.8% Propylene Glicol, <0.1% Ethylene Glicol, 4.5% Water, 0.4% Flavors and 
Additives, <5% Cadmium l, <5% Lead, <1% Mercury, <5% Chromium. 
(c) Second generation disposable cigalike e-cigarette loaded with cartridges with 
0mg nicotine, mint aroma (model 501 “ONEMint”). This is a single use e-
cigarette. Compared to “Categoria” E-cigarette (model “501”), the model ONE 
Mint has a new filter technology that comprises an integrated atomizer and a 
new long-life battery, which guarantee high performance. Externally, these 
electronic cigarettes resemble conventional tobacco cigarettes; but internally, 
they contain a lithium battery, a heater unit, an integrated circuit, and a wick 
surrounded by a cotton wad containing 0.5 mL of nicotine solution. These e-
cigarettes are neither rechargeable nor refillable; rather, they are disposable. 
Detailed toxicology and nicotine content analyses of these cartridges had been 
carried in a laboratory certified by the Italian Institute of Health and can be 
found at: http://www.categoriacigarette.com/it/studi-e-ricerche/analisi/analisi-
2013. The cartridge contains liquid comprising <0.001% Nicotine, 18.8% 
Glycerine, 72.5% Propylene Glicol, 2.1% Ethylene Glicol, 4.9% Water, 0.78% 
Flavors and Additives, <5% Cadmium l, <5% Lead, <1% Mercury, <5% Chromium.  
(d) Second generation electronic, personal vaporizer, model Ego C (tank 
cartomizer), loaded with liquid nicotine 24 mg, tobacco aroma. The e-cigarette 
(“Ego”) were supplied by, Fumo digitale (Varese,Italy). The e-cigarette Ego C 
(Joyetech), used in the study, consist of the atomizer, the tank cartomizers and 
the battery. This e-cigarette is considered—second generation; the battery has 
higher capacity compared to cigarettelike devices and the atomizer design is 
different compared to polyfil-containing cartomizers. A 24 mg/ml nicotine-
containing liquid was used (Tuscan flavor by Flavouart), which is generally 
considered high strength. The E-liquid Tuscan by Flavourart were supplied by 
Flavourart (Oleggio-NO, Italy). This E-liquid comprising 0.80 g USP Nicotine, 
44.82 g USP Glycerine, Propylene Glicol USP 46.7 g, 8.11 gWater, <0.5 g 
Flavors.(e) Participants usual classic cigarettes. 
Hiler et al.335  
2017 
Harm The authors looked at the relationship between nicotine delivery profile and 
cardiovascular and subjective effects. 
Age mean years (SD): 30.6 (9.1). Sex: Not reported. Country USA 
Duration of trial: Four sessions. Intervention 48 hours. Eight days. Participants 
completed four, double-blind ∼2.5-hour sessions at the Clinical Behavioral 
Pharmacology Laboratory. Session order was randomized and sessions were 
separated by a minimum of 48 hours 
Data source: community volunteers were recruited by advertisement and word 
of mouth 
Population size: 64. Year of data collection: Not reported 
E-cigarette, smoking and other related status: E-cigarette-experienced 
individuals and e-cigarette-naïve cigarette smokers 
Intervention and research design: Four double-blinded ~2.5hour sessions. 
Session order was randomized and sessions were separated by a minimum of 48 
hours. 
Outcomes: Plasma nicotine and heart rate, Puff topography, subjective 
questionnaires including the modified Hughes-Hatsukami on withdrawal scale, 
the Direct Effects of e-cigarette-use scale which assesses the extent to which the 
topography mouthpiece interfered with normal e-cigarette-use behaviour and 
the Tiffany-Drobes Questionnaire of Smoking Urges Brief 
The authors concluded that participants’ plasma nicotine concentration was 
related directly to liquid nicotine concentration and was dependent on user 
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in e-cigarette-experienced individuals relative to e-cigarette-naive smokers in 
each active nicotine condition.335 
Device and products: Thirty-three e-cigarette-experienced individuals and 31 e-
cigarette-naïve cigarette smokers completed four laboratory conditions that 
consisted of two, 10-puff bouts (30-second IPI) with a 3.3-volt e-cigarette 
battery attached to a 1.5 Ohm “cartomizer” (7.3 watts) filled with 1 ml e-
cigarette liquid. Conditions differed by liquid nicotine concentration: 0, 8, 18, or 
36 mg/ml 








The authors evaluated the abuse liability of three Vuse Solo e-cigarettes with a 
nicotine content ranging from 14 mg cartridge, to 29mg, and to 36 mg, relative 
to high- and low-abuse liability comparator products (usual brand combustible 
cigarettes and nicotine gum, respectively).  
Age mean years (SD): 39.7 ± 11.15. Sex: 34 males, 25 females 
Country: USA. Ethnicity: Asian (1) White (56) White, American Indian/Alaska 
Native (2) 
Duration of trial: Five test visits. 35 days. Outcomes were gathered up to six 
hours after the clinic intervention was undertaken. Prior to each visit subject the 
investigational product was ‘home used’ for 7 days. Product use during the 
ambulatory periods was non-exclusive, subjects were allowed to smoke their 
usual brand cigarettes throughout the study. In clinic product use, all ad libitum, 
consisted of up to 10 minutes use of Vuse Solo or smoking of one cigarette, or 
up to 30 minutes using nicotine gum according to the package instructions (i.e., 
‘park and chew’ method). A series of timed blood samples was collected for 
measurement of nicotine concentration to assess uptake from product. 
Collection times were up to 360 minutes relative to the subject starting use of 
product. 
Data source: Not reported 
Population size: One hundred twenty-one subjects took part in the screening 
procedures, 59 subjects were randomized, and 45 subjects completed all five 
test visits. Fourteen subjects were withdrawn from the study, including one 
subject who was discontinued due to adverse events (judged to be unrelated to 
study product), eight subjects who were discontinued due to protocol 
deviations, and five subjects who withdrew consent for study participation.  
Year of data collection: Not reported 
E-cigarette, smoking and other related status: Electronic-naive smokers. 
Subjects were required to smoke 10 or more non-menthol 83 mm (king size) to 
100 mm combustible filtered cigarettes per day for at least 6 months, and 
typically smoke their first cigarette of the day within 30 minutes of waking. 
Characteristics of the study population showed: cigarettes per day mean (SD) 
20.6 (6.34) Fagerström Test for Nicotine Dependence score Mean SD 5.8 (1.29). 
A total of 30 different usual brand cigarette brand styles were reported as 
currently being smoked at the time of screening. Nearly half of the subjects 
reported smoking the four most common usual brand cigarette styles: Marlboro 
Red (n = 8, 14%), Marlboro Gold (n = 8, 14%), Pall Mall Red (n = 6, 10%), and 
Camel Blue (n = 5, 9%). Other brand styles were smoked by four or fewer (≤7%) 
subjects each. No subject reported regular use of electronic-cigarettes prior to 
entering the study.  
Intervention and research design: Five clinic visits. Crossover. Eligible subjects 
who successfully passed all screening requirements were enrolled into the study 
and randomized to a product use sequence. A 7-day ambulatory (home use) trial 
of each investigational product (including a week of using only usual brand 
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accustomed to using the new products. Product use during the ambulatory 
periods was non-exclusive, as subjects could smoke their usual brand cigarettes 
throughout the study. Product use was tracked daily using an electronic diary, 
with subjects documenting the number of usual brand cigarettes smoked and 
the number of 'uses' of Vuse Solo or nicotine gum per day (data not presented). 
One ‘use’ of Vuse Solo or nicotine gum was defined as approximately 10 to 30 
minutes of ad libitum use, respectively, to approximate use in test visits. 
Subjects were instructed to use the assigned investigational product at least 
once per day for 6 of the 7 days prior to each test visit; subjects were not to use 
the dispensed investigational products on the day immediately prior to the test 
visit. Subjects were to abstain from all tobacco and nicotine products for at least 
12 h prior to each test visit to minimize the impact that residual nicotine 
concentrations might have on baseline subjective and physiological 
measurements. Subjects reported to the clinic on the morning of each test visit 
and were initially assessed for continued eligibility and compliance with the 
required 12-h smoking abstention. Subjects with an expired carbon monoxide 
value >12 ppm were not eligible to participate in the clinical procedures on that 
day but were allowed to reschedule one test visit for this reason. In clinic 
product use, all ad libitum, consisted of up to 10 minutes use of Vuse Solo or 
smoking of one cigarette, or up to 30 minutes using nicotine gum according to 
the package instructions (i.e., 'park and chew' method). Serial blood sampling, 
questionnaires, and physiological measurements were completed at the 
specified time points relative to the start of product use. Individual Vuse Solo 
cartridge weights, before (initial weight) and after (final weight) in-clinic use, 
were recorded to assess the amount of product use. In-clinic use of each of the 
three types of products occurred in separate sections of the clinic to minimize 
any potential effects of environmental aerosol or tobacco smoke or other 
sensory cues on subjective effects assessments. Subjects underwent End-of-
Study procedures at test visit 5 (or early termination), including a symptom-
driven physical examination, a brief oral examination, and collection of blood 
and urine samples for clinical laboratory tests. 
Outcomes: Physiological measures included pulse rate, systolic and diastolic 
blood pressure, and expired carbon monoxide. Baseline cotinine concentrations 
were also measured to assess whether subjects substantially changed their 
nicotine uptake during the study. Safety and tolerability were evaluated based 
on data collected from physical and oral examinations, clinical laboratory tests, 
vital sign measurements, electrocardiograms, and adverse events. Enrolled 
subjects’ ratings of subjective effects and nicotine uptake over 6 h were used to 
measure abuse liability and pharmacokinetics following in-clinic use of each 
electronic cigarette.  
The authors concluded that the use of Vuse Solo e-cigarettes resulted in 
subjective measures (product liking, intent to use product again, product 
effects, urge to smoke, and urge for product) and nicotine uptake that were 
between those of combustible cigarettes and nicotine gum, although generally 
closer to nicotine gum. Compared with combustible cigarettes, use of Vuse Solo 
e-cigarettes resulted in significantly lower scores in measures of product liking, 
positive effects, and intent to use again. These pharmacodynamic findings were 
consistent with the pharmacokinetic data, showing that tobacco cigarettes 
produced substantially faster and higher levels of nicotine uptake when 
compared with Vuse Solo e-cigarettes and nicotine gum. Vuse Solo e-cigarettes 
resulted in more rapid initial uptake of nicotine compared to nicotine gum, but 
peak concentration and long-term extent of uptake were not different or were 
lower with Vuse Solo e-cigarettes. Collectively, these findings suggest that Vuse 
Solo cigarettes likely have an abuse liability that is somewhat greater than 
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Device and product: Three, non-menthol, commercially available brand styles of 
Vuse Solo were evaluated in this study, containing either 14, 29, or 36 mg of 
nicotine. Vuse Solo ECs are composed of a battery, heating element, microchips, 
sensor, and a cartridge containing propylene glycol, glycerin, nicotine, 
flavourings, and water. The three electronic-cigarettes were presented without 
brand style information and were visually indistinguishable by subjects. 
Cigarettes: Usual brand cigarettes (any combustible, filtered, nonmenthol brand 
style, 83 mm [king size] to 100 mm in length) and Nicorette® White Ice Mint 
nicotine polacrilex gum, 4 mg (GlaxoSmithKline Consumer Healthcare, L.P.) were 
chosen as high and low abuse liability comparator products, respectively, to 
assess the relative abuse liability of Vuse Solo. 
The three Vuse Solo ECs and nicotine gum were provided at no cost to subjects, 




No benefit Authors reported on a three-day randomized crossover trial, focusing on the 
behavioural and experiential effects of the short-term use of the heat-not-
burn product IQOSTM, versus an e-cigarette, and versus a regular cigarette, in 
current smokers who were novice users for both IQOSTM and e-cigarettes. To 
investigate the effect of using an IQOSTM on exhaled carbon monoxide, acute 
cigarette craving, withdrawal symptoms, and subjective positive and negative 
experiences after overnight smoking abstinence, compared to using an e-
cigarette or a regular tobacco cigarette. And to investigate which product (e-
cigarette or IQOSTM) would be preferred. 
Age mean years (SD): 22 (3.09). Sex: 67% males 
Country: Belgium. Ethnicity: Belgian nationality (47%) with the remaining being 
of other nationalities (e.g., Italian, Pakistani, Indian, etc.) 
Duration of trial: Three sessions. Three consecutive days after being overnight 
smoking abstinent. During each session, participants used one of three products 
(cigarette, e-cigarette, or IQOSTM) for five minutes. Exhaled CO (eCO) 
measurements and questionnaires were repeatedly administered throughout 
the session  
Data source: Dutch and English-speaking participants via various channels 
around the University of Leuven (i.e., distribution of flyers in University buildings 
and local newspaper shops, social media). 
Population size: 30. Year of data collection: Not reported 
E-cigarette, smoking and other related status: Regarding smoking history, 
participants started smoking on average at the age of 16 (SD = 1.84) and started 
smoking regularly at the age of 18 (SD = 1.77). One-third had tried (M = 2.00 
times, SD = 0.94) to quit smoking in the past, mainly using willpower (90%). The 
longest quit-smoking period (with all using willpower) had lasted on average five 
months (SD = 9.02), with a minimum of one month and a maximum of 30 
months. 
Intervention and research design: Randomized, crossover behavioral trial. It was 
a crossover, counterbalanced, within-subjects design for the laboratory 
sessions. Participants came to the lab (individually or in group, with a maximum 
of three participants) on three consecutive days, each time at the same hour of 
the day; each session lasted 70 to 80 minutes and followed the same procedure. 
Next, participants could use one of the three products ad lib for five minutes 
outside the building (only one cigarette or heat-stick were allowed). In each 
session, only one product was used and the order of product use over the days 
was completely counterbalanced between participants to control for order 
effects. Finally, at fixed moments (T1, T2, T3, T4, and T5) participants filled out 
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end of the session, the authors scheduled the three laboratory sessions with 
each participant. They used a crossover, counterbalanced, within-subjects 
design for the laboratory sessions. Participants came to the lab (individually or 
in group, with a maximum of three participants) on three consecutive days, each 
time at the same hour of the day; each session lasted 70 to 80 minutes and 
followed the same procedure. Before each laboratory session, participants 
needed to abstain from smoking for 12 h. At the start of the session (T0), 
participants filled out questionnaires and performed an exhaled carbon 
monoxide-measurement. In the corresponding session, participants received a 
brief rehearsal on how to use the e-cigarette or IQOSTM. Next, participants 
could use one of the three products ad lib for five minutes outside the building 
(only one cigarette or heat-stick were allowed). In each session, only one 
product was used and the order of product use over the days was completely 
counterbalanced between participants to control for order effects. Finally, at 
fixed moments (T1, T2, T3, T4, and T5;) participants filled out questionnaires and 
performed exhaled carbon monoxide measurements 
Outcomes: Changes in exhaled carbon monoxide levels, changes in cigarette 
craving throughout the sessions, withdrawal symptoms measured MNWS-R, 
product evaluation and preferences 
The authors concluded that short-term use of a specific heat-not-burn product, 
IQOSTM, can be effective to momentarily reduce acute cigarette craving and 
withdrawal symptoms, while having a minimal impact on the exhaled carbon 
monoxide levels, and being slightly more liked by novice users than an e-
cigarette. They stated however that this does not guarantee that 
craving/withdrawal symptom reduction will also be sustained over longer time 
spans or in case of repeated use, nor do they provide assurance that these 
effects are sufficient to lead to smoking reduction or cessation in smokers 
willing to quit or cut down on cigarettes.1 
Device and product: Three products were used during the laboratory sessions—
a regular tobacco cigarette, an e-cigarette and the IQOSTM HnB tobacco 
product. Specifically, they were an Eleaf iStick Power 5000 milliampere hour 
battery, fixed at 8 W, with an Aspire Nautilus 2 tank containing a 1.6 Ohm coil. 
The e-liquid (“Base Aurora”) contained 18 mg/mL nicotine, a PG/VG ratio of 
70/30, to which either a tobacco flavour (“7 Leaves”, 3 vol%) or a menthol 
flavour (“Mild Winter-Peppermint”, 3 vol%) was added. Both base liquid and 





Harm The authors examined the relationship between e-cigarette use and Beta2*-
nicotinic acetylcholine receptors (β2*-nAChR) occupancy. 
Age mean years (SD): 26 ± 4. Sex: 6 males, 1 female. Country: USA 
Duration of trial: Two to three sessions with at least 2 weeks between sessions. 
Six weeks duration. Participants had between two or three scan sessions where 
e-cigarette users (8 mg/ml and 36 mg/ml, or 0, 8 and 36 mg/ml exposures n=2 
for each group) and one session where tobacco cigarette users only. The time 
period used to quantify occupancy was 180 to 210 minutes (55 to 85 minutes 
post challenge). Post-nicotine scanning continued until the end of 210 minutes 
of infusion. Measures were collected during and up to 210 minutes post 
intervention 
Data source: Not reported. Population size: 7. Year of data collection: Not 
specified 
E-cigarette, smoking and other related status: Four experienced e-cigarette 
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Intervention and research design: Before and after nicotine challenge with 0, 8, 
and 36 mg/ml nicotine in a 3.3 Volt, 1.5 Ohm EC or a standard tobacco cigarette  
Outcomes: β2*-nAChR occupancy by nicotine, arterial blood plasma nicotine 
levels and liking and craving ratings. Average β2*-nAChR occupancy was higher 
after 36 mg/ml EC challenge compared to 8 mg/ ml EC at trend level. Average 
β2*-nAChR occupancy after tobacco cigarette smoking was 68 ± 18% and was 
not different compared with 8 mg/ml (64 ± 17%,) or 36 mg/ml (84 ± 3%) nicotine 
in EC users. Area under the curve of blood nicotine level was higher in the 
cigarette smoking group compared with the 8mg/ml group (p = 0.03), but similar 
compared with the 36 mg/ml EC (p = 0.29). Drug craving was reduced after use 
of the tobacco cigarette, 8 mg/ml EC, and 36 mg/ml EC 
The authors concluded that the e-cigarettes studied have abuse liability and 
may provide an adequate alternative nicotine delivery system for cigarette 
smokers.326 
Device and product: e-Go type EC battery (3.3 V, 1000 milliampere hour) with 
1.5 ohm dual-coil 510-style cartomizer and a 70/30 propylene glycol/vegetable 
glycerine e-liquid (“tobacco flavour”) with nicotine concentration of 0 mg/ml (n 
= 2), 8 mg/ml (n = 4) and 36 mg/ml (n = 4). E-liquid nicotine concentrations were 
measured with a validated liquid chromatography tandem-mass spectrometry 
(LC-MS/MS) method with a linear range of 0.5 to 50 mcg/mL. Initially, a 0.050 
mL aliquot of each liquid was diluted 1000-fold in acetonitrile, along with the 
addition of a stable isotopically labelled internal standard (nicotined4). This 





Harm The authors reported on changes in resting state functional brain connectivity 
and withdrawal symptoms associated with acute e-cigarette use. 
Age range: 25 to 58 years. Sex: Not reported. Country: USA 
Duration of trial: One session. Measures were gathered during and shortly after 
intervention  
Data source: Participants were recruited from an online anonymous survey 
posted on websites and e-cigarette forums 
Population size: 9. Year of data collection: Not reported  
E-cigarette, smoking and other related status: Participants using an e-cigarette 
for at least 20 days out of the last 28 with a nicotine concentration in their e-
cigarette liquid of at least 12 mg/mL. 
Intervention and research design: Participants completed a before and after 
resting state functional brain connectivity. The before session was undertaken 
after 14 hours of nicotine abstinence and the after session followed an episode 
with their own e-cigarette device.  
Outcomes: Resting state functional brain connectivity (rsFC) 
The authors concluded that the preliminary results suggest that the effects of e-
cigarette use on resting state functional brain connectivity are like those seen 
with nicotine administration in other forms.332 
Device and product: All participants reported having a preferred device, but only 
5 had a preferred liquid flavour; 8 out of 9 participants used a device larger than 
a combustible cigarette that included a manual button to initiate heating of the 
coil prior to puffing. Devices cost between $15 and $160 dollars (M=52.33; 
SD=43.10) and participants reported spending between $3 and $15 dollars per 
week to maintain their device. The strength of nicotine concentration in liquids 


















The authors reported on the nicotine delivery efficiency of first- and second-
generation e-cigarettes and their impact on relief of cravings during the acute 
phase of use. 
Age mean years (SD): 28.5 ± 8.9 e-cigarette group, 26.2 ± 6.9 tobacco cigarette 
group 
Sex: All males. Country: Germany  
Duration of trial: Four study visits at one-week intervals. Measures were 
gathered during intervention.  
Data source: Volunteers were recruited for participation in the study via flyers 
and over the Internet. 
Population size: 20. Year of data collection: Not reported.  
E-cigarette, smoking and other related status: e-cigarette group (n =9) the 
tobacco cigarette group (n = 11) Participants in the e-cigarette group had been 
routine users of nicotine-containing e-cigarettes (so-called vapers) for over 3 
months and had not smoked a tobacco cigarette for more than one month. 
None of the vapers had previously used a disposable e-cigarette, i.e. a cigalike. 
Participants in the tobacco cigarette group had been smoking tobacco cigarettes 
for at least 3 years and smoked at least 5 cigarettes a day.  
Intervention and research design: The participants in the e-cigarette group 
attended four study visits at one-week intervals. At each visit, they used a 
different kind of e-cigarette in a non-randomized open design crossover 
Outcomes: Blood nicotine levels during the acute phase in people using first- 
and second-generation e-cigarettes were monitored and compared with blood 
nicotine levels in people using a tobacco cigarette. Heart rate changes were 
measured, and withdrawal symptoms and craving were assessed with the 
German version of the Questionnaire on Smoking Urges (QSU-G) before and 
immediately after the vaping/smoking sessions. After five minutes of e-cigarette 
or tobacco cigarette use, the mean nicotine plasma concentrations were as 
follows: disposable cigalikes,5.5 ng/ml; tank model, 9.3 ng/ml; tobacco 
cigarette, 17.1 ng/ml. Nicotine levels increased significantly faster in the first 4 
minutes of consuming a tobacco cigarette than with the disposable cigalikes and 
the tank mode. The highest rate of increase in nicotine concentration was found 
with the tobacco cigarette (6.8 ng/ml) and tank model (2.3 ng/ml) between the 
1st and 2nd minute, whereas the disposable cigalikes showed comparatively 
small changes in the amount delivered over the five minutes. Withdrawal and 
craving for smoking decreased with the tank mode by the same amount as with 
the tobacco cigarette, even though less nicotine was delivered to the blood and 
considerably fewer side effects occurred. 
The authors concluded that the heart rate of tank mode users was markedly 
lower than that of the tobacco cigarette users. Unlike disposable cigalikes, tank 
mode e-cigarettes represent an effective source of nicotine and might be used 
as an alternative nicotine replacement product to aid smoking cessation. 
However, nicotine plasma levels observed in tank mode users after short-term 
vaping also have the potential to produce and sustain nicotine addiction.327 
Device and product: Cigalikes: Name (Manufacturer and Nicotine content 
(mg/ml) according to manufacturer): American Heritage (American Heritage 
International (18.0 mg/ml) Vype (British American Tobacco (18.6 mg/ml)) Blu 
(Imperial Brands (18.0 mg/ml)) 
Tank model: Aspire/Joyetech Upgrade Seta (Hybrid technology with Aspire Maxi 
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Tobacco cigar: Marlboro Red (Philip Morris International (0.8 mg/cigarette 
mg/ml) 
Cobb et al.328  
2019 
Harm The authors reported on the influence of e-cigarette liquid flavours and 
nicotine concentration on subjective measures of abuse liability in young adult 
e-cigarette vapers. 
Age mean years (SD): 19.9 (1.1) . Sex: 10 males, 10 females. Country USA  
Ethnicity: 40% White Non-Hispanic, 35% Black Non-Hispanic, 25% Other 
Data source: Not reported Population size: 20. Year of data collection: Not 
reported 
E-cigarette, smoking and other related status: Smoking at least five cigarettes 
per day for the past three months 
Outcomes: Heart rate/blood pressure indicated nicotine exposure during 
nicotine-containing conditions. Own brand and tobacco/menthol 36 mg/ml 
conditions produced significant decreases in ratings of cigarette smoking urges. 
Nicotine/drug effects were elevated significantly for own brand and 36 mg/ml e-
cigarette conditions with one exception noted for the tobacco/menthol 0 mg/ml 
condition. Own brand had the highest acceptability ratings, and e-cigarette 
condition results varied by acceptability item. 
Intervention and research design: seven Latin-square order conditions differing 
by the product used: own brand cigarette or e-cigarette cartomizer loaded with 
1 ml of one of three liquid flavors (Food/ Dessert/Spice, Fruit, or 
Tobacco/Menthol at either 0 or 36 mg/ml nicotine concentration. 
The authors concluded that among young adult vapers, e-cigarette containing 
nicotine were positively associated with several, but not all, subjective measures 
of abuse liability. Flavours did not consistently mask/enhance the effects 
observed. The results reinforce continued examination of e-cigarette-delivered 
nicotine and liquid flavours in relation to abuse liability.328 
Device and product: Participant’s self-reported own brand cigarettes were 
purchased locally following enrolment. For all e-cigarette conditions, the e-
cigarette device and cartomizer used was an eGo 3.3–4.1 V, 1100 mA h battery 
and a 1.5- Ohm, dual-coil, 510-style cartomizer. E-CIGARETTE liquid nicotine 
concentration was verified by the VCU Bioanalytical Core Laboratory (levels 
were either below the level of quantification for 0 mg/ml or within 2 mg/ml for 
36 mg/ml). All e-cigarette liquids were labelled as 70% propylene glycol/30% 
vegetable glycerine. To determine the specific e-cigarette liquid flavours within 
the Food/Dessert/Spice and Fruit flavour categories, a content analysis of 
preferred e-cigarette liquid flavours among adult e-cigarette users (age 18+ and 
used an e-cigarette for at least 1 month) Four unique liquid flavours at the 
solvent and nicotine concentration ratios specified above were sourced from a 
local e-cigarette vendor (AVAIL Vapor, LLC, Richmond, VA): Food/Dessert/Spice 
(Cream), Fruit (Tropical Fruit), Tobacco, and Menthol. Participants were 
matched to their own brand menthol preference. 
De La Garza 
et al.321  
2019 
Harm The authors reported on e-cigarette-naive cigarette smokers and the effects on 
cravings after acute exposure to e-cigarettes in the laboratory. 
Age mean years (SD): 50.6 (7.6). Sex: 10 males, 5 females. Country: USA 
Duration of trial: Four sessions. Interval of 7 days.  
Data source: Participants were recruited to the study from the Houston area via 
newspaper, internet advertisements, flyers, and referral 
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E-cigarette, smoking and other related status: Participants consisted of non‐
treatment seeking combustible cigarette smokers who reported having never 
tried an e-cigarette 
Outcomes: Assessments of craving and smoking severity 
Intervention and research design: A within‐subjects, placebo‐controlled study 
design, 15 tobacco‐dependent, e‐cigarette naïve participants sustained 
abstinence overnight. They completed distinct phases of this protocol during 
four separate study sessions. Participants were randomized to an e‐cigarette 
device containing one of three doses of nicotine (0, 18, or 36 mg/ml) or their 
own cigarette. Each study visit was ~3 hours long and separated by at least 7 
days. Participants completed four distinct sessions separated by at least 7 days 
The authors concluded that e-cigarettes did not reduce cravings or smoking 
severity in e-cigarette-naive smokers.321 
Device and product: The combustible cigarettes used in this pilot study were the 
participants’ own brand. The e‐cigarettes used were eGo devices with a 3.3‐V e‐
cigarette battery attached to a 1.5‐ohm dual‐coil cartomizer (Smoktech, 
Shenzhen, China). The study’s e‐liquid was Virginia Pure tobacco flavored, 
containing 0, 18, or 36 mg/ml nicotine loaded with 1ml of a 70% propylene 
glycol/30% vegetable glycerin (Avail Liquids, Richmond, VA). Nicotine levels 
were independently assessed and confirmed. The 18 and 36 mg doses were 
chosen based on the Lopez study, which demonstrated that these were the only 







The authors reported on the symptoms of nicotine withdrawal in former 
smokers who were current daily e-cigarette users. 
Age mean years (SD): 31 (10). Sex: 80% males. Country: USA 
Duration of trial: Two weeks. Three days per week. 
Data source: Not reported Population size: 109. Year of data collection: Not 
reported  
E-cigarette, smoking and other related status: Former smokers who were 
current daily e-cigarette (e-cigarette) users 
Outcomes: Symptoms of nicotine withdrawal daily via an Interactive Voice 
Response system 
Intervention and research design: Unblinded, within-participants, pre–post 
clinical trial in which 109 former smokers who were current daily e-cigarette (e-
cigarette) users used their own e-cigarette for 7 days followed by 6 days of 
biologically confirmed abstinence engendered via an escalating contingency 
payment system 
The authors concluded that former smokers who are daily e-cigarette users 
transfer physical dependence on tobacco cigarettes to dependence on e-
cigarettes. The severity of withdrawal from e-cigarettes appears to be only 
somewhat less than that from daily tobacco cigarette use.324 
Device and product: second-generation products with high nicotine levels 
Hughes et al. 
329 
2019c 
Harm The authors reported on withdrawal symptoms from e-cigarette abstinence 
among adult never-smokers. 
Age mean years (SD): 22 (4). Sex: 60% male. Country: USA 
Duration of trial: Two week. Assessments made in three days in the second 
week. 
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E-cigarette, smoking and other related status: Never-smokers, defined as those 
who used < 100 cigarettes in their lifetime and had no current “regular use” of 
other nicotine/tobacco products other than current e-cigarette use. Participants 
also had to currently use refillable nicotine containing e-cigarettes daily and 
currently use no other nicotine or tobacco products. 
Outcomes: Withdrawal symptoms measured using the Mood and Physical 
Symptoms Scale 
Intervention and research design: Un-blinded pre-post clinical trial 
The authors concluded that withdrawal symptoms can occur in never-smokers 
who are daily e-cigarette users. However, the severity of withdrawal from e-
cigarette abstinence in never-smokers appears to be small and may not be of 
clinical or regulatory significance.329 













The authors conducted an abuse liability assessment of an e-cigarette use in 
combustible cigarette smokers. 
Ethnicity: Non-Hispanic White or Caucasian n=6, Non-Hispanic Black or African 
American 
Age mean years (SD): 30.9 (9.5). Sex: 18 males, 6 females. Country USA. 
Duration of trial: Four separate lab sessions that were separated by a minimum 
of 48 hr. Each four sessions were each approximately 5 hr long. Eight days. 
Data source: The sample was limited to e-cig-naïve smokers to ensure that the 
positive control (own brand cigarettes) would test unequivocally positive 
Population size: 24. Year of data collection: Not reported 
E-cigarette, smoking and other related status: e-cig-naïve smokers 
Intervention and research design: Once screening was complete, eligible 
participants were scheduled for four separate lab sessions that were separated 
by a minimum of 48 hours. In each session, participants used one of four study 
products: own brand cigarettes, e-cigarettes with nicotine (e-cig_36), e-cigarette 
without nicotine (e-cig_0), and IN. These four sessions were each approximately 
5 hours long, Latin square ordered, and e-cigarette conditions were double-
blind (keeping participants and staff blind to the cigarette and the inhaler 
conditions was not feasible).  
Outcomes: The Multiple-choice procedure a pen-and-paper task that measures 
and allows for comparisons of abuse liability between different drugs and drug 
delivery platforms, by choosing between increasing amounts of money or 10 
puffs from the study product used in that session. Physiological measures for 
plasma nicotine concentration, monitored heart rate (every 20 s) and blood 
pressure (every 4 minutes), expired CO.  
Specifically: Multiple-choice procedure, Plasma nicotine, heartbeat, Systolic BP, 
Diastolic BP, Subjective measures: Hughes and Hatsukami Tobacco Withdrawal 
Scale, Anxious, Craving, Depression, Difficulty concentrating, Drowsy, Hunger, 
Impatient, Irritable, Restless, Sweats, Urge 
Direct effects of nicotine: Confused, Dizzy, Headache, Heart pound, Light-
headed, Nausea, Nervous, Salivate, Sweaty, Weak, Direct effects of product: 
Awake, Calm, Concentrate, Dizzy, Pleasant, Reduced hunger, Right now, Satisfy, 
Sick, Taste good. Tiffany–Drobes: Factor 1, Factor 2 
The authors concluded that the abuse liability of the e-cigarette examined was 
higher than the Food and Drug Administration-approved nicotine inhaler but 
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Device and products: e-cigarette (1.5 Ohm, 3.3 V) filled with 36 mg/mL or 0 
mg/mL nicotine to a Food and Drug Administration-approved nicotine inhaler 







The authors evaluated the pharmacokinetic profiles of cigarettes and e-
cigarettes with nicotine salt formulations in adult smokers in the USA. 
Age mean years (SD) (range): 42.3 ± 12.41 (24 to 62). Sex: 9 males, 6 females 
Country: USA 
Duration of trial: Six sessions. Six days. Plasma nicotine pharmacokinetic 
assessment was the primary outcome measure for this study. On each study day 
(Days 1–6), 4 mL of whole blood was collected 5 minutes prior to and at 2, 3, 4, 
5, 6, 7, 8, 9, 10, 12, 15, and 30 minutes following the start of product use. 
Data source: Population size: 15. Year of data collection: Not reported  
E-cigarette, smoking and other related status: Healthy American smokers. 
Smoking characteristics 10 ‘full flavour’ cigarettes; 5 ‘light’ cigarettes, 1 
menthol, 14 non-menthol 
The five e-cigarette products tested were (1) myblu pod-system containing 25-
mg nicotine (‘freebase’) tobacco flavour; (2) myblu pod-system containing 16-
mg nicotine lactate tobacco flavour; (3) myblu pod-system containing 25-mg 
nicotine lactate tobacco flavour; (4) myblu pod-system containing 40-mg 
nicotine lactate tobacco flavour; and (5) blu PRO open system containing 48-mg 
nicotine lactate tobacco flavour. The reference cigarettes, provided by the 
subjects, were their preferred brand of commercially available conventional 
cigarette. 
Outcomes: Pharmacokinetic profiles and subjective effects of nicotine from two 
e-cigarette device platforms with varying concentrations of nicotine lactate 
(nicotine salt) e-liquid relative to conventional tobacco cigarettes 
The authors concluded that the rate of nicotine absorption into the bloodstream 
was comparable among all e-cigarettes tested and was as rapid as that for 
conventional combustible tobacco cigarettes. However, in all cases, nicotine 
delivery did not exceed that of the conventional combustible tobacco cigarette. 
The pharmacokinetic profiles of nicotine salt emissions were also dependent 
upon the properties of the e-cigarette device. Subjective scores were 
numerically highest after smoking a conventional combustible tobacco cigarette, 
followed by the Myblu 40 mg nicotine salt formulation per cigarette. The rise in 
nicotine blood levels following use of all tested e-cigarettes was quantified as ‘a 
little’ to ‘modestly’ satisfying in terms of relieving the desire to smoke. All 
products were well tolerated with no notable adverse events reported. These 
results demonstrate that, while delivering less nicotine than a conventional 
combustible tobacco cigarette, the use of nicotine salts in e-cigarettes enables 
cigarette-like pulmonary delivery of nicotine that reduces the desire to 
smoke.318 
Device and product: The five e-cigarette products tested were (1) myblu pod-
system containing 25-mg nicotine (‘freebase’) tobacco flavour; (2) myblu pod-
system containing 16-mg nicotine lactate tobacco flavour; (3) myblu pod-system 
containing 25-mg nicotine lactate tobacco flavour; (4) myblu pod-system 
containing 40-mg nicotine lactate tobacco flavour; and (5) blu PRO open system 
containing 48-mg nicotine lactate tobacco flavour. The reference cigarettes, 
provided by the subjects, were their preferred 
The myblu device is a rechargeable, closed pod-system e-cigarette, consisting of 
two segments. A rechargeable battery section (battery capacity, 350 
milliampere hour) and a replaceable e-liquid containing pod (volume, 1.5 mL; 
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aerosol per puff under machine vaping conditions. The blu PRO device is a 
rechargeable, open-system e-cigarette, consisting of two segments. A 
rechargeable battery section (battery capacity, 1100 milliampere hour) and a 
refillable clearomiser (volume, 2.0 mL; coil resistance, 1.8 ohm). The blu PRO 
device delivers on average 2–3 mg of aerosol per puff 
Solingapuram 





The authors reported on the relationship between e-cigarettes and brain 
nicotine kinetics. 
Age mean years (SD): 43 (13). Sex: 9 males, 8 females. Country: USA 
Duration of trial: One day. 
Data source: Participants in each group were recruited from the Winston-Salem, 
North Carolina area 
Population size: 17. Year of data collection: Not reported 
E-cigarette, smoking and other related status: E-cigarette users: eight current 
smokers, eight ex-smokers, and one never-smoker in the e-cigarette group 
Outcomes: nicotine delivery to the brain 
Intervention and research design: Not clearly stated but interventions (in the 
form of e-cigarettes) were provided and comparison were made with other 
conventional cigarette users  
The authors concluded that e-cigarettes can deliver nicotine to the brain with 
similar rapidity as conventional tobacco cigarettes. Therefore, to the extent that 
rapid brain uptake promotes smoking reward, e-cigarettes might maintain a 
degree of nicotine dependence and also serve as non-combustible substitutes 
for cigarettes.333 
Device and product: Not reported 





The authors reported on the relationship between e-cigarettes and nicotine 
exposure in dual users of e-cigarettes and conventional combustible tobacco 
cigarettes. 
Age mean years (SD): 21 or older. Sex: 28 males, 8 females. Country: USA 
Data source: Participants were recruited via Craigslist.com, Facebook, flyers, and 
college campus newspapers 
Duration of trial: Two weeks. Population size: 36 Year of data collection: Not 
reported  
E-cigarette, smoking and other related status: healthy dual users of e-cigarettes 
and cigarettes 
Outcomes: Plasma nicotine was analyzed by gas chromatography–tandem mass 
spectrometry; nicotine withdrawal, urge to smoke and vape, affective states, 
craving, satisfaction, and psychological reward were measured by standardized 
questionnaires Intervention and research design. Compared with findings in 
conventional usual-brand cigarettes users, maximum plasma nicotine 
concentration was lower in e-cigarettes users. Both products, (conventional 
usual brand cigarettes and e-cigarettes) resulted in a reduction in the severity of 
withdrawal symptoms, negative affect, and urge to use either product. E-
cigarettes were less rewarding and satisfying and reduced craving to a lesser 
degree than cigarettes.  
Intervention and research design: A two-arm counterbalanced, crossover study 
over two consecutive weeks. Participants arrived at the Clinical Research Center 
of the Zuckerberg San Francisco General Hospital between 7:00 to 8:00 AM on 
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AM, participants used the assigned e-cigarette or cigarette in a standardized 
protocol, taking one puff every 30 seconds; puff duration was not controlled by 
the study. 
Cig-a-like and pod users took a total of 15 puffs while fixed-power and variable-
power tank users took a total of 10 puffs. Blood samples were collected before 
and 2, 5, 15, 30, 45, 60, 90, 120, 180, and 240 minutes after the last puff of each 
product through an intravenous line in the forearm. 
The authors were not able to detect any differences in withdrawal symptoms, 
affective states, and urge to smoke cigarettes between e-cigarette and dual 
users of e-cigarettes and conventional combustible tobacco cigarettes.322 
Device and product: Participants used their usual brands of e-cigarettes and 
cigarettes, provided by the study. 
Vena et al.330 
2020 
Harm The authors reported on the relationship between passive exposure to the use 
of a female-marketed e-cigarette with selectively enhanced smoking urge, 
cigarette and e-cigarette desire, and smoking behaviour among women (versus 
men) smokers. 
Age mean years (SD): 29.1 (0.7) males, 27.4 (0.8) females.  
Sex: 31 males, 33 females. Country: USA 
Duration of trial: One time point. Three duration. Measures gathered up to 50 
minutes post intervention. 
Data source: Candidates were recruited via online advertisements and flyers for 
a study about “moods, behaviours, and social interactions” to mask the study 
purpose 
Population size: 64. Year of data collection: December 2017 and May 2018 
E-cigarette, smoking and other related status: daily smoking (5–30 cigarettes per 
day), not currently attempting to attempting to quit smoking 
Outcomes: Urge and desire for e-cigarette 
Intervention and research design: A within- and between-subjects study design 
in a 1 to 1.5 hours session consisting of a 50-minute cue exposure phase 
followed by a 50-minute smoking behaviour task. In the cue phase, the 
participant engaged in two five-minute tasks with another participant separated 
by a short rest break. The participant then took part in the smoking behaviour 
phase, which was the latency portion of the Smoking Lapse Task. This 
component ascertained each participant's ability to refrain from smoking versus 
obtain a monetary reinforcer.  
The authors concluded that both women and men were sensitive to the use of 
the female-marketed e-cigarettes as a smoking cue.330 
Device and product: The control cue was bottled water (16.9 oz. clear plastic 
bottle). The active cue was a hot pink-coloured iStick Pico e-cigarette mod 
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Author(s) year Possible 
benefit or 
harm 
Interventional trial papers cardiovascular disease 




The authors investigated the acute effects of electronic and tobacco cigarette 
smoking on complete blood count. 
Age mean years (SD): 36.8 ± 9.9 smokers. 28.87 ± 1.5 non-smokers  
Sex: Smokers-8 males, 7 females. Non-smokers-8 males, 7 females Country: 
Greece 
Data source: Two groups of adults volunteered and provided written consent  
Duration of trial: Twenty-one days. Subjects in each of the two groups 
participated in three experimental sessions assigned in a random order and 
separated by a minimum of seven days of wash-out. Blood samples were 
collected prior to, immediately after, as well as one hour after the active and 
passive smoking sessions. 
Population size: 30. Two groups of 15 regarding smoking status, four groups 
regarding exposure.  
Year of data collection: Not reported  
E-cigarette, smoking and other related status: 15 smokers (P15 cigarettes/day) 
15 never-smokers. 
Intervention and research design: The two groups participated in three 
experimental sessions assigned in a random order and separated by a 
minimum of seven days of wash-out. The group of smokers underwent a 
control session (ASCON), an active tobacco cigarette smoking session (ASTOB), 
and an active e-cigarette smoking session (ASE-CIG). The group of never 
smokers underwent a control session (PSCON), a passive tobacco cigarette 
smoking session (PSTOB), and a passive e-cigarette smoking session (PSECIG). 
All subjects participated in each experimental session once. Blood samples 
were collected prior to, immediately after, as well as one hour after the active 
and passive smoking sessions. Prior to each experimental session, each subject 
was assessed for exhaled carbon monoxide (CO). Values of CO > 15 ppm or 
reporting by the subject of active smoking or excessive passive smoking in the 
previous 10 h led to rescheduling of the said session. In the ASCON session, 
smokers were asked to ‘‘smoke’’ an unlit cigarette of their own brand for 30 
minutes. In the ASTOB session, smokers were asked to smoke two tobacco 
cigarettes of their own brand within 30 min. Finally, in the ASE-CIG session, 
smokers were asked to smoke a number of puffs on an e-cigarette (device: 
Giant, Nobacco G.P., Greece) within 30 minutes. The e-cigarette liquid used 
(Nobacco USA Mix, Nobacco G.P., Greece) had a ‘‘tobacco taste’’ and, 
according to the manufacturer, incorporated nicotine at 11 mg/ml. The 
number of e-cigarette puffs for each participant during the ASE-CIG session 
was calculated as: [(mg of nicotine in own brand of tobacco cigarettes x 1.5 x 
50)/11] x 2.  
Outcomes: white blood cells, red blood cells, hemoglobin, hematocrit, mean 
corpuscular volume, mean corpuscular hemoglobin, mean corpuscular 
hemoglobin concentration, red blood cell distribution width, platelet count, 
mean platelet volume, platelet hematocrit, and platelet distribution width. 
Moreover, different types of white blood cells – specifically, lymphocytes, 
monocytes, and granulocytes – were measured as a total count and as a 
percentage 
In the Passive smoking session, participants were exposed to normal room air 
for one hour inside a 60 m3 controlled chamber. In the PSTOB session, 
participants were exposed to air polluted with tobacco cigarette smoke at a 
stable CO concentration adjusted at bar/restaurant levels, for 1 hour inside the 





Author(s) year Possible 
benefit or 
harm 
Interventional trial papers cardiovascular disease 
combustion of cigarettes from various popular brands using an air pump set at 
an air flow rate of 4 l/minute. Cigarettes were half smoked using the air pump 
and then were left lit for 2 minutes to generate side stream smoke, and then 
the rest of the cigarettes were smoked. An average of 29.2 ± 0.9 cigarettes was 
smoked in order to achieve the required level of CO in the exposure chamber. 
In the PSE-CIG session, participants were exposed to air polluted with e-
cigarette vapor for one hour in the same chamber. In this case, a simulated a 
bar/restaurant e-cigarette smoking environment was achieved by smoking e-
cigarettes via the same air pump set at an air flow rate of 4 l/minutes for the 
same time as in the PSTOB session. 
The authors concluded that the results suggest that active e-cigarette smoking 
in smokers and passive e-cigarette smoking in never-smokers do not affect 
markers of complete blood count. By contrast, active tobacco cigarette 
smoking in smokers and passive tobacco cigarette smoking in never-smokers 
increase white blood cell count, lymphocyte count, and granulocyte count for 
at least 1 hour.336 
Device and product: In the ASE-CIG session, smokers were asked to smoke a 
number of puffs on an e-cigarette (device: Giant, Nobacco G.P., Greece) within 
30 minutes. The e-cigarette liquid used (Nobacco USA Mix, Nobacco G.P., 
Greece) had a ‘‘tobacco taste’’ and, according to the manufacturer, 
incorporated nicotine at 11 mg/ml. They were selected for this study because 
the specific liquid is the only one available in the Greek market that has been 
analysed by an independent, publicly funded research institute. This analysis 
demonstrated that the liquid used incorporates >60% propylene glycol, <10% 
nicotine, <5% linalool, <5% tobacco essence, and <1% methyl vanilyn. It was 
assumed by the authors of this study that composition of the vapor phase 
inhaled in this study is similar. The number of e-cigarette puffs for each 
participant during the ASE-CIG session was calculated as: [(mg of nicotine in 
own brand of tobacco cigarettes)] 





The authors reported on the acute effects of using an e-cigarette on 
myocardial function. 
Age mean years (SD): 36 ± 5 Smokers 35 ± 5 E-cigarette users 
Sex: 32 males 4 females. Country: Greece 
Duration of trial: One time point. Measures were gathered up to 10 minutes 
after intervention 
Data source: The study sample consisted of consecutive healthy subjects 
visiting hospital for routine examinations who volunteered to participate. 
Population size: Total 76 smokers males 36 E-cigarette users 40 
Year of data collection: Not reported 
E-cigarette, smoking and other related status: Smokers (group SM) were 
included if they were smoking for at least 5 years and were consuming at least 
15 cigarettes per day. E-cigarette users (group e-cigarette) were included if 
they had quit smoking and were using electronic-cigarettes with nicotine-
containing liquid for at least 1 month, according to self-report. To avoid 
potential compensatory effects from using lower nicotine-containing liquid, 
participants were included if they were daily consumers of similar “strength” 
liquids (9-12 mg/ml nicotine concentration) to that used in the study (11 
mg/ml). 
Intervention and research design: Before and after design. 36 healthy heavy 





Author(s) year Possible 
benefit or 
harm 
Interventional trial papers cardiovascular disease 
cigarette, age 35 ± 5 years) before and after using the device with “medium-
strength” nicotine concentration (11 mg/ml) for 7 minutes. 
Outcomes: Mitral flow diastolic velocities (E, A), their ratio (E/A), deceleration 
time (DT), isovolumetric relaxation time (IVRT) and corrected-to-heart rate 
IVRT (IVRTc) were measured. Mitral annulus systolic (Sm), and diastolic (Em, 
Am) velocities were estimated. Myocardial performance index was calculated 
from Doppler flow (MPI) and tissue Doppler (MPIt). Longitudinal deformation 
measurements of global strain (GS), systolic (SRs) and diastolic (SRe, SRa) 
strain rate were also performed. 
The authors concluded that although acute smoking causes a delay in 
myocardial relaxation, e-cigarette use has no immediate effects. E-cigarettes’ 
role in tobacco harm reduction should be studied intensively in order to 
determine whether switching to e-cigarette use may have long-term beneficial 
effects on smokers’ health. 337 
Device and product: All smokers were asked to use one commercially available 
tobacco cigarette of the same nicotine (1.0 mg), tar (10 mg) and carbon 
monoxide (10 mg) yields. E-cigarette users were asked to use a commercially 
available device with liquid containing 11 mg/ml nicotine concentration. The 
device used was an eGo-T battery (Nobacco, Athens, Greece) with an eGo-C 
atomiser (Alter Ego, Athens, Greece). It is considered a “second-generation” 
device. Unlike cigarette-like devices which consist of a small battery and a 
polyfil-containing atomiser (commonly called “cartomiser”), the e-cigarette 
used in this study is a multi-piece system. It consists of a 650 milliampere hour 
rechargeable lithium battery, delivering 3.5 volts to the atomiser (measured by 
a volt-meter), and an atomiser consisting of 4 parts: the tank which stores the 
liquid (capacity of approximately 1.1 ml), the atomiser body, the atomiser 
head which includes the resistance, and the atomiser cap. It is a manually 
activated device, by pressing a button; it does not produce any vapour when 
not activated by the user.  
The e-cigarette liquid used in the study contained 11 mg/ml nicotine and is 
considered “medium strength” according to manufacturer’s report (USA Mix 
Med, formerly known as MLB-Med, Nobacco, Athens, Greece). It is sold in 20 
ml bottles. It was the only liquid tested by an independent laboratory 
(National Centre for Scientific Research “Demokritos”, mass spectrometry and 
dioxin analysis laboratory) at the time of study initiation. According to the 
laboratory report, the contents were: propylene glycol (α -propylene glycol or 
1,2-propanediol) in a concentration > 60%, linalool (3,7-dimethylocta-1,6-dien-
3-ol) in a concentration < 5%, nicotine (<10%), tobacco essence (<5%), and 
methyl vanillin (4-hydroxy-3-methoxybenzaldehyde) at < 1%. No tobacco-
specific nitrosamines or polycyclic aromatic hydrocarbons were detected. For 
every participant, a new cartridge and atomiser head was used. One of the 
researchers filled the cartridge with 1 ml of liquid; subsequently it was 
positioned in the atomiser and the participant started using it. The battery was 
fully charged before being used by each subject 
Szoltysek-




The authors reported on the influence of inhaled nicotine from conventional 
combustible tobacco cigarettes versus e-cigarettes on arterial stiffness. 
Age mean years (SD) (range): 23 ± 2 (19 to 25). Sex: All female. Country: Poland 
Duration of trial: Two study visits separated by at least one day. Total three 
days in length. Measures were recorded during and 10 minutes post 
intervention. 
Data source: Healthy students of the Medical University of Silesia who smoked 
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Population size: 15. Year of data collection: Not reported  
E-cigarette, smoking and other related status: All participants reported using e-
cigarettes at least 10 times. More specifically they smoked 8±4 cigarettes per 
day for 4±2 years. 
Intervention and research design: The study employs a within-subject 
crossover research design with one day washout period. Every participant 
visited the laboratory for two experimental sessions. Session 1: participant 
smoked a conventional cigarette taking 10 to 12 puffs, session 2: participant 
vaped an e-cigarette taking 15 puffs, sessions 1 and 2 lasted about 1 hour each 
and were separated by at least one day. 
Outcomes: A non-invasive measurement of arterial stiffness parameters – 
Stiffness Index (SI) and Reflection Index (RI) – was conducted and systolic and 
diastolic blood pressure and heart rate were measured before and after 
smoking a conventional cigarette as well as use of an electronic cigarette. 
The authors concluded that in contrast to conventional combustible tobacco 
cigarette use, the use of e-cigarettes causes no changes in arterial stiffness. 
They suggested that this may indicate lower bioavailability of nicotine from the 
e-cigarette or an additional effect of other substances present in cigarette 
smoke but absent in an e-cigarette aerosol. 338 
Device and product: During the study participants used either their regular 
combustible cigarettes or used e-cigarettes with e-liquid supplied by the 
research team. The authors used the most common on the Polish market Ego-
3 e-cigarettes (Volish Ltd, Poland). The Ego-3 consists of clearomizer Crystal 2 
with heating coil of 2.4 Ohm resistance and stabilized voltage battery (900 
milliampere hour, 3.4V). Batteries were fully charged for 24 hours before each 
use. Participants used 24 mg nicotine/mL e-liquid during experiments. Nicotine 
content in the aerosol generated in laboratory conditions using the automatic 
smoking machine Palaczbot® [11] was 0.77±0.12 mg (15x70 mL puffs, 1.8 sec. 
puff durations, and 17 sec. puff intervals). Participants used filtered, ‘slim’ type 
combustible cigarettes defined by the manufacturer to have a nicotine content 
of 0.7 mg per cigarette 
Cooke et al.339 
2015 
Harm The authors reported on the effect of acute inhalation of vaporised nicotine 
on arterial pressure in young non-smokers. 
Age mean years (SD): 23 ± 1. Sex: 10 males, 10 females. Country: USA 
Data source: Not reported 
Duration of trial: Two weeks. The interventions were undertaken on two 
different days separated by at least 1 week. Subjects sat quietly for 10 minutes 
then had arterial pressure measured subjects then inhaled once every 30 s for 
10 minutes, subjects remained seated for an additional then asked to report 
any symptoms (nausea, lightheadedness, etc.) and had arterial pressures 
measured again. Urine cotinine concentration was also assessed at this time.  
Population size: 20. Year of data collection: Not reported 
E-cigarette, smoking and other related status: healthy non-smoking volunteers 
Intervention and research design: Experiments were conducted on two 
different days separated by at least 1 week (randomized, counterbalanced, 
and double blinded). Subjects then inhaled once every 30 s for 10 minutes 
from an e-cigarette containing nicotine (18 mg) or a placebo (0 mg nicotine). 
Data were recorded for 5 minutes with subjects’ supine, for 5 minutes in the 
70’ head-up tilt position, and for a 5-minutes supine recovery. Throughout the 
experiment, subjects breathed in time with a metronome set at a pace of 15 
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Outcomes: seated arterial pressures at rest, and on arterial pressure and 
functional autonomic control during a hemodynamic challenge associated with 
orthostatic stress. Specifically, arterial pressure, urine cotinine concentration, 
Electrocardiogram and efferent muscle sympathetic nerve activity from the 
right peroneal nerve, symptoms (nausea, light-headedness, etc.). After the 
inhalation protocol, decreases in both heart rate and systolic pressure in the 
placebo condition, and increases in heart rate and systolic pressure in the 
nicotine condition (also both p C 0.05), resulted in higher heart rates and 
systolic pressure for the nicotine compared to the placebo trial. Ranges of 
urine cotinine concentrations were higher after inhalation on the nicotine 
compared with the placebo cartridge. efferent muscle sympathetic nerve 
activity was numerically higher after nicotine inhalation compared with 
placebo in the supine position, but not statistically distinguishable. After 
inhaling on the nicotine cartridge for 10 minutes, 19 of 20 subjects reported 
feeling lightheaded, and 3 subjects also reported nausea. In comparison, no 
symptoms of physical discomfort were reported by subjects after inhaling on 
the placebo cartridge 
The authors concluded that vaporised nicotine inhalation is not harmless339 
 Device and product: Nicotine and placebo cartridges were obtained from 
Green Smart Living (Salt Lake City, UT) and Clean Electronic-cigarettes. 








The authors reported on the effects of using e-cigarettes on nicotine delivery 
and cardiovascular function in comparison with conventional combustible 
tobacco cigarettes. 
Age mean years (SD): 38.7 ± 10.77. Sex: 11 males, 12 females. Country: USA 
Ethnicity: American Indian/Alaska Native 1 Black or African American 3 White 
20 
Duration of trial: Eleven days. Subjects participating in the lead-in checked in 
on Day -2 and remained in the clinic. Subjects abstained from use of nicotine-
containing products for a period of at least 36 h prior to each product 
administration (Days 1, 3, 5, 7, 9, and 11). Days -1, 2, 4, 6, 8, and 10 were 
designated wash-out days in order to obtain the required 36-hour nicotine-
free period between product administrations. Each product administration day 
included a controlled product administration and a 1-hour ad lib use of the 
study product. The controlled product administration consisted of 50 puffs of 
the assigned e-cigarette product (5-s puffs at 30-s intervals) or smoking one 
Marlboro_ Gold King Size cigarette (30-s intervals with the subjects’ normal 
puff duration) with puff counts monitored by the clinical staff. Blood samples 
for plasma nicotine, blood pressure, pulse rate, and exhaled CO measurements 
were obtained at scheduled time points on each product administration day. 
For blood samples were collected at approximately 10 minutes prior to and at 
5, 10, 15, 20, 25, 30, 45, 60, 75, and 90 minutes following the start of the 
controlled product administration. Cardiovascular vital signs, e.g., systolic 
blood pressure, diastolic blood pressure, and heart rate, were measured at 
approximately 30 minutes prior to the start of the controlled product use and 
approximately 20 minutes following the end of the ad lib product use on Days 
1, 3, 5, 7, 9, and 11. Exhaled CO was assessed at approximately 20 minutes 
prior to the start of the controlled product use and at approximately 15 
minutes following the end of the ad lib product use. 
Data source: Not reported. Population size: 23. Year of data collection: Not 
reported 
E-cigarette, smoking and other related status: smoked an average of 10 or 
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Intervention and research design: The study design was a randomized, partially 
single blinded, six-period crossover study. The interventions or study product 
were products A to E (detailed below). Each product administration day 
included a controlled product administration and a 1-hour ad lib use of the 
study product. The controlled product administration consisted of 50 puffs of 
the assigned e-cigarette product (5-s puffs at 30-s intervals) or smoking one 
MarlboroGold King Size cigarette (30-s intervals with the subjects’ normal puff 
duration) with puff counts monitored by the clinical staff. Comparisons were 
made to evaluate differences between the e-cigarette formulations as well as 
to the market-leading conventional cigarette, Marlboro_ Gold King Size. 
Outcomes: Plasma nicotine, Cardiovascular vital signs, e.g., systolic blood 
pressure, diastolic blood pressure, and heart rate and exhaled CO. 
The authors concluded that the nicotine plasma concentrations after 1.5 hours 
of e-cigarette product use were significantly lower in the users of e-cigarettes 
than in users of Marlboro cigarettes. The combination of glycerine and 
propylene glycol as the delivery vehicle facilitated delivery of more nicotine 
than the use of glycerine alone. The heart rate, as well as systolic and diastolic 
blood pressure, were significantly elevated after use of Marlboro cigarettes, 
but the elevation was less after use of most of the e-cigarettes tested. Use of 
e-cigarettes had no impact on exhaled carbon monoxide levels, whereas the 
Marlboro cigarettes significantly increased exhaled carbon monoxide to more 
than eight times above the baseline.340 
Device and product: The blu e-cigarettes are currently sold in retail outlets 
across the United States (US) in both disposable and re-useable forms. The blu 
e-cigarettess prepared for use in the current study were 2 commercial 
products (Product D and E) that contain 16 mg/mL (1.6%) nicotine (USP grade), 
and 3 non-commercial products (Product A, B and C) that contain 24 mg/mL 
(2.4%) nicotine (USP grade), in the cartomizer device format attached to 
rechargeable batteries. In comparison, the nicotine yield of the market-leading 
conventional cigarette (Marlboro_ Gold King Size) is approximately 0.8 mg per 
cigarette (FTC 2007). As the blu e-cigarettes may yield from 250 to 400 puffs 
per cartridge, a single cartridge may equate to approximately 1–2 packs of 
conventional tobacco cigarettes. The following investigational and comparator 
product designations were used in this study.  
Product A: Classic Tobacco e-cigarette in rechargeable cartomizer (2.4% 
nicotine, ~75% glycerine vehicle), or Product A Classic e-cigarette (2.4% Nic in 
Gly) 
Product B: Classic Tobacco e-cigarette in rechargeable cartomizer (2.4% 
nicotine, ~50% glycerin/_20% propylene glycol vehicle), or Product B Classic e-
cigarette (2.4% Nic in Gly/propylene glycol) 
Product C: Magnificent Menthol e-cigarette in rechargeable cartomizer (2.4% 
nicotine, ~75% glycerine vehicle), or Product C Menthol e-cigarette (2.4% Nic 
in Gly) 
Product D: Classic Tobacco e-cigarette in rechargeable cartomizer (1.6% 
nicotine, ~75% glycerine vehicle), or Product D Classic e-cigarette (1.6% Nic in 
Gly) 
Product E: Classic Tobacco e-cigarette in rechargeable cartomizer (1.6% 
nicotine, ~50% glycerin/_20% propylene glycol vehicle), or Product E Classic e-
cigarette (1.6% Nic in Gly/propylene glycol) 
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In addition to nicotine, the blu e-cigarettes prepared for use in this study 
contain vegetable glycerin, natural and artificial flavours, distilled water, citric 




Harm The authors reported on the relationship between e-cigarettes and an 
increase in the number of endothelial progenitor cells in the blood of healthy 
volunteers. 
Age mean years (SD): 28.4. Sex: 9 males, 5 females. Country: Sweden 
Data source: The authors specifically chosen to recruit sporadic smokers as 
they would better tolerate exposure to ECV than cigarette smoke naïve 
individuals, thus minimizing the probability of developing sickness or nausea 
that are usually associated with smoke inhalation. 
Duration of trial: Two session. One-week interval. Population size: 16. 
Year of data collection: Not reported  
E-cigarette, smoking and other related status: healthy seldom smokers 
(maximum of 10 cigarettes/ month) 
Intervention and research design: Sixteen healthy seldom smokers were 
randomized into two groups either exposed or not exposed to 10 puffs of e-
cigarette vapor for 10 minutes, in a crossover design. Blood samples were 
obtained at baseline and 1, 4 and 24 hours following exposure. 
Outcomes: Endothelial progenitor cells (stem cells mainly derived from the 
bone marrow and play a pivotal role in the maintenance, differentiation and 
regeneration of endothelial cells following vascular injury or neogenesis) and 
microvesicles (cells which can be biologically active in immune responses, 
thrombosis and inflammation in determine vascular changes). FeNO and 
Cotinine levels were also assessed.  
The authors concluded that in healthy volunteers, 10 puffs of e-cigarette 
vapour inhalation caused an increase in endothelial progenitor cells. This 
increase was of the same magnitude as that following smoking one 
conventional combustible tobacco cigarette. Taken together, these results may 
represent signs of possible vascular changes after short e-cigarette inhalation. 
347 
Device and product: A popular second-generation e-cigarette device (eGo XL, 
1100 milliampere hour, operating at 3,7 V) with a dual-coil CE5 atomizer was 
used. E-liquid (nicotine 12 mg/ml: propylene glycol 49.4%, glycerine 44.4%, 5% 
ethanol, 1.2% nicotine) without any added flavouring or aroma (Valeo 
laboratories GmbH, Germany). The manufacturer has tested this product at an 
independent laboratory (Eurofins WEJ Contaminants GmbH, Germany) and at 
the national quality inspection association (TÜV e Technical Inspection 
Association, Germany). Content analysis is freely available on the 




Harm The authors examined the acute impact of tobacco and e-cigarette smoking 
on oxidative stress and vascular function. 
Age mean years (SD): 28.0 ± 5.3. Sex: 21 females (52.5%). Country: Italy 
Duration of trial: Two study visits separated by at one week. Measures were 
gathered just before and within 30 minutes after intervention  
Data source: Not reported  
Population size: 40 healthy subjects 20 smokers and 20 non-smokers, matched 
for age and sex  
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E-cigarette, smoking and other related status: For smokers only (n=20) number 
of cigarettes smoked daily 11.1 (+/-5.8) 
Intervention and research design: Crossover, single-blind study. The order of 
assignment of the two types of cigarette that had to be smoked in the two 
phases of the study was not randomized. All the subjects smoked a tobacco 
cigarette in the first phase of the study and then smoked an e-cigarette in the 
second phase of the study 
Indicators of oxidative stress (serum levels of soluble NADPH oxidase 2 
(NOX2)-derived peptide, nitric oxide bioavailability, 8-iso-prostaglandin F2α-III, 
and vitamin E) and endothelial dysfunction (flow-mediated dilation) were 
collected. 
Outcomes: Markers of oxidative stress, nitric oxide bioavailability, vitamin E 
levels, flow mediated dilation. After having smoked either a tobacco cigarette 
or an e-Cigarette, significant changes in the levels of sNOX2-dp, 8-isoPGF2a, 
vitamin E, and NO bioavailability (all, P < .001) were detected in both smokers 
and non-smokers. There was no significant difference between the groups 
(3.26 +/-0.57 mm vs 3.29 +/-0.59 mm; P =0 .827) regarding brachial artery 
diameter at baseline. Changes in flow mediated dilation values were also 
consistently decreased in all groups after smoking either a tobacco cigarette or 
an e-Cigarette. No significant changes in flow mediated dilation were seen in a 
small control group (n = 8, 4 smokers and 4 non-smokers) after smoking a 
sham cigarette (an e-Cigarette without the cartridge, P =0 .731 for smokers 
and P = .662 for non-smokers). 
The authors concluded that smoking both e-cigarettes and conventional 
combustible tobacco cigarettes led to a significant increase in the levels of 
soluble NOX2-derived peptide and 8-iso-prostaglandin F2α and a significant 
decrease in nitric oxide bioavailability, vitamin E levels, and flow mediated 
dilation.342 
Device and product: In the first phase, all subjects, both smokers (who had not 
smoked for at least 12 h) and non-smokers, smoked one tobacco cigarette 
from a leading brand (with a mean nicotine content of 0.6 mg according to the 
package label). In the second phase, 1 week after the first phase, the same 
subjects smoked a tobacco-flavoured e-Cigarette from a leading brand 
(charged with a nicotine cartridge, with a mean nicotine content of 16 mg, 






The authors reported on the effect of continuous smoking reduction and 
abstinence on blood pressure and heart rate in smokers switching to e-
cigarettes. 
Age mean years (SD): 44.0 ± 12.5. Sex: 190 males 110 females (baseline) 
Country: Italy. Duration of trial: 12-month 
Data source: Eligible participants were enrolled in a prospective 12-month 
randomised, controlled trial consisting of nine office visits at the University 
Hospital’s smoking cessation clinic (Centro per la Prevenzione e Cura del 
Tabagismo -CPCT; Università di Catania, Italy). 
Population size: 300 persons were randomised into the different arms of the 
trial. Two hundred and twenty-five subjects (75.0 %) returned at week 12, 211 
(70.3 %) at week 24, and 183 (61.0 %) at week 52 for the final follow-up visit. 
Year of data collection:  The smokers were recruited during the period June 
2010–February 2011 with a final follow-up visit at week 52. 
E-cigarette, smoking and other related status: The trial registry describes the 
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arm randomised controlled trial (RCT) with a 52-week follow-up because the 
authors decided to monitor the long-term impact of different nicotine levels 
on smoking cessation or reduction, BP and HR. This is a post hoc analysis, since 
BP and HR were not officially among the primary or secondary outcomes of 
trial in the registry entry  
Intervention and research design: Randomised, controlled trial. Regular 
smokers not intending to quit were invited to try ECs (‘‘Categoria’’, Arbi Group 
Srl, Italy). 
Outcomes: Blood pressure and heart rate 
The authors concluded that quitting smoking with the use of e-cigarettes does 
not lead to higher blood pressure values, and this is independently observed 
whether e-cigarettes are regularly used or not348 
Device and product: Participants receive an e-cigarette kit with either 
‘‘Original’’ (2.4 % nicotine—Group A), or ‘‘Categoria’’ (1.8 % nicotine— Group 
B), or ‘‘Original’’ without nicotine (‘‘sweet tobacco’’ aroma—Group C) 
cartridges 
Fogt et al.353 
2016 
Harm The authors reported on the acute cardiorespiratory and performance effects 
of vaporised nicotine delivered via e-cigarettes at rest and during cycle 
exercise in young, normotensive, non-smoking subjects. 
Age mean years (SD): 23.1 ± 2.5. Sex: 10 males 10 females. Country: USA 
Duration of trial: Two session. One-week interval. Using a double-blind design, 
20 subjects participated in two randomized trials: placebo (0 mg nicotine) or 
nicotine (18 mg nicotine). Two sessions (trials) separated by one week. 
Participants were provided a blinded e-cigarette and instructed to inhale 
deeply once every 30 s over the course of 10 minutes (20 inhalations total). 
During a 10 minutes quiet rest following use of the EC, participants completed 
a short questionnaire to assess subjective symptoms from the inhalations. At 
the conclusion of the 10 minutes rest period, participants provided a urine 
sample for the assessment of cotinine. Resting metabolic rate was assessed by 
indirect calorimetry. The incremental cycle test protocol commenced 5 
minutes following resting metabolic rate testing to evaluate participants’ peak 
power output and cardiorespiratory response and peak aerobic capacity. 
Resting metabolic rate was assessed 40 minutes later by indirect calorimetry 
followed by an incremental cycle test. 
Data source: Volunteer subjects self-reporting as healthy and non-smoking 
Population size: 20. Year of data collection: Not reported  
E-cigarette, smoking and other related status:  
Intervention and research design: Subjects participated in two randomized 
trials, double-blind design, separated by ≥1 week: placebo 0 mg•ml-1 nicotine 
e-cigarette trial and 18 mg•ml-1 nicotine e-cigarette trial.  
Outcomes: Resting systolic and diastolic blood pressure, resting metabolic 
rate, heart rate, non-protein respiratory quotient, systolic and diastolic blood 
pressure during exercise and aerobic power during exercise (cycle exercise 
(VO2). Expired air was analyzed to estimate whole-body oxygen consumption 
(VO2; L•min-1). Caloric energy expenditure (kcal•min-1) was then estimated 
using the thermal equivalents of oxygen for the non-protein respiratory 
quotient 
The authors concluded that acute vaporised nicotine inhalation via e-
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affect resting metabolic rate or cycle aerobic power in young, normotensive 
non-smokers.353 
Device and product: A single brand of over-the-counter e-cigarette was used 
for this study (Green Smart Living, Salt Lake City, UT). The 18 mg and 0 mg e-










The authors reported on the relationship between e-cigarette smoking and 
increases in aortic stiffness and blood pressure in young smokers. 
Age mean years (SD): 30 ± 8. Sex: Not reported. Country: Greece (assumed) 
Duration of trial: Four sessions. Interval period not reported. Measures were 
gathered up to 60 minutes after intervention. 
Data source: Not reported. Population size: 24 smokers. Year of data 
collection: Not reported  
E-cigarette, smoking and other related status: smokers  
Intervention and research design: Studied 4 separate occasions (total 96 
sessions): 1) simulate tobacco cigarettes (TC) over 5 minutes; 2) Electronic-
cigarettes (EC) over 5 minutes; 3) Electronic-cigarettes (EC) for a period of 30 
minutes; and 4) nothing (sham procedure) for 60 minutes. Electronic-
cigarettes 5 minutes was chosen as a direct comparison with simulate tobacco 
cigarettes (nicotine delivery rate from Electronic-cigarettes is far lower and 
slower than with simulate tobacco cigarettes), and Electronic-cigarettes 30 
minutes to mimic the common pattern of Electronic-cigarettes smoking 
(nicotine delivered obtained plasma levels comparable with those after 5 
minutes of simulate tobacco cigarettes smoking 
Outcomes: Carotid-femoral pulse-wave velocity (PWV) was used to assess 
aortic stiffness and blood pressure 
The authors concluded that various patterns of e-cigarette smoking on aortic 
stiffness and blood pressure clearly demonstrated an unfavourable effect. 
Using e-cigarettes for 30 minutes induces an unfavourable effect on aortic 
stiffness similar to tobacco cigarette smoking. The influence of e-cigarette 
smoking for 5 minutes on aortic stiffness is not as prompt (peak effect at 15 
minutes) and is less potent compared with the effect of tobacco cigarette 
smoking.341 




Harm The authors reported on the role of nicotine versus non-nicotine constituents 
in e-cigarette emissions in causing increased resting cardiac sympathetic 
nerve activity and increased susceptibility to oxidative stress in otherwise 
healthy humans.  
Age mean years (SD): 26.3 ± 0.9. Sex: 13 males, 20 females. Country: USA  
Ethnicity: 5 Black 8 Asian 5 Hispanic 15 White (non-Hispanic) 
Duration of trial: Three study visits at four-week intervals. Each participant 
underwent the each of the 3 exposure sessions, each separated by a 4-week 
washout. Subjects were studied mid-day (usually between 10:00 AM and 2:00 
PM). At commencement of each session the participant was instrumented, 
blood was drawn, and after a 10-minute rest period, blood pressure and heart 
rate were measured, and the electrocardiogram was recorded for 10 minutes. 
The subject then underwent the assigned exposure (e-cigarette with nicotine, 
e-cigarette without nicotine, or sham control). After repositioning, blood 
pressure and heart rate were measured, and the electrocardiogram was 
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Data source: Healthy volunteers  
Population size: 39 participants were enrolled 33 completed the study 
Year of data collection: Not reported  
E-cigarette, smoking and other related status: Participants were not current 
(within 1-year) e-cigarette or tobacco cigarette users or former e-cigarette or 
tobacco cigarette smokers if they had quit smoking >1 year before the study 
Intervention and research design: The design is an open-label, randomized, 
crossover study. In random order, each participant underwent the following 3 
exposure sessions, each separated by a 4-week washout: e-cigarette with 
nicotine; e-cigarette without nicotine (same flavouring and solvent as the 
“with nicotine” exposure); and sham control consisting of puffing on a device 
without e-liquid. 
Outcomes: Heart rate variability, blood tests (paraoxonase-1 activity, (PON-1 
activity), low-density lipoprotein oxidizability, and HDL antioxidant/anti-
inflammatory capacity, expressed as an HDL antioxidant index, Low-density 
lipoprotein oxidizability and HDL antioxidant index assays were performed only 
in participants who used the Greensmoke cigalike device.  
The authors concluded that the acute sympathomimetic effect of e-cigarettes 
is attributable to the inhaled nicotine, not to non-nicotine constituents in e-
cigarette aerosol, recapitulating the same heart rate variability pattern 
associated with increased cardiac risk in multiple populations with and without 
known cardiac disease. Evidence of oxidative stress, as estimated by plasma 
paraoxonase activity, was not uncovered following acute e-cigarette 
exposure.343 
Device and product: Fifteen subjects used the Greensmoke cigalike device (the 
highest rated e-cigarette brand in the United States sold online at the time of 
the study design28) with tobacco-flavoured liquid, vegetable 
glycerin/propylene glycol solvents, with 1.2% nicotine and 0% nicotine (on 
different days) content. After using the Greensmoke cigalike e-cigarette with 
1.2% nicotine, only 5 of 15 of the subjects had detectable nicotine and/or 
cotinine in plasma, so the final 18 subjects used a more- efficient nicotine 
delivery system, the second-generation penlike device (1.0 O, eGo-One by 
Joyetech, Irvine, CA), with strawberry flavouring, vegetable glycerin/propylene 
glycol solvents, with 1.2% nicotine and 0% nicotine (on different days) content. 
E-cigarette topography was standardized. Participants were verbally cued 
every 30 seconds with a recording: “Ready, set” (place e-cigarette in mouth), 
“go, 2, 3” (inhale 3 seconds), “hold, 2, 3” (hold aerosol in), then exhale. No 
plasma nicotine/cotinine was detectable in the first 6 subjects who used the 
cigalike device for 10 minutes, so the acute exposure was increased to 30 
minutes (60 puffs) for the final 27 subjects. 
Chaumont et al 
345 
2018 
Harm The authors reported on the differential effects of e-cigarettes (specifically 
the differential effects of vehicles, propylene glycol and glycerol, and 
nicotine) on macro and microvascular function, arterial stiffness, and 
oxidative stress. 
Age mean years (SD): 23 ± 0.4. Sex: 18 males, 7 females. Country: Belgium. 
Data source: Participants were enrolled based on their excellent vaping 
tolerance.  
Duration of trial: Three period crossover design. Interval period length not 
quantified. Vaping sessions (with and without nicotine) consisted of 25 puffs 
(4-s puffs at 30-s intervals) in order to create sub-ohm vaping. During the 
sham-vaping session, strict supervision of the participants ensured that they 
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turned off. The timing at which outcomes were measured varied according to 
outcome but included ongoing measure measurement during the intervention 
and measurements were made ten minutes before and five-minute after 
exposure. 
Population size: 25. Year of data collection: Not reported 
E-cigarette, smoking and other related status: Healthy occasional tobacco 
smokers median cumulative pack-year 0.2 [interquartile range 0.1–0.8]) 
Intervention and research design: This randomized study was placebo-
controlled, single-blind with a three-period crossover design. The periods 
consisted of: 1) vaping without nicotine; 2) vaping with nicotine; and 3) sham-
vaping. Blood was drawn 15 minutes before and 30 minutes after vaping (with 
and without nicotine) or sham-vaping  
Outcomes: Microvascular Endothelial Function, Arterial Stiffness and Oxidative 
Stress. The primary outcome was the impact of vaping on skin microcirculatory 
blood flow function (Ach mediated vasodilation). Secondary outcomes 
included continuous hemodynamic parameters, arterial stiffness and oxidative 
stress analyses after exposure. Hemodynamic parameters specifically finger 
systolic and diastolic blood pressure waveforms. Arterial stiffness assessment 
specifically aortic wave reflection assessment. Central aortic hemodynamics, 
and augmentation index corrected for heart rate (AIx75), were estimated using 
pulse wave and wave separation analysis. Oxidative stress and nicotine 
assessment specifically plasma total myeloperoxidase, protein-bound 3-
chlorotyrosine and homocitrulline and plasma nicotine. Neither sham-vaping 
nor vaping in the absence of nicotine resulted in modifications of 
cardiovascular parameters or oxidative stress. In contrast, vaping with 
nicotine: impaired acetylcholine mediated vasodilation, increased indices of 
arterial stiffness, namely augmentation index corrected for heart rhythm and 
pulse wave velocity, increased systolic and diastolic blood pressures as well as 
heart rate and finally; raised plasma myeloperoxidase 
The authors concluded that their findings demonstrated that high-
temperature e-cigarette vehicle vaporisation does not alter micro- and 
macrovascular function or oxidative stress, and that these effects are solely 
attributable to nicotine.345 
Device and product: The carrier used in the two e-liquids was a mix of 50% 
propylene glycol and 50% GLY pharmaceutical grade (Fagron©, Waregem, 
Belgium). One e-liquid was nicotine free (0 mg.ml−1), whereas nicotine 
(Nicobrand©, Coleraine, UK) was added to the other one at a concentration of 
3 mg.ml−1. A last-generation high-power vaping device with popular and 
commercially available parts in U.S (Smoke©, Shenzen, China) was used. E-
cigarettes were set-up at 60 Watts (0.4Ω dual coils). Vaping sessions (with and 
without nicotine) consisted of 25 puffs (4-s puffs at 30-s intervals) in order to 




Harm The authors reported on the relationship of e-cigarettes and cigarettes with 
peripheral and central haemodynamics, as well as arterial stiffness. 
Age mean years (SD): 22.9 ± 3.5. Sex: 5 males, 10 females. Country: Germany  
Duration of trial: A randomized, double-blinded pilot study. Three session with 
a 48 hour (or more) wash out period between interventions. Generally, 
measurements were started at least 30 minutes before vaping or smoking. 
Blood pressure were measured every 5 minutes and with a conventional blood 
pressure monitor every 15 minutes. Measurements discontinued not less than 
2 hours after the application. The three measurements were taken around the 
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Data source: The participants were recruited from students of the University of 
Lubeck, Germany 
Population size: 15. Year of data collection: Not reported 
E-cigarette, smoking and other related status: young, active, conventional 
combustible tobacco cigarette smokers  
Intervention and research design: This single-centre pilot study included 15 
young, active, conventional combustible tobacco cigarette smokers. The trial 
was designed as a crossover study of the acute use of three tobacco products. 
The subjects were blinded to the nicotine content of the e-cigarette. The 
participants were randomized to one of the three study groups during the first 
visit by drawing pieces of paper from a closed envelope. An elapse of 48 hours 
was scheduled between each test day to avoid any acute interaction between 
devices. The envelope contained three pieces of numbered paper (one to 
three); participants’ order was moved by drawing three times. The numbers 
denoted e-cigarette with nicotine, e-cigarette without nicotine, or cigarette. 
The three different study groups were the following: (1) smoking a cigarette 
and inhaling into the lungs (Cig) (Philip & Morris, New York, USA); (2) vaping an 
e-cigarette with nicotine (E-cigarette (+)) (DIPSE, eGo-T CE4 vaporizer (third 
generation), SSR Produkt GmbH & Co KG, Oldenburg, Germany, 3.3 volts, 1.5 
ohms and 7.26 watts; 24 mg/mL nicotine, 55% propylene glycol and 35% 
glycerin, tobacco flavour); and (3) vaping an e-cigarette without nicotine (E-
cigarette (–)) (0 mg/mL nicotine, 55% propylene glycol and 35% glycerin, 
tobacco flavour). 
Outcomes: Resting blood pressure and resting metabolic rate, and exercise 
blood pressure and aerobic power. Resting metabolic rate was not different 
between trials. Compared to the placebo, resting diastolic pressure was 3 
mmHg higher with nicotine. VO2peak was not different between the nicotine 
trial and placebo trials, and Wmax was also similar between nicotine and the 
placebo. During the cycle exercise test, average diastolic pressure was higher 
following nicotine use compared with placebo trial, and exercise diastolic 
pressure peak after nicotine was significantly higher than placebo. Resting 
systolic blood pressure was lower for nicotine trial but no systolic blood 
pressure treatment effect was observed during exercise 
The authors concluded that changes in peripheral and central blood pressure 
and also in pulse wave velocity after smoking a conventional combustible 
tobacco cigarette as well as after vaping a nicotine-containing e-cigarette. 
These findings may be associated with an increased long-term cardiovascular 
risk.350 
Devices and products: (1) smoking a cigarette and inhaling into the lungs (Cig) 
(Philip & Morris, New York, USA); (2) vaping an e-cigarette with nicotine (E-
cigarette (+)) (DIPSE, eGo-T CE4 vaporizer (third generation), SSR Produkt 
GmbH & Co KG, Oldenburg, Germany, 3.3 volts, 1.5 ohms and 7.26 watts; 24 
mg/mL nicotine, 55% propylene glycol and 35% glycerin, tobacco flavour); and 
(3) vaping an e-cigarette without nicotine (E-cigarette (–)) (0 mg/mL nicotine, 




Harm The authors reported on the relationship of conventional combustible 
tobacco cigarettes and e-cigarettes with oxidative stress and endothelial 
dysfunction. 
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Duration of trial: Two study visits. A washout period of one week before first 
assessment, and again before second assessment. Measures were gathered 
‘immediately after smoking’.  
Data source: Not reported 
Population size: 40 subjects (20 smokers, 20 non-smokers) 
Year of data collection: September 2014 to March 2015  
E-cigarette, smoking and other related status: 20 smokers, 20 non-smokers 
Intervention and research design: crossover single-blind trial with a week 
between sessions. 40 subjects (20 smokers, 20 non-smokers) underwent blood 
draws for measurement of biomarkers. After a washout of 1 month in case of 
smoking history, 40 subjects (20 smokers, 20 non-smokers) underwent blood 
draws for measurement of biomarkers, additional blood tests and brachial 
flow-mediated dilation. Smoking history (time of initiation) and intensity 
(cigarettes per day) were self-reported, but abstinence was confirmed with a 
blood cotinine test administered before each experimental smoking session. 
Specifically, liquid chromatography/tandem mass spectrometry was employed 
(Quest Diagnostics) with a 3 ng/mL cut-off. They thus were instructed to use 
either an e-cigarette (charged with a nicotine cartridge, with a mean nicotine 
content of 16 mg, equivalent to 250 puffs, with subjects taking nine puffs, 
approximately 0.6 mg of nicotine) or a conventional cigarette (with a mean 
nicotine content of 0.6 mg). Immediately after smoking, the above 
measurements were repeated. Subsequently, after an additional wash-out of 
one week, with abstinence again confirmed with a formal cotinine assay, the 
same procedure was followed but using the other product to enable within-
subject comparisons. 
Outcomes: Indicators of oxidative stress (serum levels of soluble NOX2-derived 
peptide, nitric oxide bioavailability, 8-iso-prostaglandin F2α-III, and vitamin E) 
and endothelial dysfunction (flow-mediated dilation) were collected 
The authors reported that absolute changes in oxidative stress and vascular 
features after smoking a conventional combustible tobacco cigarette and 
vaping an e-cigarette were significantly associated (all p<0.05), with the 
notable exception of 8-iso-prostaglandin F2α-III levels (p=0.030). The authors 
also stated that this post hoc analysis of the SUR-VAPES 1 trial suggests that 
the comparative oxidative and vascular effects of e-cigarettes versus 
conventional combustible tobacco cigarettes may be influenced by smoking 
status, with a potential interaction due to oral contraceptives.344 
Device and product: SUR-VAPES 
Nocella et al.354 
2018 
Harm The authors reported on the impact of conventional combustible tobacco 
cigarette versus e-cigarette smoking on platelet function. 
Age mean years (SD): 28.0 ± 5.3. Sex: 19 males 21 females. Country: Italy 
Data source: Not reported 
Duration of trial: Each participant smoked a conventional cigarette then 
returned 1 week later to vape a study e-cigarette with the same nominal 
nicotine content. Blood samples were drawn shortly before and 5 minutes 
after each episode 
Population size: 40. 20 smokers and 20 non-smokers 
Year of data collection: September 2014 and March 2015 
E-cigarette, smoking and other related status: Healthy participants, 20 smokers 
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Intervention and research design: A crossover single-blind study. The study 
was divided into 2 phases: in the first phase, all participants, both smokers 
(who had not smoked for at least 12hours) and non-smokers, smoked one 
tobacco cigarette from a leading Italian brand (with a mean nicotine content of 
0.6mg, according to the package label). In the second phase,1 week after the 
first phase, the same subjects vaped a tobacco-flavoured E- cigarette from a 
leading brand (containing a nicotine cartridge, with a mean nicotine content of 
16mg equivalent to250 puffs, according to the package label).The subjects 
vaped for a total of 9puffs (equivalent to 0.6mg of nicotine content) 
Outcomes: Platelet aggregation, soluble CD40-ligand (sCD40L) and soluble P-
selectin (sP-selectin), platelet aggregation. Cotinine concentration. 
The authors concluded that in smokers, there were no significant changes in 
sCD40L and sP-selectin, but there was a significant increase in platelet 
aggregation. In non-smokers, there was a significant increase in all markers of 
platelet activation following both conventional combustible tobacco cigarette 
and e-cigarette use. Both conventional combustible tobacco cigarette and e-
cigarettes have short-term effects on platelet activation, although in non-
smokers the use of e-cigarettes had a less important impact on platelet 
function.354 
Device and product: The study was divided into 2 phases: in the first phase, all 
participants, both smokers (who had not smoked for at least 12 hours) and 
non-smokers, smoked one Tobacco cigarette from a leading Italian brand (with 
a mean nicotine content of 0.6mg, according to the package label). In the 
second phase, 1 week after the first phase, the same subjects vaped a tobacco-
flavoured e-cigarette from a leading brand (containing a nicotine cartridge, 
with a mean nicotine content of 16mg equivalent to 250 puffs, according to 
the package label). 
Pywell et al.357 
2018 
Harm The authors reported on the effect of e-cigarettes on hand microcirculation. 
Age mean years (range): 26 years (25 to 27) smokers, 25 (22 to 29 years) non-
smokers 
Sex: Not reported. Country: England UK. Population size: 15 
Duration of trial: Two consecutive sessions. Interval not reported. Measures 
were gathered during and up to 20 minutes post intervention 
Data source: Smokers and non-smokers were recruited through word of mouth 
and advertisement posters displayed to staff members of the 2 involved 
investigative sites within staff-only areas  
Year of data collection: Baseline and a 12 month follow up point (between 
June 2015 and March 2017) 
E-cigarette, smoking and other related status: E-cigarette, smoking and other 
related status: 7 smokers and 8 non-smokers. The average cigarette 
consumption of smokers was 1.5 packs per week (0.5e3 packs per week). 
Smokers were asked to refrain from using any form of nicotine within 4 hours 
of beginning the study. The control in this study was the baseline 
microcirculation established over 5 minutes prior to e-cigarette exposure 
Intervention and research design: Participants commenced a 5-minute 
smoking protocol of non-nicotine (0-mg) e-cigarettes with continuous 
microcirculation measurements during smoking and for 20 minutes afterward. 
The intervention was repeated with nicotine (24-mg) e-cigarettes. A 5-minute 
smoking protocol of a non-nicotine (0-mg) e-cigarette was then commenced 
with the participant inhaling from the e-cigarette at a rate of 1 inhalation every 
30 seconds, a total of 10 inhalations. Measurements of microcirculation were 
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minutes thereafter. In all participants, microcirculation readings had returned 
to baseline at the end of the 20-minute monitoring period. This was then 
repeated with the nicotine (24-mg) e-cigarette. 
Outcomes: Non-invasive O2C laser Doppler probe measured a baseline control 
reading at deep (7-mm) and superficial (3-mm) levels. A 24-mg e-cigarette 
significantly reduced smokers’ hand microcirculation during and after smoking. 
Microcirculation increased in smokers after inhalation of a 0-mg e-cigarette. 
The authors concluded that a 24 mg e-cigarette significantly reduced smokers’ 
hand microcirculation during and after smoking. Microcirculation increased in 
smokers after inhalation of a 0 mg e-cigarette. The authors advised smokers 
undergoing hand surgery to avoid high-dose e-cigarettes and, if necessary, to 
use 0 mg e-cigarettes as an alternative.357 
Device and product: A 5-minute smoking protocol of a non-nicotine (0-mg) e-
cigarette was commenced with the participant inhaling from the e-cigarette at 
a rate of 1 inhalation every 30 seconds, a total of 10 inhalations. This protocol 
was not tolerated by participants who, on attempting this protocol, developed 
severe nausea, and therefore, the frequency of inhalations was reduced. It was 
subjectively agreed among both the investigators and the participants that our 
protocol mimicked a natural smoking rate. 




The authors reported on the effects of the e-cigarette liquid solvents 
propylene glycol and vegetable glycerine on user nicotine delivery, heart 
rate, subjective effects, and puff topography. 
Age mean years (SD): 18 to 55. Sex: Not reported Country: USA  
Duration of trial: Participants completed four sessions lasting ∼3.5 h and 
separated by≥48 hours 
Data source: Potential participants were recruited by advertisements (posted 
online, throughout campus, and at local vape shops) and word-of-mouth 
(some participants were informed of the study by other individuals and not via 
advertisement exposure) 
Population size: 33. Year of data collection: Not reported  
E-cigarette, smoking and other related status: E-cigarette-experienced, ≥12-h 
nicotine- abstinent participants 
Intervention and research design: Four conditions consisting of two e-cigarette 
use bouts (10 puffs, 30 seconds interpuff-interval). Participants completed four 
sessions lasting ∼3.5 hours and separated by≥48 hours. Following the one-
hour observation period, an intravenous catheter was inserted into a forearm 
vein of the participant and monitoring of heart rate commenced. Thirty 
minutes after catheter insertion, a baseline blood sample was taken, and 
participants completed a “directed” ECIG use bout consisting of 10 puffs with 
30 seconds inter-puff-interval. Participants completed a second e-cigarette use 
bout (60 min after the first) to determine the reliability of the results observed 
after the first bout. Additional blood samples were taken at 5, 15, 30, 45, and 
55 min after the onset of bout 1 and 5, 15, 30, and 45 min after the onset of 
bout 2. Subjective questionnaires were administered immediately following 
each blood sampling 
Outcomes: Nicotine delivery, subjective effects, heart rate, and puff 
topography were assessed. In the 100 propylene glycol condition, participants 
took shorter and smaller puffs but obtained significantly more nicotine relative 
to the two vegetable glycerine (VG)-based conditions. Total nicotine exposure 
(i.e., area under the curve) was also significantly higher during use of the two-
propylene glycol -based liquids. However, participants reported that the 100 
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relative to the other liquids. Increases in HR and decreases in abstinence 
symptoms (e.g., “craving”) did not differ across conditions. 
The authors concluded that the ratio of liquid propylene glycol to vegetable 
glycerine influenced nicotine delivery, some subjective effects, and puff 
topography. Lower overall product satisfaction associated with the 100% 
propylene glycol liquid suggests that factors other than nicotine delivery 
(aerosol visibility) may play a role in maintaining e-cigarette use. Regulating e-
cigarette acute effects, such as nicotine delivery, and subjective effects may 
require simultaneous attention to the ratio of liquid propylene glycol to 
vegetable glycerine, as well as device, liquid, and behavioural factors known to 
influence these outcomes. The participants’ heart rates increased significantly 
after use.351 
Device and products: Two E-cigarette-use differing only by liquid propylene 
glycol :vg ratio (2propylene glycol :98vg, 20propylene glycol :80vg, 
55propylene glycol :45vg, 100propylene glycol). Device power (7.3 W) and 
liquid nicotine concentration (18 mg/ml) remained constant. participants used 
an “eGo” (3.3 V) battery with a 1.5 ohm, dual-coil, 510 “cartomizer” (7.3 W; 
SmokTech; Shenzhen, China). “Cartomizers” were filled with 1 ml of E-
CIGARETTE liquid (“Virginia Pure” tobacco flavor), containing 18 mg/ml of 
nicotine (AVAIL Vapor, Richmond, VA). Liquid propylene glycol:vg ratio differed 
by session. the propylene glycol:vg ratios as labeled by the vendor were: 
100:0, 70:30, 30:70, and 0:100. Subsequent independent analysis revealed 
that the ratios were: 100:0, 55:45, 20:80, and 2:98. Liquid nicotine 
concentrations were independently verified as ± 1 mg/ml of the labeled 
concentrations. All “cartomizers” were verified with an Ohmmeter as±0.1 ohm 




Harm The authors reported on the acute effects of e-cigarette inhalation on the 
vasculature and the conducting airways. 
Age mean years (SD): 26 ± 3. Sex: 6 males, 9 females. Country: Sweden 
Data source: Not reported. Duration of trial: One day Population size: 17 
Year of data collection: Not reported 
E-cigarette, smoking and other related status: 17 healthy occasional users of 
tobacco products (max ten cigarettes/month), 
Intervention and research design: randomized, double-blinded, crossover 
design Volunteers inhaled 30 puffs from the e-cigarette for 30 minutes, with 
each puff lasting approximately three seconds. Sweden inhaled 30 puffs of e-
cigarette aerosol with or without nicotine during a 30-minute period on two 
separate occasions. The wash out period was a minimum of 1 week. Vascular 
measurements included systolic and diastolic blood pressure, heart rate, and 
arterial stiffness and were measured at baseline and following exposure, 
immediately (0 h), 2 h, and 4 h afterwards. These measurements were 
performed in 10-minute intervals over 30 minutes. Respiratory measurements 
included dynamic spirometry, impulse oscillometry, and fractional exhaled 
nitric oxide (FeNO) and were performed directly following the vascular 
measurements and additionally at 6-h post-exposure.  
Outcomes: Vascular measurements included heart rate, systolic and diastolic 
blood pressure, and arterial stiffness. Pulmonary measurements consisted of 
dynamic spirometry, impulse oscillometry, and fractional exhaled nitric oxide 
(FeNO). e-Cigarette aerosol with nicotine caused a significant increase in heart 
rate and arterial stiffness. Furthermore, e-cigarette aerosol-containing nicotine 
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oscillometry, indicating obstruction of the conducting airways. Both aerosols 
caused an increase in blood pressure 
The authors concluded that the present study indicates that inhaled e-
cigarette aerosol with nicotine has an acute negative impact on vascular and 
pulmonary function, and that chronic usage may lead to long-term adverse 
health effects.356 
Device and product: The e-liquid base consisted primarily of 49.4% propylene 
glycol, 44.4% vegetable glycerin, and 5% ethanol without any added 
flavourings (Valeo laboratories GmbH, Germany). Premixed e-liquids with and 
without added nicotine were used (19 mg/ml and 0 mg/ml resp.). A variable 
mod third generation e-cigarette was used (eVic-VT, Shenzhen Joyetech Co., 
Ltd., China). The same settings were used for all exposures (temperature 230 
°C, effect 32 W, resistance 0.20 ohm). A dual coil nickel atomizer was used. All 
exposures were performed in a well-ventilated, temperature-controlled room. 





The authors reported on the effects of a single bout of e-cigarette use on 
vascular measures of health. 
Age mean years (SD): 24 (3). Sex: 9 males, 7 females. Country: USA 
Duration of trial: Methods not reported. Data source: Methods not reported 
Population size: 16. Year of data collection: Not reported 
E-cigarette, smoking and other related status: Tobacco product naïve 
participants 
Outcomes: Changes in vascular and haemodynamic measures (blood pressure, 
cardio‐ankle vascular index, flow‐mediated dilation) 
Intervention and research design: three separate “vaping” trials with menthol-
flavoured quit smoking aid, electronically heated menthol-flavoured EC with 
0% or 5.4% nicotine. During each visit, measurements were performed at 
baseline, immediately post, 1, and 2 hours post‐E-cigarette exposure 
The authors concluded that there were no significant changes in heart rate, 
systolic and diastolic blood pressure, endothelial function (via flow‐mediated 
dilation), or arterial stiffness (cardio‐ankle vascular index) throughout the 
experiment.349 
Device and product: Not reported 
Sumartiningsih 
et al.352  
2019 
Harm The authors examined the exercise-induced heart rate response and heart 
rate variability in subjects caused by inhaling smoke from tobacco cigarettes 
and aerosolised vapour from e-cigarettes.  
Age mean years (SD): 23.2 ± 1.7. Sex: All males. Country: Indonesia 
Duration of trial: Each participant was subjected to three different test 
sessions held at intervals every three days. All participants started their 
sessions from 9:00 a.m. to 12:00 p.m. After arrival, participants were asked to 
rest for 5–10 minutes. Next, heartbeat and blood pressure were measured to 
obtain the baseline data. After the medical examination, participants were 
asked to smoke EC or TC without knowing the dosage of nicotine, heartbeat 
and blood pressure were measured immediately after smoking. Participants 
then performed a maximal multistage 20 m of shuttle run test (MMST). Heart 
rate and BP were measured again immediately after the MMST test 
Data source: Male smokers. Duration of trial: Three sessions. Interval 3 days. 
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E-cigarette, smoking and other related status: Regular smoker smoking 
tobacco cigarette/day (9.2 +/- 1.3 per day). Duration of smoking (year) 3.5 +/- 
0.8  
Intervention and research design: This study used an experimental design with 
repeated measures with the same participant and a randomized crossover 
design (balance order treatment). For each treatment, the participants were 
assigned to smoke electronic C with zero nicotine/electronic non-nicotine 
delivery systems (C), electronic-cigarettes with 3 mg/mL of nicotine/electronic 
nicotine delivery systems (3e-cigarette), and two tobacco cigarettes with 1.5 
mg nicotine in each without knowing the nicotine levels.  
Outcomes: Heart Rate Variability (HR and R wave intervals (RR interval)), 
Maximal Multistage 20 m Shuttle Run Test (MMST), Time-to-Exhaustion 
Analyses with maximal oxygen uptake (VO2max) and to assess the time to 
exhaustion. Heart Rate Variability was evaluated based on the beat-to-beat 
time interval during the running test. The results showed no statistically 
significant differences in the run time to exhaustion under the three 
conditions. Exercise-induced heart rate response as significantly attenuated 
under the tobacco cigarette condition. The heart rate variability standard 
deviation of normal-to-normal intervals during exercise significantly increased 
under nicotine/electronic nicotine delivery systems and tobacco cigarettes.  
The authors concluded that the results showed that a significant acute 
autonomic cardiac modulation during exercise is induced by an acute episode 
of e-cigarette and tobacco cigarette smoking.352 




Harm The authors reported on the acute effects of vaping and their reversibility on 
biological/clinical cardio-respiratory parameters (serum/urine 
pneumoproteins, haemodynamic parameters, lung function test and diffusing 
capacities, transcutaneous gas tensions (primary outcome), and skin 
microcirculatory blood flow). 
Age mean years (SD): 38 (2). Sex: All male. Country: Belgium 
Duration of trial: Three sessions. Interval of seven days between sessions. 
Data source: Healthy, former tobacco smokers with exclusive nicotine e-
cigarette use for at least one year were recruited via a Belgian vaping forum 
(UBV–BDB–Union-Belge- Pour-La-Vape/Belgische-Damp-Bond) 
Population size: 30. Year of data collection: January 2018 and November 2018 
E-cigarette, smoking and other related status: healthy, former tobacco 
smokers with exclusive nicotine e-cigarette use for at least one year 
Outcomes: The following parameters were assessed: transcutaneous O2 
(TcpO2) and carbon dioxide (TcpCO2) tensions, respiratory-parameters (pulse 
oximetry (SpO2), end-tidal CO2, respiratory rhythm), skin microcirculatory 
blood flow, cutaneous vascular conductance and hemodynamic-parameters 
(systolic (SBP) and diastolic (DBP) blood pressure, heart rate) 
Intervention and research design: A randomized investigator-blinded crossover 
three-periods study was carried out. A minimum of seven days separated each 
period. The periods included: 1) regular vaping of e-cigarettes containing 
nicotine for five days and until two hours before the experimental session 
(nicotine-session); 2) nicotine-free-vaping for five days and until two hours 
before the experimental session (nicotine-free-session); 3) complete cessation 
of e-cigarette vaping for five days prior to the experimental session (stop-
session). Participants were invited to vape acutely as follows: 1) 10 nicotine 
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session); 2) 10 nicotine-free puffs at 60W (1±0.04g) (acute nicotine-free-vaping 
in the nicotine-free-session); and 3) 10 sham puffs (acute sham-vaping in the 
stop-session). 
The authors concluded that short-term e-cigarette cessation by regular users 
decreases baseline heart rate and lung inflammation and increases forced 
expiratory flow by 25%, suggesting that high-wattage vaping alters airway 
function. Urine metabolomic signature was also slightly modified by this short-
term e-cigarette cessation. Acute nicotine and nicotine-free vaping decreased 
transcutaneous oxygen tensions likely as a result of gas exchange 
disturbances. Finally, only acute nicotine vaping increased systolic blood 
pressure, diastolic blood pressure, and heart rate.358 
Device and product: A e-liquid base of propylene glycol/glycerol was mixed by 
the pharmacy at Erasme University Hospital 50:50 v/v; pharmaceutical grade, 
Fagron©, Waregem, Belgium). One e-liquid lacked nicotine while the other 
contained nicotine at a concentration of 1.5 mg/mL. Devices included a fourth-
generation e-cigarette set at 60 W (Alien 220 box mod, TFV8 baby beast tank 
and a dual Kanthal coil [V8 Baby-Q2 Core; 0.4Ω dual coils], Smoke©, Shenzen 
China) with MXJO (Mxjotech©, Shenzen, China) IMR 18650 3000 milliampere 
hour 35A variable voltage/variable wattage batteries. Airflow was set at the 
maximum. The manufacturer’s recommendations were followed for the 
preparation of the vaping devices; they were cleaned and filled with e-liquid 
prior to each exposure. Batteries were fully charged before use, and the coil 
replaced after two exposures.  










Harm The authors reported on the short-term pulmonary effects of using an e-
cigarette, including: impact on respiratory flow resistance, impedance, and 
exhaled nitric oxide. 
Age range: 19 to 56 years. Sex: 14 males, 16 females. Country: Greece 
Duration of trial: Single session. Measures were recorded soon after the 
intervention 
Data source: recruited from a community setting in Athens. Population size: 30  
Year of data collection: Not reported  
E-cigarette, smoking and other related status: all subjects were smokers with a 
minimum pack-year index of 5 
Intervention and research design: Two groups were created: the experimental 
group (n=30) and the control group (n=10). Ab lib use of an e-cigarette for 5 
minutes with the cartridge included (experimental group, n=30) or removed from 
the device (control group, n=10) was assessed. 
Outcomes: Lung Function Assessment: Exhaled Nitric Oxide and Dynamic Lung 
Volumes i.e. spirometry: FVC, L, FEV 1, L, PEF, L/s, maximal expiratory flow 
(MEF)25, L/s, MEF50, L/s, MEF75, L/s, maximal mid-expiratory flow (MMEF), L/s 
and Total Respiratory Resistances assessed using impulse oscillometry system 
(IOS). 
The authors concluded that the e-cigarettes assessed in the context of this study 
were found to have immediate adverse physiological effects after short-term use 
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Device and product: The e-cigarettes provided to the subjects were of the same 
brand (NOBACCO e-cigarettes, black line) and of the same nicotine 
concentration. The e-cigarette itself was composed of a steel shell, a 
microprocessor powered by a lithium battery, a filter, and a removable (and 
renewable) cartridge. Three types of cartridges were available in the market for 
this e-cigarette, the medium one (NOBACCO MLB-MED filter), for which the 
manufacturer reports a measured dose of 11 mg of nicotine was used in this 
study. The e-cigarette cartridge selected for use in the experimental group has 
been analysed for its chemical composition by the National Centre for Scientific 
Research, Demokritos, in Greece. According to their analysis, the cartridge 
contained propylene glycol (a -propylene glycol or 1,2-propanediol) in a 
concentration 60%, linalool (3,7-dimethylocta-1,6-dien-3-ol) in a concentration , 
5%, nicotine (,10%), tobacco essence (,5%), and methyl vanillin (4-hydroxy- 3-










The authors conducted a comprehensive and standardised assessment of the 
acute impact of active and passive e-cigarette smoking on serum cotinine and 
lung function (plus toxins). 
Age range: 23.5 to 54 years. Sex: 16 males, 14 females. Country: Greece 
Duration of trial: Three sessions over a three-week period. Measures were 
recorded up to one hour after intervention. 
Data source: Adult. Population size: 30 (15 smokers and 15 never-smokers) 
Year of data collection: Not reported  
E-cigarette, smoking and other related status: Fifteen smokers (>=15 
cigarettes/day 10–68 pack years)   
Intervention and research design: Non-randomized repeated-measures 
controlled study. Each group attended three sessions administered in a random 
order and separated by a minimum of 7 d wash-out period. All subjects 
participated in each experimental session once. The group of smokers underwent 
a control session (ACTIVECON), an active tobacco cigarette smoking session 
(ACTIVETOB) and an active e-cigarette smoking session (ACTIVEE-CIG), each 
lasting 30 minutes. In ACTIVECON, smokers were asked to pseudo-smoke an unlit 
cigarette from a brand of their choice. In ACTIVETOB, smokers were asked to 
smoke two tobacco cigarettes from a brand of their choice. In ACTIVEE-CIG, 
smokers were asked to puff an e-cigarette in order to absorb enough nicotine to 
match two of their favourite tobacco cigarettes as described below. 
Measurements were conducted before, immediately after, and 1 h after active 
smoking. The group of never smokers underwent a control session 
(PASSIVECON), a passive tobacco cigarette smoking session (PASSIVETOB) and a 
passive e-cigarette smoking session (PASSIVEE-CIG), each lasting 1 h. In 
PASSIVECON, participants were exposed to normal room air. In PASSIVETOB and 
PASSIVEE-CIG, participants were exposed to air polluted with tobacco cigarette 
smoke and e-cigarette vapor, respectively, adjusted to simulate bar/restaurant 
levels Measurements were conducted before, immediately after and 1 h after 
each exposure. 
Outcomes: e-Cigarettes and tobacco cigarettes generated similar (p40.001) 
effects on serum cotinine levels after active (60.6_34.3 versus 61.3_36.6 ng/ml) 
and passive (2.4_0.9 versus 2.6_0.6 ng/ml) smoking. Neither a brief session of 
active e-cigarette smoking (indicative: 3% reduction in FEV1/FVC) nor a 1 h 
passive e-cigarette smoking (indicative: 2.3% reduction in FEV1/FVC) significantly 
affected the lung function (p40.001). In contrast, active (indicative: 7.2% 
reduction in FEV1/FVC; p50.001) but not passive (indicative: 3.4% reduction in 
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The authors concluded that, regarding short-term usage, the studied e-cigarettes 
generate smaller changes in lung function than, but a similar nicotinergic impact 
as, tobacco cigarettes. Future research should target the health effects of long-
term e-cigarette usage, including the effects of nicotine dosage.362 
Device and product: e-cigarette device (model: Giant, Nobacco G.P., Greece) 
within 30 minutes. In the latter session, a new cartridge (within its expiration 
date) and a fully charged battery were used for each session. Based on its label, 
the e-cigarette liquid used (Nobacco USA Mix, Nobacco G.P., Greece) had a 
‘‘tobacco taste’’ and contained 11 mg/ml of nicotine, which is an average 
concentration since the range of nicotine content in e-cigarette liquids normally 
range between 0 to 36 mg/ml. Information regarding the e-cigarette device and 
the liquid used is available at the manufacturer’s website (Nobacco G.P., 2012). 
They were selected for this study because the specific liquid is the only one 
available in the Greek market that has been analyzed by an independent publicly 
funded research institute. This analysis, reviewed in detail elsewhere, 
demonstrated that the liquid used incorporates 46% propylene glycol, 51% 










The authors reported on the short-term effects of a nicotine-free e-cigarette 
compared to a conventional combustible tobacco cigarette in smokers and non-
smokers. 
Age mean years (SD): 39.3 ± 12.6. Sex: 11 males, 9 females. Country: Italy 
Duration of trial: Two sessions. Interval period 24 hours. The subjects were asked 
to refrain from smoking in the 6 hours preceding the test session and not to eat 
or drink for at least 4 hours prior to the experimental procedure. The first 
smoking session started 5 minutes after the baseline measurement of FeCO, 
fractional nitric oxide concentration in exhaled breath (FeNO) and pulmonary 
function tests. The second smoking session started after a wash-out of 24 hours 
after the end of the first session. The measurements of FeNO, FeCO and 
pulmonary function tests were repeated immediately after each smoking session. 
Data source: Normal subjects, recruited among pulmonary fellows or attending 
physicians were studied 
Population size: 20. Year of data collection: Not reported  
E-cigarette, smoking and other related status: 10 were smokers (minimum of 5 
pack-years) and 10 were non-smokers. Among smokers’ smoke history (pack-
years) - mean ± SD (range) 19.4 ± 10.8 (5–35) 
Intervention and research design: Both smokers and non-smokers were 
randomized to smoke both the nicotine-free e-cigarette and a commercial 
“popular brand” standard cigarette ad libitum for 5 minutes in two different 
sessions according to a crossover design (5 patients within each group smoked 
first the nicotine-free e-cigarette and then the commercial cigarette and 5 
subjects smoked first the commercial and then the nicotine-free e-cigarette). All 
subjects were asked to use a similar pattern and frequency of smoke aspiration, 
although it cannot be assured that they did so. The first smoking session started 
5 minutes after the baseline measurement of FeCO, Fractional nitric oxide 
concentration in exhaled breath (FeNO) and pulmonary function tests. The 
second smoking session started after a wash-out of 24 h after the end of the first 
session. This wash-out period was to ensure that there was no carry-over effect. 
The measurements of FeNO, FeCO and pulmonary function tests were repeated 
immediately after each smoking session. 
Outcomes: exhaled nitric oxide (FeNO) and fractional concentration of carbon 
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capacity (FVC), forced expiratory volume in 1 s (FEV1), forced expiratory flow 
(FEF) 25 %, 50 % and 75 % and peak expiratory flow (PEF).  
The authors concluded that the specific brand of nicotine-free e-cigarettes used 
in this study was not associated with major acute physiological changes, causing 
only small (albeit statistically significant) decreases in forced expiratory flow (FEF) 
25% and forced expiratory volume in the first second (FEV1) in the group of 
smokers. By contrast, smoking a conventional combustible tobacco cigarette 
induced immediate bronchoconstriction in non-smokers.363 
Device and product: The nicotine-free e-cigarette used in this study, ELIPS C 
Series (Ovale Europe S.r.l., Desenzano del Garda, Brescia, Italy), was a brand 
commercially available in Italy. It was formed of a steel shell with a 
microprocessor powered by a battery, a filter and a removable cartridge. Among 
the six different types of cartridge available, we chose “Natur Smoke aroma 
Nocciola Antistress 0 mg/mL nicotina” (Angelica, Bologna, Italy), i.e., a nicotine-
free liquid with a hazelnut flavor. The liquid of the cartridge is registered by the 
Italian Regulatory Agency and had the following composition: glycerine >50 %, 
isotonic solution 5–10 %, magnesium chloride 1–5 %, natural flavour 0.1–1 %, 
and vitamin B12 0.1–1 %. The specific kind of nicotine-free e-cigarette chosen in 
the current study followed an unbiased internet search for products available 
and produced in Italy (e.g. Dea, Flatech, Flavour Roma). Use of the Angelica liquid 
was finally decided mainly due to logistic convenience since it was produced in 
the same city (Bologna) of investigation. The commercial standard cigarette, 
Marlboro® Red Label Box (Philip Morris USA Inc., Miami, FL, USA), contained 
nicotine 0.8 mg, carbon oxide (CO) 10 mg and tar 10 mg. According to the 
manufacturer, the components not exceeding 0.1 % of the weight of the tobacco 
were acetic acid 0.01, acetophenone 0.0001, ammonium hydroxide 0.3, amyl 
butyrate 0.0001, benzaldehyde 0.005, benzoin 0.005, benzyl alcohol 0.1, 
cellulose 9.3, calcium carbonate 4.6, monopotassium phosphate 1.4, potassium 




Benefit The authors reported on changes in breathomics from a 1-year randomised 
smoking cessation trial of e-cigarettes fractional nitric oxide concentration in 
exhaled breath (FeNO), exhaled carbon monoxide, and symptom scores). 
Age mean years (SD±): 42.9 ± 13.1. Sex: 79 males, 55 females. Country: Italy 
Duration of trial: One year. Subjects were asked not to smoke/vape for at least 
30 minutes prior to each visit. FeNO measurements were taken at baseline and at 
week 12, week 24 and week 52. Measurements (in ppb) were obtained from a 
10-s. exhalation at a steady airflow of 50 mL/s against a flow resistor. Exhaled 
carbon monoxide measurements were taken at baseline and at each study visits. 
Measurements (in ppm) were obtained from a single expiratory breath. Self-
reported respiratory symptoms in the previous 2 weeks were recorded at 
baseline and at each follow-up visit. 
Data source: Not reported Population size: 134 in 3 study arms. Year of data 
collection: Not reported  
E-cigarette, smoking and other related status: smoke ≥ 10 tobacco cigarettes per 
day (cig/day), for at least the past 5 years; 
Intervention and research design: A prospective 1-year RCT consisting of nine 
office visits at our smoking cessation clinic. Participants were randomized into 
three study arms to receive e-cigarette kits with cartridges of identical 
appearance containing either 2.4% (i.e. 2.4 mg/mL) nicotine (12 weeks of 
‘Original 2.4%’ – Group A) or 1.8% (i.e. 1.8 mg/mL) nicotine (6 weeks of ‘Original 
2.4%’ and a further 6 weeks of ‘Categoria 1.8%’ – Group B) or no nicotine (12 
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Outcomes: FeNO,exhaled carbon monoxide measurements and self-reported 
respiratory symptoms (cough, phlegm, shortness of breath, wheeze, tight chest, 
stuffy nose, sinus pain and frontal headache). At baseline, socio-demographic 
factors, smoking history, Fagerstrom Test for Cigarette Dependence (FTCD) 
scores were annotated. 
The authors concluded that smokers who were invited to switch to e-cigarettes 
who completely abstained from smoking showed steady progressive 
improvements in their exhaled breath measurements and symptom scores. 
Fractional exhaled nitric oxide and exhaled carbon monoxide normalisation is 
highly supportive of improved respiratory health outcomes and adds to the 
notion that quitting tobacco smoking can reverse harm in the lungs.359 
Device and product: The ‘Categoria’ EC (model ‘401’) used in this study is a 
rechargeable three-piece design that closely resembles a conventional cigarette. 
Disposable cartridges used in this study were of three different types, but of 
identical appearance: ‘Original 2.4%’ (2.27 +/-0.13% nicotine), ‘Categoria 1.8%’ 
(1.71 +/-0.09% nicotine) and ‘Original 0%’ without nicotine (‘sweet tobacco’ 
aroma). The ‘Categoria’ EC kit and cartridges were provided free of charge by the 




Benefit The authors reported on lung function and respiratory symptoms in a 
randomised smoking cessation trial of e-cigarettes, presented on the basis of 
participants’ pooled continuous smoking phenotype classification (quitters, 
reducers, or failures). 
Age mean years (SD): 42.2 ± 12.6. Sex: 75 males, 55 females. Country: Italy 
Duration of trial: One year 
Data source: Smokers not intending to quit were invited to switch to first 
generation cigarette-look-a-like ECs (‘Categoria’, Arbi Group Srl) as a complete 
substitute for tobacco smoking. 
Population size: 130 (with available spirometry data) 183 completed the study. 
Group A N=46 Group B N=43, Group C N=41 
Year of data collection: Not reported  
E-cigarette, smoking and other related status: Smokers not intending to quit. 
Intervention and research design: 1-year randomized controlled trial of smokers 
receiving e-cigarettes containing 2.4%, 1.8% or 0% nicotine 
Outcomes: Spirometric indices as well as in respiratory symptoms: exhaled 
carbon monoxide, FTND, FEV1, FEV1 (% predicted), FVC (FVC (% predicted), 
FEV1/FVC, FEF25%–75%, FEF25%–75%. Cough/phlegm, Shortness of breath 
The authors concluded that this 1-year prospective RCT shows improvements in 
spirometric indices of peripheral airways, as well as in respiratory symptoms in 
smokers who were invited to quit or reduce their cigarette consumption by 
switching to first-generation e-cigarettes. Specifically, the present study shows 
progressive and consistent improvement in forced expiratory flow (FEF) 25–75% 
among those who completely gave up cigarette smoking. Improvements in FEF 
25–75% from baseline were no different in quitters who stopped using e-
cigarettes compared with quitters who were still using e-cigarettes.360 
Device and Product: Categoria’, Arbi Group Srl 
Dicpinigaitis 
et al.368  
2016 
Harm The authors reported on the effect of e-cigarette use on the urge-to-cough 
sensation, specifically the urge-to-cough threshold, and cough reflex sensitivity. 
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Duration of trial: Three sessions on three separate days. Measures were gathered 
up to 24 hours after intervention 
Data source: Adult never-smokers. Population size: 17 (30 enrolled into study) 
Year of data collection: Not reported 
E-cigarette, smoking and other related status: Non-smokers. Subjects underwent 
capsaicin challenge testing on Day 1 to establish their baseline urge-to-cough 
threshold and cough reflex sensitivity. Intervention: On study Day 2 subjects 
underwent an e-cigarette vaping session subjects inhaled a total of 30 puffs (one 
puff every 30 seconds) from a disposable e-cigarette (Blu, Classic Tobacco 
flavour, Lorillard Technologies, Greensboro, NC). Fifteen minutes after the 
conclusion of the e-cigarette session, subjects underwent capsaicin cough 
challenge. On study Day 3, approximately 24 hours after the vaping session, 
subjects underwent repeat capsaicin challenge. In addition, the number of 
coughs induced by each of the 30 puffs of the e-cigarette was tabulated. A cough 
number of 5 was assigned for five or more coughs.  
Intervention and research design: Seventeen healthy non-smokers underwent 
cough reflex sensitivity measurement employing capsaicin cough challenge at 
baseline, 15 minutes, and 24 hours after e-cigarette exposure (30 puffs 30 
seconds apart) 
Outcomes: After e-cigarette exposure, urge-to-cough threshold and cough reflex 
sensitivity were significantly diminished compared to baseline. This effect was 
transient, as observed by the return of urge-to-cough threshold and cough reflex 
sensitivity to baseline levels 24 hours after e-cigarette exposure (comparison of 
baseline urge-to-cough threshold and cough reflex sensitivity 24 hours post-e-
cigarette exposure, P = .32). 
The authors concluded that a single exposure to an e-cigarette significantly 
inhibits the urge-to-cough threshold as measured by capsaicin cough challenge 
testing. These findings add to the growing body of evidence that e-cigarette 
vapour is not a physiologically benign substance and support further 
investigation of the effects of repeated or chronic use of e-cigarettes on cough 
sensitivity and other respiratory parameters.368 
Device and product: Disposable Blu e-cigarette contain 20–24 mg of nicotine and 
delivers approximately 400 puffs of nicotine-containing vapor. The ingredients of 
the vapor include distilled water, nicotine, vegetable glycerin, natural flavours, 
artificial flavours and citric acid. Thus, 30 puffs of the e-cigarette delivered 
approximately 1.5–1.8 mg of nicotine. In comparison, the estimated nicotine 





Harm The authors reported on the impact of e-cigarette smoking on sinonasal 
symptoms and nasal mucociliary clearance. 
Age mean years (SD): 33.9 ± 7.9 Group 1 38 ± 8.2 Group 2  
Sex: 24 males, 18 females Group 1: 16 males, 14 females Group 2 
Country and ethnicity: Turkey  
Duration of trial: One session. A saccharin granule was placed 2 cm inside the 
right nostril lateral to inferior turbinate by the tester. They were instructed to 
swallow every 30 s per minute with a chronometer. The time when the subjects 
first precepted the sweet taste of the saccharin were recorded in minutes 
Data source: This study was conducted at the Department of 
Otorhinolaryngology-Head and Neck Surgery. All patients admitted to smoking 
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Population size: Total 98. Group 1 42 Group 2 30. However, sixteen patients in 
the group 1 and ten patients in the group 2 who cannot stop smoking were 
excluded from the study.  
Year of data collection: March 2013 and November 2013 
E-cigarette, smoking and other related status: Patients smoked one pack of 
cigarettes per day for at least 5 years. All patients were willing to quit smoking. 
The mean duration of smoking was 13.5 ± 6.5 years, 
Intervention and research design: Prospective randomized single-blind clinical 
trial  
Outcomes: Changes in sinonasal symptoms and mucociliary clearance assessed 
by saccharin transit time 
Patients participating in the study were randomly divided into two groups; e-
cigarette smokers (group 1) and non- e-cigarette smokers (group 2). E-cigarette -
smokers (n = 58) were the smokers who started e-cigarette to quit smoking. Non- 
e-cigarette smokers (n = 40) were the smokers who quitted smoking without the 
aid of medical therapy and a device. Non-e-cigarette smokers had cognitive 
behavioral treatment during the course. 
The authors concluded that although e-cigarettes are widely used as a method of 
quitting smoking, they have negative effects on sinonasal symptoms and 
mucociliary clearance.369 
Device and product: In this study, patients were allowed to select the brand of 
the device and flavour of the cartridge. Liquid in the cartridge contained alkaloids 
fluid with propylene glycol, ethanol, water, tobacco flowers, essential oil, consists 
of nicotine. Light Cigarettes in the markets have 0.7 mg nicotine per stick. 
Consuming all 20 cigarettes in a pack will give 14 mg nicotine. For this reason, the 
authors chose a medium density (11- 12 mg/ml) liquid for this study. The same 






The authors reported on the acute effects of nicotine-free and flavour-free e-
cigarette use on lung functions in healthy and asthmatic individuals. 
The authors designed a crossover and placebo-controlled trial to investigate the 
impact of a 1-hour acute vaping session of nicotine-free and flavour-free e-liquid 
on the pulmonary functions and respiratory mechanics of healthy and asthmatic 
individuals. 
Age range: 20 to 37 years Healthy volunteers, 21 to 40 years asthmatic 
volunteers 
Sex: Not reported. Country: Canada 
Data source: Healthy volunteers and ten asthmatic volunteers were recruited for 
the trial.  
Duration of trial: Two sessions. Interval one week. The experimental and placebo 
sessions took place 1 week apart. A preceding visit was also planned, where 
baseline measurements were taken. On the following two sessions (experimental 
and placebo), volunteers were asked to inhale three times per minute, in sitting 
position, for a total duration of 1 hour. Respiratory mechanics and lung functions 
were measured immediately before (T0), immediately after (T60), and 30 
minutes after (T90) the inhalation sessions. Respiratory symptoms were collected 
according to the Borg perception scale at the same time points as well as every 
20 minutes during the inhalation session. The fraction of exhaled nitric oxide 
(FeNO) and serum C-reactive protein were measured in asthmatic volunteers. 
FeNO and serum samples were not collected in non-asthmatic volunteers. 
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E-cigarette, smoking and other related status: All volunteers were non-smokers, 
and none were active e-cigarette users. Moreover, none of the volunteers were 
exposed to secondary tobacco or e-cigarette vapers at home. Asthmatic 
volunteers had received a diagnosis of asthma and had airway 
hyperresponsiveness as shown by a positive methacholine challenge 
Intervention and research design: This was a crossover and placebo-controlled 
trial. Volunteers were asked to inhale three times per minute, in sitting position, 
for a total duration of 1 hour. The experimental and placebo sessions took place 
1 week apart. 
Outcomes: Symptoms, vital signs, lung function and inflammation parameters. 
Symptoms included: cough, chest tightness, breathlessness, secretions, 
wheezing, heart rate (beat/min), saturation (% O2), respiratory rate 
(respiration/min)). Spirometry (forced expiratory volume in 1 second (FEV1) (L) 
forced vital capacity (FVC) (L) FEV1/FVC. Forced oscillation technique (FOT) 
R5(forced oscillation technique) at 5 minutes (cm H2O.s/L), R19 (cm H2O.s/L), 
R5–19 (cm H2O.s/L), X5 (cm H2O.s/L), resonant frequency (Fres) (Hertz), 
reactance area (Ax) (cm H2O/L/saHz), inspiratory capacity (IC) (L), tidal volume 
(TV) (L), exhaled nitric oxide (FeNO) (ppb), C-reactive protein (mg/L) 
The authors concluded that this study shows that a 1-hour inhalation session of a 
high-grade and contaminant-free mixture of propylene glycol and glycerol using a 
commercially available e-cigarette, performed in a controlled environment, does 
not significantly impact pulmonary function or symptoms in either healthy or 
asthmatic subjects.361 
Device and product: The e-liquid consisted of a mixture of 70% USP-grade 
propylene glycol and 30% USP-grade glycerol, mixed in our laboratory under a 
biosafety cabinet. The author claimed this 70% propylene glycol /30% glycerol 
mixture is largely representative of what is used on the market to dissolve 










The authors reported on the relationship between partial or complete 
substitution of cigarettes with e-cigarettes in adult smokers with measurements 
of cardiovascular and pulmonary function endpoints and other physiological 
effects. 
Age mean years (SD): ~38. Sex: 65% males, 35% females. Country: USA 
Ethnicity: American Indian/Alaska Native =1, Black or African American =17, Black 
or African American =1, American Indian/Alaska =1, Hispanic or Latino =1, 
White=84. 
Duration of trial: Six days. Subjects checked into the clinic on Day -2 and 
continued to smoke their usual conventional combustible tobacco cigarette 
brand ad libitum through the evening of Day -1 (baseline). Participants 
completed several different questionnaires that measured nicotine dependence 
and a variety of subjective smoking-related effects over the course of the five-
day study. On the morning of Day 1, subjects were randomized into one of six 
groups (N = 15 each). With limited exceptions, all product use was ad libitum 
from 07:30 to 23:00 on Days -2 to 5. These exceptions included meals and 
questionnaire administration, 15 min prior to blood sampling and vital sign 
measurements, and 30 minutes prior to and during spirometry and exhaled CO 
and nitric oxide (NO) measurements. Cardiovascular vital signs (systolic blood 
pressure (SBP), diastolic blood pressure (DBP), and heart rate) were measured at 
least 5 minutes of rest, prior to the start of product administration at ~6:45 in the 
morning and at ~17:50 in the evening at on Days -1 through 5. All measurements 
were preceded by a 30-minutes (minimum) abstention from study product use. 
Spirometry measures of the volume of air exhaled during a forced breath in one 
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(Forced Vital Capacity e FVC). Baseline (Day -1) versus post-Baseline (Day 5) 
changes in FVC and FEV1 spirometry endpoints were performed in the afternoon 
on Days -1 and 5. Exhaled CO and NO were measured during the study in the 
afternoon on Days -1 (Baseline), 1, 3 and 5 (prior to spirometry measurements on 
Days -1 and 5). All physiological measurements were preceded by a 30-minutes 
(minimum) abstention from study product use. 
Data source: Not reported. Year of data collection: Not reported 
Population size: n=105. Exclusive E-Cigarette Use Groups: Tobacco Rechargeable 
(n=15) Cherry Rechargeable(n=15) Cherry Disposable (n=15) Dual Use Groups 
Tobacco Rechargeable Cherry Rechargeable (n=15) Cherry (n=15) Disposable 
Nicotine Cessation (n=15) 
E-cigarette, smoking and other related status: Baseline cigarettes smoked per day 
ranged from ~15 to ~21 and years smoked ranged from ~15 to ~22. Menthol 
smokers made up 37% of the subject population 
Intervention and research design: Randomized, open-label, forced-switch parallel 
arm study conducted at a single independent research center. Baseline 
assessments occurred from the morning of Day -1 through the morning of Day 1 
prior to the start of randomized product use and post-baseline assessments on 
the morning of Day 1 through the morning of Day 6. On the morning of Day 1, 
subjects were randomized into one of six groups (N = 15 each): 
Outcomes: Cardiovascular physiology (systolic and diastolic blood pressure and 
heart rate, pulmonary function (FVC, FEV1, and exhaled CO and NO) and adverse 
events. All adverse events that occurred during this clinical trial were coded using 
the Medical Dictionary for Regulatory Activities (MedDRA®), Version 17.1. 
The authors concluded that use of e-cigarettes for 5 days under the various study 
conditions did not lead to higher blood pressure or heart rate values, negative 
respiratory health outcomes, or serious adverse health events. Reductions in 
blood pressure and heart rate vital signs were observed in most of the 
participants who either ceased tobacco and nicotine product use altogether or 
switched completely to using e-cigarettes. Pulmonary function tests showed 
small but non-statistically significant improvements in forced vital capacity (FVC) 
and forced expiratory volume in the first second measurements in most usage 
groups. Statistically significant (p<0.05) benefits associated with smoking 
reduction were also noted in exhaled carbon monoxide and fractional nitric oxide 
concentration in exhaled breath. All studied products were well tolerated. The 
study findings suggest that there are potential cardiovascular and pulmonary 
function benefits when smokers switch to using e-cigarette products.364 
Device and product: Exclusive e-cigarette Use Groups 
Group A1 e Tobacco flavour rechargeable blu™ e-cigarette 
Group A2 e Cherry flavour rechargeable blu™ e-cigarette 
Group A3 e Cherry flavour disposable blu™ e-cigarette 
Dual Use Groups 
Group B1 e Tobacco flavour rechargeable blu™ e-cigarette + usual brand 
combustible tobacco cigarette 
Group B2 e Cherry flavour rechargeable blu™e-cigarette + usual brand 
combustible tobacco cigarette 
Group B3 e Cherry flavour disposable blu™ e-cigarette + usual brand combustible 
tobacco cigarette 




Harm The authors reported on the relationship of high-wattage e-cigarettes with 
tissue hypoxia and lower airway injury. 
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Duration of trial: Two sessions 7 days apart. Time points at which measure were 
assessed is not specified.  
Data source: healthy occasional smokers. Population size: 23 
Year of data collection: Not reported  
E-cigarette, smoking and other related status: Participants were enrolled on the 
basis of their excellent vaping tolerance 
Intervention and research design: Participants were exposed to 25 puffs of a 
propylene glycol/glycerol mix (50:50) vaporized at 60 W (V8 Baby-Q2 Core; 
Smoke; mean liquid volume vaporized, 260.1 ml), to create a real subohm vaping 
exposure, and to sham vaping (same procedure with e-cigarette turned off).  
Outcomes: Measure of respiratory and microcirculatory functions and 
microcirculatory blood flow regulation including measured of skin tissue hypoxia, 
serum CC16 (club cell protein 16) (a measure of lower airway injury), forced 
expiratory flow (measure of airway resistance), forced expiratory flow, forced 
mid-expiratory flow rate, skin continuous microcirculatory flow measured with 
the thermostatic probe, skin vasodilator responses to acetylcholine, plasma 
oxidative stress biomarkers 
The authors concluded that although endothelial microvascular function and 
oxidative stress remained unaffected, acute vaping of an aerosol of propylene 
glycol/glycerol at high wattage and in a large amount induced sustained tissue 
hypoxia, airway epithelial injury, and small airway constriction.370 
Device and product: A propylene glycol/glycerol mix (50:50) vaporized at 60 W 
(V8 Baby-Q2 Core; Smoke; mean liquid volume vaporized, 260.1 ml), to create a 
real subohm vaping exposure (3), and to sham vaping (same procedure with e-










The authors examined whether the active use of e-cigarettes in healthy subjects 
can cause short-term effects on lung function, and whether these effects are 
different from those associated with a similar exposure to tobacco smoke. 
Age mean years (SD) (range): 32.6 ± 2.75 (27 to 37). Sex: 17 males, 13 females 
Country: Italy 
Duration of trial: Two study visits. Interval period not qualified. Measures were 
gathered up to 60 minutes post intervention.  
Data source: Healthy non-smoking volunteers. Population size: 30. Year of data 
collection: Not reported 
E-cigarette, smoking and other related status: Thirty healthy non-smoker 
volunteers  
Intervention and research design: Before and after a 5-minute smoking session 
performed in two different days (first-day e-cigarette, second-day tobacco 
cigarette. Each participant underwent, in different days, a 5-minute session of 
active e-cigarette or tobacco cigarette smoking. All participants performed in 
different sessions both e-cigarette (first session) and tobacco cigarette (second 
session).  
Outcomes: For lung function: Forced Vital Capacity (FVC); forced expiratory 
volume in the first second (FEV 1 or FEV); Index Tiffenau (FEV1/FVC; Peak 
Expiratory Flow (PEF); forced expiratory flow at 25% of FVC (FEF25%); forced 
expiratory flow at 50% of FVC (FEF50%); forced expiratory flow at 75% of FVC 
(FEF75%); forced expiratory flow between 25% and 75% of FVC (FEF25% -75%). 
For environmental impact: measurement of the concentration of airborne dust 
with the use of Optical Particle Counter (OPC) model AEROTRAK 9306 of TSI. 
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Condensation Particle Counter (CPC) PTrak Ultrafine Particle Counter Model 8525 
TSI. Evaluation was performed at baseline, during active smoking and for 60 
minutes thereafter. Changes in the main respiratory parameters were 
significantly different than baseline after 1 minute from e-cigarette smoking (3,95 
vs 3,91 lt for FEV:P=0,03; 0,84 vs 0,83 for FEV1/FVC ratio:P=0,008; 4,23 vs 3,99 
lt/min for FEF25%-75%: P=0,03) but not after 15 minutes from active e-cigarette 
smoking, whereas after tobacco cigarette smoking, there was a significant drop in 
the 15 minutes value of FEV1(P=, FEF25%-75% (P=0.01) and the FEV1/FVC ratio 
(P=0.007). Regarding environmental exposure, the e-cigarette smoking was 
associated with the transient release of particles with a diameter < 1 micron 
which dropped to baseline after 5 minutes, whereas in the case of tobacco 
cigarette, the particles persisted for 60 minutes. 
The authors concluded that the active use of e-cigarettes for a short time caused 
similar, although less pronounced, effects as tobacco smoke on pulmonary 
function. Similarly, the particles released in the environment had a lower 
concentration and persistence than those of tobacco cigarettes. These data 
suggest that e-cigarettes may potentially be dangerous for active smokers and 
the environment.365 
Device and product: The e-cigarette model was a popular model EGO P (L) with 
manual start; the liquid used, the aroma of Latakia tobacco containing nicotine 
1.8% (18 ml / L), propylene glycol, glycerol, vegetable flavourings, and deionized 
water. The volunteers were asked to smoke the e-cigarette over 5-minutes time 
(the same time required for volunteers smoking a conventional combustible 
tobacco cigarette), performing 15 puffs. The used e-cig had a composition equal 




Harm The authors investigated the duration of immediate respiratory effects of e-
cigarette smoking and tested the hypothesis that e-cigarette smoking has more 
prominent effects in asthmatics compared with healthy smokers. 
Age mean years (SD): 23.0 ± 3.2. Sex: 33 males, 21 females. Country: Greece 
Duration of trial: Three consecutive sessions (screening, control, experiment) . 
Measures were gathered up to 30 minutes post intervention 
Data source: Not reported. Population size: 54 smokers, 27 healthy smokers and 
27 with intermittent asthma 
Year of data collection: Not reported 
E-cigarette, smoking and other related status:  
Intervention and research design: A control session (no liquid, no resistor coil 
inside e-cigarette cartridge) and an experimental session of ECS using 
standardized puffing settings. Impulse oscillometry impedance (Z), resistance (R), 
reactance (X) and fractional exhaled nitric oxide (FeNO) were measured before 
and 0, 15 and 30 minutes after control and experimental sessions. All participants 
individually completed three consecutive sessions: screening, control (C) and 
experimental (E). 
Outcomes: Impulse oscillometry impedance (Z), resistance (R), reactance (X) and 
fractional exhaled nitric oxide (FeNO) were measured before and 0, 15 and 30 
minutes after control and experimental sessions. 
The authors concluded that the present study provides evidence that a single 
session of e-cigarette smoking had immediate mechanical and inflammatory 
respiratory effects in healthy smokers and in asymptomatic smokers with 
intermittent asthma. These actions persisted for 15 (International Organization 
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in exhaled breath). The intensity and duration of these changes were more 
prominent in the individuals with intermittent asthma.371 
Device and product: All participants used the same new-generation e-cigarette 
(adjustable voltage) and liquid with 12 mg/mL nicotine concentration. Analysis of 
the e-liquid using gas and liquid chromatography-mass spectrometry 
techniques10 showed it contained propylene glycol 46.13% w/v, glycerol 34.3% 




Harm The authors reported on the altered lung biology of healthy never-smokers 
following acute inhalation of e-cigarettes. 
Age mean years (SD): 40.2 ± 9.7. Sex: 5 males, 5 females. Country: USA 
Duration of trial: Two sessions (control, experiment) Upon study enrolment, 
participants were assessed on day 1 (baseline) for vital signs (blood pressure, 
temperature, heart rate, respiratory rate), O2 saturation, chest X-ray, lung 
function, plasma endothelial microparticles and bronchoscopy with brushings to 
sample the small airway epithelium and bronchoalveolar lavage to obtain 
alveolar macrophages (AM) at baseline. One week later, subjects were trained 
how to use EC then inhaled 10 puffs of “Blu” brand EC, waited 30 minutes, then 
inhaled another 10 puffs. Immediately after the 1st and 2nd EC exposures, the 
questionnaires were administered and vital signs and O2 saturation were 
assessed. Within 2 h post the 2nd EC exposure, lung function, plasma EMPs and 
repeat bronchoscopy with brushing and lavage were obtained. 
Data source: Not reported 
Population size: Total cohort of n = 10, Of the n = 10 total subjects, n = 7 were 
randomized to Blu EC with nicotine and n = 3 to Blu EC without nicotine. 
Year of data collection: Not reported  
E-cigarette, smoking and other related status: healthy never-smokers with no 
history of exposure to any tobacco products or EC, 
Intervention and research design: Never smokers were assessed at baseline for 
outcomes of interest. One week later, subjects inhaled 10 puffs of “Blu” brand 
EC, waited 30 minutes, then another 10 puff; n = 7 were randomized to EC with 
nicotine and n = 3 to EC without nicotine to assess biological responses in 
healthy, naive individual 
Outcomes: Pulmonary function: FVC (% predicted), FEV1 (% predicted), FEV1/FVC 
(% observed), TLC (% predicted), DLCO (% predicted), O2 saturation, 
bronchoalveolar lavage % recovery, Total cells recovered: epithelial cells, 
macrophages, lymphocytes, neutrophils, eosinophils, small airway epithelium, 
epithelial cells, inflammatory cells, ciliated cells, secretory cells, undifferentiated 
cells, basal cells.  
The authors concluded that the data in the present study suggest that even 
limited, acute exposure to e-cigarette aerosols dysregulates the biology of the 
human lung in vivo. Whether or not chronic exposure to e-cigarettes will result in 
lung disease is unknown and can only be evaluated by large-scale, long-term 
trials of individuals who are not former or current cigarette smokers who have 
used only e-cigarettes, a study that would be challenging to carry out at present, 
as most e-cigarette users have had prior or current cigarette smoke exposure. 
However, the observed changes in the biology of the small airway epithelium, 
alveolar macrophages, and (indirectly) lung capillary endothelium may signal that 
e-cigarette use may not be as safe as has been assumed.372 
Device and product: “Blu” brand EC 
Barna et al.366  Harm, 
but less 
The authors aimed to examine the effects of combustible and non-combustible 















the degree of alveolocapillary membrane damage, measured by dynamic 
inhalation scintigraphy. 
Age range: 20 to 64 years. Sex: All male. Country: Hungary 
Duration of trial: Two session periods over two weeks. Measures were assessed 
on the seventh day of each session. 
Data source: Healthy cooperative male volunteers. Population size: 24 
Year of data collection: Not reported 
E-cigarette, smoking and other related status: Heavy smokers in the past who 
regularly used e-cigarette containing at least 10 mg nicotine/ml at the time of 
examination 
Intervention and research design: Every volunteer underwent a baseline 
examination to assess respiratory function on regular e-cigarette use. The 
authors then asked participants to return to normal cigarette smoking for a week 
consuming at least 20–25 cigarettes/day. There were no smoking-free days 
between the two types of cigarette use. The second examination was performed 
after 7 days of conventional combustible tobacco cigarette smoking.  
Outcomes: Respiration tests [forced vital capacity (FVC), forced expiratory 
volume in 1 s (FEV1), peak expiratory flow rate (PEF), Tiffeneau-Pinelli index 
(FEV1/FVC)] and carbonmonoxide and carboxyhemoglobin concentrations from 
exhaled air and scintigraphy. Outcomes: Level of carbonmonoxide and 
carboxyhemoglobin were significantly increased after conventional combustible 
tobacco cigarette use (P< 0.001). Among respiratory parameters, FVC and FEV1 
were decreased after conventional combustible tobacco cigarette use (P <0.05, 
paired t-test), but we could not find significant changes in PEF, and Tiffeneau-
Pinelli index. The clearance of the inhaled radioaerosol through the lungs became 
significantly faster after conventional combustible tobacco cigarette use 
compared with e-cigarette smoking on the individual basis. The CTl/2 values 
calculated from DIS were significantly lower in patients with smoking 
conventional combustible tobacco cigarette compared with e-cigarette users 
(P<0.001). the clearance rate was significantly faster in the right lung after 1 
week of conventional combustible tobacco cigarette smoking, but there was no 
difference between the right and left lung on the baseline study. 
The authors concluded that e-cigarette smoking is less harmful to lung function 
than conventional combustible tobacco cigarette smoking, and that it can be 
recommended to heavy smokers who are unable to stop smoking.366 




Harm The authors reported on the acute response to aerosol inhalation of non-
nicotinised e-cigarettes in terms of oxidative stress and indices of endothelial 
activation in human pulmonary microvascular endothelial cells. 
Age mean years (SD): 28.7 (5.5). Sex: both sexes. Country: USA 
Trial duration: Two sessions. Seven-day interval. 
Data source: Subjects were selected from a pool of individuals who had 
participated in previous trials in the Department of Radiology and who had also 
agreed to be contacted for possible participation in future trials  
Population size: 10. Year of data collection: Not reported 
E-cigarette, smoking and other related status: Non-smokers 
Outcomes: Biomarkers of inflammation C-reactive protein and soluble 
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Intervention and research design: Subjects were instructed to drag and inhale in 
a standardized fashion in the presence of the research coordinator. The paradigm 
consisted of 16–17 inhalations or puffs, each 2 s long, during which subjects did 
not breathe in through the nose. The total time spent on the entire protocol 
(including inhalation, release of vapor, and a few seconds between puffs) was ~3 
minutes and is equivalent to smoking an entire conventional cigarette. Overall, 
the protocol represents the average e-cigarette puffing topography in young 
adults 
The authors concluded that the findings suggest that even in the absence of 
nicotine, acute e-cigarette aerosol inhalation leads to a transient increase in 
oxidative stress and inflammation. This can adversely affect the vascular 
endothelial network by promoting oxidative stress and immune cell adhesion. 
Thus, e-cigarette inhalation has the potential to drive the onset of vascular 
pathologies.373 
Device and product: E-puffer exhaled carbon monoxide-disposable e-cigarettes 
were purchased from E-Puffer (New York, NY). E-puffer was chosen as it is a 
brand of non-nicotinized e-cigarette that is popular among young adults. Other 
brands that are popular lacked nicotine-free versions. The device consists of a 
cylindrical lithium battery that supplies 3.7 V to a dual-coil atomizer (heating coil) 
with a resistance of 2.7 ohms. The liquid tank attached to the atomizer is 1.3 ml 
in volume and is filled with e-liquid composed of 70% pharma-grade propylene 
glycol (PG) and 30% vegetable glycerine (VG). The atomizer temperature in a 
similar device has been reported to vary between 145 and 334°C 
Kerr et al.374  
2019 
Harm The authors reported on the acute effects of electronic and tobacco cigarettes 
on vascular and respiratory function in healthy volunteers; this was a crossover 
study. 
Age mean years (SD): mean age 31.6 ± 10.5. Sex: All male. Country: UK 
Duration of trial: Two sessions. All participants attended for two study visits at 
the same time of day, with a minimum of 24 h between each visit. The number of 
days between study visits was six but ranged ~ 1 to 13 days. Prior to each study 
visit participants were asked to fast for a minimum of 4 h and to refrain from 
tobacco smoking, e-cigarette use and from consuming caffeinated and alcoholic 
products for 12 h. Participants were exposed to each intervention (either tobacco 
cigarette smoking or e-cigarette use) on separate study days. Study investigations 
were performed preintervention and post intervention. Three repetitive BP 
recordings were taken and the mean SBP and DBP recordings were calculated. 
Post-intervention BP measurements were taken 10 minutes following the 
intervention. Heart rate (HR) was measured immediately before and 1 minutes 
following the intervention. Reactive hyperaemia index (RHI), a measure of 
endothelial function via peripheral arterial tonometry (PAT); and augmentation 
index, a measure of arterial stiffness, were assessed. Baseline pulse wave 
amplitude (PWA) was measured for 5 minutes. The BP cuff was then rapidly 
inflated on the experimental arm 60mmHg and SBP (the occlusion pressure did 
not exceed 200mmHg) for a duration of 5 minutes. After exactly 5 minutes of 
occlusion the BP cuff was rapidly deflated to induce flow mediated reactive 
hyperaemia. A post occlusion recording was then measured for a further 5 
minutes. Postintervention PAT was recorded 15 minutes following the 
intervention. Blood samples were collected before and 5 minutes following each 
intervention. 
Data source: Twenty healthy male smokers were sequentially screened and 
recruited into the study 
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E-cigarette, smoking and other related status: habitual tobacco smokers of one 
or more tobacco cigarette per day  
Intervention and research design: Single-centre prospective randomized 
crossover study. 20 healthy male smokers were randomized in a crossover 
fashion to electronic and tobacco cigarette study arms (i.e. Participants were 
randomly assigned to study arms ‘A’ or ‘B’ in a 1:1 ratio). Randomization 
determined the order that participants received each intervention. Study 
investigations were performed before and after each intervention. Washout 
period between study visits was a minimum of 24 h. smokers immediately before 
and after electronic cigarettes use and tobacco smoking. All participants 
attended for two study visits at the same time of day, with a minimum of 24 
hours between each visit.  
Outcomes: Heart rate, blood pressure, reactive hyperaemia index (RHI, 
microvascular reactivity), augmentation index (arterial stiffness) and respiratory 
function. PWA occluded arm (AU), PWA control arm (AU), augmentation index, 
exhaled carbon monoxide, FEV1, forced expiratory volume in 1 s; FEV1/FVC, 
forced expiratory volume in 1 s/forced vital capacity ratio; PEF, peak expiratory 
flow; PWA, pulse wave amplitude; RHI, reactive hyperaemia index. Heart rate 
increased after electronic cigarettes use and tobacco smoking, whereas blood 
pressure remained unchanged. Reactive hyperaemia index, augmentation index 
(P¼0.010) but not augmentation index standardized to heart 75bpm increased 
with electronic cigarettes use but not with tobacco smoking. Following tobacco 
smoking, there was a significant increase in total microparticles (P<0.001), EMPs 
(P<0.001) and PMPs (P<0.001). In contrast, electronic cigarettes were only 
associated with an increase in PMPs (P<0.001), with no significant changes in the 
total microparticle fraction or EMPs (all P>0.05). Peak expiratory flow 
significantly decreased following electronic cigarettes use. 
The authors concluded that acute exposure to tobacco smoking as well as to e-
cigarettes influences vascular and respiratory function. Where tobacco smoking 
significantly increased microparticle formation, indicative of possible endothelial 
injury, e-cigarette use induced vasoreactivity and decreased peak expiratory 
flow. These findings suggest that both e-cigarette and tobacco smoking 
negatively impact vascular and respiratory function.374 
Device and product: For the e-cigarette intervention participants were asked to 
use a commercially available second-generation e-cigarette device with nicotine-
containing e-liquid. The device consisted of a 1300mAh variable voltage 
rechargeable battery, a tank and an atomizer (SmokeMax; Groove Trading Ltd, 
Glasgow, UK). Each tank contained approximately 1.5 ml of e-liquid. The e-liquid 
used in the study was reported by the manufacture to contain 18 mg/ml nicotine, 
and was tobacco flavoured (Pillbox38 UK Ltd, Totally Wicked, Blackburn, UK). All 
the e-liquid used in the study was manufactured from the same batch. The e-
liquid control of substances hazardous to health (COSSH) assessment report from 
the manufacture stated that the contents per 10 ml bottle were: 360-mg 
nicotine, 12.6-ml propylene glycol, 6.2-ml vegetable glycerine, 120-mg vanillin, 
48mg furaneol and 80-mg ethyl vanillin. An independent analysis of the e-liquid 
was performed at the Nicotine and Tobacco Product Assessment Shared 
Resource (NicoTAR), Roswell Park Cancer Institute, Buffalo, New York, USA. 
Nicotine concentrations were determined using gas chromatography (GC) with a 
nitrogen–phosphorus detector (GC–NPD). Flavouring compounds were also 
identified in each liquid using a GC/mass spectrometry method. According to the 
laboratory report, the average nicotine content was 17.27 mg/ml and the 
identified flavouring compounds correlated closely with the manufactures COSSH 
report Each participant was provided with a new e-cigarette device, which was 
prepared by the study investigator. The investigator filled the tank with e-liquid 
and set the battery voltage to 3.3 V. When asked to use the e-cigarette 
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considered to be comparable with the amount of nicotine obtained from 
smoking a conventional combustible tobacco cigarette, approximately 0.5mg 










Benefit The authors reported on the immediate effects of e-cigarettes on perfusion in 
buccal mucosal tissue in non-smokers. 
Age range: 27 to 38 years. Sex: 7 males, 3 females. Country: UK 
Duration of trial: Two sessions on separate days. Interval not reported. Measures 
were gathered up to 30 minutes post intervention 
Data source: Volunteers, members of staff from the oral and maxillofacial 
department and ward, Non-smokers 
Population size: 10. Year of data collection: Not reported 
E-cigarette, smoking and other related status: Not reported 
Intervention and research design: Crossover design. Each was given 2 electronic 
cigarettes, one containing plain “e-liquid” (a solution of propylene glycol and 
vegetable glycerine) as a control, the second containing nicotine (16 mg nicotine/g 
of e-liquid). A baseline of capillary blood flow to the buccal mucosa was taken with 
the laser Doppler probe, both before and after 5 minutes of vaping, and this was 
recorded as “Prevape” and “0 Minute”, respectively. After vaping, measurements 
were repeated at 5-minute intervals for 30 minutes. The volunteers were not told 
whether the e-cigarette contained nicotine, but both types were used by all 
volunteers on separate days. Using a laser Doppler, the moorVMS-LDF2, (Moor 
Instruments Axminster, Devon, UK) the authors analysed the effect of electronic-
cigarettes on the flow of buccal mucosal blood, before and immediately after 
vaping. 
Outcomes: After vaping for 5 minutes, capillary blood flow was measured in the 
buccal mucosa at 5-minute intervals using a laser Doppler probe, and the results 
were expressed as arbitrary perfusion units. There was a wide variation in results 
and a small but significant rise (p=0.008) as a result of nicotine vaping, but these fell 
to the same levels as before within 30 minutes 
The authors concluded that e-cigarettes may influence blood flow to the oral 
mucosa, although further trials are needed to show whether they improve healing 
time after operation.375 
Device and product: Each participant was given two electronic cigarettes, one 
containing plain “e-liquid” (a solution of propylene glycol and vegetable glycerine) as 




Harm The authors reported findings from a pilot study on gingival response when 
smokers switched from smoking to vaping. 
Age mean years (SD): Not reported. Sex: Not reported. Country: UK 
Duration of trial: Two weeks  
Data source: Established smokers (all staff members at Guy’s Hospital) with mild 
periodontal disease 
Population size: 18. Year of data collection: Not reported  










Interventional trial papers oral diseases 
Intervention and research design: Measure were taken before and after 
substituting vaping for smoking tobacco  
Outcomes: gingival inflammation measures such as bleeding on probing, levels of 
selected pro-inflammatory cytokines (specifically IL 1β and IL 8) in gingival 
crevicular fluid, saliva and serum samples 
The authors concluded that there was a statistically significant increase in gingival 
inflammation when tobacco smokers switched from smoking to vaping for 2 weeks, 
but results should be interpreted with extreme caution since this was only a pilot 
study.376 
Device and product: At visit one, subjects were given a blu PROTM e cigarette kit 
(Electric Tobacconist®), an extra bottle of blu PRO Tobacco™ e Liquid (Electric 
Tobacconist) and written instructions. The e Liquid was Classic Tobacco flavoured 
and contained 18 mg of nicotine (medium strength). The choice of this particular 
brand of e cigarette was random and there was no commercial sponsorship from 
the company. The participants agreed to substitute their regular smoking habits 
with the use of e cigarettes. They were asked to make a note of any cigarette 






The authors reported on findings following the monitoring of nicotine intake from 
e-cigarettes; specifically, the measurement of parent drug and metabolites in oral 
fluid and plasma. 
Age mean years (SD): 23.9 ± 3.5. Sex: All male. Country: Italy  
Duration of trial: Two sessions. Two-day interval. Subjects participated as 
outpatients in two different randomly assigned 2-h experimental sessions, carried 
out with at least 2 days washout period between them. Each nicotine 
administration, monitored by the researcher, consisted of 10 puffs with a 30-s 
interpuff interval. Blood samples were collected just before the first administration 
(baseline, time –5 minutes), 5 (after the first administration), 15, 30 and 45 minutes 
and also just before the second administration (time 55 minutes), then immediately 
after the second administration (65 minutes after the first administration), and 
then at 75, 90, 105, and 120 minutes. 
Data source: The subjects were recruited from the surrounding community by word 
of mouth  
Population size: 9. Year of data collection: Not reported  
E-cigarette, smoking and other related status: All subjects were smokers of at least 
three tobacco cigarettes per day (mean=9 cigarettes, SD=5) and by at least 1 year 
(mean=7 years, SD=4 years) without serious adverse reactions to nicotine. Neither 
of them reported to have tried e-cigarette. 
Intervention and research design: The study design was a dose, randomized, 
crossover, and controlled trial with nicotine. Subjects participated in two different 
randomly assigned 2-hour experimental sessions, in which they were given: one 
dose of 0.8 mg of nicotine followed by another 0.8 mg nicotine dose 60 minutes 
later, both administered as a second generation e-cigarette (Nhoss®, e-liquid 16 
mg/mL nicotine, flavour “blond”, France) or tobacco cigarette (Marlboro®, 0.8 mg 
nicotine per cigarette, USA).  
Outcomes: oral fluid and plasma nicotine, cotinine, and trans-3′-hydroxycotinine 
The authors concluded that the obtained results support the measurement of 
nicotine and metabolites in oral fluid in the assessment of intake after e-cigarette 
use and appear to be a suitable alternative to plasma when monitoring nicotine 
delivery from e-cigarettes for clinical and toxicological trials.377 
Device and product: One dose of 0.8 mg of nicotine followed by another 0.8 mg 
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cigarette (Nhoss®, e-liquid 16 mg/mL nicotine, flavour “blond”, France) or tobacco 
cigarette (Marlboro®, 0.8 mg nicotine per cigarette, USA) 
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van Staden 








The authors reported on carboxyhaemoglobin levels, and on health and lifestyle 
perceptions in smokers converting from tobacco cigarettes to e-cigarettes. 
Age range: 18 to 50 years. Sex: 8 males, 5 females. Country: South Africa 
Data source: Participant were recruited from 1 Military Hospital, Pretoria. 
Duration of trial: Two sessions. One, of two, week intervals  
Population size: 13. Year of data collection: Not reported  
E-cigarette, smoking and other related status: Smoking 10 - 30 cigarettes per day 
Intervention and research design: A single group within-subject design. The 
participants exchanged their cigarettes for the Twisp e-cigarette and were instructed 
to smoke this exclusively for a period of two weeks. Participants were evaluated at 
baseline prior to using the Twisp e-cigarette (visit 1) and again after two weeks (visit 
2). 
Outcomes: Carboxyhaemoglobin levels and oxygen saturation, serum cotinine levels, 
perception of smoking-related symptoms and lifestyle: carboxyhemoglobin levels 
(%) were significantly reduced after smoking Twisp e-cigarettes for 2 weeks (mean 
+/- standard deviation (SD) arterial carboxyhemoglobin before 4.66+/-1.99 v. after 
2.46+/-1.35; p=0.014 and mean+/-SD venous carboxyhemoglobin before 4.37+/-2.1 
v. after 2.50+/-1.23; p=0.018). A decrease in cotinine levels (p=0.001) and an 
increase in oxygen saturation (p=0.002) were also observed. Most participants 
perceived improvements in their health and lifestyle parameters. 
The authors concluded that smoking the Twisp e-cigarette may be a healthier and 
more acceptable alternative to smoking tobacco cigarettes.378 








The authors reported on the nicotine intake from e-cigarettes following initial use 
and after 4 weeks of regular use. 
Age mean years (SD) (range): 52 ± 16 (32 to 74). Sex: 1 male, 5 females. Country: UK 
Duration of trial: Two sessions. Four weeks interval  
Data source: Adult smokers interested in stopping smoking recruited through 
advertisements in local newspapers 
Population size: 6. Year of data collection: Not reported 
E-cigarette, smoking and other related status: At the beginning of the study, they 
smoked on average 25 cigarettes/day (SD = 16, range 10–60) and scored 5.7 (SD = 
3.2, range 1–9) on Fagerström Test for Nicotine Dependence. During the study, they 
reported using on average 1.2 EC cartridges per day (SD = 0.7, range 0.7–2.5). 
Intervention and research design: On the target quit date (Baseline assessment 
week 1), participants were provided with an e-cigarette and 15 cartridges and 
instructions on its use, they attended standard withdrawal oriented behavioural 
support weekly for 4 weeks. Further supplies of cartridges were available at each 
session as needed. The instructions suggested that smokers usually find their own 
way of using e-cigarette; that e-cigarette can be puffed on for 5–10 minutes and 
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use one cartridge per day, but enough cartridges are provided to use up to two per 
day. All six participants were smoking and using e-cigarette during the week of their 
second assessment (week 4). One participant reported smoking less than five 
cigarettes over the previous week; the others smoked more than five cigarettes. At 
the two PK sessions, a blood sample was taken after which participants were asked 
to smoke a fully charged e-cigarette ad lib for 5 minutes. 
Outcomes: e-cigarette pharmacokinetics (plasma nicotine concentrations) data on 
the two occasions, that is, when the participants were new to EC use (baseline week 
1) and after using e-cigarette for 4 weeks. The peak nicotine levels were achieved 
within 5 minutes of starting the e-cigarette use, which suggests that e-cigarette may 
provide nicotine via pulmonary absorption. There were large individual differences 
in nicotine intake. Compared with the PK profile when using e-cigarette for the first 
time, 4 weeks of practice generated a 24% increase in the peak plasma 
concentrations and a 79% increase in overall nicotine intake. 
The authors concluded that first-generation e-cigarettes provide faster nicotine 
absorption than nicotine replacement products, but to compete successfully with 
conventional combustible tobacco cigarettes, e-cigarettes may need to provide 
higher doses of nicotine. Nicotine intake from e-cigarettes can increase with 
practice, but further trials are needed to confirm this effect.387 
Device and product: Green Smoke EC with cartridges labelled 2.4% nicotine. This 
was a first-generation “cig-a-like” re-chargeable device. EC were purchased from the 
manufacturer. The labelling of nicotine content was accurate, and the model had 
good consistency in nicotine delivery. It delivered 9 mg of nicotine in vapor more 
than 300 puffs, which was in the middle of the range of the products tested. 
Cartridges used in this study were tobacco flavoured and contained nicotine 
dissolved in a mixture of propylene glycol and vegetable glycerol. 
McRobbie 








The authors investigated exposure to carbon monoxide (CO), nicotine (by 
measuring cotinine in urine), and acrolein (by measuring its primary metabolite, S-
(3-hydroxypropyl) mercapturic acid (3-HPMA) in urine) in smokers and e-cigarette 
users. 
Age mean years (SD): 44.8 ± 13.22 EC use only 48.2 ± 12.37 dual users 
Sex: 8 male (50%) EC use only: male 9 (52.9%) dual users. Country: England, UK.  
Duration of trial: Five session. One-week interval. 
Data source: Adult smokers wanting to stop smoking were recruited through 
advertisements in free London newspapers 
Population size: 40. Year of data collection: Not reported  
E-cigarette, smoking and other related status: Smokers 
Intervention and research design: Exposures in a cohort of 40 smokers before and 
after 4 weeks of e-cigarette use, both in exclusive e-cigarette users and dual users. 
On the target quit date, participants were provided with their e-cigarette and 
received instructions on its use. They were instructed to use e-cigarette ad-lib. Two 
cartridges per day were supplied initially, with the supply adjusted to actual use 
later. Participants received standard withdrawal-oriented behavioural support at 
baseline, target quit date, and at four further weekly sessions.  
Outcomes: Changes in CO, cotinine, and acrolein (as measured by its primary 
metabolite, S-(3-hydroxypropyl) mercapturic acid (3-HPMA; other name N-Acetyl-S-
(3-hydroxypropyl)-L-cysteine (i.e. (3-HPMA) from baseline to 4 weeks after target 
quit date. 
The authors concluded that a significant reduction in carbon monoxide was 
observed in e-cigarette users and dual users of e-cigarettes and conventional 
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at 17% decrease compared to their baseline measure; and dual users at 44% 
decrease. Mean acrolein (3-HPMA) levels had decreased at 4 weeks, with a 79% 
decrease in e-cigarette-only users compared to their baseline measure and a 60% 
decrease in dual users. In dual users, e-cigarette use significantly reduced exposure 
to carbon monoxide and acrolein because of a reduction in smoke intake. E-
cigarettes may reduce harm even in smokers who continue to smoke, but long-term 
follow-up trials are needed to confirm this.379 
Device and product: Green Smoke e-cigarette (labelled 2.4% nicotine), a first-
generation "cig-a-like" device, purchased directly from the manufacturer's website. 
At the time of the study, the company produced only one model. From a previous 
study, the model was noted to provide a consistent nicotine content and delivered 9 
mg of nicotine in aerosol over 300 puffs which was in the middle range of the 
products tested. Peak mean plasma nicotine concentration achieved after 5 minutes 
of ad lib use, after overnight abstinence, was 5.7 ng/mL (15). While many e-
cigarettes include propylene glycol only, Green Smoke includes propylene glycol and 
vegetable glycerine, the latter being the precursor to acrolein. The authors tested 
aerosol generated from 5 Green Smoke cartridges for acrolein content using a 
smoking machine. The average acrolein yield in aerosol delivered in 15 puffs was 










The authors reported on reductions in biomarkers of exposure to harmful or 
potentially harmful constituents following partial or complete substitution of 
cigarettes with e-cigarettes in adult smokers. 
Age mean years (SD±): 37.8 (11.1). Sex: 68 males 37 females. Country: USA 
Ethnicity: American Indian/Alaska Native: n=1 Black or African American: n=17 Black 
or African American: n=1 Indian/Alaska White: n=86 
Data source: Potential smokers were recruited from the Lincoln, NE (USA) area using 
standard advertising methods (i.e., print and radio advertisements) and from a 
database of subjects who had previously participated in a clinical research study or 
who had expressed interest in participating in a study  
Duration of trial: Six days. Randomization and a five-day forced-switch from usual 
brand conventional combustible cigarettes to: (i) exclusive commercial e-cigarette 
use; (ii) dual-use of commercial e-cigarettes and the subject’s usual cigarette brand; 
or (iii) discontinued use of all tobacco or nicotine products. All urine voided by each 
subject was collected in 24-h intervals from 07:30 on Day -1 through 07:30 on Day 1, 
and from 07:30 on Day 5 through 07:30 on Day 6, and aliquots were prepared from 
the 24-h collections. Blood samples were collected on Days -1 and 5 in the evening 
following dinner to assess exposure to CO and nicotine. 
Population size: Total 105. Exclusive E-Cigarette use groups: Tobacco rechargeable 
n=15, Cherry rechargeable n=15, Cherry disposable n=15, Dual use groups: Tobacco 
rechargeable n=15, Cherry rechargeable n=15, Cherry disposable n=15; Nicotine 
cessation n=15 
Year of data collection: Not reported  
E-cigarette, smoking and other related status: a smoker for at least 12 months and 
currently smoked an average of 10 or more conventional manufactured tobacco 
cigarettes per day (any brand, flavour or style); consistent use of their current usual 
brand style for 14 days prior to check-in; positive urine cotinine at screening (>=500 
ng/mL); and exhaled carbon monoxide CO >12 ppm at screening. 
Intervention and research design: On the morning of Day 1, subjects were 
randomized into one of six groups (N=15 each): exclusive E-Cigarette use groups: 
Tobacco rechargeable, Cherry rechargeable, Cherry disposable, Dual use groups: 
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Outcomes: The urine, blood and inhalation biomarkers of tobacco smoke exposures 
of: Nicotine equivalents measured: included nicotine and five major nicotine 
metabolites: nicotine gluc; cotinine; cotinine-gluc; trans-3’-hydroxycotinine; and 
trans-3’-hydroxycotinine-gluc. NNAL: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; 
1-HOP: 1-hydroxypyrene; 3-HPMA: 3-hydroxypropylmercapturic acid; S-PMA: S-
phenylmercapturic acid; MHBMA: Monohydroxy-3-butenyl mercapturic acid; 
HMPMA: 3-hydroxy-1-ethylpropylmercapturic acid; CEMA: 2-cyanoethylmercapturic 
acid. Exhaled breath biomarkers Exhaled CO and NO are measures of acute carbon 
monoxide exposure and nitric oxide synthase activity 
The authors concluded that the levels of urinary biomarkers in subjects who 
completely substituted their usual conventional combustible tobacco cigarettes with 
e-cigarettes were significantly lower (29–95%) after 5 days. Percentage reductions in 
eight of nine urinary biomarkers of exposure were indistinguishable from smokers 
who had quit smoking, except for nicotine equivalents, which declined by 25–40%. 
Dual users who halved self-reported daily cigarette consumption by replacing them 
with e-cigarettes exhibited reductions (7–38%) in eight of nine urinary biomarkers 
but had increased (1–20%) nicotine equivalents. Reductions were broadly 
proportional to the reduced numbers of cigarettes smoked. Dual user urinary 
nicotine equivalents were slightly higher when compared to other groups (e-
cigarette only group and non-user or cessation group), but not statistically 
significant. After 5 days, blood nicotine biomarker levels were lower in the and non-
user or cessation group (75–96%) and exclusive e-cigarette use group (11–83%), 
with dual users experiencing no significant reductions. All subjects experienced 
significant decreases in exhaled carbon monoxide; these decreases in the cessation 
and exclusive use groups ranged from 88–89%, and from 27–32% in dual users. 
Exhaled fractional nitric oxide concentration in exhaled breath (FeNO) increased in 
the cessation and exclusive use groups (46% and 63%, respectively), whereas the 
dual users experienced minimal changes. Overall, smokers who completely or 
partially substituted conventional combustible tobacco cigarettes with e-cigarettes 
over 5 days experienced reductions in harmful or potentially harmful 
constituents.380 
Device and product: Three commercially available closed system bluTM e-cigarette 
products (manufacturer, Fontem Ventures B.V., The Netherlands) were evaluated 
during this study: rechargeable tobacco flavour, rechargeable cherry flavour, and 
disposable cherry flavour. The rechargeable e-cigarettes consist of a battery 
segment and a cartomizer segment comprising the heating unit and a liquid 
reservoir which can be separated from the battery for recharging or replaced when 
the e-liquid is depleted. The disposable e-cigarette was similar in form with the 
exception that the battery and cartomizer segments are included as a single, non-
separable unit. Both units operated at a voltage of 3.7 volts (nominal). The 
resistance of the heating element was _3 ohms for the disposable unit and about 3.5 
ohms for the rechargeable unit. The maximum operating temperature of each unit 
was dependent on the charge level of the battery, the state of reservoir fluid fill and 
on the manner of use and was not recorded in this study. All e-cigarette products 
contained 24 mg/mL (2.4%) USP grade nicotine, USP grade vegetable glycerol (~50% 
in cherry flavour and ~80% in tobacco flavour), USP grade propylene glycol 
(~45% in cherry flavour and ~10% in tobacco flavour), distilled water, and 
flavourings. Each e-cigarette contained ~1mL of e-liquid by volume. Subjects were 
provided unopened packs of their reported usual brand of conventional combustible 
tobacco cigarettes for use during the study. 
Subjects were randomized into one of six groups (N=15 each): 
Exclusive E-Cigarette Use Groups 
Group A1 – Tobacco flavour rechargeable bluTM e-cigarette 
Group A2 – Cherry flavour rechargeable bluTM e-cigarette 
Group A3 – Cherry flavour disposable bluTM e-cigarette 
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Group B1 – Tobacco flavour rechargeable bluTM e-cigarette + usual brand 
combustible tobacco cigarette 
Group B2 – Cherry flavour rechargeable bluTM e-cigarette + usual brand l brand 
combustible tobacco cigarette 
Group B3 – Cherry flavour disposable bluTM e- cigarette + usual brand usual brand 
combustible tobacco cigarette 
Cessation Group 






The authors reported on acute active and e-cigarette changes on antioxidant 
responses and subsequent pathologies measuring redox status. 
Age mean years (SD): smokers 36.8 (9.9) non-smokers 28.8 (10.5) 
Sex: 16 males, 14 females. Country: Greece 
Duration of trial: Three sessions. Seven-day interval. Active smokers underwent a 
control session consisting of an active tobacco cigarette smoking session and an 
active e- cigarette smoking session. Blood samples were collected prior to, 
immediately after, as well as one hour after the smoking sessions. Non-smokers 
underwent a control session a passive tobacco cigarette smoking session and a 
passive e-cigarette smoking session. Blood samples were collected prior to, 
immediately after, as well as 1 h after the smoking sessions. Three different 
experimental sessions that were performed in a random order (separated by a 
minimum of seven days). 
Data source: Two groups of healthy adult volunteers. Active smokers. Passive 
smokers.  
Population size: 30. Year of data collection: Not reported 
E-cigarette, smoking and other related status: 15 smokers (more than 15 cigarettes 
per day) and 15 non-smokers 
Intervention and research design: A randomized single-blind crossover design 
Outcomes: Total antioxidant capacity, catalase activity and reduced glutathione 
The authors concluded that tobacco and e-cigarette smoking exposure do not 
acutely alter the response of the antioxidant system, under either active or passive 
smoking conditions. Overall, there is no distinction between tobacco and e-cigarette 
active and passive smoking effects on specific redox status indices.390 
Device and product: device: GIANT, NOBACCO GP, Greece. The e-cigarette liquid 
(NOBACCO USA MIX, NOBACCO GP, Greece) used, had tobacco taste and contained 




Harm The authors reported on the effects of alcohol-containing e-cigarettes on young 
adult smokers. 
Age mean years (SD): 25.7 ± 2.7. Sex: 14 males, 6 females. Country: USA 
Duration of trial: Two sessions. Two-day interval. Test sessions were conducted in 
the early afternoon and participants were instructed to abstain from alcohol for 48 
hours, and from all tobacco and nicotine products for 12 hours, before the sessions. 
Prior to each test session, an indwelling 20-gauge, flexible catheter was inserted into 
an antecubital vein for blood sample collection. Each test session consisted of a 5-
minute directed puffing session (10 puffs total) followed by two, 20 minutes ad lib 
sessions separated by 20 minutes. The sessions were conducted at least 48 hours 
apart to minimize carry over effects.  
Data source: Not reported Population size: 16. Year of data collection: Not reported 
E-cigarette, smoking and other related status: Smokers who reported drinking 
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use of tobacco cigarettes within the past 6 months, were enrolled. All participants 
reported daily use of cigarettes for the 6 months prior to study entry. Participants 
smoked for an average of 8.7 (4.3) years and scored 4.6 (2.4) on the Fagerström Test 
for Nicotine Dependence (FTND) indicating moderate dependence. The median 
lifetime duration of e-cigarette use was 2 months with a range 0–16 months. 
Twenty-seven percent of participants reported preferring e-cigarettes, 47% 
cigarettes, 13% having no preference and 13% that their preference was dependent 
on the context of use. The cumulative percentage of responses to four different 
intensity intervals (in number days) of any e-cigarette in the past month was20% no 
use, 93% 1–10 days, 93% 11–20 days and 100% over 21 days. 
Intervention and research design: Randomized, double blind, crossover design 
(randomized, within-subjects, counterbalanced design). Acute changes in subjective 
drug effects, motor performance and biochemical measures of alcohol and nicotine 
intake were evaluated after directed and ad lib puffing from two commercially 
available e-liquids containing nicotine (8 mg/ml), vanilla flavour and either 23.5% 
(high) or 0.4% (trace) alcohol.  
Outcomes: Drug Effects Questionnaire, the Biphasic Alcohol Effects Scale and the 
Purdue Pegboard Dexterity Test (PPDT, Lafayette Instruments, Lafayette, IN) 
measures two types of motor performance: fine finger dexterity and gross 
movements of the fingers, hands, and arms. 
The authors concluded that brief use of a widely available type of e-cigarette 
containing an e-liquid purchased from an Internet vendor can negatively impact 
psychomotor performance and, in some instances, produce detectable levels of a 
urine alcohol metabolite.193 
Device and product: Two commercially available e-liquids containing nicotine (8 
mg/ml), vanilla flavour and either 23.5% (high) or 0.4% (trace) alcohol. Type of e-
cigarette, the Joyetech eGo-CTM, with a single coil atomizer (2.2 ohms), 2 ml tank, 
and a 650 milliampere hour battery operating at 3.7 V (6.2 W). To reduce variability 
in aerosol delivery during test sessions, subjects practiced using the e-cigarette in an 
adaptation session, inhaling more softly, but for a longer duration (3–4 s) than is 
customary for a tobacco cigarette. Participants were instructed to notify research 
staff immediately if any undesirable flavours developed that indicated overheating 
of the e-liquid (i.e. ‘dry puffs’). Subjects were told the purpose of the study was “to 
measure the effects of alcohol contained in a commercially avail-able e-cigarette 
refill liquid”. 
Goniewicz 








The authors reported on the relationship of e-cigarettes with a range of 
carcinogens and toxicants. 
Age mean years (SD) (range): 31.0 ± 9.7 (20 to 52). Sex: 60% female 
Country: Poland. Ethnicity: Caucasian. Duration of trial: Two sessions. Two weeks 
Data source: Subjects were recruited from the local metropolitan area using 
advertisements in the media, the internet, posted advertisements in clinics and 
offices, and by word of mouth. Advertisements used to recruit healthy adult daily 
smokers referred to the opportunity to reduce cigarette smoking by use of a 
modified risk tobacco product (MRTP). 
Population size: 20. Year of data collection: March and June 2011  
E-cigarette, smoking and other related status: Subjects smoked an average of 12.1 
(7.5) years (range: 4–35); the mean level of nicotine dependence among subjects (as 
measured by the Fagerstrom Test for Cigarette Dependence [FTCD])39 was 3.9 (2.7) 
(range: 0–9). At the time of screening, 95% of subjects (n = 19) reported planning to 
quit smoking, with 80% (n = 16) reporting that they have made at least one quit 
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Intervention and research design: Before and after use of the pen-style M201 e-
cigarettes  
Outcomes: Mean Levels of Biomarkers in Smokers (N = 20) at Baseline, after 1 Week 
and 2 Weeks of Using Electronic Cigarettes. Biomarker urine concentration 
(Toxicant): Nicotine metabolites: 3-Hydroxycotinine (Nicotine), Cotinine(Nicotine), 
Nicotine(Nicotine), Cotinine N-Oxide(Nicotine), Nicotine N-Oxide(Nicotine), 
Norcotinine(Nicotine), Nornicotine(Nicotine), Nicotine equivalents. Nitrosamines 
(TSNAs): -4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone). Mercapturic acids: 2-hydroxyethylmercapturic acid 
(Ethylene oxide), 2-Hydroxy-3-buten-1-yl-ylmercapturic acid; (1,3-Butadiene), 3-
hydroxy-1-methylpropylmercapturic acid (Crotonaldehyde), 3-hydroxypropyl 
mercapturic acid (Acrolein), S-phenylmercapturic acid (Benzene), 2-
carbamoylethylmercapturic acid (Acrylamide), 2-cyanoethyl mercapturic acid 
(Acrylonitrile), 2-hydroxypropyl mercapturic acid (Propylene Oxide). Metabolites of 
polycyclic aromatic hydrocarbons: 1-Hydroxyfluorene (Fluorene), 3-, 4-
Hydroxyphenanthrenes (Phenanthrene), 2-Hydroxyfluorene (Fluorene), 1-
Hydroxypyrene (Pyrene), 3-Hydroxyfluorene (Fluorene), 2-Hydroxyphenanthrene 
(Phenanthrene), 1-Hydroxyphenanthrene (Phenanthrene), 2-Naphthol 
Naphthalene). Toxic gases Carbon monoxide (Carbon monoxide). In total, 45% of 
participants reported complete abstinence from cigarette smoking at 2 weeks, while 
55% reported continued smoking. 
The authors concluded that the study showed that after switching from tobacco to 
e-cigarettes, nicotine exposure remains unchanged, while exposure to selected 
carcinogens and toxicants is substantially reduced. These findings suggest that e-
cigarettes may effectively reduce exposure to toxic and carcinogenic substances 
among smokers who switched to e-cigarette products.381 
Device and product: (M201 Mild, Poland) with 20 tobacco-flavoured cartridges per 
week containing 11.0 ± 1.5 mg of nicotine in a mixture of propylene glycol and 










The authors reported on the nicotine delivery profiles and harmful constituent 
exposures of second-generation and third-generation e-cigarette users. 
Age mean years (SD): 33.8 ± 10.9. Sex: 60% males. Country: USA  
Ethnicity: 43% white, 10% black/African-American and 47% multi-race/ethnicity. 
Data source: Recruited via internet advertisements, flyers and word-of-mouth.  
Duration of trial: Two sessions. One-week interval. The study design consisted of 
two phases, a baseline and pharmacokinetic (PK) assessment phase (standardised 
and ad libitum vaping session). Participation in the baseline phase lasted ∼45 
minutes G2 (2nd generation device users) and G3 (3rd generation device users) e-
cigarette users attended a second study visit within the next week and were asked 
to abstain from nicotine containing products 12 hours prior to the visit. 
Population size: N=30 Smokers n=10, 2nd generation device users n=9, 3rd 
generation device users n=11  
Year of data collection: Not reported  
E-cigarette, smoking and other related status: Specific eligibility criteria for exclusive 
e-cigarette users included denying use of any other tobacco/nicotine product ≥3 
months and using the same style of e-cigarette device for ≥3 months, and using a G2 
device (specified as entry-level tank systems/eGo style tank system without 
modifications to the tank, atomiser or battery) or a G3 device (specified as an 
advanced device such as mechanical mods, rebuildable drip tanks, rebuildable 
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included smoking cigarettes ≥3 months and no other tobacco/nicotine product for≥3 
months.  
Intervention and research design: The study design consisted of two phases, a 
baseline and pharmacokinetic (PK) assessment phase (standardised and ad libitum 
vaping session. G2 and G3 e-cigarette users attended a second study visit 
(pharmacokinetic assessment) within the next week and were asked to abstain from 
nicotine containing products 12 hours prior to the visit.  
Outcomes: Saliva and urine samples were collected for an analysis of salivary 
cotinine (metabolite of nicotine) and total urinary NNAL (a metabolite of the lung 
carcinogen NNK). Exhaled carbon monoxide (eCO; a cardiovascular toxicant) was 
also assessed.  
The authors concluded that while baseline cotinine concentration levels among 
exclusive smokers, second-generation e-cigarette users, and third-generation e-
cigarette users are similar (which may have implications for addiction and e-
cigarettes’ viability as a substitute for smoking), second-generation and third-
generation e-cigarette users had significantly lower levels of exposure to a potent 
lung carcinogen and a cardiovascular toxicant. These findings have significant 
implications for understanding the addiction potential of these devices and their 
viability/suitability as aids for smoking cessation. 
For e-cigarette users, information regarding the nicotine concentration of their e-
liquid and specifications of their e-cigarette device (e.g., number of 
atomiser/heating coils) was also collected. Voltage and resistance metres were used 
to objectively measure volts and ohms of the e-cigarette device.382 
Device and product: Mean (SD) voltage applied to the atomiser was not significantly 
different between G2 and G3 devices (G2: 4.1 (0.5) volts vs G3: 4.0 (0.4) volts, 
p=0.74), but resistance of the atomiser was significantly higher in G2 compared with 
G3 devices (G2: 2.0 (0.3) Ω vs G3: 0.4 (0.2) Ω, p<0.00001), resulting in significantly 
higher vaping power in G3 devices (G2: 8.6 (1.9) watts vs G3: 71.6 (50.0) watts, 
p=0.001). Number of atomiser coils was not significantly different between G2 and 
G3 devices 




The authors reported on the pharmacokinetics of nicotine following the use of a 
prototype novel tobacco vapour product in comparison to a conventional 
combustible tobacco cigarette. 
Age mean years (range): 39.0 (21 to 63). Sex: All males. Country: Japan 
Duration of trial: Four days On Day 1, Subjects checked in to the clinic and abstained 
from their regular tobacco product use. Days 2 and 3 were product use days. On 
each product use day, subjects used a prototype novel tobacco vapor product or 
smoked one conventional cigarette under controlled use according to the 
randomization schedule. The controlled use of both prototype novel tobacco vapor 
product and conventional cigarette consisted of 10 puffs for 3 minutes at 
approximately 20-s intervals. On Day 4, subjects were discharged following 
completion of health assessments. The nicotine yield of the prototype novel tobacco 
vapor product in 50 puffs, which is the intended puff number of one capsule, was 
1.10mg per capsule as measured by the Health Canada machine-smoking test 
regimen (puff volume: 55 mL, puff duration: 2 s, and puff frequency: 2/min). Blood 
samples (2 mL) for plasma nicotine analysis were collected via an intravenous 
catheter inserted into the cutaneous vein of the forearm. Blood was collected at 
approximately 5 minutes prior to and at 2, 3, 4, 5, 10, 15, 20, 25, 30, 45, 60, 90, and 
120 minutes after the start of product use on Days 2 or 3. Three additional blood 
samples were collected following the use of prototype novel tobacco vapor product 
(at 6, 7, and 8 minutes following the start of prototype novel tobacco vapor product 
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Data source: Healthy Japanese adult male smokers. Population size: 24  
Year of data collection: Not reported  
E-cigarette, smoking and other related status: Healthy adult male smokers smoking 
an average of 11 or more manufactured cigarettes per day at screening and had 
smoked for at least 12 months before entering the trial.  
Intervention and research design: An open-label, randomized, two period crossover 
design. Blood was collected at approximately 5 minutes prior to and at 2, 3, 4, 5, 10, 
15, 20, 25, 30, 45, 60, 90, and 120 minutes after the start of product use on Days 2 
or 3. Three additional blood samples were collected following the use of PNTV 
product (at 6, 7, and 8 minutes following the start of prototype novel tobacco vapor 
product use), with consideration given to a delayed peak concentration of nicotine.  
Outcomes: The pharmacokinetic parameters of the maximum observed plasma 
concentration (Cmax), the time to reach Cmax (tmax), the terminal elimination half-
life (t1/2), and the area under the plasma concentration versus time curve from time 
0 to the last quantifiable concentration (AUClast) were determined from the 
nicotine concentrations mouth level exposure, mean plasma nicotine concentration 
The authors concluded that the results suggest that the prototype novel tobacco 
vapour product shows a similar pharmacokinetic profile to conventional 
combustible tobacco cigarettes, while delivering less nicotine following controlled 
use.386 
Device and product: The prototype novel tobacco Vapor product consisted of a 
power supply unit, a cartridge with a heater and liquid, and a capsule filled with 
tobacco blend. The prototype novel tobacco vapor product use product generates a 
nicotine-free vapor via electrical heating of a liquid, which contains glycerin, 
propylene glycol and water and does not contain nicotine and flavour unlike major 
e-liquids for electronic cigarettes. The nicotine yield of the prototype novel tobacco 
vapor product in 50 puffs, which is the intended puff number of one capsule, was 
1.10mg per capsule as measured by the Health Canada machine-smoking test 
regimen (puff volume: 55 mL, puff duration: 2 s, and puff frequency: 2/min). 
(conventional cigarette 1:1 mg tar and 0.1 mg nicotine values, measured by ISO 
machine-smoking (ISO 3308, 2000) and printed on the package. The prototype novel 
tobacco vapor product differs from most existing “heated tobacco” products in that 
the tobacco is not directly heated during use. prototype novel tobacco vapor 
product also differs from many e-cigarettes in that the liquid being vaporized does 
not contain nicotine. In this study, the pharmacokinetics of nicotine between this 
novel tobacco product and conventional cigarette smoking were compared. The 
pharmacokinetic parameters were calculated from the blood nicotine 
concentrations and the estimated mouth level exposure of nicotine following 
controlled product use. In this study, the mouth level exposure of nicotine from 
prototype novel tobacco vapor product use product use was estimated in a different 










The authors reported on the relationship between tobacco and e-cigarette use with 
a range of biomarkers including carbon monoxide (CO), 1-hydroxypyrene (1-HOP), 
and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL). 
Age mean years (SD): 36 (11.7). Sex: 71% male. Country: Canada  
Duration of trial: Four sessions. Seven-day interval. Participants were asked to 
attend four laboratory visits: at baseline and one each after a 7-day period 
Data source: Participants were recruited from September 2015 to March 2016 via 
advertisements placed in newspapers, online, and in local vape shops, and received 
$295 for participating in the study 
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E-cigarette, smoking and other related status: Dual users of tobacco cigarettes and 
e-cigarettes. Dual users were identified as current daily tobacco cigarette smokers 
(had smoked ≥100 cigarettes in their lifetime and smoked ≥5 cigarettes/day) and 
current daily e-cigarette users (had used an e-cigarette at least once a day for each 
of the past 7 days). 
Intervention and research design: Nonblinded within-subjects crossover experiment. 
Participants completed three consecutive 7-day periods in which the use of tobacco 
cigarettes and e-cigarettes was experimentally manipulated, resulting in four study 
conditions: Dual use, Tobacco cigarette use, E-cigarette use, and No product use 
Outcomes: Compared to dual use, cotinine remained stable when participants 
exclusively smoked, but significantly decreased when they exclusively vaped, despite 
significant increases in e-cigarette consumption. Levels of biomarkers of exposure to 
toxicants, including carbon monoxide (CO), 1-hydroxypyrene (1-HOP), and 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL).  
The authors concluded that although dual use may reduce exposure to tobacco 
smoke constituents to some extent, abstaining from smoking is the most effective 
way to reduce such exposure. They also stated that public health authorities should 
clearly communicate the relative risk of e-cigarettes and tobacco cigarettes to the 
general public, focusing on two salient points: (1) e-cigarettes are not harmless, but 
they are less harmful than tobacco cigarettes; and (2) using e-cigarettes while 
smoking may not necessarily reduce health risks; therefore, consumers should stop 
smoking completely in order to maximise the potential health benefits.383 










The authors reported on the outcome levels of a range of biomarkers of tobacco 
exposure after smokers switch to an e-cigarette or nicotine gum. 
Age: 21–60 years of age non-menthol; smoker— Vuse Solo original (41.63 ± 11.22) 
Non-menthol smoker—nicotine gum (40.18 ± 11.44) Menthol smoker— Vuse Solo 
menthol (42.55 ± 10.87) M smoker—nicotine gum (41.46 ± 10.00) 
Sex: Non-menthol smoker— Vuse Solo original (27 male 11 female) Non-menthol; 
smoker—nicotine gum (25 male 14 female) Menthol smoker— Vuse Solo menthol 
(25 male 15 female) Menthol smoker—nicotine gum (30 male 11 female)  
Country: USA  
Ethnicity: Non-menthol smoker—VS original (37 Hispanic 1 Latino Non-Hispanic or 
Latino); Non-menthol smoker—nicotine gum (39 Hispanic 0 Latino Non-Hispanic or 
Latino); Menthol smoker—VS menthol (40 Hispanic 0 Latino Non-Hispanic or Latino); 
Menthol smoker—nicotine gum (40 Hispanic 1 Latino Non-Hispanic or Latino)  
Data source: Generally healthy males and females  
Duration of trial: Five days. The authors enrolled smokers to switch to Vuse Solo (VS) 
Digital Vapor Cigarettes (Original or Menthol) or Nicorette 4 mg nicotine gum (NG) 
in a controlled setting. Subjects who smoked combustible cigarettes ad libitum for 2 
days during a baseline period were then randomized to ad libitum use of either Vuse 
Solo or nicotine gum for 5 days. Biomarkers of 23 toxicants were measured in 24-
hour urine samples and blood collected at baseline and following product switch. 
Subjects who smoked combustible cigarettes ad libitum for 2 days during a baseline 
period were then randomized to ad libitum use of either Vuse Solo or nicotine gum 
for 5 days. Biomarkers of 23 toxicants were measured in 24-hour urine samples and 
blood collected at baseline and following product switch. 
Population size: 153. Non-menthol; smoker— Vuse Solo original (N = 38) Non-
menthol; smoker—nicotine gum (N = 39) Menthol smoker— Vuse Solo menthol (N = 
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Year of data collection: Not reported   
E-cigarette, smoking and other related status: Generally healthy males and females, 
who reported smoking at least 10 combustible, filtered, menthol or non-menthol 
cigarettes per day and reported smoking their first cigarette within 30 minutes of 
waking were included in the study. In addition, potential participants had to be 
willing to switch from their usual brand (UB) cigarettes to Vuse Solo Original flavour, 
Vuse Solo Menthol flavour, or NG while in clinic. Potential subjects completed a 
prescreening telephone interview and one screening visit to assess eligibility within 
30 days of study enrollment on Day −3. On Day −3, eligible subjects were enrolled in 
the study and started a 9-day in-clinic residence. Baseline assessments during 
smoking of subjects’ UB cigarettes occurred for the first 3 days (Day −3 through Day 
−1). On Day 1, smokers were randomized to one of four cohorts. Smokers of non-
menthol cigarettes were randomized to one of two cohorts: • Cohort 1: EC − Vuse 
Solo Original, or • Cohort 2: NG Smokers of menthol cigarettes were randomized to 
one of two cohorts: • Cohort 3: EC − Vuse Solo Menthol, or • Cohort 4: NG Post–
product switch assessments occurred for 6 days (Day 1 through Day 6). Upon 
completion of study procedures on Day 6, subjects were discharged from the clinic. 
The Fagerström Test for Nicotine Dependence and a demographic questionnaire 
were administered to all potential subjects at the screening visit 
Intervention and research design: randomized, parallel-group, clinical study 
Outcomes: Urinary nicotine equivalents, Plasma cotinine at 07:00 pm, Plasma 
nicotine at 07:00 pm; Biomarkers (toxicant) COHb = carboxyhemoglobin (Carbon 
monoxide), SPMA = S-phenylmercapturic acid (Benzene), 3-HPMA = 3-hydroxypropyl 
mercapturic acid (Acrolein), HMPMA = 3-hydroxy-1-methylpropylmercapturic acid 
(Crotonaldehyde), MHBMA = monohydroxybutyl mercapturic acid (1,3-butadiene), 
CEMA = 2-cyanoethylmercapturic acid (Acrylonitrile), HEMA = 2-
hydroxyethylmercapturic acid (Ethylene oxide), NNAL-T = free plus N-glucuronidated 
(total) 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNK = 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone)), NNN-T = free plus N-glucuronidated (total) N’-
nitrosonornicotine (NNN = N’-nitrosonornicotine), NAT-T = free plus N-
glucuronidated (total) N’-nitrosoanatabine (NAT = N’-nitrosoanatabine), NAB-T = 
free plus N-glucuronidated (total) N’-nitrosoanabasine (NAB = N’-nitrosoanabasine), 
1-AN = 1-aminonaphthalene (1-aminonaphthalene), 2-AN = 2-aminonaphthalene (2-
aminonaphthalene), 3-ABP = 3-aminobiphenyl (3-aminobiphenyl), 4-ABP = 4-
aminobiphenyl (4-aminobiphenyl), o-toluidine (o-toluidine), Naphthalene 
equivalents (Naphthalene), 3-OH-B[a]P = 3-OH-benzo[a]pyrene (Benzo[a]pyrene), 2-
OH-fluorene (Fluorene), 1-OH-pyrene (Pyrene), Acrylamide equivalents 
(Acrylamide), Thiocyanate (Hydrogen cyanide), Urine mutagenicity (General 
measure of mutagenic properties of urine) 
The authors concluded that the results indicate that exposure to toxicants when 
using Vuse Solo is significantly reduced compared with combustible cigarette 
smoking, and these reductions are similar to those observed with use of nicotine 
gum. Although statistically significantly decreased, nicotine exposure is maintained 
closer to conventional combustible tobacco cigarette smoking with Vuse Solo use 
compared with nicotine gum use. This research suggests that use of Vuse Solo 
exposes consumers to fewer and lower levels of smoke toxicants than combustible 
cigarettes, while still providing nicotine to the consumer.384 
Device and product: VS Digital Vapor Cigarettes were introduced commercially by 
R.J. Reynolds Vapor Company in March 2013. The product is a first-generation cig-
alike product composed of a battery, heating element, microchip, sensor, and a 
cartridge containing e-liquid composed of propylene glycol, glycerin, nicotine, 
flavourings, and water. During use, the heating element aerosolizes the liquid in the 
cartridge and produces a puff of aerosol that contains aerosol-forming excipients 
(propylene glycol and glycerin) and nicotine. A microchip in the cartridge tracks 
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informative parameter of an EC with respect to the heating of the e-liquid. The 
effective power to the VS cartridge is controlled to approximately 3 W during a puff. 
The two brand styles used in this study include VS Original, a tobacco flavour, and VS 
Menthol. Both brand styles contain approximately 600 μL of a 4.8% nicotine e-liquid, 
or approximately 29 mg of nicotine. Nicorette nicotine polacrilex gum 
(GlaxoSmithKline Consumer Healthcare, LP, Philadelphia, PA) is commercially 
available in 2 and 4 mg strengths. The 4-mg NG was chosen for use in this study in 
order to include smokers who typically have higher levels of nicotine exposure. 
Instructions on the package state: “If you smoke your first cigarette within 30 
minutes of waking up, use 4 mg nicotine gum.” The White Ice Mint flavour was 
provided for use in this study. Subjects received written instructions for use based 
on the Nicorette gum package label. Nicorette gum was the current market leader 










The authors reported on exhaled carbon monoxide levels in smokers after fully 
switching to e-cigarettes or to a tobacco heating system. 
Age mean years (SD): 49.8. Sex: 40 males. Country: Italy 
Duration of trial: Six months. Data source: Not reported  
Population size: 40. Year of data collection: Not reported  
E-cigarette, smoking and other related status: 40 male smokers unwilling or unable 
to stop smoking were switched to e-cigarettes or tobacco heating systems for six 
months 
Outcomes: nicotine addiction and levels of carbon monoxide 
Intervention and research design: Observations study with intervention.  
The authors concluded that reduced levels of percentage carboxyhemoglobin did 
not significantly differ between the two groups, while the tobacco heating system 
group had a significantly greater reduction in levels of CO parts per million versus 
the e-cigarette group. Both e-cigarettes and tobacco heating systems are capable of 
significantly reducing exhaled carbon monoxide at least in the medium term, hence 
constituting a viable tobacco harm-reduction approach in smokers who are unwilling 
or unable to stop smoking.385 
Device and product: The tobacco heating system used in this study consists of a 
tobacco stick (with processed tobacco made from tobacco powder), a holder (which 
heats the tobacco by means of an electronically controlled heating blade) and a 
charger that is used to recharge the holder after each use. THS releases nicotine and 
other volatile compounds by heating the tobacco rod at temperatures not exceeding 
350’C. The e-cigarette used in the study was disposable, with a pre-filled cartridge, a 
low–medium supply power and nicotine 18mg/ml. A low potential e-cigarette 
(disposable, pre-filled cartridge, low–medium supply power, nicotine 18mg/ml) or a 
tobacco heating system (THS) 2.2 (sticks with mean nicotine content of 0.50 mg per 
stick) 
St. Helen et 
al.388 
2020 
Harm The authors reported on the relationship between e-cigarette use, conventional 
combustible tobacco cigarette use, and abstention from smoking with a range of 
volatile organic compounds (specifically 10 mercapturic acid metabolites of volatile 
organic compounds). 
Age mean years (SD): Sex: 28 males, 8 females. 
Country: USA. Duration of trial: Two sessions. Two-day interval. 
Data source: Not reported. Population size: 36. Year of data collection: Not reported  
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Outcomes: A range of volatile organic compounds (2-hydroxypropylmercapturic 
acid; 3-hydroxypropylmercapturic acid; 2-carbamoylethylmercapturic acid; 2-
cyanoethylmercapturic acid; 2-hydroxyethylmercapturic acid (acrylonitrile, vinyl 
chloride, ethylene oxide); 3-hydroxy-1-methyl-propylmercapturic acid; sum of 
isomers 1-hydroxy-3-buten-2-yl-mercapturic acid and 2-hydroxy-3-buten-1-yl-
mercapturic acid; 4-hydroxy-2-buten-1-yl-mercapturic acid; methylmercapturic acid, 
and phenylmercapturic acid) 
Intervention and research design: a crossover study with two days of ad libitum 
vaping or cigarette-only use and two days of enforced abstention 
The authors concluded that concentrations of volatile organic compound 
metabolites were higher during smoking compared with during vaping, except for 
the methylating agents’ metabolite. Metabolites of acrylamide were higher during 
vaping compared with abstention. The 1,3-butadiene and propylene oxide 
metabolites were higher in variable-power tank users compared with users of 
cigalikes. E-cigarettes expose users to lower levels of toxic volatile organic 
compounds compared with cigarette smoking, supporting their harm-reduction 
potential among smokers. However, some e-cigarettes expose users to volatile 
organic compounds such as acrylamide, benzene, and propylene oxide, and may 
pose health risks to non-smoking users.388 
Device and product: Participants used their usual brands of e-cigarettes and 
cigarettes, provided by the study. The types of e-cigarettes used by study 
participants were as follows: cig-a-likes (n=12 participants); fixed-power tanks 
(n=15), variable-power tanks (n=6) and, pod e-cigarettes (n=3, all JUULs) 
 










Harm The authors reported on how initial puffing behaviours and subjective responses 
differ between an electronic nicotine delivery system (ENDS) and conventional 
combustible tobacco cigarettes. 
Age mean years (SD): 45.5 ± 3.5. Sex: 37.5 % males, 62.5 % female. Country: USA 
Duration of trial: Three lab visits over 5 days. 
Data source: Participants were recruited via advertising in local newspapers 
(advertising did not mention the study focused on electronic nicotine delivery 
system) 
Population size: 16 compliant with study protocol 30 completed study, results 
represent findings from16 individuals  
Year of data collection: February 2011- May 2012  
E-cigarette, smoking and other related status: smoked at least 10 cigarettes daily, 
were not concurrently using other tobacco or nicotine products, had no use of e-
cigarette in the last 30 days, reported no intention of quitting smoking within the 
next 30 days 
Intervention and research design: Participants were asked to visit the laboratory on 
3 separate occasions (Days 1, 2, and 5) over 5 days at consistent times of the day 
and were asked to abstain from regular cigarettes for 72 hours in favour of 
electronic nicotine delivery system (Smoke 51 TRIO – 3 piece, First Generation with 
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Outcomes: Saliva specimen, a spot urine specimen, and an exhaled breath sample 
for carbon monoxide (CO) testing 
The authors concluded that ENDS were smoked more intensively than own-brand 
cigarettes, but delivered significantly less nicotine and were less satisfying. These 
findings have implications for the viability of certain ENDS as alternatives to 
cigarettes.391 
Device and product: The ‘cigarette-like’ “Smoke 51 TRIO” e-cigarette - 3-piece, First 
Generation with 11 mg/ml cartridges (Vapor Corp, Miami, FL) was tested in this 
study, as during the study period it was sold in local shopping mall kiosks. All 
participants used 11 mg nicotine cartridges with flavour (tobacco, menthol) 
matched to that of their usual cigarette brand; this concentration was chosen as it 
was the midpoint of the range offered for this brand at the time. Instructions on e-
cigarette use and proper charging were also provided verbally during the lab session 
and in writing for participant home reference. The regular cigarettes were the usual 










The authors undertook a randomised, parallel group study in order to evaluate the 
safety profile of an e-vapour product over 12 weeks. 
Age mean years (SD): 34.1 ± 10.6 EVP 35.1 ± 10.6 CC 
Sex: EVP 168 (54.9%) male 138 (45.1%) female CC 58 (56.9%) male 44 (43.1%) 
female  
Country: UK. Duration of trial: 12 weeks. Data source: Not reported  
Population size: 408. 419 were enrolled onto the study and randomised in a 3:1 
ratio to the e-cigarette or conventional cigarette (CC) arm. E-cigarette (N = 306) CC 
(N = 102). Eleven subjects out of the 419 were excluded prior to any product use. 
The remaining 408 (full analysis set) used the study product at least once. Of these 
408 subjects, twenty in the e-cigarette arm and one in the conventional cigarette 
arm were withdrawn from the study, leading to a total of 387 subjects (94.9% of the 
full analysis set) having completed the study 
Year of data collection: Not reported  
E-cigarette, smoking and other related status:  
Intervention and research design: Multi-centred (two) open-label, randomised, 
parallel group, clinical trial conducted in two centres 
Outcomes: Primary outcomes (safety)  
Adverse events (AEs): coded using the Medical Dictionary for Regulatory Activities 
(MedDRA), version 16.1, 2013. Respiratory, thoracic and mediastinal disorders (Sore 
Throat, Cough), Nervous system disorders (Headache), Infection and infestation 
(Nasopharyngitis), Psychiatric disorders (Desire to smoke), General disorders and 
administration site conditions (Irritability), Metabolism and nutrition disorders 
(Increased appetite) 
Vital signs: Sitting systolic and diastolic blood pressure, pulse rate and oral 
temperature 
12-lead electrocardiogram: 10-s strips, after the subject has been resting for at least 
five minutes: heart rate (60/R-R duration), PR interval, QT interval, QTcB, QTcF, QRS 
duration 
Lung function tests: Sitting spirometry to measure forced vital capacity (FVC), forced 
expiratory flow 25%e75% (FEF25%-75%), peak expiratory flow (PEF) and forced 
expiratory volume in one second (FEV1). 
Haematology: White blood cell count (WBC), red blood cell count (RBC), 
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(MCH), mean cell haemoglobin concentration (MCHC), platelet count, differential 
WBC  
Clinical biochemistry: Blood levels of aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase, gamma-glutamyl transferase (GGT), 
sodium, potassium, chloride, calcium, inorganic phosphate, glucose, urea nitrogen 
(BUN), total bilirubin, creatinine, total protein, albumin, cholesterol (HDL, LDL, and 
total) 
Urinalysis: pH, protein, glucose, ketones, urobilinogen, blood and specific gravity 
Secondary outcomes 
Biomarkers of exposure in urine: Amount excreted in 24-h urine (Ae24h) for: 
nicotine equivalents (NEQs: nicotine, cotinine, nicotine-N-glucuronide, cotinine-
Nglucuronide,trans 3’-hydroxycotinine and trans 3’-hydroxycotinine glucuronide); S-
PMA; 3-HPMA; propylene glycol; total NNAL (NNAL þ NNAL-glucuronide). 
Other biomarkers of exposure: Exhaled CO, blood COHb 
Biomarkers of biological effect: Haemoglobin, PCV, RBC, WBC and cholesterol (LDL, 
HDL and total)  
MWS-R scores (MWS-R: revised Minnesota Nicotine Withdrawal Scale): The core 
total scores (sum of the first nine questions on behaviour) and the extended total 
scores (sum of all 15 questions) were calculated. Symptoms (e.g. angry, irritable, 
frustrated, depressed, restless, insomnia) were rated from 0 (none) to 4 (severe). 
Extended total scores may range from 0 to a maximum of 60.  
QSU-brief scores: Ten statements such as “I have a desire for a cigarette right now”, 
were rated by a number ranging from 1 (strongly disagree) to 7 (strongly agree). 
Factor 1 scores (sum of questions 1, 3, 6, 7, and 10 for desire and intention to 
smoke), Factor 2 scores (sum of questions 2, 4, 5, 8, and 9, for anticipation of relief 
from negative effects with urgent desire to smoke) and total scores (sum of all 
questions) were calculated. Total scores may range from 0 to a maximum of 70 
Adverse events 
In the EVP group, 271 subjects (88.6%) reported a total of 1515 AEs, and in the CC 
group, 80 subjects (78.4%) reported a total of 225 AEs. 
Vital signs, clinical laboratory parameters and body weight There were no clinically 
significant findings or changes from baseline in sitting BP, sitting pulse rate, body 
temperature or 12-lead electrocardiogram parameters at any study visit, with the 
following exceptions: one subject in the EVP group experienced frequent ventricular 
ectopic beats from Study Day 28, and several subjects in both groups experienced 
occurrences of increased heart rate-corrected QT intervals compared with baseline 
(24 subjects in EVP group and 7 subjects in the CC group had occurrences of 
increased QTcB > 30 ms and 17 subjects in EVP group and 3 subjects in the CC group 
had occurrences of increased QTcF > 30 ms). 
Lung function tests  
No clinically significant changes from baseline were observed in any lung function 
test parameter, at any study visit. Forced vital capacity (FVC), forced expiratory 
volume in one second (FEV1) and forced expiratory flow 25%e75% (FEF25%-75%) 
appeared to decrease during the course of the study by a maximum of 2.5, 2.4 and 
1.5% in the EVP group, respectively, and by a maximum of 3.2, 3.0 and 5.8% in the 
CC group. The RMANCOVA analysis indicated that the decrease was more 
pronounced in the CC group compared with the EVP group for FEV1 at Week 8, and 
for FEF25%-75% at Week 8 and 12. On the contrary, peak expiratory flow (PEF) 
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EVP group and a maximum of 3.8% in the CC group. These observed changes in PEF 
were not different between the two study groups. 
Biomarkers of biological effect 
Mean haemoglobin levels appeared to be lower than at baseline during the course 
of the study by a maximum of 2.9% in the EVP group and 2.1% in the CC group. 
Mean WBC appeared to be lower than at baseline during the study in the EVP 
group, by a maximum of 6.6%, whereas in the CC group, no consistent changes 
were observed. Regarding cholesterol, the mean level of HDL cholesterol remained 
stable throughout the study in the EVP group, whereas in the CC group, it appeared 
to decrease during the study by a maximum of 3.5%. 
From this trial, the authors reported the safety profile of an e-vapour product (2.0% 
nicotine) in smokers of conventional combustible tobacco cigarettes switching to 
using an e-vapour product for 12 weeks. During the study, no clinically significant 
product-related findings were observed in terms of vital signs, electrocardiogram, 
lung function tests, and standard clinical laboratory parameters. Adverse events 
reported by e-vapour product subjects were more frequent during the first week 
after switching to the e-vapour product. The frequency of adverse events reduced 
thereafter and, out of a total of 1,515 reported adverse events, 495 were judged as 
being related to nicotine withdrawal symptoms. The most frequently stated adverse 
events were headache, sore throat, desire to smoke, and cough, reported by 47.4%, 
27.8%, 27.5%, and 17.0% of subjects, respectively. Only 6% of adverse events were 
judged as being probably or definitely related to an e-vapour product. Additional 
observations in e-vapour product subjects included a decrease in the level of urine 
nicotine equivalents by up to 33.8%, and decreases in the level of three biomarkers 
of exposure to toxicants known to be present in tobacco cigarette smokers 
(benzene, acrolein, and NNK). The decrease in nicotine equivalents coincided with 
an increase in nicotine withdrawal symptoms, measured by a questionnaire, which 
subsided after 2 weeks. The data presented here show the potential that e-vapour 
products may offer smokers looking for an alternative to tobacco cigarettes.392 
Device and product: The EVP prototype used in this study was developed by Fontem 
Ventures B.V. (Amsterdam, the Netherlands). It consisted of a rechargeable battery 
(voltage range of 3.0e4.2 V), an atomiser and a capsule (small cartridge) containing 
e-liquid. The capsules were replaceable, and the battery and atomiser were 
reusable. The wick consisted in a fiberglass string, and the heating coil was a 
nichrome resistance wire. The base components of the e-liquids used were 
propylene glycol (70e75% w/w), glycerol (18e20% w/w) and water (5% w/w). 
Subjects randomised to the EVP arm could choose between two different e-liquids, 
which differed solely in their flavour: a menthol-flavoured eliquid with 2.0% nicotine 
(2.7 mg nicotine/capsule) and a tobacco flavoured e-liquid with 2.0% nicotine (2.7 
mg nicotine/capsule). Each capsule was expected to provide 40 to 60 puffs, 
depending on the user's puffing behaviour. Subjects randomised to the CC arm used 
their own usual CC brand (representative of the UK market; mean ISO nicotine yield 




Benefit The authors reported on the relationship between e-cigarettes and weight gain. 
Age mean years (SD): 44 (12.5). Sex: 63 males, 37 females. Country: Italy 
Duration of trial: One year. Data source: June 2010 to February 2011 
Population size: 300 (at recruitment) 100 at completion 
Year of data collection: Not reported  
E-cigarette, smoking and other related status:  
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Intervention and research design: 12-month, randomized controlled trial of smokers 
invited to switch to e-cigarettes  
The authors concluded that smokers who quit smoking by switching to e-cigarettes 
may limit their post-cessation weight gain, with substantial reversal in weight gain 
manifesting at later timepoints.334 
Device and product: Categoria” Arbi Group Srl, Italy. EC kits with either “Original 
2.4%” cartridges for 12 weeks (Group A), or “Original 2.4%” for 6 weeks and a 
further 6 weeks with “Categoria 1.8%” (Group B), or “Original 0%” cartridges for 12 









The authors reported on the sensory effects of menthol and nicotine in an e-
cigarette. 
Age range: 18–45 years. Sex: 16 males, 16 females. Country: USA 
Duration of trial: Two sessions on two separate days. Each session contained several 
trials, 10 in session 1 and six in session two. There was a 10-minute break between 
each trial. Measures were assessed during the trials  
Data source: Participants were paid to participate in each experiment and were 
recruited by flyers posted around the Yale University campus and online 
advertisements in the New Haven, Connecticut area  
Population size: 32. Three females and three males served in both experiments, the 
remaining 26 participants in the second experiment were new to the study. 
Year of data collection: Not reported 
E-cigarette, smoking and other related status: all participants were self-reported 
menthol cigarette smokers 
Intervention and research design: Adult cigarette smokers sampled aerosolized E-
liquids containing five different concentrations of nicotine with 0%, 0.5%, or 3.5% l-
menthol, as well as two commercial menthol flavours with and without nicotine. All 
testing was done using the V2 Standard E-Cigarette (79 mm; VMR Products, LLC) 
and V2 blank cartridges. In experiment 1, the blank cartridges were filled with 15 
different E-liquids that were prepared by Pace Engineering Concepts, LLC: five 
concentrations of nicotine (0, 6, 12, 18, 24 mg/ml) with 0.0%, 0.5% or 3.5% l-
menthol in a 70% propylene glycol (propylene glycol)/30% vegetable glycerine (VG) 
base. The decision to use 3.5% menthol was based on preliminary tests which 
indicated this concentration produced cool/cold sensations approximately equal to 
those experienced from a mentholated commercial flavour E-liquid (Menthol, 
AmericanELiquidStore) when inhaled using the V2 E-cigarette. In experiment 2, the 
blank cartridges were filled with six different E-liquids, also in a 70% propylene 
glycol /30%VG base: two Menthol and two Menthol–Mint commercial flavours 
(AmericanELiquidStore) with one of each flavour containing 0 or 24 mg/ml nicotine; 
and two Unflavoured E-liquids (propylene glycol /VG base only) containing 0 or 24 
mg/ml nicotine prepared by Pace Engineering Concepts, LLC. 
Outcomes :Perceived Irritation/Harshness was unaffected by a low (0.5%) menthol 
concentration, whereas a high menthol concentration (3.5%) led to higher 
perceived Irritation/Harshness at low nicotine concentrations but to lower 
Irritation/Harshness at the highest nicotine concentration (24 mg/ml); (2) a 
commercial Menthol–Mint flavour produced similar results; (3) nicotine tended to 
enhance rather than suppress sensations of Coolness/Cold; and (4) menthol tended 
to slightly increase liking independently of nicotine concentration 
The authors concluded that the evidence indicated that menthol can potentially 
improve the appeal of e-cigarettes not only via its coolness and minty flavour, but 
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Device and product: the V2 Standard E-Cigarette (79 mm; VMR Products, LLC) and 
V2 blank cartridges. In experiment 1, the blank cartridges were filled with 15 
different E-liquids that were prepared by Pace Engineering Concepts, LLC: five 
concentrations of nicotine (0, 6, 12, 18, 24 mg/ml) with 0.0%, 0.5% or 3.5% l-
menthol in a 70% propylene glycol/30% vegetable glycerine (VG) base. The decision 
to use 3.5% menthol was based on preliminary tests which indicated this 
concentration produced cool/cold sensations approximately equal to those 
experienced from a mentholated commercial flavour E-liquid (Menthol, 
AmericanELiquidStore) when inhaled using the V2 E-cigarette. In experiment 2, the 
blank cartridges were filled with six different E-liquids, also in a 70%PROPYLENE 
GLYCOL /30%VG base: two Menthol and two Menthol–Mint commercial flavours 
(AmericanELiquidStore) with one of each flavour containing 0 or 24 mg/ml nicotine; 
and two Unflavoured E-liquids (PROPYLENE GLYCOL /VG base only) containing 0 or 
24 mg/ml nicotine prepared by Pace Engineering Concepts, LLC. For all stimuli 0.5 
ml of the E-liquids was carefully pipetted into the blank cartridges. Leakage of the E-
liquid onto the heating element inside each cartridge was prevented by inserting a 
cylindrical wooden toothpick into the core during pipetting. After filling, each 
cartridge was pre-tested using a syringe to create simulated puffs and was used 




Benefit The authors investigated the effectiveness of nicotine delivered through e-
cigarettes for managing levodopa-induced dyskinesia, associated with Parkinson’s 
disease, with nicotine.  
Age years (SD): 45. Sex: female. Country: Sweden 
Data source: The first author of the paper was the sole study participant 
Duration of trial: One session. One hour. Population size:1 
Year of data collection: Not reported 
E-cigarette, smoking and other related status: 
Outcomes: self-tracking of levodopa- induced dyskinesia with nicotine 
The authors used the term patient-driven N-of-1 for self-tracking the effect, in this 
instance managing levodopa-induced dyskinesia with nicotine, with the explicit 
intention to disseminate the results by academic publishing. 
The authors concluded that nicotine administered via e-cigarettes may have a 
reducing effect on levodopa-induced dyskinesia in individual patients with 
Parkinson’s disease.395 
Device and product: Two identical sets of e-cigarettes (KangerTech mini starter kit) 
were purchased together with two bottles of e-juice of identical flavour, one with 
nicotine (3 mg/ml) and the other without. The subject took additional levodopa (25 
mg) an hour before the start of the experiment to increase the likelihood of 
dyskinesia. The e-cigarettes were used as the therapeutic intervention 
Lee et al.396 
2018 
Harm The authors reported on the effects of second-hand exposure to nicotine from e-
cigarettes. 
Age mean years (SD): 29.4 (6.0). Sex: 60% males. Country: USA 
Duration of trial: Two sessions. Two consecutive days. Each session one-hour 
duration. 
Data source: Healthy non-smoking adults (fewer than 100 cigarettes in lifetime and 
no smoking in the past 30 days) without cardiovascular disease and with no current 
use of any medication recruited from the Harvard T.H. Chan School of Public Health 
in Boston, MA 
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E-cigarette, smoking and other related status: healthy non-smoking volunteers  
Outcomes: Cardiac autonomic effects of short-term second-hand exposure to 
nicotine from e-cigarettes emissions, specifically heart rate variability and heart 
rate–corrected QT interval 
Intervention and research design: randomized, repeated measures crossover study  
The authors concluded that there are cardiac autonomic effects of short-term 
second-hand exposure to nicotine from e-cigarette emissions in healthy non-
smokers.127 
Device and product: An automatic multiple smoking machine (Modified TE-2 
system, Teaque Enterprises, Davis, CA) was used to provide two standard puffs per 
minutes. Twenty-five percent of the flow from the smoking machine was diluted 
using particle free, humidified room air in a mixing tube at an output flow of 120 
LPM into a cone, from which the participant breathed the diluted EC vapor in a 
sitting position with breathing as usual. Dilution ratio (1:370) was calculated to be 
approximately equivalent to that of an exposure chamber (27 m3) with an air 




Harm The authors reported on the systemic absorption of nicotine following acute 
second-hand exposure to e-cigarette aerosol in a realistic social setting. 
Age mean years (SD): 28–54 years. Sex: 4 males, 2 females 
Country: USA. Ethnicity 4 white and 2 African-American 
Duration of trial: Two sessions. Seven-day interval period. Data source: Not 
reported  
Duration of trial: The recruitment period began in February 2015. The first exposure 
session was conducted on March 19, and the second on March 26, 2015. 
Population size: 6. Year of data collection: February 2015 to March 2015 
E-cigarette, smoking and other related status: Six non-users of nicotine-containing 
products were exposed to second-hand aerosol from ad libitum e-cigarette use by 
three e-cigarette users for 2 hours during two separate sessions (disposables, tank-
style). All participants were present for both sessions. On each study day, within 2 h 
prior to the 2-hour exposure, the following were obtained from the non-users: 
blood, urine, and saliva samples; blood pressure; pulse; expired carbon monoxide 
and self-reported symptoms. Before and following each exposure, the masses of 
the e-cigarette products were measured to determine the amount of e-cigarette 
solution used during the exposure. After each 2-hour exposure, the active users 
were discharged, and the non-users monitored for an additional 6 h for collection of 
biological samples. Characteristics of the six non-users were as follows: four male 
and two females; ages 28–54; four white and two African-American. Three habitual 
e-cigarette users had a median length of e-cigarette use of 1 year and reported 
using e-cigarette liquid strength ≥18 mg/ml at a median of 50 puffs/hour. One 
active user currently used both first generation and tank systems. No active user 
reported using other tobacco products. 
Intervention and research design: Pre-exposure (baseline) and post-exposure peak 
levels (Cmax) of cotinine were measured in non-users’ serum, saliva, and urine over 
a 6-hour follow-up, plus a saliva sample the following morning. Six non-users of 
nicotine-containing products were exposed to second-hand aerosol from ad libitum 
e-cigarette use by three e-cigarette users for 2 hours during two separate sessions 
(disposables, tank-style). 
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The authors concluded that although exposures may vary considerably, non-users 
can systemically absorb nicotine following acute exposure to second-hand e-
cigarette aerosol.397 
Device and product: Two separate exposure sessions were undertaken to account 
for e-cigarettes’ market diversity. During the first session, the active users used first 
generation e-cigarettes and tank-style second generation e-cigarettes during the 
second. Except for the type of e-cigarette used, both sessions were conducted 
identically. The amount of nicotine consumed was calculated by converting the 
mass of solution consumed into volume by dividing the mass of solution by either 
the specific density of propylene glycol (1.032 g/cm3) or of VG (1.261 g/cm3) or, if 
the solution was a blend, by estimating it to be a 50:50 ratio and averaging the 
specific density to 1.147 g/cm3. The volume was multiplied by the measured 
nicotine concentration to yield mass of nicotine consumed during the exposure. The 
unused e-cigarette cartridges and solutions were collected and sent to the Centers 
for Disease Control and Prevention (CDC) for analysis of pH and nicotine 
concentrations, where the latter analysis was performed in a manner that aligned 
with the method described in Stanfill et al (Stanfill et al., 2009). Analysis of pH was 
performed as previously described with minor modifications Using the measured pH 
values, pKanicotine=8.02 and the Henderson-Hasselbalch equation 
pH=pKa+log10([Base]/[Acid]), the percentage of nicotine in the unionized, or free-
base, form was calculated. 
Each active user was given an iTaste (Innokin Technology Co. LTD, Shenzen, China 
PRC) variable voltage v3.0 tank (distributed by Mt Baker Vapor) and several selected 
blu (blu e-cigarettes, Imperial Tobacco Group, Bristol, UK) or Fling (White Cloud 
Electronic Cigarettes, Tarpon Springs, Florida) disposable e-cigarettes, based on the 
user’s preferred flavours. The devices were identical to those they would use during 
the exposure sessions and allowed each active user to become familiar with these 
products. The blu disposable e-cigarette brand was selected and the flavours 
offered for both study days were based on their position as most popular according 
to US market share, using existing retail scanner data at the time of the study. The 
Fling disposable e-cigarette was added to expand the flavour choices. Given the lack 
of retail scanner data for tank-style systems, the iTaste was selected as a common 
brand. No flavour ingredient that has known concerns based on a literature review 
was used (e.g., known to contain diacetyl). The blu e-cigarettes were purchased at 
the same time from a local Baltimore tobacco retailer and the Fling e-cigarettes was 
purchased on-line from an e-cigarette retailer. All e-liquid for the second exposure 
was purchased from a local Baltimore “vape shop” at the same time as custom 
manufactured solutions. Flavours selected by the users were blu® classic tobacco 
and cherry crush, Fling® iced berry and custom manufactured solutions were java, 











The authors reported on the safety profile of Puritane™, a closed-system e-vapour 
product, when used by smokers of conventional combustible tobacco cigarettes in a 
real-life setting over a 24-month period. Outcome measures included adverse 
events, vital signs, electrocardiogram, lung function tests, exposure to nicotine and 
selected smoke constituents, nicotine withdrawal effects, and smoking desire. No 
serious adverse events related to e-vapour product use were observed. 
Age mean years (SD): Overall (N=209) 36.6 ± 10.2. Sex: males 115 (55.0%)  
Country: UK 
Duration of trial: Twenty-four months. Subjects attended the study centres for 
assessments at Months 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24. Measures were assessed 
at each visit, reflecting levels in samples, or questionnaire information, provided at 










Interventional trial papers other outcomes 
Data source: Two-centre ambulatory clinical study with 209 healthy volunteers, 
participants included subjects who had used an electronic vapour product in a 
previous study 
Population size: 209 enrolled and assigned to intervention 102 subjects competed 
the study 
Year of data collection: Not reported.  
E-cigarette, smoking and other related status PRIOR TO ENROLLEMENT: Subjects 
had to be smokers of 5–30 cigarettes per day for at least one year (self-reported). 
Intervention and research design: subjects were randomised to use either an EVP 
prototype (EVP arm) or continue using their usual CC brand (CC arm) 
Outcomes: Outcome measures included adverse events (adverse events were 
coded using the Medical Dictionary for Regulatory Activities, version 16.1, 2013), 
12-lead electrocardiogram parameters, vital signs, lung function tests and clinical 
laboratory parameters (clinical chemistry, haematology and urinalysis) exposure to 
nicotine and selected smoke constituents, nicotine withdrawal effects and smoking 
desire. Secondary outcomes included the level of selected biomarker of exposure 
(BoE) in urine (to harmful and potentially harmful constituents [HPHCs] typically 
found in CC smoke, and for which a biomarker of exposure in urine has been 
identified), the level of selected biomarkers of biological effect (BoBE) in blood, 
nicotine withdrawal symptoms and desire to smoke.  
Adverse events: Throughout the study, 159 (76.1%) subjects reported a total of 971 
adverse events. This represented 35 outcomes grouped under 13 categories 
Nervous system disorders (Headache, Migraine) Infection and infestation 
(Nasopharyngitis, Influenza, Urinary tract infection, Lower respiratory tract 
infection, Upper respiratory tract infection, Ear infection, Gastroenteritis, Tooth 
abscess, Sinusitis) Respiratory, thoracic and mediastinal disorders (Sore throat, 
Cough, Nasal congestion) Psychiatric disorders (Nicotine dependence*, Insomnia, 
Anxiety, Restlessness) Gastrointestinal disorders (Toothache, Nausea, Vomiting, 
Dyspepsia, Abdominal pain, Diarrhoea) Musculoskeletal and connective tissue 
disorders (Back pain, Musculoskeletal pain, Pain in extremity, Neck pain) General 
disorders and administration site conditions (Fatigue) Injury, poisoning and 
procedural complications (Exposure during pregnancy) Surgical and medical 
procedures (Tooth extraction) Immune system disorders (Seasonal allergy) 
Metabolism and nutrition disorders (Increased appetite) Reproductive system and 
breast disorders (Dysmenorrhoea) Investigations (Weight increased)  
Vital signs, electrocardiogram, clinical laboratory parameters and body weight: Vital 
signs (Sitting systolic blood pressure, Sitting diastolic blood pressure, Sitting pulse) 
Electrocardiogram parameters (PR Interval, QRS Duration, QTcB Interval, QTcF 
Interval) Lung function tests (forced expiratory volume in one second (FVC (L)), 
forced expiratory flow (FEV1 (L)), FEF25%-75% (L/sec), peak expiratory flow (PEF) 
Biomarkers of exposure (also biomarkers of effect): nicotine equivalents (NEQ), 3-
hydroxypropyl mercapturic acid (3-HPMA; BoE to acrolein), S-phenylmercapturic 
acid (S-PMA; BoE to benzene), total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL; BoE to 4-[methylnitrosamino]-1-[3-pyridyl]-1-butanone [NNK]) and 
propylene glycol excreted in urine in 24 h (Ae24h) 
Levels of biomarkers of biological effect: Haemoglobin, White blood cells (WBC), 
HDL cholesterol, LDL cholesterol 
Minnesota Withdrawal Scale (MWS-R) and Brief Questionnaire of Smoking Urges 
(QSU-Brief) 
The authors concluded that few serious adverse events, or withdrawals due to 
adverse events, occurred during the 24 months of Puritane™ use, none of which 










Interventional trial papers other outcomes 
sore throat, and nicotine dependence (desire to smoke) were the most common 
adverse events and were more frequently reported early after product switch. No 
clinically relevant, product-related findings were observed for the other safety 
parameters, namely vital signs, electrocardiogram, and lung function. Regarding 
lung function, small, statistically significant decreases from baseline to month 24 in 
all four spirometry parameters were observed. These decreases were not judged to 
be clinically significant. In the present study, no group of subjects continuing to 
smoke tobacco cigarettes was included; therefore, a comparison with lung function 
evolution in subjects who would have continued smoking tobacco cigarettes is not 
possible within this study. However, in the study, e-vaping-compliant subjects who 
did not use more cartomisers but fewer conventional combustible tobacco 
cigarettes than the whole study population, showed similar or greater declines in 
lung function parameters than the overall study population, confirming the positive 
effect of smoking reduction, even if accompanied by e-vaping product use. In this 
study, no clinically relevant changes were observed in biomarkers of biological 
effect. The subjects in the study maintained their urine nicotine equivalents to 
levels within 75% of their baseline levels (including the pre-tobacco cigarette 
smoking subgroup), which may have been sufficient to prevent further decreases in 
white blood cells. Regarding haemoglobin (a marker of haematology) and high-
density lipoprotein and low-density lipoprotein cholesterol (markers of lipid 
metabolism), no clear and consistent trends were observed, with no clear 
differences between the whole study population, e-vaping-compliant subjects, and 
completers. Body weight remained stable during the 2 years of Puritane™ use. In 
conclusion, the use of the e-vaping product for up to 2 years in this study appears to 
be an acceptable alternative for smokers, with the advantage of reducing the 
exposure to potentially harmful smoke constituents.393 
Device and product: Commercially available Puritane™, representative of a typical 
closed system electronic vapour product, consists of a lithium-ion rechargeable 
battery and a replaceable cartomiser comprising of an e-liquid reservoir pre-filled 
by the manufacturer, a heating element and a mouthpiece. The battery can be 
recharged at least 100 times, and one single cartomiser provides 300–350 puffs 
depending on the user's puffing behaviour. The cartomisers contain 1 mL of e-
liquid, which is comprised of 67.5–69.0% (w/w) propylene glycol (propylene glycol), 
30.0% (w/w) glycerol, 1.6% nicotine (16 mg/g) and 0.54–1.0% (w/w) flavouring. 
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The authors reported on levels of carbon monoxide, carboxyhaemoglobin, nicotine, and 
urine mutagenicity (specifically urine nicotine and five of its metabolites (nicotine-N-
glucuronide, cotinine, cotinine-N-glucuronide, trans-3′-hydroxycotinine, and trans-3′-
hydroxycotinine-O-glucuronide)) in conventional combustible tobacco cigarette brand 
users, electrically heated cigarette smoking system users, and low-tar conventional 
combustible tobacco cigarette users.  
Age mean (SD): 31 (10) years. Sex: 55 males, 55 females. Country: Nebraska. USA 
Data source: Male and female subjects smoking between 5 and 25 conventional 
combustible tobacco cigarettes (Marlboro Lights) daily were recruited from the general 
population in Lincoln, Nebraska 
Trial duration: This was a single-centre, open-label, randomized, forced-switching, 
controlled, parallel-group design study. Volunteers were admitted to the clinical study site 
(MDS Pharma Services, Lincoln, Neb) for a 2-day pre-randomization phase beginning in the 
evening of day –3 and remained confined at the clinical site through day 8 
Population size: 110  
E-cigarette, smoking and other related status: subjects smoking between 5 and 25 
conventional combustible tobacco cigarettes 
Outcomes: Biomarkers of nicotine equivalents, urine mutagenicity, carbon monoxide, 
carboxyhaemoglobin and analyte (respirable suspended particulates, carbon monoxide) 
and total volatile organic compounds (not detailed) 
The authors concluded that lowering the temperature during tobacco combustion results 
in a substantial reduction in exposure to the smoke constituents measured.401 
Device and products: The four cigarette products used in this study were evaluated for tar, 
nicotine, and CO delivery in mainstream smoke using a standardized method Federal Trade 
Commission. The first-generation EHCSS1 (Accord first-generation EHCSS series E4) 
delivered 3 mg tar, 0.2mg nicotine, and 0.7mg CO. EHCSS2 (Oasis first-generation EHCSS 
series E4) included a charcoal filter and delivered 2 mg tar, 0.2 mg nicotine, and 0.7 mg CO. 
The conventional combustible tobacco cigarette brand (CC1, Marlboro Lights) delivered 11 
mg tar, 0.8 mg nicotine, and 12 mg CO. The low-tar conventional combustible tobacco 
cigarette (CC2, Marlboro Ultra) delivered 3 mg tar, 0.3 mg nicotine, and 4 mg CO. 











The authors reported on the relationship between use of the THS 2.1 or conventional 
combustible tobacco cigarettes, and the pharmacokinetics of nicotine, specifically a range 
of mean nicotine concentration curves. 
Age: 23 to 65 years. Sex: Not reported. Country: Northern Ireland, United Kingdom The 
study was conducted at Celerion GB Ltd.  
Data source: Subjects were recruited via the clinical site’s database and by advertisements. 
Trial duration: The trial included a 7-day confined study period with data gathered in two 
consecutive periods. Each period consisted of a 24-hour (at least) nicotine washout period, 
1 day of single product use, and 1 day of ad libitum product use.  
Population size: 28 










Interventional trial papers on dependence and abuse liability 
E-cigarette, smoking and other related status: The subjects have smoked at least 10 
commercially available non-menthol conventional combustible tobacco cigarettes per day 
for the last 4 weeks prior to screening, with a maximum International Organization for 
Standardization yield of 1 mg nicotine per conventional combustible tobacco cigarettes, as 
labelled on the cigarette pack. 
Outcomes: Nicotine concentration curves (below) and measures such as urge to smoke, 
cough assessment, modified cigarette evaluation questionnaire  
• AUC0–last = area under the plasma concentration–time curve from time 0 to the last 
quantifiable concentration 
• Cmax = maximum observed plasma concentration; 
• Cpeak = maximum observed plasma concentration 
• Ctrough = lowest observed plasma concentration during the same sampling interval in 
which Cpeak was observed 
• t½ = terminal elimination half-life;  
• tmax = time to Cmax;  
• tpeak = time to the maximum observed concentration 
 
The authors concluded that the THS 2.1 effectively delivers nicotine and achieves similar 
pharmacokinetic profiles as conventional combustible tobacco cigarettes. The THS 2.1 
also reduced the urge to smoke to a similar degree as conventional combustible tobacco 
cigarettes.402 
Device and products: The Tobacco Heating System THS 2.1, developed by Philip Morris 
International, has three components, the heatstick, the holder, and the charger. The 
heatstick has a tobacco plug containing processed tobacco cast leaf, which is covered by a 
paper wrap. Except for the much shorter length than conventional combustible tobacco 
cigarettes, the overall appearance of the heatstick is similar to that of a conventional 
combustible tobacco cigarette. The holder includes a battery, controlling electronics, and 
the heater element. The heatstick is inserted into the holder and heats the tobacco via an 
electronically controlled heating blade. The charger recharges the holder. The energy 






Equal effect The authors reported on the pharmacokinetics of nicotine following the use of a 
prototype novel tobacco vapour product in comparison to a conventional combustible 
tobacco cigarette. 
Age mean: 21 to 63 years. Sex: All males Country: Japan 
Data source: Not reported 
Trial duration: An open-label, two-sequence, two period, randomized crossover design. On 
Day 1, Subjects checked in to the clinic and abstained from their regular tobacco product 
use. Days 2 and 3 were product use days. On each product use day, subjects used a 
prototype novel tobacco vapor (PNTV) product or smoked one conventional combustible 
tobacco cigarette under controlled use according to the randomization schedule. The 
controlled use of both prototype novel tobacco vapour product and conventional 
combustible tobacco cigarettes consisted of 10 puffs for 3 min at approximately 20-s 
intervals. On Day 4, subjects were discharged following completion of health assessments. 
Population size: 24  
E-cigarette, smoking and other related status: Persons who smoked an average of 11 or 
more manufactured cigarettes per day at screening and had smoked for at least 12 months 
before entering the trial. The usual brand of cigarettes with a mean tar value of 8.8 mg 
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Outcomes: Estimation of mouth levels of nicotine exposure, pharmacokinetics, safety 
(adverse events). 
The authors concluded that under the conditions of the present study, the 
pharmacokinetics of nicotine following prototype novel tobacco vapour product use 
were not markedly different from those following conventional combustible tobacco 
cigarette use, while the prototype novel tobacco vapour product provided less nicotine 
following a controlled single use.386 
Device and product: The prototype novel tobacco vapor product consisted of a power 
supply unit, a cartridge with a heater and liquid, and a capsule filled with tobacco blend. 
The prototype novel tobacco vapor product generates a nicotine-free vapor via electrical 
heating of a liquid, which contains glycerine, propylene glycol and water and does not 
contain nicotine and flavour unlike major e-liquids for electronic cigarettes. The vapor then 
passes through the tobacco capsule. In doing so, evaporated constituents arising from the 
tobacco blend, including nicotine and flavours, pass into the vapor, which can then be 
inhaled by the user. The nicotine yield of the prototype novel tobacco vapor product in 50 
puffs, which is the intended puff number of one capsule, was 1.10mg per capsule as 
measured by the Health Canada machine-smoking test regimen (puff volume: 55 mL, puff 
duration: 2 s, and puff frequency: 2/min). The conventional combustible tobacco cigarette 
(CC1: 1 mg tar and 0.1 mg nicotine values, measured by ISO machine-smoking and printed 
on the package). 
  University-based trials 
Adriaens 
et al. 1 
2018 
 
Benefit The authors reported on a 3-day randomised crossover trial, focusing on the behavioural 
and experiential effects of the short-term use of the heat-not-burn product IQOS™, 
versus an e-cigarette and versus a conventional combustible tobacco cigarette, in current 
smokers who were novice users of both IQOS™ and of e-cigarettes. The purpose was to 
investigate the effect of using IQOS™ on exhaled carbon monoxide, acute cigarette 
craving, withdrawal symptoms, and subjective positive and negative experiences after 
overnight smoking abstinence, compared to using an e-cigarette or a conventional 
combustible tobacco cigarette, and to investigate which product (the e-cigarette or IQOS™) 
would be preferred. 
Age mean (SD) years: 22 (3.09). Sex: 67% male. Country: Belgium. Almost half of the 
participants were of Belgian nationality (47%) with the remaining being of other 
nationalities (e.g., Italian, Pakistani, Indian, etc.). 
Data source: Dutch and English-speaking participants were recruited via various channels 
around the University of Leuven (through distribution of flyers in University buildings and 
local newspaper shops, social media). 
Trial duration: Depending on the enrolments, intake sessions were carried out in group 
(with a maximum of six participants) or individually, and lasted approximately 30 min. The 
authors used a crossover, counterbalanced, within-subjects design for the laboratory 
sessions. Participants came to the lab (individually or in group, with a maximum of three 
participants) on three consecutive days, each time at the same hour of the day; each 
session lasted 70 to 80 min and followed the same procedure. Before each laboratory 
session, participants needed to abstain from smoking for 12 hours. Participants could use 
one of the three products ad libitum for five minutes outside the building (only one 
cigarette or heat-stick was allowed). In each session, only one product was used and the 
order of product use over the days was completely counterbalanced between participants 
to control for order effects. At fixed times (T1, T2, T3, T4, and T5) participants filled out 
questionnaires and performed exhaled carbon monoxide measurements 
Population size: 30. 46 interested individuals signed up for the intake session, of whom 34 
completed all sessions. After data collection, another four participants were excluded due 










Interventional trial papers on dependence and abuse liability 
E-cigarette, smoking and other related status: Individuals recruited had to be a smoker for 
at least three years, and smoke at least 10 cigarettes per day 
Outcomes: Physiological Measures: exhaled carbon monoxide measurements. A subjective 
effect questionnaire was used to assess sociodemographics variables and information on 
smoking history, mental health status, and tobacco cigarette dependence, using the 
Fagerström Test for Nicotine Dependence. Outcomes of cigarette craving, withdrawal 
symptoms and product evaluation and preferences were gathered. Looking at the effects 
of using the IQOSTM heat-not-burn product compared to smoking and vaping, exhaled 
carbon monoxide levels decreased significantly from Intake to T0, with at T0 average 
exhaled carbon monoxide levels (about 3 ppm) approaching that of nonsmokers. After five 
minutes of IQOSTM, the increase in the exhaled carbon monoxide levels was 11% (0.3 ppm) 
of the baseline values (T0 to T1), with a maximum increase of 27% (T0 to T2; 0.8 ppm). 
Using the IQOSTM resulted in a reduction of 28% (less than smoking but 2% point more than 
e-cigarettes).  
The authors concluded that short-term use of a specific heat-not-burn product, IQOS™, 
can be effective in momentarily reducing acute conventional combustible tobacco 
cigarette craving and withdrawal symptoms, while having a minimal impact on exhaled 
carbon monoxide levels and being slightly more liked by novice users than an e-cigarette. 
They stated, however, that this does not guarantee that craving/withdrawal symptom 
reduction will also be sustained over longer time spans or in cases of repeated use, nor do 
they provide assurance that these effects are sufficient to lead to smoking reduction or 
cessation in smokers willing to quit or cut down on conventional combustible tobacco 
cigarettes.1 
Device and products: Three products were used during the laboratory sessions—a regular 
tobacco cigarette, an e-cigarette and the IQOSTM heat-not-burn tobacco product. The 
IQOSTM was purchased in an official IQOS-shop in the Netherlands, since heat-not-burn 
products are not available in the Belgian market. Both regular and menthol-flavoured heat-
sticks were purchased. The menthol e-liquid and heat-sticks were only destined for regular 
menthol cigarette smokers; however, because nobody happened to smoke menthol 
cigarettes, the menthol products were not used in this study. The e-cigarette was an Eleaf 
iStick Power 5000 mAh battery, fixed at 8 W, with an Aspire Nautilus 2 tank containing a 
1.6 Ohm coil. The e-liquid (“Base Aurora”) contained 18 mg/mL nicotine, a PG/VG ratio of 
70/30, to which either a tobacco flavour (“7 Leaves”, 3 vol%) or a menthol flavour (“Mild 
Winter-Peppermint”, 3 vol%) was added. 
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The authors reported on the acute effects of a single use of heat-not-burn cigarettes, 
electronic vaping cigarettes, and conventional combustible tobacco cigarettes in healthy 
smokers. 
Age (SD): 35 (13) years. Sex: 6 males, 14 females. Country: Italy 
Data source: Healthy subjects who smoked were recruited 
Trial duration: Four weeks. This was a university-based, randomized, crossover study. A 
one-week washout from any tobacco product was recommended at study entry and before 
each experimental cycle, and smoking history (time when smoking had begun) and 
intensity (i.e. number of daily cigarettes) was self-reported. Participants were randomly 
allocated to six different cycles of using a single heat-not-burn cigarette, electronic vaping 
cigarettes, and traditional tobacco combustion cigarettes. Participants eventually used all 










Interventional trial papers on cardiovascular diseases 
Population size: 20 
Data collection period: 2017 
E-cigarette, smoking and other related status: A one-week washout from any tobacco 
product was recommended at study entry and before each experimental cycle, and 
smoking history (time when smoking had begun) and intensity (i.e., number of daily 
cigarettes) was self-reported. 
Outcomes: Antioxidant status (enzymatic and nonenzymatic antioxidants – specifically 
levels of vitamin E, a powerful endogenus nonenzymatic antioxidant, and HBA, a measure 
of H2O2 neutralized by cellular enzymes. Platelet activation (two markers: sCD40L and 
soluble P-selectin). Endothelial dysfunction (flow-mediated dilation, nitric oxide 
bioavailability, and blood pressure)  
The authors concluded that the acute effects of heat-not-burn cigarettes, electronic 
vaping cigarettes, and conventional combustible tobacco cigarettes are different on 
several oxidative stress, antioxidant reserve, platelet function, cardiovascular, and 
satisfaction dimensions, with conventional combustible tobacco cigarettes showing the 
most detrimental changes in clinically relevant features, thus suggesting that these 
modified-risk products may indeed prove useful as tools to quit smoking conventional 
combustible tobacco cigarettes. 22 
 
Device and products: Tobacco cigarettes from a leading brand (Marlboro Gold; Philip 
Morris International, Neuchatel, Switzerland) with a mean nicotine content of 0.60 mg per 
cigarette according to the package label, vaped 9 puffs from a leading tobacco-flavoured. 
Electronic vaping cigarettes (Blu Pro, Fontem, Netherlands), charged with a nicotine 
cartridge with a mean nicotine content of 16 mg, equivalent to 250 puffs according to the 
package label, thus yielding 0.58 mg of nicotine content in 9 puffs. A leading heat-not-burn 
cigarette (Tobacco Heating System THS2.2 IQOS with Heets; Amber Label, Philip Morris 
International) having a mean nicotine content of 0.50 mg per stick according to the 
manufacturer. 
  Industry-based trials 
Unverdor











The authors reported on exercise performance following reduced exposure to 
conventional combustible tobacco cigarette smoke and no smoking in adult smokers 
switching from conventional combustible tobacco cigarettes to an electrically heated 
cigarette smoking system or smoking abstinence.  
Age: 35 to 60 years. Sex: All male. Country: Republic of South Africa 
Data source: Male adult smokers in good general health 
Trial duration: During the 7 weeks before the start of the clinical conduct, after giving 
informed consent and passing initial screening including Symptom-Limited Spiroergometry, 
each subject was familiarised with the research unit and study procedures. Successful 
candidates underwent two more Symptom-Limited Spiroergometry, 3 to 7 days apart, to 
assure that the peak oxygen uptake of the second and the third Symptom-Limited 
Spiroergometry would not differ by 12% or more. Qualified subjects were admitted to the 
clinical unit within 7 to 21 days after completion of the screening procedures and 
randomized to 1 of the 6 exposure sequences. The subjects were not allowed to leave the 
unit for 10 days unless they withdrew from the study. 
Population size: 18 
Trial duration: The study was designed as an open-label, randomized, controlled, three-
period, crossover study conducted at a single research center in the Republic of South 
Africa. 
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Outcomes: Improve exercise performance assessed by Symptom-Limited Spiroergometry 
parameters (measures of dyspnea, lung working capacity, oxygen uptake, anaerobic 
threshold) and bioanalysis (carboxyhaemoglobin) 
The authors concluded that this study demonstrates that reduced exposure to 
conventional combustible tobacco cigarette smoke and not smoking for 3 days translates 
into improvements in cardiovascular function as detected by symptom-limited 
spiroergometry.403 
Device and products: The products used in the study were a conventional combustible 
tobacco cigarette (tar, 11 mg; nicotine, 0.8 mg; carbon monoxide, 11 mg) and a second-
generation electrically heated cigarette smoking system series JLI (tar, 3 mg; nicotine, 0.2 
mg; carbon monoxide, 0.4 mg [Federal Trade Commission method]).The EHCSS consists of 
a cigarette containing a column of standard cigarette tobacco filler, wrapped in a tobacco 
mat and paper overwrap, which is inserted into a puff-activated lighter. The lighter’s 8 
blades heat the cigarette only when the smoker takes a puff, thereby avoiding smouldering 
of the cigarette between puffs. Using this design, the tobacco reaches a peak temperature 
of approximately 500°C during puffing. This contrasts with the burning cone of a 
conventional combustible tobacco cigarette, which can reach approximately 900 °C during 
puffing.  
Unverdor












The authors reported on the prognostic parameters of heart rate (HR) and rate-pressure-
product (RPP) on exercise performance in adult smokers switching from a conventional 
combustible tobacco cigarette to a potential exposure-reduced electrically heated 
cigarette smoking system and no smoking. 
Age: 35 and 60 years of age. Sex: All males. Country: Republic of South Africa 
Data source: Smokers in good general health 
Population size: 18  
Trial duration: The study was designed as a single-blind (exercise laboratory staff), 
randomised, controlled, 3-period, crossover study conducted at a single research centre 
Republic of South Africa. 
E-cigarette, smoking and other related status: Smokers in good general health, a smoking 
history of 20 to 40 cigarettes/day for at least 10 years with brand and daily cigarette use 
stable for at least 3 months prior to enrolment, and a carboxyhaemoglobin concentration 
of >2.5% at the initial screening visit 
Outcomes: Cardiovascular measures of heart rate and carbon monoxide  
• Carboxyhaemoglobin  
• Resting heart rate  
• Heart rate maximum 
• Heart rate 1-minute post exercise, parameters composed from these measures such 
as:  
o Chronotropic response: Heart rate max — Heart rate rest 
o Heart rate recovery: Heart rate max - Heart rate min post 
o Rate—pressure-product at rest: Heart rate max x systolic blood pressure 
o Rate—pressure-product maximum: Heart rate max x systolic blood pressure 
o Rate—pressure-product 1-minute post exercise: Heart rate min post X systolic 
blood pressure 1 min post 
o Rate—pressure-product response: RPPmax-rest 
o Rate—pressure-product recovery: RPPmax-1min post 
The authors concluded that this study demonstrates that reduced exposure to tobacco 
smoke and not smoking for 3 days may translate into improvements in heart rate and 
rate-pressure-product parameters that are associated with cardiovascular prognosis. 
These improvements seem to be more pronounced during no smoking than during the use 
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Device and products: The products used in the study were conventional test cigarettes 
(Philip Morris USA, Richmond, VA) whereas for generation of reduced exposure a second-
generation electrically heated cigarette smoking system (EHCSS series JLI, Philip Morris 
USA, Richmond, VA) was used. According to the Federal Trade Commission (FTC) method, 
the conventional combustible tobacco cigarettes delivered 11 mg of tar, 0.8 mg of nicotine, 
and 11 mg of carbon monoxide whereas EHCSS delivered 3 mg of tar, 0.2 mg of nicotine, 
and 0.4 mg of carbon monoxide The EHCSS consists of a cigarette containing a column of 
standard cigarette tobacco filler, wrapped in a tobacco mat and paper overwrap, which is 
inserted into an electrical puff-activated lighter. The lighter's 8 blades heat the cigarette 
only while the smoker takes a puff, thereby avoiding smouldering of the cigarette between 
puffs. Using this design, the tobacco reaches a peak temperature of approximately 500°C 
during puffing. This contrasts with the burning cone of a conventional combustible tobacco 









Authors reported on cardiovascular risk factors in adults’ smokers switching from 
conventional tobacco cigarettes to a second-generation electronic heated cigarette 
smoking system 
Age years: 25 to 65 years Sex: males and females. Country: USA 
Data source: Not reported 
Duration of trial: 12 months. Population size: 82 
Year of data collection: Not reported  
E-cigarette, smoking and other related status: Smokers of 10 to 40 manufactured, 
nonmenthol cigarettes with 1 to 7 mg tar as measured by the Federal Trade Commission 
method daily for at least 10 years.  
Outcomes: Subjects had three baseline urine and blood biomarker determinations over a 
2-week interval in a controlled, confined clinical setting. Examples: nicotine equivalents 
(urine nicotine), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its glucuronides 
(total NNAL). Total 1-OHP, 3-hydroxypropylmercapturic acid (3-HPMA), a metabolite of 
acrolein, 4-aminobiphenyl hemoglobin (4-ABP Hb), Carboxyhemoglobin (COHb), 3-HPMA) 
and cardiovascular risk factors (haemoglobin, haematocrit, red blood cells, white blood 
cells, LDL and HDL Cholesterol, Triglycerides, Fibrinogen, hs-CRP, 11-Dehydrothromboxane 
B2, 8-epi-Prostaglandin F2α, Bilirubin, von Willebrand Factor, Urine Microalbumin) and 
safety results i.e. adverse events (e.g. headache). To assess changes in exposure to 
selected cigarette smoke constituents. 
Intervention and research design: 12-month, randomized, controlled study controlled, 
forced-switching, open label parallel-group study. Eligible adult smokers were randomly 
switched to a second-generation electrically heated cigarette smoking system or to a 6-mg 
tar Federal Trade Commission conventional cigarette in a 2:1 ratio. After randomization, 
each subject returned to the clinic at 2 weeks and at 1, 2, 3, 4, 5, 6, 9, and 12 months for 
blood and 24-hour urine sampling in a controlled, confined clinic setting 
The authors concluded that there was a rapid and sustained reduction in all biomarkers of 
exposure after switching to the electronic heated cigarette smoking system, with 
statistically significant reductions from baseline405 











The authors reported on the tone of the autonomic nervous system as reflected by heart 
rate variability among users of different tobacco products. 
Age: 35 to 60 years. Mean age + SD; 42.8 +5.7 years. Sex: All males. Country: Not reported 
Data source: Male smokers without any evidence of cardiovascular disease were enrolled 
within 28 days of the screening period 
Population size: In all, 34 male adult smokers were enrolled in the study, and 30 
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tobacco 
cigarettes 
Trial duration: A prospective randomized, controlled, 3-period, crossover study design 
conducted over three days. For each exposure sequence, the first period was initiated from 
4:00 PM to 5:30 PM on day 1 (hour 0) and 72 hours of smoking/no-smoking was allowed. 
Each day, participants in a smoking group could smoke up to 30 cigarettes at specified 
smoking opportunities offered at equal intervals (every 32 minutes) from 7:00 AM to 10:59 
PM. Smoking was not allowed overnight from 11:00 PM to 6:59 AM. 
E-cigarette, smoking and other related status: Participants smoked between 20 and 40 
non-menthol cigarettes per day for at least 10 years. 
Outcomes: Heart rate variability derived from the 24-hour electrocardiogram. Specifically,  
• NN interval: normal-to-normal heart beat interval 
• SDNN: Standard deviation of all NN intervals 
• SDANN: Standard deviation of all 5-minute averaged 
• NN intervals in a 24-hour period 
• RMSSD: The square root of the mean of all squared differences between adjacent NN 
intervals in 24-hour period 
• SDNNI: Mean of the standard deviations of the NN intervals calculated from all 5-mi-
nute segments in a 24-hour period 
• PNN50: Percentage (P) of all NN intervals that differ by 50 milliseconds of all NN (%) 
• HRVTI: Total number of all NN intervals divided by the height of the histogram of all 
NN intervals measured on a discrete scale with bins of 7 8125 ms (1/128 seconds) 
• Heart Rate: Average beats per minute during ambulatory period 
 
The authors concluded that adult smokers tend to show increased heart rate variability 
with reduced exposure to conventional combustible tobacco cigarette smoke after 3 
days, indicating a physiologically favourable change in the autonomous nervous 
system.406 
Device and products: The products used in the study were a conventional combustible 
tobacco cigarette; tar: 11 mg, nicotine: 0.8 mg, carbon monoxide: 11 mg; according to the 
Federal Trade Commission method) and a potential reduced-exposure product, the third-
generation, electrically heated cigarette smoking system (EHCSS series K; tar: 5mg, 
nicotine: 0.3mg, carbon monoxide: 0.45mg).This device serves solely as a research tool for 
the development of various risk related assays since it reproducibly reduces exposure to 
tobacco constituents in humans. The EHCSS consists of a cigarette containing a column of 
standard cigarette tobacco filler, wrapped in a tobacco mat and paper overwrap, which is 
inserted into an electronic cigarette lighter. The lighter’s 8 blades heat the cigarette only 
when the smoker takes a puff, thereby avoiding smoldering of the cigarette between puffs. 
Using this design, the tobacco reaches a peak temperature of approximately 500’C during 
puffing. This is in contrast to the burning cone of a lit end cigarette, which can reach 


















The authors reported on biomarkers associated with cardiovascular risk and biomarkers 
of exposure to 10 selected harmful and potentially harmful constituents in conventional 
combustible tobacco cigarette smoke, comparing findings in conventional combustible 
tobacco cigarette smokers with those smoking the EHCSS series-K cigarette, the EHCSS-K6. 
Age: 30 to 60 years. Sex: 161 males, 155 females. Country: Poland 
Data source: Not reported 
Trial duration: This was a randomised, open-label, controlled study with two study groups, 
EHCSS-K6 and conventional combustible tobacco cigarettes. The study schedule consisted 
of eight main study visits, screening (Visit 1), two baseline, weekly assessments (Visits 2 
and 3), and five post-randomization weekly assessments (Visits 4–8). The whole study 
duration was approximately 8 weeks, with the investigational period defined as 5 weeks 


















assessment schedule of biomarkers over the course of the study consisted of blood 
sampling (in fasted state) on Visits 2, 3, 5, 7, and 8, and a 24-hour urine collection prior to 
Visits 3 and 8 (for urinary biomarkers). Carbon monoxide breath testing was performed at 
all visits from Visit 2 through Visit 8. 
Population size: A total of 338 subjects were enrolled in the study and 316 were 
randomised. The study was completed by 309 subjects, with 234 and 75 subjects for the 
EHCSS-K6 and conventional combustible tobacco cigarette groups, respectively. There 
were 7 subjects who did not complete the study. In the EHCSS-K6 group, 2 subjects were 
withdrawn as they did not attend study visits and 1 subject withdrew consent. In the 
conventional combustible tobacco cigarette group, 2 subjects were withdrawn as they did 
not attend study visits, 1 subject was withdrawn due to influenza and 1 subject for 
violation of selection criteria  
Data collection period: The study was conducted in two sessions between October 2007 
and April 2008 
E-cigarette, smoking and other related status: Subjects were current smokers of 
commercially available, non-mentholated conventional combustible tobacco cigarettes 
with a 3–10 mg tar yield with a smoking history of at least 10 years prior to screening 
Outcomes: Biomarkers and selected harmful and potentially harmful constituents: 
• White blood cell (WBC) count 
• WBC differential 
• Platelet count 
• Red blood cell (RBC) count 
• Haemoglobin 
• Haematocrit 
• High-sensitivity C-reactive protein (hs-CRP) 
• Interleukin-6 (IL-6) 
• Oxidized low-density lipoprotein (oxLDL cholesterol) 
• Myeloperoxidase 
• Homocysteine 
• High-density lipoprotein (HDL) 
• Low-density lipoprotein (LDL) 
• Total cholesterol 
• von Willebrand factor (vWF) 
• Fibrinogen 
• Adenosine diphosphate (ADP)-induced platelet aggregation 
• 8-epi-prostaglandin F2a (8-epi-PGF2a) 
• 11-dehydro-thromboxane B2 (11-DTXB2) 
Selected harmful and potentially harmful constituents: 
• 1,3-Butadiene (Monohydroxybutenyl mercapturic acid (MHBMA)) 
• 2-Naphthylamine (2-Naphthylamine (2-NA)) 
• 4-Aminobiphenyl (4-Aminobiphenyl (4-ABP)) 
• Acrolein (3-Hydroxypropyl mercapturic acid (3-HPMA)) 
• Benzene (S-Phenyl mercapturic acid (S-PMA)) 
• Carbon monoxide (Carboxyhemoglobin (COHb)) 
• Nicotine (Nicotine equivalents (NEq)) 
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• Pyrene (Total 1-hydroxypyrene (total 1-OHP)) 
• o-Toluidine (o-Toluidine (o-TOL)) 
The authors concluded that there were no statistically significant differences in the two 
primary biomarkers between the study groups at the end of the study. End-of-study 
comparisons of secondary biomarkers between study groups indicated an increase in high-
density lipoprotein (HDL) cholesterol, and reductions in red blood cell count, haemoglobin, 
and haematocrit levels in the EHCSS-K6 group. All biomarkers of exposure to the selected 
harmful and potentially harmful constituents in conventional combustible tobacco 
cigarette smoke were decreased in the EHCSS-K6 group, despite an increase in cigarette 
consumption, compared to the levels found in the conventional combustible tobacco 
cigarette group. There were no apparent differences in any of the safety assessment 
parameters between the groups, and the overall incidence of study-related adverse events 
was low.407 
Device and products: The electrically heated cigarette smoking system series-K cigarette 
was analysed for tar, nicotine and carbon monoxide mainstream smoke yields according to 
International Organization for Standardization methods. All study cigarettes were 
conditioned according to International Organization for Standardization standard 3402. 
Mainstream smoke from electrically heated cigarette smoking system series-K cigarettes 
was generated on a modified smoking machine with a carousel adapted to use the 
electrically heated cigarette smoking system series-K cigarette EHCSS series-K lighter. The 
EHCSS smoke generation conformed with International Organization for Standardization 
standard; however, some slight technical deviations were required. Tar, nicotine and 
carbon monoxide were determined according to International Organization for 
Standardization standards 4387, 10315, and 8454, respectively (International Organization 
for Standardization, 2000b, 2000c; International Organization for Standardization, 1995). 
The International Organization for Standardization yields as declared on the electrically 
heated cigarette smoking system series-K cigarette EHCSS-K6 pack were as follows: 5 mg 
tar, 0.3 mg nicotine, and 1.0 mg carbon monoxide. As electrically heated cigarette smoking 
system series-K cigarette EHCSS-K6 cigarettes were not commercially available on the 
Polish market they were provided free-of-charge to the subjects. Conventional combustible 
tobacco cigarettes were not analysed or provided to subjects in the conventional 
combustible tobacco cigarette group, and were purchased by the subjects according to 











The authors reported on changes in biomarkers of biological effect among adult 
conventional combustible tobacco cigarette smokers who switched to tobacco-heating 
systems, snus, or ultra-low machine yield tobacco-burning cigarettes for 24 weeks. 
Comparisons were made between smokers and a group of never-smokers at baseline, and 
among the three tobacco-using groups over time and in comparison with each other.  
Age: Adults. Sex: Not reported. Country: USA 
Data source: Not reported 
Trial duration: This was a randomized, multi-centre study of adult cigarette smokers 
randomly assigned to switch to a tobacco-heating system (Eclipse brand cigarette, non-
menthol and menthol varieties, depending on subject preference), snus (Camel SNUS, 
subject choice of Frost, Spice and Mellow varieties) or an ultra-low machine yield tobacco-
burning cigarette (5 mg Cambridge Filter Method ‘‘tar’’; Camel or Salem, non-menthol and 
menthol, respectively, depending on subject preference). A fourth group of never smokers 
was included for baseline (week 0) comparisons. Subjects’ experience with the randomised 
products was followed for 24 weeks at five clinical research units in the USA managed by 
Covance Early Clinical Development 
Population size: 150 (50 per group) 
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Outcomes: Biomarkers of the following biological effects inflammation/oxidative damage, 
lipids, hypercoagulable state, Insulin resistance, endothelial function and DNA damage 
specifically  
• Isoprostane 
• Isomers and metabolites (e.g.iPF2a-III, 2,3-dinoriPF2a- III, iPF2a-VI, 8,12-isoiPF2a- VI, 
and PGF2a) 
• Soluble intercellular adhesion molecule 1 
• C-reactive protein 






• Haemoglobin A1c 
• High density 
• lipoprotein 
• Low density 
• lipoprotein 
• HDL/LDL 
• Oxidized LDL 
• Triglycerides 
• Circulating endothelial precursor cells 
• Sister chromatid exchange 
The authors concluded that half of the biomarkers of biological effect evaluated were 
statistically significantly different in the baseline comparisons between smokers and 
never-smokers. Differences in C-reactive proteins, high-density lipoproteins (HDL), low-
density lipoproteins (LDL), HDL/LDL, triglycerides, fibrinogen, and platelets between 
smokers and non-smokers, were not observed in this study. However, such differences 
have been noted previously in some but not all studies examining these relationships. They 
noted that consistent and statistically significant differences in pairwise comparisons 
between product groups were not observed.408 
Device and products: A tobacco-heating system (Eclipse brand cigarette, non-menthol and 
menthol varieties, depending on subject preference), snus (Camel SNUS, subject choice of 
Frost, Spice and Mellow varieties) or an ultra-low machine yield tobacco-burning cigarette 
(5 mg Cambridge Filter Method ‘‘tar’’; Camel or Salem, non-menthol and menthol, 













The authors reported on the risk profile of a new tobacco product, the menthol THS 2.2, 
an alternative to conventional combustible tobacco cigarettes. 
Age:23 to 65 (inclusion criteria). Sex: Not reported. Country: Japan Ethnicity: Japanese 
Data source: Not reported 
Trial duration: The study comprised a 4-week screening period (Days −30 to −3), an 8-day 
confinement period (Days −2 to Day 6), an 85-day ambulatory period (Days 6 to 91), and a 
28-day safety follow-up period.  
Population size: A total of 670 individuals were screened at two study sites, of which 231 
tried the menthol Tobacco Heating System (THS 2.2) and 216 were enrolled and 
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55 were discontinued following the closure of one of the two study sites due to non-
compliance with sample collection and data recording procedures. 
One-hundred and sixty participants were randomised to the menthol Tobacco Heating 
System (n=78), conventional combustible tobacco cigarettes (n=42), and smoking 
abstinence (n=40) groups. Data analysis was carried out on 104 study participants. 
Data collection period: The study was conducted and completed between August 2013 and 
July 2014 at the Tokyo Heart Center Osaki Hospital, Tokyo, Japan 
E-cigarette, smoking and other related status: Smoked ≥10 menthol conventional 
combustible tobacco cigarettes per day with a maximum International Organization for 
Standardization yield of 1 mg for the previous 4 weeks (self-reported) and had smoked for 
≥3 consecutive years. No plan to quit smoking in the next 3 months. 
Outcomes: The following clinically relevant risk markers were measured:  
• Oxidative stress—8-epi-PGF2α; platelet activity—11-DTX-B2;  
• Endothelial function—soluble intracellular adhesion molecule-1 (sICAM-1);  
• Lipid metabolism—HDL cholesterol, low-density lipoprotein (LDL) cholesterol, triglyc-
erides, and total cholesterol; inflammation—total WBC;  
• Cardiovascular risk/function—homocysteine, high-sensitivity C-reactive protein (hs-
CRP), fibrinogen,  
• Systolic blood pressure, and diastolic blood pressure; and  
• Metabolic syndrome—blood glucose, hemoglobin A1c (HbA1c), body weight, and 
waist circumference. 
The authors concluded that switching from conventional combustible tobacco cigarettes 
to the menthol THS 2.2 was associated with reductions in biomarkers of exposure to 
conventional combustible tobacco cigarette smoke, and changes were observed in 
clinically relevant biomarkers of oxidative stress (8-epi-prostaglandin F2α), platelet 
activity (11-dehydro-thromboxane B2), endothelial function (soluble intracellular 
adhesion molecule-1), lipid metabolism (high-density lipoprotein (HDL) cholesterol), and 
lung function (forced expiratory volume in 1 second) which were similar to the smoking 
abstinent group. The results suggest that switching to the menthol THS 2.2 has the 
potential to reduce the adverse health effects of using conventional combustible tobacco 
cigarettes.409 
Device and products: The menthol Tobacco Heating System (2.62 mg/stick menthol, 1.21 
mg/stick nicotine and 3.94 mg/stick of glycerine used as aerosol former, obtained under 
Health Canada Intense smoking regimen, maximum heating temperature 350 °C) was used 
in this study. Reference products were menthol conventional combustible tobacco 
cigarettes of the participants’ preferred commercially available brand. 
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The authors reported on the extent and potential reversibility of changes in pulmonary 
function in adult smokers of conventional combustible tobacco cigarettes after 3 days of 
smoking conventional combustible tobacco cigarettes, or the potential reduced exposure 















Age: 35–60 years. Sex: Males. Country: Republic of South Africa 
Data source: Not reported 
Trial duration: The pilot study was designed as a single-blind (technicians and laboratory 
staff), randomized, controlled, three-period, crossover study conducted at a single 
research centre. Republic of South Africa. The subjects were not allowed to leave the unit 
for 10 days unless they withdrew from the study. Data collection timepoint are not clearly 
reported 
Population size: 49 
E-cigarette, smoking and other related status: Male smokers in good general health 
without any history or clinical signs of pulmonary disease were recruited through the 
database of volunteers at the clinical research unit to evaluate cigarette smoking related 
influences on pulmonary function 
Outcomes: The parameters measured or computed by the spiroergometry system 
specifically:  
• Airways resistance (measured by sGaw Specific conductance (1/cmH2O x s, Gaw con-
ductance (1/cmH2O x s, sRaw Specific resistance (cmH2O x s, Raw resistance (cmH2O 
x s)  
• Spirometry (measured by FEV1 Forced expiratory volume after one second (L), FEF 
25% Forced expiratory flow after the first 25% of the vital capacity (L/s), FEF 50% 
Forced expiratory flow after the first 50% of the vital capacity (L/s), FEF 25–75% 
Forced mid expiratory flow (L/s), PEF Peak expiratory flow (L/s), PIF Peak inspiratory 
flow (L/s))  
• Lung volumes (Vital capacity (L), Forced inspiratory vital capacity (L), Thoracic gas vol-
ume (L)) 
The authors concluded that the data indicated acute and reversible effects of different 
cigarette smoke exposures and no smoking on mid- to small-size pulmonary airways in a 
dose-dependent manner.410 
Device and products: The products used in the study were conventional combustible 
tobacco cigarettes (Philip Morris USA, Richmond, VA, USA) and as a potential reduced-
exposure product the third generation electrically heated cigarette smoking system (EHCSS 
series K, Philip Morris USA, Richmond, VA, USA). According to the Federal Trade 
Commission method, the conventional combustible tobacco cigarettes delivered 11 mg tar, 
0.8 mg nicotine, and 11 mg carbon monoxide while EHCSS delivered 5 mg tar, 0.3 mg 
nicotine, and 0.45 mg carbon monoxide. The EHCSS has been shown to reliably reduce the 
delivery of selected smoke constituents and smokers’ exposure to particulate and gas-
phase smoke constituents by 40–95% compared to conventional combustible tobacco 
cigarettes, and was therefore used as the reduced exposure product. The EHCSS is not 
intended to be marketed. EHCSS consists of a cigarette containing a column of standard 
cigarette tobacco filler, wrapped in a tobacco mat and paper overwrap, which is inserted 
into a Puff Activated Lighter™. One of the lighter’s eight blades at a time heats the 
cigarette only while the smoker takes a puff, thereby avoiding smouldering of the cigarette 
between puffs. Using this design, the tobacco reaches a peak temperature of 
approximately 500 °C during puffing This contrasts with the burning cone of a conventional 
combustible tobacco cigarette, which reaches approximately 900 °C during puffing. 






Interventional trial papers on exposure to heat-not-burn toxins 










Interventional trial papers on exposure to heat-not-burn toxins 














The authors reported on levels of biomarkers of exposure to nine selected harmful and 
potentially harmful constituents in conventional combustible tobacco cigarette smoke 
(Marlboro cigarettes containing 6 mg tar, 0.5 mg nicotine, and 7.0 mg carbon monoxide 
(CO)) and levels of urinary excretion of mutagenic material in smokers and in users of one 
of two EHCSS series-K cigarettes, the EHCSS-K3 cigarette or the EHCSS-K6 cigarette. 
Age: 19–50 years of age. Sex: 88 males, 87 females. Country: United Kingdom 
Data source: Subjects normally smoking the Marlboro non-menthol cigarette (M6UK) were 
randomized into one of the five groups  
Population size: 175. 160 subjects completed the trial 
Trial duration: All recruited subjects (N = 175, 88 males and 87 females) completed a 7-day 
diary prior to check-in on Day -2. All subjects were confined to the clinic from Day -2 to Day 
9 under medical supervision. Vital signs were measured, and a physical examination 
performed. On Day -1, vital signs and a 12-lead ECG were measured, and blood samples 
drawn for clinical laboratory tests. On Day 0 (baseline), assessments included 
determination of biomarkers of exposure in a 24-h urine sample, vital signs, carbon 
monoxide carboxyhemoglobin 17:00, and plasma cotinine. One hundred and sixty subjects 
(80 males and 80 females) were randomised into 1 of 5 parallel groups (EHCSS-K3, EHCSS-
K6, M6UK, and PM1 cigarettes, and no-smoking; N = 32 subjects per group). From Day 1 
through Day 8, subjects participated in their assigned study groups. Assessments included 
determination of biomarkers of exposure in 24-h urine samples, vital signs, and 
determination of carbon monoxide carboxyhemoglobin 17:00 and COT-P17:00. On Day 9 
(end of study), vital signs, ECG, clinical laboratory tests, and a physical examination were 
performed. On Day -2 through Day 0, subjects were only permitted to smoke the M6UK 
cigarette, on Day 1 through Day 8 subjects smoked their randomized study cigarette or 
stopped smoking if they were randomized to the no-smoking group. M6UK and PM1 
cigarettes were lit using a blue flame gas lighter. EHCSS-K3 and EHCSS-K6 cigarettes were 
smoked using the EHCSS heater. To ensure study integrity, all M6UK and PM1 cigarette 
butts and smoked EHCSS-K3 and EHCSS-K6 cigarettes were collected. 
E-cigarette, smoking and other related status: Adult male and female smokers with 
acceptable health conditions who had smoked 10–25 cigarettes per day and the Marlboro 
non-menthol cigarette (6 mg tar, 0.5 mg nicotine, and 7.0 mg carbon monoxide) as their 
exclusive brand for at least 4 weeks prior to screening were recruited 
Outcomes: selected harmful and potentially harmful constituents in cigarette smoke and 
excretion of mutagenic material in urine 
• 1,3-Butadiene Monohydroxybutenyl mercapturic acid (MHBMA) 
• Acrolein 3-Hydroxypropyl mercapturic acid (3-HPMA) 
• Benzene S-Phenyl mercapturic acid (S-PMA) 
• Carbon monoxide Carboxyhemoglobin (COHb) 
• Crotonaldehyde 3-Hydroxy-1-methylpropyl mercapturic acid (3-HMPMA) 
• Nicotine Cotinine (COT-P) 
• Nicotine equivalents (NEq)c 
• NNKb Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) 
• Pyrene Total 1-hydroxypyrene (1-OHP)e 
• o-Toluidine o-Toluidine (o-TOL) 
• Mutagens Salmonella mutagenicity (YG1024 with S9) 
 
The authors concluded that the study showed strong mean reductions in uptake of 
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in excretion of mutagenic material in urine, from baseline to day 8 in M6UK non-menthol 
cigarette smokers who switched to smoking either the EHCSS-K3 or the EHCSS-K6 non-
menthol cigarettes. Smokers who switched to smoking PM1, a conventional combustible 
tobacco non-menthol cigarette representative of the low-tar cigarette market, showed 
smaller reductions. The largest mean reductions occurred in smokers who stopped 
smoking.412 
Device and products: Conventional combustible tobacco cigarette brands were selected to 
include a leading market share cigarette of similar International Organization for 
Standardization tar and nicotine yields to the EHCSS-K6 and a representative conventional 
combustible tobacco cigarette with a low ISO tar and nicotine yield. The cigarettes also had 
a similar tobacco blend to that used in the EHCSS test cigarettes. Study cigarettes were 
analysed for tar and nicotine according to ISO methods. All study cigarettes were 
conditioned according to ISO standard 3402 (International Organization for 
Standardization, 1991). Conventional combustible tobacco cigarettes were smoked on a 
smoking machine according to ISO standard 3308 (International Organization for 
Standardization, 2000a). Tar, nicotine and CO were determined according to ISO standards 
4387, 10315, and 8454. Mainstream smoke from EHCSS cigarettes was generated on a 
modified smoking machine with a carousel adapted to use the EHCSS series-K lighter. The 
EHCSS smoke generation conformed to ISO standard 3308; some slight technical deviations 
were required. The ISO yields as declared on the cigarette packaging were as follows: 
Marlboro (M6UK; 6 mg tar, 0.5 mg nicotine, and 7.0 mg CO), Philip Morris One (PM1; 1 mg 
tar, 0.1 mg nicotine, and 2.0 mg CO), EHCS EHCSSK6 (5 mg tar, 0.3 mg nicotine, and 0.6 mg 













The authors reported on levels of biomarkers of exposure to 12 selected harmful and 
potentially harmful constituents in conventional combustible tobacco cigarette smoke 
(Lark1 cigarettes containing 1.0 mg tar, 0.1 mg nicotine, and 1.5 mg carbon monoxide 
(CO)), and levels of urinary excretion of mutagenic material. The study involved the 
following three groups: smokers of Lark1 cigarettes; users of EHCSS-K3 cigarettes (3 mg tar, 
0.2 mg nicotine, and 0.6 mg carbon monoxide (CO)); and non-smokers.  
Age: 20 to 50 years. Sex: 75 males 24 females Country: South Korea 
Data source: Korea  
Population size: Seventy-two subjects (54 males and 18 females) were randomized into 1 
of 3 parallel groups (Lark1: N = 28; EHCSS-K3: N = 28; and no-smoking: N = 16) using a 
stratification based on median daily cigarette consumption (10–19 and 20–30 cigarettes 
per day) 
Trial duration: Enrolled subjects completed a 7-day smoking diary prior to check-in on Day -
2 On Day -2, subjects entered the clinic before 08:00. All subjects were confined to the 
clinic from Day -2 to Day 9 under medical supervision. On Day -1 (baseline), assessments 
included determination of biomarkers of exposure in a 24-h urine sample, vital signs, COHb 
(COHb0700 and COHb17:00), plasma cotinine and nicotine (COT-P17:00 and NICP).  
E-cigarette, smoking and other related status: Adult male and female Korean smokers with 
acceptable health conditions who smoked 10–30 conventional combustible tobacco non-
menthol cigarettes (1.0–3.0 mg tar) per day and the Lark1 (1.0 mg tar, 0.1 mg nicotine, and 
1.5 mg CO) as their exclusive brand for at least 2 weeks prior to admission to the clinic 
were recruited.  
Outcomes: biomarkers of exposure to 10 of 12 selected conventional combustible tobacco 
cigarette smoke harmful and potentially harmful constituents 
• 1,3-Butadiene Monohydroxybutenyl mercapturic acid (MHBMA) 
• 2-Naphthylamine 2-Naphthylamine (2-NA) 
• 4-Aminobiphenyl 4-Aminobiphenyl (4-ABP) 
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• Acrylamide Acrylamide mercapturic acid (AAMA) 
• Glycidamide mercapturic acid (GAMA) 
• Benzene S-Phenyl mercapturic acid (S-PMA) 
• CO Carboxyhemoglobin (COHb) 
• Crotonaldehyde 3-Hydroxy-1-methylpropyl mercapturic acid (3-HMPMA) 
• Nicotine Cotinine (COT-P) 
• Nicotine (NIC-P) 
• Nicotine equivalents (NEq)c 
• NNK Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) 
• Pyrene Total 1-hydroxypyrene (1-OHP)e 
• o-Toluidine o-Toluidine (o-TOL) 
• Mutagens Salmonella mutagenicity (YG1024 with S9) 
 
The authors concluded that the study showed mean reductions in biomarkers of exposure 
to 10 of 12 selected harmful and potentially harmful constituents of conventional 
combustible tobacco cigarette smoke (1,3-butadiene, 2-naphthylamine, 4-
aminobiphenyl, acrylamide, benzene, carbon monoxide (CO), nicotine, Total 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), pyrene, and o-toluidine) from 
baseline to day 8 in Lark1 smokers who switched to smoking EHCSS-K3 cigarettes. No 
change was determined for biomarkers of exposure to crotonaldehyde and acrolein. In 
smokers who continued to smoke Lark1 cigarettes, exposure to the majority of the 
harmful and potentially harmful constituents of conventional combustible tobacco 
cigarette smoke (1,3-butadiene, 2-naphthylamine, 4-aminobiphenyl, acrylamide, 
benzene, carbon monoxide (CO), crotonaldehyde, nicotine, Total 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol (NNAL) and o-toluidine) increased, while biomarkers of exposure 
to acrolein and pyrene decreased. With the exception of 1,3-butadiene, 2-
naphthylamine, benzene, carbon monoxide (CO), nicotine, and 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone (NNK), few of the changes reached the level of statistical 
significance. The largest mean reductions in all harmful and potentially harmful 
constituents of conventional combustible tobacco cigarette smoke occurred in smokers 
who switched to no smoking. Excretion of mutagenic material in urine was significantly 
decreased in the EHCSS-K3 and no-smoking groups, and was significantly increased in the 
Lark1 group.413 
Device and products: A leading commercial conventional combustible tobacco cigarette 
brand (Lark One) was chosen to represent the Korean cigarette market in which smokers 
have a preference for smoking cigarettes with very low International Organization for 
Standardization (ISO) tar and nicotine yields. Lark1 also has a similar tobacco blend to that 
used in the EHCSS test cigarettes. Lark1 was analysed for tar and nicotine according to ISO 
methods. All study cigarettes were conditioned according to ISO standard 3402. Lark1 was 
smoked on a smoking machine according to ISO standard 3308 (International Organization 
for Standardization, 2000a). Tar, nicotine and CO were determined according to ISO 
standards 4387, 10315, and 8454, respectively (International Organization for 
Standardization, 2000b,c, 1995). Mainstream smoke from EHCSS cigarettes was generated 
on a modified smoking machine with a carousel adapted to use the EHCSS series-K lighter. 
The EHCSS smoke generation conformed with ISO standard 3308; some slight technical 
deviations were required. The ISO yields as declared on the cigarette packaging were as 
follows: Lark One (Lark1; 1.0 mg tar, 0.1 mg nicotine, and 1.5 mg CO) and EHCSS-K3 (3 mg 








The authors reported on levels of biomarkers of exposure to 12 selected harmful and 
potentially harmful constituents of tobacco smoke (in Marlboro cigarettes containing 6 
mg tar, 0.5 mg nicotine, and 7.0 mg carbon monoxide (CO)), and on levels of urinary 
















EHCSS-K6 (5 mg tar, 0.3 mg nicotine, and 0.6 mg carbon monoxide (CO)); users of the 
EHCSS-K3 (3 mg tar, 0.2 mg nicotine, and 0.6 mg carbon monoxide (CO)); smokers who 
switched to smoking Lark1 cigarettes (1 mg tar, 0.1 mg nicotine, and 2.0 mg carbon 
monoxide (CO)); and non-smokers.  
Age: 19–50 years of age. Sex: 91 males and 40 females. Country: Japanese smokers 
Data source: Not reported 
Trial duration: All recruited subjects (N = 131; 91 males and 40 females) completed a 7-day 
diary prior to admission to the clinic during the morning on Day 2. All subjects were 
confined to the clinic from Day -2 to Day 9 under medical supervision. On Day 2, the 
eligibility for study inclusion was re-confirmed. Assessments included carbon monoxide 
carboxyhemoglobin, vital signs, and a physical examination. On Day -1, vital signs and a 12-
lead ECG were measured, and blood samples drawn for clinical laboratory tests. On Day 0 
(baseline), assessments included determination of biomarkers of exposure in a 24-h urine, 
vital signs, carbon monoxide carboxyhemoglobin, plasma cotinine and nicotine. On Day -2 
through Day 0, subjects were only permitted to smoke M6J cigarettes. On Day 1 through 
Day 8 subjects smoked their randomized study cigarette or stopped smoking if they were 
randomized to the no-smoking group. 
Population size: All recruited subjects (N = 131; 91 males and 40 females). One hundred 
and twenty-eight subjects (89 males and 39 females) were randomized into 1 of 5 parallel 
groups (EHCSS-K3, EHCSS-K6, M6J, Lark1, and no-smoking; N = 28 per smoking group, and 
N = 16 in the no-smoking group) 
E-cigarette, smoking and other related status: Smokers with acceptable health conditions 
who had smoked 10–30 cigarettes per day were recruited. Subjects were to have smoked 
the Marlboro non-menthol cigarette (6 mg tar, 0.5 mg nicotine, and 7.0 mg carbon 
monoxide) as their exclusive brand for at least 2 weeks prior to study confinement. 
Outcomes: biomarkers of exposure to selected tobacco smoke harmful and potentially 
harmful constituents and excretion of mutagenic material in urine 
• 1,3-Butadiene Monohydroxybutenyl mercapturic acid (MHBMA) 
• 2-Naphthylamine 2-Naphthylamine (2-NA) 
• 4-Aminobiphenyl 4-Aminobiphenyl (4-ABP) 
• Acrolein 3-Hydroxypropyl mercapturic acid (3-HPMA) 
• Acrylamide Acrylamide mercapturic acid (AAMA) 
• Glycidamide mercapturic acid (GAMA) 
• Benzene S-Phenyl mercapturic acid (S-PMA) 
• Carbon monoxide Carboxyhemoglobin (COHb) 
• Crotonaldehyde 3-Hydroxy-1-methylpropyl mercapturic acid (3-HMPMA) 
• Nicotine Cotinine (COT-P) 
• Nicotine (NIC-P) 
• Nicotine equivalents (NEq)c 
• NNKb Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) 
• Pyrene Total 1-hydroxypyrene (1-OHP)e 
• o-Toluidine o-Toluidine (o-TOL) 
• Mutagens Salmonella mutagenicity (YG1024 with S9) 
 
The authors concluded that this study showed statistically significant mean reductions in 
biomarkers of exposure to selected harmful and potentially harmful constituents in 
tobacco cigarette smoke and in excretion of mutagenic material in urine of smokers who 
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the EHCSS-K3 or the EHCSS-K6 cigarette at day 8, compared to baseline. In smokers who 
switched to smoking the Lark1 cigarette, a conventional combustible tobacco cigarette 
representative of the low-tar cigarette market, smaller mean reductions were observed, 
most of which were statistically significant. The largest mean reductions occurred in 
smokers who switched to no smoking.414 
Device and products: Conventional combustible tobacco cigarette brands were selected to 
include a leading market share cigarette on the Japanese market of similar ISO tar and 
nicotine yields to the EHCSS-K6 and a representative conventional combustible tobacco 
cigarette with a low ISO tar and nicotine yield. Both cigarettes also had a similar tobacco 
blend to that used in the EHCSS test cigarettes. Study cigarettes were analysed for tar and 
nicotine according to ISO methods. All study cigarettes were conditioned according to ISO 
standard 3402. Conventional combustible tobacco cigarettes were smoked on a smoking 
machine according to ISO standard 3308 (International Organization for Standardization, 
2000a). Tar, nicotine and carbon monoxide were determined according to ISO standards 













The authors reported on levels of biomarkers of exposure to 12 selected harmful and 
potentially harmful constituents in conventional combustible tobacco cigarette smoke 
(Marlboro Ultra Lights Menthol cigarettes, the M4J(M) (4 mg tar and 0.3 mg nicotine)), and 
on levels of urinary excretion of mutagenic material and serum Clara cell 16-kDa protein 
(CC16) in the following four groups: smokers of conventional combustible tobacco 
cigarettes; users of the M4J(M) cigarettes; participants who switched to smoking either the 
EHCSS-K6M cigarette (5 mg tar and 0.3 mg nicotine) or the Lark1 menthol cigarette 
(Lark1M) (1 mg tar and 0.1 mg nicotine); and non-smokers.  
Age: 21–50 years of age. Sex: 62 males and 40 females Country: Japan 
Data source: Not reported 
Trial duration: The recruited subjects completed a 7-day diary prior to in-clinic admission 
on Day -3. On Day -3, the eligibility for study inclusion was re-confirmed. The subjects were 
confined to the clinic from Day 3 to Day 7 under medical supervision. Assessments included 
carbon monoxide carboxyhemoglobin and vital signs, and a physical examination. On Day 
2, vital signs and a 12-lead ECG were measured, and blood samples drawn for clinical 
laboratory tests. On Day -1 and Day 0 (baseline days), assessments included determination 
of biomarkers of exposure in a 24-h urine sample, vital signs, serum, and plasma cotinine. 
On Day 0, one hundred subjects (61 males and 39 females) were randomized into 1 of 4 
parallel groups (EHCSS-K6M, M4JM, Lark1M, and no-smoking; N = 28 per smoking group, 
and N = 16 in the no-smoking group). From Day 1 through Day 6, subjects participated in 
their assigned study groups. 
Population size: 102 
E-cigarette, smoking and other related status: Adult male and female Japanese smokers 
with acceptable health conditions who smoked for at least a year, and had smoked 
exclusively 10–30 menthol cigarettes (3–6 mg tar yield) per day for at least 2 months were 
recruited 
Outcomes: biomarkers of exposure to selected conventional combustible tobacco cigarette 
smoke harmful and potentially harmful constituents 
• 1,3-Butadiene Monohydroxybutenyl mercapturic acid (MHBMA) 
• 2-Naphthylamine 2-Naphthylamine (2-NA) 
• 4-Aminobiphenyl 4-Aminobiphenyl (4-ABP) 
• Acrolein 3-Hydroxypropyl mercapturic acid (3-HPMA) 
• Acrylamide Acrylamide mercapturic acid (AAMA) 
• Glycidamide mercapturic acid (GAMA) 
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• Carbon monoxide Carboxyhemoglobin (COHb) 
• Crotonaldehyde 3-Hydroxy-1-methylpropyl mercapturic acid (3-HMPMA) 
• Nicotine Cotinine (COT-P) 
• Nicotine equivalents (NEq)c 
• NNKb Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) 
• Pyrene Total 1-hydroxypyrene (1-OHP)e 
• o-Toluidine o-Toluidine (o-TOL) 
• Mutagens Salmonella mutagenicity (YG1024 with S9) 
 
The authors concluded that this study showed reductions in the mean values of individual 
biomarkers of exposure to selected harmful and potentially harmful constituents in 
tobacco cigarette smoke from baseline to day 5 or 6 in smokers of the M4J(M) cigarette 
who switched to using the EHCSS series-K lighter and smoking the EHCSS-K6M menthol 
cigarette. In smokers who switched to smoking the Lark1M menthol cigarette, a 
conventional combustible tobacco cigarette representative of the low-tar menthol 
cigarette market, reductions in exposure to individual harmful and potentially harmful 
constituents in tobacco cigarette smoke were smaller. The largest reductions in 
individual harmful and potentially harmful constituents in tobacco cigarette smoke 
occurred in smokers who switched to no smoking. Reductions in the mean excretion of 
mutagenic material in urine occurred in the EHCSS-K6M and no-smoking groups, but not 
in the M4J(M) and Lark1M groups. Changes in serum concentrations of Clara cell 16-kDa 
protein could not be meaningfully interpreted.415 
Device and products: Conventional combustible tobacco cigarette brands were selected to 
include a leading market share cigarette of similar ISO tar and nicotine yields to the EHCSS- 
K6M and a representative conventional combustible tobacco cigarette with a low ISO tar 
and nicotine yield. The cigarettes also had a similar tobacco blend to that used in the 
EHCSS test cigarettes. Study cigarettes were analysed for tar and nicotine according to ISO 
methods. Study cigarettes were conditioned according to ISO standard 3402 (International 
Organization for Standardization, 1991). Conventional combustible tobacco cigarettes were 
smoked on a smoking machine according to ISO standard 3308. Tar and, nicotine were 
determined according to ISO standards 4387 and 10315, respectively (International 
Organization for Standardization, 2000b,c). These methods are essentially similar to 
methods used by the Tobacco Institute of Japan for declaration of tar and nicotine levels 
on cigarette packaging. Mainstream smoke from EHCSS cigarettes was generated on a 
modified smoking machine with a carousel adapted to use the EHCSS series-K lighter. The 
EHCSS smoke generation conformed with ISO standard 3308; some slight technical 
deviations were required. The ISO yields as declared on the cigarette packaging were as 
follows: Marlboro Ultra Lights Menthol (M4JM; 4 mg tar and 0.3 mg nicotine), Lark One 
Menthol (Lark1M; 1 mg tar and 0.1 mg nicotine), and EHCSS series-K menthol (EHCSS-K6M; 
5 mg tar, 0.3 mg nicotine). All cigarettes used in the study contained menthol. 
  Prototype heated cigarette 
Sakaguchi 











The authors reported on changes in levels of biomarkers of exposure in healthy smokers 
who switched to a prototype heated cigarette. Measures on 10 biomarkers of exposure 
(nicotine, carbon monoxide (CO), benzene, 1,3-butadiene, acrolein, hydrogen cyanide, 
crotonaldehyde, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), pyrene, and 4-
aminobiphenyl), and urine mutagenicity, were recorded 
Age: 21–49 years. Sex: All males. Country: Japan 
Data source: Healthy Japanese male smokers 
Population size: 70 
Trial duration: This study used a controlled, semi-randomized, open-label, parallel group, 
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Following enrolment, subjects were admitted to the clinical study site for 2 days (baseline 
period) and stayed for four consecutive weeks (investigation period). On Day-1 and Day 0 
(baseline period), the subjects were asked to smoke their usual brand of cigarettes in a 
manner like their routine smoking. On Day-1, participants could smoke at any time until 
bedtime (11:00 p.m.). On Day 0, subjects could smoke from the completion of medical 
check-up and blood and urine sampling in the morning to bedtime (11:00 p.m.). During the 
baseline period, the number of cigarettes smoked per day was approximately the same as 
their routine use. On Day 1 (first day of the investigation period), the subjects were 
allocated randomly either to the prototype heated cigarette group (47 smokers) or the 
conventional combustible tobacco cigarette 10 group (23 smokers) such that the ratio of 
sample size in the HC group and the conventional combustible tobacco cigarette 10 group 
was approximately 2:1. Assignment to study groups was stratified by age (21–30, 31–40 
and 41–50 years) and BMI (<18.5, P18.5 to <25.0, P25.0) so that the prototype heated 
cigarette group and conventional combustible tobacco cigarette 10 group were evenly 
matched for these two parameters. Subjects were to smoke their assigned cigarettes in the 
smoking room. In the prototype heated cigarette and the conventional combustible 
tobacco cigarette 10 groups, each subject was to smoke in a prescribed controlled manner 
(i.e. smoking approximately 20 prototype heated cigarettes or conventional combustible 
tobacco cigarette 10s per day, eight puffs per cigarette) 
E-cigarette, smoking and other related status: Healthy Japanese male smokers aged who 
reported smoking at least 20 conventional combustible tobacco cigarettes (10–15 mg tar 
value, printed on the package) per day for more than one year and the same brand for at 
least eight weeks preceding screening were recruited. 
Outcomes: Nicotine equivalents and urine mutagenicity (specifically) 
• COHb - carboxyhemoglobin 
• Total NNAL - 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) plus NNAL-glucu-
ronide 
• 4-ABP - 4-aminobiphenyl 
• 1-OHP - 1-hydroxypyrene 
• TMA - trans, trans-muconic acid 
• S-PMA - S-phenylmercapturic acid 
• MHBMA - monohydroxybutenylmercapturic acid 
• 3-HPMA - 3-hydroxypropylmercapturic acid 
• HMPMA - 3-hydroxyl-1-methylpropyl mercapturic acid 
• thiocyanate (SCN) a biomarker of exposure for hydrogen cyanide 
The authors concluded that exposure to most tobacco cigarette smoke constituents, 
except carbon monoxide (CO), can be reduced by switching from a conventional 
combustible tobacco cigarette containing 10 mg tar to a prototype heated cigarette.416 
Device and products: The reference cigarette, conventional combustible tobacco cigarette 
10, was a commercially available cigarette brand in Japan with the values of 10 mg tar and 
0.8 mg nicotine printed on the package. The test cigarette, prototype heated cigarette, was 
a prototype of a heat-not-burn tobacco product prepared by Japan Tobacco International. 











The authors reported on levels of harmful and potentially harmful constituents in 
smokers continuing to smoke conventional combustible tobacco cigarettes, smokers 
switching to the THS 2.2, and smokers abstaining from smoking for 5 days. 
 
Age: 23 to 65 years old. Sex: 80 males, 80 females. Country: Japanese smokers 











Interventional trial papers on exposure to heat-not-burn toxins 
tobacco 
cigarettes 
Trial duration: This study was a controlled, randomized, 3-arm parallel, single centre study 
in confinement. The Screening Period covered a maximum of 4 weeks (Day -30 to Day -3) 
prior to admission and enrolment to the study site on Day -2. All subjects tested THS 2.2 
using up to 3 THS Tobacco Sticks prior to enrolment. Eligible candidates were enrolled and 
confined under medical supervision until Discharge on Day 6. On Day -1 and Day 0 
(Baseline), participants smoked their own preferred brand of conventional combustible 
tobacco cigarettes and baseline assessments were performed. On Day 0, 160 participants 
were randomized to THS 2.2 use (n = 80), conventional combustible tobacco cigarette 
smoking (n = 40) or to abstain from smoking (n = 40). From Day 1 to Day 5, participants in 
the THS 2.2 and conventional combustible tobacco cigarette groups used THS 2.2 or their 
own brand of non-menthol conventional combustible tobacco cigarettes, respectively, and 
exclusively. After Discharge on Day 6, or in case of an early discontinuation, participants 
entered a 7-day Safety Follow-Up Period for recording of spontaneously reported adverse 
events. During the designated smoking hours from 06:30 to 23:00, conventional 
combustible tobacco cigarette smoking was allowed ad libitum on Day -1 and Day 0, and 
depending on the participant's product allocation, exclusive use of THS 2.2 or exclusive. 
Twenty-four-hour urine was collected on each day. Conventional combustible tobacco 
cigarette smoking was allowed ad libitum from Day 1 to Day 5 
Population size: 160. THS 2.2 use (n = 80), conventional combustible tobacco cigarette 
smoking (n = 40) or to abstain from smoking (n = 40) 
E-cigarette, smoking and other related status: Adult healthy Japanese smokers, were 
eligible if they smoked >=10 commercially available non-menthol conventional 
combustible tobacco cigarette s per day with a maximum yield of 1 mg nicotine per 
conventional combustible tobacco cigarette (ISO yield) for the last 4 weeks and had 
smoked conventional combustible tobacco cigarette for >= 3 consecutive years prior to 
enrolment. 
Outcomes: harmful and potentially harmful constituents: 
• Total NNAL [Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol] 4-(methylnitrosa-
mino)-1-(3-pyridyl)-1-butanone (NNK) 
• Total NNN [Total N-nitrosonornicotine] N-nitrosonornicotine (NNN) 
• MHBMA [Monohydroxybutenyl mercapturic acid] 1,3-butadiene 
• 3-HPMA [3-hydroxypropylmercapturic acid] Acrolein 
• S-PMA [S-phenylmercapturic acid] Benzene 
• COHb [Carboxyhemoglobin1] Carbon monoxide 
• Total 1-OHP [Total 1-hydroxypyrene] Pyrene 
• Total 3-OH-B[a]P [3-hydroxy-benzo(a)pyrene] Benzo(a)pyrene 
• 4-ABP [4-aminobiphenyl] 4-aminobiphenyl 
• 1-NA [1-aminonaphthalene] 1-aminonaphthalene 
• 2-NA [2-aminonaphthalene] 2-aminonaphthalene 
• o-tol [o-toluidine] o-toluidine 
• CEMA [2-cyanoethylmercapturic acid] Acrylonitrile 
• HEMA [2-hydroxyethylmercapturic acid] Ethylene oxide 
• 3-HMPMA [3-hydroxy-1-methylpropylmercapturic acid] Crotonaldehyde 
• S-BMA [S-benzylmercapturic acid] Toluene 
 
The authors concluded that switching from smoking conventional combustible tobacco 
cigarettes to using the THS 2.2 resulted in substantial reductions in exposure to 15 
selected harmful and potentially harmful constituents of tobacco smoke. The kinetics 
and the magnitude of the decrease in levels of biomarkers of exposure observed in the 
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the majority of the biomarkers of exposure. Nicotine uptake was similar between the 
THS 2.2 and conventional combustible tobacco cigarette groups at the end of the 5-day 
exposure period; after users had started to adapt to a new product, and with a 
transitional period of changing puffing behaviour, users were able to achieve their 
desired nicotine level. The combination of the results of nicotine exposure and subjective 
effect measures indicated that the THS 2.2 offered comparable satisfaction, with regard 
to taste and sensorial experience, to that which was observed in conventional 
combustible tobacco cigarette smokers. No adverse event or severe adverse events were 
reported during this study, with the total number of adverse events being very low and 
evenly balanced across study groups.417 
Device and products: The test product THS 2.2 was developed and provided by Philip 
Morris Products S.A. (part of Philip Morris International group of companies). THS 2.2 has 
three components: the THS tobacco Stick, the holder, and the charger. The THS tobacco 
stick contains a tobacco plug of processed tobacco cast leaf, which is covered by a paper 
wrap. The overall appearance of the THS tobacco stick is like that of a conventional 
combustible tobacco cigarette, except it is much shorter. The holder includes a battery, 
controlling electronics, and the heater element. The THS tobacco stick is inserted into the 
holder, and an electronically controlled heating blade within the holder heats the tobacco 
according to a carefully controlled temperature profile <350‘C. The charger recharges the 
holder. To use THS 2.2, the THS tobacco stick is inserted into the holder, the heating of the 
THS tobacco stick is initiated by pressing the button on the holder and a LED indicates 
when the initial heating process is complete. The holder and THS tobacco stick are 
designed to deliver over approximately 6 min or around 14 puffs. At the end of each 
product use session, the THS holder requires recharging and for the next use a new THS 
tobacco stick must be used. The test product THS 2.2 contained 0.5 mg nicotine and 4.9 ± 
0.5 mg/stick of glycerine as determined under ISO conditions using machine puffing 
methods. The reference product in this study were the participants’ own preferred brand 
of non-menthol conventional combustible tobacco cigarettes used in the conventional 
combustible tobacco cigarette group. Conventional combustible tobacco cigarettes were 
not provided by the sponsor, and subjects were asked to buy and bring their own 













The authors reported on levels of harmful and potentially harmful constituents in 
smokers continuing to smoke conventional combustible tobacco cigarettes, smokers 
switching to the THS 2.2, and smokers abstaining from smoking for 5 days. 
 
Age: 21 to 65 years Sex: 80 males, 80 females. Country: Adult Caucasian in Poland 
Data source: Study participants were recruited via the clinical site's database and through 
advertisements 
Trial duration: This study was designed as a controlled, randomized, three arm parallel, 
single-centre study in confinement. The Screening Period covered a maximum of 4 weeks 
(Day -30 to Day -3) prior to Admission on Day -2 to the study site. Prior to enrolment on 
Day -2, as the last procedure of the eligibility assessments on that day, all subjects 
participated in a product trial of THS 2.2 (using up to three THS 2.2 tobacco sticks. On Day -
2, after all inclusion/exclusion criteria had been met, eligible candidates were enrolled and 
confined under medical supervision until Discharge on Day 6. On Day -1 and Day 0, 
participants smoked their own preferred brand of conventional combustible tobacco 
cigarette s for baseline assessments. From Day 1 to Day 5, participants in the THS and 
conventional combustible tobacco cigarette groups used, respectively, THS 2.2 or their 
own brand of non-menthol conventional combustible tobacco cigarettes exclusively. 
Participants in the smoking abstinence arm were asked to completely abstain from 
smoking from Day 1 to Day 5. No participant could use any supportive medication for 
smoking abstention. On Day 6 or on the day of early discontinuation, end of study 
procedures was conducted. After discharge on Day 6, or in case of an early discontinuation, 
participants entered a 7-day Safety Follow-Up Period for recording of spontaneously 
reported new adverse events, serious adverse events, or follow-up of any ongoing adverse 
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conventional combustible tobacco cigarette, and from Day 1 to Day 5 for THS 2.2, product 
use was allowed during the designated product use hours from 06:30 to 23:00 ad libitum, 
and 24-h urine was collected on each day.  
Population size: 160. THS 2.2 use (n = 80), conventional combustible tobacco cigarette 
smoking (n = 40) or to abstain from smoking (n = 40) 
Data collection period: The study was conducted between June and September 2013 at 
BioVirtus Research Site (Kajetany, Poland) 
E-cigarette, smoking and other related status: Adult Caucasian smokers aged 21e65 years 
were eligible for participation in the study. Potential participants were eligible if they 
smoked >=10 commercially available non-menthol conventional combustible tobacco 
cigarettes per day with a maximum yield of 1 mg nicotine per cigarette (ISO yield) for the 
last 4 weeks and had smoked CC for >=3 consecutive years before enrolment  
Data source: Study participants were recruited via the clinical site's database and through 
advertisements 
Outcomes: reported by acronym [biomarker of exposure] (harmful or potentially harmful 
smoke constituent)  
o Total NNAL [Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol] 4-(methylnitros-
amino)-1-(3-pyridyl)-1-butanone (NNK) 
o Total NNN [Total N-nitrosonornicotine] N-nitrosonornicotine (NNN) 
o MHBMA [Monohydroxybutenyl mercapturic acid] 1,3-butadiene 
o 3-HPMA [3-hydroxypropylmercapturic acid] Acrolein 
o S-PMA [S-phenylmercapturic acid] Benzene 
o COHb [Carboxyhemoglobin1] Carbon monoxide 
o Total 1-OHP [Total 1-hydroxypyrene] Pyrene 
o Total 3-OH-B[a]P [3-hydroxy-benzo(a)pyrene] Benzo(a)pyrene 
o 4-ABP [4-aminobiphenyl] 4-aminobiphenyl 
o 1-NA [1-aminonaphthalene] 1-aminonaphthalene 
o 2-NA [2-aminonaphthalene] 2-aminonaphthalene 
o o-tol [o-toluidine] o-toluidine 
o CEMA [2-cyanoethylmercapturic acid] Acrylonitrile 
o HEMA [2-hydroxyethylmercapturic acid] Ethylene oxide 
o 3-HMPMA [3-hydroxy-1-methylpropylmercapturic acid] Crotonaldehyde 
o S-BMA [S-benzylmercapturic acid] Toluene 
 
The authors concluded that biomarkers of exposure, except those associated with 
nicotine exposure, were significantly reduced in the THS 2.2 group compared with the 
conventional combustible tobacco cigarette group, and approached the levels observed 
in the smoking abstinence group. Increased product consumption and total puff volume 
were reported in the THS 2.2 group. However, exposure to nicotine was similar to that in 
the conventional combustible tobacco cigarette group at the end of the confinement 
period. Reduction in the urge to smoke was comparable between the THS 2.2 and 
conventional combustible tobacco cigarette groups, and the THS 2.2 product was well 
tolerated.418 
 
Device and products: The THS 2.2 product was developed and provided by Philip Morris 
Products S.A. (part of Philip Morris International group of companies). The product is 
described in part 1 of this series (Smith et al.., 2016). Briefly, THS 2.2 has three 
components: the tobacco stick, the holder, and the charger. The tobacco stick (FR1 blend) 
contains a tobacco plug of processed tobacco cast leaf, which is enclosed in a paper wrap. 
The overall appearance of the tobacco stick is like a conventional combustible tobacco 
cigarette, except it is much shorter. The holder includes a battery, controlling electronics, 
and the heating element. The tobacco stick is inserted into the holder, and an 
electronically controlled heating blade heats the tobacco according to a carefully 
controlled temperature profile to temperatures not exceeding 300 C. The charger 
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heating of the tobacco stick is initiated by pressing the button on the holder. An LED 
indicates when the initial heating process is complete. The holder and tobacco stick are 
designed for a usage period of approximately 6 minutes or for around 14 puffs. The holder 
must be recharged after each usage period of 6 min and a new tobacco stick must be used 
for the next usage cycle. The THS 2.2 test product contained 0.5 mg nicotine as determined 
under ISO conditions and 56.4 mg/stick of glycerine as aerosol former. The reference 
product in this clinical study were the participant's own preferred brand of non-menthol 
conventional combustible tobacco cigarettes used in the conventional combustible 
tobacco cigarette group. Conventional combustible tobacco cigarettes were not provided 
by the Sponsor, and subjects were asked to buy and bring their own conventional 













The authors reported on levels of biomarkers of exposure in smokers continuing to smoke 
conventional combustible tobacco cigarettes, smokers switching to the menthol THS 2.2, 
and smokers abstaining from smoking for 5 days in a confined setting, followed by an 86-
day ambulatory period. 
Age: 37.7 ± 11.45. Sex: 96 males, 64 females. Country: White (99), Black or African 
American (51), Other (9), Missing (1) 
Data source: The study was conducted in Dallas, Texas, and Daytona Beach, Florida 
Trial duration: The study was composed of four main periods. After the screening period, 
from day −30 to day −3, which included a product trial, subjects were enrolled (day −2) and 
randomized (day 0) in a 2:1:1 ratio to the mTHS, menthol Conventional combustible 
tobacco cigarettes, and smoking abstinence groups. The 5-day confinement period (day 1 
to day 5) was followed by an 86-day ambulatory period (day 6 to day 91) and an additional 
28-day safety follow-up period in order to record spontaneously reported new adverse 
events or serious adverse events and to monitor the active follow-up of ongoing adverse 
events and serious adverse events by the site. On day −1 and day 0, all subjects smoked 
their own brand of menthol conventional combustible tobacco cigarettes for baseline 
assessments. During the confinement period, subjects in the mTHS and menthol 
conventional combustible tobacco cigarettes groups used exclusively ad libitum mTHS or 
their own brand of menthol conventional combustible tobacco cigarettes, respectively, 
during the designated smoking hours (06:30 am–11:00 pm). Subjects in the smoking 
abstinence group were asked to abstain from tobacco product use completely. On day 6, 
subjects were discharged from the study site and instructed to continue using their 
assigned product or to abstain from smoking for 86 days. Subjects were required to make 
three monthly visits of two consecutive days including one overnight stay each (day 30, 60, 
and 90) at the investigational site.  
Population size: The safety population included 165 subjects who had tried mTHS, of which 
160 (full analysis set) were randomized to mTHS (80), menthol conventional combustible 
tobacco cigarettes (41), and smoking abstinence (39). 
Data collection period: December 2013 and October 2014 
E-cigarette, smoking and other related status: Healthy male and female US smokers were 
eligible. 
Outcomes: Biomarkers of exposure: 
• Total NNAL [Total NNAL was determined as the molar sum of 4-(methylnitrosamino)-
1-(3-pyridy1)-1-butanol and its O-glucuronide conjugate] 
• Total NNN [Total NNN was determined as the molar sum of free and conjugated NNN 
i.e.N-nitrosonornicotine] 
• COHb (%) [carboxyhemoglobin] 
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• 3-HPMA [3-hydroxypropylmercapturic acid] 
• S-PMA [S-phenylmercapturic acid] 
• Total 1-OHP [1-hydroxypyrene] 
• 4-ABP [4-aminobiphenyl] 
• 1-NA [1-aminonaphthalene] 
• 2-NA [2-aminonaphthalene] 
• o-tol [o-toluidine] 
• CEMA [Cyanoethylmercapturic Acid] 
• HEMA [Hydroxybutyl Mercapturic Acid] 
• HMPMA [Not named in full] 
• B[a]P [benzo[a]pyren] 
• NEQ [nicotine equivalent] 
The authors concluded that switching to the menthol THS 2.2 led to significant reductions 
in exposure to Total NNAL the molar sum of 4-(methylnitrosamino)-1-(3-pyridy1)-1-
butanol and its O-glucuronide conjugate, Total NNN the molar sum of free and 
conjugated NNN i.e.N-nitrosonornicotine, carboxyhemoglobin, monohydroxybutenyl 
mercapturic acid, 3-hydroxypropylmercapturic acid, S-phenylmercapturic acid1-
hydroxypyrene, 4-aminobiphenyl, 1-aminonaphthalene, 2-aminonaphthalene, o-
toluidine, Cyanoethylmercapturic Acid, Hydroxybutyl Mercapturic Acid, HMPMA, and 
benzo[a]pyren after 5 days in confinement, which were maintained throughout the 
subsequent ambulatory period of 86 days. The reductions were comparable to those 
observed upon smoking abstinence.419 
Device and products: The investigational product was mTHS 2.2. Maximum heating 
temperature is 350°C; per stick, menthol (2.62 mg/stick), nicotine (1.21 mg/stick), and 
glycerine (3.94 mg/stick) yields were obtained under the Health Canada Intense smoking 
regimen. Reference products were menthol conventional combustible tobacco cigarettes 
of the subjects’ preferred commercially available brands. Cigarettes were not provided to 
the subjects, who were asked to purchase their own preferred brand. Heatsticks, together 
with the THS 2.2 device, were provided to the subjects as THS 2.2 was not commercialized 













The authors reported on the impact of switching to the THS 2.1 on biomarkers of exposure 
to harmful and potentially harmful constituents. 
Age mean (SD): 23 to 65 years Sex: Country: Not reported 
Data source: Subjects were recruited via the clinical site’s database and through 
advertisements. 
Trial duration: Five days 
Population size:42 
E-cigarette, smoking and other related status: current smokers  
Outcomes: harmful or potential harmful smoking constituents 
• COHb - carboxyhaemoglobin 
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• MHBMA - monohydroxybutenyl mercapturic acid 
• S-PMA - S-phenylmercapturic acid 
• Total NNAL -4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; 
• 1-OHP - 1-hydroxypyrene  
• Total NNN - determined as the molar sum of 4-(methylnitrosamino)-1-(3-pyridy1)-1-
butanol and its O-glucuronide conjugate 
• 4-ABP - 4-aminobiphenyl; 
• 2-NA - 2-aminonaphthalene 
• o-tol -o-toluidine 
• CEMA - 2-cyanoethylmercapturic acid 
• NEQ – nicotine equivalent 
• Nicotine  
• Cotinine 
 
The authors concluded that the THS 2.1 is a promising alternative to smoking 
conventional combustible tobacco cigarettes. Notwithstanding possible use adaption 
through consumption or puffing behaviour, the exposure to harmful smoke constituents 
was markedly reduced following use of the new heat-not-burn tobacco product 
platform.421 
Device and products: The test product THS 2.1 contain 0.3 mg nicotine and 50 mg glycerol 
as aerosol former determined under smoke chemistry ISO conditions (12 puffs). It was 
developed by Philip Morris International and provided by the Sponsor. THS 2.1 has three 
components: the THS tobacco stick, the holder, and the charger. The THS tobacco stick has 
a tobacco plug containing processed tobacco cast leaf, which is covered by a paper wrap. 
The holder includes a battery, controlling electronics, and the heater element. The THS 
tobacco stick is inserted into the holder and heats the tobacco via an electronically 
controlled heating blade. The charger recharges the holder. The THS tobacco sticks were 
preheated for 30 seconds in the THS holder and the energy capacity of the holder was 
sufficient to maintain a product use session for up to 6 minutes. At the end of each product 
use session, the THS holder required recharging. The reference product in this study was 
nonmenthol conventional combustible tobacco cigarettes of the subject’s own preferred 
commercially available brand. Conventional combustible tobacco cigarettes were not 
provided by the Sponsor, and subjects were asked to buy and bring their own conventional 













The authors reported on the impact of switching to the menthol THS 2.2 on biomarkers of 
exposure to harmful and potentially harmful constituents relative to smoking menthol 
conventional combustible tobacco cigarettes and smoking abstinence. 
Age mean (SD): 37.2 +/- 10.54 years. Sex: 68 males 92 females. Country: Japan. Ethnicity: 
Japanese adult smokers  
Data source: Japanese smokers were recruited via the clinical site’s database and via 
advertisements. 
Trial duration: The study comprised a 4-week screening period (days −30 to −3), a 
confinement period (days −2 to 6), an 85-day ambulatory period (days 6–91) and a 28-day 
safety follow-up period for the recording of spontaneously reported adverse events or 
serious adverse events. On days −1 and 0, participants smoked their own brand of menthol 
conventional combustible tobacco cigarettes and underwent baseline assessments. On day 
1, the participants were randomized to one of three groups in a 2:1:1 ratio to switch to 
Menthol Tobacco Heating System (Menthol Tobacco Heating System group), continue 
smoking menthol conventional combustible tobacco cigarettes, or abstain from smoking 
(smoking abstinence group), respectively. Randomization was performed with stratification 
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consumption (10–19 vs. >19 menthol conventional combustible tobacco cigarettes/day). 
Between days 1 and 5, participants in the Menthol Tobacco Heating System and menthol 
conventional combustible tobacco cigarettes groups used the allocated product ad libitum 
during the designated smoking hours (06:30 am to 11:00 pm), while participants in the 
smoking abstinence group completely abstained from smoking. During the 85-day 
ambulatory period, the participants returned to the study site and stayed overnight on the 
days 30, 60, and 90 visits. 
Population size: The full analysis set comprised 160 participants, randomized as follows: 78 
to switching to menthol Tobacco Heating System, 42 to continuing smoking menthol 
conventional combustible tobacco cigarettes, and 40 to smoking abstinence, of which two, 
one, and two participants, respectively, voluntarily discontinued. The safety analysis (n = 
175) contained the 15 subjects who tried the menthol Tobacco Heating System but were 
discontinued from enrolment, and thus, not randomized. 
E-cigarette, smoking and other related status: Persons who smoked ≥10 commercially 
available menthol conventional combustible tobacco cigarettes per day (self-reported) in 
the last 4 weeks (maximum yield of 1 mg nicotine per cigarette), and if they reported to 
have smoked menthol conventional combustible tobacco cigarettes for ≥3 years 
Outcomes:  
• Total NNAL -4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; 
• Total NNN - determined as the molar sum of 4-(methylnitrosamino)-1-(3-pyridy1)-1-
butanol and its O-glucuronide conjugate 
• COHb - carboxyhemoglobin; 
• MHBMA - monohydroxybutenyl mercapturic acid 
• 3-HPMA - 3-hydroxypropylmercapturic acid 
• S-PMA - S-phenylmercapturic acid 
• Total 1-OHP - determined as the molar sum of 1-hydroxypyrene and its glucuronide 
and sulfate conjugates 
• 4-ABP - 4-aminobiphenyl; 
• 1-NA - 1-aminonaphtalene 
• 2-NA - 2-aminonaphthalene 
• o-tol -o-toluidine 
• CEMA - 2-cyanoethylmercapturic acid 
• HEMA - 2-hydroxyethylmercapturic acid 
• 3-HMPMA - 3-hydroxy-1-methylpropylmercapturic acid 
• 3-OH-B[a]P -3-hydroxy(a)benzopyrene 
• NEQ – nicotine equivalent 
 
The authors concluded that switching from menthol conventional combustible tobacco 
cigarettes to the menthol THS 2.2 significantly reduced exposure to harmful and 
potentially harmful constituents relative to continuing smoking menthol conventional 
combustible tobacco cigarettes, with concentrations in those who switched being similar 
to the concentrations observed following smoking abstinence in Japanese adult 
smokers.422 
Device and products: The menthol Tobacco Heating System (2.62 mg/stick of menthol, 1.21 
mg/stick of nicotine, and 3.94 mg/stick of glycerine used as aerosol former, obtained under 
Health Canada Intense smoking regimen, maximum heating temperature 350°C) was used 
in this study. Reference products were menthol conventional combustible tobacco 
cigarettes of the participant’s preferred commercially available brand. 
























The authors aimed to investigate the effects of exposure to selected harmful and 
potentially harmful constituents of conventional combustible tobacco cigarette smoke in 
adult smokers who switched to a carbon-heated tobacco product, compared with adult 
smokers who continued to smoke conventional combustible tobacco cigarettes and those 
who abstained from smoking for 5 days. 
Age mean (SD) years: carbon-heated tobacco product group 36 (8.2); combustible tobacco 
cigarettes group 35.4 (7.4); abstinence group 37.9 (8.4) sex: 56 males, 56 females; country: 
single-centre confinement study conducted in Warsaw, Poland. 
Data source: Not reported  
Trial duration: Controlled, randomized, open-label, three-arm parallel group. Eligible 
subjects were enrolled on Day −2. (Admission) Subjects were randomly assigned into one 
of the three study arms by an interactive voice response system. The study was conducted 
in four successive cohorts. All subjects of a cohort were randomly assigned in the evening 
of Day 0 (D0). Randomization was stratified by sex and self-reported daily conventional 
combustible tobacco cigarette consumption (10−19 conventional combustible tobacco 
cigarettes per day [cpd] and 20−30 cpd). During the 2-day baseline period (D −1 and D0), 
subjects smoked their own brand of conventional combustible tobacco cigarettes ad 
libitum with each subject’s maximum daily conventional combustible tobacco cigarette 
consumption limited to 120% of the median daily conventional combustible tobacco 
cigarette consumption, derived from a 7-day self-reported conventional combustible 
tobacco cigarette consumption diary recorded prior to admission. The exposure period 
lasted 5 days (D1−D5). During the exposure period, conventional combustible tobacco 
cigarette smoking or carbon-heated tobacco product use was allowed ad libitum in 
separate rooms until 11:00 PM. Subjects using the carbon-heated tobacco product did not 
have access to conventional combustible tobacco cigarettes and vice versa. Participants in 
the smoking abstinence group were denied access to these rooms and underwent 
counselling on smoking cessation, but no pharmacotherapy. Subjects were discharged 
during the morning of D6 after undergoing all safety examination procedures. They 
entered a 7-day passive adverse event follow-up period 
Population size: 112 subjects were randomly assigned into one of the three study groups 
(carbon-heated tobacco product: 56 subjects, conventional combustible tobacco cigarette: 
28 subjects, smoking abstinence: 28 subjects; full analysis set). 
Data collection period: Not reported 
E-cigarette, smoking and other related status: Smoking habit of 10−30 cigarettes per day 
(maximum International Organization for Standardization [ISO] tar yield of 10 mg), smoking 
history of at least 5 consecutive years 
Outcomes: Biomarkers of exposure assessed as part of this study were  
• COHb (biomarker for carbon monoxide),  
• MHBMA (biomarker for 1,3-butadiene), 3-HPMA (biomarker for acrolein),  
• total 1-OHP (biomarker for pyrene),  
• O-toluidine (biomarker for ortho-toluidine),  
• 2-NA (biomarker for 2-aminonaphthalene),  
• 4-ABP (biomarker for 4-aminobiphenyl),  
• S-PMA (biomarker for benzene),  
• total NNAL (biomarker for NNK) and  
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•  cotinine (biomarker of exposure for nicotine)  
Switching to the carbon-heated tobacco product or smoking abstinence resulted in marked 
decreases from baseline to Day 5 in all biomarkers of exposure measured, including 
carboxyhaemoglobin (43% and 55% decrease in the carbon-heated tobacco product and SA 
groups, respectively). The urinary excretion of mutagenic material was also markedly 
decreased on Day 5 compared with baseline (89% and 87% decrease in the carbon-heated 
tobacco product and smoking abstinence groups, respectively). No changes in biomarkers 
of exposure to harmful and potentially harmful constituents or urinary mutagenic material 
were observed between baseline and Day 5 in the conventional combustible tobacco 
cigarette group. 
The authors concluded that the results provide clear evidence supporting a reduction in 
the level of exposure to harmful and potentially harmful constituents of tobacco 
cigarette smoke in smokers who switched to a carbon-heated tobacco product under 
controlled conditions, and that the reduction was similar to that observed in the smoking 
abstinence group.420 
Device and products: The carbon-heated tobacco product prototype MD2-E7 (3 mg tar, 2 
mg glycerol, 0.4 mg nicotine, and 1 mg carbon monoxide yield; aerosol chemistry 
determined under ISO conditions, 12 puffs). It consists of a carbon heat source, a tobacco 
plug wrapped in paper, an empty tube (to allow aerosol transfer), and a filter (a strip of 
aluminium foil that attaches the carbon heat source to the tobacco plug). Its appearance is 
like that of a combustible cigarette, but the carbon-heated tobacco product is based on 
technology that avoids pyrolysis/ combustion of tobacco. The aerosol chemistry of the 
carbon-heated tobacco product was previously reported.9 The test product and a 
specifically designed electric lighter were provided to the subjects. Reference and baseline 
products were commercially available non-menthol combustible cigarettes, with an ISO tar 
yield of up to 10 mg. All subjects purchased the anticipated amount of their usual 
combustible cigarettes brand required for the confinement period and handed them over 
to the site staff at admission. All products were stored at room temperature in a locked 
room with restricted access. Used combustible cigarettes and carbon-heated tobacco 
product were returned to the site product accountability. 
  glo™ THP 1.0 versus IQOS/THS 







The authors reported on the relationship of using two tobacco heating products (the glo™ 
THP 1.0 or the in-market comparator, the IQOS/THS) with biomarkers of toxicant 
exposure. 
Age mean age range: 31 to 35 years. Sex: A male:female ratio of 1:1. Country: Japan 
Ethnicity: Japanese  
Data source: Healthy male and female smokers 
Population size: Overall 182 participants were enrolled into the study on day –1 and 
randomized to one of the six study groups. During the baseline period, two participants 
were withdrawn from the study. 180 participants entered the exposure period and 
completed the study in accordance with the protocol 
Trial duration: The study ranged from baseline to end of study (days 6–7). For biomarker 
data, the mean of the two values taken prior to first randomized product use (i.e. days –1 
to 1 and days 1–2) was used as the baseline value. 
E-cigarette, smoking and other related status: All subjects had a smoking history of at least 
3 years and smoked between 10 and 30 cigarettes daily 
Outcomes: Urinary biomarkers of toxicant exposure: total nicotine equivalents (TNeq; 
nicotine, cotinine, 3-hydroxycotinine, and their glucuronide conjugates); total 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL); total N-nitrosonornicotine (NNN); 3-
hydroxypropylmercapturic acid (3-HPMA); 3-hydroxy-1-methylpropylmercapturic acid 
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(MHBMA); 2-cyanoethylmercapturic acid (CEMA); 4-aminobiphenyl (4-ABP); o-toluidine (o-
Tol); 2-aminonaphthalene (2-AN); 1-hydroxypyrene (1-OHP); 2-hydroxyethylmercapturic 
acid (HEMA); N-acetyl-S-(2-carbamoylethyl)cysteine (AAMA); and N-acetyl-S-(2-hydroxy-2-
carbamoylethyl)cysteine (GAMA) 
The authors concluded that glo™ or IQOS use for 5 days reduced exposure to smoke 
toxicants in a manner comparable to quitting tobacco use. The tobacco heating system 
product reduced exposure to tobacco products with that glo™ or IQOS have the potential 
to be regarded as modified risk tobacco products.423 
Device and products: A 7-mg/cig ISO tar combustible tobacco non-menthol cigarette, 
glo™/THP1.0 with non-menthol Neostiks, a 7-mg/cig ISO tar combustible tobacco menthol 
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Appendix 8: List of harmful and potentially harmful constituents of 
tobacco smoke 
The FDA has established a list of harmful and potentially harmful constituents, as required by the 
Federal Food, Drug, and Cosmetic Act.452 The list consists of 93 named harmful and potentially 
harmful constituents. The harmful and potentially harmful constituents are reported to be: 
carcinogenic, toxic (to the respiratory, cardiovascular, and/or reproductive systems or development 
of the embryo or foetus), or addictive. Specifically, there are 79 named carcinogens, 25 respiratory 
toxins, 12 cardiovascular toxins, and 14 reproductive or developmental toxins. Some constituents 
adversely impact on health in more than one way.452 













in food  
Total 4 12 79 25 14  
Acetaldehyde Addictive 
substance 















Acrolein   Cardiovascular 
toxicant 
  Respiratory 
toxicant  






Acrylonitrile     Carcinogen  Respiratory 
toxicant  



































Arsenic   Cardiovascular 
toxicant 











Benz[a]anthracene   Cardiovascular 
toxicant 






Benzene   Cardiovascular 
toxicant 





Benzo[b]fluoranthene   Cardiovascular 
toxicant 
Carcinogen       
Benzo[k]fluoranthene   Cardiovascular 
toxicant 


















































































Chrysene   Cardiovascular 
toxicant 
Carcinogen       
Cobalt   Cardiovascular 
toxicant 
Carcinogen       
Coumarin  
     
Banned 
in food 
Cresols (o-, m-, and p-cresol)     Carcinogen  Respiratory 
toxicant  




































































in food  







Formaldehyde     Carcinogen  Respiratory 
toxicant  



















Hydrazine     Carcinogen  Respiratory 
toxicant  
   
Hydrogen cyanide   Cardiovascular 
toxicant 
  Respiratory 
toxicant  


















Lead   Cardiovascular 
toxicant 
















Methyl ethyl ketone 
















Naphthalene     Carcinogen  Respiratory 
toxicant  
   
Nickel     Carcinogen  Respiratory 
toxicant  
   
Nicotine Addictive 
substance 

























































































    
 
Phenol   Cardiovascular 
toxicant 
  Respiratory 
toxicant  












Propionaldehyde   Cardiovascular 
toxicant 
  Respiratory 
toxicant  
   
Propylene oxide     Carcinogen  Respiratory 
toxicant  










































Uranium-235     Carcinogen  Respiratory 
toxicant  
   
Uranium-238     Carcinogen  Respiratory 
toxicant  
   
Vinyl acetate     Carcinogen  Respiratory 
toxicant  
   
Vinyl chloride    
  
Carcinogen  
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